


**CUMULATIVE  
SUPPLEMENT 12  
December 2025**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**45th EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**45<sup>th</sup> EDITION**

**Cumulative Supplement 12  
December 2025**

**CONTENTS**

*PAGE*

**Contents**

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	ix
1.5	AVAILABILITY OF THE EDITION.....	x
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	xi
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xii
<b>DRUG PRODUCT LISTS</b>		
	Prescription Drug Product List .....	1-1
	OTC Drug Product List .....	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	3-1
	Orphan Products Designations and Approvals List .....	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	5-1
<b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>		
A.	Patent and Exclusivity Lists .....	A-1
B.	Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**45<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 12  
December 2025**

**1.0 INTRODUCTION**

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section

2., How To Use The Drug Product Lists, describes the layout and usage of the List.

## 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ALLIED PHARMA INC (ALLIED)	ANDA REPOSITORY LLC (ANDA REPOSITORY)
ANDA REPOSITORY LLC (ANDA REPOSITORY)	TP ANDA HOLDINGS LLC (TP ANDA HOLDINGS)
APPCO PHARMA LLC (APPCO)	SOMERSET THERAPEUTICS LLC (SOMERSET THERAPS LLC)
AVIV PHARMA INC (AVIV PHARMA)	PHARMOBEDIANT CONSULTING LLC (PHARMOBEDIANT)
BEXIMCO PHARMACEUTICALS USA INC (BEXIMCO PHARMS USA)	REGCON HOLDINGS LLC (REGCON HOLDINGS)
BEXIMCO PHARMACEUTICALS USA INC (BEXIMCO USA)	REGCON HOLDINGS LLC (REGCON HOLDINGS)
CARNEGIE PHARMACEUTICALS LLC (CARNEGIE)	PHARMOBEDIANT CONSULTING LLC (PHARMOBEDIANT)

DR REDDYS LABORATORIES INC (DR REDDYS LABS INC)	SENORES PHARMACEUTICALS INC (SENORES PHARMS)
DR REDDYS LABORATORIES LTD (DR REDDYS)	SENORES PHARMACEUTICALS INC (SENORES PHARMS)
DR REDDYS LABORATORIES LTD (DR REDDYS LABS LTD)	SENORES PHARMACEUTICALS INC (SENORES PHARMS)
DR REDDYS LABORATORIES SA (DR REDDYS LABS SA)	SENORES PHARMACEUTICALS INC (SENORES PHARMS)
ENDO OPERATIONS LTD (ENDO OPERATIONS)	PH HEALTH LTD (PH HEALTH)
ESJAY PHARMA LLC (ESJAY PHARMA)	NOVITIUM PHARMA LLC (NOVITIUM PHARMA)
GRAVITI PHARMACEUTICALS INC (GRAVITI PHARMS)	RISING PHARMA HOLDINGS INC (RISING)
GRAVITI PHARMACEUTICALS PRIVATE LTD (GRAVITI PHARMS)	RISING PHARMA HOLDINGS INC (RISING)
ICU MEDICAL INC (ICU MEDICAL INC)	OTSUKA ICU MEDICAL LLC (OTSUKA ICU MEDCL)
INDOCO REMEDIES LTD (INDOCO)	REGCON HOLDINGS LLC (REGCON HOLDINGS)
INDOCO REMEDIES LTD (INDOCO REMEDIES)	REGCON HOLDINGS LLC (REGCON HOLDINGS)
MYLAN INSTITUTIONAL LLC (MYLAN INSTITUTIONAL)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN PHARMACEUTICALS INC (MYLAN)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN TECHNOLOGIES INC (MYLAN TECHNOLOGIES)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)	PHARMOBEDIENT CONSULTING LLC (PHARMOBEDIENT)
RUBICON RESEARCH PRIVATE LTD (RUBICON)	RUBICON RESEARCH LTD (RUBICON RESEARCH)
SENORES PHARMACEUTICALS INC (SENORES PHARMS)	ANDA REPOSITORY LLC (ANDA REPOSITORY)

STERISCIENCE SPECIALITIES PTE LTD (STERISCIENCE SPECLTS)	ONESOURCE SPECIALTY PTE LTE (ONESOURCE SPECIALTY)
STRIDES PHARMA GLOBAL PTE LTD (STRIDES PHARMA)	STRIDES PHARMA INTERNATIONAL AG (STRIDES PHARMA INTL)
STRIDES SOFTGELS PTE LTD (STRIDES SOFTGELS)	ONESOURCE SPECIALTY PTE LTD (ONESOURCE SPECIALTY)
TARO PHARMACEUTICALS INC (TARO)	SUN PHARMA CANADA INC (SUN PHARMA CANADA)
TRUPHARMA LLC (TRUPHARMA)	TP ANDA HOLDINGS LLC (TP ANDA HOLDINGS)
WOCKHARDT LTD (WOCKHARDT)	WOCKHARDT BIO AG (WOCKHARDT BIO AG)
XTTRIUM LABORATORIES INC (XTTRIUM)	PHARMOBEDIENT CONSULTING LLC (PHARMOBEDIENT)
XTTRIUM LABORATORIES INC (XTTRIUM LABS INC)	PHARMOBEDIENT CONSULTING LLC (PHARMOBEDIENT)

#### 1.4 LEVOTHYROXINE SODIUM<sup>1</sup>

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.<sup>2</sup>

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).

<sup>1</sup> In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

<sup>2</sup> Please consult the Active Section of the Orange Book for information on other strengths.

- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM <sup>3</sup>	MYLAN	0.3MG	A076187	-	RS

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data

<sup>3</sup> Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

at <http://www.fda.gov/Drugs/InformationOnDrugs/ucml29689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

## REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2024</u>	<u>MAR</u> <u>2025</u>	<u>JUN</u> <u>2025</u>	<u>SEP</u> <u>2025</u>	<u>DEC</u> <u>2025</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	23856 2772 (11.8%)	23679 2740 (11.6%)	23798 2744 (11.5%)	24012 2776 (11.6%)	24120 2765 (11.5%)
MULTISOURCE	20814 (88.2%)	20939 (88.4%)	21054 (88.5%)	21236 (88.4%)	21355 (88.5%)
THERAPEUTICALLY EQUIVALENT	20741 (87.9%)	20826 (88%)	20952 (88%)	21137 (88%)	21260 (88.1%)
NOT THERAPEUTICALLY EQUIVALENT	73 (0.3%)	113 (0.5%)	102 (0.4%)	99 (0.4%)	95 (0.4%)
EXCEPTIONS <sup>4</sup>	47 (0.2%)	47 (0.2%)	47 (0.2%)	47 (0.2%)	47 (0.2%)
NEW MOLECULAR ENTITIES APPROVED	43	13	7	20	19
NUMBER OF APPLICANTS	1197	1209	1226	1200	1198

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN <sup>5</sup>	Applicant holder firm name has changed

<sup>4</sup> Amino acid containing products of varying composition (see Introduction, page xx of the List).

<sup>5</sup> The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long

CAIN Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR Change. Dosage Form; Route of Administration

CFTG Change. A TE Code is added when a first time generic for an innovator is approved.

CMFD Change. The product is moved from the Discontinued Section due to a change in marketing status.

CMKT Change. RX to OTC marketing status switch.

CMS1 Change. Miscellaneous addition to list.

CMS2 Change. Miscellaneous deletion from list.

CPOT Change. Potency amount/unit.

CRLD Change. Reference Listed Drug

CHRS Change. Reference Standard

CTEC Change. Therapeutic Equivalence Code.

CTNA Change. Trade Name.

DISC Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

---

name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB		HETERO LABS LTD V	EQ 600MG BASE;300MG	A205412	001	Apr 16, 2025	Apr NEWA
	@	MACLEODS PHARMS LTD	EQ 600MG BASE;300MG	A212663	001	Dec 19, 2024	Jun DISC

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE

>D>		! LUPIN LTD	EQ 300MG BASE;150MG;300MG	A202912	001	Dec 05, 2013	Dec DISC
>A>	@		EQ 300MG BASE;150MG;300MG	A202912	001	Dec 05, 2013	Dec DISC

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB		FLORIDA	500MG	A215086	001	Mar 23, 2023	Nov CAHN
AB		REGCON HOLDINGS	500MG	A215086	001	Mar 23, 2023	Sep CAHN
	@	TEVA PHARMS USA	250MG	A208432	001	Oct 31, 2018	Mar DISC
	@		500MG	A210726	001	Jan 26, 2023	Mar DISC

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

AB		BIONPHARMA	333MG	A219904	001	Sep 18, 2025	Sep NEWA
AB	!	GLENMARK PHARMS LTD	333MG	A202229	001	Jul 16, 2013	Nov CHRS
AB			333MG	A202229	001	Jul 16, 2013	Mar CMFD
AB		ZYDUS PHARMS	333MG	A205995	001	May 26, 2017	Nov CHRS

ACECLIDINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
 VIZZ

	+	!	LENZ THERAP	EQ 1.44% BASE	N218585	001	Jul 31, 2025	Jul NEWA
--	---	---	-------------	---------------	---------	-----	--------------	----------

ACETAMINOPHEN

SOLUTION;INTRAVENOUS

ACETAMINOPHEN

AP1		ASPIRO	1GM/100ML (10MG/ML)	A216617	001	Jul 27, 2022	Mar CTEC	
AP	+	!	B BRAUN MEDICAL	500MG/50ML (10MG/ML)	N204957	001	Feb 18, 2021	Mar CFTG
AP2	+	!	BAXTER HLTHCARE CORP	1GM/100ML (10MG/ML)	N204957	002	Feb 18, 2021	Mar CFTG
			650MG/65ML (10MG/ML)	A214331	002	May 21, 2025	May NEWA	
AP1			1GM/100ML (10MG/ML)	A214331	001	Sep 17, 2021	Mar CTEC	
AP1		CAPLIN	1GM/100ML (10MG/ML)	A219096	001	Dec 05, 2025	Nov NEWA	
AP1		EUGIA PHARMA	1GM/100ML (10MG/ML)	A210969	001	Oct 21, 2020	Mar CTEC	
AP		GLAND	500MG/50ML (10MG/ML)	A219215	001	Apr 02, 2025	Mar NFTG	
AP2			1GM/100ML (10MG/ML)	A219215	002	Apr 02, 2025	Mar NFTG	
AP1		HIKMA	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Mar CTEC	
AP1		INFORLIFE	1GM/100ML (10MG/ML)	A215403	001	May 03, 2023	Mar CTEC	
AP1		MYLAN	1GM/100ML (10MG/ML)	A213255	001	Aug 07, 2020	Mar CTEC	
AP1	!	SANDOZ	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Mar CTEC	
AP1		WOCKHARDT BIO AG	1GM/100ML (10MG/ML)	A205746	001	Apr 18, 2023	Mar CTEC	

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

ALLZITAL

AA	!	PHARMOBEDIENT	325MG;25MG	A203484	001	Dec 04, 2015	Sep CAHN
			BUTALBITAL AND ACETAMINOPHEN				
AA		ANDA REPOSITORY	300MG;50MG	A207386	001	Nov 15, 2016	Sep CAHN
AA		PHARMOBEDIENT	325MG;50MG	A203484	002	Dec 04, 2015	Sep CAHN
			BUTAPAP				
AA	!	ANDA REPOSITORY	325MG;50MG	A089987	001	Oct 26, 1992	Sep CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

SOLUTION;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	!	GENUS	325MG/15ML;50MG/15ML;40MG/15ML	A040387	001	Jan 31, 2003	Oct CAHN
--	---	-------	--------------------------------	---------	-----	--------------	----------

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>D>	AA		ANDA REPOSITORY	325MG;50MG;40MG	A089175	001	Jan 21, 1987	Dec CAHN
	AA			325MG;50MG;40MG	A089175	001	Jan 21, 1987	Sep CAHN
>A>	AA		MIKART	325MG;50MG;40MG	A089175	001	Jan 21, 1987	Dec CAHN

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>D>	AA	STRIDES PHARMA	325MG;50MG;40MG	A 203647	001	Sep 21, 2020	Dec	DISC
>A>	@		325MG;50MG;40MG	A 203647	001	Sep 21, 2020	Dec	DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

>D>	AB	AVIV PHARMA	325MG;50MG;40MG;30MG	A 075929	001	Apr 22, 2002	May	CAHN
>A>	@	STRIDES PHARMA	325MG;50MG;40MG;30MG	A 204649	001	Jul 08, 2020	Dec	DISC
	@		325MG;50MG;40MG;30MG	A 204649	001	Jul 08, 2020	Dec	DISC

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET;ORAL

ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

@	PHARMOBEDIENT	325MG;30MG;16MG	A 204209	001	Sep 30, 2016	Sep	CAHN
---	---------------	-----------------	----------	-----	--------------	-----	------

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@	CHARTWELL	120MG/5ML;12MG/5ML	A 089450	001	Oct 27, 1992	Feb	DISC
!	GENUS LIFESCIENCES	120MG/5ML;12MG/5ML	A 087508	001		Feb	CTEC
@	XTTRIUM LABS INC	120MG/5ML;12MG/5ML	A 087006	001		Feb	CAHN

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@	ANI PHARMS	300MG;15MG	A 088629	002	Mar 06, 1985	May	CAHN
@		300MG;30MG	A 088629	003	Mar 06, 1985	May	CAHN
@ +		300MG;60MG	A 088629	001	Mar 06, 1985	May	CAHN
AA	HIBROW HLTHCARE	300MG;15MG	A 211610	001	Jun 27, 2019	Sep	CAHN
AA		300MG;30MG	A 211610	002	Jun 27, 2019	Sep	CAHN
AA		300MG;60MG	A 211610	003	Jun 27, 2019	Sep	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@	CHARTWELL	325MG/15ML;7.5MG/15ML	A 040482	001	Sep 25, 2003	Feb	DISC	
AA	!	WES PHARMA INC	325MG/15ML;7.5MG/15ML	A 211023	001	Mar 08, 2019	Feb	CHRS

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@	CHARTWELL	300MG;5MG	A 040658	001	Jan 19, 2006	Feb	DISC
@		300MG;7.5MG	A 040658	002	Mar 24, 2006	Feb	DISC
@		300MG;10MG	A 040658	003	Jun 23, 2004	Feb	DISC
@		325MG;7.5MG	A 040432	001	Jan 22, 2003	Feb	DISC
AA	HIBROW HLTHCARE	300MG;5MG	A 207509	001	Oct 29, 2018	Sep	CAHN
AA		300MG;7.5MG	A 207509	002	Oct 29, 2018	Sep	CAHN
AA		300MG;10MG	A 207509	003	Oct 29, 2018	Sep	CAHN
@	RHODES PHARMS	300MG;5MG	A 207808	001	Mar 30, 2018	Jan	DISC
@		300MG;7.5MG	A 207808	002	Mar 30, 2018	Jan	DISC
@		300MG;10MG	A 207808	003	Mar 30, 2018	Jan	DISC
AA	!	SPECGX LLC	A 206718	001	Mar 31, 2017	Feb	CHRS
AA	!		A 206718	002	Mar 31, 2017	Feb	CHRS
AA	!		A 206718	003	Mar 31, 2017	Feb	CHRS

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

!	ABHAI LLC	325MG/5ML;5MG/5ML	A 211499	001	Dec 31, 2018	Sep	CTEC
@	SANKALP LIFECARE	325MG/5ML;5MG/5ML	A 201448	001	Aug 26, 2021	Sep	DISC
AA		325MG/5ML;5MG/5ML	A 201448	001	Aug 26, 2021	Apr	CAHN

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

@	CHARTWELL	325MG;5MG	A 207834	001	Aug 15, 2019	Feb	DISC
@		325MG;7.5MG	A 207834	002	Aug 15, 2019	Feb	DISC
@		325MG;10MG	A 207834	003	Aug 15, 2019	Feb	DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

@	MPP PHARMA	325MG;37.5MG	A 078778	001	Apr 07, 2014	Jun	CAHN
---	------------	--------------	----------	-----	--------------	-----	------

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL		ACETAZOLAMIDE					
AB	MPP PHARMA	500MG	A204691	001	Mar 29, 2016	May	CAHN
TABLET;ORAL		ACETAZOLAMIDE					
AB	AUROBINDO PHARMA LTD	125MG	A212089	001	May 30, 2025	May	NEWA
AB		250MG	A212089	002	May 30, 2025	May	NEWA
AB	HIBROW HLTHCARE	125MG	A211556	001	Oct 18, 2019	Nov	CTEC
AB		250MG	A211556	002	Oct 18, 2019	Nov	CTEC
DIAMOX							
@ +	TEVA BRANDED PHARM	125MG	N008943	001		Feb	CAHN
@ +		250MG	N008943	002		Feb	CAHN

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION		ACETAZOLAMIDE SODIUM					
AP	GLAND	EQ 500MG BASE/VIAL	A219775	001	Jun 17, 2025	Jun	NEWA

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC		ACETIC ACID					
@	TARO	2%	A088638	001	Sep 06, 1984	Aug	DISC

ACETYLCYSTEINE

SOLUTION;INHALATION, ORAL		ACETYLCYSTEINE					
AN	CONBA USA	10%	A214177	001	Mar 14, 2025	Mar	NEWA
AN		20%	A214177	002	Mar 14, 2025	Mar	NEWA
AN	SOMERSET THERAPS LLC	10%	A219194	001	Feb 12, 2025	Jan	NEWA
AN		20%	A219194	002	Feb 12, 2025	Jan	NEWA

ACETYLCYSTEINE LYSINE

FOR SOLUTION;ORAL		LEGUBETI					
@ +	GALEPHAR	EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Jul	DISC
+		EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Jun	CMFD
@ +		EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Jul	DISC
+		EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Jun	CMFD

ACITRETIN

CAPSULE;ORAL		ACITRETIN					
@	MYLAN	17.5MG	A203707	001	Sep 10, 2015	Apr	CAHN
@		22.5MG	A203707	002	Sep 10, 2015	Apr	CAHN

ACOLTREMON

SOLUTION/DROPS;OPHTHALMIC		TRYPTYR					
+	ALCON LABS INC	0.003%	N217370	001	May 28, 2025	May	NEWA

ACYCLOVIR

CAPSULE;ORAL		ACYCLOVIR					
AB	REGCON HOLDINGS	200MG	A075090	001	Jan 26, 1999	Sep	CAHN
CREAM;TOPICAL		ACYCLOVIR					
@	CIPLA	5%	A212981	001	May 02, 2025	May	DISC
AB		5%	A212981	001	May 02, 2025	Apr	NEWA
BX	ZYDUS LIFESCIENCES	5%	A206770	001	Feb 28, 2023	Mar	CTEC
OINTMENT;TOPICAL		ACYCLOVIR					
@	APOTEX	5%	A210774	001	Sep 06, 2019	Jan	DISC
@	CHARTWELL MOLECULAR	5%	A206437	001	Jul 31, 2017	Feb	CAHN
@	CIPLA	5%	A211794	001	Jan 18, 2019	May	DISC
BX		5%	A211794	001	Jan 18, 2019	Mar	CTEC
TABLET;BUCCAL		SITAVIG					
@ +	LIGAND PHARMS	50MG	N203791	001	Apr 12, 2013	Jul	DISC
+		50MG	N203791	001	Apr 12, 2013	Jun	CAHN

TABLET;ORAL

	ACYCLOVIR							
AB	AUROBINDO PHARMA USA	400MG	A075211	001	Sep 28, 1998	Aug	CMFD	
AB		800MG	A075211	002	Sep 28, 1998	Aug	CMFD	

ACYCLOVIR SODIUM

	INJECTABLE; INJECTION							
	ACYCLOVIR SODIUM							
AP	FRESENIUS KABI USA	EQ 50MG BASE/ML	A215404	001	Jun 25, 2024	May	CMFD	
	@	EQ 50MG BASE/ML	A215404	001	Jun 25, 2024	Feb	DISC	

>A> AFICAMTEN

>A>	TABLET;ORAL							
>A>	MYQORZO							
>A>	+! CYTOKINETICS	5MG	N219083	001	Dec 19, 2025	Dec	NEWA	
>A>	+	10MG	N219083	002	Dec 19, 2025	Dec	NEWA	
>A>	+	15MG	N219083	003	Dec 19, 2025	Dec	NEWA	
>A>	+	20MG	N219083	004	Dec 19, 2025	Dec	NEWA	

ALBUTEROL SULFATE

	AEROSOL, METERED; INHALATION							
	ALBUTEROL SULFATE							
AB2	AMNEAL IRELAND LTD	EQ 0.09MG BASE/INH	A211600	001	Dec 01, 2025	Nov	NEWA	
AB2	PADAGIS US	EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Mar	CMFD	
	POWDER, METERED; INHALATION							
	PROAIR DIGIHALER							
	@ + TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018	Feb	CAHN	
	PROAIR RESPICLICK							
	+! TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	001	Mar 31, 2015	Feb	CAHN	
	SOLUTION; INHALATION							
	ALBUTEROL SULFATE							
AN	RITEDOSE CORP	EQ 0.5% BASE	A218386	001	Mar 12, 2025	Feb	NEWA	
	SYRUP;ORAL							
	ALBUTEROL SULFATE							
	@ COSETTE	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Jan	DISC	
	TABLET;ORAL							
	ALBUTEROL SULFATE							
AB	ACERTIS PHARMS	EQ 2MG BASE	A211397	001	Oct 26, 2018	May	CAHN	
AB		EQ 4MG BASE	A211397	002	Oct 26, 2018	May	CAHN	

ALCLOMETASONE DIPROPIONATE

	CREAM; TOPICAL							
	ALCLOMETASONE DIPROPIONATE							
	@ GLENMARK PHARMS LTD	0.05%	A079061	001	Jun 23, 2009	Jul	DISC	
	OINTMENT; TOPICAL							
	ALCLOMETASONE DIPROPIONATE							
	@ GLENMARK PHARMS LTD	0.05%	A079227	001	Jul 30, 2009	Jul	DISC	

ALCOHOL

	SOLUTION; INTRA-ARTERIAL							
	ABLYSINOL							
AP	+! BPI LABS	99% (5ML)	N207987	002	Jun 21, 2018	Jun	CFTG	
	DEHYDRATED ALCOHOL							
AP	ACCORD HLTHCARE	99% (5ML)	A217845	001	Jun 23, 2025	Jun	NFTG	
AP	BRECKENRIDGE	99% (5ML)	A219444	001	Jun 23, 2025	Jun	NFTG	
AP	INGENUS PHARMS LLC	99% (5ML)	A219569	001	Jul 09, 2025	Jun	NEWA	
AP	XGEN PHARMS	99% (5ML)	A219400	001	Jun 23, 2025	Jun	NFTG	
	SOLUTION; INTRAVENOUS							
	DEHYDRATED ALCOHOL							
	+! ROYAL PHARMS	98% (5ML)	N214988	001	Oct 23, 2025	Oct	NEWA	

ALENDRONATE SODIUM

	TABLET;ORAL							
	ALENDRONATE SODIUM							
	@ APOTEX	EQ 5MG BASE	A077982	001	Aug 04, 2008	Mar	DISC	
	@	EQ 10MG BASE	A077982	002	Aug 04, 2008	Mar	DISC	
	@	EQ 35MG BASE	A077982	003	Aug 04, 2008	Mar	DISC	
	@	EQ 70MG BASE	A077982	004	Aug 04, 2008	Mar	DISC	

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

+! RISING

EQ 0.5MG BASE/ML

N019353 001 Dec 29, 1986 Aug CTEC

ALFENTANIL

@ HOSPIRA

EQ 0.5MG BASE/ML

A075221 001 Oct 28, 1999 Aug DISC

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB AUROBINDO PHARMA LTD 100MG

A215091 001 Apr 14, 2025 Apr NEWA

AB 300MG

A215091 002 Apr 14, 2025 Apr NEWA

AB INDOCO 200MG

A204467 003 May 22, 2025 May NEWA

@ NORTHSTAR HLTHCARE 100MG

A078253 001 Sep 11, 2007 Aug DISC

@ 300MG

A078253 002 Sep 11, 2007 Aug DISC

AB ZYDUS PHARMS 200MG

A210117 003 Jun 13, 2025 Jun NEWA

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB HIBROW HLTHCARE EQ 0.5MG BASE

A211621 001 Sep 16, 2019 Aug CMFD

AB EQ 1MG BASE

A211621 002 Sep 16, 2019 Aug CMFD

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

@ APOTEX INC 0.25MG

A077741 001 Jan 19, 2007 Mar DISC

@ 0.5MG

A077741 002 Jan 19, 2007 Mar DISC

@ 1MG

A077741 003 Jan 19, 2007 Mar DISC

@ 2MG

A077741 004 Jan 19, 2007 Mar DISC

@ CHARTWELL RX 0.25MG

A207507 001 Jul 09, 2018 Nov DISC

@ 0.5MG

A207507 002 Jul 09, 2018 Nov DISC

@ 1MG

A207507 003 Jul 09, 2018 Nov DISC

@ 2MG

A207507 004 Jul 09, 2018 Nov DISC

@ SUN PHARM 0.25MG

A090082 001 Jun 17, 2010 Jul DISC

@ 0.5MG

A090082 002 Jun 17, 2010 Jul DISC

@ 1MG

A090082 003 Jun 17, 2010 Jul DISC

@ 2MG

A090082 004 Jun 17, 2010 Jul DISC

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ APOTEX INC 0.5MG

A078449 001 Nov 12, 2008 Mar DISC

@ 1MG

A078449 004 Dec 23, 2015 Mar DISC

@ 2MG

A078449 002 Nov 12, 2008 Mar DISC

@ 3MG

A078449 003 Nov 12, 2008 Mar DISC

ALPROSTADIL

SUPPOSITORY; URETHRAL

MUSE

@ + VIATRIS 0.125MG

N020700 001 Nov 19, 1996 Feb CAHN

@ + 0.25MG

N020700 002 Nov 19, 1996 Feb CAHN

@ + 0.5MG

N020700 003 Nov 19, 1996 Feb CAHN

@ + 1MG

N020700 004 Nov 19, 1996 Feb CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMANTADINE HYDROCHLORIDE

@ ZYDUS EQ 68.5MG BASE

A214897 001 Aug 26, 2024 May DISC

GOCOVRI

+ SUPERNUS PHARMS EQ 68.5MG BASE

N208944 001 Aug 24, 2017 May CTEC

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

@ ADAPTIS 50MG/5ML

A075819 001 Sep 11, 2002 Sep CAHN

@ AEONIUM PHARMA PVT 50MG/5ML

A075819 001 Sep 11, 2002 Sep CAHN

@ BAJAJ 50MG/5ML

A075819 001 Sep 11, 2002 Mar CAHN

AA SHREE HARI INTL 50MG/5ML

A214178 001 Aug 20, 2021 Aug CAHN

AMCINONIDE

LOTION;TOPICAL

AMCINONIDE

! SOLUBIOMIX 0.1% A076329 001 Nov 06, 2002 Feb CAHN

OINTMENT;TOPICAL

AMCINONIDE

! GENUS 0.1% A076096 001 Nov 19, 2002 Aug CTEC

@ TARO PHARM INDS 0.1% A076367 001 Mar 19, 2003 Aug DISC

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION;INTRAVENOUS

KABIVEN IN PLASTIC CONTAINER

+! FRESENIUS KABI USA 3.3%;29MG/100ML;9.8GM/100ML;96 N200656 004 Aug 25, 2014 Nov CHRS  
MG/100ML;174MG/100ML;239MG/100  
ML ;147MG/100ML;3.9GM/100ML  
(1026ML)

+! 3.3%;29MG/100ML;9.8GM/100ML;96 N200656 005 Aug 25, 2014 Nov CHRS  
MG/100ML;174MG/100ML;239MG/100  
ML;147MG/100ML;3.9GM/100ML  
(1540ML)

+! 3.3%;29MG/100ML;9.8GM/100ML;96 N200656 006 Aug 25, 2014 Nov CHRS  
MG/100ML;174MG/100ML;239MG/100  
ML;147MG/100ML;3.9GM/100ML  
(2053ML)

PERIKABIVEN IN PLASTIC CONTAINER

+! FRESENIUS KABI USA 2.4%;20MG/100ML;6.8GM/100ML;68 N200656 001 Aug 25, 2014 Nov CHRS  
MG/100ML;124MG/100ML;170MG/100  
ML;105MG/100ML;3.5GM/100ML  
(1440ML)

+! 2.4%;20MG/100ML;6.8GM/100ML;68 N200656 002 Aug 25, 2014 Nov CHRS  
MG/100ML;124MG/100ML;170MG/100  
ML;105MG/100ML;3.5GM/100ML  
(1920ML)

AMINOCAPROIC ACID

INJECTABLE;INJECTION

AMINOCAPROIC ACID

AP GEN ILAC 250MG/ML A215374 001 Aug 28, 2025 Aug NEWA

SOLUTION;ORAL

AMINOCAPROIC ACID

AA AJENAT PHARMS 0.25GM/ML A213825 001 Apr 08, 2021 Jan CAHN

AA APOZEAL PHARMS 0.25GM/ML A213216 001 May 19, 2025 May NEWA

>D> AA CARNEGIE 0.25GM/ML A214140 001 Jan 26, 2021 Dec CAHN

>A> AA PHARMOBEDIENT 0.25GM/ML A214140 001 Jan 26, 2021 Dec CAHN

AA REGCON HOLDINGS 0.25GM/ML A215510 001 Mar 23, 2022 Sep CAHN

AA SCIEGEN PHARMS 0.25GM/ML A213216 001 May 19, 2025 Sep CAHN

@ TARO 0.25GM/ML A214458 001 Mar 24, 2023 Aug DISC

AA ! TP ANDA HOLDINGS 0.25GM/ML A212494 001 Aug 11, 2020 Aug CAHN

TABLET;ORAL

AMINOCAPROIC ACID

AB SOMERSET THERAPS LLC 500MG A213944 001 Sep 14, 2022 Sep CAHN

AB 1GM A213944 002 Sep 14, 2022 Sep CAHN

AMINOLEVULINIC ACID HYDROCHLORIDE

GEL;TOPICAL

AMELUZ

>D> +! BIOFRONTERA 10% N208081 001 May 10, 2016 Dec CAHN

>A> +! 10% N208081 001 May 10, 2016 Dec CAHN

AMINOPHYLLINE

INJECTABLE;INJECTION

AMINOPHYLLINE

+! HOSPIRA 25MG/ML A087242 001 Oct 26, 1983 Jun CRLD

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE;ORAL

PASER

! ADAPTIS 4GM/PACKET A074346 001 Jun 30, 1994 Sep CAHN

AMIODARONE HYDROCHLORIDE

TABLET;ORAL

AMIODARONE HYDROCHLORIDE

@	TARO	300MG	A 076362	002	Dec 02, 2003	Aug	DISC
@		400MG	A 076362	001	Nov 29, 2002	Aug	DISC

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

@	BRECKENRIDGE	10MG	A 216243	001	Jun 06, 2022	Aug	DISC
@		25MG	A 216243	002	Jun 06, 2022	Aug	DISC
@		50MG	A 216243	003	Jun 06, 2022	Aug	DISC
@		75MG	A 216243	004	Jun 06, 2022	Aug	DISC
@		100MG	A 216243	005	Jun 06, 2022	Aug	DISC
@		150MG	A 216243	006	Jun 06, 2022	Aug	DISC
BX	RUBICON	10MG	A 215376	001	May 01, 2023	Mar	CTEC
BX		25MG	A 215376	002	May 01, 2023	Mar	CTEC
BX		50MG	A 215376	003	May 01, 2023	Mar	CTEC
BX		75MG	A 215376	004	May 01, 2023	Mar	CTEC
BX		100MG	A 215376	005	May 01, 2023	Mar	CTEC
BX		150MG	A 215376	006	May 01, 2023	Mar	CTEC
AB	UNIQUE PHARM	10MG	A 218389	001	Jun 23, 2025	Jun	NEWA
AB		25MG	A 218389	002	Jun 23, 2025	Jun	NEWA
AB		50MG	A 218389	003	Jun 23, 2025	Jun	NEWA
AB		75MG	A 218389	004	Jun 23, 2025	Jun	NEWA
AB		100MG	A 218389	005	Jun 23, 2025	Jun	NEWA
AB		150MG	A 218389	006	Jun 23, 2025	Jun	NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

>D>	@	ANDA REPOSITORY	EQ 25MG BASE;10MG	A 070766	001	Dec 10, 1986	Dec	CAHN
	@	MICRO LABS	EQ 12.5MG BASE;5MG	A 211925	001	Feb 02, 2022	Apr	DISC
	@		EQ 25MG BASE;10MG	A 211925	002	Feb 02, 2022	Apr	DISC
		MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A 071297	002	Dec 10, 1986	Apr	CTEC
	!		EQ 25MG BASE;10MG	A 071297	001	Dec 10, 1986	Apr	CTEC
	@	TP ANDA HOLDINGS	EQ 12.5MG BASE;5MG	A 070765	001	Dec 10, 1986	Sep	CAHN
>A>	@		EQ 25MG BASE;10MG	A 070766	001	Dec 10, 1986	Dec	CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

@	CHARTWELL RX	50MG;4MG	A 071863	001	Dec 21, 1987	Jun	CAHN
---	--------------	----------	----------	-----	--------------	-----	------

AMLODIPINE BESYLATE

FOR SOLUTION;ORAL

SDAMLO

@ +	BRILLIAN PHARMA	EQ 2.5MG BASE/BOT	N 219531	001	Jul 24, 2025	Aug	DISC
+	!	EQ 2.5MG BASE/BOT	N 219531	001	Jul 24, 2025	Jul	NEWA
@ +		EQ 5MG BASE/BOT	N 219531	002	Jul 24, 2025	Aug	DISC
+	!	EQ 5MG BASE/BOT	N 219531	002	Jul 24, 2025	Jul	NEWA
@ +		EQ 10MG BASE/BOT	N 219531	003	Jul 24, 2025	Aug	DISC
+	!	EQ 10MG BASE/BOT	N 219531	003	Jul 24, 2025	Jul	NEWA

TABLET;ORAL

AMLODIPINE BESYLATE

>D>	@	GRAVITI PHARMS	EQ 5MG BASE	A 201380	001	Apr 13, 2012	Dec	CMFD
>A>	AB		EQ 5MG BASE	A 201380	001	Apr 13, 2012	Dec	CMFD
>D>	@		EQ 10MG BASE	A 201380	002	Apr 13, 2012	Dec	CMFD
>A>	AB		EQ 10MG BASE	A 201380	002	Apr 13, 2012	Dec	CMFD
	AB	PURACAP LABS BLU	EQ 2.5MG BASE	A 207821	001	Jul 11, 2016	Nov	CAHN
	AB		EQ 5MG BASE	A 207821	002	Jul 11, 2016	Nov	CAHN
	AB		EQ 10MG BASE	A 207821	003	Jul 11, 2016	Nov	CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB	ALEMBIC	EQ 2.5MG BASE;EQ 10MG BASE	A 217279	001	May 22, 2025	May	NEWA
AB		EQ 2.5MG BASE;EQ 20MG BASE	A 217279	002	May 22, 2025	May	NEWA
AB		EQ 2.5MG BASE;EQ 40MG BASE	A 217279	003	May 22, 2025	May	NEWA
AB		EQ 5MG BASE;EQ 10MG BASE	A 217279	004	May 22, 2025	May	NEWA
AB		EQ 5MG BASE;EQ 20MG BASE	A 217279	005	May 22, 2025	May	NEWA
AB		EQ 5MG BASE;EQ 40MG BASE	A 217279	006	May 22, 2025	May	NEWA

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		EQ 5MG BASE;EQ 80MG BASE	A217279	007	May 22, 2025	May	NEWA
AB		EQ 10MG BASE;EQ 10MG BASE	A217279	008	May 22, 2025	May	NEWA
AB		EQ 10MG BASE;EQ 20MG BASE	A217279	009	May 22, 2025	May	NEWA
AB		EQ 10MG BASE;EQ 40MG BASE	A217279	010	May 22, 2025	May	NEWA
AB		EQ 10MG BASE;EQ 80MG BASE	A217279	011	May 22, 2025	May	NEWA
AB	APDM PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Feb	CAHN
AB		EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Feb	CAHN
AB		EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Feb	CAHN
AB		EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Feb	CAHN
AB		EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Feb	CAHN
AB		EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Feb	CAHN
AB		EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Feb	CAHN
AB		EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Feb	CAHN
AB		EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Feb	CAHN
AB		EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Feb	CAHN
AB		EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Feb	CAHN
AB	NEOCUBES PHARMA	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Sep	CAHN
AB		EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Sep	CAHN
AB		EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Sep	CAHN
AB		EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Sep	CAHN
AB		EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Sep	CAHN
AB		EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Sep	CAHN
AB		EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Sep	CAHN
AB		EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Sep	CAHN
AB		EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Sep	CAHN
AB		EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Sep	CAHN
AB		EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Sep	CAHN

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@	CHARTWELL RX	EQ 2.5MG BASE;10MG	A078381	001	Jul 29, 2010	Apr	CAHN
@		EQ 5MG BASE;10MG	A078381	002	Jul 29, 2010	Apr	CAHN
@		EQ 5MG BASE;20MG	A078381	003	Jul 29, 2010	Apr	CAHN
@		EQ 5MG BASE;40MG	A078381	005	Jul 29, 2010	Apr	CAHN
@		EQ 10MG BASE;20MG	A078381	004	Jul 29, 2010	Apr	CAHN
@		EQ 10MG BASE;40MG	A078381	006	Jul 29, 2010	Apr	CAHN
@	RISING	EQ 2.5MG BASE;10MG	A077375	001	May 21, 2010	Aug	CAHN
@		EQ 5MG BASE;10MG	A077375	002	May 21, 2010	Aug	CAHN
@		EQ 5MG BASE;20MG	A077375	003	May 21, 2010	Aug	CAHN
@		EQ 10MG BASE;20MG	A077375	004	May 21, 2010	Aug	CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

AB	HETERO LABS LTD V	EQ 5MG BASE;12.5MG;20MG	A209242	001	Oct 06, 2025	Sep	NEWA
AB		EQ 5MG BASE;12.5MG;40MG	A209242	002	Oct 06, 2025	Sep	NEWA
AB		EQ 5MG BASE;25MG;40MG	A209242	003	Oct 06, 2025	Sep	NEWA
AB		EQ 10MG BASE;12.5MG;40MG	A209242	004	Oct 06, 2025	Sep	NEWA
AB		EQ 10MG BASE;25MG;40MG	A209242	005	Oct 06, 2025	Sep	NEWA
AB	MACLEODS PHARMS LTD	EQ 5MG BASE;12.5MG;20MG	A207088	001	Jul 18, 2025	Jul	NEWA
AB		EQ 5MG BASE;12.5MG;40MG	A207088	002	Jul 18, 2025	Jul	NEWA
AB		EQ 5MG BASE;25MG;40MG	A207088	003	Jul 18, 2025	Jul	NEWA
AB		EQ 10MG BASE;12.5MG;40MG	A207088	004	Jul 18, 2025	Jul	NEWA
AB		EQ 10MG BASE;25MG;40MG	A207088	005	Jul 18, 2025	Jul	NEWA
AB	MICRO LABS	EQ 5MG BASE;12.5MG;20MG	A207437	001	Nov 24, 2025	Nov	NEWA
AB		EQ 5MG BASE;12.5MG;40MG	A207437	002	Nov 24, 2025	Nov	NEWA
AB		EQ 5MG BASE;25MG;40MG	A207437	003	Nov 24, 2025	Nov	NEWA
AB		EQ 10MG BASE;12.5MG;40MG	A207437	004	Nov 24, 2025	Nov	NEWA
AB		EQ 10MG BASE;25MG;40MG	A207437	005	Nov 24, 2025	Nov	NEWA
AB	PIRAMAL	EQ 5MG BASE;12.5MG;20MG	A210718	001	May 14, 2025	May	NEWA
AB		EQ 5MG BASE;12.5MG;40MG	A210718	002	May 14, 2025	May	NEWA
AB		EQ 5MG BASE;25MG;40MG	A210718	003	May 14, 2025	May	NEWA
AB		EQ 10MG BASE;12.5MG;40MG	A210718	004	May 14, 2025	May	NEWA
AB		EQ 10MG BASE;25MG;40MG	A210718	005	May 14, 2025	May	NEWA
@	TORRENT	EQ 5MG BASE;12.5MG;20MG	A203580	001	Oct 26, 2016	Jun	DISC
@		EQ 10MG BASE;12.5MG;40MG	A203580	004	Oct 26, 2016	Jun	DISC
@		EQ 10MG BASE;25MG;40MG	A203580	005	Oct 26, 2016	Jun	DISC

AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN

TABLET; ORAL

WIDAPLIK

@ +	AZURITY	EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Sep CAHN
@ +		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Sep CAHN
@ +		EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Sep CAHN
+ +	GEORGE MEDICINES	EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Jun NEWA
@ +		EQ 1.25MG BASE;0.625MG;10MG	N219423	001	Jun 05, 2025	Jun DISC
+ +		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Jun NEWA
@ +		EQ 2.5MG BASE;1.25MG;20MG	N219423	002	Jun 05, 2025	Jun DISC
+!		EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Jun NEWA
@ +		EQ 5MG BASE;2.5MG;40MG	N219423	003	Jun 05, 2025	Jun DISC

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	HETERO LABS LTD V	EQ 5MG BASE;20MG	A209591	001	Feb 14, 2025	Feb NEWA
AB		EQ 5MG BASE;40MG	A209591	002	Feb 14, 2025	Feb NEWA
AB		EQ 10MG BASE;20MG	A209591	003	Feb 14, 2025	Feb NEWA
AB		EQ 10MG BASE;40MG	A209591	004	Feb 14, 2025	Feb NEWA

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	SOFIE	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204465	001	Oct 23, 2014	Mar CAHN
----	-------	------------------------------------	---------	-----	--------------	----------

AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN

CAPSULE, DELAYED RELEASE; ORAL

TALICIA

+!	TALICIA HOLDINGS	250MG;EQ 10MG BASE;12.5MG	N213004	001	Nov 01, 2019	Nov CAHN
----	------------------	---------------------------	---------	-----	--------------	----------

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL

ADZENYS XR-ODT

AB	+ NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jul CTEC
AB	+ +	EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jul CTEC
AB	+ +	EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jul CTEC
AB	+ +	EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jul CTEC
AB	+ +	EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jul CTEC
AB	+!	EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jul CTEC

AMPHETAMINE

AB	ACTAVIS LABS FL INC	EQ 3.1MG BASE	A209253	001	Jun 22, 2023	Jul CMFD
AB		EQ 6.3MG BASE	A209253	002	Jun 22, 2023	Jul CMFD
AB		EQ 9.4MG BASE	A209253	003	Jun 22, 2023	Jul CMFD
AB		EQ 12.5MG BASE	A209253	004	Jun 22, 2023	Jul CMFD
AB		EQ 15.7MG BASE	A209253	005	Jun 22, 2023	Jul CMFD
AB		EQ 18.8MG BASE	A209253	006	Jun 22, 2023	Jul CMFD

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	CEDIPROF INC	1.25MG;1.25MG;1.25MG;1.25MG	A210754	001	Jul 05, 2022	Jan CMFD
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210754	002	Jul 05, 2022	Jan CMFD
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210754	003	Jul 05, 2022	Jan CMFD
AB		5MG;5MG;5MG;5MG	A210754	004	Jul 05, 2022	Jan CMFD
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210754	005	Jul 05, 2022	Jan CMFD
@	COREPHARMA	1.25MG;1.25MG;1.25MG;1.25MG	A206721	001	Nov 10, 2015	Nov CAHN
@		1.875MG;1.875MG;1.875MG;1.875MG	A206721	002	Nov 10, 2015	Nov CAHN
@		2.5MG;2.5MG;2.5MG;2.5MG	A206721	003	Nov 10, 2015	Nov CAHN
@		3.125MG;3.125MG;3.125MG;3.125MG	A206721	004	Nov 10, 2015	Nov CAHN
@		3.75MG;3.75MG;3.75MG;3.75MG	A206721	005	Nov 10, 2015	Nov CAHN
@		5MG;5MG;5MG;5MG	A206721	006	Nov 10, 2015	Nov CAHN
@		7.5MG;7.5MG;7.5MG;7.5MG	A206721	007	Nov 10, 2015	Nov CAHN
AB	ORYZA	1.25MG;1.25MG;1.25MG;1.25MG	A210293	001	Apr 03, 2020	Nov CAHN
AB		1.875MG;1.875MG;1.875MG;1.875MG	A210293	002	Apr 03, 2020	Nov CAHN
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210293	003	Apr 03, 2020	Nov CAHN
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210293	004	Apr 03, 2020	Nov CAHN
AB		5MG;5MG;5MG;5MG	A210293	005	Apr 03, 2020	Nov CAHN
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210293	006	Apr 03, 2020	Nov CAHN

<u>TABLET;ORAL</u>							
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE							
AB	PHARMOBEDIANT	1.25MG;1.25MG;1.25MG;1.25MG	A210293	001	Apr 03, 2020	Sep	CAHN
AB		1.875MG;1.875MG;1.875MG;1.875MG	A210293	002	Apr 03, 2020	Sep	CAHN
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210293	003	Apr 03, 2020	Sep	CAHN
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210293	004	Apr 03, 2020	Sep	CAHN
AB		5MG;5MG;5MG;5MG	A210293	005	Apr 03, 2020	Sep	CAHN
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210293	006	Apr 03, 2020	Sep	CAHN
<u>AMPHETAMINE SULFATE</u>							
TABLET;ORAL							
AMPHETAMINE SULFATE							
@	RHODES PHARMS	5MG	A213852	001	Sep 07, 2021	Jan	DISC
@		10MG	A213852	002	Sep 07, 2021	Jan	DISC
<u>AMPHOTERICIN B</u>							
INJECTABLE, LIPID COMPLEX;INJECTION							
ABELCET							
@ +	LEADIANT BIOSCI INC	5MG/ML	N050724	001	Nov 20, 1995	Aug	DISC
INJECTABLE, LIPOSOMAL;INJECTION							
AMPHOTERICIN B							
AB	AVET LIFESCIENCES	50MG/VIAL	A215354	001	Jun 02, 2025	May	NEWA
AB	MYLAN LABS LTD	50MG/VIAL	A212967	001	Jun 30, 2025	Jun	NEWA
<u>AMPICILLIN SODIUM</u>							
POWDER;INTRAVENOUS							
AMPICILLIN SODIUM							
@	SANDOZ	EQ 1GM BASE/VIAL	A062738	001	Feb 19, 1987	Oct	DISC
@		EQ 2GM BASE/VIAL	A062738	002	Feb 19, 1987	Oct	DISC
<u>AMPICILLIN SODIUM; SULBACTAM SODIUM</u>							
INJECTABLE;INJECTION							
AMPICILLIN AND SULBACTAM							
@	HIKMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002	Mar	DISC
@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002	Mar	DISC
@	SANDOZ	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065310	001	Jul 25, 2006	Oct	DISC
@		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065310	002	Jul 25, 2006	Oct	DISC
<u>ANAGRELIDE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
ANAGRELIDE HYDROCHLORIDE							
@	BARR LABS	EQ 0.5MG BASE	A076530	001	Apr 18, 2005	Mar	CAHN
@		EQ 1MG BASE	A076530	002	Apr 18, 2005	Mar	CAHN
AB	CIPLA	EQ 0.5MG BASE	A076468	001	Apr 18, 2005	Aug	CAHN
AB	!	EQ 1MG BASE	A076468	002	Apr 18, 2005	Aug	CAHN
AB	NOVITIUM PHARMA	EQ 0.5MG BASE	A076811	001	Apr 18, 2005	Sep	CMFD
AB		EQ 1MG BASE	A076811	002	Apr 18, 2005	Sep	CMFD
<u>ANASTROZOLE</u>							
TABLET;ORAL							
ANASTROZOLE							
@	PHARMOBEDIANT	1MG	A091051	001	Jun 28, 2010	Sep	CAHN
<u>ANGIOTENSIN II ACETATE</u>							
SOLUTION;INTRAVENOUS							
ANGIOTENSIN II ACETATE							
AP	GLAND	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	A216966	001	Jun 03, 2025	May	NFTG
GIAPREZA							
AP	+!	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	May	CFTG
<u>APALUTAMIDE</u>							
TABLET;ORAL							
APALUTAMIDE							
AB	ZYDUS	60MG	A217113	001	Mar 17, 2025	Mar	NFTG
ERLEADA							
AB	+ JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018	Mar	CFTG

APIXABAN

	FOR SUSPENSION;ORAL						
	ELIQUIS SPRINKLE						
	+	BRISTOL	0.15MG	N220073	001	Apr 17, 2025	Apr NEWA
	TABLET;ORAL						
	APIXABAN						
	@	HETERO LABS LTD V	2.5MG	A210066	001	Nov 21, 2023	Apr DISC
	@		5MG	A210066	002	Nov 21, 2023	Apr DISC
	@	IMPAX	2.5MG	A209810	001	Feb 14, 2025	Jul DISC
AB	@		2.5MG	A209810	001	Feb 14, 2025	Feb NEWA
	@		5MG	A209810	002	Feb 14, 2025	Jul DISC
AB	@		5MG	A209810	002	Feb 14, 2025	Feb NEWA
	@	MACLEODS PHARMS LTD	2.5MG	A210067	001	Feb 27, 2025	Jun DISC
AB	@		2.5MG	A210067	001	Feb 27, 2025	Feb NEWA
	@		5MG	A210067	002	Feb 27, 2025	Jun DISC
AB	@		5MG	A210067	002	Feb 27, 2025	Feb NEWA
	@	TORRENT	2.5MG	A210156	001	Dec 17, 2024	Jun DISC
	@		5MG	A210156	002	Dec 17, 2024	Jun DISC
	TABLET, FOR SUSPENSION;ORAL						
	ELIQUIS						
	+	BRISTOL MYERS SQUIBB	0.5MG	N202155	003	Apr 17, 2025	Apr NEWA

APOMORPHINE HYDROCHLORIDE

	SOLUTION;SUBCUTANEOUS						
	ONAPGO						
	+	MDD US	98MG/20ML (4.9MG/ML)	N214056	001	Feb 03, 2025	Feb NEWA

APREMILAST

	TABLET;ORAL						
	APREMILAST						
	@	GLENMARK PHARMS LTD	10MG	A211674	001	Oct 16, 2023	Jun DISC
	@		20MG	A211674	002	Oct 16, 2023	Jun DISC
	@		30MG	A211674	003	Oct 16, 2023	Jun DISC
	@	MACLEODS PHARMS LTD	10MG	A211788	001	Nov 25, 2024	Jun DISC
	@		20MG	A211788	002	Nov 25, 2024	Jun DISC
	@		30MG	A211788	003	Nov 25, 2024	Jun DISC
	@	TORRENT	10MG	A211834	001	Jun 20, 2025	Jul DISC
AB	@		10MG	A211834	001	Jun 20, 2025	Jun NEWA
	@		20MG	A211834	002	Jun 20, 2025	Jul DISC
AB	@		20MG	A211834	002	Jun 20, 2025	Jun NEWA
	@		30MG	A211834	003	Jun 20, 2025	Jul DISC
AB	@		30MG	A211834	003	Jun 20, 2025	Jun NEWA
	TABLET, EXTENDED RELEASE;ORAL						
	OTEZLA XR						
	+	AMGEN INC	75MG	N210745	001	Aug 29, 2025	Aug NEWA

APREPITANT

	CAPSULE;ORAL						
	EMEND						
	@ +	MSD	40MG	N021549	003	Jun 30, 2006	Aug CAHN
AB	+		80MG	N021549	001	Mar 26, 2003	Aug CAHN
AB	+		125MG	N021549	002	Mar 26, 2003	Aug CAHN

ARFORMOTEROL TARTRATE

	SOLUTION;INHALATION						
	ARFORMOTEROL TARTRATE						
AN		AUCTA	EQ 0.015MG BASE/2ML	A218380	001	Feb 03, 2025	Jan NEWA
AN	!	MANKIND PHARMA	EQ 0.015MG BASE/2ML	A216128	001	Nov 15, 2022	Oct CHRS
AN		MICRO LABS	EQ 0.015MG BASE/2ML	A218555	001	Mar 07, 2025	Feb NEWA
AN		NEOCUBES PHARMA	EQ 0.015MG BASE/2ML	A216303	001	May 17, 2024	Sep CAHN
AN		SABA ILAC SANAYI	EQ 0.015MG BASE/2ML	A218429	001	Apr 25, 2025	Apr NEWA
AN		SLATE RUN PHARMA	EQ 0.015MG BASE/2ML	A213762	001	Jun 22, 2021	Sep CAHN
	BROVANA						
	@ +	LUPIN	EQ 0.015MG BASE/2ML	N021912	001	Oct 06, 2006	Oct DISC

ARGATROBAN

	INJECTABLE;INJECTION						
	ARGATROBAN						
	@	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Jul DISC

INJECTABLE; INTRAVENOUS

ARGATROBAN IN SODIUM CHLORIDE

AP	+!	PLANO PHARMS	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	Mar	CAHN
----	----	--------------	----------------------	---------	-----	--------------	-----	------

ARIPIPIRAZOLE

FILM; ORAL

MEZOIFY

@ +	CMG PHARM CO LTD	5MG	N211448	001	Apr 15, 2025	Aug	DISC
+		5MG	N211448	001	Apr 15, 2025	Apr	NEWA
@ +		10MG	N211448	002	Apr 15, 2025	Aug	DISC
+!		10MG	N211448	002	Apr 15, 2025	Apr	NEWA
@ +		15MG	N211448	003	Apr 15, 2025	Aug	DISC
+		15MG	N211448	003	Apr 15, 2025	Apr	NEWA

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ABILIFY MAINTENA KIT

+	OTSUKA PHARM CO LTD	300MG/VIAL	N202971	001	Feb 28, 2013	Jan	CTEC
+!		400MG/VIAL	N202971	002	Feb 28, 2013	Jan	CTEC
+!		400MG	N202971	004	Sep 29, 2014	Jul	CHRS

ARIPIPIRAZOLE

@	MYLAN	300MG/VIAL	A216608	001	Dec 03, 2024	Jan	DISC
@		400MG/VIAL	A216608	002	Dec 03, 2024	Jan	DISC

SOLUTION; ORAL

ARIPIPIRAZOLE

AA		QUAGEN	1MG/ML	A215582	001	Oct 22, 2025	Oct	NEWA
AA		VISTAPHARM LLC	1MG/ML	A212870	001	Dec 26, 2019	Jan	CAHN

TABLET; ORAL

ARIPIPIRAZOLE

>D>	AB	LUPIN	2MG	A205589	001	Mar 18, 2024	Dec	DISC
>A>	@		2MG	A205589	001	Mar 18, 2024	Dec	DISC
>D>	AB		5MG	A205589	002	Mar 18, 2024	Dec	DISC
>A>	@		5MG	A205589	002	Mar 18, 2024	Dec	DISC
>D>	AB		10MG	A205589	003	Mar 18, 2024	Dec	DISC
>A>	@		10MG	A205589	003	Mar 18, 2024	Dec	DISC
>D>	AB		15MG	A205589	004	Mar 18, 2024	Dec	DISC
>A>	@		15MG	A205589	004	Mar 18, 2024	Dec	DISC
>D>	AB		20MG	A205589	005	Mar 18, 2024	Dec	DISC
>A>	@		20MG	A205589	005	Mar 18, 2024	Dec	DISC
>D>	AB		30MG	A205589	006	Mar 18, 2024	Dec	DISC
>A>	@		30MG	A205589	006	Mar 18, 2024	Dec	DISC
	@	RISING	2MG	A206240	001	Sep 19, 2018	Aug	CAHN
	@		5MG	A206240	002	Sep 19, 2018	Aug	CAHN
	@		10MG	A206240	003	Sep 19, 2018	Aug	CAHN
	@		15MG	A206240	004	Sep 19, 2018	Aug	CAHN
	@		20MG	A206240	005	Sep 19, 2018	Aug	CAHN
	@		30MG	A206240	006	Sep 19, 2018	Aug	CAHN

ARMODAFINIL

TABLET; ORAL

NUVIGIL

AB	+	NUVO PHARMS	50MG	N021875	001	Jun 15, 2007	Jan	CAHN
	@ +		100MG	N021875	002	Mar 26, 2009	Jan	CAHN
AB	+		150MG	N021875	003	Jun 15, 2007	Jan	CAHN
AB	+		200MG	N021875	005	Mar 26, 2009	Jan	CAHN
AB	+!		250MG	N021875	004	Jun 15, 2007	Jan	CAHN

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

ARSENIC TRIOXIDE

AP		MSN	1MG/ML	A217413	001	Apr 20, 2023	Sep	CAHN
AP			2MG/ML	A217413	002	Apr 20, 2023	Sep	CAHN
AP		NOVAST LABS	1MG/ML	A209315	001	Nov 15, 2018	Aug	CAHN
	@		2MG/ML	A209315	002	Jan 14, 2021	Aug	CAHN

ARTICAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYKLX

	+!	AM GENOMICS	EQ 8% BASE	N218643	001	Aug 15, 2025	Aug	NEWA
--	----	-------------	------------	---------	-----	--------------	-----	------

ASCIMINIB HYDROCHLORIDE

TABLET;ORAL  
SCEMBLIX

>D>	+!	NOVARTIS	EQ 40MG BASE	N215358	002	Oct 29, 2021	Dec	CHRS
>A>	+		EQ 40MG BASE	N215358	002	Oct 29, 2021	Dec	CHRS
>D>	+		EQ 100MG BASE	N215358	003	Apr 18, 2024	Dec	CHRS
>A>	+!		EQ 100MG BASE	N215358	003	Apr 18, 2024	Dec	CHRS

ASCORBIC ACID

SOLUTION;INTRAVENOUS  
ASCOR

AP	+!	MCGUFF	25,000MG/50ML (500MG/ML)	N209112	001	Oct 02, 2017	Aug	CFTG
AP		FRESENIUS KABI USA	25,000MG/50ML (500MG/ML)	A217131	001	Aug 07, 2025	Aug	NFTG

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL  
PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID  
@ TARO 4.7GM;100GM;1.015GM;5.9GM;2.69 1GM;7.5GM A207498 001 Jun 28, 2024 Aug DISC

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL  
BUTALBITAL, ASPIRIN AND CAFFEINE

AA		MPP PHARMA	325MG;50MG;40MG	A078149	001	Jun 13, 2007	May	CAHN
>D>								
>D>								
>D>	!	STRIDES PHARMA	325MG;50MG;40MG	A204195	001	Sep 22, 2016	Dec	DISC
>A>	@		325MG;50MG;40MG	A204195	001	Sep 22, 2016	Dec	DISC

ASPIRIN; CARISOPRODOL

TABLET;ORAL  
CARISOPRODOL AND ASPIRIN

>D>	@	CHARTWELL	325MG;200MG	A040116	001	Apr 25, 1996	Dec	CAHN
>A>	@	GENUS	325MG;200MG	A040116	001	Apr 25, 1996	Sep	CAHN
>A>	@		325MG;200MG	A040116	001	Apr 25, 1996	Dec	CAHN

ATENOLOL

TABLET;ORAL  
ATENOLOL

AB		AIPING PHARM INC	25MG	A072304	002	Jul 31, 1992	Jul	CAHN
AB			50MG	A072304	003	Jul 18, 1988	Jul	CAHN
AB			100MG	A072304	001	Jul 15, 1988	Jul	CAHN
	@	NOVITIUM PHARMA	100MG	A073543	001	Dec 19, 1991	Aug	CAHN
AB		PHARMOBEDIENT	25MG	A073026	002	May 01, 1992	Sep	CAHN
AB			50MG	A073026	003	Sep 17, 1991	Sep	CAHN
AB			100MG	A073026	001	Sep 17, 1991	Sep	CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL  
ATENOLOL AND CHLORTHALIDONE

AB		AIPING PHARM INC	50MG;25MG	A072302	002	May 31, 1990	Jul	CAHN
AB			100MG;25MG	A072302	001	May 31, 1990	Jul	CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL  
ATOMOXETINE HYDROCHLORIDE

AB	!	HETERO LABS LTD V	EQ 60MG BASE	A202682	005	Mar 11, 2021	Aug	CHRS
		STRATTERA						
	@ +	LILLY	EQ 10MG BASE	N021411	002	Nov 26, 2002	Aug	DISC
	@ +		EQ 18MG BASE	N021411	003	Nov 26, 2002	Aug	DISC
	@ +		EQ 25MG BASE	N021411	004	Nov 26, 2002	Aug	DISC
	@ +		EQ 40MG BASE	N021411	005	Nov 26, 2002	Aug	DISC
	@ +		EQ 60MG BASE	N021411	006	Nov 26, 2002	Aug	DISC
	@ +		EQ 80MG BASE	N021411	007	Feb 14, 2005	Aug	DISC
	@ +		EQ 100MG BASE	N021411	008	Feb 14, 2005	Aug	DISC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB		APOTEX	EQ 10MG BASE	A214969	001	Sep 02, 2021	Jun	CAHN
AB			EQ 20MG BASE	A214969	002	Sep 02, 2021	Jun	CAHN
AB			EQ 40MG BASE	A214969	003	Sep 02, 2021	Jun	CAHN
AB			EQ 80MG BASE	A214969	004	Sep 02, 2021	Jun	CAHN
	@	SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Mar	DISC
	@		EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr	DISC
	@		EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr	DISC
	@		EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr	DISC
AB		TEVA PHARMS INC	EQ 10MG BASE	A220276	001	Nov 13, 2025	Oct	NEWA
AB			EQ 20MG BASE	A220276	002	Nov 13, 2025	Oct	NEWA
AB			EQ 40MG BASE	A220276	003	Nov 13, 2025	Oct	NEWA
AB			EQ 80MG BASE	A220276	004	Nov 13, 2025	Oct	NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LYPQOZET

NORVIUM BIOSCIENCE

EQ 10MG BASE;10MG  
EQ 20MG BASE;10MG  
EQ 40MG BASE;10MG  
EQ 80MG BASE;10MG

A206084 001 Apr 26, 2017 Aug CAHN  
A206084 002 Apr 26, 2017 Aug CAHN  
A206084 003 Apr 26, 2017 Aug CAHN  
A206084 004 Apr 26, 2017 Aug CAHN

ATOVAQUONE

SUSPENSION; ORAL

ATOVAQUONE

	@	APOTEX	750MG/5ML	A209750	001	Oct 11, 2017	Mar	DISC
>D>	AB	LUPIN LTD	750MG/5ML	A209105	001	Sep 11, 2018	Dec	DISC
>A>	@		750MG/5ML	A209105	001	Sep 11, 2018	Dec	DISC
AB		PAI HOLDINGS	750MG/5ML	A214272	001	Oct 25, 2021	Jun	CAHN

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

@ EUGIA PHARMA 10MG/ML  
ATRACURIUM BESYLATE PRESERVATIVE FREE  
@ EUGIA PHARMA 10MG/ML

A206011 001 Apr 08, 2015 Jul DISC  
A206010 001 Apr 08, 2015 Jul DISC

ATRASENTAN HYDROCHLORIDE

TABLET; ORAL

VANRAFIA

+! NOVARTIS EQ 0.75MG BASE

N219208 001 Apr 02, 2025 Apr NEWA

ATROPINE SULFATE

SOLUTION; INTRAVENOUS

ATROPINE SULFATE

	@ +	ACCORD HLTHCARE	0.4MG/ML (0.4MG/ML)	N214652	001	Sep 29, 2020	Oct	DISC
AP	+		1MG/ML (1MG/ML)	N214652	002	Sep 29, 2020	Sep	CHRS
AP	!	AM REGENT	0.4MG/ML (0.4MG/ML)	A216120	001	May 26, 2022	Oct	CHRS
AP	!		1MG/ML (1MG/ML)	A216120	002	May 26, 2022	Sep	CHRS
AP		HIKMA	0.4MG/ML (0.4MG/ML)	A217345	001	Oct 24, 2025	Oct	NEWA
AP			1MG/ML (1MG/ML)	A217345	002	Oct 24, 2025	Oct	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

+! HIKMA 0.025MG/5ML; 2.5MG/5ML

A087708 001 May 03, 1982 Jul CRLD

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA		ANI PHARMS	0.025MG; 2.5MG	A086727	001		Sep	CMFD
----	--	------------	----------------	---------	-----	--	-----	------

AVANAFIL

TABLET; ORAL

STENDRA

AB	+	VIVUS LLC	50MG	N202276	001	Apr 27, 2012	Jul	CAHN
AB	+		100MG	N202276	002	Apr 27, 2012	Jul	CAHN
AB	+!		200MG	N202276	003	Apr 27, 2012	Jul	CAHN

AVATROMBOPAG MALEATE

GRANULE;ORAL  
DOPTELET SPRINKLE  
+! AKARX INC

EQ 10MG BASE

N219696 001 Jul 24, 2025 Jul NEWA

AVIBACTAM SODIUM; AZTREONAM

POWDER;INTRAVENOUS  
EMBLAVEO  
+! ABBVIE

EQ 0.5GM BASE/VIAL;1.5GM/VIAL

N217906 001 Feb 07, 2025 Feb NEWA

AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE

CAPSULE, TABLET;ORAL  
AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)  
+! VERASTEM INC

EQ 0.8MG BASE;EQ 200MG BASE

N219616 001 May 08, 2025 May NEWA

AXITINIB

TABLET;ORAL  
AXITINIB

AB APOTEX  
AB

1MG  
5MG

A211650 001 Oct 30, 2025 Oct NFTG  
A211650 002 Oct 30, 2025 Oct NFTG

INLYTA  
AB + PF PRISM CV  
AB +!

1MG  
5MG

N202324 001 Jan 27, 2012 Oct CFTG  
N202324 002 Jan 27, 2012 Oct CFTG

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS  
AZACITIDINE

>D> @ NORVIUM BIOSCIENCE  
>A> @ PHARMOBEDIENT  
AP RELIANCE LIFE

100MG/VIAL  
100MG/VIAL  
100MG/VIAL

A204949 001 Apr 28, 2016 Dec CAHN  
A204949 001 Apr 28, 2016 Dec CAHN  
A217453 001 May 20, 2025 May NEWA

AZELAIC ACID

AEROSOL, FOAM;TOPICAL  
AZELAIC ACID

>A> @ AUROBINDO PHARMA USA  
>D> @ TEVA PHARMS USA

15%  
15%

A210928 001 Oct 07, 2020 Dec CAHN  
A210928 001 Oct 07, 2020 Dec CAHN

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
OPTIVAR

@ + RISING

0.05%

N021127 001 May 22, 2000 Sep CAHN

SPRAY, METERED;NASAL

ASTELIN  
@ + RISING  
ASTEPRO

0.137MG/SPRAY  
0.137MG/SPRAY  
0.2055MG/SPRAY  
0.137MG/SPRAY  
0.2055MG/SPRAY

N020114 001 Nov 01, 1996 Sep CAHN  
N022203 001 Oct 15, 2008 Jan CAHN  
N022203 002 Aug 31, 2009 Jan CAHN  
N022203 001 Oct 15, 2008 Apr CAHN  
N022203 002 Aug 31, 2009 Apr CAHN

AZELASTINE HYDROCHLORIDE

@ BIONPHARMA  
@ PADAGIS US

0.137MG/SPRAY  
0.137MG/SPRAY  
0.137MG/SPRAY

A090176 001 Jul 28, 2015 Jan DISC  
A202609 001 Mar 17, 2017 Aug DISC  
A202609 001 Mar 17, 2017 Jun CAHN

AB

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL  
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB TEVA PHARMS USA INC

0.137MG/SPRAY;0.05MG/SPRAY

A208436 001 Apr 08, 2025 Mar NEWA

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL  
AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE

AB ALKEM LABS LTD  
AB

EQ 40MG MEDOXOMIL;12.5MG  
EQ 40MG MEDOXOMIL;25MG

A217490 001 Jan 21, 2025 Jan NFTG  
A217490 002 Jan 21, 2025 Jan NFTG

EDARBYCLOR  
AB + AZURITY  
AB +!

EQ 40MG MEDOXOMIL;12.5MG  
EQ 40MG MEDOXOMIL;25MG

N202331 001 Dec 20, 2011 Jan CFTG  
N202331 002 Dec 20, 2011 Jan CFTG

AZITHROMYCIN

FOR SUSPENSION; ORAL		AZITHROMYCIN							
	@	AMNEAL	EQ 100MG BASE/5ML	A205666	001	Jul 19, 2018	Sep	DISC	
	@		EQ 200MG BASE/5ML	A205666	002	Jul 19, 2018	Sep	DISC	
AB		CHARTWELL RX	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	Feb	CMFD	
AB			EQ 200MG BASE/5ML	A065488	002	May 15, 2015	Feb	CMFD	
AB		ZHEJIANG POLY PHARM	EQ 100MG BASE/5ML	A217036	001	Jul 27, 2023	Mar	CAHN	
AB			EQ 200MG BASE/5ML	A217036	002	Jul 27, 2023	Mar	CAHN	
ZITHROMAX									
	@ +	PFIZER	EQ 1GM BASE/PACKET	N050693	001	Sep 28, 1994	Apr	DISC	
INJECTABLE; INJECTION		AZITHROMYCIN							
	@	HOSPIRA	EQ 500MG BASE/VIAL	A065511	001	Jun 26, 2009	Apr	DISC	

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC		LUMI-SPORYN							
AT	+	CASPER PHARMA LLC	400 UNITS/GM; EQ 3.5MG BASE/GM; 10,000 UNITS/GM	N050417	001		Feb	CPOT	

BACLOFEN

GRANULES; ORAL		LYVISPAH							
	@ +	AMNEAL	5MG/PACKET	N215422	001	Nov 22, 2021	Jun	DISC	
	@ +		10MG/PACKET	N215422	002	Nov 22, 2021	Jun	DISC	
	@ +		20MG/PACKET	N215422	003	Nov 22, 2021	Jun	DISC	
SOLUTION; ORAL		BACLOFEN							
AA		RUBICON RESEARCH	5MG/5ML	A214445	001	Dec 06, 2024	May	CAHN	
			10MG/5ML	A214445	002	Jun 03, 2025	May	NFTG	
AA	+	METACEL PHARMS LLC	10MG/5ML	N208193	002	Oct 12, 2023	May	CFTG	
TABLET; ORAL		BACLOFEN							
AB		APPCO	5MG	A090334	003	Jan 31, 2025	Jan	NEWA	
AB		AUROBINDO PHARMA LTD	5MG	A214099	003	Nov 21, 2025	Nov	NEWA	
AB	!	RUBICON RESEARCH	5MG	A209102	001	Nov 28, 2017	Jul	CAHN	
AB			10MG	A209102	002	Nov 28, 2017	Jul	CAHN	
AB			15MG	A209102	004	Feb 05, 2024	Jul	CAHN	
AB			20MG	A209102	003	Nov 28, 2017	Jul	CAHN	
AB		YILING	10MG	A074584	001	Aug 19, 1996	Jun	CAHN	
AB			20MG	A074584	002	Aug 19, 1996	Jun	CAHN	

BALOXAVIR MARBOXIL

FOR SUSPENSION; ORAL		XOFLUZA							
	+	GENENTECH INC	30MG/PACKET	N214410	002	May 30, 2025	Jun	NEWA	
	+		40MG/PACKET	N214410	003	May 30, 2025	Jun	NEWA	

BALSALAZIDE DISODIUM

CAPSULE; ORAL		BALSALAZIDE DISODIUM							
AB		CARNEGIE	750MG	A219422	001	Apr 03, 2025	Mar	NEWA	
AB		NOVITIUM PHARMA	750MG	A077807	001	Dec 28, 2007	Oct	CMFD	
TABLET; ORAL		BALSALAZIDE DISODIUM							
	@	AARXION ANDA HLDING	1.1GM	A206336	001	Sep 08, 2015	Aug	CAHN	

BARICITINIB

TABLET; ORAL		OLUMIANT							
AB	+	ELI LILLY AND CO	1MG	N207924	002	Oct 08, 2019	Aug	CTEC	
AB	+		2MG	N207924	001	May 31, 2018	Aug	CTEC	
AB	+		4MG	N207924	003	May 10, 2022	Aug	CFTG	
AB		MSN	1MG	A217585	001	Aug 08, 2025	Aug	NEWA	
AB			2MG	A217585	002	Aug 08, 2025	Aug	NEWA	
AB			4MG	A217585	003	Aug 08, 2025	Aug	NFTG	

BARIUM SULFATE

FOR SUSPENSION; ORAL

E-Z-CAT DRY

@ + BRACCO 40% N208036 003 Jan 03, 2017 Aug CPOT

E-Z-HD

+! BRACCO 98% N208036 001 Jan 11, 2016 Aug CPOT

E-Z-PAQUE

+! BRACCO 96% N208036 002 Apr 07, 2017 Aug CPOT

VARIBAR THIN LIQUID

+! BRACCO 81% N208036 004 Apr 30, 2019 Aug CPOT

SUSPENSION; ORAL

ENTERO VU 24%

+! BRACCO 24% N208143 008 May 29, 2020 Aug CPOT

LIQUID E-Z-PAQUE

+! BRACCO 60% N208143 003 Mar 01, 2017 Aug CPOT

READI-CAT 2

+! BRACCO 2% N208143 001 Jan 15, 2016 Aug CPOT

READI-CAT 2 SMOOTHIE

+! BRACCO 2% N208143 002 Jan 15, 2016 Aug CPOT

TAGITOL V

+! BRACCO 40% N208143 005 Aug 04, 2017 Aug CPOT

VARIBAR HONEY

+! BRACCO 40% N208143 007 Mar 26, 2018 Aug CPOT

VARIBAR NECTAR

+! BRACCO 40% N208143 004 Jul 07, 2017 Aug CPOT

VARIBAR THIN HONEY

+! BRACCO 40% N208143 006 Jan 23, 2018 Aug CPOT

TABLET; ORAL

E-Z-DISK

+! BRACCO 700MG N219840 001 Aug 01, 2025 Aug NEWA

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

&gt;A&gt; BECLOMETHASONE DIPROPIONATE

&gt;A&gt; ! AMNEAL IRELAND LTD 0.04MG/INH A213811 001 Dec 16, 2025 Dec NFTG

&gt;A&gt; ! 0.08MG/INH A213811 002 Dec 16, 2025 Dec NFTG

QVAR 40

@ + TEVA BRANDED PHARM 0.04MG/INH N020911 002 Sep 15, 2000 Mar CAHN

QVAR 80

@ + TEVA BRANDED PHARM 0.08MG/INH N020911 001 Sep 15, 2000 Mar CAHN

QVAR REDIHALER

&gt;D&gt; + NORTON WATERFORD 0.04MG/INH N207921 001 Aug 03, 2017 Dec CHRS

&gt;A&gt; +! 0.04MG/INH N207921 001 Aug 03, 2017 Dec CHRS

&gt;D&gt; + 0.08MG/INH N207921 002 Aug 03, 2017 Dec CHRS

&gt;A&gt; +! 0.08MG/INH N207921 002 Aug 03, 2017 Dec CHRS

AEROSOL, METERED; NASAL

QNASL

+ TEVA BRANDED PHARM 0.04MG/ACTUATION N202813 002 Dec 17, 2014 Feb CAHN

+! 0.08MG/ACTUATION N202813 001 Mar 23, 2012 Feb CAHN

BENDAMUSTINE HYDROCHLORIDE

POWDER; INTRAVENOUS

BENDAMUSTINE HYDROCHLORIDE

@ APOTEX 25MG/VIAL A204230 001 Jun 05, 2023 May DISC

@ 100MG/VIAL A204230 002 Jun 05, 2023 May DISC

SOLUTION; INTRAVENOUS

BENDAMUSTINE HYDROCHLORIDE

@ + DR REDDYS 100MG/4ML (25MG/ML) N219014 001 Jul 03, 2025 Jul DISC

+! 100MG/4ML (25MG/ML) N219014 001 Jul 03, 2025 Jul NEWA

BENZOYL PEROXIDE

CREAM; TOPICAL

EPSOLAY

+! MAYNE PHARMA 5% N214510 001 Apr 22, 2022 May CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL  
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE  
 AB ENCUBE 5%;EQ 1% BASE A204087 001 Jun 27, 2017 Oct CMFD

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL  
 AKTIPAK  
 >D> @ + BIOFRONTERA 5%;3% N050769 001 Nov 27, 2000 Dec CAHN  
 >A> @ + 5%;3% N050769 001 Nov 27, 2000 Dec CAHN

BENZOYL PEROXIDE; TRETINOIN

CREAM;TOPICAL  
 TWYNEO  
 +! MAYNE PHARMA 3%;0.1% N214902 001 Jul 26, 2021 May CAHN

BENZTROPINE MESYLATE

TABLET;ORAL  
 BENZTROPINE MESYLATE  
 AA QUAGEN 0.5MG A212694 001 Feb 11, 2025 Jan NEWA  
 AA 1MG A212694 002 Feb 11, 2025 Jan NEWA  
 AA 2MG A212694 003 Feb 11, 2025 Jan NEWA

>A> BEROTRALSTAT DIHYDROCHLORIDE

>A> CAPSULE;ORAL  
 >A> ORLADEYO  
 >A> + BIOCRYST EQ 110MG BASE N214094 001 Dec 03, 2020 Dec CAIN  
 >A> +! EQ 150MG BASE N214094 002 Dec 03, 2020 Dec CAIN  
 >A> PELLETS;ORAL  
 >A> ORLADEYO  
 >A> + BIOCRYST EQ 72MG BASE/PACKET N219776 001 Dec 11, 2025 Dec NEWA  
 >A> + EQ 96MG BASE/PACKET N219776 002 Dec 11, 2025 Dec NEWA  
 >A> + EQ 108MG BASE/PACKET N219776 003 Dec 11, 2025 Dec NEWA  
 >A> +! EQ 132MG BASE/PACKET N219776 004 Dec 11, 2025 Dec NEWA

>D> BEROTRALSTAT HYDROCHLORIDE

>D> CAPSULE;ORAL  
 >D> ORLADEYO  
 >D> + BIOCRYST EQ 110MG BASE N214094 001 Dec 03, 2020 Dec CAIN  
 >D> +! EQ 150MG BASE N214094 002 Dec 03, 2020 Dec CAIN

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED;TOPICAL  
 BETAMETHASONE DIPROPIONATE  
 @ CHARTWELL MOLECULAR EQ 0.05% BASE A076603 001 Jan 23, 2004 Feb CAHN  
 @ GLENMARK PHARMS INC EQ 0.05% BASE A078930 001 Sep 23, 2008 Jul DISC  
 AB ! TARO EQ 0.05% BASE A076543 001 Dec 09, 2003 Jul CHRS  
 LOTION, AUGMENTED;TOPICAL  
 BETAMETHASONE DIPROPIONATE  
 >D> @ ENCUBE EQ 0.05% BASE A206389 001 Feb 13, 2018 Dec CMFD  
 >A> AB EQ 0.05% BASE A206389 001 Feb 13, 2018 Dec CMFD  
 OINTMENT;TOPICAL  
 BETAMETHASONE DIPROPIONATE  
 @ TARO EQ 0.05% BASE A074271 001 Sep 15, 1994 Jul DISC  
 OINTMENT, AUGMENTED;TOPICAL  
 BETAMETHASONE DIPROPIONATE  
 @ TARO EQ 0.05% BASE A076753 001 Oct 12, 2004 Aug DISC

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

SUSPENSION;TOPICAL  
 CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE  
 @ PADAGIS ISRAEL 0.064%;0.005% A212367 001 Sep 11, 2020 Jan DISC

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL  
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE  
 @ GLENMARK SPECLT EQ 0.05% BASE;1% A202894 001 Oct 30, 2015 Aug DISC

BETAMETHASONE VALERATE

LOTION;TOPICAL

BETAMETHASONE VALERATE

AB	KANCHAN HLTHCARE	EQ 0.1% BASE	A 070052	001	Jul 31, 1985	Aug	CAHN
AB	SENORES PHARMS	EQ 0.1% BASE	A 070052	001	Jul 31, 1985	Oct	CAHN

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT	CHARTWELL RX	EQ 0.5% BASE	A 078694	001	Nov 16, 2009	Aug	CAHN
	@ PHARMOBEDIANT	EQ 0.5% BASE	A 075386	001	Jun 30, 2000	Sep	CAHN
	@ RENOVA PHARMS	EQ 0.5% BASE	A 075386	001	Jun 30, 2000	Jun	CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

AA	HERITAGE PHARMA	5MG	A 091256	001	May 04, 2010	Jul	CMFD
AA		10MG	A 091256	002	May 04, 2010	Jul	CMFD
AA		25MG	A 091256	003	May 04, 2010	Jul	CMFD
AA		50MG	A 091256	004	May 04, 2010	Jul	CMFD

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

	@ CIPLA	75MG	A 210352	001	Dec 10, 2024	Jan	DISC
AB	+! BAUSCH	75MG	N 021055	001	Dec 29, 1999	Nov	CAHN

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

	@ APOTEX	50MG	A 200274	001	May 21, 2015	Mar	DISC
--	----------	------	----------	-----	--------------	-----	------

BIMATOPROST

GEL;OPHTHALMIC

ZOLYMBUS

	+! THEA PHARMA	0.01%	N 217307	001	Sep 09, 2025	Sep	NEWA
--	----------------	-------	----------	-----	--------------	-----	------

SOLUTION/DROPS;OPHTHALMIC

BIMATOPROST

AB	AMNEAL	0.01%	A 217289	001	Sep 22, 2025	Sep	NEWA
>D>	AT LUPIN LTD	0.03%	A 203991	001	Feb 20, 2015	Dec	DISC
>A>	@	0.03%	A 203991	001	Feb 20, 2015	Dec	DISC
AB	MANKIND PHARMA	0.01%	A 218196	001	Mar 17, 2025	Mar	NFTG
	LUMIGAN						
AB	+! ABBVIE	0.01%	N 022184	001	Aug 31, 2010	Mar	CFTG

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

	RUBICON	2.5MG	A 075643	003	Mar 07, 2025	Mar	NEWA
AB	TP ANDA HOLDINGS	5MG	A 075474	001	Oct 25, 2002	Aug	CAHN
AB		10MG	A 075474	002	Oct 25, 2002	Aug	CAHN
AB	UNIQUE PHARM	5MG	A 219044	001	Apr 16, 2025	Apr	NEWA
AB		10MG	A 219044	002	Apr 16, 2025	Apr	NEWA
	ZEBETA						
	@ + TEVA BRANDED PHARM	5MG	N 019982	002	Jul 31, 1992	Apr	CAHN
	@ +	10MG	N 019982	001	Jul 31, 1992	Apr	CAHN

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ZIAC

AB	+ TEVA BRANDED PHARM	2.5MG;6.25MG	N 020186	003	Mar 26, 1993	Apr	CAHN
AB	+	5MG;6.25MG	N 020186	001	Mar 26, 1993	Apr	CAHN
AB	+!	10MG;6.25MG	N 020186	002	Mar 26, 1993	Apr	CAHN

BIVALIRUDIN

INJECTABLE; INTRAVENOUS  
BIVALIRUDIN

@	EUGIA PHARMA	250MG/VIAL	A205962	001	Jul 27, 2018	Oct	DISC
---	--------------	------------	---------	-----	--------------	-----	------

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS  
BORTEZOMIB

@	BAXTER HLTHCARE CORP	3.5MG/VIAL	A213823	001	May 02, 2022	May	DISC
AP	MEDICAMEN BIOTECH	3.5MG/VIAL	A218688	001	Jun 02, 2025	May	NEWA
>A>	AP SHUANGCHENG	3.5MG/VIAL	A216528	001	Dec 17, 2025	Dec	NEWA
AP	VILIN BIO MED	3.5MG/VIAL	A218688	001	Jun 02, 2025	Aug	CAHN

POWDER; INTRAVENOUS, SUBCUTANEOUS

>A> BORTEZOMIB

>A>	AP	GLAND	1MG/VIAL	A219167	001	Jan 06, 2026	Dec	NFTG
>A>	AP		2.5MG/VIAL	A219167	002	Jan 06, 2026	Dec	NFTG
>D>	+	HOSPIRA	1MG/VIAL	N209191	001	May 02, 2022	Dec	CFTG
>A>	AP	+	1MG/VIAL	N209191	001	May 02, 2022	Dec	CFTG
>D>	+		2.5MG/VIAL	N209191	002	May 02, 2022	Dec	CFTG
>A>	AP	+	2.5MG/VIAL	N209191	002	May 02, 2022	Dec	CFTG

BOSENTAN

TABLET, FOR SUSPENSION; ORAL  
BOSENTAN

AB	NATCO PHARMA LTD	32MG	A213154	001	Feb 05, 2025	Jan	NFTG	
AB	TRACLEER							
AB	+	ACTELION	32MG	N209279	001	Sep 05, 2017	Jan	CFTG

BOSUTINIB MONOHYDRATE

TABLET; ORAL  
BOSULIF

AB	+	PF PRISM CV	EQ 100MG BASE	N203341	001	Sep 04, 2012	May	CFTG
AB	+		EQ 500MG BASE	N203341	002	Sep 04, 2012	May	CFTG
AB		BOSUTINIB MONOHYDRATE						
AB		ALEMBIC	EQ 100MG BASE	A209543	001	May 23, 2025	May	NFTG
AB			EQ 500MG BASE	A209543	002	May 23, 2025	May	NFTG

BRENSOCATIB

TABLET; ORAL  
BRINSUPRI

+	INSMED INC	10MG	N217673	001	Aug 12, 2025	Aug	NEWA
+		25MG	N217673	002	Aug 12, 2025	Aug	NEWA

BREXANOLONE

SOLUTION; INTRAVENOUS  
ZULRESSO

@ +	SAGE THERAP	100MG/20ML (5MG/ML)	N211371	001	Jun 17, 2019	Jan	DISC
-----	-------------	---------------------	---------	-----	--------------	-----	------

BREXPIRAZOLE

TABLET; ORAL  
BREXPIRAZOLE

AB		ALEMBIC	0.25MG	A213683	001	Jan 13, 2025	Jan	NEWA
AB			0.5MG	A213683	002	Jan 13, 2025	Jan	NEWA
AB			1MG	A213683	003	Jan 13, 2025	Jan	NEWA
AB			2MG	A213683	004	Jan 13, 2025	Jan	NEWA
AB			3MG	A213683	005	Jan 13, 2025	Jan	NEWA
AB			4MG	A213683	006	Jan 13, 2025	Jan	NEWA
AB	@	APOTEX	0.25MG	A213731	001	Feb 24, 2025	Mar	DISC
AB			0.25MG	A213731	001	Feb 24, 2025	Feb	NEWA
AB	@		0.5MG	A213731	002	Feb 24, 2025	Mar	DISC
AB			0.5MG	A213731	002	Feb 24, 2025	Feb	NEWA
AB	@		1MG	A213731	003	Feb 24, 2025	Mar	DISC
AB			1MG	A213731	003	Feb 24, 2025	Feb	NEWA
AB	@		2MG	A213731	004	Feb 24, 2025	Mar	DISC
AB			2MG	A213731	004	Feb 24, 2025	Feb	NEWA
AB	@		3MG	A213731	005	Feb 24, 2025	Mar	DISC
AB			3MG	A213731	005	Feb 24, 2025	Feb	NEWA
AB	@	CHARTWELL RX	0.25MG	A213758	001	Oct 25, 2023	Sep	CAHN
AB	@		0.5MG	A213758	002	Oct 25, 2023	Sep	CAHN
AB	@		1MG	A213758	003	Oct 25, 2023	Sep	CAHN
AB	@		2MG	A213758	004	Oct 25, 2023	Sep	CAHN

**TABLET;ORAL**

		BREXPIPIRAZOLE							
	@		3MG	A213758	005	Oct 25, 2023	Sep	CAHN	
	@		4MG	A213758	006	Oct 25, 2023	Sep	CAHN	
		REXULTI							
AB	+	OTSUKA	0.25MG	N205422	001	Jul 10, 2015	Jan	CTEC	
AB	+		0.5MG	N205422	002	Jul 10, 2015	Jan	CTEC	
AB	+		1MG	N205422	003	Jul 10, 2015	Jan	CTEC	
AB	+		2MG	N205422	004	Jul 10, 2015	Jan	CTEC	
AB	+		3MG	N205422	005	Jul 10, 2015	Jan	CTEC	
AB	+		4MG	N205422	006	Jul 10, 2015	Jan	CTEC	

**BRIMONIDINE TARTRATE**

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

>D>	AB	UPSHER SMITH LABS	0.1%	A217599	001	Jul 30, 2025	Dec	DISC	
>A>		@	0.1%	A217599	001	Jul 30, 2025	Dec	DISC	
	AB		0.1%	A217599	001	Jul 30, 2025	Jul	NEWA	

**BRIMONIDINE TARTRATE; TIMOLOL MALEATE**

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

	@	AMNEAL	0.2%;EQ 0.5% BASE	A217288	001	Dec 30, 2024	Jan	DISC	
AB		CAPLIN	0.2%;EQ 0.5% BASE	A219093	001	Feb 25, 2025	Feb	NEWA	
AB		REGCON HOLDINGS	0.2%;EQ 0.5% BASE	A201949	001	Oct 04, 2022	Sep	CAHN	

**BRINZOLAMIDE**

SUSPENSION/DROPS;OPHTHALMIC

BRINZOLAMIDE

	@	PADAGIS US	1%	A211914	001	Jul 28, 2023	Jul	DISC	
--	---	------------	----	---------	-----	--------------	-----	------	--

**BRIVARACETAM**

TABLET;ORAL

BRIVARACETAM

AB		MSN	10MG	A214921	001	Nov 13, 2025	Nov	NEWA	
AB			25MG	A214921	002	Nov 13, 2025	Nov	NEWA	
AB			50MG	A214921	003	Nov 13, 2025	Nov	NEWA	
AB			75MG	A214921	004	Nov 13, 2025	Nov	NEWA	
AB			100MG	A214921	005	Nov 13, 2025	Nov	NEWA	

BRIVIACT

AB	+	UCB INC	10MG	N205836	001	May 12, 2016	Nov	CTEC	
AB	+		25MG	N205836	002	May 12, 2016	Nov	CTEC	
AB	+		50MG	N205836	003	May 12, 2016	Nov	CTEC	
AB	+		75MG	N205836	004	May 12, 2016	Nov	CTEC	
AB	+		100MG	N205836	005	May 12, 2016	Nov	CTEC	

**BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE**

SYRUP;ORAL

BROMFED-DM

AA	+	XTTRIUM LABS INC	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985	Feb	CAHN	
									BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE
AA		BIONPHARMA	2MG/5ML;10MG/5ML;30MG/5ML	A203997	001	Sep 30, 2020	May	CMFD	
AA		HIBROW HLHCARE	2MG/5ML;10MG/5ML;30MG/5ML	A211170	001	Jun 16, 2020	Sep	CAHN	
	@	TARO	2MG/5ML;10MG/5ML;30MG/5ML	A205112	001	Feb 27, 2017	Aug	DISC	

**BUDESONIDE**

POWDER, METERED; INHALATION

PULMICORT FLEXHALER

>D>		+	CHEPLAPHARM	0.08MG/INH	N021949	001	Jul 12, 2006	Dec	CHRS
>A>			+	0.08MG/INH	N021949	001	Jul 12, 2006	Dec	CHRS

SUSPENSION; INHALATION

BUDESONIDE

AN		EUGIA PHARMA	0.5MG/2ML	A216667	001	Nov 29, 2023	Aug	CMFD	
	@	SANDOZ	0.25MG/2ML	A201966	003	Sep 27, 2013	Feb	DISC	
	@		0.5MG/2ML	A201966	002	Sep 27, 2013	Feb	DISC	
	@		1MG/2ML	A201966	001	Sep 27, 2013	Feb	DISC	

BUMETANIDE

INJECTABLE; INJECTION		BUMETANIDE					
AP	ASPIRO	0.25MG/ML	A218746	001	Feb 27, 2025	Feb	NEWA
SPRAY; NASAL		ENBUMYST					
	+! CORSTASIS THERAP	0.5MG/SPRAY	N219500	001	Sep 12, 2025	Sep	NEWA
TABLET; ORAL		BUMETANIDE					
AB	JUBILANT GENERICS	0.5MG	A212470	001	Aug 05, 2025	Jul	NEWA
AB		1MG	A212470	002	Aug 05, 2025	Jul	NEWA
AB		2MG	A212470	003	Aug 05, 2025	Jul	NEWA
AB	MANKIND PHARMA	0.5MG	A219291	001	Apr 03, 2025	Mar	NEWA
AB		1MG	A219291	002	Apr 03, 2025	Mar	NEWA
AB		2MG	A219291	003	Apr 03, 2025	Mar	NEWA

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION		BUPIVACAINE LIPOSOME					
@	HENGRUI PHARMA	133MG/10ML (13.3MG/ML)	A214348	001	Jul 01, 2024	Aug	DISC
@		266MG/20ML (13.3MG/ML)	A214348	002	Jul 01, 2024	Aug	DISC
EXPAREL							
	+! PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496	001	Oct 28, 2011	Aug	CTEC
	+!	266MG/20ML (13.3MG/ML)	N022496	002	Oct 28, 2011	Aug	CTEC

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL		BUPRENORPHINE					
AB	STRIDES PHARMA INTL	5MCG/HR	A207490	001	May 17, 2022	Sep	CAHN
@		7.5MCG/HR	A207490	005	Mar 21, 2023	Sep	CAHN
AB		10MCG/HR	A207490	002	May 17, 2022	Sep	CAHN
AB		15MCG/HR	A207490	003	May 17, 2022	Sep	CAHN
AB		20MCG/HR	A207490	004	May 17, 2022	Sep	CAHN

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION		BUPRENORPHINE HYDROCHLORIDE						
AP	SOMERSET THERAPS LLC	EQ 0.3MG BASE/ML	A219302	001	Jan 30, 2025	Jan	NEWA	
TABLET; SUBLINGUAL		BUPRENORPHINE HYDROCHLORIDE						
>A>	AB	ASCENT PHARMS INC	EQ 2MG BASE	A219401	001	Dec 18, 2025	Dec	NEWA
>A>	AB		EQ 8MG BASE	A219401	002	Dec 18, 2025	Dec	NEWA
AB		ETHYPHARM	EQ 2MG BASE	A090622	001	Sep 24, 2010	Nov	CAHN
AB			EQ 8MG BASE	A090622	002	Sep 24, 2010	Nov	CAHN
@		PHARMOBEDIENT	EQ 2MG BASE	A201066	001	Mar 06, 2015	Jun	CAHN
@			EQ 8MG BASE	A201066	002	Mar 06, 2015	Jun	CAHN
AB		SPECGX LLC	EQ 2MG BASE	A218473	001	Dec 10, 2025	Nov	NEWA
AB			EQ 8MG BASE	A218473	002	Dec 10, 2025	Nov	NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL		BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE						
AB		DIFGEN PHARMS	EQ 2MG BASE; EQ 0.5MG BASE	A212756	003	Feb 13, 2025	Feb	NEWA
AB			EQ 4MG BASE; EQ 1MG BASE	A212756	004	Feb 13, 2025	Feb	NEWA
TABLET; SUBLINGUAL		BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE						
>A>	AB	ASCENT PHARMS INC	EQ 2MG BASE; EQ 0.5MG BASE	A219727	001	Dec 15, 2025	Dec	NEWA
>A>	AB		EQ 8MG BASE; EQ 2MG BASE	A219727	002	Dec 15, 2025	Dec	NEWA
AB		ETHYPHARM	EQ 2MG BASE; EQ 0.5MG BASE	A204431	001	Oct 16, 2015	Nov	CAHN
AB			EQ 8MG BASE; EQ 2MG BASE	A204431	002	Oct 16, 2015	Nov	CAHN
ZUBSOLV								
>A>	+	EDENBRIDGE PHARMS	EQ 0.7MG BASE; EQ 0.18MG BASE	N204242	006	Oct 04, 2016	Dec	CAHN
>A>	+		EQ 1.4MG BASE; EQ 0.36MG BASE	N204242	001	Jul 03, 2013	Dec	CAHN
>A>	+		EQ 2.9MG BASE; EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Dec	CAHN
>A>	+		EQ 5.7MG BASE; EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Dec	CAHN
>A>	+		EQ 8.6MG BASE; EQ 2.1MG BASE	N204242	003	Dec 11, 2014	Dec	CAHN
>A>	+!		EQ 11.4MG BASE; EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Dec	CAHN
>D>	+	OREXO US INC	EQ 0.7MG BASE; EQ 0.18MG BASE	N204242	006	Oct 04, 2016	Dec	CAHN
>D>	+		EQ 1.4MG BASE; EQ 0.36MG BASE	N204242	001	Jul 03, 2013	Dec	CAHN
>D>	+		EQ 2.9MG BASE; EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Dec	CAHN
>D>	+		EQ 5.7MG BASE; EQ 1.4MG BASE	N204242	002	Jul 03, 2013	Dec	CAHN

TABLET;SUBLINGUAL  
ZUBSOLV

>D>	+	EQ 8.6MG BASE;EQ 2.1MG BASE	N204242	003	Dec 11, 2014	Dec CAHN
>D>	+!	EQ 11.4MG BASE;EQ 2.9MG BASE	N204242	004	Dec 11, 2014	Dec CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
BUPROPION HYDROCHLORIDE

AB3	ANNORA PHARMA	150MG	A217898	001	Oct 01, 2025	Sep NEWA
AB3		300MG	A217898	002	Oct 01, 2025	Sep NEWA
AB1	AUROBINDO PHARMA USA	100MG	A090325	001	Apr 08, 2010	Aug CMFD
AB1		150MG	A090325	002	Apr 08, 2010	Aug CMFD
AB1		200MG	A090325	003	Apr 08, 2010	Aug CMFD
AB1	IPCA LABS LTD	100MG	A207874	001	May 02, 2025	Apr NEWA
AB1		150MG	A207874	002	May 02, 2025	Apr NEWA
AB1		200MG	A207874	003	May 02, 2025	Apr NEWA
@	SUN PHARM	150MG	A200216	001	Nov 30, 2020	Feb DISC
@		300MG	A203650	001	Dec 31, 2020	Feb DISC
@	TWI PHARMS	150MG	A210081	001	Nov 03, 2017	Aug DISC
@		300MG	A210081	002	Nov 03, 2017	Aug DISC
	FORFIVO XL					
	+! TWI PHARMS	450MG	N022497	001	Nov 10, 2011	Oct CMFD
@	+	450MG	N022497	001	Nov 10, 2011	Jun DISC

BUSPIRONE HYDROCHLORIDE

CAPSULE;ORAL  
BUCAPSOL

	EPIC PHARMA LLC	7.5MG	A218628	001	Mar 13, 2025	Oct CAHN
		7.5MG	A218628	001	Mar 13, 2025	Feb NEWA
		10MG	A218628	002	Mar 13, 2025	Oct CAHN
		10MG	A218628	002	Mar 13, 2025	Feb NEWA
!		15MG	A218628	003	Mar 13, 2025	Nov CHRS
		15MG	A218628	003	Mar 13, 2025	Oct CAHN
		15MG	A218628	003	Mar 13, 2025	Feb NEWA
	PANGEA	7.5MG	A218628	001	Mar 13, 2025	Oct CTNA
		7.5MG	A218628	001	Mar 13, 2025	Jul CAHN
		10MG	A218628	002	Mar 13, 2025	Oct CTNA
		10MG	A218628	002	Mar 13, 2025	Jul CAHN
		15MG	A218628	003	Mar 13, 2025	Oct CTNA
		15MG	A218628	003	Mar 13, 2025	Jul CAHN

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	15MG	A202557	004	Dec 30, 2014	Apr CHRS
AB	AIPING PHARM INC	7.5MG	A202087	005	Jul 03, 2025	Jun NEWA
BX	EPIC PHARMA LLC	5MG	A208972	001	Apr 16, 2019	Mar CTEC
BX		7.5MG	A208972	002	Apr 16, 2019	Mar CTEC
BX		10MG	A208972	003	Apr 16, 2019	Mar CTEC
BX		15MG	A208972	004	Apr 16, 2019	Mar CTEC
BX		30MG	A208972	005	Apr 16, 2019	Mar CTEC
BX	INVENTIA HLTHCARE	5MG	A209696	001	May 03, 2018	Mar CTEC
BX		7.5MG	A209696	002	May 03, 2018	Mar CTEC
BX		10MG	A209696	003	May 03, 2018	Mar CTEC
BX		15MG	A209696	004	May 03, 2018	Mar CTEC
BX		30MG	A209696	005	May 03, 2018	Mar CTEC
AB	RISING	5MG	A075413	001	Mar 19, 2002	Nov CMFD
AB		7.5MG	A075413	004	Oct 06, 2025	Sep NEWA
AB		10MG	A075413	002	Mar 19, 2002	Nov CMFD
AB		15MG	A075413	003	Mar 19, 2002	Nov CMFD
AB		30MG	A075413	005	Oct 06, 2025	Sep NEWA
AB	! UNICHEM	15MG	A210907	003	Nov 14, 2019	Apr CHRS

BUSULFAN

INJECTABLE;INJECTION  
BUSULFAN

@	APOTEX	6MG/ML	A210448	001	May 07, 2019	Jan DISC
---	--------	--------	---------	-----	--------------	----------

BUTABARBITAL SODIUM

TABLET;ORAL

BUTISOL SODIUM

@	PHARMOBEDIENT	15MG	N000793	002		Sep CAHN
@	+	30MG	N000793	004		Sep CAHN
@		50MG	N000793	003		Sep CAHN
@		100MG	N000793	005		Sep CAHN

BUTORPHANOL TARTRATE

	SPRAY, METERED;NASAL							
	BUTORPHANOL TARTRATE							
AB	!	HIKMA	1MG/SPRAY	A 075824	001	Mar 12, 2002	May	CHRS
	@	RISING	1MG/SPRAY	A 075759	001	Aug 08, 2001	May	DISC
	STADOL							
	@ +	BRISTOL MYERS SQUIBB	1MG/SPRAY	N 019890	001	Dec 12, 1991	May	CRLD

CABERGOLINE

	TABLET;ORAL							
	CABERGOLINE							
AB		AMNEAL	0.5MG	A 218618	001	Jun 26, 2024	Sep	CAHN

CAFFEINE CITRATE

	SOLUTION;INTRAVENOUS							
	CAFFEINE CITRATE							
	@	EUGIA PHARMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A 205013	001	Sep 22, 2015	Jul	DISC
	SOLUTION;ORAL							
	CAFFEINE CITRATE							
	@	SUN PHARM	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A 090357	001	Sep 30, 2009	Feb	DISC

CAFFEINE; ERGOTAMINE TARTRATE

	TABLET;ORAL							
	ERGOTAMINE TARTRATE AND CAFFEINE							
	!	ANDA REPOSITORY	100MG;1MG	A 040590	001	Sep 16, 2005	Sep	CAHN

CALCITONIN SALMON

	INJECTABLE;INJECTION							
	CALCITONIN-SALMON							
AP		AMNEAL	200 IU/ML	A 216294	001	Sep 26, 2025	Sep	NEWA
AP		SAGENT	200 IU/ML	A 219196	001	Jul 09, 2025	Jun	NEWA

CALCITRIOL

	CAPSULE;ORAL							
	CALCITRIOL							
AB		ONESOURCE SPECIALTY	0.25MCG	A 091356	001	Dec 12, 2014	Jun	CAHN
AB	!		0.5MCG	A 091356	002	Dec 12, 2014	Jun	CAHN

CALCIUM ACETATE

	CAPSULE;ORAL							
	CALCIUM ACETATE							
AB		MPP PHARMA	667MG	A 203179	001	Oct 26, 2015	May	CAHN
	PHOSLO							
	@	FRESENIUS MEDCL CARE	333.5MG	N 021160	001	Apr 02, 2001	Sep	CAHN
	@		667MG	N 021160	002	Apr 02, 2001	Sep	CAHN
	PHOSLO GELCAPS							
	@ +	FRESENIUS MEDCL CARE	667MG	N 021160	003	Apr 02, 2001	Sep	CAHN
	SOLUTION;ORAL							
	PHOSLYRA							
	@ +	FRESENIUS MEDCL CARE	667MG/5ML	N 022581	001	Apr 18, 2011	Sep	CAHN
	TABLET;ORAL							
	PHOSLO							
	@ +	FRESENIUS MEDCL CARE	667MG	N 019976	001	Dec 10, 1990	Sep	CAHN

CALCIUM CHLORIDE

	INJECTABLE;INJECTION							
	CALCIUM CHLORIDE 10%							
AP		SQUARE PHARMS PLC	100MG/ML	A 217463	001	Sep 29, 2025	Sep	NEWA

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

	INJECTABLE;INJECTION							
	PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER							
	@ +	VANTIVE US HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N 021703	010	Oct 10, 2008	Feb	CAHN
	PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER							
	@	VANTIVE US HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4	N 021703	012	Oct 10, 2008	Feb	CAHN

## INJECTABLE; INJECTION

## PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)

## PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Feb	CAHN
---	---	---------------------	---	---------	-----	--------------	-----	------

## PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

@	+	VANTIVE US HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Feb	CAHN
---	---	---------------------	--	---------	-----	--------------	-----	------

## PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Feb	CAHN
---	---	---------------------	--	---------	-----	--------------	-----	------

## PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Feb	CAHN
---	---	---------------------	---	---------	-----	--------------	-----	------

## PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Feb	CAHN
---	---	---------------------	--	---------	-----	--------------	-----	------

## PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Feb	CAHN
---	--	---------------------	---	---------	-----	--------------	-----	------

## PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Feb	CAHN
---	---	---------------------	---	---------	-----	--------------	-----	------

## PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Feb	CAHN
---	---	---------------------	--	---------	-----	--------------	-----	------

## PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Feb	CAHN
---	--	---------------------	--	---------	-----	--------------	-----	------

## PRISMASOL BK 0/0 IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Feb	CAHN
---	--	---------------------	--	---------	-----	--------------	-----	------

## PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+	!	VANTIVE US HLTHCARE	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Feb	CAHN
---	---	---------------------	--	---------	-----	--------------	-----	------

## PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

@	+	VANTIVE US HLTHCARE	5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Feb	CAHN
---	---	---------------------	---	---------	-----	--------------	-----	------

## PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

@		VANTIVE US HLTHCARE	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Feb	CAHN
---	--	---------------------	---	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

## SOLUTION; INTRAPERITONEAL

## DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

+	!	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018883	001	Nov 30, 1984	Feb	CTEC
---	---	-----------------	---	---------	-----	--------------	-----	------

SOLUTION;INTRAPERITONEAL									
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
	+	FRESENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML	N018883	002	Nov 30, 1984	Feb	CTEC	
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
	+	FRESENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018883	003	Nov 30, 1984	Feb	CTEC	
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER									
@		VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	001		Feb	CAHN	
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
@		VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	003		Feb	CAHN	
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
@		VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	002		Feb	CAHN	
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	001	Dec 04, 1992	Feb	CAHN	
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	002	Dec 04, 1992	Feb	CAHN	
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER									
@	+	VANTIVE US HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	003	Dec 04, 1992	Feb	CAHN	
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020183	004	Dec 04, 1992	Feb	CAHN	
DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	012	Jan 10, 1989	Feb	CAHN	
DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	013	Jul 11, 1990	Feb	CAHN	
DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER									
	+	VANTIVE US HLTHCARE	18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	014	Jul 11, 1990	Feb	CTEC	
AT	+		18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	014	Jul 11, 1990	Feb	CAHN	
DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	015	Jul 11, 1990	Feb	CAHN	
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER									
@		VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	007	Jul 09, 1984	Feb	CAHN	
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER									
@		VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	008	Jul 09, 1984	Feb	CAHN	
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER									
@		VANTIVE US HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	010	Nov 18, 1985	Feb	CAHN	
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER									
@		VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	009	Jul 09, 1984	Feb	CAHN	
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER									
AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	004		Feb	CAHN	
AT	+		25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;	N020163	001	Dec 04, 1992	Feb	CAHN	

SOLUTION;INTRAPERITONEAL

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER										
448MG/100ML										
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER										
AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;5.08M	N017512	005				Feb	CAHN
			G/100ML;538MG/100ML;448MG/100ML							
AT	+		25.7MG/100ML;2.5GM/100ML;5.08M	N020163	002	Dec 04, 1992			Feb	CAHN
			G/100ML;538MG/100ML;448MG/100ML							
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER										
@	+	VANTIVE US HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08M	N017512	011	Nov 18, 1985			Feb	CAHN
			G/100ML;538MG/100ML;448MG/100ML							
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER										
AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;5.08	N017512	006				Feb	CAHN
			MG/100ML;538MG/100ML;448MG/100ML							
AT	+		25.7MG/100ML;4.25GM/100ML;5.08	N020163	003	Dec 04, 1992			Feb	CAHN
			MG/100ML;538MG/100ML;448MG/100ML							

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER										
+	!	VANTIVE US HLTHCARE	N/A/1000ML;3.05GM/1000ML;0.314	N207026	002	Jan 13, 2015			Feb	CAHN
			GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)							
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER										
+	!	VANTIVE US HLTHCARE	3.68GM/1000ML;3.05GM/1000ML;0.314	N207026	001	Jan 13, 2015			Feb	CAHN
			GM/1000ML;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)							

CALCIUM GLUCONATE

SOLUTION;INTRAVENOUS

CALCIUM GLUCONATE IN SODIUM CHLORIDE										
>D>	!	AMNEAL	1GM/50ML (20MG/ML)	A217174	001	Sep 05, 2023			Dec	CTEC
>A>	AP	!	1GM/50ML (20MG/ML)	A217174	001	Sep 05, 2023			Dec	CTEC
	AP	!	1GM/50ML (20MG/ML)	A217174	001	Sep 05, 2023			Aug	CHRS
		!	1GM/50ML (20MG/ML)	A217174	001	Sep 05, 2023			Aug	CTEC
>D>	!		2GM/100ML (20MG/ML)	A217174	002	Sep 05, 2023			Dec	CTEC
>A>	AP	!	2GM/100ML (20MG/ML)	A217174	002	Sep 05, 2023			Dec	CTEC
	AP	!	2GM/100ML (20MG/ML)	A217174	002	Sep 05, 2023			Aug	CHRS
		!	2GM/100ML (20MG/ML)	A217174	002	Sep 05, 2023			Aug	CTEC
	@	+	FRESENIUS KABI USA	1GM/50ML (20MG/ML)	N208418	004	Jun 17, 2021		Aug	DISC
	@	+		2GM/100ML (20MG/ML)	N208418	005	Jun 17, 2021		Aug	DISC
>A>	AP	SAGENT	1GM/50ML (20MG/ML)	A219619	001	Dec 30, 2025			Dec	NEWA
>A>	AP		2GM/100ML (20MG/ML)	A219619	002	Dec 30, 2025			Dec	NEWA

CANDESARTAN CILEXETIL

TABLET;ORAL

CANDESARTAN CILEXETIL										
AB		ZYDUS LIFESCIENCES	4MG	A091390	001	Aug 23, 2017			Jan	CMFD
AB			8MG	A091390	002	Aug 23, 2017			Jan	CMFD
AB			16MG	A091390	003	Aug 23, 2017			Jan	CMFD
AB			32MG	A091390	004	Aug 23, 2017			Jan	CMFD

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE										
>D>	AB	MYLAN	16MG;12.5MG	A090704	001	Dec 04, 2012			Dec	CAHN
>D>	AB		32MG;12.5MG	A090704	002	Dec 04, 2012			Dec	CAHN
>D>	AB		32MG;25MG	A090704	003	Dec 04, 2012			Dec	CAHN
>A>	AB	NORVIUM BIOSCIENCE	16MG;12.5MG	A090704	001	Dec 04, 2012			Dec	CAHN
>A>	AB		32MG;12.5MG	A090704	002	Dec 04, 2012			Dec	CAHN
>A>	AB		32MG;25MG	A090704	003	Dec 04, 2012			Dec	CAHN
>A>	AB	PHARMOBEDIENT	16MG;12.5MG	A090704	001	Dec 04, 2012			Dec	CAHN
>A>	AB		32MG;12.5MG	A090704	002	Dec 04, 2012			Dec	CAHN
>A>	AB		32MG;25MG	A090704	003	Dec 04, 2012			Dec	CAHN

CANGRELOR

POWDER; INTRAVENOUS  
CANGRELOR

AP	GLAND	50MG/VIAL	A213551	001	Aug 11, 2025	Aug	NFTG
AP	KENGREAL						
AP	+! CHIESI	50MG/VIAL	N204958	001	Jun 22, 2015	Aug	CFTG

CAPECITABINE

TABLET; ORAL  
CAPECITABINE

BX	TEYRO LABS	150MG	A217237	001	Oct 23, 2023	Mar	CTEC
BX		500MG	A217237	002	Oct 23, 2023	Mar	CTEC

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION  
CAPREOMYCIN SULFATE  
@ PHARMOBEDIANT

EQ 1GM BASE/VIAL

A202634 001 Nov 27, 2017 Sep CAHN

CAPTOPRIL

TABLET; ORAL  
CAPOTEN

	@ + AARXION ANDA HLDING	12.5MG	N018343	005	Jan 17, 1985	Sep	CAHN
	@ +	25MG	N018343	002		Sep	CAHN
	@ +	37.5MG	N018343	006	Sep 17, 1986	Sep	CAHN
	@ +	50MG	N018343	001		Sep	CAHN
	@ +	75MG	N018343	007	Jun 13, 1995	Sep	CAHN
	@ +	100MG	N018343	003		Sep	CAHN
	@ +	150MG	N018343	004	Jun 13, 1995	Sep	CAHN
	CAPTOPRIL						
AB	AIPING PHARM INC	12.5MG	A214442	001	Jan 27, 2023	Jul	CAHN
AB		25MG	A214442	002	Jan 27, 2023	Jul	CAHN
AB		50MG	A214442	003	Jan 27, 2023	Jul	CAHN
AB		100MG	A214442	004	Jan 27, 2023	Jul	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL  
CARBAMAZEPINE

AB	ANI PHARMS	100MG	A076697	001	May 20, 2011	May	CAHN
AB		200MG	A076697	002	May 20, 2011	May	CAHN
AB		300MG	A076697	003	May 20, 2011	May	CAHN
	@ TARO	100MG	A201106	001	Jun 21, 2013	Aug	DISC
	@	200MG	A201106	002	Jun 21, 2013	Aug	DISC
	@	300MG	A201106	003	Jun 21, 2013	Aug	DISC

TABLET; ORAL  
CARBAMAZEPINE

AB	ALEMBIC	200MG	A216623	001	Apr 16, 2025	Apr	NEWA
	TABLET, EXTENDED RELEASE; ORAL CARBAMAZEPINE						
AB	ALEMBIC	100MG	A219939	001	Jul 25, 2025	Jul	NEWA
AB		200MG	A219939	002	Jul 25, 2025	Jul	NEWA
AB		400MG	A219939	003	Jul 25, 2025	Jul	NEWA
AB	ALKEM LABS LTD	100MG	A217277	001	Jan 14, 2025	Jan	NEWA
AB		200MG	A217277	002	Jan 14, 2025	Jan	NEWA
AB		400MG	A217277	003	Jan 14, 2025	Jan	NEWA
	@ OSMOTICA PHARM US	100MG	A215664	001	Oct 22, 2024	Apr	DISC
	@	200MG	A215664	002	Oct 22, 2024	Apr	DISC
	@	400MG	A215664	003	Oct 22, 2024	Apr	DISC
AB	SCIECURE PHARMA INC	100MG	A216235	001	Mar 02, 2023	Jun	CAHN
AB		200MG	A216235	002	Mar 02, 2023	Jun	CAHN
AB		400MG	A216235	003	Mar 02, 2023	Jun	CAHN
AB	TORRENT	100MG	A212524	001	Jan 13, 2025	Jan	NEWA
AB		200MG	A212524	002	Jan 13, 2025	Jan	NEWA
AB		400MG	A212524	003	Jan 13, 2025	Jan	NEWA
AB	YICHANG HUMANWELL	100MG	A219072	001	Jan 16, 2025	Jan	NEWA
AB		200MG	A219072	002	Jan 16, 2025	Jan	NEWA
AB		400MG	A219072	003	Jan 16, 2025	Jan	NEWA

CARBIDOPA

TABLET;ORAL

CARBIDOPA

@	ALVOGEN	25MG	A 204291	001	Jan 08, 2016	Aug	DISC
---	---------	------	----------	-----	--------------	-----	------

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	MACLEODS PHARMS LTD	12.5MG;200MG;50MG	A 214495	001	Apr 15, 2025	Apr	NEWA
AB		18.75MG;200MG;75MG	A 214495	002	Apr 15, 2025	Apr	NEWA
AB		25MG;200MG;100MG	A 214495	003	Apr 15, 2025	Apr	NEWA
AB		31.25MG;200MG;125MG	A 214495	004	Apr 15, 2025	Apr	NEWA
AB		37.5MG;200MG;150MG	A 214495	005	Apr 15, 2025	Apr	NEWA
AB		50MG;200MG;200MG	A 214495	006	Apr 15, 2025	Apr	NEWA
	@ SUN PHARM	25MG;200MG;100MG	A 079085	001	May 10, 2012	Jul	DISC
	@	37.5MG;200MG;150MG	A 079085	002	May 10, 2012	Jul	DISC

CARBIDOPA; LEVODOPA

TABLET;ORAL

CARBIDOPA AND LEVODOPA

	@ APOTEX INC	10MG;100MG	A 077120	001	Jun 02, 2008	Mar	DISC
	@	25MG;100MG	A 077120	002	Jun 02, 2008	Mar	DISC
	@	25MG;250MG	A 077120	003	Jun 02, 2008	Mar	DISC
AB	ASCENT PHARMS INC	10MG;100MG	A 218939	001	Jan 14, 2025	Jan	NEWA
AB		25MG;100MG	A 218939	002	Jan 14, 2025	Jan	NEWA
AB		25MG;250MG	A 218939	003	Jan 14, 2025	Jan	NEWA
	@ NORVIUM BIOSCIENCE	10MG;100MG	A 090324	001	Sep 28, 2009	Jul	DISC
	@	25MG;250MG	A 090324	003	Sep 28, 2009	Jun	DISC

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

	@ APOTEX	25MG;100MG	A 076212	001	Jun 16, 2004	Mar	DISC
	@	50MG;200MG	A 076212	002	Jun 16, 2004	Mar	DISC

TABLET, ORALLY DISINTEGRATING;ORAL

CARBIDOPA AND LEVODOPA

AB	RISING	10MG;100MG	A 078893	001	Sep 18, 2008	Oct	CMFD
AB		25MG;100MG	A 078893	002	Sep 18, 2008	Oct	CMFD
AB		25MG;250MG	A 078893	003	Sep 18, 2008	Oct	CMFD
AB	SUN PHARM	10MG;100MG	A 078690	001	Jul 31, 2009	Oct	CTEC
AB		25MG;100MG	A 078690	002	Jul 31, 2009	Oct	CTEC
AB	!	25MG;250MG	A 078690	003	Jul 31, 2009	Oct	CTEC

CARBINOXAMINE MALEATE

TABLET;ORAL

CARBINOXAMINE MALEATE

@	SENORES PHARMS	4MG	A 090435	001	Apr 15, 2010	Oct	CAHN
@		4MG	A 090435	001	Apr 15, 2010	Jan	CAHN

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

@	FRESENIUS KABI USA	450MG/45ML (10MG/ML)	A 077247	003	Oct 21, 2004	Oct	DISC
---	--------------------	----------------------	----------	-----	--------------	-----	------

SOLUTION;INTRAVENOUS

KYXATA

@ +	AVYXA HOLDINGS	20MG/2ML (10MG/ML)	N 219921	001	Aug 08, 2025	Sep	DISC
+	!	20MG/2ML (10MG/ML)	N 219921	001	Aug 08, 2025	Aug	NEWA
+	!	80MG/8ML (10MG/ML)	N 219921	002	Aug 08, 2025	Aug	NEWA
+	!	500MG/50ML (10MG/ML)	N 219921	003	Aug 08, 2025	Aug	NEWA

CARFILZOMIB

POWDER;INTRAVENOUS

KYPROLIS

+	!	ONYX PHARMS AMGEN	10MG/VIAL	N 202714	003	Jun 07, 2018	Jun	CHRS
+	!		30MG/VIAL	N 202714	002	Jun 03, 2016	Jun	CHRS

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL

CARIPRAZINE HYDROCHLORIDE

>A>	AB	AUROBINDO PHARMA LTD	EQ 1.5MG BASE	A 213982	001	Dec 16, 2025	Dec	NEWA
>A>	AB		EQ 3MG BASE	A 213982	002	Dec 16, 2025	Dec	NEWA
>A>	AB		EQ 6MG BASE	A 213982	003	Dec 16, 2025	Dec	NEWA

CAPSULE;ORAL

VRAYLAR

>A>	+	ABBVIE	EQ 0.5MG BASE	N204370	005	Dec 18, 2025	Dec	NEWA
>A>	+		EQ 0.75MG BASE	N204370	006	Dec 18, 2025	Dec	NEWA
>D>	+	!	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Dec	CTEC
>A>	AB	+	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Dec	CTEC
>D>		+	EQ 3MG BASE	N204370	002	Sep 17, 2015	Dec	CTEC
>A>	AB	+	EQ 3MG BASE	N204370	002	Sep 17, 2015	Dec	CTEC
>D>		+	EQ 6MG BASE	N204370	004	Sep 17, 2015	Dec	CTEC
>A>	AB	+	EQ 6MG BASE	N204370	004	Sep 17, 2015	Dec	CTEC

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

>A>	AA		ALLIED	350MG	A081025	001	Apr 13, 1989	Dec	CAHN
>D>	AA		FOSUN WANBANG	350MG	A081025	001	Apr 13, 1989	Dec	CAHN
	AA			350MG	A081025	001	Apr 13, 1989	Jan	CAHN
	AB		HERITAGE	250MG	A205126	001	Jul 08, 2015	Jun	CAHN
	AA			350MG	A205126	002	Jul 08, 2015	Jun	CAHN
	AB		INDICUS PHARMA	250MG	A205126	001	Jul 08, 2015	Jun	CAHN
	AA			350MG	A205126	002	Jul 08, 2015	Jun	CAHN
	AB		MPP PHARMA	250MG	A207237	001	May 11, 2017	May	CAHN
	AA			350MG	A207237	002	Sep 21, 2020	May	CAHN
	AA		POINTVIEW HLDINGS	350MG	A211789	001	Oct 20, 2021	Apr	CAHN
>A>	AA		SENORES PHARMS	350MG	A081025	001	Apr 13, 1989	Dec	CAHN

CARMUSTINE

INJECTABLE;INJECTION

CARMUSTINE

@		HENGRUI PHARMA	100MG/VIAL	A211202	001	Mar 12, 2021	Sep	DISC
@		NOVAST LABS	100MG/VIAL	A211011	001	Jun 21, 2022	Aug	CAHN

CARVEDILOL

TABLET;ORAL

CARVEDILOL

AB			GRAVITI PHARMS	3.125MG	A076649	001	Sep 05, 2007	Feb	CAHN
AB				6.25MG	A076649	002	Sep 05, 2007	Feb	CAHN
AB				12.5MG	A076649	003	Sep 05, 2007	Feb	CAHN
AB				25MG	A076649	004	Sep 05, 2007	Feb	CAHN
	@		NORVIUM BIOSCIENCE	3.125MG	A077316	001	Sep 05, 2007	Feb	CAHN
	@			6.25MG	A077316	002	Sep 05, 2007	Mar	DISC
AB				6.25MG	A077316	002	Sep 05, 2007	Feb	CAHN
	@			12.5MG	A077316	003	Sep 05, 2007	Apr	DISC
AB				12.5MG	A077316	003	Sep 05, 2007	Feb	CAHN
	@			25MG	A077316	004	Sep 05, 2007	Apr	DISC
AB				25MG	A077316	004	Sep 05, 2007	Feb	CAHN
	@		TARO	3.125MG	A077780	001	Sep 05, 2007	Aug	DISC
	@			6.25MG	A077780	002	Sep 05, 2007	Aug	DISC
	@			12.5MG	A077780	003	Sep 05, 2007	Aug	DISC
	@			25MG	A077780	004	Sep 05, 2007	Aug	DISC

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE;ORAL

COREG CR

AB	+	WAYLIS THERAP	10MG	N022012	001	Oct 20, 2006	Jun	CMFD
AB	+		20MG	N022012	002	Oct 20, 2006	Jun	CMFD
AB	+		40MG	N022012	003	Oct 20, 2006	Jun	CMFD
AB	+		80MG	N022012	004	Oct 20, 2006	Jun	CMFD

CASPOFUNGIN ACETATE

POWDER;INTRAVENOUS

CASPOFUNGIN ACETATE

AP		HANGZHOU ZHONGMEI	50MG/VIAL	A216506	001	Jul 18, 2025	Jul	NEWA
AP			70MG/VIAL	A216506	002	Jul 18, 2025	Jul	NEWA

CEDAZURIDINE; DECITABINE

TABLET;ORAL

INQOVI

	+	!	TAIHO ONCOLOGY	100MG;35MG	N212576	001	Jul 07, 2020	Feb	CAHN
--	---	---	----------------	------------	---------	-----	--------------	-----	------

CEFAZOLIN SODIUM

INJECTABLE; INJECTION		CEFAZOLIN SODIUM					
	QILU ANTIBIOTICS	EQ 3GM BASE/VIAL	A203661	003	Jan 24, 2024	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A203661	001	Dec 28, 2015	Jan	CAHN
		EQ 2GM BASE/VIAL	A203661	002	Mar 11, 2022	Jan	CAHN
AP	!	EQ 10GM BASE/VIAL	A209217	001	Oct 17, 2018	Jan	CAHN
	@ SANDOZ	EQ 1GM BASE/VIAL	A065345	001	May 09, 2007	Oct	DISC

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION		CEFEPIME HYDROCHLORIDE					
	! QILU ANTIBIOTICS	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan	CAHN
AP	!	EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan	CAHN
AP	!	EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan	CAHN

CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM

POWDER; INTRAVENOUS		EXBLIFE					
>D>	@ + ALLECRA THERAPS	EQ 2GM BASE/VIAL; 0.5GM/VIAL	N216165	001	Feb 22, 2024	Dec	CAHN
>A>	@ + ORCHID PHARMA	EQ 2GM BASE/VIAL; 0.5GM/VIAL	N216165	001	Feb 22, 2024	Dec	CAHN

CEFIXIME

FOR SUSPENSION; ORAL		CEFIXIME					
AB	AJENAT PHARMS	100MG/5ML	A206938	001	Feb 06, 2017	Jul	CAHN
AB		200MG/5ML	A206938	002	Feb 06, 2017	Jul	CAHN
AB		500MG/5ML	A206939	001	Feb 06, 2017	Jul	CAHN
TABLET; ORAL		CEFIXIME					
	@ FDC LTD	400MG	A206358	001	Dec 17, 2024	Jul	DISC
>D>	TABLET, CHEWABLE; ORAL						
>D>	SUPRAX						
>D>	LUPIN LTD	100MG	A065380	001	Oct 25, 2010	Dec	DISC
>A>	@	100MG	A065380	001	Oct 25, 2010	Dec	DISC
>D>		150MG	A065380	002	Oct 25, 2010	Dec	DISC
>A>	@	150MG	A065380	002	Oct 25, 2010	Dec	DISC
>D>	!	200MG	A065380	003	Oct 25, 2010	Dec	DISC
>A>	@	200MG	A065380	003	Oct 25, 2010	Dec	DISC

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL		VANTIN					
	@ + PFIZER	EQ 50MG BASE/5ML	N050675	001	Aug 07, 1992	Mar	CAHN
	@ +	EQ 100MG BASE/5ML	N050675	002	Aug 07, 1992	Mar	CAHN
TABLET; ORAL		VANTIN					
	@ + PFIZER	EQ 100MG BASE	N050674	001	Aug 07, 1992	Mar	CAHN
	@ +	EQ 200MG BASE	N050674	002	Aug 07, 1992	Mar	CAHN

CEFPROZIL

FOR SUSPENSION; ORAL		CEFPROZIL					
	@ APOTEX INC	125MG/5ML	A065351	001	Feb 29, 2012	Mar	DISC
	@	250MG/5ML	A065351	002	Feb 29, 2012	Mar	DISC
TABLET; ORAL		CEFPROZIL					
	@ APOTEX INC	250MG	A065327	001	Mar 26, 2008	Mar	DISC
	@	500MG	A065327	002	Mar 26, 2008	Mar	DISC

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL		CEDAX					
	@ BURKE THERAP	EQ 400MG BASE	N050685	002	Dec 20, 1995	Jul	CAHN
FOR SUSPENSION; ORAL		CEDAX					
	@ + BURKE THERAP	EQ 90MG BASE/5ML	N050686	001	Dec 20, 1995	Jul	CAHN
	@ +	EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995	Jul	CAHN

CEFTOBIPROLE MEDOCARIL SODIUM

POWDER; INTRAVENOUS  
ZEVTERA

	+!	ISTX	667MG/VIAL	N218275	001	Apr 03, 2024	Apr	CMFD
	@	+	667MG/VIAL	N218275	001	Apr 03, 2024	Mar	CAHN

CEFTRIAZONE SODIUM

INJECTABLE; INJECTION  
CEFTRIAZONE

AP		APOTEX	EQ 1GM BASE/VIAL	A065180	001	May 12, 2006	Nov	CAHN
AP		QILU ANTIBIOTICS	EQ 10GM BASE/VIAL	A209218	001	Oct 17, 2018	Jan	CAHN

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS  
CEFTRIAZONE

AP		QILU ANTIBIOTICS	EQ 250MG BASE/VIAL	A203702	001	Jun 29, 2016	Jan	CAHN
AP			EQ 500MG BASE/VIAL	A203702	002	Jun 29, 2016	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A203702	003	Jun 29, 2016	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A203702	004	Jun 29, 2016	Jan	CAHN

CEFUROXIME AXETIL

TABLET; ORAL  
CEFUROXIME AXETIL

	@	APOTEX	EQ 250MG BASE	A065069	001	Oct 02, 2002	Mar	DISC
	@		EQ 500MG BASE	A065069	002	Oct 02, 2002	Mar	DISC
AB	!	AUROBINDO PHARMA	EQ 500MG BASE	A065308	003	Mar 29, 2006	Nov	CHRS
	@	LUPIN	EQ 250MG BASE	A065135	001	Jul 25, 2003	Nov	DISC
	@		EQ 500MG BASE	A065135	002	Jul 25, 2003	Nov	DISC

CELECOXIB

CAPSULE; ORAL  
CELECOXIB

	@	PANGEA	200MG	A212925	001	Dec 09, 2020	Feb	CAHN
	@		400MG	A212925	002	Dec 09, 2020	Feb	CAHN
	@	STRIDES PHARMA	100MG	A213127	001	Apr 29, 2025	Jul	DISC
AB			100MG	A213127	001	Apr 29, 2025	Apr	NEWA
	@		200MG	A213127	002	Apr 29, 2025	Jul	DISC
AB			200MG	A213127	002	Apr 29, 2025	Apr	NEWA
	@		400MG	A213127	003	Apr 29, 2025	Jul	DISC
AB			400MG	A213127	003	Apr 29, 2025	Apr	NEWA
>D>	AB	ZYDUS PHARMS	50MG	A205938	001	Jul 14, 2025	Dec	DISC
>A>	@		50MG	A205938	001	Jul 14, 2025	Dec	DISC
AB			50MG	A205938	001	Jul 14, 2025	Jul	NEWA
>D>	AB		100MG	A205938	002	Jul 14, 2025	Dec	DISC
>A>	@		100MG	A205938	002	Jul 14, 2025	Dec	DISC
AB			100MG	A205938	002	Jul 14, 2025	Jul	NEWA
>D>	AB		200MG	A205938	003	Jul 14, 2025	Dec	DISC
>A>	@		200MG	A205938	003	Jul 14, 2025	Dec	DISC
AB			200MG	A205938	003	Jul 14, 2025	Jul	NEWA
>D>	AB		400MG	A205938	004	Jul 14, 2025	Dec	DISC
>A>	@		400MG	A205938	004	Jul 14, 2025	Dec	DISC
AB			400MG	A205938	004	Jul 14, 2025	Jul	NEWA

SUSPENSION; ORAL  
VYSCOXIA

	+!	CARWIN PHARM ASSOC	10MG/ML	N211759	001	Jul 29, 2025	Aug	CAHN
	+!	CODADOSE INC	10MG/ML	N211759	001	Jul 29, 2025	Jul	NEWA

CEPHALEXIN

CAPSULE; ORAL  
CEPHALEXIN

AB		AJENAT PHARMS	EQ 250MG BASE	A062713	001	Jul 15, 1988	Jul	CAHN
AB			EQ 500MG BASE	A062713	002	Jul 15, 1988	Jul	CAHN

TABLET; ORAL  
CEPHALEXIN

		TEVA	EQ 250MG BASE	A063024	002	Jan 12, 1989	Aug	CMS1
--	--	------	---------------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

SOLUTION; ORAL  
CETIRIZINE HYDROCHLORIDE

AA		BIONPHARMA	5MG/5ML	A078488	001	Oct 06, 2008	May	CMFD
	@	ZYRTEC						
	@	J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Feb	CRLD

CETRORELIX ACETATE

POWDER; SUBCUTANEOUS  
 CETRORELIX ACETATE  
 AP XIROMED EQ 0.25MG BASE/VIAL A218061 001 Jun 03, 2025 May NEWA

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL  
 CEVIMELINE HYDROCHLORIDE  
 AB RUBICON 30MG A216682 001 Apr 06, 2023 Jun CTEC  
 BX 30MG A216682 001 Apr 06, 2023 Mar CTEC

CHENODIOL

TABLET; ORAL  
 CTEXLI  
 +! MIRUM 250MG N219488 001 Feb 21, 2025 Feb NEWA

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION  
 CHLOROTHIAZIDE SODIUM  
 AP SUN PHARM EQ 500MG BASE/VIAL A091546 001 Jul 26, 2011 Jun CMFD

CHLOROTHIAZIDE; RESERPINE

TABLET; ORAL  
 CHLOROTHIAZIDE-RESERPINE  
 @ PHARMOBEDIANT 500MG; 0.125MG A087745 001 May 06, 1982 Sep CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL  
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE  
 @ APOZEAL PHARMS 4MG/5ML; 5MG/5ML; 60MG/5ML A206660 001 May 15, 2017 Apr CAHN  
 @ SCIEGEN PHARMS 4MG/5ML; 5MG/5ML; 60MG/5ML A206660 001 May 15, 2017 Sep CAHN

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL  
 CHLORPROMAZINE HYDROCHLORIDE  
 AB ! GENUS 30MG/ML A214542 001 Jun 02, 2021 Oct CTEC  
 AB ! 100MG/ML A214542 002 Jun 02, 2021 Oct CTEC  
 AB RUBICON 30MG/ML A216678 001 Oct 10, 2025 Oct NEWA  
 AB 100MG/ML A216678 002 Oct 10, 2025 Oct NEWA  
 SONAZINE  
 @ ALLIED 30MG/ML A080983 004 Jul CAHN  
 @ 100MG/ML A080983 005 Jul CAHN  
 @ SAPTALIS PHARMS 30MG/ML A080983 004 Sep CAHN  
 @ 100MG/ML A080983 005 Sep CAHN

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE  
 AB AUROBINDO PHARMA LTD 10MG A216788 001 Apr 25, 2025 Apr NEWA  
 AB 25MG A216788 002 Apr 25, 2025 Apr NEWA  
 AB 50MG A216788 003 Apr 25, 2025 Apr NEWA  
 AB 100MG A216788 004 Apr 25, 2025 Apr NEWA  
 AB 200MG A216788 005 Apr 25, 2025 Apr NEWA  
 AB CHARTWELL RX 10MG A212630 001 Nov 29, 2021 Sep CAHN  
 AB 25MG A212630 002 Nov 29, 2021 Sep CAHN  
 AB 50MG A212630 003 Nov 29, 2021 Sep CAHN  
 AB 100MG A212630 004 Nov 29, 2021 Sep CAHN  
 AB 200MG A212630 005 Nov 29, 2021 Sep CAHN  
 @ SUN PHARM 10MG A214256 001 Oct 26, 2020 Jul DISC  
 @ 25MG A214256 002 Oct 26, 2020 Jul DISC  
 @ 50MG A214256 003 Oct 26, 2020 Jul DISC  
 @ 100MG A214256 004 Oct 26, 2020 Jul DISC  
 @ 200MG A214256 005 Oct 26, 2020 Jul DISC  
 AB ZAMEER PHARMS 10MG A212630 001 Nov 29, 2021 Feb CAHN  
 AB 25MG A212630 002 Nov 29, 2021 Feb CAHN  
 AB 50MG A212630 003 Nov 29, 2021 Feb CAHN  
 AB 100MG A212630 004 Nov 29, 2021 Feb CAHN  
 AB 200MG A212630 005 Nov 29, 2021 Feb CAHN

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@	PHARMOBEDIANT	100MG	A 088549	002	Jun 01, 1984	Sep CAHN
@		250MG	A 088549	001	Jun 01, 1984	Sep CAHN

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

@	AIPING PHARM INC	25MG	A 087380	001		Jan CAHN
@		25MG	A 087381	002		Aug CMS1
@		50MG	A 087381	001		Jan CAHN
HEMICLOR						
+	PRM PHARMA	12.5MG	N 218647	001	Mar 17, 2025	Mar NEWA

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AA	AJENAT PHARMS	250MG	A 215540	001	Jan 24, 2023	Jan CAHN
AA	! ANDA REPOSITORY	250MG	A 207483	001	Jun 24, 2016	Sep CAHN
AB	!	375MG	A 040861	001	Jun 01, 2010	Sep CAHN
AB	!	750MG	A 040861	002	Jun 01, 2010	Sep CAHN
AB	APPCO	375MG	A 212047	001	Jan 27, 2023	Mar CAHN
AB		750MG	A 212047	002	Jan 27, 2023	Mar CAHN
	@ CHARTWELL RX	250MG	A 087981	001	Sep 20, 1983	Apr CAHN
AA	RISING	500MG	A 213126	002	Apr 05, 2022	Oct CTEC

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

@	AIPING PHARM INC	EQ 4GM RESIN/PACKET	A 214877	001	Jan 21, 2022	Jul CAHN
@		EQ 4GM RESIN/SCOOPFUL	A 214877	002	Jan 21, 2022	Jul CAHN
CHOLESTYRAMINE LIGHT						
@	MACLEODS PHARMS LTD	EQ 4GM RESIN/SCOOPFUL	A 209109	001	Oct 31, 2024	Jun DISC
@		EQ 4GM RESIN/PACKET	A 209109	002	Oct 31, 2024	Jun DISC
AB	PHARMOBEDIANT CNSLTG	EQ 4GM RESIN/PACKET	A 209599	001	Nov 12, 2020	Apr CAHN
AB		EQ 4GM RESIN/SCOOPFUL	A 209599	002	Nov 12, 2020	Apr CAHN
PREVALITE						
AB	AIPING PHARM INC	EQ 4GM RESIN/PACKET	A 073263	001	Feb 22, 1996	Jul CAHN
AB		EQ 4GM RESIN/SCOOPFUL	A 073263	002	Oct 30, 1997	Jul CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

AB	! AUROBINDO PHARMA LTD	EQ 135MG FENOFIBRIC ACID	A 212598	002	Jul 25, 2019	Apr CHRS
TRILIPIX						
@	+	ABBVIE	EQ 45MG FENOFIBRIC ACID	N 022224	001	Dec 15, 2008
@	+		EQ 135MG FENOFIBRIC ACID	N 022224	002	Dec 15, 2008

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

AT	ENCUBE	1%	A 209975	001	Apr 05, 2018	Oct CMFD
AT	! PADAGIS US	1%	A 078594	001	Feb 16, 2010	Mar CHRS
LOPROX						
@	+	BAUSCH		N 021159	001	Feb 28, 2003
SOLUTION; TOPICAL						
CICLOPIROX						
@	TARO PHARM INDS	8%	A 078144	001	Sep 18, 2007	Aug DISC
SUSPENSION; TOPICAL						
CICLOPIROX						
@	TARO	0.77%	A 077092	001	Aug 10, 2005	Aug DISC

CIDOFOVIR

SOLUTION; INTRAVENOUS

CIDOFOVIR

AP	AVET LIFESCIENCES	EQ 75MG BASE/ML	A 202501	001	Jul 26, 2012	May CDFR
AP		EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	A 202501	001	Jul 26, 2012	May CPOT
AP	! MYLAN INSTITUTIONAL	EQ 75MG BASE/ML	A 201276	001	Jun 27, 2012	May CDFR
AP	!	EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	A 201276	001	Jun 27, 2012	May CPOT

SOLUTION; INTRAVENOUS  
CIDOFOVIR

		BASE/ML)				
VISTIDE						
@ +	GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	May CDFR
@ +		EQ 375MG BASE/5ML (EQ 75MG BASE/ML)	N020638	001	Jun 26, 1996	May CPOT

CILOSTAZOL

TABLET; ORAL						
CILOSTAZOL						
@	SANKALP LIFECARE	50MG	A077708	001	Sep 28, 2009	Apr CAHN
@		100MG	A077708	002	Sep 28, 2009	Apr CAHN

CIMETIDINE

TABLET; ORAL						
CIMETIDINE						
@	HIKMA	200MG	A074890	001	Dec 18, 1998	Jun CAHN
@		300MG	A074890	002	Dec 18, 1998	Jun CAHN
@		400MG	A074890	003	Dec 18, 1998	Jun CAHN
@		800MG	A074890	004	Dec 18, 1998	Jun CAHN

CINACALCET HYDROCHLORIDE

TABLET; ORAL						
CINACALCET HYDROCHLORIDE						
AB	PIRAMAL	EQ 30MG BASE	A210207	001	Aug 01, 2018	Jan CAHN
AB		EQ 60MG BASE	A210207	002	Aug 01, 2018	Jan CAHN
AB		EQ 90MG BASE	A210207	003	Aug 01, 2018	Jan CAHN
	@ RISING	EQ 30MG BASE	A203422	001	Oct 16, 2018	Aug CAHN
	@	EQ 60MG BASE	A203422	002	Oct 16, 2018	Aug CAHN
	@	EQ 90MG BASE	A203422	003	Oct 16, 2018	Aug CAHN

CIPROFLOXACIN

INJECTABLE; INJECTION						
CIPROFLOXACIN						
	@ BAXTER HLTHCARE CORP	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Oct DISC
	@	400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Oct DISC
	! HIKMA FARMACEUTICA	200MG/20ML (10MG/ML)	A076717	001	Dec 22, 2009	Oct CTEC
AP	!	200MG/20ML (10MG/ML)	A076717	001	Dec 22, 2009	Oct CHRS
	!	400MG/40ML (10MG/ML)	A076717	002	Dec 22, 2009	Oct CTEC
AP	!	400MG/40ML (10MG/ML)	A076717	002	Dec 22, 2009	Oct CHRS

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC						
CIPROFLOXACIN HYDROCHLORIDE						
	@ PHARMOBEDIANT	EQ 0.3% BASE	A076555	001	Dec 11, 2008	Sep CAHN
SOLUTION/DROPS; OTIC						
CETRAXAL						
AB	+! LAB SALVAT	EQ 0.2% BASE	N021918	001	May 01, 2009	Aug CAHN
AB		CIPROFLOXACIN HYDROCHLORIDE				
	NEW HEIGHTSRX	EQ 0.2% BASE	A217887	001	Nov 05, 2024	Jul CAHN

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS; OTIC						
CIPRO HC						
AB	+! SANDOZ	EQ 0.2% BASE; 1%	N020805	001	Feb 10, 1998	Oct CFTG
CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE						
AB	COSETTE PHARMS NC	EQ 0.2% BASE; 1%	A218273	001	Nov 10, 2025	Oct NFTG

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS; OTIC						
CIPROFLOXACIN AND DEXAMETHASONE						
AB	AMNEAL	0.3%; 0.1%	A216501	001	Mar 22, 2024	Apr CTNA
>A>	AB UPSHER SMITH LABS	0.3%; 0.1%	A216487	001	Jan 06, 2026	Dec NEWA

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION						
CISATRACURIUM BESYLATE						
	@ EUGIA PHARMA	EQ 2MG BASE/ML	A209144	001	May 08, 2020	Jul DISC
AP	GLAND	EQ 2MG BASE/ML	A215516	001	May 24, 2022	Mar CAHN
AP		EQ 2MG BASE/ML	A215516	003	Dec 14, 2022	Mar CAHN
AP		EQ 10MG BASE/ML	A215516	002	May 24, 2022	Mar CAHN

INJECTABLE; INJECTION  
CISATRACURIUM BESYLATE

AP	@	HAINAN POLY	EQ 2MG BASE/ML	A216538	001	Mar 08, 2024	Feb	DISC
		HENGRUI PHARMA	EQ 2MG BASE/ML	A204960	003	Aug 30, 2017	Feb	CMS1
		CISATRACURIUM BESYLATE PRESERVATIVE FREE						
	@	EUGIA PHARMA	EQ 2MG BASE/ML	A209665	001	Oct 27, 2020	Jul	DISC
	@	HAINAN POLY	EQ 2MG BASE/ML	A216539	001	Aug 27, 2024	Feb	DISC
	@		EQ 10MG BASE/ML	A216539	002	Aug 27, 2024	Feb	DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

	@	APOTEX	EQ 10MG BASE	A077046	001	Nov 24, 2004	Mar	DISC
	@		EQ 20MG BASE	A077046	002	Nov 24, 2004	Mar	DISC
	@		EQ 40MG BASE	A077046	003	Nov 24, 2004	Mar	DISC
	@	GLENMARK PHARMS LTD	EQ 10MG BASE	A077654	001	Feb 27, 2009	Aug	DISC
	@		EQ 20MG BASE	A077654	002	Feb 27, 2009	Aug	DISC
	@		EQ 40MG BASE	A077654	003	Feb 27, 2009	Aug	DISC

CLADRIBINE

TABLET; ORAL

CLADRIBINE

AB		APOTEX	10MG	A218425	001	Nov 24, 2025	Nov	NFTG
		MAVENCLAD						
AB	+!	EMD SERONO INC	10MG	N022561	001	Mar 29, 2019	Nov	CFTG

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

	@	JUBILANT CADISTA	250MG	A206714	001	Apr 25, 2019	Apr	CAHN
	@		500MG	A206714	002	Apr 25, 2019	Apr	CAHN
AB		NOVITIUM PHARMA	250MG	A202710	001	Jun 10, 2013	Aug	CAHN
AB			500MG	A202710	002	Jun 10, 2013	Aug	CAHN

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

AB		MPP PHARMA	500MG	A203243	001	Feb 29, 2016	May	CAHN
----	--	------------	-------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

	@	ALMAJECT	EQ 150MG BASE/ML	A062800	001	Jul 24, 1987	Feb	DISC
	@		EQ 150MG BASE/ML	A062943	001	Sep 29, 1988	Feb	DISC
	@	FRESENIUS KABI USA	EQ 150MG BASE/ML	A065346	001	Mar 29, 2007	Jun	DISC
	@		EQ 150MG BASE/ML	A065347	001	May 09, 2007	Jun	DISC

>D> SOLUTION; TOPICAL

>D> CLINDAMYCIN PHOSPHATE

>D>	AT	CARNEGIE	EQ 1% BASE	A219612	001	Jun 13, 2025	Dec	CDFR
	AT		EQ 1% BASE	A219612	001	Jun 13, 2025	Jun	NEWA

>A> SWAB; TOPICAL

>A> CLINDAMYCIN PHOSPHATE

>A>	AT	CARNEGIE	EQ 1% BASE	A219612	001	Jun 13, 2025	Dec	CDFR
-----	----	----------	------------	---------	-----	--------------	-----	------

CLOBAZAM

FILM; ORAL

SYMPAZAN

	+	ASSERTIO SPECLTY	5MG	N210833	001	Nov 01, 2018	Aug	CAHN
	+		10MG	N210833	002	Nov 01, 2018	Aug	CAHN
	+!		20MG	N210833	003	Nov 01, 2018	Aug	CAHN

SUSPENSION; ORAL

CLOBAZAM

>D>	AB	LUPIN LTD	2.5MG/ML	A210546	001	Dec 28, 2018	Dec	DISC
>A>	@		2.5MG/ML	A210546	001	Dec 28, 2018	Dec	DISC
	@	VISTAPHARM LLC	2.5MG/ML	A210746	001	Jul 10, 2019	Jan	CAHN

TABLET; ORAL

CLOBAZAM

	@	CHARTWELL RX	10MG	A211959	001	Dec 09, 2020	Sep	CAHN
	@		20MG	A211959	002	Dec 09, 2020	Sep	CAHN
	@	ESJAY PHARMA	5MG	A209308	003	Oct 19, 2021	Feb	CAHN
	@		10MG	A209308	001	Oct 22, 2018	Jul	DISC
AB			10MG	A209308	001	Oct 22, 2018	Feb	CAHN
	@		20MG	A209308	002	Oct 22, 2018	Feb	CAHN

CLOBETASOL PROPIONATE

	AEROSOL, FOAM;TOPICAL							
	CLOBETASOL PROPIONATE							
	@	NOVAST LABS	0.05%	A206805	001	Jul 31, 2017	Sep	CAHN
	@	TARO	0.05%	A208563	001	Mar 14, 2024	Aug	DISC
AB1		XIROMED	0.05%	A210638	001	Nov 20, 2025	Nov	NEWA
	CREAM;TOPICAL							
	CLOBETASOL PROPIONATE							
	@	GLENMARK SPECLT	0.05%	A209095	001	May 10, 2018	Jul	DISC
	LOTION;TOPICAL							
	CLOBETASOL PROPIONATE							
	@	BEACH PRODS	0.05%	A208667	001	Nov 29, 2016	May	CAHN
	@ +	NORVIUM BIOSCIENCE	0.05%	N213691	001	May 19, 2020	Jan	CAHN
	OINTMENT;TOPICAL							
	CLOBETASOL PROPIONATE							
	@	GLENMARK SPECLT	0.05%	A208933	001	Mar 20, 2017	Jul	DISC
	SOLUTION;TOPICAL							
	CLOBETASOL PROPIONATE							
	@	GLENMARK PHARMS LTD	0.05%	A210190	001	Apr 18, 2018	Jul	DISC
	@	TARO	0.05%	A075363	001	Dec 29, 2000	Aug	DISC
	SPRAY;TOPICAL							
	CLOBETASOL PROPIONATE							
>D> AT	@	GLENMARK SPECLT	0.05%	A209004	001	Mar 26, 2018	Jul	DISC
>A>		LUPIN LTD	0.05%	A208125	001	Mar 26, 2018	Dec	DISC
	@		0.05%	A208125	001	Mar 26, 2018	Dec	DISC
	@	MACLEODS PHARMS LTD	0.05%	A214345	001	Dec 02, 2024	Jun	DISC
	SUSPENSION/DROPS;OPHTHALMIC							
	BYQLOVI							
	+	FORMOSA	0.05%	N218158	001	Mar 04, 2024	May	CTNA
	+		0.05%	N218158	001	Mar 04, 2024	Feb	CAHN
	+	HARROW EYE	0.05%	N218158	001	Mar 04, 2024	Sep	CAHN

CLOFARABINE

	SOLUTION;INTRAVENOUS							
	CLOFARABINE							
AP	!	MEITHEAL	20MG/20ML (1MG/ML)	A213461	001	Oct 23, 2020	Jul	CHRS
	CLOLAR							
	@ +	GENZYME	20MG/20ML (1MG/ML)	N021673	001	Dec 28, 2004	Jul	DISC

CLOMIPHENE CITRATE

	TABLET;ORAL							
	CLOMIPHENE CITRATE							
AB		ACCORD HLTHCARE	50MG	A219406	001	Oct 03, 2025	Sep	NEWA
AB		NOVITIUM PHARMA	50MG	A219781	001	Oct 17, 2025	Oct	NEWA
	MILOPHENE							
AB		GRANATA BIO CORP	50MG	A072196	001	Dec 20, 1988	Aug	CMFD
	@		50MG	A072196	001	Dec 20, 1988	Aug	CAHN

CLOMIPRAMINE HYDROCHLORIDE

	CAPSULE;ORAL							
	CLOMIPRAMINE HYDROCHLORIDE							
AB		IXORA LIFESCIENCE	25MG	A211364	001	Feb 07, 2020	Sep	CAHN
AB			50MG	A211364	002	Feb 07, 2020	Sep	CAHN
AB			75MG	A211364	003	Feb 07, 2020	Sep	CAHN
AB		LEADING	25MG	A211364	001	Feb 07, 2020	Jun	CAHN
AB			50MG	A211364	002	Feb 07, 2020	Jun	CAHN
AB			75MG	A211364	003	Feb 07, 2020	Jun	CAHN

CLONAZEPAM

	TABLET, ORALLY DISINTEGRATING;ORAL							
	CLONAZEPAM							
	@	SUN PHARM INDS INC	0.125MG	A078654	001	Aug 27, 2014	Jan	DISC
	@		0.25MG	A078654	002	Aug 27, 2014	Jan	DISC
	@		0.5MG	A078654	003	Aug 27, 2014	Jan	DISC
	@		1MG	A078654	004	Aug 27, 2014	Jan	DISC
	@		2MG	A078654	005	Aug 27, 2014	Jan	DISC

CLONIDINE

SYSTEM; TRANSDERMAL		CLONIDINE					
	@	INGENUS PHARMS LLC	0.1MG/24HR	A076157	001	Aug 18, 2009	Oct DISC
AB			0.1MG/24HR	A076157	001	Aug 18, 2009	Sep CAHN
	@		0.2MG/24HR	A076157	002	Aug 18, 2009	Oct DISC
AB			0.2MG/24HR	A076157	002	Aug 18, 2009	Sep CAHN
	@		0.3MG/24HR	A076157	003	Aug 18, 2009	Oct DISC
AB			0.3MG/24HR	A076157	003	Aug 18, 2009	Sep CAHN

CLONIDINE HYDROCHLORIDE

SOLUTION; ORAL		JAVADIN					
	+	AZURITY	0.02MG/ML	N220256	001	Oct 23, 2025	Oct NEWA
TABLET, EXTENDED RELEASE; ORAL		CLONIDINE HYDROCHLORIDE					
	@	RUBICON RESEARCH	0.1MG	A210680	001	Apr 30, 2018	Apr CAHN
AB1		SOMERSET THERAPS LLC	0.1MG	A211433	001	Oct 12, 2018	Mar CMFD

CLOPIDOGREL BISULFATE

TABLET; ORAL		CLOPIDOGREL BISULFATE					
AB		PURACAP LABS BLU	EQ 75MG BASE	A213351	001	Jul 17, 2020	Nov CAHN
AB			EQ 300MG BASE	A213351	002	Jul 17, 2020	Nov CAHN

CLOTRIMAZOLE

SOLUTION; TOPICAL		CLOTRIMAZOLE					
AT		TP ANDA HOLDINGS	1%	A212281	001	Jul 25, 2019	Aug CAHN
SOLUTION/DROPS; OTIC		CLOTIC					
	+	CARWIN PHARM ASSOC	1%	N217628	001	Sep 26, 2025	Oct CAHN
	+	LAB SALVAT	1%	N217628	001	Sep 26, 2025	Sep NEWA

CLOZAPINE

TABLET; ORAL		CLOZAPINE					
	@	SUN PHARM INDS INC	25MG	A075713	001	Nov 15, 2002	Apr DISC
	@		50MG	A075713	003	Aug 19, 2005	Apr DISC
	@		100MG	A075713	002	Nov 15, 2002	Apr DISC
	@		200MG	A075713	004	Nov 07, 2017	Apr DISC
TABLET, ORALLY DISINTEGRATING; ORAL		FAZACLO ODT					
	@ +	JAZZ	50MG	N021590	003	Jun 03, 2005	Oct CRLD

COBICISTAT

TABLET; ORAL		TYBOST					
	@ +	GILEAD SCIENCES INC	90MG	N203094	002	Jun 20, 2025	Oct DISC
	+		90MG	N203094	002	Jun 20, 2025	Jul NEWA

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET; ORAL		PREZCOBIX					
	+	JANSSEN PRODS	150MG; EQ 675MG BASE	N205395	002	Mar 21, 2025	Mar NEWA
	+		150MG; EQ 800MG BASE	N205395	001	Jan 29, 2015	Mar CPOT
	+		150MG; 800MG	N205395	001	Jan 29, 2015	Mar CAIN

COCAINE HYDROCHLORIDE

SOLUTION; NASAL		GOPRELTO					
>A>	+	LXO IRELAND	4%	N209963	001	Dec 14, 2017	Dec CAHN
>D>	+	NODEN PHARMA	4%	N209963	001	Dec 14, 2017	Dec CAHN

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL		PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE					
AA	!	CHARTWELL	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A040660	001	Dec 07, 2006	Sep CAHN
AA	!	GENUS LIFESCIENCES	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A040660	001	Dec 07, 2006	Oct CAHN

SYRUP;ORAL

PROMETH VC W/ CODEINE

@ CHARTWELL RX 10MG/5ML; 5MG/5ML; 6.25MG/5ML A 088764 001 Oct 31, 1984 Apr CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA CHARTWELL RX 10MG/5ML; 6.25MG/5ML A 090180 001 Mar 17, 2010 Apr CAHN

AA ! COSETTE 10MG/5ML; 6.25MG/5ML A 200386 001 Jun 29, 2012 May CAHN

AA XTTRIUM LABS INC 10MG/5ML; 6.25MG/5ML A 088875 001 Dec 17, 1984 Feb CAHN

PROMETHAZINE WITH CODEINE

@ PHARM ASSOC 10MG/5ML; 6.25MG/5ML A 040650 001 Jan 31, 2006 Jan DISC

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

@ HIKMA 30MG/5ML N 202245 001 Jun 30, 2011 Jun CAHN

TABLET;ORAL

CODEINE SULFATE

AB + HIKMA 15MG N 022402 001 Jul 16, 2009 Jun CAHN

AB + 30MG N 022402 002 Jul 16, 2009 Jun CAHN

AB +! 60MG N 022402 003 Jul 16, 2009 Jun CAHN

COLESEVELAM HYDROCHLORIDE

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

@ MACLEODS PHARMS LTD 625MG A 204893 001 Apr 18, 2025 Jul DISC

AB 625MG A 204893 001 Apr 18, 2025 Apr NEWA

COLESTIPOL HYDROCHLORIDE

TABLET;ORAL

COLESTIPOL HYDROCHLORIDE

AB CARNEGIE 1GM A 220012 001 Sep 15, 2025 Sep NEWA

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

@ ADRASTEIA PHARMA EQ 150MG BASE/VIAL A 064216 001 Feb 26, 1999 Jul DISC

@ NEXUS EQ 150MG BASE/VIAL A 065177 001 Mar 19, 2004 Apr DISC

@ PHARMOBEDIENT EQ 150MG BASE/VIAL A 064216 001 Feb 26, 1999 Sep CAHN

COPPER

SYSTEM;INTRAUTERINE

MIUDELLA

+! SEBELA WOMENS HLTH N/A N 218201 001 Feb 24, 2025 Feb NEWA

COPPER CU-64 DOTATATE

SOLUTION;INTRAVENOUS

DETECTNET

+! CURIUM 4mL (1mCi/ML) N 213227 001 Sep 03, 2020 Jan CAHN

COSYNTROPIN

INJECTABLE;INJECTION

COSYNTROPIN

>D> @ NORVIUM BIOSCIENCE 0.25MG/VIAL A 090574 001 Dec 17, 2009 Dec CAHN

>A> @ PHARMOBEDIENT 0.25MG/VIAL A 090574 001 Dec 17, 2009 Dec CAHN

CROMOLYN SODIUM

CONCENTRATE;ORAL

GASTROCROM

AA +! VIATRIS SPECIALTY 100MG/5ML N 020479 001 Feb 29, 1996 Feb CAHN

SOLUTION;INHALATION

CROMOLYN SODIUM

AN FERA PHARMS LLC 10MG/ML A 075437 001 Apr 21, 2000 Apr CAHN

@ HIKMA 10MG/ML A 075333 001 Apr 30, 2002 Jun CAHN

CUPRIC SULFATE

INJECTABLE; INJECTION  
CUPRIC SULFATE

!	AM REGENT	EQ 0.4MG COPPER/ML	A216324	001	Dec 16, 2022	Jan CTEC
@	APOTEX CORP	EQ 0.4MG COPPER/ML	A218745	001	Aug 19, 2024	Jan DISC

CYANOCOBALAMIN

INJECTABLE; INJECTION  
CYANOCOBALAMIN

AP	EUGIA PHARMA	1MG/ML	A213874	001	Dec 08, 2020	Oct CMFD
AP	MEITHEAL	1MG/ML	A214316	001	Nov 15, 2024	Apr CAHN
	DODEX					
@	ACCORD HLTHCARE	1MG/ML	A083022	001		Jan DISC
	SPRAY, METERED; NASAL					
	CALOMIST					
@	PH HEALTH	25MCG/SPRAY	N022102	001	Jul 27, 2007	Jul CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL  
CYCLOBENZAPRINE HYDROCHLORIDE

@	SUN PHARM INDS LTD	5MG	A078722	001	May 12, 2008	Oct DISC
@		7.5MG	A078722	002	May 12, 2008	Oct DISC
@		10MG	A078722	003	May 12, 2008	Oct DISC

TABLET; SUBLINGUAL  
TONMYA

+	!	TONIX	2.8MG	N219428	001	Aug 15, 2025	Aug NEWA
---	---	-------	-------	---------	-----	--------------	----------

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC  
CYCLOMYDRIL

+	!	ALCON LABS INC	0.2%; 1%	A084300	001		May CRLD
---	---	----------------	----------	---------	-----	--	----------

CYCLOPHOSPHAMIDE

CAPSULE; ORAL  
CYCLOPHOSPHAMIDE

AB	EIRGEN	25MG	A218282	001	Dec 03, 2024	Aug CAHN
AB		50MG	A218282	002	Dec 03, 2024	Aug CAHN
AB	SENORES PHARMS	25MG	A209872	001	May 07, 2018	Sep CAHN
AB		50MG	A209872	002	May 07, 2018	Sep CAHN
AB	TRI-SOURCE PHARMA	25MG	A218282	001	Dec 03, 2024	Apr CAHN
AB		50MG	A218282	002	Dec 03, 2024	Apr CAHN

SOLUTION; INTRAVENOUS  
FRINDOVYX

+	!	AVYXA HOLDINGS	500MG/ML (500MG/ML)	N210852	001	Jun 07, 2023	Sep CTNA
+	!		1GM/2ML (500MG/ML)	N210852	002	Jun 07, 2023	Sep CTNA
+	!		2GM/4ML (500MG/ML)	N210852	003	Jun 07, 2023	Sep CTNA

CYCLOSPORINE

CAPSULE; ORAL  
CYCLOSPORINE

AB1	QILU	25MG	A219049	001	Sep 15, 2025	Sep NEWA
AB1		100MG	A219049	002	Sep 15, 2025	Sep NEWA

EMULSION; OPHTHALMIC  
CYCLOSPORINE

AB	AMNEAL	0.05%	A211909	001	Nov 28, 2025	Nov NEWA	
	@	APOTEX	0.05%	A207606	001	Jan 12, 2023	Apr DISC
BX		0.05%	A207606	001	Jan 12, 2023	Mar CTEC	

SOLUTION; ORAL  
CYCLOSPORINE

@	ABBVIE	100MG/ML	A065025	001	Mar 03, 2000	Feb DISC
---	--------	----------	---------	-----	--------------	----------

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL  
CYPROHEPTADINE HYDROCHLORIDE

AA	INVATECH	2MG/5ML	A209108	001	Oct 16, 2018	Sep CAHN
----	----------	---------	---------	-----	--------------	----------

CYTARABINE; DAUNORUBICIN

POWDER; INTRAVENOUS  
VYXEOS

+! JAZZ PHARMS THERAP 100MG;44MG N209401 001 Aug 03, 2017 Jul CAHN

DABIGATRAN ETEXILATE MESYLATE

CAPSULE; ORAL

DABIGATRAN ETEXILATE MESYLATE

AB	AUROBINDO PHARMA	EQ 75MG BASE	A208039	001	May 14, 2025	May	NEWA
AB		EQ 110MG BASE	A208039	002	May 14, 2025	May	NEWA
AB		EQ 150MG BASE	A208039	003	May 14, 2025	May	NEWA
	@ BRECKENRIDGE	EQ 75MG BASE	A207922	001	Dec 19, 2024	Jun	DISC
	@	EQ 110MG BASE	A207922	003	Dec 19, 2024	Jun	DISC
	@	EQ 150MG BASE	A207922	002	Dec 19, 2024	Jun	DISC
AB	DR REDDYS	EQ 75MG BASE	A208048	001	Jan 28, 2025	Jan	NEWA
AB		EQ 110MG BASE	A208048	002	Jan 28, 2025	Jan	NEWA
AB		EQ 150MG BASE	A208048	003	Jan 28, 2025	Jan	NEWA
AB	MYLAN	EQ 75MG BASE	A208067	001	Feb 03, 2025	Jan	NEWA
AB		EQ 150MG BASE	A208067	002	Feb 03, 2025	Jan	NEWA

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

@ HOSPIRA 200MG/VIAL A075940 001 Oct 18, 2001 Mar DISC

DALBAVANCIN HYDROCHLORIDE

POWDER; INTRAVENOUS

DALBAVANCIN HYDROCHLORIDE

AP	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A217591	001	Nov 10, 2025	Oct	NEWA
AP	KINDOS	EQ 500MG BASE/VIAL	A218929	001	Nov 26, 2025	Nov	NEWA
AP	TEVA PHARMS INC	EQ 500MG BASE/VIAL	A219465	001	Oct 23, 2025	Oct	NFTG
	DALVANCE						
AP	+! ABBVIE	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	Oct	CFTG

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

AMPYRA

AB	+! MERZ	10MG	N022250	001	Jan 22, 2010	Feb	CAHN
	DALFAMPRIDINE						
	@ SUN PHARM	10MG	A208292	001	May 21, 2019	Aug	DISC

DANTROLENE SODIUM

CAPSULE; ORAL

DANTRIUM

AB	+ PH HEALTH	25MG	N017443	001		Nov	CAHN
AB	+ PH HEALTH	50MG	N017443	003		Nov	CAHN
AB	+! PH HEALTH	100MG	N017443	002		Nov	CAHN

INJECTABLE; INJECTION

DANTRIUM

AP +! PH HEALTH 20MG/VIAL N018264 001 Nov CAHN

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

QTERN

@ + ASTRAZENECA AB 5MG;EQ 5MG BASE N209091 002 May 02, 2019 Jun DISC  
 @ + 10MG;EQ 5MG BASE N209091 001 Feb 27, 2017 Jun DISC

DAPSONE

GEL; TOPICAL

ACZONE

AB +! ALMIRALL 5% N021794 001 Jul 07, 2005 Oct CAHN  
 DAPSONE

AB AUROBINDO PHARMA LTD 5% A218457 001 Apr 04, 2025 Mar NEWA

TABLET; ORAL

DAPSONE

AB SOLIS PHARMS 25MG A203887 001 May 06, 2016 Apr CAHN  
 AB 100MG A203887 002 May 06, 2016 Apr CAHN

DAPTOMYCIN

POWDER; INTRAVENOUS  
DAPTOMYCIN

@	FRESENIUS KABI USA	350MG/VIAL	A213396	001	Aug 01, 2024	Jan	DISC
@	HANGZHOU ZHONGMEI	500MG/VIAL	A215215	001	Nov 26, 2021	Jun	DISC
@ +	MAIA PHARMS INC	350MG/VIAL	N217630	001	Nov 21, 2024	May	DISC
+		500MG/VIAL	N217630	002	Nov 21, 2024	Jun	CHRS
+		500MG/VIAL	N217630	002	Nov 21, 2024	Jun	CMFD
@ +		500MG/VIAL	N217630	002	Nov 21, 2024	May	DISC

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL  
DARIFENACIN HYDROBROMIDE

AB	PURACAP LABS BLU	EQ 7.5MG BASE	A211045	001	Jan 06, 2020	Nov	CAHN
AB		EQ 15MG BASE	A211045	002	Jan 06, 2020	Nov	CAHN

DARUNAVIR

TABLET; ORAL  
DARUNAVIR

AB	ANNORA PHARMA	600MG	A216168	001	Jan 21, 2025	Jan	NEWA
AB		800MG	A216168	002	Jan 21, 2025	Jan	NEWA
AB	HETERO LABS LTD III	400MG	A202083	001	Sep 14, 2023	Jul	CTEC
AB	MYLAN	75MG	A202136	001	Jul 22, 2025	Jul	NFTG
AB		150MG	A202136	002	Jul 22, 2025	Jul	NFTG
		300MG	A202136	003	Jul 22, 2025	Jul	NFTG
AB		400MG	A202136	004	Jul 22, 2025	Jul	NEWA
AB		600MG	A202136	005	Jul 22, 2025	Jul	NEWA
@	TEVA PHARMS USA	600MG	A202118	001	Nov 21, 2017	Jul	DISC
	PREZISTA						
AB	+ JANSSEN PRODS	75MG	N021976	004	Dec 18, 2008	Jul	CFTG
AB	+	150MG	N021976	005	Dec 18, 2008	Jul	CFTG

DASATINIB

TABLET; ORAL  
DASATINIB

AB	ALEMBIC	20MG	A216261	001	Nov 06, 2025	Oct	NEWA
AB		50MG	A216261	002	Nov 06, 2025	Oct	NEWA
AB		70MG	A216261	003	Nov 06, 2025	Oct	NEWA
AB		80MG	A216261	004	Nov 06, 2025	Oct	NEWA
AB		100MG	A216261	005	Nov 06, 2025	Oct	NEWA
AB		140MG	A216261	006	Nov 06, 2025	Oct	NEWA
AB	BIOCON PHARMA	20MG	A217217	001	Mar 03, 2025	Feb	NEWA
AB		50MG	A217217	002	Mar 03, 2025	Feb	NEWA
AB		70MG	A217217	003	Mar 03, 2025	Feb	NEWA
AB		80MG	A217217	004	Mar 03, 2025	Feb	NEWA
AB		100MG	A217217	005	Mar 03, 2025	Feb	NEWA
AB		140MG	A217217	006	Mar 03, 2025	Feb	NEWA
AB	DR REDDYS	20MG	A213383	001	Mar 03, 2025	Feb	NEWA
AB		50MG	A213383	002	Mar 03, 2025	Feb	NEWA
AB		70MG	A213383	003	Mar 03, 2025	Feb	NEWA
AB		80MG	A213383	004	Mar 03, 2025	Feb	NEWA
AB		100MG	A213383	005	Mar 03, 2025	Feb	NEWA
AB		140MG	A213383	006	Mar 03, 2025	Feb	NEWA
AB	EUGIA PHARMA	20MG	A216547	001	Apr 22, 2025	Apr	NEWA
AB		50MG	A216547	002	Apr 22, 2025	Apr	NEWA
AB		70MG	A216547	003	Apr 22, 2025	Apr	NEWA
AB		80MG	A216547	004	Apr 22, 2025	Apr	NEWA
AB		100MG	A216547	005	Apr 22, 2025	Apr	NEWA
AB		140MG	A216547	006	Apr 22, 2025	Apr	NEWA
AB	LUPIN	20MG	A214350	001	Aug 25, 2025	Aug	NEWA
AB		50MG	A214350	002	Aug 25, 2025	Aug	NEWA
AB		70MG	A214350	003	Aug 25, 2025	Aug	NEWA
AB		80MG	A214350	004	Aug 25, 2025	Aug	NEWA
AB		100MG	A214350	005	Aug 25, 2025	Aug	NEWA
AB		140MG	A214350	006	Aug 25, 2025	Aug	NEWA
AB	TEVA PHARMS USA	20MG	A211094	001	Aug 27, 2025	Aug	NEWA
AB		50MG	A211094	002	Aug 27, 2025	Aug	NEWA
AB		70MG	A211094	003	Aug 27, 2025	Aug	NEWA
AB		80MG	A211094	004	Aug 27, 2025	Aug	NEWA
AB		100MG	A211094	005	Aug 27, 2025	Aug	NEWA
AB		140MG	A211094	006	Aug 27, 2025	Aug	NEWA
AB	ZYDUS PHARMS	20MG	A218719	001	Mar 03, 2025	Feb	NEWA

TABLET; ORAL  
DASATINIB

AB		50MG	A218719	002	Mar 03, 2025	Feb	NEWA
AB		70MG	A218719	003	Mar 03, 2025	Feb	NEWA
AB		80MG	A218719	004	Mar 03, 2025	Feb	NEWA
AB		100MG	A218719	005	Mar 03, 2025	Feb	NEWA
AB		140MG	A218719	006	Mar 03, 2025	Feb	NEWA

PHYRAGO

	+	HANDA THERAP	20MG	N216099	001	Dec 05, 2023	Jan	CAHN
	+		50MG	N216099	002	Dec 05, 2023	Jan	CAHN
	+		70MG	N216099	003	Dec 05, 2023	Jan	CAHN
	+		80MG	N216099	004	Dec 05, 2023	Jan	CAHN
	+		100MG	N216099	005	Dec 05, 2023	Jan	CAHN
	+		140MG	N216099	006	Dec 05, 2023	Jan	CAHN

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION  
DAUNORUBICIN HYDROCHLORIDE

>D>		FRESENIUS KABI USA	EQ 5MG BASE/VIAL	A065034	001	Nov 20, 2001	Dec	DISC
>A>	@		EQ 5MG BASE/VIAL	A065034	001	Nov 20, 2001	Dec	DISC

DECITABINE

INJECTABLE; INTRAVENOUS  
DECITABINE

AP		ACCORD HLTHCARE	50MG/VIAL	A203475	001	Feb 27, 2017	Apr	CHRS
AP	!	DR REDDYS	50MG/VIAL	A203131	001	Jul 11, 2013	Apr	CHRS
	@	EUGIA PHARMA	50MG/VIAL	A214569	001	Sep 20, 2021	Oct	DISC
	@	LUPIN LTD	50MG/VIAL	A210756	001	Nov 09, 2018	Nov	DISC
>A>	AP	RELIANCE LIFE SCI	50MG/VIAL	A217814	001	Dec 19, 2025	Dec	NEWA
		POWDER; INTRAVENOUS						
		DECITABINE						
	@ +	SUN PHARM	50MG/VIAL	N205582	001	Jan 28, 2014	Aug	DISC

DEFERASIROX

GRANULE; ORAL  
DEFERASIROX

>A>	AB	AUCTA	90MG	A214559	001	Mar 09, 2021	Dec	CAHN
>A>	AB		180MG	A214559	002	Mar 09, 2021	Dec	CAHN
>A>	AB		360MG	A214559	003	Mar 09, 2021	Dec	CAHN
	AB	AUROBINDO PHARMA	90MG	A215137	001	Sep 08, 2025	Aug	NEWA
	AB		180MG	A215137	002	Sep 08, 2025	Aug	NEWA
	AB		360MG	A215137	003	Sep 08, 2025	Aug	NEWA
>D>	AB	EPIC PHARMA LLC	90MG	A214559	001	Mar 09, 2021	Dec	CAHN
	AB		90MG	A214559	001	Mar 09, 2021	Sep	CAHN
>D>	AB		180MG	A214559	002	Mar 09, 2021	Dec	CAHN
	AB		180MG	A214559	002	Mar 09, 2021	Sep	CAHN
>D>	AB		360MG	A214559	003	Mar 09, 2021	Dec	CAHN
	AB		360MG	A214559	003	Mar 09, 2021	Sep	CAHN
>D>	AB	TEVA PHARMS USA	90MG	A214180	001	Nov 19, 2021	Dec	DISC
>A>	@		90MG	A214180	001	Nov 19, 2021	Dec	DISC
>D>	AB		180MG	A214180	002	Nov 19, 2021	Dec	DISC
>A>	@		180MG	A214180	002	Nov 19, 2021	Dec	DISC
>D>	AB		360MG	A214180	003	Nov 19, 2021	Dec	DISC
>A>	@		360MG	A214180	003	Nov 19, 2021	Dec	DISC

TABLET; ORAL

DEFERASIROX

AB		JUBILANT GENERICS	90MG	A211660	001	Apr 11, 2025	Apr	NEWA
AB			180MG	A211660	002	Apr 11, 2025	Apr	NEWA
AB			360MG	A211660	003	Apr 11, 2025	Apr	NEWA
	@	SUN PHARM	90MG	A211641	001	Jan 02, 2020	Apr	DISC
	@		180MG	A211641	003	Jun 15, 2020	Apr	DISC
	@		360MG	A211641	002	Jan 02, 2020	Apr	DISC

TABLET, FOR SUSPENSION; ORAL

DEFERASIROX

@		PHARMOBEDIANT	125MG	A206585	001	May 17, 2024	Sep	CAHN
@			250MG	A206585	002	May 17, 2024	Sep	CAHN
@			500MG	A206585	003	May 17, 2024	Sep	CAHN
@		TORRENT	125MG	A209426	001	Nov 05, 2024	Jun	DISC
@			250MG	A209426	002	Nov 05, 2024	Jun	DISC
@			500MG	A209426	003	Nov 05, 2024	Jun	DISC

DEFERIPRONE

TABLET; ORAL  
DEFERIPRONE

>A>	AB	SENORES PHARMS	500MG	A220132	001	Dec 11, 2025	Dec	NEWA
>A>	AB		1GM	A220132	002	Dec 11, 2025	Dec	NEWA

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION  
DEFERAL

AP	+	MITEM PHARMA	500MG/VIAL	N016267	001		Aug	CAHN
	@	+	2GM/VIAL	N016267	002	May 25, 2000	Aug	CAHN

DEFLAZACORT

SUSPENSION; ORAL  
DEFLAZACORT

AB		UPSHER SMITH LABS	22.75MG/ML	A216992	001	Aug 11, 2025	Aug	NEWA
AB		ZYDUS LIFESCIENCES	22.75MG/ML	A220042	001	Oct 03, 2025	Sep	NEWA
AB		PYQUVI						
AB		AUCTA	22.75MG/ML	A219417	001	Jun 30, 2025	Jun	NEWA

TABLET; ORAL  
DEFLAZACORT

>A>	AB	AMNEAL	6MG	A217173	001	Dec 12, 2025	Dec	NEWA
>A>	AB		18MG	A217173	002	Dec 12, 2025	Dec	NEWA
>A>	AB		30MG	A217173	003	Dec 12, 2025	Dec	NEWA
>A>	AB		36MG	A217173	004	Dec 12, 2025	Dec	NEWA
	AB	SUN PHARM	6MG	A217741	001	Mar 18, 2025	Mar	NEWA
	AB		18MG	A217741	002	Mar 18, 2025	Mar	NEWA
	AB		30MG	A217741	003	Mar 18, 2025	Mar	NEWA
	AB		36MG	A217741	004	Mar 18, 2025	Mar	NEWA
		JAYTHARI						
AB		ZYDUS LIFESCIENCES	6MG	A219254	001	Apr 08, 2025	Mar	NEWA
AB			18MG	A219254	002	Apr 08, 2025	Mar	NEWA
AB			30MG	A219254	003	Apr 08, 2025	Mar	NEWA
AB			36MG	A219254	004	Apr 08, 2025	Mar	NEWA

DELGOCITINIB

CREAM; TOPICAL  
ANZUPGO

	+	LEO PHARMA AS	2%	N219155	001	Jul 23, 2025	Jul	NEWA
--	---	---------------	----	---------	-----	--------------	-----	------

DESLORATADINE

SOLUTION; ORAL  
DESLORATADINE

!	TARO		0.5MG/ML	A202936	001	May 26, 2016	Sep	CMFD
---	------	--	----------	---------	-----	--------------	-----	------

TABLET; ORAL  
DESLORATADINE

AB		AJENAT PHARMS	5MG	A078355	001	Apr 19, 2012	Jan	CAHN
----	--	---------------	-----	---------	-----	--------------	-----	------

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION  
DDAVP

AP	+	NORDIC PHARMA	0.004MG/ML	N018938	001	Mar 30, 1984	Aug	CAHN
	@		0.015MG/ML	N018938	002	Apr 25, 1995	Aug	CAHN

TABLET; ORAL  
DESMOPRESSIN ACETATE

@	GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015	May	DISC
@		0.2MG	A201831	002	May 28, 2015	May	DISC

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-21  
AVERI

	AVION PHARMS	0.15MG;0.03MG	A218933	001	May 02, 2025	Apr	NEWA
--	--------------	---------------	---------	-----	--------------	-----	------

TABLET; ORAL-28  
AVERI

AB	AVION PHARMS	0.15MG;0.03MG	A218933	002	May 02, 2025	Apr	NEWA
----	--------------	---------------	---------	-----	--------------	-----	------

DESONIDE

		CREAM; TOPICAL							
		DESONIDE							
AB	!	CADILA	0.05%	A210198	001	Nov 20, 2019	Jul	CHRS	
	@	GLENMARK SPECLT	0.05%	A209729	001	Jul 24, 2017	Jul	DISC	
	@ +	PADAGIS US	0.05%	N017010	001		Jul	DISC	
		GEL; TOPICAL							
		DESONIDE							
	!	SENORES PHARMS	0.05%	A202470	001	May 11, 2020	Sep	CAHN	
		LOTION; TOPICAL							
		DESONIDE							
AB	!	ALEMBIC	0.05%	A213632	001	Aug 24, 2020	Sep	CHRS	
	@	GLENMARK SPECLT	0.05%	A209494	001	Sep 26, 2017	Jul	DISC	
		DESOWEN							
	@	GALDERMA LABS LP	0.05%	A072354	001	Jan 24, 1992	Sep	DISC	
		OINTMENT; TOPICAL							
		DESONIDE							
	@	GLENMARK PHARMS LTD	0.05%	A209996	001	Sep 15, 2017	Jul	DISC	
		DESOWEN							
	@	GALDERMA LABS LP	0.05%	A071425	001	Jun 15, 1988	May	DISC	

DESOXIMETASONE

		OINTMENT; TOPICAL							
		DESOXIMETASONE							
	@	GLENMARK PHARMS LTD	0.25%	A202838	001	Sep 20, 2013	Jul	DISC	
AB	!	ZYDUS LIFESCIENCES	0.25%	A205206	001	Sep 19, 2017	Jul	CHRS	
		SPRAY; TOPICAL							
		TOPICORT							
AT	+!	SUN PHARMA CANADA	0.25%	N204141	001	Apr 11, 2013	Aug	CAHN	

DESVENLAFAXINE SUCCINATE

		TABLET, EXTENDED RELEASE; ORAL							
		DESVENLAFAXINE SUCCINATE							
AB		HIKMA	EQ 25MG BASE	A204083	002	Feb 16, 2016	Aug	CMS1	
AB			EQ 50MG BASE	A204083	003	Feb 16, 2016	Aug	CMS1	
AB		MACLEODS PHARMS LTD	EQ 50MG BASE	A211427	001	Jan 15, 2025	Jan	NEWA	
AB			EQ 100MG BASE	A211427	002	Jan 15, 2025	Jan	NEWA	
AB		MEDICAP LABS	EQ 50MG BASE	A204805	001	May 07, 2019	Feb	CAHN	
AB			EQ 100MG BASE	A204805	002	May 07, 2019	Feb	CAHN	

DEUTETRABENAZINE

		TABLET; ORAL							
		AUSTEDO							
	+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017	Feb	CAHN	
	+		6MG	N208082	001	Apr 03, 2017	Jan	CTEC	
	+		9MG	N208082	002	Apr 03, 2017	Feb	CAHN	
	+		9MG	N208082	002	Apr 03, 2017	Jan	CTEC	
	+!		12MG	N208082	003	Apr 03, 2017	Feb	CAHN	
	+!		12MG	N208082	003	Apr 03, 2017	Jan	CTEC	
		DEUTETRABENAZINE							
	@	AUROBINDO PHARMA LTD	6MG	A215971	001	Dec 26, 2024	Jan	DISC	
	@		9MG	A215971	002	Dec 26, 2024	Jan	DISC	
	@		12MG	A215971	003	Dec 26, 2024	Jan	DISC	
		TABLET, EXTENDED RELEASE; ORAL							
		AUSTEDO XR							
	+	TEVA	24MG	N216354	003	Feb 17, 2023	Jul	CHRS	
	+!		48MG	N216354	007	May 29, 2024	Jul	CHRS	

DEXAMETHASONE

		TABLET; ORAL							
		DEXAMETHASONE							
AB	+	HIKMA	0.5MG	A084612	002		Apr	CMS1	
AB	+		0.75MG	A084612	003		Apr	CMS1	
AB	+!		1MG	A084612	004	Sep 15, 1983	Apr	CMS1	
AB	+		1.5MG	A084612	005		Apr	CMS1	
AB	+!		2MG	A084612	006		Apr	CMS1	
AB	+!		6MG	A084612	007	Sep 15, 1983	Apr	CMS1	
AB		PHARMOBEDIANT	1.5MG	A201270	001	Jul 17, 2017	Sep	CAHN	

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION  
DEXAMETHASONE SODIUM PHOSPHATE

	@	EUGIA PHARMA	EQ 4MG PHOSPHATE/ML	A206781	001	Dec 01, 2015	Jul	DISC
>D>	AP		EQ 10MG PHOSPHATE/ML	A210967	001	Jun 07, 2019	Dec	DISC
>A>	@		EQ 10MG PHOSPHATE/ML	A210967	001	Jun 07, 2019	Dec	DISC

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL  
POLMON

	!	CARWIN PHARM ASSOC	2MG/5ML	A202520	001	Jul 16, 2018	Mar	CAHN
	!	CARWIN PHARMS	2MG/5ML	A202520	001	Jul 16, 2018	Feb	CAHN
	!	PHARMOBEDIENT	2MG/5ML	A202520	001	Jul 16, 2018	Aug	CAHN

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL  
DEXLANSOPRAZOLE

AB		ALEMBIC	30MG	A219115	001	Nov 12, 2025	Oct	NEWA
AB			60MG	A219115	002	Nov 12, 2025	Oct	NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION  
DEXMEDETOMIDINE HYDROCHLORIDE

AP		HIKMA	EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	A206407	003	May 30, 2025	May	NFTG
AP			EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	A206407	001	Jan 30, 2020	May	CAHN
AP			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	A206407	002	Jan 30, 2020	May	CAHN
		PRECEDEX						
AP	+!	HOSPIRA	EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	N021038	005	Jan 31, 2020	May	CFTG

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		MEDICAP LABS	5MG	A078992	001	Nov 23, 2021	Feb	CAHN
AB			10MG	A078992	002	Nov 23, 2021	Feb	CAHN
AB			15MG	A078992	003	Nov 18, 2013	Feb	CAHN
AB			30MG	A078992	004	Nov 18, 2013	Feb	CAHN
AB			20MG	A078992	005	Nov 23, 2021	Feb	CAHN
AB			40MG	A078992	006	Nov 23, 2021	Feb	CAHN
	@	SUN PHARM INDS INC	5MG	A206734	001	Nov 05, 2021	Jul	DISC
	@		10MG	A206734	002	Nov 05, 2021	Jul	DISC
	@		15MG	A206734	003	Nov 05, 2021	Jul	DISC
	@		20MG	A206734	004	Nov 05, 2021	Jul	DISC
	@		25MG	A206734	005	Nov 05, 2021	Jul	DISC
	@		30MG	A206734	006	Nov 05, 2021	Jul	DISC
	@		35MG	A206734	007	Nov 05, 2021	Jul	DISC
	@		40MG	A206734	008	Nov 05, 2021	Jul	DISC
		TABLET; ORAL						
		DEXMETHYLPHENIDATE HYDROCHLORIDE						
AB		ABHAI LLC	2.5MG	A206931	001	Dec 04, 2015	Nov	CAHN
AB			5MG	A206931	002	Dec 04, 2015	Nov	CAHN
AB			10MG	A206931	003	Dec 04, 2015	Nov	CAHN
	@	RHODES PHARMS	2.5MG	A208756	001	Nov 20, 2017	Jan	DISC
	@		5MG	A208756	002	Nov 20, 2017	Jan	DISC
	@		10MG	A208756	003	Nov 20, 2017	Jan	DISC

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION  
DEXRAZOXANE HYDROCHLORIDE

AP		MSN	EQ 250MG BASE/VIAL	A216748	001	Mar 26, 2025	Mar	NEWA
AP			EQ 500MG BASE/VIAL	A216748	002	Mar 26, 2025	Mar	NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL  
DEXTROAMPHETAMINE SULFATE

>D>	@	ANDA REPOSITORY	5MG	A076137	001	Jan 18, 2002	Dec	CAHN
>D>	@		10MG	A076137	002	Jan 18, 2002	Dec	CAHN
>D>	@		15MG	A076137	003	Jan 18, 2002	Dec	CAHN
>A>	@	SENORES PHARMS	5MG	A076137	001	Jan 18, 2002	Dec	CAHN

CAPSULE, EXTENDED RELEASE;ORAL  
 DEXTROAMPHETAMINE SULFATE

>A>	@	10MG	A 076137	002	Jan 18, 2002	Dec	CAHN
>A>	@	15MG	A 076137	003	Jan 18, 2002	Dec	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

AA	!	PAI HOLDINGS	15MG/5ML;6.25MG/5ML	A 040649	001	Feb 14, 2006	Apr	CAHN
AA		PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE						
AA		COSETTE	15MG/5ML;6.25MG/5ML	A 091687	001	Jun 28, 2012	May	CAHN
AA		PROMETHAZINE W/ DEXTROMETHORPHAN						
AA		XTTRIUM LABS INC	15MG/5ML;6.25MG/5ML	A 088864	001	Jan 04, 1985	Feb	CAHN

DIAZEPAM

GEL;RECTAL

AB	!	BAUSCH	2.5MG/0.5ML (5MG/ML)	N 020648	001	Jul 29, 1997	Nov	CFTG
AB		NAVINTA LLC	2.5MG/0.5ML (5MG/ML)	A 217468	001	Nov 14, 2025	Nov	NFTG
AB			10MG/2ML (5MG/ML)	A 217468	002	Nov 14, 2025	Nov	NEWA
AB			20MG/4ML (5MG/ML)	A 217468	003	Nov 14, 2025	Nov	NEWA

INJECTABLE; INJECTION

AP		GALENICUM HLTH	50MG/10ML (5MG/ML)	A 216422	001	May 19, 2025	May	NEWA
AP	!	REGCON HOLDINGS	10MG/2ML (5MG/ML)	A 210363	001	Mar 18, 2019	Oct	CAHN
AP			50MG/10ML (5MG/ML)	A 211998	001	Dec 26, 2019	Oct	CAHN

DIAZOXIDE CHOLINE

TABLET, EXTENDED RELEASE;ORAL

		VYKAT XR						
	+	SOLENO THERAP	25MG	N 216665	001	Mar 26, 2025	Mar	NEWA
	+		75MG	N 216665	002	Mar 26, 2025	Mar	NEWA
	+		150MG	N 216665	003	Mar 26, 2025	Mar	NEWA

DICHLORPHENAMIDE

TABLET;ORAL

AB		RISING	50MG	A 218783	001	Nov 18, 2025	Nov	NEWA
----	--	--------	------	----------	-----	--------------	-----	------

DICLOFENAC POTASSIUM

CAPSULE;ORAL

AB		ONESOURCE SPECIALTY	25MG	A 210078	001	Dec 03, 2019	Jun	CAHN
AB	!	ASIO HOLDINGS	25MG	N 022202	001	Jun 16, 2009	Aug	CAHN

FOR SOLUTION;ORAL

AB	!	ASIO HOLDINGS	50MG	N 022165	001	Jun 17, 2009	Aug	CAHN
AB		TORRENT	50MG	A 215891	001	Jan 22, 2025	Jan	NEWA
AB		UMEDICA	50MG	A 217010	001	Aug 29, 2025	Aug	NEWA

TABLET;ORAL

AB		RK PHARMA	50MG	A 075463	001	Jul 26, 1999	Mar	CHRS
AB	!	RUBICON	50MG	A 075229	001	Nov 20, 1998	Mar	CHRS
AB		UMEDICA	25MG	A 215750	002	Jun 30, 2025	Jun	NEWA

DICLOFENAC SODIUM

GEL;TOPICAL

BX		ALEMBIC	3%	A 212351	001	Jul 27, 2022	Mar	CTEC
----	--	---------	----	----------	-----	--------------	-----	------

SOLUTION;TOPICAL

AB		ENCUBE	2%	A 217646	001	Apr 09, 2025	Mar	NEWA
----	--	--------	----	----------	-----	--------------	-----	------

TABLET, DELAYED RELEASE;ORAL

AB		AUROBINDO PHARMA USA	50MG	A 075281	002	Feb 12, 2002	Apr	CMFD
AB			75MG	A 075281	003	Feb 12, 2002	Apr	CMFD
AB		UMEDICA	25MG	A 219945	001	Nov 05, 2025	Oct	NEWA
AB			50MG	A 219945	002	Nov 05, 2025	Oct	NEWA

	TABLET, DELAYED RELEASE;ORAL DICLOFENAC SODIUM							
AB		75MG	A219945	003	Nov 05, 2025	Oct	NEWA	
	TABLET, EXTENDED RELEASE;ORAL DICLOFENAC SODIUM							
AB	NOVAST LABS	100MG	A216275	001	Sep 23, 2022	Apr	CAHN	
	<u>DICYCLOMINE HYDROCHLORIDE</u>							
	CAPSULE;ORAL DICYCLOMINE HYDROCHLORIDE							
AB	RISING	10MG	A219242	001	Jun 23, 2025	Jun	NEWA	
	INJECTABLE;INJECTION DICYCLOMINE HYDROCHLORIDE							
	@ NEXUS	10MG/ML	A206468	001	Feb 01, 2019	Apr	DISC	
	TABLET;ORAL DICYCLOMINE HYDROCHLORIDE							
AB	PRINSTON INC	20MG	A218310	001	Jun 06, 2025	May	NEWA	
AB	RUBICON RESEARCH	20MG	A216736	001	Dec 14, 2022	Mar	CAHN	
	!	40MG	A216736	002	Mar 25, 2025	Mar	NEWA	
	<u>DIETHYLPROPION HYDROCHLORIDE</u>							
	TABLET;ORAL TENUATE							
	@ + MPP PHARMA	25MG	N011722	002		Jun	CAHN	
	TABLET, EXTENDED RELEASE;ORAL TENUATE DOSPAN							
	@ + ANI PHARMS	75MG	N012546	001		Apr	CAHN	
	<u>DIFELIKEFALIN ACETATE</u>							
	SOLUTION;INTRAVENOUS KORSUVA							
	+! VIFOR INTL	EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)	N214916	001	Aug 23, 2021	Apr	CAHN	
	<u>DIFLUPREDNATE</u>							
	EMULSION;OPHTHALMIC DIFLUPREDNATE							
AB	MYLAN LABS LTD	0.05%	A212566	001	Mar 20, 2025	Mar	NEWA	
AB	UPSHER SMITH LABS	0.05%	A218191	001	Feb 11, 2025	Jan	NEWA	
	<u>DIGOXIN</u>							
	ELIXIR;ORAL DIGOXIN							
AA	+! HIKMA	0.05MG/ML	N021648	001	Aug 26, 2004	Jun	CAHN	
	<u>DIHYDROERGOTAMINE MESYLATE</u>							
	INJECTABLE;INJECTION DIHYDROERGOTAMINE MESYLATE							
	@ BAXTER HLTHCARE CORP	1MG/ML	A216747	001	Jan 07, 2025	Jun	DISC	
	@ CIPLA	1MG/ML	A212334	001	Sep 20, 2024	Jan	DISC	
AP	MILLA PHARMS	1MG/ML	A212046	001	Jan 07, 2020	Sep	CAHN	
	POWDER;NASAL ATZUMI							
	+! SATSUMA PHARMS	EQ 5.2MG BASE	N217901	001	Apr 30, 2025	Apr	NEWA	
	SOLUTION;SUBCUTANEOUS BREKIYA (AUTOINJECTOR)							
	+! AMNEAL	1MG/ML	N215400	001	May 14, 2025	May	NEWA	
	SPRAY, METERED;NASAL DIHYDROERGOTAMINE MESYLATE							
AB	AGGREGA	0.5MG/SPRAY	A215228	001	Feb 26, 2025	Feb	NEWA	
AB	SOMERSET THERAPS LLC	0.5MG/SPRAY	A215228	001	Feb 26, 2025	Sep	CAHN	
	<u>DILTIAZEM HYDROCHLORIDE</u>							
	CAPSULE, EXTENDED RELEASE;ORAL DILTIAZEM HYDROCHLORIDE							
AB1	AMTA	60MG	A219073	001	Mar 24, 2025	Mar	NEWA	
AB1		90MG	A219073	002	Mar 24, 2025	Mar	NEWA	
AB1		120MG	A219073	003	Mar 24, 2025	Mar	NEWA	
AB1	NOVAST LABS	60MG	A218032	001	Jul 02, 2025	Jun	NEWA	
AB1		90MG	A218032	002	Jul 02, 2025	Jun	NEWA	
AB1		120MG	A218032	003	Jul 02, 2025	Jun	NEWA	

CAPSULE, EXTENDED RELEASE;ORAL							
DILTIAZEM HYDROCHLORIDE							
	@	SUN PHARM	120MG	A203023	001	Jun 08, 2017	Apr DISC
	@		180MG	A203023	002	Jun 08, 2017	Mar DISC
	@		240MG	A203023	003	Jun 08, 2017	Mar DISC
	@		300MG	A203023	004	Jun 08, 2017	Feb DISC
AB1		UTOPIC PHARMS	60MG	A219073	001	Mar 24, 2025	Apr CAHN
AB1			90MG	A219073	002	Mar 24, 2025	Apr CAHN
AB1			120MG	A219073	003	Mar 24, 2025	Apr CAHN
INJECTABLE;INJECTION							
DILTIAZEM HYDROCHLORIDE							
	@	EUGIA PHARMA	5MG/ML	A216552	001	Mar 29, 2023	Aug DISC
	@	HOSPIRA	5MG/ML	A074941	001	Apr 15, 1998	Nov DISC
SOLUTION;INTRAVENOUS							
DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE							
	+	HQ SPCLT PHARMA	100MG/100ML (1MG/ML)	N218038	001	Feb 21, 2025	Feb NEWA
	+		250MG/250ML (1MG/ML)	N218038	002	Feb 21, 2025	Feb NEWA
TABLET;ORAL							
DILTIAZEM HYDROCHLORIDE							
AB		ALEMBIC	30MG	A217633	001	Nov 14, 2025	Nov NEWA
AB			60MG	A217633	002	Nov 14, 2025	Nov NEWA
AB			90MG	A217633	003	Nov 14, 2025	Nov NEWA
AB			120MG	A217633	004	Nov 14, 2025	Nov NEWA
AB		ZYDUS LIFESCIENCES	30MG	A219253	001	Aug 08, 2025	Aug NEWA
AB			60MG	A219253	002	Aug 08, 2025	Aug NEWA
AB			90MG	A219253	003	Aug 08, 2025	Aug NEWA
AB			120MG	A219253	004	Aug 08, 2025	Aug NEWA
<u>DIMETHYL FUMARATE</u>							
CAPSULE, DELAYED RELEASE;ORAL							
DIMETHYL FUMARATE							
	@	CIPLA	120MG	A210305	001	Sep 24, 2020	Feb DISC
	@		240MG	A210305	002	Sep 24, 2020	Feb DISC
	@	TORRENT	120MG	A210390	001	Jan 06, 2025	Jun DISC
	@		240MG	A210390	002	Jan 06, 2025	Jun DISC
<u>DIPHENHYDRAMINE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
DIPHENHYDRAMINE HYDROCHLORIDE							
AP		AVET LIFESCIENCES	50MG/ML	A205336	001	Jun 24, 2025	Jun NEWA
AP			50MG/ML	A205337	001	Nov 14, 2025	Nov NEWA
AP		MICRO LABS	50MG/ML	A219845	001	Aug 22, 2025	Aug NEWA
AP	!	NORVIUM BIOSCIENCE	50MG/ML	A040498	001	Jul 12, 2005	Feb CAHN
<u>DIPYRIDAMOLE</u>							
TABLET;ORAL							
DIPYRIDAMOLE							
AB		BARR LABS	75MG	A087717	001	Oct 03, 1990	Mar CAHN
<u>DIROXIMEL FUMARATE</u>							
CAPSULE, DELAYED RELEASE;ORAL							
DIROXIMEL FUMARATE							
AB		ZYDUS	231MG	A218596	001	Nov 12, 2025	Oct NFTG
AB		VUMERITY					
AB	+	BIOGEN INC	231MG	N211855	001	Oct 29, 2019	Oct CFTG
<u>DIVALPROEX SODIUM</u>							
CAPSULE, DELAYED REL PELLETS;ORAL							
DIVALPROEX SODIUM							
AB		MANKIND PHARMA	EQ 125MG VALPROIC ACID	A217358	001	Aug 12, 2025	Aug NEWA
TABLET, DELAYED RELEASE;ORAL							
DIVALPROEX SODIUM							
	@	APOTEX	EQ 125MG VALPROIC ACID	A077615	003	Jul 29, 2008	Mar DISC
	@		EQ 250MG VALPROIC ACID	A077615	002	Jul 29, 2008	Mar DISC
	@		EQ 500MG VALPROIC ACID	A077615	001	Jul 29, 2008	Mar DISC
TABLET, EXTENDED RELEASE;ORAL							
DIVALPROEX SODIUM							
AB		SCIEGEN PHARMS	EQ 250MG VALPROIC ACID	A078705	002	Feb 10, 2009	Jul CAHN
AB			EQ 500MG VALPROIC ACID	A078705	001	Aug 04, 2009	Jul CAHN
	@	YICHANG HUMANWELL	EQ 250MG VALPROIC ACID	A214462	001	Mar 15, 2021	Jul CAHN
	@		EQ 500MG VALPROIC ACID	A214462	002	Mar 15, 2021	Jul CAHN

DOCETAXEL

INJECTABLE; INJECTION

AP	!	AMNEAL	20MG/ML (20MG/ML)	A209640	001	Jan 19, 2018	Apr	CHRS
AP	!		80MG/4ML (20MG/ML)	A209640	002	Jan 19, 2018	Apr	CHRS
AP	!		160MG/8ML (20MG/ML)	A209640	003	Jan 19, 2018	Apr	CHRS
	@	EUGIA PHARMA	20MG/2ML (10MG/ML)	A214575	001	Jun 25, 2021	Aug	DISC
	@		80MG/8ML (10MG/ML)	A214575	002	Jun 25, 2021	Aug	DISC
	@		160MG/16ML (10MG/ML)	A214575	003	Jun 25, 2021	Aug	DISC
AP		GUANGDONG SUNHO	20MG/ML (20MG/ML)	A213768	001	May 13, 2025	May	NEWA
AP			80MG/4ML (20MG/ML)	A213768	002	May 13, 2025	May	NEWA
	@	NOVAST LABS	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Sep	CAHN
AP			80MG/8ML (10MG/ML)	A207563	002	Aug 31, 2017	Sep	CAHN
AP			160MG/16ML (10MG/ML)	A207563	003	Aug 31, 2017	Sep	CAHN
		TAXOTERE						
	@ +	SANOFI AVENTIS US	20MG/ML (20MG/ML)	N020449	003	Aug 03, 2010	Apr	DISC
	@ +		80MG/4ML (20MG/ML)	N020449	004	Aug 02, 2010	Apr	DISC
AP	+		160MG/8ML (20MG/ML)	N020449	005	Apr 13, 2012	Apr	CHRS

SOLUTION; INTRAVENOUS

	!	ZHUHAI	80MG/4ML (20MG/ML)	N218711	001	Oct 23, 2024	Sep	CMFD
	@ +		80MG/4ML (20MG/ML)	N218711	001 <td>Oct 23, 2024</td> <td>Apr <td>DISC</td> </td>	Oct 23, 2024	Apr <td>DISC</td>	DISC

DONEPEZIL HYDROCHLORIDE

SYSTEM; TRANSDERMAL

	@ +	CORIUM	5MG/DAY	N212304	001	Mar 11, 2022	Oct	DISC
	@ +		10MG/DAY	N212304	002	Mar 11, 2022	Oct	DISC

TABLET; ORAL

	@	AIPING PHARM INC	5MG	A090290	001	May 31, 2011	Oct	CAHN
	@		10MG	A090290	002	May 31, 2011	Oct	CAHN
	@	INDICUS PHARMA	5MG	A201634	001	Jun 13, 2012	Apr	DISC
	@		10MG	A201634	002	Jun 13, 2012	Apr	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

	@	AIPING PHARM INC	5MG	A091198	001	May 10, 2011	Oct	CAHN
	@		10MG	A091198	002	May 10, 2011	Oct	CAHN

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		AMNEAL	10MG; 7MG	A208328	003	Feb 27, 2025	Feb	NFTG
AB			10MG; 21MG	A208328	004	Feb 27, 2025	Feb	NEWA
AB		MACLEODS PHARMS LTD	10MG; 14MG	A208672	001	Jul 15, 2025	Jul	NEWA
AB			10MG; 28MG	A208672	002	Jul 15, 2025	Jul	NEWA
AB		XIAMEN LP PHARM CO	10MG; 14MG	A216901	001	Jul 15, 2025	Jul	NEWA
AB			10MG; 28MG	A216901	002	Jul 15, 2025	Jul	NEWA
		NAMZARIC						
AB	+	ABBVIE	10MG; 7MG	N206439	003	Jul 18, 2016	Feb	CFTG

DONIDALORSEN SODIUM

SOLUTION; SUBCUTANEOUS

	!	IONIS PHARMS INC	EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML)	N219407	001	Aug 21, 2025	Aug	NEWA
--	---	------------------	---	---------	-----	--------------	-----	------

DORDAVIPRONE HYDROCHLORIDE

CAPSULE; ORAL

	!	CHIMERIX	EQ 125MG BASE	N219876	001	Aug 06, 2025	Aug	NEWA
--	---	----------	---------------	---------	-----	--------------	-----	------

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

		SOMERSET THERAPS LLC	EQ 2% BASE	A215004	001	Feb 11, 2025	Jan	NEWA
--	--	----------------------	------------	---------	-----	--------------	-----	------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC  
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT2	IDENTIRX	EQ 2% BASE;EQ 0.5% BASE	A216308	001	Feb 18, 2025	Feb	NEWA
AT2	NEW HEIGHTSRX	EQ 2% BASE;EQ 0.5% BASE	A216308	001	Feb 18, 2025	Jul	CAHN

DOXAZOSIN MESYLATE

TABLET;ORAL  
DOXAZOSIN MESYLATE

AB	APPCO	EQ 1MG BASE	A209013	001	Apr 17, 2018	Mar	CAHN
AB		EQ 2MG BASE	A209013	002	Apr 17, 2018	Mar	CAHN
AB		EQ 4MG BASE	A209013	003	Apr 17, 2018	Mar	CAHN
AB		EQ 8MG BASE	A209013	004	Apr 17, 2018	Mar	CAHN

DOXECITINE; DOXRIBTIMINE

FOR SOLUTION;ORAL  
KYGEVVI  
+! UCB INC

		2GM/PACKET;2GM/PACKET	N219792	001	Nov 03, 2025	Nov	NEWA
--	--	-----------------------	---------	-----	--------------	-----	------

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL  
DOXEPIN HYDROCHLORIDE

	@	ADAPTIS	EQ 150MG BASE	A213796	001	Apr 19, 2022	Jan	DISC
AB		IXORA LIFESCIENCE	EQ 10MG BASE	A211619	001	Mar 09, 2021	Sep	CAHN
AB			EQ 25MG BASE	A211619	002	Mar 09, 2021	Sep	CAHN
AB			EQ 50MG BASE	A211619	003	Mar 09, 2021	Sep	CAHN
AB			EQ 75MG BASE	A211619	004	Mar 09, 2021	Sep	CAHN
AB			EQ 100MG BASE	A211619	005	Mar 09, 2021	Sep	CAHN
AB		PTS CONSULTING	EQ 10MG BASE	A217975	001	Aug 21, 2023	Mar	CAHN
AB			EQ 25MG BASE	A217975	002	Aug 21, 2023	Mar	CAHN
AB			EQ 50MG BASE	A217975	003	Aug 21, 2023	Mar	CAHN
AB			EQ 75MG BASE	A217975	004	Aug 21, 2023	Mar	CAHN
AB			EQ 100MG BASE	A217975	005	Aug 21, 2023	Mar	CAHN
	@	TARO	EQ 10MG BASE	A213063	001	Jul 01, 2020	Aug	DISC
	@		EQ 25MG BASE	A213063	002	Jul 01, 2020	Aug	DISC
	@		EQ 50MG BASE	A213063	003	Jul 01, 2020	Aug	DISC
	@		EQ 75MG BASE	A213063	004	Jul 01, 2020	Aug	DISC
	@		EQ 100MG BASE	A213063	005	Jul 01, 2020	Aug	DISC
BX		ZYDUS LIFESCIENCES	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar	CTEC
BX			EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar	CTEC
BX			EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar	CTEC
BX			EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar	CTEC
BX			EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar	CTEC
BX			EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar	CTEC

TABLET;ORAL  
DOXEPIN HYDROCHLORIDE

AB		AJANTA PHARMA LTD	EQ 3MG BASE	A218564	001	Jul 01, 2024	Aug	CMFD
AB			EQ 6MG BASE	A218564	002	Jul 01, 2024	Aug	CMFD
AB		AUROBINDO PHARMA LTD	EQ 3MG BASE	A216041	001	Jul 25, 2024	Jun	CMFD
AB			EQ 6MG BASE	A216041	002	Jul 25, 2024	Jun	CMFD
BX		MSN	EQ 3MG BASE	A214823	001	Apr 03, 2023	Mar	CTEC
BX			EQ 6MG BASE	A214823	002	Apr 03, 2023	Mar	CTEC
AB		TARO	EQ 3MG BASE	A219058	001	Aug 06, 2025	Jul	NEWA
AB			EQ 6MG BASE	A219058	002	Aug 06, 2025	Jul	NEWA

DOXERCALCIFEROL

CAPSULE;ORAL  
DOXERCALCIFEROL

AB	!	AVET	2.5MCG	A205360	003	Sep 15, 2020	Aug	CHRS
		HECTOROL						
	@ +	SANOFI	0.5MCG	N020862	002	Apr 23, 2004	Aug	DISC
	@ +		1MCG	N020862	003	Jul 13, 2009	Aug	DISC
	@ +		2.5MCG	N020862	001	Jun 09, 1999	Aug	DISC

INJECTABLE;INJECTION  
DOXERCALCIFEROL

>D>	AP	EUGIA PHARMA	2MCG/ML (2MCG/ML)	A213717	001	Jan 24, 2022	Dec	DISC
>A>			2MCG/ML (2MCG/ML)	A213717	001	Jan 24, 2022	Dec	DISC
	@ +	HOSPIRA	4MCG/2ML (2MCG/ML)	N208614	001	Jul 24, 2018	Oct	DISC
	@	LUPIN LTD	4MCG/2ML (2MCG/ML)	A210801	001	Nov 01, 2018	Nov	DISC
>D>	AP	MEITHEAL	4MCG/2ML (2MCG/ML)	A211670	001	Feb 07, 2020	Dec	CHRS
>A>		!	4MCG/2ML (2MCG/ML)	A211670	001	Feb 07, 2020	Dec	CHRS

INJECTABLE; INJECTION  
HECTOROL

>D>	AP	+	SANOFI	2MCG/ML (2MCG/ML)	N021027	002	Apr 06, 2000	Dec	DISC
>A>		@	+	2MCG/ML (2MCG/ML)	N021027	002	Apr 06, 2000	Dec	DISC
>D>	AP	+	!	4MCG/2ML (2MCG/ML)	N021027	001	Apr 06, 2000	Dec	DISC
>A>		@	+	4MCG/2ML (2MCG/ML)	N021027	001	Apr 06, 2000	Dec	DISC

DOXORUBICIN HYDROCHLORIDE

INJECTABLE, LIPOSOMAL; INJECTION  
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)

AB			ALEMBIC	20MG/10ML (2MG/ML)	A219199	001	Jun 27, 2025	Jun	NEWA
AB				50MG/25ML (2MG/ML)	A219199	002	Jun 27, 2025	Jun	NEWA

DOXYCYCLINE

CAPSULE; ORAL  
DOXYCYCLINE

AB			CHANGZHOU PHARM	40MG	A219978	001	Oct 01, 2025	Sep	NEWA
AB			MACLEODS PHARMS LTD	40MG	A210381	001	Mar 27, 2025	Mar	NEWA
AB			PRINSTON INC	40MG	A217098	001	Jan 27, 2025	Jan	NEWA

TABLET; ORAL

DOXYCYCLINE

@			APPCO	EQ 50MG BASE	A065377	001	Nov 07, 2006	Oct	CAHN
@				EQ 75MG BASE	A065377	002	Nov 07, 2006	Oct	CAHN
@				EQ 100MG BASE	A065377	003	Nov 07, 2006	Oct	CAHN
@				EQ 150MG BASE	A065427	001	Jun 07, 2007	Oct	CAHN
@			CHARTWELL RX	EQ 50MG BASE	A065377	001	Nov 07, 2006	Oct	CAHN
@				EQ 75MG BASE	A065377	002	Nov 07, 2006	Oct	CAHN
@				EQ 100MG BASE	A065377	003	Nov 07, 2006	Oct	CAHN
@				EQ 150MG BASE	A065427	001	Jun 07, 2007	Oct	CAHN

DOXYCYCLINE HYCLATE

CAPSULE; ORAL  
DOXYCYCLINE HYCLATE

@			BIONPHARMA	EQ 50MG BASE	A209393	001	Dec 10, 2020	Apr	CAHN
@				EQ 100MG BASE	A209393	002	Dec 10, 2020	Apr	CAHN
AB		!	HIKMA INTL PHARMS	EQ 100MG BASE	A062396	001	May 07, 1984	Feb	CHRS
AB			MACLEODS PHARMS LTD	EQ 100MG BASE	A211137	001	Dec 09, 2025	Nov	NEWA
AB			STRIDES PHARMA	EQ 50MG BASE	A062337	001	Mar 29, 1982	Jul	CMFD
AB				EQ 100MG BASE	A062337	002	Mar 29, 1982	Jul	CMFD

VIBRAMYCIN

@	+		PFIZER	EQ 100MG BASE	N050007	002		Feb	DISC
---	---	--	--------	---------------	---------	-----	--	-----	------

INJECTABLE; INJECTION  
DOXYCYCLINE HYCLATE

@			AMNEAL	EQ 100MG BASE/VIAL	A217487	001	Dec 04, 2024	Jan	DISC
AP			ASPIRO	EQ 100MG BASE/VIAL	A218888	001	Aug 05, 2025	Jul	NEWA
AP			DR REDDYS	EQ 100MG BASE/VIAL	A218753	001	Jul 01, 2025	Jun	NEWA
AP			PRECISION DOSE INC	EQ 100MG BASE/VIAL	A217078	001	Feb 21, 2025	Feb	NEWA
AP			STERISCIENCE	EQ 100MG BASE/VIAL	A217972	001	Nov 06, 2025	Oct	NEWA

TABLET; ORAL

DOXYCYCLINE HYCLATE

@			AVIV PHARMA	EQ 100MG BASE	A209560	001	Apr 15, 2024	May	CAHN
AB			MACLEODS PHARMS LTD	EQ 100MG BASE	A211418	001	Nov 19, 2025	Nov	NEWA
@			MYLAN	EQ 100MG BASE	A062432	001	Feb 15, 1983	Jun	DISC
@			ORYZA	EQ 100MG BASE	A213475	001	Mar 10, 2021	Nov	CAHN
AB			PHARMOBEDIENT	EQ 20MG BASE	A065287	001	Feb 28, 2006	Sep	CAHN
@				EQ 100MG BASE	A213475	001	Mar 10, 2021	Sep	CAHN
AB			STRIDES PHARMA INTL	EQ 50MG BASE	A062538	002	Nov 24, 2025	Nov	NEWA
>D>		@		EQ 100MG BASE	A062538	001	Apr 07, 1986	Dec	CMFD
>A>	AB			EQ 100MG BASE	A062538	001	Apr 07, 1986	Dec	CMFD

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE; ORAL  
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

>D>	AB		MYLAN PHARMS INC	10MG;10MG	A207825	001	Jul 06, 2020	Dec	CAHN
>A>	AB		NORVIUM BIOSCIENCE	10MG;10MG	A207825	001	Jul 06, 2020	Dec	CAHN
>A>	AB		PHARMOBEDIENT	10MG;10MG	A207825	001	Jul 06, 2020	Dec	CAHN

DROSPIRENONE; ESTRADIOL

TABLET;ORAL

ANGELIQ

AB	+	BAYER HLTHCARE	0.5MG;1MG	N021355	002	Sep 28, 2005	Oct	CFTG
		DROSPIRENONE AND ESTRADIOL						
AB		NOVAST LABS	0.5MG;1MG	A218031	001	Oct 28, 2025	Oct	NFTG

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB		PHARMOBEDIENT	3MG;0.02MG	A203291	001	Jul 18, 2017	Sep	CAHN
----	--	---------------	------------	---------	-----	--------------	-----	------

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

AB		JUBILANT CADISTA	100MG	A214391	001	Feb 18, 2021	Apr	CAHN
AB			200MG	A214391	002	Feb 18, 2021	Apr	CAHN
AB			300MG	A214391	003	Feb 18, 2021	Apr	CAHN
>D>	AB	LUPIN PHARMS	100MG	A211652	001	Feb 18, 2021	Dec	DISC
>A>	@		100MG	A211652	001	Feb 18, 2021	Dec	DISC
>D>	AB		200MG	A211652	002	Feb 18, 2021	Dec	DISC
>A>	@		200MG	A211652	002	Feb 18, 2021	Dec	DISC
>D>	AB		300MG	A211652	003	Feb 18, 2021	Dec	DISC
>A>	@		300MG	A211652	003	Feb 18, 2021	Dec	DISC

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

CYMBALTA

@ + LILLY

@ +

@ +

DULOXETINE HYDROCHLORIDE

			EQ 20MG BASE	N021427	001	Aug 03, 2004	Aug	DISC
			EQ 30MG BASE	N021427	002	Aug 03, 2004	Aug	DISC
			EQ 60MG BASE	N021427	004	Aug 03, 2004	Aug	DISC
>A>	@	ADAPTIS	EQ 20MG BASE	A090723	001	Dec 11, 2013	Dec	CAHN
	@		EQ 20MG BASE	A090723	001	Dec 11, 2013	Aug	CAHN
>A>	@		EQ 30MG BASE	A090723	002	Dec 11, 2013	Dec	CAHN
	@		EQ 30MG BASE	A090723	002	Dec 11, 2013	Aug	CAHN
>A>	@		EQ 60MG BASE	A090723	003	Dec 11, 2013	Dec	CAHN
	@		EQ 60MG BASE	A090723	003	Dec 11, 2013	Aug	CAHN
AB	!	AJANTA PHARMA LTD	EQ 60MG BASE	A208706	003	Jan 06, 2017	Aug	CHRS
>D>	@	GRAVITI PHARMS	EQ 20MG BASE	A090723	001	Dec 11, 2013	Dec	CAHN
	@		EQ 20MG BASE	A090723	001	Dec 11, 2013	Sep	CAHN
>D>	@		EQ 30MG BASE	A090723	002	Dec 11, 2013	Dec	CAHN
	@		EQ 30MG BASE	A090723	002	Dec 11, 2013	Sep	CAHN
>D>	@		EQ 60MG BASE	A090723	003	Dec 11, 2013	Dec	CAHN
	@		EQ 60MG BASE	A090723	003	Dec 11, 2013	Sep	CAHN
	@	TORRENT	EQ 20MG BASE	A090774	001	Dec 11, 2013	Jul	DISC
	@		EQ 30MG BASE	A090774	002	Dec 11, 2013	Jul	DISC
	@		EQ 60MG BASE	A090774	003	Dec 11, 2013	Jul	DISC

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

>A>	AB	ADAPTIS	0.5MG	A204376	001	Apr 07, 2017	Dec	CAHN
	@	AVIV PHARMA	0.5MG	A204705	001	Nov 20, 2015	May	CAHN
>D>	AB	GRAVITI PHARMS	0.5MG	A204376	001	Apr 07, 2017	Dec	CAHN
	AB		0.5MG	A204376	001	Apr 07, 2017	Sep	CAHN
	@	PH HEALTH	0.5MG	A202421	001	Nov 20, 2015	Jul	CAHN

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB	!	ZYDUS PHARMS	0.5MG;0.4MG	A207769	001	May 24, 2018	Sep	CHRS
		JALYN						
AB	+	WAYLIS THERAP	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Sep	CHRS

EDARAVONE

SOLUTION;INTRAVENOUS

EDARAVONE

AP	!	GLAND	30MG/100ML (0.3MG/ML)	A216199	001	May 06, 2024	Oct	CHRS
	@	LONG GROVE PHARMS	30MG/100ML (0.3MG/ML)	A218354	001	May 06, 2024	Oct	DISC
	@		30MG/100ML (0.3MG/ML)	A218354	001	May 06, 2024	Apr	DISC

## SOLUTION;INTRAVENOUS

## EDARAVONE

AP		PHARMOBEDIENT	30MG/100ML (0.3MG/ML)	A217565	001	Oct 31, 2024	Sep CAHN
AP	!		60MG/100ML (0.6MG/ML)	A217565	002	Oct 31, 2024	Oct CHRS
AP			60MG/100ML (0.6MG/ML)	A217565	002	Oct 31, 2024	Sep CAHN
RADICAVA							
>D>	@ +	MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Dec CAHN
	@ +		30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Oct DISC
>D>	AP	+	60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Dec CAHN
	AP	+	60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Oct CHRS
>A>	@ +	TANABE PHARMA	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Dec CAHN
>A>	AP	+	60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Dec CAHN

## SUSPENSION;ORAL

## RADICAVA ORS

	+	!	KK BCJ-94	105MG/5ML	N215446	001	May 12, 2022	Jul CAHN
--	---	---	-----------	-----------	---------	-----	--------------	----------

EFAVIRENZ

## TABLET;ORAL

## EFAVIRENZ

>D>	AB		NORVIUM BIOSCIENCE	600MG	A204869	001	Mar 12, 2018	Dec CAHN
	AB			600MG	A204869	001	Mar 12, 2018	May CAHN
>A>	AB		PHARMOBEDIENT	600MG	A204869	001	Mar 12, 2018	Dec CAHN

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

## TABLET;ORAL

## EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

@	CHARTWELL RX	600MG;200MG;300MG	A201802	001	Oct 03, 2023	Apr CAHN
---	--------------	-------------------	---------	-----	--------------	----------

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

## TABLET;ORAL

## EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

>D>	AB		LAURUS	400MG;300MG;300MG	A213038	001	May 14, 2020	Dec CTEC	
>A>				400MG;300MG;300MG	A213038	001	May 14, 2020	Dec CTEC	
>A>		!		400MG;300MG;300MG	A213038	001	May 14, 2020	Dec CHRS	
>D>			SYMFI LO						
>D>	AB	+	!	MYLAN	400MG;300MG;300MG	N208255	001	Feb 05, 2018	Dec DISC
>A>		@ +			400MG;300MG;300MG	N208255	001	Feb 05, 2018	Dec DISC

EFLORNITHINE HYDROCHLORIDE

## CREAM;TOPICAL

## VANIQA

@ +	ABBVIE	13.9%	N021145	001	Jul 27, 2000	Feb CAHN
-----	--------	-------	---------	-----	--------------	----------

ELAMIPRETIDE HYDROCHLORIDE

## SOLUTION;SUBCUTANEOUS

## FORZINITY

+	!	STEALTH BIOTHERAPS	EQ 280MG BASE/3.5ML (EQ 80MG BASE/ML)	N215244	001	Sep 19, 2025	Sep NEWA
---	---	--------------------	---------------------------------------	---------	-----	--------------	----------

>D>	<u>ELBASVIR; GRAZOPREVIR</u>								
>D>	TABLET;ORAL								
>D>	ZEPATIER								
>D>		+	!	MSD SUB MERCK	50MG;100MG	N208261	001	Jan 28, 2016	Dec DISC
>A>		@ +			50MG;100MG	N208261	001	Jan 28, 2016	Dec DISC

ELETRIPTAN HYDROBROMIDE

## TABLET;ORAL

## ELETRIPTAN HYDROBROMIDE

AB		ANNORA PHARMA	EQ 20MG BASE	A219143	001	Jul 07, 2025	Jun NEWA
AB			EQ 40MG BASE	A219143	002	Jul 07, 2025	Jun NEWA

ELIGLUSTAT TARTRATE

## CAPSULE;ORAL

## ELIGLUSTAT TARTRATE

@	APOTEX	EQ 84MG BASE	A212425	001	Jul 10, 2024	Jan DISC
---	--------	--------------	---------	-----	--------------	----------

ELINZANETANT

## CAPSULE;ORAL

## LYNKUET

+	!	BAYER HLTHCARE	60MG	N219469	001	Oct 24, 2025	Oct NEWA
---	---	----------------	------	---------	-----	--------------	----------

ELTROMBOPAG OLAMINE

TABLET; ORAL

ELTROMBOPAG OLAMINE

AB		HETERO LABS LTD V	EQ 12.5MG ACID	A206788	001	Jan 17, 2025	Jan NFTG
AB			EQ 25MG ACID	A206788	002	Jan 17, 2025	Jan NFTG
AB			EQ 50MG ACID	A206788	003	Jan 17, 2025	Jan NFTG
AB			EQ 75MG ACID	A206788	004	Jan 17, 2025	Jan NFTG
		PROMACTA					
AB	+	NOVARTIS	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Jan CFTG
AB	+		EQ 25MG ACID	N022291	001	Nov 20, 2008	Jan CFTG
AB	+		EQ 50MG ACID	N022291	002	Nov 20, 2008	Jan CFTG
AB	+	!	EQ 75MG ACID	N022291	003	Sep 08, 2009	Jan CFTG

ELUXADOLINE

TABLET; ORAL

ELUXADOLINE

AB	@	ZYDUS PHARMS	75MG	A213522	001	Mar 14, 2025	Aug DISC
			75MG	A213522	001	Mar 14, 2025	Mar NFTG
	@		100MG	A213522	002	Mar 14, 2025	Aug DISC
AB			100MG	A213522	002	Mar 14, 2025	Mar NFTG
		VIBERZI					
	+	ABBVIE	75MG	N206940	001	May 27, 2015	Aug CTEC
AB	+		75MG	N206940	001	May 27, 2015	Mar CFTG
	+	!	100MG	N206940	002	May 27, 2015	Aug CTEC
AB	+	!	100MG	N206940	002	May 27, 2015	Mar CFTG

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

AB	+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123	001	Aug 10, 2011	May CFTG
		EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE					
AB		MYLAN	200MG;EQ 25MG BASE;300MG	A208452	001	May 20, 2025	May NFTG

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB		HETERO LABS LTD III	100MG;150MG	A201806	002	Mar 03, 2025	Feb NEWA
AB			133MG;200MG	A201806	003	Mar 03, 2025	Feb NEWA
AB			167MG;250MG	A201806	004	Mar 03, 2025	Feb NEWA

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

AB		SENORES PHARMS	2.5MG	A075483	001	Aug 22, 2000	Jun CAHN
AB			5MG	A075483	002	Aug 22, 2000	Jun CAHN
AB			10MG	A075483	003	Aug 22, 2000	Jun CAHN
AB			20MG	A075483	004	Aug 22, 2000	Jun CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

>D>	AB	ANDA REPOSITORY	5MG;12.5MG	A075909	001	Oct 15, 2001	Dec CAHN
>D>	AB		10MG;25MG	A075909	002	Oct 15, 2001	Dec CAHN
	@	MPP PHARMA	5MG;12.5MG	A076486	001	Oct 27, 2004	Jun CAHN
	@		10MG;25MG	A076486	002	Oct 27, 2004	Jun CAHN
>A>	AB	SENORES PHARMS	5MG;12.5MG	A075909	001	Oct 15, 2001	Dec CAHN
>A>	AB		10MG;25MG	A075909	002	Oct 15, 2001	Dec CAHN

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

@	HOSPIRA	1.25MG/ML	A075458	001	Aug 22, 2000	Aug DISC
---	---------	-----------	---------	-----	--------------	----------

ENFUVRTIDE

INJECTABLE; SUBCUTANEOUS

FUZEON

@	+	ROCHE	90MG/VIAL	N021481	001	Mar 13, 2003	Mar DISC
---	---	-------	-----------	---------	-----	--------------	----------

ENOXAPARIN SODIUM

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS  
ENOXAPARIN SODIUM

AB	EMERGE BIOSCIENCE	300MG/3ML (100MG/ML)	A214856	001	Jun 14, 2022	Sep CAHN
INJECTABLE;SUBCUTANEOUS						
ENOXAPARIN SODIUM (PRESERVATIVE FREE)						
AP	EMERGE BIOSCIENCE	30MG/0.3ML (100MG/ML)	A206834	001	Nov 29, 2019	Sep CAHN
AP		40MG/0.4ML (100MG/ML)	A206834	002	Nov 29, 2019	Sep CAHN
AP		60MG/0.6ML (100MG/ML)	A206834	003	Nov 29, 2019	Sep CAHN
AP		80MG/0.8ML (100MG/ML)	A206834	004	Nov 29, 2019	Sep CAHN
AP		100MG/ML (100MG/ML)	A206834	005	Nov 29, 2019	Sep CAHN
AP		120MG/0.8ML (150MG/ML)	A206834	006	Nov 29, 2019	Sep CAHN
AP		150MG/ML (150MG/ML)	A206834	007	Nov 29, 2019	Sep CAHN
>A>	HEBEI CHANGSHAN	30MG/0.3ML (100MG/ML)	A218775	001	Jan 07, 2026	Dec NEWA
>A>		40MG/0.4ML (100MG/ML)	A218775	002	Jan 07, 2026	Dec NEWA
>A>		60MG/0.6ML (100MG/ML)	A218775	003	Jan 07, 2026	Dec NEWA
>A>		80MG/0.8ML (100MG/ML)	A218775	004	Jan 07, 2026	Dec NEWA
>A>		100MG/ML (100MG/ML)	A218775	005	Jan 07, 2026	Dec NEWA
>A>		120MG/0.8ML (150MG/ML)	A218775	006	Jan 07, 2026	Dec NEWA
>A>		150MG/ML (150MG/ML)	A218775	007	Jan 07, 2026	Dec NEWA

ENTECAVIR

TABLET;ORAL  
ENTECAVIR

@	BRECKENRIDGE	0.5MG	A208721	001	Mar 15, 2018	May DISC
@		1MG	A208721	002	Mar 15, 2018	May DISC

ENZALUTAMIDE

CAPSULE;ORAL  
ENZALUTAMIDE

@	ZYDUS PHARMS	40MG	A209667	001	Sep 26, 2024	Feb DISC
+	ASTELLAS	40MG	N203415	001	Aug 31, 2012	Feb CTEC

EPHEDRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS  
REZIPRES

@ +	DR REDDYS LABS SA	47MG/10ML (4.7MG/ML)	N213536	004	Dec 07, 2023	May DISC
-----	-------------------	----------------------	---------	-----	--------------	----------

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS  
AKOVAZ

AP3	EXELA PHARMA	25MG/5ML (5MG/ML)	N208289	002	Aug 02, 2021	Mar CTEC
EMERPHED						
AP1	NEXUS	50MG/10ML (5MG/ML)	N213407	001	Apr 17, 2020	Mar CTEC
AP		50MG/10ML (5MG/ML)	N213407	001	Apr 17, 2020	Jan CFTG
EPHEDRINE SULFATE						
>A>	CIVICA	50MG/ML (50MG/ML)	A215593	001	Dec 23, 2025	Dec NEWA
AP2	ENDO OPERATIONS	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Mar CTEC
AP		25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Feb CFTG
AP2		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Mar CTEC
AP		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Feb CFTG
AP2	FRESENIUS KABI USA	25MG/5ML (5MG/ML)	A218271	001	Mar 11, 2025	Mar CTEC
AP		25MG/5ML (5MG/ML)	A218271	001	Mar 11, 2025	Feb NFTG
AP2		50MG/10ML (5MG/ML)	A218271	002	Mar 11, 2025	Mar CTEC
AP		50MG/10ML (5MG/ML)	A218271	002	Mar 11, 2025	Feb NFTG
AP1	GLAND	50MG/10ML (5MG/ML)	A218211	001	Jan 16, 2025	Mar CTEC
AP		50MG/10ML (5MG/ML)	A218211	001	Jan 16, 2025	Jan NFTG
AP3	HIKMA	25MG/5ML (5MG/ML)	A217721	001	Oct 11, 2024	Mar CTEC
AP2	PH HEALTH	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Aug CAHN
AP2		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Aug CAHN

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
EPINASTINE HYDROCHLORIDE

@	PHARMOBEDIANT	0.05%	A090870	001	Mar 14, 2011	Sep CAHN
@	RENOVA PHARMS	0.05%	A090870	001	Mar 14, 2011	Feb CAHN

EPINEPHRINE

	INJECTABLE; INTRAMUSCULAR								
	EPI E Z PEN JR								
	@	VIATRIS	0.15MG/DELIVERY	N019430	004	Aug 03, 1995	May	CAHN	
	EPIPEN E Z PEN								
	@	VIATRIS	0.3MG/DELIVERY	N019430	003	Aug 03, 1995	May	CAHN	
	INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS								
	EPIPEN								
AB	+	VIATRIS	0.3MG/DELIVERY	N019430	001	Dec 22, 1987	May	CAHN	
	EPIPEN JR.								
AB	+	VIATRIS	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	May	CAHN	
	TWINJECT								
	@	IMPAX	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	May	CTNA	
	@		EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	May	CTNA	
	SOLUTION; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS								
	EPINEPHRINE								
AP		GLAND PHARMA LTD	10MG/10ML (1MG/ML)	A219239	001	Feb 06, 2025	Jan	NFTG	
	SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS								
	ADRENALIN								
AP	+	PH HEALTH	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Nov	CTEC	
	EPINEPHRINE								
AP		AMNEAL	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A218208	001	Dec 08, 2025	Nov	NEWA	
AP			EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	A217485	001	Oct 14, 2025	Oct	NEWA	
AP	+	BPI LABS	10MG/10ML (1MG/ML)	N205029	002	Feb 04, 2022	Jan	CFTG	
AP	+		30MG/30ML (1MG/ML)	N205029	004	Feb 14, 2024	Sep	CFTG	
AP	+	FRESENIUS KABI USA	30MG/30ML (1MG/ML)	N215425	001	Mar 13, 2025	Mar	NEWA	
AP		GLAND	10MG/10ML (1MG/ML)	A219239	001	Feb 06, 2025	Mar	CDFR	
AP			30MG/30ML (1MG/ML)	A219239	002	Oct 02, 2025	Sep	NFTG	
	SOLUTION; INTRAVENOUS								
	ADRENALIN								
	+	PH HEALTH	2MG/250ML (8MCG/ML)	N215875	001	Apr 21, 2023	Jul	CAHN	
	+		4MG/250ML (16MCG/ML)	N215875	002	Apr 21, 2023	Jul	CAHN	
	+		5MG/250ML (20MCG/ML)	N215875	003	Apr 21, 2023	Jul	CAHN	
	+		8MG/250ML (32MCG/ML)	N215875	004	Apr 21, 2023	Jul	CAHN	
	+		10MG/250ML (40MCG/ML)	N215875	005	Apr 21, 2023	Jul	CAHN	
	SOLUTION; INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS								
	EPINEPHRINE								
AP		GLAND	1MG/ML (1MG/ML)	A218144	001	Jun 03, 2025	May	NEWA	
	SPRAY; NASAL								
	NEFFY								
	+	ARS PHARMS OPERATION	1MG/SPRAY	N214697	002	Mar 05, 2025	Apr	CHRS	
	+		1MG/SPRAY	N214697	002	Mar 05, 2025	Mar	NEWA	

EPINEPHRINE BITARTRATE

	SOLUTION; INTRAVENOUS								
	EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE								
	+	BAXTER HLTHCARE CORP	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N218475	001	Feb 28, 2025	Feb	NEWA	

EPIRUBICIN HYDROCHLORIDE

	INJECTABLE; INJECTION								
	EPIRUBICIN HYDROCHLORIDE								
	@	HISUN PHARM HANGZHOU	50MG/25ML (2MG/ML)	A090075	001	Mar 25, 2010	Oct	DISC	
	@		200MG/100ML (2MG/ML)	A090075	002	Mar 25, 2010	Oct	DISC	
	@	PHARMOBEDIANT	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Aug	CAHN	
	@		200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Aug	CAHN	

EPLERENONE

	TABLET; ORAL								
	EPLERENONE								
	@	AARXION ANDA HLDING	25MG	A203896	001	Feb 02, 2017	Sep	CAHN	
	@		50MG	A203896	002	Feb 02, 2017	Sep	CAHN	
	@	THINKRX	25MG	A203896	001	Feb 02, 2017	Mar	CAHN	
	@		50MG	A203896	002	Feb 02, 2017	Mar	CAHN	

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION  
EPOPROSTENOL SODIUM

>A>	AP2	GLAND	EQ 0.5MG BASE/VIAL	A219237	001	Dec 29, 2025	Dec	NEWA	
>A>	AP2		EQ 1.5MG BASE/VIAL	A219237	002	Dec 29, 2025	Dec	NEWA	
>D>	AP1	MEITHEAL	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Dec	CHRS	
>A>	AP1	!	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Dec	CHRS	
>A>		!	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Dec	CTEC	
>D>	AP1		EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Dec	CHRS	
>A>	AP1	!	EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Dec	CHRS	
>A>		!	EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Dec	CTEC	
>D>		FLOLAN							
>D>	AP1	+!	GLAXOSMITHKLINE LLC	EQ 0.5MG BASE/VIAL	N020444	001	Sep 20, 1995	Dec	DISC
>A>		@ +		EQ 0.5MG BASE/VIAL	N020444	001	Sep 20, 1995	Dec	DISC
>D>	AP1	+!		EQ 1.5MG BASE/VIAL	N020444	002	Sep 20, 1995	Dec	DISC
>A>		@ +		EQ 1.5MG BASE/VIAL	N020444	002	Sep 20, 1995	Dec	DISC

EPTIFIBATIDE

INJECTABLE; INJECTION  
EPTIFIBATIDE

AP		MEITHEAL	2MG/ML	A213599	001	May 09, 2024	Apr	CAHN
AP			75MG/100ML	A213599	002	May 09, 2024	Apr	CAHN

ERGOALCIFIEROL

CAPSULE; ORAL  
ERGOALCIFIEROL

AA		!	ONESOURCE SPECIALTY	50,000 IU	A090455	001	Aug 03, 2010	Jun	CAHN
----	--	---	---------------------	-----------	---------	-----	--------------	-----	------

ERIBULIN MESYLATE

SOLUTION; INTRAVENOUS  
ERIBULIN MESYLATE

AP			CHIA TAI TIANQING	1MG/2ML (0.5MG/ML)	A218743	001	Mar 04, 2025	Feb	NEWA
AP			DR REDDYS	1MG/2ML (0.5MG/ML)	A217473	001	Jul 03, 2025	Jun	NEWA
AP			GLENMARK PHARMS INC	1MG/2ML (0.5MG/ML)	A218142	001	Aug 05, 2025	Sep	CAHN
AP			JIANGXI KVVIT PHARM	1MG/2ML (0.5MG/ML)	A218281	001	Jun 28, 2024	Apr	CAHN
AP			SANDOZ	1MG/2ML (0.5MG/ML)	A214310	001	Jun 09, 2025	May	NEWA
AP			XILING LAB	1MG/2ML (0.5MG/ML)	A218142	001	Aug 05, 2025	Jul	NEWA

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL  
ERLOTINIB HYDROCHLORIDE

@		APOTEX	EQ 25MG BASE	A208396	001	Nov 05, 2019	Jan	DISC
@			EQ 100MG BASE	A208396	002	Nov 05, 2019	Jan	DISC
@			EQ 150MG BASE	A208396	003	Nov 05, 2019	Jan	DISC
@		NATCO PHARMA LTD	EQ 100MG BASE	A208488	002	Nov 05, 2019	Aug	DISC
@		SUN PHARM	EQ 25MG BASE	A210300	001	Nov 05, 2019	Jan	DISC
@			EQ 100MG BASE	A210300	002	Nov 05, 2019	Feb	DISC
@			EQ 150MG BASE	A210300	003	Nov 05, 2019	Jan	DISC

ERTUGLIFLOZIN

TABLET; ORAL  
ERTUGLIFLOZIN

@		HETERO LABS LTD V	5MG	A217071	001	Sep 17, 2024	Apr	DISC
@			15MG	A217071	002	Sep 17, 2024	Apr	DISC
@		HIKMA	5MG	A216842	001	Jan 21, 2025	Feb	DISC
AB			5MG	A216842	001	Jan 21, 2025	Jan	NEWA
@			15MG	A216842	002	Jan 21, 2025	Feb	DISC
AB			15MG	A216842	002	Jan 21, 2025	Jan	NEWA
		STEGLATRO						
		+ MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017	Apr	CTEC
		+!	15MG	N209803	002	Dec 19, 2017	Apr	CTEC

ERYTHROMYCIN

GEL; TOPICAL  
ERYGEL

@		+ MYLAN	2%	N050617	001	Oct 21, 1987	Oct	DISC
		ERYTHROMYCIN						
AT		! PADAGIS US	2%	A063211	001	Jan 29, 1993	Oct	CHRS
		TABLET; ORAL						
		ERYTHROMYCIN						
AB		ABON PHARMS LLC	250MG	A219691	001	Sep 23, 2025	Sep	NEWA

TABLET;ORAL  
ERYTHROMYCIN

AB		500MG	A219691	002	Sep 23, 2025	Sep	NEWA
AB	PHARMOBEDIENT	250MG	A061621	001		Sep	CAHN
AB		500MG	A061621	002		Sep	CAHN

TABLET, DELAYED RELEASE;ORAL  
ERY-TAB

>D>	AB	PHARMOBEDIENT	250MG	A062298	001		Dec	CAHN
>A>	AB		250MG	A062298	001		Dec	CAHN
>D>	AB		333MG	A062298	003	Mar 29, 1982	Dec	CAHN
>A>	AB		333MG	A062298	003	Mar 29, 1982	Dec	CAHN
>D>	AB	!	500MG	A062298	002		Dec	CAHN
>A>	AB	!	500MG	A062298	002		Dec	CAHN

ERYTHROMYCIN STEARATE

TABLET;ORAL  
ERYTHROCIN STEARATE  
@ AZURITY

EQ 250MG BASE	A060359	001		Apr	DISC
---------------	---------	-----	--	-----	------

ESCITALOPRAM OXALATE

CAPSULE;ORAL  
ESCITALOPRAM  
+! ALMATICA  
ESCITALOPRAM OXALATE

EQ 15MG BASE	N219130	001	Aug 29, 2025	Aug	NEWA
--------------	---------	-----	--------------	-----	------

@ RISING	EQ 5MG BASE	A077660	001	Jul 31, 2007	Aug	CAHN
@	EQ 10MG BASE	A077660	002	Jul 31, 2007	Aug	CAHN
@	EQ 20MG BASE	A077660	003	Jul 31, 2007	Aug	CAHN

SOLUTION;ORAL  
ESCITALOPRAM OXALATE

@ TARO	EQ 5MG BASE/5ML	A079121	001	May 03, 2012	Aug	DISC
--------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL  
ESCITALOPRAM OXALATE

AB	ASCENT PHARMS INC	EQ 5MG BASE	A215177	001	Jul 15, 2025	Jul	NEWA
AB		EQ 10MG BASE	A215177	002	Jul 15, 2025	Jul	NEWA
AB		EQ 20MG BASE	A215177	003	Jul 15, 2025	Jul	NEWA

ESLICARBAZEPINE ACETATE

TABLET;ORAL  
ESLICARBAZEPINE ACETATE

AB	APOTEX	200MG	A211236	001	Dec 07, 2023	Apr	CMFD
AB		400MG	A211236	002	Dec 07, 2023	Apr	CMFD
AB		600MG	A211236	003	Dec 07, 2023	Apr	CMFD
AB		800MG	A211236	004	Dec 07, 2023	Apr	CMFD
AB	JUBILANT GENERICS	200MG	A211219	001	Aug 04, 2025	Jul	NEWA
AB		400MG	A211219	002	Aug 04, 2025	Jul	NEWA
AB		600MG	A211219	003	Aug 04, 2025	Jul	NEWA
AB		800MG	A211219	004	Aug 04, 2025	Jul	NEWA
AB	LUPIN LTD	200MG	A211246	001	Mar 27, 2024	Mar	CMFD
AB		400MG	A211246	002	Mar 27, 2024	Mar	CMFD
AB		600MG	A211246	003	Mar 27, 2024	Mar	CMFD
AB		800MG	A211246	004	Mar 27, 2024	Mar	CMFD
AB	SPH ZHONGXI PHARM	200MG	A211247	001	Nov 03, 2025	Oct	NEWA
AB		400MG	A211247	002	Nov 03, 2025	Oct	NEWA
AB		600MG	A211247	003	Nov 03, 2025	Oct	NEWA
AB		800MG	A211247	004	Nov 03, 2025	Oct	NEWA
AB	TORRENT	200MG	A211227	001	Feb 27, 2024	May	CMFD
AB		400MG	A211227	002	Feb 27, 2024	May	CMFD
AB		600MG	A211227	003	Feb 27, 2024	May	CMFD
AB		800MG	A211227	004	Feb 27, 2024	May	CMFD

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL  
ESOMEPRAZOLE MAGNESIUM

@ CIPLA	EQ 20MG BASE	A078003	001	Jan 26, 2015	Aug	CAHN	
@	EQ 40MG BASE	A078003	002	Jan 26, 2015	Aug	CAHN	
AB	ETHYPHARM	EQ 20MG BASE	A090841	001	Mar 31, 2021	Nov	CAHN
AB		EQ 40MG BASE	A090841	002	Mar 31, 2021	Nov	CAHN
AB	GUANGZHOU NOVAKEN	EQ 20MG BASE	A213859	001	Nov 18, 2020	Apr	CAHN
AB		EQ 40MG BASE	A213859	002	Nov 18, 2020	Apr	CAHN
@	IVAX SUB TEVA PHARMS	EQ 20MG BASE	A078003	001	Jan 26, 2015	Feb	DISC
@		EQ 40MG BASE	A078003	002	Jan 26, 2015	Feb	DISC
@	MACLEODS PHARMS LTD	EQ 20MG BASE	A208511	001	Oct 23, 2024	Jun	DISC

CAPSULE, DELAYED REL PELLETS;ORAL  
ESOMEPRAZOLE MAGNESIUM

	@		EQ 40MG BASE	A208511	002	Oct 23, 2024	Jun	DISC
AB		SUN PHARM	EQ 20MG BASE	A209735	001	Apr 30, 2018	Jul	CMFD
AB			EQ 40MG BASE	A209735	002	Apr 30, 2018	Jul	CMFD

FOR SUSPENSION, DELAYED RELEASE;ORAL  
ESOMEPRAZOLE MAGNESIUM

AB		AUROBINDO PHARMA LTD	EQ 5MG BASE/PACKET	A218948	001	Apr 15, 2025	Apr	NEWA
AB			EQ 10MG BASE/PACKET	A219213	001	Apr 15, 2025	Apr	NEWA
AB			EQ 20MG BASE/PACKET	A218948	002	Apr 15, 2025	Apr	NEWA
AB			EQ 40MG BASE/PACKET	A218948	003	Apr 15, 2025	Apr	NEWA
AB		TORRENT	EQ 2.5MG BASE/PACKET	A212651	001	Mar 05, 2025	Feb	NEWA
AB			EQ 5MG BASE/PACKET	A212651	002	Mar 05, 2025	Feb	NEWA
AB			EQ 10MG BASE/PACKET	A212652	001	Mar 05, 2025	Feb	NEWA
AB			EQ 20MG BASE/PACKET	A212651	003	Mar 05, 2025	Feb	NEWA
AB			EQ 40MG BASE/PACKET	A212651	004	Mar 05, 2025	Feb	NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL  
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

	@	NORVIUM BIOSCIENCE	EQ 20MG BASE;375MG	A204920	001	Jul 20, 2021	Feb	CAHN
	@		EQ 20MG BASE;500MG	A204920	002	Jul 20, 2021	Feb	CAHN

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS  
ESOMEPRAZOLE SODIUM

AP		EPIC PHARMA LLC	EQ 40MG BASE/VIAL	A214046	001	Jan 08, 2025	Jul	CAHN
	@	EUGIA PHARMA	EQ 40MG BASE/VIAL	A204657	002	Aug 10, 2016	Jul	DISC
	@	PHARMOBEDIENT	EQ 20MG BASE/VIAL	A202686	001	May 17, 2017	Jul	CAHN
	@		EQ 40MG BASE/VIAL	A202686	002	May 17, 2017	Jul	CAHN
AP		YANGTZE	EQ 40MG BASE/VIAL	A214046	001	Jan 08, 2025	Jan	NEWA

ESTRADIOL

CREAM;VAGINAL  
ESTRADIOL

AB		ENCUBE	0.01%	A209767	001	Mar 05, 2018	Jan	CAHN
----	--	--------	-------	---------	-----	--------------	-----	------

GEL;TRANSDERMAL  
ESTRADIOL

AB		ENCUBE	0.1% (0.25GM/PACKET)	A218507	001	Mar 05, 2025	Feb	NEWA
AB			0.1% (0.5GM/PACKET)	A218507	002	Mar 05, 2025	Feb	NEWA
AB			0.1% (0.75GM/PACKET)	A218507	003	Mar 05, 2025	Feb	NEWA
AB			0.1% (1.25GM/PACKET)	A218507	005	Mar 05, 2025	Feb	NEWA
AB			0.1% (1GM/PACKET)	A218507	004	Mar 05, 2025	Feb	NEWA

GEL, METERED;TRANSDERMAL  
ELESTRIN

	+	VIATRIS	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Feb	CAHN
--	---	---------	---------------------------	---------	-----	--------------	-----	------

INSERT;VAGINAL  
ESTRADIOL

AB		TEVA PHARMS USA INC	0.004MG	A214137	001	Dec 08, 2025	Nov	NFTG
AB			0.01MG	A214137	002	Dec 08, 2025	Nov	NFTG

IMVEXXY

>D>	AB	+	MAYNE PHARMA	0.004MG	N208564	001	May 29, 2018	Dec	CHRS
>A>	AB	+	!	0.004MG	N208564	001	May 29, 2018	Dec	CHRS
	AB	+		0.004MG	N208564	001	May 29, 2018	Nov	CFTG
	AB	+	!	0.01MG	N208564	002	May 29, 2018	Nov	CFTG

TABLET;ORAL  
ESTRADIOL

	@	RUBICON RESEARCH	0.5MG	A040114	003	Mar 14, 1996	Apr	CAHN
	@		1MG	A040114	001	Mar 14, 1996	Apr	CAHN
	@		2MG	A040114	002	Mar 14, 1996	Apr	CAHN

ESTRADIOL VALERATE

INJECTABLE;INJECTION  
DELESTROGEN

AO		+	PH HEALTH	10MG/ML	N009402	002		Aug	CAHN
AO		+	!	20MG/ML	N009402	004		Aug	CAHN
	@	+		40MG/ML	N009402	003		Aug	CAHN

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

TABLET; ORAL

MYFEMBREE

+! SUMITOMO PHARMA AM 1MG;0.5MG;40MG N214846 001 May 26, 2021 Aug CAHN

ESTROGENS, CONJUGATED

TABLET; ORAL

CONJUGATED ESTROGENS

AB	NOVAST LABS	0.3MG	A214025	001	Oct 15, 2025	Oct	NFTG
AB		0.45MG	A214025	002	Oct 15, 2025	Oct	NFTG
AB		0.625MG	A214025	003	Oct 15, 2025	Oct	NFTG
AB		0.9MG	A214023	001	Oct 15, 2025	Oct	NFTG
AB		1.25MG	A214023	002	Oct 15, 2025	Oct	NFTG
	PREMARIN						
AB	+ WYETH PHARMS	0.3MG	N004782	003		Oct	CFTG
AB	+	0.45MG	N004782	006	Jul 16, 2003	Oct	CFTG
AB	+!	0.625MG	N004782	004		Oct	CFTG
AB	+!	0.9MG	N004782	005	Jan 26, 1984	Oct	CFTG
AB	+!	1.25MG	N004782	001		Oct	CFTG

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

@	AVIV PHARMA	1MG	A203087	001	May 08, 2019	May	CAHN
@		2MG	A203087	002	May 08, 2019	May	CAHN
@		3MG	A203087	003	May 08, 2019	May	CAHN

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

ETHACRYNATE SODIUM

@ MYLAN INSTITUTIONAL EQ 50MG BASE/VIAL A204634 001 Aug 23, 2016 Oct DISC

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

KELNOR 1/50

>A>	!	WATSON LABS	0.05MG;1MG	A072723	001	Dec 30, 1991	Dec	CTNA	
>D>		ZOVIA 1/50E-28							
>D>	AB	!	WATSON LABS	0.05MG;1MG	A072723	001	Dec 30, 1991	Dec	CTNA

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB	NAARI PTE	0.03MG;0.15MG	A203871	001	Nov 13, 2015	Sep	CAHN
AB		0.03MG,0.01MG;0.15MG,N/A	A203872	001	Dec 22, 2015	Sep	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

GENCEPT 10/11-28

@	BARR LABS	0.035MG,0.035MG;0.5MG,1MG	A072697	001	Feb 28, 1992	Mar	CAHN	
	NORTREL 0.5/35-28							
AB	BARR LABS	0.035MG;0.5MG	A072695	001	Feb 28, 1992	Mar	CAHN	
	NORTREL 1/35-28							
AB	!	BARR LABS	0.035MG;1MG	A072696	001	Feb 28, 1992	Mar	CAHN

TABLET, CHEWABLE; ORAL

KAITLIB FE

AB	!	LUPIN LTD	0.025MG;0.8MG	A203448	001	Dec 17, 2015	Apr	CHRS
		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
@	+	TEVA BRANDED PHARM	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Apr	DISC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	BARR LABS	0.02MG;1MG	A090938	001	Dec 01, 2014	Mar	CAHN
	TABLET; ORAL-21						
	JUNEL 1/20						
AB	BARR LABS	0.02MG;1MG	A076380	001	May 30, 2003	Mar	CAHN
	TABLET; ORAL-28						
	BLISOVI FE 1.5/30						
AB	LUPIN LTD	0.03MG;1.5MG	A201585	001	Nov 18, 2015	Apr	CTEC

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28		NORGESTIMATE AND ETHINYL ESTRADIOL					
	@ NAARI PTE	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG	A203870	001	Nov 12, 2015	Sep	CAHN
	@	0.035MG; 0.25MG	A203865	001	Oct 27, 2015	Sep	CAHN
AB		0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG	A203873	001	May 12, 2016	Sep	CAHN

ETHIONAMIDE

TABLET; ORAL		TRECATOR					
	@ + WYETH PHARMS	250MG	N013026	002		Oct	DISC

ETHOSUXIMIDE

SYRUP; ORAL		ETHOSUXIMIDE					
AA	CHARTWELL RX	250MG/5ML	A040506	001	Dec 22, 2003	Aug	CAHN

ETODOLAC

TABLET; ORAL		ETODOLAC					
>A>	AB PHARMACO	400MG	A210704	001	Dec 16, 2020	Dec	CAHN
>A>	AB	500MG	A210704	002	Dec 16, 2020	Dec	CAHN
	@ SENORES PHARMS	400MG	A074839	001	Jul 11, 1997	Jul	CAHN
>D>	AB UNICHEM	400MG	A210704	001	Dec 16, 2020	Dec	CAHN
>D>	AB	500MG	A210704	002	Dec 16, 2020	Dec	CAHN

ETOPOSIDE

CAPSULE; ORAL		VEPESID					
	@ + ONESOURCE SPECIALTY	50MG	N019557	001	Dec 30, 1986	Jun	CAHN
	@ +	100MG	N019557	002	Dec 30, 1986	Jun	CAHN

ETRAVIRINE

TABLET; ORAL		ETRAVIRINE					
AB	BIONPHARMA	100MG	A219152	001	Oct 02, 2025	Sep	NEWA
AB		200MG	A219152	002	Oct 02, 2025	Sep	NEWA

>A> <u>ETRIPIAMIL</u>		SPRAY; NASAL					
>A>	CARDAMYST						
>A>	+! MILESTONE PHARMS USA	70MG	N218571	001	Dec 12, 2025	Dec	NEWA

EVEROLIMUS

TABLET; ORAL		EVEROLIMUS					
AB	BIOCON PHARMA	0.25MG	A216140	001	Apr 09, 2025	Mar	NEWA
AB		0.5MG	A216140	002	Apr 09, 2025	Mar	NEWA
AB		0.75MG	A216140	003	Apr 09, 2025	Mar	NEWA
AB		1MG	A216140	004	Apr 09, 2025	Mar	NEWA
AB	BRECKENRIDGE	1MG	A205432	004	Sep 03, 2025	Aug	NEWA
	@ MYLAN	2.5MG	A212936	001	Jun 08, 2020	Mar	DISC
	@	5MG	A212936	002	Jun 08, 2020	Mar	DISC
	@	7.5MG	A212936	003	Jun 08, 2020	Mar	DISC
	@	10MG	A212936	004	Jun 08, 2020	Mar	DISC
AB	NOVUGEN	2.5MG	A219955	001	Oct 30, 2025	Oct	NEWA
AB		5MG	A219955	002	Oct 30, 2025	Oct	NEWA
AB		7.5MG	A219955	003	Oct 30, 2025	Oct	NEWA
AB		10MG	A219955	004	Oct 30, 2025	Oct	NEWA
TABLET, FOR SUSPENSION; ORAL		EVEROLIMUS					
AB	AMNEAL	2MG	A218863	001	Jan 10, 2025	Jan	NEWA
AB		3MG	A218863	002	Jan 10, 2025	Jan	NEWA
AB		5MG	A218863	003	Jan 10, 2025	Jan	NEWA
	@ MYLAN	2MG	A210130	001	Apr 19, 2019	Nov	DISC
	@	3MG	A210130	002	Apr 19, 2019	Nov	DISC
	@	5MG	A210130	003	Apr 19, 2019	Nov	DISC
AB	NATCO	2MG	A217640	001	Jan 28, 2025	Jan	NEWA
AB		3MG	A217640	002	Jan 28, 2025	Jan	NEWA
AB		5MG	A217640	003	Jan 28, 2025	Jan	NEWA

EXEMESTANE

TABLET;ORAL

EXEMESTANE

@ HIKMA 25MG A077431 001 Apr 01, 2011 Sep DISC

EXENATIDE SYNTHETIC

INJECTABLE;SUBCUTANEOUS

BYETTA

@ + ASTRAZENECA AB 300MCG/1.2ML (250MCG/ML) N021773 001 Apr 28, 2005 Apr DISC

@ + 600MCG/2.4ML (250MCG/ML) N021773 002 Apr 28, 2005 Apr DISC

EXENATIDE SYNTHETIC

! AMNEAL 300MCG/1.2ML (250MCG/ML) A206697 001 Nov 19, 2024 Apr CTEC

! 300MCG/1.2ML (250MCG/ML) A206697 001 Nov 19, 2024 Apr CHRS

! 600MCG/2.4ML (250MCG/ML) A206697 002 Nov 19, 2024 Apr CTEC

! 600MCG/2.4ML (250MCG/ML) A206697 002 Nov 19, 2024 Apr CHRS

SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

BYDUREON BCISE

@ + ASTRAZENECA AB 2MG/0.85ML (2MG/0.85ML) N209210 001 Oct 20, 2017 Mar DISC

EZETIMIBE

TABLET;ORAL

EZETIMIBE

@ MACLEODS PHARMS LTD 10MG A211159 001 Apr 29, 2024 Jun DISC

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

@ AMNEAL PHARMS CO 10MG;10MG A208831 001 Nov 21, 2017 Jul DISC

@ 10MG;20MG A208831 002 Nov 21, 2017 Jul DISC

@ 10MG;40MG A208831 003 Nov 21, 2017 Jul DISC

@ 10MG;80MG A208831 004 Nov 21, 2017 Jul DISC

@ SCIEGEN PHARMS 10MG;10MG A211663 001 Dec 10, 2024 Jun DISC

@ 10MG;20MG A211663 002 Dec 10, 2024 Jun DISC

@ 10MG;40MG A211663 003 Dec 10, 2024 Jun DISC

@ 10MG;80MG A211663 004 Dec 10, 2024 Jun DISC

@ TORRENT 10MG;10MG A209461 001 Jan 27, 2025 Jun DISC

AB @ 10MG;10MG A209461 001 Jan 27, 2025 Jan NEWA

AB @ 10MG;20MG A209461 002 Jan 27, 2025 Jun DISC

AB @ 10MG;20MG A209461 002 Jan 27, 2025 Jan NEWA

AB @ 10MG;40MG A209461 003 Jan 27, 2025 Jun DISC

AB @ 10MG;40MG A209461 003 Jan 27, 2025 Jan NEWA

AB @ 10MG;80MG A209461 004 Jan 27, 2025 Jun DISC

AB @ 10MG;80MG A209461 004 Jan 27, 2025 Jan NEWA

FAMOTIDINE

FOR SUSPENSION;ORAL

FAMOTIDINE

AB APPCO 40MG/5ML A217655 001 Jun 16, 2023 Mar CAHN

AB AUROBINDO PHARMA LTD 40MG/5ML A219091 001 Jul 09, 2025 Jun NEWA

@ BIONPHARMA 40MG/5ML A219153 001 Jun 23, 2025 Jul DISC

AB 40MG/5ML A219153 001 Jun 23, 2025 Jun NEWA

AB LANNETT CO INC 40MG/5ML A217982 001 Jun 02, 2025 May NEWA

AB MSN 40MG/5ML A219863 001 Jul 24, 2025 Jul NEWA

AB NOVITIUM PHARMA 40MG/5ML A201995 001 May 30, 2014 Jun CAHN

SOLUTION;INTRAVENOUS

FAMOTIDINE

+! SAGENT 20MG/5ML (4MG/ML) N219935 001 Jul 16, 2025 Jul NEWA

+! 40MG/10ML (4MG/ML) N219935 002 Jul 16, 2025 Jul NEWA

+! 200MG/50ML (4MG/ML) N219935 003 Jul 16, 2025 Jul NEWA

TABLET;ORAL

FAMOTIDINE

@ APOTEX 20MG A075611 001 Jul 23, 2001 Mar DISC

@ 40MG A075611 002 Jul 23, 2001 Mar DISC

>D> AB BEXIMCO PHARMS USA 20MG A218631 001 Mar 25, 2025 Dec CAHN

AB 20MG A218631 001 Mar 25, 2025 Mar NEWA

>D> AB 40MG A218631 002 Mar 25, 2025 Dec CAHN

AB 40MG A218631 002 Mar 25, 2025 Mar NEWA

>A> AB REGCON HOLDINGS 20MG A218631 001 Mar 25, 2025 Dec CAHN

>A> AB 40MG A218631 002 Mar 25, 2025 Dec CAHN

AB RISING 20MG A075704 001 Apr 16, 2001 Aug CMFD

AB 40MG A075704 002 Apr 16, 2001 Aug CMFD

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

IBUPROFEN AND FAMOTIDINE

>D>	AB	AUROBINDO PHARMA LTD	26.6MG;800MG	A219538	001	Jun 30, 2025	Dec	DISC
>A>		@	26.6MG;800MG	A219538	001	Jun 30, 2025	Dec	DISC
	AB		26.6MG;800MG	A219538	001	Jun 30, 2025	Jun	NEWA
	AB	ENDO OPERATIONS	26.6MG;800MG	A203658	001	Mar 22, 2024	Feb	CTNA
>D>	AB	TEVA PHARMS USA	26.6MG;800MG	A211278	001	Oct 29, 2021	Dec	DISC
>A>		@	26.6MG;800MG	A211278	001	Oct 29, 2021	Dec	DISC
		@	TORRENT	A215925	001	Mar 18, 2024	Feb	CTNA
	AB	ZYDUS PHARMS	26.6MG;800MG	A218684	001	Feb 20, 2025	Feb	NEWA

FEBUXOSTAT

TABLET;ORAL

FEBUXOSTAT

	AB	MSN	40MG	A210461	001	Dec 30, 2019	Jan	CTEC
	AB		80MG	A210461	002	Dec 30, 2019	Jan	CTEC

FELBAMATE

SUSPENSION;ORAL

FELBAMATE

>D>	AB	NOVITIUM PHARMA	600MG/5ML	A211333	001	May 31, 2019	Dec	CHRS
>A>	AB	!	600MG/5ML	A211333	001	May 31, 2019	Dec	CHRS
>D>	AB	+! MYLAN SPECIALITY LP	600MG/5ML	N020189	003	Jul 29, 1993	Dec	DISC
>A>		@ +	600MG/5ML	N020189	003	Jul 29, 1993	Dec	DISC

TABLET;ORAL

FELBAMATE

		@	ALVOGEN	400MG	A204595	001	Jan 11, 2016	May	DISC
		@		600MG	A204595	002	Jan 11, 2016	May	DISC

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE (MICRONIZED)

	AB	CHARTWELL RX	43MG	A090859	001	Mar 01, 2012	Apr	CAHN	
	AB		130MG	A090859	002	Mar 01, 2012	Apr	CAHN	
		@	SUN PHARM INDS LTD	43MG	A201748	001	Oct 31, 2014	Nov	DISC
	AB		43MG	A201748	001	Oct 31, 2014	Nov	CTNA	
		@		130MG	A201748	002	Oct 31, 2014	Nov	DISC
	AB		130MG	A201748	002	Oct 31, 2014	Nov	CTNA	

TABLET;ORAL

FENOFIBRATE

		@	BAUSCH	48MG	A090715	001	Apr 05, 2012	Aug	DISC
	AB		48MG	A090715	001	Apr 05, 2012	Aug	CAHN	
		@		145MG	A090715	002	Apr 05, 2012	Aug	DISC
	AB		145MG	A090715	002	Apr 05, 2012	Aug	CAHN	
	AB	BOSTAL	48MG	A208476	001	Feb 10, 2021	Aug	CAHN	
	AB		54MG	A207803	001	Dec 19, 2017	Aug	CAHN	
	AB		145MG	A208476	002	Feb 10, 2021	Aug	CAHN	
	AB		160MG	A207803	002	Dec 19, 2017	Aug	CAHN	
	AB	CREEKWOOD PHARMS	40MG	A217732	001	Sep 07, 2023	Mar	CTEC	
	AB		120MG	A217732	002	Sep 07, 2023	Mar	CTEC	
		@	MYLAN	54MG	A076520	001	Oct 25, 2007	Feb	DISC
		@		160MG	A076520	003	Oct 25, 2007	Feb	DISC
		@	SUN PHARM	48MG	A200884	001	Sep 07, 2017	Jan	DISC
		@		145MG	A200884	002	Sep 07, 2017	Apr	DISC

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

		@ +	ATHENA	105MG	N022418	002	Aug 14, 2009	Sep	DISC
		+!		105MG	N022418	002	Aug 14, 2009	Jun	CMFD

FENOPROFEN CALCIUM

CAPSULE;ORAL

NALFON

		@ +	PHARMACO	EQ 200MG BASE	N017604	003		Nov	CAHN
		@		EQ 300MG BASE	N017604	002		Nov	CAHN
		@ +		EQ 400MG BASE	N017604	004	Jul 21, 2009	Nov	CAHN

<u>TABLET;ORAL</u>							
FENOPROFEN CALCIUM							
>D>	@	KEY THERAP	EQ 600MG BASE	A072267	001	Aug 17, 1988	Dec CAHN
>A>	@	PHARMACO	EQ 600MG BASE	A072267	001	Aug 17, 1988	Dec CAHN
<u>FERUMOXYTOL</u>							
SOLUTION;INTRAVENOUS							
FERABRIGHT							
	+	COVIS	EQ 300MG IRON/10ML (EQ 30MG IRON/ML)	N219868	001	Oct 16, 2025	Oct NEWA
	+		EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N219868	002	Oct 16, 2025	Oct NEWA
<u>FIDAXOMICIN</u>							
TABLET;ORAL							
DIFICID							
AB	+	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011	Jul CTEC
FIDAXOMICIN							
AB		ACTAVIS LABS FL	200MG	A208443	001	Jan 16, 2024	Jul CMFD
<u>FINASTERIDE; TADALAFIL</u>							
CAPSULE;ORAL							
FINASTERIDE AND TADALAFIL							
		NOVITIUM PHARMA	5MG;5MG	A218499	001	Mar 19, 2025	Mar NEWA
<u>FINERENONE</u>							
TABLET;ORAL							
KERENDIA							
	+	BAYER HLTHCARE	40MG	N215341	003	Jul 11, 2025	Jul NEWA
<u>FINGOLIMOD HYDROCHLORIDE</u>							
CAPSULE;ORAL							
FINGOLIMOD HYDROCHLORIDE							
	@	MYLAN	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Oct DISC
<u>FITUSIRAN SODIUM</u>							
SOLUTION;SUBCUTANEOUS							
QFITLIA							
	+	GENZYME CORP	EQ 20MG BASE/0.2ML (EQ 20MG BASE/0.2ML)	N219019	001	Mar 28, 2025	Mar NEWA
	+		EQ 50MG BASE/0.5ML (EQ 50MG BASE/0.5ML)	N219019	002	Mar 28, 2025	Mar NEWA
<u>FLUCONAZOLE</u>							
TABLET;ORAL							
FLUCONAZOLE							
>A>	AB	FDC LTD	50MG	A218692	001	Jan 08, 2026	Dec NEWA
>A>	AB		100MG	A218692	002	Jan 08, 2026	Dec NEWA
>A>	AB		150MG	A218692	003	Jan 08, 2026	Dec NEWA
>A>	AB		200MG	A218692	004	Jan 08, 2026	Dec NEWA
	@	TARO	50MG	A076507	001	Jul 29, 2004	Aug DISC
	@		100MG	A076507	002	Jul 29, 2004	Aug DISC
	@		150MG	A076507	003	Jul 29, 2004	Aug DISC
	@		200MG	A076507	004	Jul 29, 2004	Aug DISC
<u>FLUCYTOSINE</u>							
CAPSULE;ORAL							
FLUCYTOSINE							
AB		LAURUS	250MG	A218005	001	Jul 23, 2025	Jul NEWA
AB			500MG	A218005	002	Jul 23, 2025	Jul NEWA
<u>FLUDEOXYGLUCOSE F-18</u>							
INJECTABLE;INTRAVENOUS							
FLUDEOXYGLUCOSE F18							
AP		BAMF	20-400mCi/ML	A216125	001	Mar 11, 2025	Feb NEWA
	@	MEM SLOAN-KETTERING	20-300mCi/ML	A208679	001	Dec 08, 2016	Oct DISC
AP		SOFIE	20-300mCi/ML	A204463	001	Oct 21, 2014	Mar CAHN
>D>	@	WEILL MEDCL COLL	10-100mCi/ML	N021768	001	Aug 05, 2004	Dec CRLD
>A>	@	+	10-100mCi/ML	N021768	001	Aug 05, 2004	Dec CRLD
	@	WISCONSIN	20-500mCi/ML	A203709	001	Oct 23, 2013	Aug DISC

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

>D>	AB	BARR	0.1MG	A 040425	001	Jan 21, 2003	Dec	DISC
>A>	@		0.1MG	A 040425	001	Jan 21, 2003	Dec	DISC

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

@	TARO	0.025%	A 087104	001	Apr 27, 1982	Aug	DISC
---	------	--------	----------	-----	--------------	-----	------

OIL; TOPICAL

FLUCINOLONE ACETONIDE

@	GLENMARK PHARMS LTD	0.01%	A 210556	001	Oct 25, 2018	Jul	DISC
---	---------------------	-------	----------	-----	--------------	-----	------

FLUOCINONIDE ACETONIDE

@	GLENMARK PHARMS LTD	0.01%	A 210539	001	Oct 26, 2018	Aug	DISC
---	---------------------	-------	----------	-----	--------------	-----	------

OIL/DROPS; OTIC

FLUOCINONIDE ACETONIDE

@	GLENMARK PHARMS LTD	0.01%	A 211815	001	Dec 14, 2018	Aug	DISC
---	---------------------	-------	----------	-----	--------------	-----	------

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

@	TARO	0.025%	A 040041	001	Sep 15, 1994	Aug	DISC
---	------	--------	----------	-----	--------------	-----	------

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

AB1	ENCUBE	0.05%	A 211410	001	Oct 16, 2018	Feb	CMFD
-----	--------	-------	----------	-----	--------------	-----	------

@	GLENMARK PHARMS LTD	0.1%	A 091282	001	Jul 14, 2014	Aug	DISC
---	---------------------	------	----------	-----	--------------	-----	------

@ +	SUN PHARMA CANADA	0.05%	N 019117	001	Jun 26, 1984	Aug	CAHN
-----	-------------------	-------	----------	-----	--------------	-----	------

GEL; TOPICAL

FLUOCINONIDE

AB	PADAGIS US	0.05%	A 209030	001	Jun 19, 2018	Feb	CMFD
----	------------	-------	----------	-----	--------------	-----	------

SOLUTION; TOPICAL

FLUOCINONIDE

AT	QUAGEN	0.05%	A 216389	001	Feb 26, 2025	Feb	NEWA
----	--------	-------	----------	-----	--------------	-----	------

@	SAPTALIS PHARMS	0.05%	A 207554	001	Mar 18, 2019	Feb	CAHN
---	-----------------	-------	----------	-----	--------------	-----	------

@	SCIEGEN PHARMS	0.05%	A 207554	001	Mar 18, 2019	Sep	CAHN
---	----------------	-------	----------	-----	--------------	-----	------

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

AK-FLUOR 25%

@ +	LONG GROVE PHARMS	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N 022186	002	Aug 08, 2008	May	DISC
-----	-------------------	--------------------------------------	----------	-----	--------------	-----	------

FLUORESCEIN SODIUM

AP	NEXUS	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A 215709	001	Sep 25, 2023	Mar	CAHN
----	-------	--------------------------------------	----------	-----	--------------	-----	------

!		EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A 215709	002	Sep 25, 2023	May	CTEC
---	--	--------------------------------------	----------	-----	--------------	-----	------

AP		EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A 215709	002	Sep 25, 2023	Mar	CAHN
----	--	--------------------------------------	----------	-----	--------------	-----	------

FLUORODOPA F-18

SOLUTION; INTRAVENOUS

FLUORODOPA F18

+!	FEINSTEIN	1-40mCi/ML	N 200655	001	Oct 10, 2019	Feb	CPOT
----	-----------	------------	----------	-----	--------------	-----	------

FLUOROURACIL

CREAM; TOPICAL

FLUOROURACIL

AB	ENCUBE	5%	A 216942	001	Feb 12, 2025	Jan	NEWA
----	--------	----	----------	-----	--------------	-----	------

INJECTABLE; INJECTION

FLUOROURACIL

AP	ACCORD HLTHCARE	500MG/10ML (50MG/ML)	A 040743	002	Apr 26, 2007	Jul	CHRS
----	-----------------	----------------------	----------	-----	--------------	-----	------

AP		1GM/20ML (50MG/ML)	A 040743	001	Apr 26, 2007	Jul	CHRS
----	--	--------------------	----------	-----	--------------	-----	------

@		2.5GM/50ML (50MG/ML)	A 040798	002	Apr 26, 2007	May	DISC
---	--	----------------------	----------	-----	--------------	-----	------

AP		5GM/100ML (50MG/ML)	A 040798	001	Apr 26, 2007	Jul	CHRS
----	--	---------------------	----------	-----	--------------	-----	------

AP	!	ALEMBIC	A 217295	001	Mar 03, 2023	May	CHRS
----	---	---------	----------	-----	--------------	-----	------

AP	!	FRESENIUS KABI USA	A 040279	002	Sep 30, 1998	Jul	CHRS
----	---	--------------------	----------	-----	--------------	-----	------

AP	!		A 040279	001	Sep 30, 1998	Jul	CHRS
----	---	--	----------	-----	--------------	-----	------

AP	!		A 040278	002	Sep 30, 1998	Jul	CHRS
----	---	--	----------	-----	--------------	-----	------

AP		KINDOS	A 215699	001	Feb 06, 2025	Jan	NEWA
----	--	--------	----------	-----	--------------	-----	------

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL		FLUOXETINE HYDROCHLORIDE					
	@	CHARTWELL RX	EQ 10MG BASE	A 078143	001	Jan 16, 2008	Jul CAHN
	@		EQ 20MG BASE	A 078143	002	Jan 16, 2008	Jul CAHN
	@		EQ 40MG BASE	A 078143	003	Jan 16, 2008	Jul CAHN
SOLUTION;ORAL		FLUOXETINE HYDROCHLORIDE					
AA		SCIEGEN PHARMS	EQ 20MG BASE/5ML	A 075525	001	Jun 27, 2002	Jun CMFD
AA		SOLIS PHARMS	EQ 20MG BASE/5ML	A 075292	001	Feb 07, 2002	Apr CAHN
TABLET;ORAL		FLUOXETINE HYDROCHLORIDE					
	@	APPCO	EQ 10MG BASE	A 211696	001	Jan 30, 2019	Feb CAHN
	@		EQ 20MG BASE	A 211696	002	Jan 30, 2019	Feb CAHN
AB			EQ 60MG BASE	A 211477	001	Nov 21, 2018	Jun CAHN
AB	!	AUROBINDO PHARMA LTD	EQ 20MG BASE	A 213286	002	Apr 08, 2020	Jun CHRS
AB	!		EQ 60MG BASE	A 213265	001	Jun 10, 2020	Apr CHRS
	@	CHARTWELL RX	EQ 10MG BASE	A 211444	001	Sep 13, 2022	Mar CAHN
	@		EQ 20MG BASE	A 211444	002	Sep 13, 2022	Mar CAHN
AB		DR REDDYS	EQ 20MG BASE	A 076006	002	Apr 23, 2018	Jun CHRS
	@ +	TWI PHARMS	EQ 60MG BASE	N 202133	001	Oct 06, 2011	Apr DISC

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE;ORAL		OLANZAPINE AND FLUOXETINE HYDROCHLORIDE					
AB	!	TEVA PHARMS	EQ 50MG BASE;EQ 6MG BASE	A 077528	003	Jun 19, 2012	Jun CHRS
SYMBYAX							
	@ +	LILLY	EQ 25MG BASE;EQ 3MG BASE	N 021520	001	Apr 09, 2007	Feb DISC
	@ +		EQ 25MG BASE;EQ 6MG BASE	N 021520	002	Dec 24, 2003	Feb DISC
	@ +		EQ 25MG BASE;EQ 12MG BASE	N 021520	004	Dec 24, 2003	Feb DISC
	@ +		EQ 50MG BASE;EQ 6MG BASE	N 021520	003	Dec 24, 2003	Feb DISC
	@ +		EQ 50MG BASE;EQ 12MG BASE	N 021520	005	Dec 24, 2003	Feb DISC

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL		FLUPHENAZINE HYDROCHLORIDE					
>D>	AB	APOTEX	1MG	A 216649	001	Jul 15, 2022	Dec DISC
>A>		@	1MG	A 216649	001	Jul 15, 2022	Dec DISC
>D>	AB		2.5MG	A 216649	002	Jul 15, 2022	Dec DISC
>A>		@	2.5MG	A 216649	002	Jul 15, 2022	Dec DISC
>D>	AB		5MG	A 216649	003	Jul 15, 2022	Dec DISC
>A>		@	5MG	A 216649	003	Jul 15, 2022	Dec DISC
>D>	AB		10MG	A 216649	004	Jul 15, 2022	Dec DISC
>A>		@	10MG	A 216649	004	Jul 15, 2022	Dec DISC
AB		CHARTWELL RX	1MG	A 215141	001	Oct 20, 2021	Sep CAHN
AB			2.5MG	A 215141	002	Oct 20, 2021	Sep CAHN
AB			5MG	A 215141	003	Oct 20, 2021	Sep CAHN
AB			10MG	A 215141	004	Oct 20, 2021	Sep CAHN
AB		HETERO LABS LTD III	1MG	A 218769	001	Nov 18, 2025	Nov NEWA
AB			2.5MG	A 218769	002	Nov 18, 2025	Nov NEWA
AB			5MG	A 218769	003	Nov 18, 2025	Nov NEWA
AB			10MG	A 218769	004	Nov 18, 2025	Nov NEWA
	@	TWI PHARMS	1MG	A 215848	004	Dec 14, 2022	Jul DISC
	@		2.5MG	A 215848	001	Apr 01, 2022	Jul DISC
	@		5MG	A 215848	002	Apr 01, 2022	Jul DISC
	@		10MG	A 215848	003	Apr 01, 2022	Jul DISC
AB		ZAMEER PHARMS	1MG	A 215141	001	Oct 20, 2021	Feb CAHN
AB			2.5MG	A 215141	002	Oct 20, 2021	Feb CAHN
AB			5MG	A 215141	003	Oct 20, 2021	Feb CAHN
AB			10MG	A 215141	004	Oct 20, 2021	Feb CAHN

FLURANDRENOLIDE

CREAM;TOPICAL		CORDRAN SP					
	@ +	INA PHARMS	0.025%	N 012806	003		May CAHN
	@ +		0.05%	N 012806	002		May CAHN
LOTION;TOPICAL		CORDRAN					
	@ +	INA PHARMS	0.05%	N 013790	001		May CAHN

	OINTMENT;TOPICAL							
	CORDRAN							
	@ +	INA PHARMS	0.025%		N012806	004		May CAHN
	@ +		0.05%		N012806	001		May CAHN
	<u>FLURAZEPAM HYDROCHLORIDE</u>							
	CAPSULE;ORAL							
	FLURAZEPAM HYDROCHLORIDE							
	@	NOVITIUM PHARMA	15MG		A070444	001	Mar 20, 1986	Aug CAHN
	<u>FLURBIPROFEN</u>							
	TABLET;ORAL							
	FLURBIPROFEN							
	!	NEW HEIGHTSRX	100MG		A074431	001	May 31, 1995	Jul CAHN
	<u>FLUTICASONE PROPIONATE</u>							
	CREAM;TOPICAL							
	FLUTICASONE PROPIONATE							
AB		ENCUBE	0.05%		A076633	001	May 14, 2004	Oct CMFD
	LOTION;TOPICAL							
	FLUTICASONE PROPIONATE							
	@	GLENMARK PHARMS LTD	0.05%		A090759	001	May 02, 2011	Aug DISC
	!	PADAGIS ISRAEL	0.05%		A091553	001	Jul 30, 2013	Aug CTEC
AB	!		0.05%		A091553	001	Jul 30, 2013	Aug CHRS
	OINTMENT;TOPICAL							
	FLUTICASONE PROPIONATE							
	@	CHARTWELL RX	0.005%		A076300	001	May 14, 2004	Mar CAHN
	SPRAY, METERED;NASAL							
	FLUTICASONE PROPIONATE							
AB		RUBICON RESEARCH	0.05MG/SPRAY		A218321	001	Jun 05, 2025	May NEWA
	XHANCE							
	+!	PARATEK PHARMS	0.093MG		N209022	001	Sep 18, 2017	Nov CAHN
	<u>FLUVOXAMINE MALEATE</u>							
	CAPSULE, EXTENDED RELEASE;ORAL							
	FLUVOXAMINE MALEATE							
AB		ANNORA PHARMA	100MG		A217024	001	Jul 30, 2025	Jul NEWA
AB			150MG		A217024	002	Jul 30, 2025	Jul NEWA
	TABLET;ORAL							
	FLUVOXAMINE MALEATE							
AB		AIPING PHARM INC	25MG		A075888	001	Nov 29, 2000	Jul CAHN
AB			50MG		A075888	002	Nov 29, 2000	Jul CAHN
AB	!		100MG		A075888	003	Nov 29, 2000	Jul CAHN
	@	QUAGEN	25MG		A075889	001	Nov 29, 2000	Sep CAHN
	@		50MG		A075889	002	Nov 29, 2000	Sep CAHN
	@		100MG		A075889	003	Nov 29, 2000	Sep CAHN
	<u>FOLIC ACID</u>							
	TABLET;ORAL							
	FOLIC ACID							
AA		AIPING PHARM INC	1MG		A091145	001	Jul 12, 2013	Mar CAHN
AA		RISING	1MG		A211064	001	Mar 08, 2019	Oct CAHN
	<u>FONDAPARINUX SODIUM</u>							
	INJECTABLE;SUBCUTANEOUS							
	FONDAPARINUX SODIUM							
	@	BRIGHTGENE	2.5MG/0.5ML		A218312	001	Dec 18, 2024	Oct DISC
	@	HANGZHOU ZHONGMEI	2.5MG/0.5ML		A216493	001	Aug 19, 2024	Jul DISC
	@		5MG/0.4ML		A216493	002	Aug 19, 2024	Jul DISC
	@		7.5MG/0.6ML		A216493	003	Aug 19, 2024	Jul DISC
	@		10MG/0.8ML		A216493	004	Aug 19, 2024	Jul DISC
	<u>FORMOTEROL FUMARATE</u>							
	SOLUTION;INHALATION							
	FORMOTEROL FUMARATE							
AN		DEVA HOLDING AS	0.02MG/2ML		A218308	001	Feb 11, 2025	Jan NEWA
AN		DR REDDYS	0.02MG/2ML		A215907	001	Jan 30, 2025	Jan NEWA
	PERFORMOMIST							
AN	+!	VIATRIS SPECIALTY	0.02MG/2ML		N022007	001	May 11, 2007	Feb CAHN

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS  
FOSAPREPITANT DIMEGLUMINE

@	LUPIN LTD	EQ 150MG BASE/VIAL	A210689	001	Sep 05, 2019	Nov	DISC
@	PIRAMAL CRITICAL	EQ 150MG BASE/VIAL	A214683	001	May 16, 2023	Apr	DISC
@	PRAXGEN	EQ 150MG BASE/VIAL	A213199	001	Oct 04, 2021	Jan	CAHN

FOSCARNET SODIUM

SOLUTION; INTRAVENOUS  
FOSCARNET SODIUM

AP	AMNEAL	2.4GM/100ML	A216602	001	Mar 01, 2024	Sep	CDFR	
AP		6GM/250ML (24MG/ML)	A216602	001	Mar 01, 2024	Sep	CPOT	
AP	AVET LIFESCIENCES	2.4GM/100ML	A213807	001	Jun 05, 2023	Sep	CDFR	
AP		6GM/250ML (24MG/ML)	A213807	001	Jun 05, 2023	Sep	CPOT	
AP	FRESENIUS KABI USA	2.4GM/100ML	A212483	001	Jan 29, 2021	Sep	CDFR	
AP		6GM/250ML (24MG/ML)	A212483	001	Jan 29, 2021	Sep	CPOT	
AP	GLAND	2.4GM/100ML	A213001	001	Apr 21, 2021	Sep	CDFR	
AP		6GM/250ML (24MG/ML)	A213001	001	Apr 21, 2021	Sep	CPOT	
@	HOSPIRA	2.4GM/100ML	A077174	001	May 31, 2005	Sep	CDFR	
@		6GM/250ML (24MG/ML)	A077174	001	May 31, 2005	Sep	CPOT	
@		12GM/500ML (24MG/ML)	A077174	002	May 31, 2005	Sep	DISC	
@		12GM/500ML (24MG/ML)	A077174	002	May 31, 2005	Sep	NEWA	
AP	SCIECURE	2.4GM/100ML	A213987	001	Nov 29, 2023	Sep	CDFR	
AP		6GM/250ML (24MG/ML)	A213987	001	Nov 29, 2023	Sep	CPOT	
	FOSCAVIR							
AP	+!	CLINIGEN HLTHCARE	2.4GM/100ML	N020068	001	Sep 27, 1991	Sep	CDFR
AP	+!		6GM/250ML (24MG/ML)	N020068	001	Sep 27, 1991	Sep	CPOT
@	+		12GM/500ML (24MG/ML)	N020068	002	Sep 27, 1991	Sep	DISC
	+		12GM/500ML (24MG/ML)	N020068	002	Sep 27, 1991	Sep	NEWA

FOSFOMYCIN DISODIUM

POWDER; INTRAVENOUS  
CONTEPO

+!	MEITHEAL	EQ 6GM BASE/VIAL	N212271	001	Oct 22, 2025	Oct	NEWA
----	----------	------------------	---------	-----	--------------	-----	------

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION; ORAL  
FOSFOMYCIN TROMETHAMINE

AA	AUROBINDO PHARMA LTD	EQ 3GM BASE/PACKET	A217608	001	Nov 14, 2025	Nov	NEWA
AA	PRECISION DOSE INC	EQ 3GM BASE/PACKET	A217187	001	Jun 03, 2025	May	NEWA

FOSINOPRIL SODIUM

TABLET; ORAL  
FOSINOPRIL SODIUM

@	APOTEX	10MG	A076906	001	May 17, 2005	Mar	DISC
@		20MG	A076906	002	May 17, 2005	Mar	DISC
@		40MG	A076906	003	May 17, 2005	Mar	DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL  
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@	CHARTWELL RX	10MG;12.5MG	A079025	001	Sep 17, 2010	Oct	CAHN
@		20MG;12.5MG	A079025	002	Sep 17, 2010	Oct	CAHN

FOSPHENYTOIN SODIUM

SOLUTION; INTRAVENOUS  
SESQUIENT

@	+	LUPIN	EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML)	N210864	001	Nov 05, 2020	Sep	DISC
	+!		EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML)	N210864	001	Nov 05, 2020	Aug	CMFD
@	+		EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML)	N210864	002	Nov 05, 2020	Sep	DISC
	+!		EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML)	N210864	002	Nov 05, 2020	Aug	CMFD

FROVATRIPTAN SUCCINATE

TABLET; ORAL  
FROVATRIPTAN SUCCINATE

AB	LEADING	EQ 2.5MG BASE	A216998	001	Apr 16, 2025	Apr	NEWA
AB	RENATA	EQ 2.5MG BASE	A213891	001	Apr 06, 2022	Aug	CAHN

FULVESTRANT

SOLUTION;INTRAMUSCULAR

FULVESTRANT

@ EUGIA PHARMA 250MG/5ML (50MG/ML) A208811 001 Jul 23, 2019 Aug DISC

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP APOTEX 10MG/ML A077941 001 Mar 22, 2007 Nov CAHN

SOLUTION;ORAL

FUROSEMIDE

>D> HIKMA 40MG/5ML A070433 001 Apr 22, 1987 Dec CHRS

>A> ! 40MG/5ML A070433 001 Apr 22, 1987 Dec CHRS

LASIX

@ + SANOFI AVENTIS US 10MG/ML N017688 001 Oct CRLD

SOLUTION;SUBCUTANEOUS

LASIX ONYU

+! SQ INNOVATION 80MG/2.67ML (30MG/ML) N217294 001 Oct 07, 2025 Oct NEWA

TABLET;ORAL

FUROSEMIDE

AB AUROBINDO PHARMA LTD 20MG A218831 001 Jul 17, 2025 Jul NEWA

AB 40MG A218831 002 Jul 17, 2025 Jul NEWA

AB 80MG A218831 003 Jul 17, 2025 Jul NEWA

AB ESJAY PHARMA 20MG N018415 001 Jul 27, 1982 Oct CMFD

AB 40MG N018415 002 Jul 27, 1982 Oct CMFD

AB 80MG N018415 003 Nov 26, 1984 Oct CMFD

AB ! GRAVITI PHARMS 80MG A216629 003 Oct 17, 2022 Nov CHRS

AB HIKMA 20MG N018823 001 Nov 10, 1983 Jun CAHN

AB 40MG N018823 002 Nov 10, 1983 Jun CAHN

@ NORVIUM BIOSCIENCE 80MG A070082 001 Oct 29, 1986 Feb CAHN

LASIX

@ + VALIDUS PHARMS 20MG N016273 002 Nov DISC

@ + 40MG N016273 001 Nov DISC

@ + 80MG N016273 003 Nov DISC

FUTIBATINIB

TABLET;ORAL

LYTGOBI

+ TAIHO ONCOLOGY 16MG N214801 002 Jul 28, 2025 Aug NEWA

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

AB ANDA REPOSITORY 100MG A219319 001 Aug 07, 2025 Sep CAHN

AB 300MG A219319 002 Aug 07, 2025 Sep CAHN

AB 400MG A219319 003 Aug 07, 2025 Sep CAHN

AB SENORES PHARMS 100MG A219319 001 Aug 07, 2025 Nov CAHN

AB 100MG A219319 001 Aug 07, 2025 Sep CAHN

AB 300MG A219319 002 Aug 07, 2025 Nov CAHN

AB 300MG A219319 002 Aug 07, 2025 Sep CAHN

AB 400MG A219319 003 Aug 07, 2025 Nov CAHN

AB 400MG A219319 003 Aug 07, 2025 Sep CAHN

AB STALLION LABS 100MG A219319 001 Aug 07, 2025 Aug NEWA

AB 300MG A219319 002 Aug 07, 2025 Aug NEWA

AB 400MG A219319 003 Aug 07, 2025 Aug NEWA

@ TARO 100MG A077261 001 Aug 02, 2013 Aug DISC

@ 300MG A077261 002 Aug 02, 2013 Aug DISC

@ 400MG A077261 003 Aug 02, 2013 Aug DISC

SOLUTION;ORAL

GABAPENTIN

AA AJENAT PHARMS 250MG/5ML A091286 001 Mar 14, 2016 Jan CAHN

AA PAI HOLDINGS PHARM 250MG/5ML A211330 001 Dec 03, 2019 Apr CMFD

@ TARO 250MG/5ML A076672 001 Jul 03, 2013 Aug DISC

TABLET;ORAL

GABAPENTIN

@ ACTAVIS ELIZABETH 600MG A075694 001 Oct 21, 2004 Jul DISC

@ 800MG A075694 002 Oct 21, 2004 Jul DISC

@ ALLIED 600MG A076877 001 Jul 06, 2006 Jul CAHN

@ 800MG A076877 002 Jul 06, 2006 Jul CAHN

>D> @ ANDA REPOSITORY 600MG A076877 001 Jul 06, 2006 Dec CAHN

>D> @ 800MG A076877 002 Jul 06, 2006 Dec CAHN

TABLET; ORAL

GABAPENTIN

	@	APOTEX	100MG	A077894	001	Oct 10, 2006	Mar	DISC
	@		300MG	A077894	002	Oct 10, 2006	Mar	DISC
	@		400MG	A077894	003	Oct 10, 2006	Mar	DISC
		IVAX SUB TEVA PHARMS	300MG	A076017	002	Apr 28, 2004	Mar	CTEC
AB2		SCIEGEN PHARMS	300MG	A218491	001	Sep 19, 2025	Sep	NEWA
AB2			600MG	A218491	002	Sep 19, 2025	Sep	NEWA
>A>	@	SENORES PHARMS	600MG	A076877	001	Jul 06, 2006	Dec	CAHN
	@		600MG	A076877	001	Jul 06, 2006	Sep	CAHN
>A>	@		800MG	A076877	002	Jul 06, 2006	Dec	CAHN
	@		800MG	A076877	002	Jul 06, 2006	Sep	CAHN
AB		ZYDUS PHARMS	450MG	A203934	003	Aug 25, 2025	Aug	NFTG
AB			750MG	A203934	004	Aug 25, 2025	Aug	NFTG
AB			900MG	A203934	005	Aug 25, 2025	Aug	NFTG

GRALISE

AB	+	ALMATICA	450MG	N022544	003	Apr 18, 2023	Aug	CFTG
AB	+		750MG	N022544	004	Apr 18, 2023	Aug	CFTG
AB	+	!	900MG	N022544	005	Apr 18, 2023	Aug	CFTG

GADOBUTROL

SOLUTION; INTRAVENOUS

GADOBUTROL

AP		HAINAN POLY PHARM	1.20944GM/2ML (604.72MG/ML)	A217480	003	Apr 16, 2025	Apr	NEWA
AP			6.0472GM/10ML (604.72MG/ML)	A217480	004	Apr 16, 2025	Apr	NEWA
AP			18.1416GM/30ML (604.72MG/ML)	A217480	005	Apr 16, 2025	Apr	NEWA
AP			39.3068GM/65ML (604.72MG/ML)	A217480	006	Apr 16, 2025	Apr	NEWA

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS

GADOTERATE MEGLUMINE

	@	HENGRUI PHARMA	1.8845GM/5ML (376.9MG/ML)	A215304	001	Apr 11, 2022	Oct	DISC
	@		3.769GM/10ML (376.9MG/ML)	A215304	002	Apr 11, 2022	Oct	DISC
	@		5.6535GM/15ML (376.9MG/ML)	A215304	003	Apr 11, 2022	Oct	DISC
	@		7.538GM/20ML (376.9MG/ML)	A215304	004	Apr 11, 2022	Oct	DISC
	@		37.69GM/100ML (376.9MG/ML)	A215304	005	Apr 15, 2022	Oct	DISC

GADOTERIDOL

INJECTABLE; INJECTION

GADOTERIDOL

AP		HAINAN POLY	279.3MG/ML	A218749	001	Feb 11, 2025	Jan	NFTG
AP	+	!	BRACCO	N020131	001	Nov 16, 1992	Jan	CFTG

GALLIUM GA-68 EDOTREOTIDE

SOLUTION; INTRAVENOUS

GALLIUM GA 68 EDOTREOTIDE

AP		METHODIST	0.5-4mCi/ML	A218845	001	Oct 10, 2025	Oct	NFTG
AP	+	!	UIHC PET IMAGING	N210828	001	Aug 21, 2019	Oct	CFTG

GALLIUM GA-68 GOZETOTIDE

POWDER; INTRAVENOUS

GOZELLIX

	+	!	TELIX INNOVATIONS	N/A	N219592	001	Mar 20, 2025	Mar	NEWA
--	---	---	-------------------	-----	---------	-----	--------------	-----	------

GANCICLOVIR

SOLUTION; INTRAVENOUS

GANZYK-RTU

	@	+	EXELA PHARMA	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017	Apr	DISC
--	---	---	--------------	----------------------	---------	-----	--------------	-----	------

GANIRELIX ACETATE

INJECTABLE; INJECTION

GANIRELIX ACETATE

AP		QILU	250MCG/0.5ML	A218855	001	Apr 23, 2025	Apr	NEWA
AP		TRIS PHARMA INC	250MCG/0.5ML	A219454	001	Jun 27, 2025	Jun	NEWA

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

AT		CAPLIN	0.5%	A213542	001	Nov 03, 2021	Sep	CMFD
	@		0.5%	A213542	001	Nov 03, 2021	May	CAHN
>D>	AT	LUPIN LTD	0.5%	A202653	001	Aug 28, 2013	Dec	DISC

	SOLUTION/DROPS;OPHTHALMIC								
	GATIFLOXACIN								
>A>	@	0.5%		A202653	001	Aug 28, 2013	Dec	DISC	
	<u>GEFITINIB</u>								
	TABLET;ORAL								
	GEFITINIB								
AB	CIPLA	250MG		A211826	001	May 16, 2025	May	NEWA	
	<u>GEMCITABINE HYDROCHLORIDE</u>								
	INJECTABLE;INJECTION								
	GEMCITABINE HYDROCHLORIDE								
	@	HIKMA INTL PHARMS	EQ 200MG BASE/VIAL	A206617	001	Jun 25, 2021	May	DISC	
	@		EQ 1GM BASE/VIAL	A206617	002	Jun 25, 2021	May	DISC	
	SOLUTION;INTRAVENOUS								
	AVGEMSI								
	@ +	AVYXA HOLDINGS	EQ 200MG BASE/5.26ML (EQ 38MG BASE/ML)	N219920	001	Jun 27, 2025	Aug	DISC	
	+!		EQ 200MG BASE/5.26ML (EQ 38MG BASE/ML)	N219920	001	Jun 27, 2025	Jun	NEWA	
	+!		EQ 1GM BASE/26.3ML (EQ 38MG BASE/ML)	N219920	002	Jun 27, 2025	Jun	NEWA	
	+!		EQ 2GM BASE/52.6ML (EQ 38MG BASE/ML)	N219920	003	Jun 27, 2025	Jun	NEWA	
	SYSTEM;INTRAVESICAL								
	INLEXZO								
	+!	JANSSEN BIOTECH	EQ 225MG BASE	N219683	001	Sep 09, 2025	Sep	NEWA	
	<u>GEMFIBROZIL</u>								
	TABLET;ORAL								
	GEMFIBROZIL								
	@	APOTEX	600MG	A075034	001	Jul 20, 1998	Mar	DISC	
	<u>GENTAMICIN SULFATE</u>								
	INJECTABLE;INJECTION								
	GENTAMICIN SULFATE								
>D> AP		EUGIA PHARMA	EQ 10MG BASE/ML	A215236	001	Jan 08, 2024	Dec	DISC	
>A>	@		EQ 10MG BASE/ML	A215236	001	Jan 08, 2024	Dec	DISC	
	GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
		BAXTER HLTHCARE	EQ 1.2MG BASE/ML	A062373	007	Sep 07, 1982	Aug	CTEC	
			EQ 1.6MG BASE/ML	A062373	008	Sep 07, 1982	Aug	CTEC	
			EQ 80MG BASE/100ML	A062373	002	Sep 07, 1982	Aug	CTEC	
			EQ 100MG BASE/100ML	A062373	005	Sep 07, 1982	Aug	CTEC	
	@	HOSPIRA	EQ 1.2MG BASE/ML	A062414	001	Aug 15, 1983	Aug	DISC	
	@		EQ 1.6MG BASE/ML	A062414	003	Aug 15, 1983	Aug	DISC	
	@		EQ 80MG BASE/100ML	A062414	008	Aug 15, 1983	Aug	DISC	
	@		EQ 100MG BASE/100ML	A062414	010	Aug 15, 1983	Aug	DISC	
	OINTMENT;TOPICAL								
	GENTAMICIN SULFATE								
	@	TARO	EQ 0.1% BASE	A062477	001	Dec 23, 1983	Jul	DISC	
	SOLUTION/DROPS;OPHTHALMIC								
	GENTAK								
	@	PHARMOBEDIANT	EQ 0.3% BASE	A064163	001	Oct 12, 2001	Sep	CAHN	
	<u>GEPIRONE HYDROCHLORIDE</u>								
	TABLET, EXTENDED RELEASE;ORAL								
	EXXUA								
	+!	FABRE KRAMER	EQ 18.2MG BASE	N021164	001	Sep 22, 2023	Sep	CMFD	
	+		EQ 36.3MG BASE	N021164	002	Sep 22, 2023	Sep	CMFD	
	+		EQ 54.5MG BASE	N021164	003	Sep 22, 2023	Sep	CMFD	
	+!		EQ 72.6MG BASE	N021164	004	Sep 22, 2023	Sep	CMFD	
	<u>GEPOTIDACIN MESYLATE</u>								
	TABLET;ORAL								
	BLUJEPA								
	+!	GLAXOSMITHKLINE	EQ 750MG BASE	N218230	001	Mar 25, 2025	Mar	NEWA	

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS  
GLATIRAMER ACETATE

AP	CHEMI SPA	20MG/ML	A208468	001	May 07, 2025	Apr	NEWA
AP		40MG/ML	A208468	002	May 07, 2025	Apr	NEWA
>A>	SCINOPHARM TAIWAN	20MG/ML	A214741	001	Dec 31, 2025	Dec	NEWA
>A>		40MG/ML	A214741	002	Dec 31, 2025	Dec	NEWA

GLIMEPIRIDE

TABLET; ORAL  
AMARYL

	@ + SANOFI AVENTIS US	1MG	N020496	001	Nov 30, 1995	Feb	DISC
	@ +	2MG	N020496	002	Nov 30, 1995	Feb	DISC
	@ +	4MG	N020496	003	Nov 30, 1995	Feb	DISC
	<u>GLIMEPIRIDE</u>						
>D>	@ ANDA REPOSITORY	1MG	A076802	001	Oct 06, 2005	Dec	CAHN
	@	1MG	A076802	001	Oct 06, 2005	Sep	CAHN
>D>	@	2MG	A076802	002	Oct 06, 2005	Dec	CAHN
	@	2MG	A076802	002	Oct 06, 2005	Sep	CAHN
>D>	@	4MG	A076802	003	Oct 06, 2005	Dec	CAHN
	@	4MG	A076802	003	Oct 06, 2005	Sep	CAHN
AB	! DR REDDYS LABS LTD	1MG	A077091	001	Oct 06, 2005	Feb	CHRS
	@ QUAGEN	1MG	A077624	001	Nov 28, 2005	Sep	CAHN
	@	2MG	A077624	002	Nov 28, 2005	Sep	CAHN
	@	4MG	A077624	003	Nov 28, 2005	Sep	CAHN
>A>	@ SENORES PHARMS	1MG	A076802	001	Oct 06, 2005	Dec	CAHN
>A>	@	2MG	A076802	002	Oct 06, 2005	Dec	CAHN
>A>	@	4MG	A076802	003	Oct 06, 2005	Dec	CAHN

GLIPIZIDE

TABLET; ORAL  
GLIPIZIDE

	@ AIPING PHARM INC	5MG	A074305	001	Apr 07, 1995	Jan	CAHN
	@	10MG	A074305	002	Apr 07, 1995	Jan	CAHN
AB	OXFORD PHARMS	5MG	A074378	001	Nov 28, 1994	Apr	CMFD
AB		10MG	A074378	002	Nov 28, 1994	Apr	CMFD
	<u>TABLET, EXTENDED RELEASE; ORAL</u>						
	<u>GLUCOTROL XL</u>						
	@ + PFIZER	2.5MG	N020329	003	Aug 10, 1999	Apr	DISC
AB	+	5MG	N020329	001	Apr 26, 1994	Apr	CMFD
AB	+	10MG	N020329	002	Apr 26, 1994	Apr	CHRS

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

	@ NOVITIUM PHARMA	2.5MG; 250MG	A078083	001	Apr 12, 2007	Sep	CAHN
	@	2.5MG; 500MG	A078083	002	Apr 12, 2007	Sep	CAHN
	@	5MG; 500MG	A078083	003	Apr 12, 2007	Sep	CAHN

GLUCAGON

INJECTABLE; INJECTION  
GLUCAGON

AP	CIPLA	1MG/VIAL	A218813	001	Sep 15, 2025	Sep	NEWA
AP	LUPIN LTD	1MG/VIAL	A214457	001	Jul 22, 2025	Jul	NEWA
	<u>SOLUTION; INTRAVENOUS</u>						
	<u>GVOKE VIALDX</u>						
	+! XERIS	1MG/0.2ML (1MG/0.2ML)	N212097	006	Mar 14, 2025	Mar	NEWA

GLYBURIDE

TABLET; ORAL

GLYBURIDE (MICRONIZED)

	TEVA	1.5MG	A074686	001	Apr 20, 1999	Nov	CTEC
		3MG	A074686	002	Apr 20, 1999	Nov	CTEC
	!	6MG	A074686	004	Apr 20, 1999	Nov	CTEC
AB	!	6MG	A074686	004	Apr 20, 1999	Nov	CHRS
	<u>GLYNASE</u>						
	@ + PFIZER	1.5MG	N020051	001	Mar 04, 1992	Nov	DISC
	@ +	3MG	N020051	002	Mar 04, 1992	Nov	DISC
	@ +	6MG	N020051	004	Sep 24, 1993	Nov	DISC

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

AA	GLYCEROL PHENYLBUTYRATE							
	PH HEALTH	1.1GM/ML	A205742	001	Dec 02, 2021	Oct	CMFD	
	RAVICTI							
AA	+! HORIZON THERAP US	1.1GM/ML	N203284	001	Feb 01, 2013	Oct	CTEC	

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

>D>	AP	APOTEX	0.2MG/ML	A210246	001	Oct 29, 2019	Dec	DISC
>A>	@		0.2MG/ML	A210246	001	Oct 29, 2019	Dec	DISC
	@	XIROMED	0.2MG/ML	A212227	001	Mar 04, 2021	Jan	DISC
		ROBINUL						
AP	+ HIKMA	0.2MG/ML	N017558	001		Oct	CMFD	
	POWDER; INHALATION							
	SEEBRI NEOHALER							
	@ + NOVARTIS	15.6MCG/INH	N207923	001	Oct 29, 2015	May	CTNA	
	SOLUTION; INTRAMUSCULAR, INTRAVENOUS							
	GLYRX-PF							
>D>	+! EXELA PHARMA	0.2MG/ML (0.2MG/ML)	N210997	001	Jul 11, 2018	Dec	DISC	
>A>	@ +	0.2MG/ML (0.2MG/ML)	N210997	001	Jul 11, 2018	Dec	DISC	

SOLUTION; ORAL

GLYCOPYRROLATE

AA	AJENAT PHARMS	1MG/5ML	A219267	001	Oct 27, 2025	Oct	NEWA	
>A>	AA BIONPHARMA	1MG/5ML	A220062	001	Dec 23, 2025	Dec	NEWA	
AA	MSN	1MG/5ML	A216084	001	Apr 08, 2025	Mar	NEWA	
AA	SCIEGEN PHARMS	1MG/5ML	A216297	001	Oct 07, 2024	Sep	CAHN	

TABLET; ORAL

GLYCOPYRROLATE

AA	CHARTWELL RX	1MG	A040847	001	Mar 21, 2008	Feb	CAHN	
AA		2MG	A040847	002	Mar 21, 2008	Feb	CAHN	
AA	REGCON HOLDINGS	1MG	A091182	001	Feb 03, 2014	Sep	CAHN	
AA		2MG	A091182	002	Feb 03, 2014	Sep	CAHN	

GLYCOPYRROLATE; INDACATEROL MALEATE

POWDER; INHALATION

UTIBRON NEOHALER

	@ + NOVARTIS	15.6MCG/INH; 27.5MCG/INH	N207930	001	Oct 29, 2015	May	CTNA	
--	--------------	--------------------------	---------	-----	--------------	-----	------	--

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT	SAPTALIS PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A065187	001	Oct 28, 2005	Feb	CAHN	
AT	SCIEGEN PHARMS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A065187	001	Oct 28, 2005	Sep	CAHN	

GRANISETRON HYDROCHLORIDE

SOLUTION; ORAL

GRANISETRON HYDROCHLORIDE

	INTRA SANA LABS	EQ 2MG BASE/10ML	A219282	001	Mar 17, 2025	Mar	NEWA	
--	-----------------	------------------	---------	-----	--------------	-----	------	--

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

	@ APOTEX INC	EQ 1MG BASE	A078843	001	Feb 27, 2008	Mar	DISC	
	@ TARO	EQ 1MG BASE	A090817	001	May 28, 2010	Aug	DISC	

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB	AIPING PHARM INC	EQ 1MG BASE	A216399	001	Jun 08, 2022	Jul	CAHN	
AB		EQ 2MG BASE	A216399	002	Jun 08, 2022	Jul	CAHN	
BX	RUBICON	EQ 1MG BASE	A216762	001	Oct 17, 2023	Mar	CTEC	
BX		EQ 2MG BASE	A216762	002	Oct 17, 2023	Mar	CTEC	

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

AB	FOSUN WANBANG	EQ 1MG BASE	A217638	001	Jun 12, 2024	Mar	CMFD	
	@	EQ 1MG BASE	A217638	001	Jun 12, 2024	Jan	CAHN	
AB		EQ 2MG BASE	A217638	002	Jun 12, 2024	Mar	CMFD	
	@	EQ 2MG BASE	A217638	002	Jun 12, 2024	Jan	CAHN	
AB		EQ 3MG BASE	A217638	003	Jun 12, 2024	Mar	CMFD	

TABLET, EXTENDED RELEASE;ORAL  
GUANFACINE HYDROCHLORIDE

	@		EQ 3MG BASE	A217638	003	Jun 12, 2024	Jan	CAHN
AB			EQ 4MG BASE	A217638	004	Jun 12, 2024	Mar	CMFD
	@		EQ 4MG BASE	A217638	004	Jun 12, 2024	Jan	CAHN
AB		RUBICON	EQ 1MG BASE	A219689	001	Apr 15, 2025	Apr	NEWA
AB			EQ 2MG BASE	A219689	002	Apr 15, 2025	Apr	NEWA
AB			EQ 3MG BASE	A219689	003	Apr 15, 2025	Apr	NEWA
AB			EQ 4MG BASE	A219689	004	Apr 15, 2025	Apr	NEWA
	@	SUN PHARM	EQ 1MG BASE	A205689	001	Nov 16, 2017	Nov	DISC
	@		EQ 2MG BASE	A205689	002	Nov 16, 2017	Nov	DISC
	@		EQ 3MG BASE	A205689	003	Nov 16, 2017	Nov	DISC
	@		EQ 4MG BASE	A205689	004	Nov 16, 2017	Nov	DISC

HALCINONIDE

CREAM;TOPICAL								
HALOG								
	@ +	WESTWOOD SQUIBB	0.025%	N017818	001		Aug	CRLD
OINTMENT;TOPICAL								
HALOG								
	@ +	BRISTOL MYERS SQUIBB	0.025%	N018125	001		Aug	CRLD
SOLUTION;TOPICAL								
HALCINONIDE								
AT	!	ENCUBE	0.1%	A217671	001	May 29, 2024	Nov	CTEC
	!		0.1%	A217671	001	May 29, 2024	Mar	CMFD
	@		0.1%	A217671	001	May 29, 2024	Jan	DISC
HALOG								
AT	+	SUN PHARM INDS INC	0.1%	N017823	001		Nov	CMFD

HALOBETASOL PROPIONATE

CREAM;TOPICAL								
HALOBETASOL PROPIONATE								
	@	TARO	0.05%	A077227	001	Aug 04, 2005	Aug	DISC
LOTION;TOPICAL								
ULTRAVATE								
	+!	LACER PHARMA	0.05%	N208183	001	Nov 06, 2015	Apr	CMFD
	@ +		0.05%	N208183	001	Nov 06, 2015	Jan	CAHN
OINTMENT;TOPICAL								
HALOBETASOL PROPIONATE								
	@	TARO	0.05%	A076994	001	Dec 16, 2004	Aug	DISC

HALOBETASOL PROPIONATE; TAZAROTENE

LOTION;TOPICAL								
DUOBRII								
AB	+	BAUSCH	0.01%;0.045%	N209354	001	Apr 25, 2019	Apr	CFTG
HALOBETASOL PROPIONATE AND TAZAROTENE								
AB		SUN PHARMA CANADA	0.01%;0.045%	A217190	001	May 02, 2025	Oct	CAHN
AB		TARO	0.01%;0.045%	A217190	001	May 02, 2025	Apr	NFTG

HALOPERIDOL

TABLET;ORAL								
HALOPERIDOL								
AB		APPCO	0.5MG	A211061	001	Jan 08, 2020	Feb	CAHN
AB			1MG	A211061	002	Jan 08, 2020	Feb	CAHN
AB			2MG	A211061	003	Jan 08, 2020	Feb	CAHN
AB			5MG	A211061	004	Jan 08, 2020	Feb	CAHN
AB			10MG	A211061	005	Jan 08, 2020	Feb	CAHN
AB			20MG	A211061	006	Jan 08, 2020	Feb	CAHN
>A>	AB	CREEKWOOD PHARMS	0.5MG	A218162	001	Dec 18, 2025	Dec	NEWA
>A>	AB		1MG	A218162	002	Dec 18, 2025	Dec	NEWA
>A>	AB		2MG	A218162	003	Dec 18, 2025	Dec	NEWA
>A>	AB		5MG	A218162	004	Dec 18, 2025	Dec	NEWA
>A>	AB		10MG	A218162	005	Dec 18, 2025	Dec	NEWA
>A>	AB		20MG	A218162	006	Dec 18, 2025	Dec	NEWA

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION								
HALDOL								
	@ +	JANSSEN PHARMS	EQ 50MG BASE/ML	N018701	001	Jan 14, 1986	Nov	DISC
	@ +		EQ 100MG BASE/ML	N018701	002	Jan 31, 1997	Nov	DISC

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE							
AO	CAPLIN	EQ 50MG BASE/ML	A219168	001	May 13, 2025	May	NEWA
AO		EQ 100MG BASE/ML	A219168	002	May 13, 2025	May	NEWA
AO	! MANKIND PHARMA	EQ 50MG BASE/ML	A216730	001	May 23, 2023	Nov	CHRS
AO	!	EQ 100MG BASE/ML	A216730	002	May 23, 2023	Nov	CHRS

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL							
@	FRESENIUS KABI USA	EQ 5MG BASE/ML	A210356	001	Jul 01, 2019	Feb	DISC
@	GLAND PHARMA LTD	EQ 5MG BASE/ML	A076774	001	Aug 25, 2004	Nov	DISC

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM							
@	B BRAUN MEDICAL	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018	Jan	DISC
AP	EMERGE BIOSCIENCE	1,000 UNITS/ML	A211005	001	Dec 14, 2018	Sep	CAHN
AP		1,000 UNITS/ML	A211007	001	May 28, 2019	Sep	CAHN
AP		5,000 UNITS/ML	A211007	002	May 28, 2019	Sep	CAHN
AP		5,000 UNITS/ML	A212061	001	Jul 15, 2020	Sep	CAHN
AP		10,000 UNITS/ML	A211007	003	May 28, 2019	Sep	CAHN
AP		20,000 UNITS/ML	A211004	001	Feb 24, 2020	Sep	CAHN
AP	HIKMA	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jan	CTEC
AP	NORVIUM BIOSCIENCE	1,000 UNITS/ML	A203851	001	Nov 30, 2017	May	CAHN
AP		5,000 UNITS/ML	A203851	002	Nov 30, 2017	May	CAHN
AP		10,000 UNITS/ML	A203851	003	Nov 30, 2017	May	CAHN
AP		20,000 UNITS/ML	A203852	001	Nov 30, 2017	May	CAHN
@ +	PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011	Oct	DISC
@ +		5,000 UNITS/ML	N201370	002	Jul 21, 2011	Oct	DISC
@	PHARMOBEDIANT	20,000 UNITS/ML	A203852	001	Nov 30, 2017	Aug	DISC
AP	PLANO PHARMS	1,000 UNITS/ML	A091682	001	Jun 08, 2011	Mar	CAHN
AP		5,000 UNITS/ML	A091682	002	Jun 08, 2011	Mar	CAHN
AP		10,000 UNITS/ML	A201002	001	Jun 08, 2011	Mar	CAHN
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
+!	B BRAUN	5,000 UNITS/100ML	N019953	003	Mar 25, 2025	Mar	NEWA
+!		10,000 UNITS/100ML	N019953	004	Mar 25, 2025	Mar	NEWA
HEPARIN SODIUM PRESERVATIVE FREE							
AP	EMERGE BIOSCIENCE	10,000 UNITS/ML	A212060	001	Apr 02, 2020	Sep	CAHN
@ +	PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011	Oct	DISC

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE							
@	APOZEAL PHARMS	1.5MG/5ML; 5MG/5ML	A204765	001	Mar 06, 2017	Apr	CAHN
@	CHARTWELL	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Sep	CAHN
@	GENUS LIFESCIENCES	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Oct	CAHN
@	SANKALP LIFECARE	1.5MG/5ML; 5MG/5ML	A210663	001	Jun 11, 2019	Apr	CAHN
@	SIEGEN PHARMS	1.5MG/5ML; 5MG/5ML	A204765	001	Mar 06, 2017	Sep	CAHN
AA	XTTRIUM LABS INC	1.5MG/5ML; 5MG/5ML	A088008	001	Mar 03, 1983	Feb	CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE							
@	ADRASTEIA PHARMA	20MG/ML	A203110	001	Jun 29, 2015	Jun	DISC
AP	BAXTER HLTHCARE CORP	20MG/ML	A219797	001	Jul 17, 2025	Jul	NEWA
AP	KINDOS	20MG/ML	A217501	001	Jun 02, 2025	May	NEWA
@	PHARMOBEDIANT	20MG/ML	A203110	001	Jun 29, 2015	Sep	CAHN

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE							
@	MACLEODS PHARMS LTD	10MG	A211010	001	Aug 21, 2024	Jun	DISC
@		25MG	A211010	002	Aug 21, 2024	Jun	DISC
@		50MG	A211010	003	Aug 21, 2024	Jun	DISC
@		100MG	A211010	004	Aug 21, 2024	Jun	DISC

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE							
>A>	AB I3 PHARMS	37.5MG; 20MG	A215988	001	Jan 17, 2024	Dec	CAHN
>D>	AB MLV	37.5MG; 20MG	A215988	001	Jan 17, 2024	Dec	CAHN
AB		37.5MG; 20MG	A215988	001	Jan 17, 2024	Sep	CAHN
AB	NOVAST LABS	37.5MG; 20MG	A215586	001	Apr 06, 2022	Aug	CAHN

HYDROCHLOROTHIAZIDE

	CAPSULE;ORAL							
	HYDROCHLOROTHIAZIDE							
	@ QUAGEN	12.5MG	A 075640	001	Jan 28, 2000	Sep	CAHN	
	MICROZIDE							
AB	+! TEVA BRANDED PHARM	12.5MG	N 020504	001	Dec 27, 1996	Apr	CAHN	
	FOR SUSPENSION;ORAL							
	INZIRQO							
	+! NOVITIUM PHARMA	10MG/ML	N 219141	001	Jan 28, 2025	Jan	NEWA	
	TABLET;ORAL							
	HYDROCHLOROTHIAZIDE							
AB	UNICHEM	12.5MG	A 040907	003	Apr 03, 2025	Mar	NEWA	

HYDROCHLOROTHIAZIDE; IRBESARTAN

	TABLET;ORAL							
	IRBESARTAN AND HYDROCHLOROTHIAZIDE							
	@ LUPIN LTD	12.5MG;150MG	A 201524	001	Feb 27, 2013	Nov	DISC	
	@	12.5MG;300MG	A 201524	002	Feb 27, 2013	Nov	DISC	

HYDROCHLOROTHIAZIDE; LISINAPRIL

	TABLET;ORAL							
	LISINAPRIL AND HYDROCHLOROTHIAZIDE							
AB	AIPING PHARM INC	12.5MG;10MG	A 076262	001	Jul 01, 2002	Nov	CAHN	
AB		12.5MG;20MG	A 076262	002	Jul 01, 2002	Nov	CAHN	
AB		25MG;20MG	A 076262	003	Jul 01, 2002	Nov	CAHN	

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

	TABLET;ORAL							
	METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE							
AB	SENORES PHARMS	25MG;50MG	A 215789	001	Jan 08, 2025	Jan	NEWA	
AB		25MG;100MG	A 215789	002	Jan 08, 2025	Jan	NEWA	

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

	TABLET;ORAL							
	MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE							
	@ GLENMARK PHARMS	12.5MG;7.5MG	A 090718	001	Mar 17, 2010	Aug	DISC	
	@	12.5MG;15MG	A 090718	002	Mar 17, 2010	Aug	DISC	
	@	25MG;15MG	A 090718	003	Mar 17, 2010	Aug	DISC	
	TEVA	12.5MG;7.5MG	A 076980	001	Mar 07, 2007	Aug	CTEC	
		12.5MG;15MG	A 076980	003	Mar 07, 2007	Aug	CTEC	
	!	25MG;15MG	A 076980	002	Mar 07, 2007	Aug	CTEC	

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

	TABLET;ORAL							
	OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE							
AB	ALKEM LABS LTD	12.5MG;20MG	A 207037	001	Jul 11, 2024	Aug	CTNA	
AB		12.5MG;40MG	A 207037	002	Jul 11, 2024	Aug	CTNA	
AB		25MG;40MG	A 207037	003	Jul 11, 2024	Aug	CTNA	
AB	HANGZHOU BINJIANG	12.5MG;20MG	A 214427	001	Aug 20, 2025	Sep	CAHN	
AB		12.5MG;40MG	A 214427	002	Aug 20, 2025	Sep	CAHN	
AB		25MG;40MG	A 214427	003	Aug 20, 2025	Sep	CAHN	
AB	HETERO LABS LTD V	12.5MG;20MG	A 209199	001	Jul 25, 2025	Aug	CTNA	
AB		12.5MG;20MG	A 209199	001	Jul 25, 2025	Jul	NEWA	
AB		12.5MG;40MG	A 209199	002	Jul 25, 2025	Aug	CTNA	
AB		12.5MG;40MG	A 209199	002	Jul 25, 2025	Jul	NEWA	
AB		25MG;40MG	A 209199	003	Jul 25, 2025	Aug	CTNA	
AB		25MG;40MG	A 209199	003	Jul 25, 2025	Jul	NEWA	
AB	MSN	12.5MG;20MG	A 217398	001	Sep 26, 2025	Sep	NEWA	
AB		12.5MG;40MG	A 217398	002	Sep 26, 2025	Sep	NEWA	
AB		25MG;40MG	A 217398	003	Sep 26, 2025	Sep	NEWA	
AB	ZHEJIANG NUODE	12.5MG;20MG	A 214427	001	Aug 20, 2025	Aug	NEWA	
AB		12.5MG;40MG	A 214427	002	Aug 20, 2025	Aug	NEWA	
AB		25MG;40MG	A 214427	003	Aug 20, 2025	Aug	NEWA	

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

	TABLET;ORAL							
	QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE							
	@ APOTEX	12.5MG;EQ 10MG BASE	A 091524	001	Mar 12, 2013	Jan	DISC	
	@	12.5MG;EQ 20MG BASE	A 091524	002	Mar 12, 2013	Jan	DISC	
	@	25MG;EQ 20MG BASE	A 091524	003	Mar 12, 2013	Jan	DISC	

HYDROCHLOROTHIAZIDE; TELMISARTAN

	TABLET; ORAL								
	TELMISARTAN AND HYDROCHLOROTHIAZIDE								
	@ MANKIND PHARMA	12.5MG; 40MG		A 218406	001	Mar 03, 2025	Aug	DISC	
AB		12.5MG; 40MG		A 218406	001	Mar 03, 2025	Feb	NEWA	
	@	12.5MG; 80MG		A 218406	002	Mar 03, 2025	Aug	DISC	
AB		12.5MG; 80MG		A 218406	002	Mar 03, 2025	Feb	NEWA	
	@	25MG; 80MG		A 218406	003	Mar 03, 2025	Aug	DISC	
AB		25MG; 80MG		A 218406	003	Mar 03, 2025	Feb	NEWA	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

	CAPSULE; ORAL								
	TRIAMTERENE AND HYDROCHLOROTHIAZIDE								
	@ MACLEODS PHARMS LTD	25MG; 37.5MG		A 214611	001	Jan 28, 2025	Jun	DISC	
AB		25MG; 37.5MG		A 214611	001	Jan 28, 2025	Jan	NEWA	

HYDROCODONE BITARTRATE; IBUPROFEN

	TABLET; ORAL								
	HYDROCODONE								
	@ STRIDES PHARMA	5MG; 200MG		A 077723	003	Nov 06, 2006	Apr	CAHN	
	HYDROCODONE BITARTRATE AND IBUPROFEN								
	@ STRIDES PHARMA	7.5MG; 200MG		A 077723	001	Nov 06, 2006	Apr	CAHN	
	@	10MG; 200MG		A 077723	002	Nov 06, 2006	Apr	CAHN	

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

	SOLUTION; ORAL								
	HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE								
	@ APOZEAL PHARMS	5MG/5ML; 60MG/5ML		A 206661	001	Jan 23, 2019	Apr	CAHN	
	@ SCIEGEN PHARMS	5MG/5ML; 60MG/5ML		A 206661	001	Jan 23, 2019	Sep	CAHN	

HYDROCORTISONE

	GEL; TOPICAL								
	NUTRACORT								
	@ + HEALTHPOINT	1%		A 084698	001		Sep	CRLD	
	LOTION; TOPICAL								
	ALA-SCALP								
	+ LEGACY PHARMA	2%		A 083231	001		Mar	CRLD	
	HYDROCORTISONE								
	@ TARO	2.5%		A 040247	001	Jul 23, 1999	Aug	DISC	
	STIE-CORT								
	! PADAGIS US	2.5%		A 089074	001	Nov 26, 1985	Aug	CTEC	
	OINTMENT; TOPICAL								
	HYDROCORTISONE								
	@ TARO	1%		A 086257	001		Aug	DISC	
	SOLUTION; ORAL								
	KHINDIVI								
	+! ETON	1MG/ML		N 218980	001	May 28, 2025	May	NEWA	
	TABLET; ORAL								
	HYDROCORTISONE								
AB	NOVITIUM PHARMA	5MG		A 217881	001	May 02, 2025	Apr	NEWA	
AB		10MG		A 217881	002	May 02, 2025	Apr	NEWA	
AB		20MG		A 217881	003	May 02, 2025	Apr	NEWA	

HYDROCORTISONE ACETATE

	AEROSOL, METERED; RECTAL								
	CORTIFOAM								
	+! VIATRIS	10%		N 017351	001	Feb 10, 1982	Feb	CAHN	
	CREAM; TOPICAL								
	MICORT-HC								
	@ LEGACY PHARMA	2%		A 040398	001	Mar 29, 2002	Jan	CAHN	

HYDROCORTISONE BUTYRATE

	CREAM; TOPICAL								
	HYDROCORTISONE BUTYRATE								
	@ GLENMARK PHARMS LTD	0.1%		A 202145	001	Sep 27, 2013	Aug	DISC	

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE

@ GLENMARK PHARMS LTD 0.2% A211129 001 Oct 12, 2018 Jul DISC

OINTMENT;TOPICAL

HYDROCORTISONE VALERATE

@ GLENMARK PHARMS LTD 0.2% A211750 001 Dec 14, 2018 Aug DISC

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT AMNEAL 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A217803 001 Oct 29, 2025 Oct NEWA

@ SAPTALIS PHARMS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A065216 001 Oct 31, 2005 Feb CAHN

SUSPENSION/DROPS;OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT AMNEAL 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A217735 001 Sep 30, 2025 Sep NEWA

AT SAPTALIS PHARMS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A065219 001 May 01, 2006 Feb CAHN

AT SCIEGEN PHARMS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A065219 001 May 01, 2006 Sep CAHN

HYDROMORPHONE HYDROCHLORIDE

SOLUTION;ORAL

HYDROMORPHONE HYDROCHLORIDE

>D> @ CHARTWELL 5MG/5ML A207108 001 Apr 22, 2020 Dec CAHN

@ 5MG/5ML A207108 001 Apr 22, 2020 Sep CAHN

>A> @ GENUS 5MG/5ML A207108 001 Apr 22, 2020 Dec CAHN

TABLET;ORAL

HYDROMORPHONE HYDROCHLORIDE

>D> @ CHARTWELL 2MG A077471 002 Dec 09, 2009 Dec CAHN

@ 2MG A077471 002 Dec 09, 2009 Sep CAHN

>D> @ 4MG A077471 003 Dec 09, 2009 Dec CAHN

@ 4MG A077471 003 Dec 09, 2009 Sep CAHN

>D> @ 8MG A077471 001 Dec 09, 2009 Dec CAHN

@ 8MG A077471 001 Dec 09, 2009 Sep CAHN

>A> @ GENUS 2MG A077471 002 Dec 09, 2009 Dec CAHN

@ 4MG A077471 003 Dec 09, 2009 Dec CAHN

>A> @ 8MG A077471 001 Dec 09, 2009 Dec CAHN

@ MPP PHARMA 8MG A076723 001 Oct 18, 2005 Jun CAHN

HYDROXYUREA

CAPSULE;ORAL

DROXIA

@ + WAYLIS THERAP 200MG N016295 002 Feb 25, 1998 Sep CAHN

@ + 300MG N016295 003 Feb 25, 1998 Sep CAHN

@ + 400MG N016295 004 Feb 25, 1998 Sep CAHN

HYDREA

AB +! WAYLIS THERAP 500MG N016295 001 Sep CAHN

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDE

AA BIONPHARMA 10MG/5ML A219289 001 Apr 28, 2025 Apr NEWA

>A> AA NOVITIUM PHARMA 10MG/5ML A219648 001 Dec 16, 2025 Dec NEWA

@ RISING 10MG/5ML A086880 001 Aug CAHN

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

@ APPCO 10MG A040812 001 Mar 12, 2008 Apr CAHN

@ 25MG A040812 002 Mar 12, 2008 Apr CAHN

@ 50MG A040812 003 Mar 12, 2008 Apr CAHN

AB ! GRAVITI PHARMS 50MG A217652 003 Aug 17, 2023 Mar CHRS

AB HERITAGE 10MG A204279 001 Aug 20, 2014 Nov CAHN

AB 25MG A204279 002 Aug 20, 2014 Nov CAHN

AB 50MG A204279 003 Aug 20, 2014 Nov CAHN

AB + PLIVA 50MG A088619 001 Jan 10, 1986 Mar CHRS

@ SOMERSET THERAPS LLC 10MG A040812 001 Mar 12, 2008 Sep CAHN

@ 25MG A040812 002 Mar 12, 2008 Sep CAHN

@ 50MG A040812 003 Mar 12, 2008 Sep CAHN

@ + STRIDES PHARMA 50MG A087604 001 Jan 22, 1982 Mar CRLD

HYDROXYZINE PAMOATE

CAPSULE; ORAL		HYDROXYZINE PAMOATE							
AB	BARR LABS	EQ 50MG HYDROCHLORIDE	A 088487	001	Jun 15, 1984	Mar	CAHN		
		EQ 100MG HYDROCHLORIDE	A 088488	001	Jun 15, 1984	Mar	CAHN		
SUSPENSION; ORAL		VISTARIL							
	@ + PFIZER	EQ 25MG HYDROCHLORIDE/5ML	N 011795	001		Jul	CRLD		

IBREXAFUNGERP CITRATE

TABLET; ORAL		BREXAFEMME							
	+! GLAXOSMITHKLINE	EQ 150MG BASE	N 214900	001	Jun 01, 2021	Nov	CAHN		

ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS		ICATIBANT ACETATE							
	@ CAPLIN	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A 213054	001	Oct 05, 2020	Apr	CAHN		

ICODEXTRIN

SOLUTION; INTRAPERITONEAL		EXTRANEAAL							
	+! VANTIVE US HLTHCARE	7.5GM/100ML	N 021321	001	Dec 20, 2002	Feb	CAHN		

ICOSAPENT ETHYL

CAPSULE; ORAL		ICOSAPENT ETHYL							
AB	PHARMOBEDIENT	1GM	A 218994	001	Dec 20, 2024	Sep	CAHN		
AB	XIAMEN LP PHARM CO	1GM	A 219156	001	Aug 06, 2025	Jul	NEWA		

IDARUBICIN HYDROCHLORIDE

POWDER; INTRAVENOUS		IDAMYCIN							
	@ PFIZER	5MG/VIAL	N 050661	002	Sep 27, 1990	Oct	CDFR		
	@	10MG/VIAL	N 050661	001	Sep 27, 1990	Oct	CDFR		
	@	20MG/VIAL	N 050661	003	Apr 25, 1995	Oct	CDFR		
IDARUBICIN HYDROCHLORIDE									
	@ TEVA PARENTERAL	5MG/VIAL	A 065037	003	May 01, 2002	Oct	CDFR		
	@	10MG/VIAL	A 065037	002	May 01, 2002	Oct	CDFR		
	@	20MG/VIAL	A 065037	001	May 01, 2002	Oct	CDFR		
SOLUTION; INTRAVENOUS		IDAMYCIN PFS							
AP	+! PFIZER	1MG/ML	N 050734	001	Feb 17, 1997	Oct	CDFR		
AP	+!	5MG/5ML (1MG/ML)	N 050734	001	Feb 17, 1997	Oct	CPOT		
IDARUBICIN HYDROCHLORIDE									
	@ FRESENIUS KABI USA	1MG/ML	A 065440	001	Aug 04, 2009	Oct	CDFR		
	@	5MG/5ML (1MG/ML)	A 065440	001	Aug 04, 2009	Oct	CPOT		
	@	10MG/10ML (1MG/ML)	A 065440	002	Aug 04, 2009	Oct	NEWA		
	@	20MG/20ML (1MG/ML)	A 065440	003	Aug 04, 2009	Oct	NEWA		
AP	HIKMA	1MG/ML	A 065275	001	Dec 14, 2006	Oct	CDFR		
AP		1MG/ML	A 065288	001	May 15, 2007	Oct	CDFR		
AP		5MG/5ML (1MG/ML)	A 065275	001	Dec 14, 2006	Oct	CPOT		
AP		5MG/5ML (1MG/ML)	A 065288	001	May 15, 2007	Oct	CPOT		
AP		10MG/10ML (1MG/ML)	A 065275	002	Dec 14, 2006	Oct	NEWA		
AP		10MG/10ML (1MG/ML)	A 065288	002	May 15, 2007	Oct	NEWA		
AP		20MG/20ML (1MG/ML)	A 065275	003	Dec 14, 2006	Oct	NEWA		
AP		20MG/20ML (1MG/ML)	A 065288	003	May 15, 2007	Oct	NEWA		
AP	MEITHEAL	1MG/ML	A 065036	001	May 01, 2002	Oct	CDFR		
AP		5MG/5ML (1MG/ML)	A 065036	001	May 01, 2002	Oct	CPOT		
AP		10MG/10ML (1MG/ML)	A 065036	002	May 01, 2002	Oct	NEWA		
AP		20MG/20ML (1MG/ML)	A 065036	003	May 01, 2002	Oct	NEWA		
AP	+! PFIZER	10MG/10ML (1MG/ML)	N 050734	002	Feb 17, 1997	Oct	NEWA		
AP	+!	20MG/20ML (1MG/ML)	N 050734	003	Feb 17, 1997	Oct	NEWA		
	@ RISING	1MG/ML	A 200144	001	Oct 11, 2012	Oct	CDFR		
	@	5MG/5ML (1MG/ML)	A 200144	001	Oct 11, 2012	Oct	CPOT		
	@	10MG/10ML (1MG/ML)	A 200144	002	Oct 11, 2012	Oct	NEWA		
	@	20MG/20ML (1MG/ML)	A 200144	003	Oct 11, 2012	Oct	NEWA		
	@ SANDOZ	1MG/ML	A 091293	001	Mar 29, 2011	Oct	CDFR		
	@	5MG/5ML (1MG/ML)	A 091293	001	Mar 29, 2011	Oct	CPOT		
	@	10MG/10ML (1MG/ML)	A 091293	002	Mar 29, 2011	Oct	NEWA		

SOLUTION; INTRAVENOUS  
 IDARUBICIN HYDROCHLORIDE  
 @

20MG/20ML (1MG/ML)

A091293 003 Mar 29, 2011 Oct NEWA

IMATINIB MESYLATE

TABLET; ORAL  
 IMATINIB MESYLATE

AB	CSPC OUYI	EQ 100MG BASE	A212193	001	Apr 21, 2025	Apr	NEWA
AB		EQ 400MG BASE	A212193	002	Apr 21, 2025	Apr	NEWA
AB	HETERO LABS LTD V	EQ 100MG BASE	A212975	001	Apr 14, 2025	Apr	NEWA
AB		EQ 400MG BASE	A212975	002	Apr 14, 2025	Apr	NEWA

IMIQUIMOD

CREAM; TOPICAL  
 IMIQUIMOD  
 @ APOTEX INC

5%

A091308 001 Apr 06, 2012 Mar DISC

IMLUNESTRANT TOSYLATE

TABLET; ORAL  
 INLURIYO  
 +! ELI LILLY AND CO

EQ 200MG BASE

N218881 001 Sep 25, 2025 Sep NEWA

INDOCYANINE GREEN

INJECTABLE; INJECTION  
 IC-GREEN

AP	+ RENEW PHARMS	25MG/VIAL	N011525	001		May	CMFD
AP	! RENEW PHARMS	25MG/VIAL	A040811	001	Nov 21, 2007	May	CTEC

INDOMETHACIN

SUPPOSITORY; RECTAL  
 INDOMETHACIN

AB	AMNEAL	50MG	A215399	001	Feb 24, 2025	Feb	NEWA
AB	ANNORA PHARMA	50MG	A216905	001	Jul 03, 2025	Jun	NEWA

IOBENGUANE SULFATE I-123

SOLUTION; INTRAVENOUS  
 ADREVIEW

+! GE HEALTHCARE 10mCi/5ML (2mCi/ML)  
 IOBENGUANE I-123  
 @ BWXT MEDCL 10mCi/5ML (2mCi/ML)

N022290 001 Sep 19, 2008 Jun CTEC  
 A213637 001 Dec 09, 2024 Jun DISC

IOHEXOL

SOLUTION; INJECTION, ORAL, RECTAL  
 IOHEXOL

AP	AMNEAL	64.7%	A217737	001	Nov 13, 2025	Oct	NFTG
AP	+! GE HEALTHCARE	64.7%	N018956	003	Dec 26, 1985	Oct	CFTG

IOMEPROL

SOLUTION; INTRA-ARTERIAL  
 IOMERVU

@ + BRACCO 15GM IODINE/50ML (300MG IODINE/ML)  
 @ + 17.5GM IODINE/50ML (350MG IODINE/ML)  
 @ + 20GM IODINE/50ML (400MG IODINE/ML)  
 @ + 25GM IODINE/100ML (250MG IODINE/ML)  
 @ + 30GM IODINE/100ML (300MG IODINE/ML)  
 @ + 35GM IODINE/100ML (350MG IODINE/ML)  
 @ + 40GM IODINE/100ML (400MG IODINE/ML)  
 @ + 60GM IODINE/150ML (400MG IODINE/ML)  
 @ + 45GM IODINE/150ML (300MG IODINE/ML)  
 @ + 52.5GM IODINE/150ML (350MG IODINE/ML)  
 @ + 60GM IODINE/200ML (300MG IODINE/ML)

N216016 002 Nov 27, 2024 Mar DISC  
 N216016 006 Nov 27, 2024 Mar DISC  
 N216016 010 Nov 27, 2024 Mar DISC  
 N216016 001 Nov 27, 2024 Mar DISC  
 N216016 003 Nov 27, 2024 Mar DISC  
 N216016 007 Nov 27, 2024 Mar DISC  
 N216016 011 Nov 27, 2024 Mar DISC  
 N216016 012 Nov 27, 2024 Mar DISC  
 N216016 004 Nov 27, 2024 Mar DISC  
 N216016 008 Nov 27, 2024 Mar DISC  
 N216016 005 Nov 27, 2024 Mar DISC

<u>SOLUTION; INTRA-ARTERIAL</u>						
IOMERVU						
@ +		70GM IODINE/200ML (350MG IODINE/ML)	N216016	009	Nov 27, 2024	Mar DISC
@ +		80GM IODINE/200ML (400MG IODINE/ML)	N216016	013	Nov 27, 2024	Mar DISC
<u>SOLUTION; INTRAVENOUS</u>						
IOMERVU						
@ +	BRACCO	15GM IODINE/50ML (300MG IODINE/ML)	N216017	002	Nov 27, 2024	Mar DISC
@ +		17.5GM IODINE/50ML (350MG IODINE/ML)	N216017	006	Nov 27, 2024	Mar DISC
@ +		20GM IODINE/50ML (400MG IODINE/ML)	N216017	010	Nov 27, 2024	Mar DISC
@ +		25GM IODINE/100ML (250MG IODINE/ML)	N216017	001	Nov 27, 2024	Mar DISC
@ +		30GM IODINE/100ML (300MG IODINE/ML)	N216017	003	Nov 27, 2024	Mar DISC
@ +		35GM IODINE/100ML (350MG IODINE/ML)	N216017	007	Nov 27, 2024	Mar DISC
@ +		40GM IODINE/100ML (400MG IODINE/ML)	N216017	011	Nov 27, 2024	Mar DISC
@ +		60GM IODINE/150ML (400MG IODINE/ML)	N216017	012	Nov 27, 2024	Mar DISC
@ +		45GM IODINE/150ML (300MG IODINE/ML)	N216017	004	Nov 27, 2024	Mar DISC
@ +		52.5GM IODINE/150ML (350MG IODINE/ML)	N216017	008	Nov 27, 2024	Mar DISC
@ +		60GM IODINE/200ML (300MG IODINE/ML)	N216017	005	Nov 27, 2024	Mar DISC
@ +		70GM IODINE/200ML (350MG IODINE/ML)	N216017	009	Nov 27, 2024	Mar DISC
@ +		80GM IODINE/200ML (400MG IODINE/ML)	N216017	013	Nov 27, 2024	Mar DISC
<u>IOVERSOL</u>						
INJECTABLE; INJECTION						
OPTIRAY 300						
@ +	LIEBEL-FLARSHEIM	64%	N020923	004	May 13, 1999	Jul DISC
<u>IPRATROPIUM BROMIDE</u>						
SOLUTION; INHALATION						
IPRATROPIUM BROMIDE						
@	PHARMOBEDIENT	0.02%	A074755	001	Jan 10, 1997	Jun CAHN
@	SUN PHARM	0.02%	A207903	001	Jan 03, 2017	Aug DISC
SPRAY, METERED; NASAL						
IPRATROPIUM BROMIDE						
AB	LUPIN	0.021MG/SPRAY	A217912	001	Feb 07, 2025	Jan NEWA
AB		0.042MG/SPRAY	A217886	001	Jan 27, 2025	Jan NEWA
AB	RUBICON	0.021MG/SPRAY	A219222	001	Jan 14, 2025	Jan NEWA
<u>IRBESARTAN</u>						
TABLET; ORAL						
IRBESARTAN						
@	LUPIN LTD	75MG	A201531	001	Oct 15, 2012	Nov DISC
@		150MG	A201531	002	Oct 15, 2012	Nov DISC
@		300MG	A201531	003	Oct 15, 2012	Nov DISC
AB	MSN	75MG	A219539	001	Nov 04, 2025	Oct NEWA
AB		150MG	A219539	002	Nov 04, 2025	Oct NEWA
AB		300MG	A219539	003	Nov 04, 2025	Oct NEWA
@	YILING	75MG	A200461	001	Sep 27, 2012	Sep CAHN
@		150MG	A200461	002	Sep 27, 2012	Sep CAHN
@		300MG	A200461	003	Sep 27, 2012	Sep CAHN
<u>IRINOTECAN HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
IRINOTECAN HYDROCHLORIDE						
@	HENGRUI PHARMA	40MG/2ML (20MG/ML)	A090675	002	Dec 16, 2011	Sep DISC
@		100MG/5ML (20MG/ML)	A090675	001	Dec 16, 2011	Sep DISC
AP	PHARMOBEDIENT	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	Aug CAHN
AP		100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	Aug CAHN

IRON DEXTRAN

INJECTABLE; INJECTION		DEXFERRUM	
	@ AM REGENT	EQ 50MG IRON/ML	N040024 001 Feb 23, 1996 Aug CAIN
	INFED		
BP	+! ALLERGAN	EQ 100MG IRON/2ML (EQ 50MG IRON/ML)	N017441 001 Aug CAIN
IRON DEXTRAN			
	@ SANOFI AVENTIS US	EQ 50MG IRON/ML	N010787 002 Aug CAIN
	PROFERDEX		
	@ NEW RIVER	EQ 50MG IRON/ML	N017807 001 Aug CAIN

IRON SUCROSE

INJECTABLE; INTRAVENOUS		IRON SUCROSE	
AB	INTL MEDICATION SYS	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	A208977 001 Aug 08, 2025 Aug NFTG
AB		EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	A208977 002 Aug 08, 2025 Aug NFTG
AB		EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	A208977 003 Aug 08, 2025 Aug NFTG
AB	MYLAN LABS LTD	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	A212559 001 Aug 08, 2025 Aug NFTG
AB		EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	A212559 002 Aug 08, 2025 Aug NFTG
AB		EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	A212559 003 Aug 08, 2025 Aug NFTG
AB	SANDOZ	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	A212340 001 Aug 08, 2025 Aug NFTG
AB		EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	A212340 002 Aug 08, 2025 Aug NFTG
AB		EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	A212340 003 Aug 08, 2025 Aug NFTG
VENOFER			
AB	+ AM REGENT	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	N021135 002 Mar 20, 2005 Aug CFTG
	+	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	N021135 002 Mar 20, 2005 Aug CAIN
	@	EQ 65MG IRON/3.25ML (EQ 20MG IRON/ML)	N021135 005 Mar 29, 2013 Aug CAIN
	@	EQ 75MG IRON/3.75ML (EQ 20MG IRON/ML)	N021135 003 Mar 29, 2005 Aug CAIN
AB	+!	EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	N021135 001 Nov 06, 2000 Aug CFTG
	+!	EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	N021135 001 Nov 06, 2000 Aug CAIN
AB	+	EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	N021135 004 Feb 09, 2007 Aug CFTG
	+	EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	N021135 004 Feb 09, 2007 Aug CAIN

ISOCARBOXAZID

TABLET; ORAL		MARPLAN	
	+! LIFSA DRUGS	10MG	N011961 001 Jun CAHN

ISOFLURANE

LIQUID; INHALATION		ISOFLURANE	
AN	SHANDONG	99.9%	A216527 001 Nov 04, 2025 Oct NEWA

ISONIAZID

SYRUP; ORAL		ISONIAZID	
AA	CHARTWELL RX	50MG/5ML	A081118 001 Jul 21, 1997 Feb CMFD
AA	+! CMP PHARMA INC	50MG/5ML	A088235 001 Nov 10, 1983 Feb CTEC
TABLET; ORAL		ISONIAZID	
	@ GENUS	100MG	A080936 001 Aug DISC
	@	300MG	A080937 002 Aug DISC
AA	! OMNIVIVUM PHARMS	100MG	A040090 001 Jun 26, 1997 Aug CHRS
AA	!	300MG	A040090 002 Jun 26, 1997 Aug CHRS

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION  
 ISOPROTERENOL HYDROCHLORIDE  
 AP DEVA HOLDING AS 0.2MG/ML A213305 001 Dec 10, 2025 Nov NEWA

ISOSORBIDE DINITRATE

TABLET; ORAL  
 ISOSORBIDE DINITRATE  
 AB HIKMA INTL PHARMS 5MG A088088 003 Oct 29, 1987 Jul CMS1  
 AB HIKMA INTL PHARMS 10MG A088088 002 Oct 29, 1987 Jul CMS1  
 TABLET; SUBLINGUAL  
 ISOSORBIDE DINITRATE  
 @ HIKMA INTL PHARMS 2.5MG A086055 002 Oct 29, 1987 Jul CMS1

ISOSULFAN BLUE

SOLUTION; SUBCUTANEOUS  
 ISOSULFAN BLUE  
 @ SABA ILAY SANAYI 50MG/5ML (10MG/ML) A210714 001 Jan 16, 2019 Jun CAHN

ISOTRETINOIN

CAPSULE; ORAL  
 AMNESTEEM  
 AB1 MYLAN PHARMS INC 30MG A075945 004 Mar 17, 2025 Mar NEWA  
 ISOTRETINOIN  
 AB2 AMNEAL PHARMS NY 10MG A216097 001 Oct 07, 2025 Sep NEWA  
 AB2 20MG A216097 002 Oct 07, 2025 Sep NEWA  
 AB2 25MG A216097 003 Oct 07, 2025 Sep NEWA  
 AB2 30MG A216097 004 Oct 07, 2025 Sep NEWA  
 AB2 35MG A216097 005 Oct 07, 2025 Sep NEWA  
 AB2 40MG A216097 006 Oct 07, 2025 Sep NEWA  
 AB2 ZYDUS PHARMS 10MG A216633 001 May 22, 2025 May NEWA  
 AB2 20MG A216633 002 May 22, 2025 May NEWA  
 AB2 25MG A216633 003 May 22, 2025 May NEWA  
 AB2 30MG A216633 004 May 22, 2025 May NEWA  
 AB2 35MG A216633 005 May 22, 2025 May NEWA  
 AB2 40MG A216633 006 May 22, 2025 May NEWA

ITRACONAZOLE

CAPSULE; ORAL  
 ITRACONAZOLE  
 AB RISING 100MG A205724 001 Dec 13, 2016 Feb CMFD  
 SOLUTION; ORAL  
 ITRACONAZOLE  
 AA ! AMNEAL PHARMS 10MG/ML A205573 001 Oct 30, 2015 Aug CHRS  
 SPORANOX  
 @ + JANSSEN PHARMS 10MG/ML N020657 001 Feb 21, 1997 Aug DISC

IVABRADINE HYDROCHLORIDE

TABLET; ORAL  
 IVABRADINE HYDROCHLORIDE  
 AB MSN EQ 5MG BASE A213483 001 Apr 28, 2025 Apr NEWA  
 AB EQ 7.5MG BASE A213483 002 Apr 28, 2025 Apr NEWA

IVERMECTIN

TABLET; ORAL  
 IVERMECTIN  
 AB EPIC PHARMA LLC 3MG A218805 001 Sep 09, 2025 Aug NEWA  
 AB RUBICON 3MG A215922 001 Jan 22, 2025 Jan NEWA  
 A215922 002 Jan 22, 2025 Jan NFTG

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION  
 KETAMINE HYDROCHLORIDE  
 AP CAPLIN EQ 10MG BASE/ML A217858 001 Aug 07, 2025 Sep CAHN  
 AP FRESENIUS KABI USA EQ 100MG BASE/ML A215808 003 Apr 18, 2025 Apr NEWA  
 AP PHARMATHER EQ 10MG BASE/ML A217858 001 Aug 07, 2025 Aug NEWA  
 SOLUTION; INTRAMUSCULAR, INTRAVENOUS  
 KETAMINE HYDROCHLORIDE  
 ! BAXTER HLTHCARE CORP EQ 100MG BASE/10ML (EQ 10MG BASE/ML) A219684 001 Sep 17, 2025 Sep NEWA

KETOCONAZOLE

	AEROSOL, FOAM;TOPICAL EXTINA						
	@ + RISING	2%	N021738	001	Jun 12, 2007	Aug	CAHN
	CREAM;TOPICAL KETOCONAZOLE						
AB	! ENCUBE	2%	A212443	001	May 20, 2021	Sep	CHRS
AB	PADAGIS US	2%	A215185	001	Nov 17, 2021	Sep	CAHN
AB	TEVA	2%	A075581	001	Apr 25, 2000	Sep	CHRS
AB	TP ANDA HOLDINGS	2%	A215185	001	Nov 17, 2021	Sep	CAHN
	GEL;TOPICAL XOLEGEL						
	@ + INA PHARMS	2%	N021946	001	Jul 28, 2006	May	CAHN
	SHAMPOO;TOPICAL KETOCONAZOLE						
AB	ZYDUS LIFESCIENCES	2%	A218559	001	Mar 07, 2025	Feb	NEWA
	TABLET;ORAL KETOCONAZOLE						
AB	ESJAY PHARMA	200MG	A219129	001	Jul 03, 2025	Jun	NEWA
AB	NOVITIUM PHARMA	200MG	A219129	001	Jul 03, 2025	Aug	CAHN

KETOROLAC TROMETHAMINE

	INJECTABLE;INJECTION KETOROLAC TROMETHAMINE						
AP	APOTEX	15MG/ML	A077942	001	Mar 27, 2007	Nov	CAHN
AP		30MG/ML	A077942	002	Mar 27, 2007	Nov	CAHN
	@ FRESENIUS KABI USA	15MG/ML	A203242	001	Oct 07, 2015	Jul	DISC
	@ HOSPIRA	30MG/ML	A074993	002	Jan 27, 1999	Jul	DISC
	@ SUN PHARM	15MG/ML	A078737	001	Oct 06, 2008	Jul	DISC
	@	30MG/ML	A078737	002	Oct 06, 2008	Jul	DISC
	TABLET;ORAL KETOROLAC TROMETHAMINE						
	@ ATNAHS PHARMA US	10MG	A216407	001	Oct 21, 2022	Nov	DISC

LABETALOL HYDROCHLORIDE

	INJECTABLE;INJECTION LABETALOL HYDROCHLORIDE						
AP	AMNEAL	5MG/ML	A218870	001	Oct 02, 2025	Sep	NEWA
	TABLET;ORAL LABETALOL HYDROCHLORIDE						
AB	AIPING PHARM INC	100MG	A075113	001	Aug 04, 1998	Nov	CAHN
AB	!	200MG	A075113	002	Aug 04, 1998	Nov	CAHN
AB		300MG	A075113	003	Aug 04, 1998	Nov	CAHN
AB	MACLEODS PHARMS LTD	100MG	A217949	001	Sep 23, 2025	Sep	NEWA
AB		200MG	A217949	002	Sep 23, 2025	Sep	NEWA
AB		300MG	A217949	003	Sep 23, 2025	Sep	NEWA
AB	RUBICON RESEARCH	100MG	A211953	001	Aug 18, 2021	Jul	CAHN
AB		200MG	A211953	002	Aug 18, 2021	Jul	CAHN
AB		300MG	A211953	003	Aug 18, 2021	Jul	CAHN

LACOSAMIDE

	SOLUTION;INTRAVENOUS LACOSAMIDE						
AP	WESTMINSTER PHARMS	200MG/20ML (10MG/ML)	A218706	001	May 23, 2025	May	NEWA
	SOLUTION;ORAL LACOSAMIDE						
AA	AJENAT PHARMS	10MG/ML	A219699	001	Jun 26, 2025	Jun	NEWA
AA	APOTEX	10MG/ML	A206355	001	Sep 26, 2022	May	CMFD
	@	10MG/ML	A206355	001	Sep 26, 2022	Feb	DISC
AA	KANCHAN HLTHCARE	10MG/ML	A216461	001	Feb 06, 2023	Sep	CAHN

LACTULOSE

	FOR SOLUTION;ORAL LACTULOSE						
AA	! CUMBERLAND PHARMS	10GM/PACKET	A074712	001	Dec 10, 1997	Mar	CTEC
AA	!	20GM/PACKET	A074712	002	Dec 10, 1997	Mar	CTEC
AA	PAI HOLDINGS	10GM/PACKET	A217914	001	Mar 14, 2025	Mar	NEWA
AA		20GM/PACKET	A217914	002	Mar 14, 2025	Mar	NEWA

SOLUTION;ORAL

LACTULOSE

	@	VISTAPHARM LLC	10GM/15ML	A 074138	001	Sep 30, 1992	Jan CAHN
AA		SCIEGEN PHARMS	10GM/15ML	A 203762	001	Mar 27, 2015	Sep CAHN

LAMIVUDINE

TABLET;ORAL

LAMIVUDINE

AB		APPCO	150MG	A 206974	001	Nov 21, 2016	Mar CAHN
AB			300MG	A 206974	002	Nov 21, 2016	Mar CAHN
	@	BRECKENRIDGE	150MG	A 203586	001	Nov 21, 2016	Oct DISC
	@	NORVIUM BIOSCIENCE	150MG	A 078545	001	Mar 05, 2019	Feb CAHN
	@		300MG	A 078545	002	Mar 05, 2019	Feb CAHN

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE

	@	LUPIN LTD	150MG;300MG	A 090246	001	May 15, 2012	Nov DISC
>D> AB		NORVIUM BIOSCIENCE	150MG;300MG	A 079128	001	May 13, 2015	Dec CAHN
AB			150MG;300MG	A 079128	001	May 13, 2015	May CAHN
>A> AB		PHARMOBEDIANT	150MG;300MG	A 079128	001	May 13, 2015	Dec CAHN

LAMOTRIGINE

SUSPENSION;ORAL

SUBVENITE

+! OWP PHARMS 10MG/ML

N218879 001 Sep 16, 2025 Sep NEWA

TABLET;ORAL

LAMOTRIGINE

	@	AIPING PHARM INC	25MG	A 078645	001	Jan 27, 2009	Jan CAHN
	@		100MG	A 078645	002	Jan 27, 2009	Jan CAHN
	@		150MG	A 078645	003	Jan 27, 2009	Jan CAHN
	@		200MG	A 078645	004	Jan 27, 2009	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

AB		PH HEALTH	25MG	A 201374	001	Dec 26, 2012	Sep CMFD
AB			50MG	A 201374	002	Dec 26, 2012	Sep CMFD
AB			100MG	A 201374	003	Dec 26, 2012	Sep CMFD
AB			200MG	A 201374	004	Dec 26, 2012	Sep CMFD
AB			250MG	A 201374	005	Dec 26, 2012	Sep CMFD
AB			300MG	A 201374	006	Dec 26, 2012	Sep CMFD

TABLET, FOR SUSPENSION;ORAL

LAMOTRIGINE

	@	TARO	5MG	A 079204	001	Feb 04, 2009	Aug DISC
	@		25MG	A 079204	002	Feb 04, 2009	Aug DISC

TABLET, ORALLY DISINTEGRATING;ORAL

LAMOTRIGINE

AB		TARO	25MG	A 219677	001	Oct 07, 2025	Sep NEWA
AB			50MG	A 219677	002	Oct 07, 2025	Sep NEWA
AB			100MG	A 219677	003	Oct 07, 2025	Sep NEWA
AB			200MG	A 219677	004	Oct 07, 2025	Sep NEWA

LANDIOLOL HYDROCHLORIDE

POWDER; INTRAVENOUS

RAPIBLYK

+! AOP HLTH US EQ 280MG BASE/VIAL

N217202 001 Nov 22, 2024 Oct CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

AB		APOTEX	15MG	A 202176	001	Sep 14, 2012	Nov CAHN
AB			30MG	A 202176	002	Sep 14, 2012	Nov CAHN
	@	MACLEODS PHARMS LTD	15MG	A 208671	001	Nov 04, 2024	Jun DISC
	@		30MG	A 208671	002	Nov 04, 2024	Jun DISC

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL  
LANTHANUM CARBONATE

AB	ALKEM LABS LTD	EQ 500MG BASE	A202329	001	Mar 13, 2025	Mar	NEWA
AB		EQ 750MG BASE	A202329	002	Mar 13, 2025	Mar	NEWA
AB		EQ 1GM BASE	A202329	003	Mar 13, 2025	Mar	NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC  
LATANOPROST

	@	CARNEGIE	0.005%	A202077	001	Feb 11, 2013	Apr	CAHN
>A>	AT	MANKIND PHARMA	0.005%	A220360	001	Dec 17, 2025	Dec	NEWA
	AT	MICRO LABS	0.005%	A219306	001	Apr 14, 2025	Apr	NEWA

LATANOPROSTENE BUNOD

SOLUTION/DROPS;OPHTHALMIC  
LATANOPROSTENE BUNOD

AB	GLAND	0.024%	A217387	001	Apr 29, 2025	Apr	NFTG
	VYZULTA						
AB	+! BAUSCH AND LOMB	0.024%	N207795	001	Nov 02, 2017	Apr	CFTG

LEFLUNOMIDE

TABLET;ORAL  
LEFLUNOMIDE

AB	FOSUN WANBANG	10MG	A077087	001	Sep 13, 2005	Jan	CAHN
AB		20MG	A077087	002	Sep 13, 2005	Jan	CAHN

LENACAPAVIR SODIUM

SOLUTION;SUBCUTANEOUS  
YEZTUGO

	+!	GILEAD SCIENCES INC	EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML)	N220018	001	Jun 18, 2025	Jun	NEWA
--	----	---------------------	--	---------	-----	--------------	-----	------

TABLET;ORAL  
YEZTUGO

	+!	GILEAD SCIENCES INC	EQ 300MG BASE	N220020	001	Jun 18, 2025	Jun	NEWA
--	----	---------------------	---------------	---------	-----	--------------	-----	------

LENALIDOMIDE

CAPSULE;ORAL  
LENALIDOMIDE

AB	ACCORD HLTHCARE	2.5MG	A218872	001	Nov 14, 2025	Nov	NEWA
AB		5MG	A218872	002	Nov 14, 2025	Nov	NEWA
AB		10MG	A218872	003	Nov 14, 2025	Nov	NEWA
AB		15MG	A218872	004	Nov 14, 2025	Nov	NEWA
AB		20MG	A218872	005	Nov 14, 2025	Nov	NEWA
AB		25MG	A218872	006	Nov 14, 2025	Nov	NEWA
AB	AMNEAL	2.5MG	A216213	001	Jan 31, 2025	Nov	CMFD
	@	2.5MG	A216213	001	Jan 31, 2025	Jun	DISC
AB		2.5MG	A216213	001	Jan 31, 2025	Jan	NEWA
AB	@	5MG	A216213	002	Jan 31, 2025	Nov	CMFD
	@	5MG	A216213	002	Jan 31, 2025	Jun	DISC
AB		5MG	A216213	002	Jan 31, 2025	Jan	NEWA
AB		10MG	A216213	003	Jan 31, 2025	Nov	CMFD
	@	10MG	A216213	003	Jan 31, 2025	Jun	DISC
AB		10MG	A216213	003	Jan 31, 2025	Jan	NEWA
AB		15MG	A216213	004	Jan 31, 2025	Nov	CMFD
	@	15MG	A216213	004	Jan 31, 2025	Jun	DISC
AB		15MG	A216213	004	Jan 31, 2025	Jan	NEWA
AB		20MG	A216213	005	Jan 31, 2025	Nov	CMFD
	@	20MG	A216213	005	Jan 31, 2025	Jun	DISC
AB		20MG	A216213	005	Jan 31, 2025	Jan	NEWA
AB		25MG	A216213	006	Jan 31, 2025	Nov	CMFD
	@	25MG	A216213	006	Jan 31, 2025	Jun	DISC
AB		25MG	A216213	006	Jan 31, 2025	Jan	NEWA
AB	BIOCON PHARMA	2.5MG	A215759	001	Mar 03, 2025	Feb	NEWA
AB		5MG	A215759	002	Mar 03, 2025	Feb	NEWA
AB		10MG	A215759	003	Mar 03, 2025	Feb	NEWA
AB		15MG	A215759	004	Mar 03, 2025	Feb	NEWA
AB		20MG	A215759	005	Mar 03, 2025	Feb	NEWA
AB		25MG	A215759	006	Mar 03, 2025	Feb	NEWA
AB	DEVA HOLDING AS	2.5MG	A217554	001	May 22, 2025	May	NEWA
AB		5MG	A217554	002	May 22, 2025	May	NEWA
AB		10MG	A217554	003	May 22, 2025	May	NEWA

CAPSULE;ORAL  
LENALIDOMIDE

AB			15MG	A217554	004	May 22, 2025	May	NEWA
AB			20MG	A217554	005	May 22, 2025	May	NEWA
AB			25MG	A217554	006	May 22, 2025	May	NEWA
AB		LUPIN LTD	2.5MG	A214398	001	Sep 16, 2025	Sep	NEWA
AB			5MG	A214398	002	Sep 16, 2025	Sep	NEWA
AB			10MG	A214398	003	Sep 16, 2025	Sep	NEWA
AB			15MG	A214398	004	Sep 16, 2025	Sep	NEWA
AB			20MG	A214398	005	Sep 16, 2025	Sep	NEWA
AB			25MG	A214398	006	Sep 16, 2025	Sep	NEWA
>D>	@	QILU	2.5MG	A217265	001	Feb 22, 2024	Dec	CMFD
>A>	AB		2.5MG	A217265	001	Feb 22, 2024	Dec	CMFD
>D>	@		5MG	A217265	002	Feb 22, 2024	Dec	CMFD
>A>	AB		5MG	A217265	002	Feb 22, 2024	Dec	CMFD
>D>	@		10MG	A217265	003	Feb 22, 2024	Dec	CMFD
>A>	AB		10MG	A217265	003	Feb 22, 2024	Dec	CMFD
>D>	@		15MG	A217265	004	Feb 22, 2024	Dec	CMFD
>A>	AB		15MG	A217265	004	Feb 22, 2024	Dec	CMFD
>D>	@		20MG	A217265	005	Feb 22, 2024	Dec	CMFD
>A>	AB		20MG	A217265	005	Feb 22, 2024	Dec	CMFD
>D>	@		25MG	A217265	006	Feb 22, 2024	Dec	CMFD
>A>	AB		25MG	A217265	006	Feb 22, 2024	Dec	CMFD
AB		TORRENT	15MG	A213405	004	Nov 04, 2025	Oct	NEWA

LETROZOLE

TABLET;ORAL  
LETROZOLE

@	CARNEGIE	2.5MG	A091191	001	Jun 03, 2011	Sep	CAHN
---	----------	-------	---------	-----	--------------	-----	------

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION  
LEUCOVORIN CALCIUM

AP		GLAND	EQ 350MG BASE/VIAL	A218200	001	Nov 12, 2025	Oct	NEWA
----	--	-------	--------------------	---------	-----	--------------	-----	------

LEUPROLIDE ACETATE

SOLUTION;SUBCUTANEOUS  
LEUPROLIDE ACETATE

AP		ENDO OPERATIONS	14MG/2.8ML (1MG/0.2ML)	A217437	001	Jun 09, 2025	May	NEWA
	@	PH HEALTH	14MG/2.8ML (1MG/0.2ML)	A217437	001	Jun 09, 2025	Aug	DISC
AP		ZYDUS PHARMS	14MG/2.8ML (1MG/0.2ML)	A215826	001	Nov 13, 2025	Oct	NEWA

LEUPROLIDE MESYLATE

EMULSION;SUBCUTANEOUS  
CAMCEVI ETM

+!	FORESEE PHARMS	EQ 21MG BASE	N219745	001	Aug 25, 2025	Aug	NEWA
----	----------------	--------------	---------	-----	--------------	-----	------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION  
LEVALBUTEROL HYDROCHLORIDE

@	MANKIND PHARMA	EQ 0.0103% BASE	A218770	001	Oct 21, 2024	Apr	DISC
@		EQ 0.021% BASE	A218770	002	Oct 21, 2024	Apr	DISC
@		EQ 0.042% BASE	A218770	003	Oct 21, 2024	Apr	DISC

LEVETIRACETAM

INJECTABLE;INTRAVENOUS  
LEVETIRACETAM

AP		KNACK	500MG/5ML (100MG/ML)	A215465	001	Dec 02, 2025	Nov	NEWA
		LEVETIRACETAM IN SODIUM CHLORIDE						
AP		CAPLIN	500MG/100ML (5MG/ML)	A219562	001	Jan 16, 2025	Jan	NEWA
AP			1GM/100ML (10MG/ML)	A219562	002	Jan 16, 2025	Jan	NEWA
AP			1.5GM/100ML (15MG/ML)	A219562	003	Jan 16, 2025	Jan	NEWA
AP		FRESENIUS KABI USA	500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Oct	CMFD
AP			1GM/100ML (10MG/ML)	A208619	002	Jan 31, 2023	Oct	CMFD
AP			1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Oct	CMFD

SOLUTION;ORAL

LEVETIRACETAM

AA		AJENAT PHARMS	100MG/ML	A090461	001	Sep 30, 2010	Jan	CAHN
AA		BIONPHARMA	100MG/ML	A079120	001	Jan 16, 2009	May	CMFD
AA		GUARDIAN DRUG	100MG/ML	A218080	001	Nov 21, 2025	Nov	NEWA
>D>	AA	LUPIN LTD	100MG/ML	A090893	001	Oct 17, 2011	Dec	DISC
>A>	@		100MG/ML	A090893	001	Oct 17, 2011	Dec	DISC

TABLET;ORAL

LEVETIRACETAM

AB		ANDA REPOSITORY	250MG	A076920	001	Jan 15, 2009	Sep	CAHN
AB			500MG	A076920	002	Jan 15, 2009	Sep	CAHN
AB			750MG	A076920	003	Jan 15, 2009	Sep	CAHN
	@	CHINA RESOURCES	500MG	A205102	004	Dec 16, 2015	Jan	CAHN
	@		1GM	A205102	003	Dec 16, 2015	Jan	CAHN
	@	MPP PHARMA	250MG	A090511	001	Aug 18, 2011	Jun	CAHN
	@		500MG	A090511	002	Aug 18, 2011	Jun	CAHN
	@		750MG	A090511	003	Aug 18, 2011	Jun	CAHN
	@		1GM	A090511	004	Aug 18, 2011	Jun	CAHN
>D>	AB	STRIDES PHARMA	250MG	A078042	001	Jan 15, 2009	Dec	DISC
>A>	@		250MG	A078042	001	Jan 15, 2009	Dec	DISC
>D>	AB		500MG	A078042	002	Jan 15, 2009	Dec	DISC
>A>	@		500MG	A078042	002	Jan 15, 2009	Dec	DISC
>D>	AB		750MG	A078042	003	Jan 15, 2009	Dec	DISC
>A>	@		750MG	A078042	003	Jan 15, 2009	Dec	DISC
>D>	AB		1GM	A078042	004	Jan 15, 2009	Dec	DISC
>A>	@		1GM	A078042	004	Jan 15, 2009	Dec	DISC
	@	TARO	250MG	A078960	004	Feb 01, 2010	Aug	DISC
	@		500MG	A078960	003	Feb 01, 2010	Aug	DISC
	@		750MG	A078960	002	Feb 01, 2010	Aug	DISC
	@		1GM	A078960	001	Feb 01, 2010	Aug	DISC

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

	@	APOTEX	1GM	A202958	001	Feb 25, 2015	Mar	DISC
AB		TORRENT PHARMS LTD	500MG	A091338	001	May 29, 2012	Nov	CMFD
AB			750MG	A091338	002	May 29, 2012	Nov	CMFD

TABLET, FOR SUSPENSION;ORAL

SPRITAM

	+!	APRECIA PHARMS	500MG	N207958	002	Jul 31, 2015	Apr	CHRS
	@ +		750MG	N207958	003	Jul 31, 2015	Apr	DISC
	@ +		1GM	N207958	004	Jul 31, 2015	Apr	DISC

LEVOCARNITINE

INJECTABLE;INJECTION

LEVOCARNITINE

AP		DEVA HOLDING AS	200MG/ML	A217430	001	Jun 30, 2025	Jun	NEWA
----	--	-----------------	----------	---------	-----	--------------	-----	------

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

	@	TARO	2.5MG/5ML	A202673	001	Jul 26, 2013	Aug	DISC
--	---	------	-----------	---------	-----	--------------	-----	------

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB		SYNTHON BV	5MG	A090229	001	Nov 26, 2010	Feb	CAHN
----	--	------------	-----	---------	-----	--------------	-----	------

LEVODOPA

POWDER;INHALATION

INBRIJA

	+!	MERZ	42MG	N209184	001	Dec 21, 2018	Feb	CAHN
--	----	------	------	---------	-----	--------------	-----	------

LEVOFLOXACIN

TABLET;ORAL

LEVOFLOXACIN

	@	APOTEX INC	250MG	A090787	001	Sep 29, 2011	Mar	DISC
	@		500MG	A090787	002	Sep 29, 2011	Mar	DISC
	@		750MG	A090787	003	Sep 29, 2011	Mar	DISC
	@	CHARTWELL RX	250MG	A090367	001	Jun 20, 2011	Sep	CAHN
	@		500MG	A090367	002	Jun 20, 2011	Sep	CAHN
	@		750MG	A090367	003	Jun 20, 2011	Sep	CAHN

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

FETZIMA

AB	+	ABBVIE	EQ 20MG BASE	N204168	001	Jul 25, 2013	Oct	CTEC
AB	+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Oct	CTEC
AB	+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Oct	CTEC
AB	+		EQ 120MG BASE	N204168	004	Jul 25, 2013	Oct	CTEC

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

AB	ACERTIS PHARMS	2MG	A211484	001	Dec 13, 2018	Apr	CAHN
BX	NOVITIUM PHARMA	1MG	A213479	003	Jul 20, 2021	Mar	CTEC
BX		2MG	A213479	001	Jul 01, 2020	Mar	CTEC
BX		3MG	A213479	002	Jan 12, 2021	Mar	CTEC
AB		3MG	A213479	002	Jan 12, 2021	Mar	CHRS
AB	! SUN PHARM INDS INC	3MG	A213906	002	Apr 25, 2023	Mar	CTEC
AB	!	3MG	A213906	002	Apr 25, 2023	Mar	CHRS

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

LEVOTHYROXINE SODIUM

@ ANI PHARMS

@

@

@

@

@

@

@

@

@

@

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

AP	ONESOURCE SPECIALTY	100MCG/VIAL	A216729	001	Mar 05, 2025	May	CAHN
AP		200MCG/VIAL	A216729	002	Mar 05, 2025	May	CAHN
AP		500MCG/VIAL	A216729	003	Mar 05, 2025	May	CAHN
AP	STERISCIENCE	100MCG/VIAL	A216729	001	Mar 05, 2025	Feb	NEWA
AP		200MCG/VIAL	A216729	002	Mar 05, 2025	Feb	NEWA
AP		500MCG/VIAL	A216729	003	Mar 05, 2025	Feb	NEWA

SOLUTION;ORAL

THYQUIDITY

+! STEVENS J

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

EUTHYROX

AB2	EMD SERONO INC	0.025MG	N021292	001	May 31, 2002	Apr	CAHN
AB2		0.05MG	N021292	002	May 31, 2002	Apr	CAHN
AB2		0.075MG	N021292	003	May 31, 2002	Apr	CAHN
AB2		0.088MG	N021292	004	May 31, 2002	Apr	CAHN
AB2		0.1MG	N021292	005	May 31, 2002	Apr	CAHN
AB2		0.112MG	N021292	006	May 31, 2002	Apr	CAHN
AB2		0.125MG	N021292	007	May 31, 2002	Apr	CAHN
AB2		0.137MG	N021292	008	May 31, 2002	Apr	CAHN
AB2		0.15MG	N021292	009	May 31, 2002	Apr	CAHN
AB2		0.175MG	N021292	010	May 31, 2002	Apr	CAHN
AB2		0.2MG	N021292	011	May 31, 2002	Apr	CAHN
AB2	@	0.3MG	N021292	012	May 31, 2002	Apr	CAHN
	LEVOTHYROXINE SODIUM						
@	AUROBINDO PHARMA	0.137MG	A216414	001	Jul 16, 2024	Jan	DISC
@		0.15MG	A216414	002	Jul 16, 2024	Jan	DISC
@		0.175MG	A216414	003	Jul 16, 2024	Jan	DISC
@		0.2MG	A216414	004	Jul 16, 2024	Jan	DISC
@		0.3MG	A216414	005	Jul 16, 2024	Jan	DISC
AB1,AB2, AB3,AB4	MACLEODS PHARMS LTD	0.025MG	A211417	001	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB4		0.025MG	A211417	001	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB3,AB4		0.05MG	A211417	002	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB4		0.05MG	A211417	002	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB3,AB4		0.075MG	A211417	003	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB4		0.075MG	A211417	003	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB3,AB4		0.088MG	A211417	004	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB4		0.088MG	A211417	004	Dec 21, 2022	Feb	CTEC
AB1,AB2,		0.1MG	A211417	005	Dec 21, 2022	Feb	CTEC

TABLET;ORAL  
LEVOTHYROXINE SODIUM

AB3,AB4							
AB1,AB2, AB4	0.1MG		A211417	005	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB3,AB4	0.112MG		A211417	006	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB4	0.112MG		A211417	006	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB3,AB4	0.125MG		A211417	007	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB4	0.125MG		A211417	007	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB3,AB4	0.137MG		A211417	008	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB4	0.137MG		A211417	008	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB3,AB4	0.15MG		A211417	009	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB4	0.15MG		A211417	009	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB3,AB4	0.175MG		A211417	010	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB4	0.175MG		A211417	010	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB3,AB4	0.2MG		A211417	011	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB4	0.2MG		A211417	011	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB3,AB4	0.3MG		A211417	012	Dec 21, 2022	Feb	CTEC
AB1,AB2, AB4	0.3MG		A211417	012	Dec 21, 2022	Feb	CTEC

LIDOCAINE

OINTMENT;TOPICAL  
LIDOCAINE

BX	ALEMBIC	5%	A211469	001	Nov 23, 2018	Mar	CTEC
AT	CHARTWELL RX	5%	A208660	001	Jan 05, 2021	Apr	CAHN
PATCH;TOPICAL							
LIDOCAINE							
AB	ALKEM LABS LTD	5%	A216484	001	Oct 06, 2025	Sep	NEWA
AB	AVEVA	1.8%	A217221	001	Mar 25, 2025	Mar	NFTG
AB	DIFGEN PHARMS	1.8%	A217221	001	Mar 25, 2025	Sep	CAHN
ZTLIDO							
AB	+! SCILEX PHARMS	1.8%	N207962	001	Feb 28, 2018	Mar	CFTG
SYSTEM;TOPICAL							
BONDLIDO							
	+! MEDRX USA	10%	N215029	001	Sep 24, 2025	Sep	NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

>D>	@	AFAXYS	1%	A215132	001	Jun 09, 2022	Dec	CMFD
>A>	AP		1%	A215132	001	Jun 09, 2022	Dec	CMFD
	@		1%	A215132	001	Jun 09, 2022	Jul	DISC
	AP	ANTHEA PHARMA	1%	A219535	001	Apr 02, 2025	Nov	CAHN
	AP		1%	A219535	001	Apr 02, 2025	Mar	NEWA
>D>	AP	+! HOSPIRA	1%	A083158	001		Dec	DISC
>A>	@ +		1%	A083158	001		Dec	DISC
>D>	AP	+!	2%	A083158	002		Dec	DISC
>A>	@ +		2%	A083158	002		Dec	DISC
	AP	NEOCUBES PHARMA	1%	A219535	001	Apr 02, 2025	Sep	CAHN
	AP	YILING	1%	A214267	001	Sep 19, 2022	Sep	CAHN
	AP		2%	A214267	002	Sep 19, 2022	Sep	CAHN
	AP		4%	A214269	001	May 05, 2022	Sep	CAHN
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE								
	@	EUGIA PHARMA	1%	A203040	001	Mar 14, 2013	Jul	DISC
	@		2%	A203040	002	Mar 14, 2013	Jul	DISC
SOLUTION;ORAL								
LIDOCAINE HYDROCHLORIDE								
AT	AUROBINDO PHARMA LTD	2%	A219759	001	Jul 29, 2025	Jul	NEWA	
AT	XTTRIUM LABS INC	2%	A087872	001	Nov 18, 1982	Feb	CAHN	

SOLUTION;TOPICAL

LIDOCAINE HYDROCHLORIDE  
 AT XTTRIUM LABS INC 4% A087881 001 Nov 18, 1982 Feb CAHN

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL

LIDOCAINE AND PRILOCAINE  
 @ CHARTWELL RX 2.5%;2.5% A213253 001 Sep 21, 2020 Oct CAHN  
 >D> AB PAI HOLDINGS PHARM 2.5%;2.5% A205887 001 Jun 29, 2018 Dec DISC  
 >A> @ 2.5%;2.5% A205887 001 Jun 29, 2018 Dec DISC

LIDOCAINE; TETRACAINE

CREAM;TOPICAL

PLIAGLIS

+! CRESCITA THERAP 7%;7% N021717 001 Jun 29, 2006 Sep CMFD

LINAGLIPTIN

TABLET;ORAL

LINAGLIPTIN

AB AUROBINDO PHARMA LTD 5MG A208415 001 Nov 03, 2025 Oct NEWA  
 AB DR REDDYS 5MG A208428 001 Nov 03, 2025 Oct NEWA  
 AB MSN 5MG A208457 001 Nov 03, 2025 Oct NEWA  
 AB MYLAN 5MG A208431 001 Nov 03, 2025 Oct NEWA  
 AB ZYDUS PHARMS 5MG A208448 001 Mar 30, 2023 Sep CMFD

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

LINAGLIPTIN AND METFORMIN HYDROCHLORIDE

AB DR REDDYS 2.5MG;500MG A208427 001 Nov 03, 2025 Oct NEWA  
 AB 2.5MG;850MG A208427 002 Nov 03, 2025 Oct NEWA  
 AB 2.5MG;1GM A208427 003 Nov 03, 2025 Oct NEWA  
 AB MSN 2.5MG;500MG A208459 001 Nov 03, 2025 Oct NEWA  
 AB 2.5MG;850MG A208459 002 Nov 03, 2025 Oct NEWA  
 AB 2.5MG;1GM A208459 003 Nov 03, 2025 Oct NEWA  
 AB ZYDUS PHARMS 2.5MG;500MG A208449 001 Mar 30, 2023 Sep CMFD  
 AB 2.5MG;850MG A208449 002 Mar 30, 2023 Sep CMFD  
 AB 2.5MG;1GM A208449 003 Mar 30, 2023 Sep CMFD

LINEZOLID

SOLUTION;INTRAVENOUS

LINEZOLID

AP CAPLIN 600MG/300ML (2MG/ML) A219558 001 Dec 08, 2025 Nov NEWA  
 AP NORVIUM BIOSCIENCE 200MG/100ML (2MG/ML) A205154 001 Dec 06, 2017 Feb CAHN  
 AP 600MG/300ML (2MG/ML) A205154 002 Dec 06, 2017 Feb CAHN

TABLET;ORAL

LINEZOLID

AB ! ALKEM LABS LTD 600MG A205517 001 Dec 21, 2015 Oct CHRS  
 @ MACLEODS PHARMS LTD 600MG A210378 001 Oct 10, 2024 Jun DISC  
 ZYVOX  
 @ + PFIZER 600MG N021130 002 Apr 18, 2000 Oct DISC

LIOTHYRONINE SODIUM

INJECTABLE;INJECTION

TRIOSTAT

@ + PH HEALTH EQ 0.01MG BASE/ML N020105 001 Dec 31, 1991 Jul CAHN

LIRAGLUTIDE

SOLUTION;SUBCUTANEOUS

LIRAGLUTIDE

AP1 HIKMA 18MG/3ML (6MG/ML) A215503 001 Dec 23, 2024 Aug CTEC  
 AP1 LUPIN LTD 18MG/3ML (6MG/ML) A215421 001 Jul 22, 2025 Aug CTEC  
 AP 18MG/3ML (6MG/ML) A215421 001 Jul 22, 2025 Jul NEWA  
 AP1 NANJING KING FRIEND 18MG/3ML (6MG/ML) A218115 001 Apr 02, 2025 Aug CTEC  
 AP NANJING KING-FRIEND 18MG/3ML (6MG/ML) A218115 001 Apr 02, 2025 Mar NEWA  
 AP2 TEVA PHARMS 18MG/3ML (6MG/ML) A214568 001 Aug 27, 2025 Aug NFTG  
 SAXENDA  
 AP2 +! NOVO 18MG/3ML (6MG/ML) N206321 001 Dec 23, 2014 Aug CFTG  
 VICTOZA  
 AP1 +! NOVO NORDISK INC 18MG/3ML (6MG/ML) N022341 001 Jan 25, 2010 Aug CTEC

LISDEXAMFETAMINE DIMESYLATE

CAPSULE;ORAL

LISDEXAMFETAMINE DIMESYLATE

AB	GRANULES	10MG	A218987	001	Jan 29, 2025	Jan	NEWA
AB		20MG	A218987	002	Jan 29, 2025	Jan	NEWA
AB		30MG	A218987	003	Jan 29, 2025	Jan	NEWA
AB		40MG	A218987	004	Jan 29, 2025	Jan	NEWA
AB		50MG	A218987	005	Jan 29, 2025	Jan	NEWA
AB		60MG	A218987	006	Jan 29, 2025	Jan	NEWA
AB		70MG	A218987	007	Jan 29, 2025	Jan	NEWA
AB	SANDOZ	20MG	A202836	001	Jul 26, 2024	Jan	CMFD
AB		30MG	A202836	002	Jul 26, 2024	Jan	CMFD
AB		40MG	A202836	003	Jul 26, 2024	Jan	CMFD
AB		50MG	A202836	004	Jul 26, 2024	Jan	CMFD
AB		60MG	A202836	005	Jul 26, 2024	Jan	CMFD
AB		70MG	A202836	006	Jul 26, 2024	Jan	CMFD

SOLUTION;ORAL

ARYNTA

+! AZURITY

10MG/ML

N219847 001 Jun 16, 2025 Jun NEWA

LISINOPRIL

TABLET;ORAL

LISINOPRIL

AB	ANNORA PHARMA	2.5MG	A075903	001	Jul 01, 2002	Nov	CAHN
AB		5MG	A075903	002	Jul 01, 2002	Nov	CAHN
AB		10MG	A075903	003	Jul 01, 2002	Nov	CAHN
AB		20MG	A075903	004	Jul 01, 2002	Nov	CAHN
AB		30MG	A075903	005	Jul 01, 2002	Nov	CAHN
AB		40MG	A075903	006	Jul 01, 2002	Nov	CAHN

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

@ NORVIUM BIOSCIENCE

300MG

A202288 001 Jun 29, 2012 Jul DISC

@

450MG

A202219 001 Aug 08, 2012 Mar DISC

AB

450MG

A202219 001 Aug 08, 2012 Feb CAHN

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

ALOMIDE

@ + NOVARTIS

EQ 0.1% BASE

N020191 001 Sep 23, 1993 May DISC

LOFEXIDINE HYDROCHLORIDE

TABLET;ORAL

LOFEXIDINE HYDROCHLORIDE

AB	MSN	EQ 0.18MG BASE	A218699	001	Feb 24, 2025	Feb	NEWA
AB	NOVITIUM PHARMA	EQ 0.18MG BASE	A219917	001	Oct 22, 2025	Oct	NEWA
AB	LUCEMYRA						
AB	+! BIOCORRX PHARMS	EQ 0.18MG BASE	N209229	001	May 16, 2018	May	CAHN

LOMUSTINE

CAPSULE;ORAL

GLEOSTINE

@ + AZURITY

5MG

N017588 004 Dec 19, 2014 Aug CAHN

AB

+

10MG

N017588 001 Oct CFTG

+

10MG

N017588 001 Aug CAHN

AB

+!

40MG

N017588 002 Oct CFTG

+!

40MG

N017588 002 Aug CAHN

AB

+

100MG

N017588 003 Oct CFTG

+

100MG

N017588 003 Aug CAHN

LOMUSTINE

AB	CARNEGIE	10MG	A219265	001	Oct 27, 2025	Oct	NFTG
AB		40MG	A219265	002	Oct 27, 2025	Oct	NFTG
AB		100MG	A219265	003	Oct 27, 2025	Oct	NFTG

LOPINAVIR; RITONAVIR

SOLUTION;ORAL

KALETRA

>D>	AA	+! ABBVIE	80MG/ML;20MG/ML	N021251	001	Sep 15, 2000	Dec	CTEC
>A>		+!	80MG/ML;20MG/ML	N021251	001	Sep 15, 2000	Dec	CTEC

		SOLUTION;ORAL					
>D>		LOPINA VIR AND RITONAVIR					
>D>	AA	LANNETT CO INC	80MG/ML;20MG/ML	A 207407	001	Dec 27, 2016	Dec DISC
>A>		@	80MG/ML;20MG/ML	A 207407	001	Dec 27, 2016	Dec DISC
		TABLET;ORAL					
		LOPINA VIR AND RITONAVIR					
>A>	AB	MICRO LABS	100MG;25MG	A 214696	001	Dec 11, 2025	Dec NEWA
>A>	AB		200MG;50MG	A 214696	002	Dec 11, 2025	Dec NEWA
		<u>LORAZEPAM</u>					
		CONCENTRATE;ORAL					
		LORAZEPAM					
>D>	AA	LUPIN LTD	2MG/ML	A 091407	001	Feb 19, 2013	Dec DISC
>A>		@	2MG/ML	A 091407	001	Feb 19, 2013	Dec DISC
		INJECTABLE;INJECTION					
		LORAZEPAM					
		@	AVIV PHARMA	A 074551	003	Sep 12, 1996	May CAHN
		@		A 074535	001	Sep 12, 1996	Apr CAHN
		@		A 074551	001	Sep 12, 1996	May CAHN
		@		A 074535	002	Sep 12, 1996	Apr CAHN
		@		A 074551	002	Sep 12, 1996	May CAHN
		@	CAPLIN	A 074551	003	Sep 12, 1996	Nov CAHN
		@		A 074551	001	Sep 12, 1996	Nov CAHN
		@		A 074551	002	Sep 12, 1996	Nov CAHN
		@	HOSPIRA	A 074282	001	May 27, 1994	Apr DISC
		@		A 074282	002	May 27, 1994	Apr DISC
		TABLET;ORAL					
		LORAZEPAM					
AB		AUROBINDO PHARMA	0.5MG	A 203572	001	Dec 22, 2017	Aug CAHN
AB			1MG	A 203572	002	Dec 22, 2017	Aug CAHN
AB			2MG	A 203572	003	Dec 22, 2017	Aug CAHN
AB		GRAVITI PHARMS	0.5MG	A 218597	001	Jul 24, 2025	Jul NEWA
AB			1MG	A 218597	002	Jul 24, 2025	Jul NEWA
AB			2MG	A 218597	003	Jul 24, 2025	Jul NEWA
		<u>LOSARTAN POTASSIUM</u>					
		SUSPENSION;ORAL					
		ARBLI					
		+!	SCIENTURE	N 218772	001	Mar 13, 2025	Mar NEWA
		TABLET;ORAL					
		LOSARTAN POTASSIUM					
AB		AIPING PHARM INC	25MG	A 090544	001	Oct 06, 2010	Jul CMFD
AB			50MG	A 090544	002	Oct 06, 2010	Jul CMFD
AB			100MG	A 090544	003	Oct 06, 2010	Jul CMFD
		@	APOTEX	A 218551	001	Jun 04, 2024	Jan DISC
		@		A 218551	002	Jun 04, 2024	Jan DISC
		@		A 218551	003	Jun 04, 2024	Jan DISC
AB		GRAVITI PHARMS	25MG	A 219859	001	Sep 19, 2025	Sep NEWA
AB			50MG	A 219859	002	Sep 19, 2025	Sep NEWA
AB			100MG	A 219859	003	Sep 19, 2025	Sep NEWA
		<u>LOTEPREDNOL ETABONATE</u>					
		GEL;OPHTHALMIC					
		LOTEMAX SM					
AB		+!	BAUSCH AND LOMB INC	N 208219	001	Feb 22, 2019	Jun CFTG
		LOTEPREDNOL ETABONATE					
>D>	AB	HIKMA	0.5%	A 213956	001	Nov 29, 2023	Dec DISC
>A>		@	0.5%	A 213956	001	Nov 29, 2023	Dec DISC
AB			0.5%	A 213956	001	Nov 29, 2023	Sep CMFD
AB		LUPIN LTD	0.38%	A 218087	001	Jun 30, 2025	Jun NFTG
		SUSPENSION/DROPS;OPHTHALMIC					
		LOTEPREDNOL ETABONATE					
AB		AMNEAL	0.5%	A 217484	001	May 20, 2025	May NEWA
AB		PADAGIS US	0.5%	A 215204	001	Jan 29, 2025	Jan NEWA
		<u>LOTEPREDNOL ETABONATE; TOBRAMYCIN</u>					
		SUSPENSION/DROPS;OPHTHALMIC					
		LOTEPREDNOL ETABONATE AND TOBRAMYCIN					
AB		ALEMBIC	0.5%;0.3%	A 217597	001	Dec 10, 2025	Nov NFTG
		ZYLET					
AB		+!	BAUSCH AND LOMB	N 050804	001	Dec 14, 2004	Nov CFTG

LOVASTATIN

TABLET, EXTENDED RELEASE;ORAL  
ALTOPREV

@ +	COVIS	20MG	N021316	002	Jun 26, 2002	May	DISC
@ +		40MG	N021316	003	Jun 26, 2002	May	DISC
@ +		60MG	N021316	004	Jun 26, 2002	May	DISC

LOXAPINE

POWDER; INHALATION  
ADASUVE

>D>	+	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012	Dec	CAHN
>A>	+	NOVA PNEUMA	10MG	N022549	001	Dec 21, 2012	Dec	CAHN

LUBIPROSTONE

CAPSULE;ORAL  
LUBIPROSTONE

@	AMNEAL	8MCG	A209450	001	Nov 30, 2021	Sep	DISC
@		24MCG	A209450	002	Nov 30, 2021	Sep	DISC

LURASIDONE HYDROCHLORIDE

TABLET;ORAL  
LURASIDONE HYDROCHLORIDE

>D>	AB	AMNEAL PHARMS CO	20MG	A208002	001	Jan 03, 2019	Dec	DISC
>A>		@	20MG	A208002	001	Jan 03, 2019	Dec	DISC
>D>	AB		40MG	A208002	002	Jan 03, 2019	Dec	DISC
>A>		@	40MG	A208002	002	Jan 03, 2019	Dec	DISC
>D>	AB		60MG	A208002	003	Jan 03, 2019	Dec	DISC
>A>		@	60MG	A208002	003	Jan 03, 2019	Dec	DISC
>D>	AB		80MG	A208002	004	Jan 03, 2019	Dec	DISC
>A>		@	80MG	A208002	004	Jan 03, 2019	Dec	DISC
>D>	AB		120MG	A208002	005	Jan 03, 2019	Dec	DISC
>A>		@	120MG	A208002	005	Jan 03, 2019	Dec	DISC
	AB	CHARTWELL RX	20MG	A212091	001	Dec 28, 2020	Mar	CAHN
	AB		40MG	A212091	002	Dec 28, 2020	Mar	CAHN
	AB		60MG	A212091	003	Dec 28, 2020	Mar	CAHN
	AB		80MG	A212091	004	Dec 28, 2020	Mar	CAHN
	AB		120MG	A212091	005	Dec 28, 2020	Mar	CAHN
		@	120MG	A208066	005	Jan 04, 2019	Oct	DISC
	AB	TORRENT	60MG	A208055	005	Jan 13, 2025	Jan	NEWA

MACITENTAN

TABLET;ORAL  
MACITENTAN

	AB	ALEMBIC	10MG	A211128	001	Aug 18, 2025	Aug	NEWA
	AB	AUROBINDO PHARMA LTD	10MG	A211198	001	Apr 18, 2023	Nov	CMFD
	AB	LAURUS	10MG	A211120	001	Nov 05, 2025	Oct	NEWA
	AB	MSN	10MG	A211136	001	Aug 20, 2025	Aug	NEWA
>D>	AB	MYLAN	10MG	A211161	001	Dec 03, 2025	Dec	DISC
>A>		@	10MG	A211161	001	Dec 03, 2025	Dec	DISC
	AB		10MG	A211161	001	Dec 03, 2025	Nov	NEWA
>D>	AB	SEASONS BIOTECH	10MG	A211026	001	Dec 03, 2025	Dec	DISC
>A>		@	10MG	A211026	001	Dec 03, 2025	Dec	DISC
	AB		10MG	A211026	001	Dec 03, 2025	Nov	NEWA
	AB	SUN PHARM	10MG	A211123	001	Aug 26, 2025	Aug	NEWA
		OPSUMIT						
	AB	+	ACTELION	N204410	001	Oct 18, 2013	Aug	CTEC

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION  
MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5

@	FRESENIUS KABI USA	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	A215370	001	Jun 29, 2022	Jun	DISC
---	--------------------	---	---------	-----	--------------	-----	------

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017378	001		Jun	CTEC
---	-----------------	---	---------	-----	--	-----	------

MAGNESIUM SULFATE

	INJECTABLE; INJECTION							
	MAGNESIUM SULFATE IN PLASTIC CONTAINER							
	@ MYLAN LABS LTD	4GM/100ML (40MG/ML)	A209911	002	Sep 14, 2018	Oct	DISC	
	SOLUTION; INTRAMUSCULAR, INTRAVENOUS							
	MAGNESIUM SULFATE							
AP	ASPIRO	1GM/2ML (500MG/ML)	A219777	001	May 28, 2025	May	NFTG	
AP		5GM/10ML (500MG/ML)	A219777	002	May 28, 2025	May	NEWA	
AP		10GM/20ML (500MG/ML)	A219777	003	May 28, 2025	May	NEWA	
AP		25GM/50ML (500MG/ML)	A219777	004	May 28, 2025	May	NFTG	
AP	+! FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986	May	CFTG	
AP	+!	25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016	May	CFTG	

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE

	FOR SOLUTION; ORAL							
	SUFLAVE							
	+! AZURITY	0.9GM/BOT; 178.7GM/BOT; 1.12GM/BOT; 0.5GM/BOT; 7.3GM/BOT	N215344	001	Jun 15, 2023	Nov	CAHN	

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE

	TABLET; ORAL							
	SUTAB							
	+! AZURITY	0.225GM; 0.188GM; 1.479GM	N213135	001	Nov 10, 2020	Nov	CAHN	

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

	SOLUTION; ORAL							
	SUPREP BOWEL PREP KIT							
AA	+! AZURITY	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	N022372	001	Aug 05, 2010	Nov	CAHN	

MANGANESE CHLORIDE

	INJECTABLE; INJECTION							
	MANGANESE CHLORIDE							
AP	FRESENIUS KABI USA	EQ 0.1MG MANGANESE/ML	A217583	001	Jul 07, 2025	Jun	NFTG	
	MANGANESE CHLORIDE IN PLASTIC CONTAINER							
AP	+! HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986	Jun	CFTG	

MARALIXIBAT CHLORIDE

	TABLET; ORAL							
	LIVMARLI							
	+ MIRUM	EQ 10MG BASE	N219485	001	Apr 10, 2025	Apr	NEWA	
	+	EQ 15MG BASE	N219485	002	Apr 10, 2025	Apr	NEWA	
	+	EQ 20MG BASE	N219485	003	Apr 10, 2025	Apr	NEWA	
	+!	EQ 30MG BASE	N219485	004	Apr 10, 2025	Apr	NEWA	

MARAVIROC

	TABLET; ORAL							
	MARAVIROC							
AB	NAVINTA LLC	150MG	A217880	001	May 13, 2025	May	NEWA	
AB		300MG	A217880	002	May 13, 2025	May	NEWA	
AB	RHODES PHARMS	150MG	A216143	001	Nov 04, 2025	Oct	NEWA	
AB		300MG	A216143	002	Nov 04, 2025	Oct	NEWA	

MECLIZINE HYDROCHLORIDE

	TABLET; ORAL							
	MECLIZINE HYDROCHLORIDE							
AA	ALLIED	25MG	A084092	003	May 22, 1989	Jul	CAHN	
	@ HERITAGE	12.5MG	A205136	001	Feb 22, 2019	Jul	CAHN	
	@	25MG	A205136	002	Feb 22, 2019	Jul	CAHN	
	@	50MG	A205136	003	Feb 22, 2019	Jul	CAHN	
	@ INDICUS PHARMA	12.5MG	A205136	001	Feb 22, 2019	Jun	CAHN	
	@	25MG	A205136	002	Feb 22, 2019	Jun	CAHN	
	@	50MG	A205136	003	Feb 22, 2019	Jun	CAHN	
AA	SCIEGEN PHARMS	25MG	A084092	003	May 22, 1989	Sep	CAHN	

MEFENAMIC ACID

	CAPSULE; ORAL							
	MEFENAMIC ACID							
AB	AJENAT PHARMS	250MG	A091608	001	Jun 02, 2014	Jan	CAHN	
	@ MPP PHARMA	250MG	A090359	001	Feb 05, 2013	Jun	CAHN	

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL							
MEFLOQUINE HYDROCHLORIDE							
AB		CHARTWELL RX	250MG	A 076175	001	Feb 20, 2002	Jun CMFD
	@	HIKMA	250MG	A 076523	001	Oct 01, 2004	Sep DISC

MEGESTROL ACETATE

SUSPENSION; ORAL							
MEGACE ES							
	@ +	ENDO OPERATIONS	125MG/ML	N 021778	001	Jul 05, 2005	Feb DISC
	!	TWI PHARMS	125MG/ML	A 203139	001	Aug 27, 2014	Feb CTEC
AB	!		125MG/ML	A 203139	001	Aug 27, 2014	Feb CHRS
AB		XTTRIUM LABS INC	40MG/ML	A 076721	001	Nov 01, 2004	Apr CMFD

MELOXICAM

SOLUTION; INTRAVENOUS							
QAMZOVA							
	+!	NANJING DELOVA	30MG/ML (30MG/ML)	N 217593	001	Apr 22, 2025	Apr NEWA
	+!	AZURITY	30MG/ML (30MG/ML)	N 218395	001	Jun 05, 2025	Jun NEWA
TABLET; ORAL							
MELOXICAM							
AB		GRAVITI PHARMS	7.5MG	A 077931	001	Jul 25, 2006	Feb CAHN
AB			15MG	A 077931	002	Jul 25, 2006	Feb CAHN
>D>	AB	LUPIN PHARMS	7.5MG	A 077944	001	Jul 19, 2006	Dec DISC
>A>	@		7.5MG	A 077944	001	Jul 19, 2006	Dec DISC
>D>	AB		15MG	A 077944	002	Jul 19, 2006	Dec DISC
>A>	@		15MG	A 077944	002	Jul 19, 2006	Dec DISC
	@	TARO	7.5MG	A 078102	001	Nov 07, 2006	Aug DISC
	@		15MG	A 078102	002	Nov 07, 2006	Aug DISC

MELOXICAM; RIZATRIPTAN BENZOATE

TABLET; ORAL							
SYMBRAVO							
	+!	AXSOME	20MG;EQ 10MG BASE	N 215431	001	Jan 30, 2025	Jan NEWA

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION							
MELPHALAN HYDROCHLORIDE							
	@	ALMAJECT	EQ 50MG BASE/VIAL	A 204817	001	May 17, 2019	Oct DISC
	@	NOVAST LABS	EQ 50MG BASE/VIAL	A 210947	001	Feb 18, 2020	Sep DISC
AP			EQ 50MG BASE/VIAL	A 210947	001	Feb 18, 2020	Aug CAHN

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL							
MEMANTINE HYDROCHLORIDE							
	@	APOTEX	7MG	A 206135	001	Nov 22, 2016	Mar DISC
	@		14MG	A 206135	002	Nov 22, 2016	Mar DISC
	@		21MG	A 206135	003	Nov 22, 2016	Mar DISC
	@		28MG	A 206135	004	Nov 22, 2016	Mar DISC
AB		MACLEODS PHARMS LTD	7MG	A 206310	001	Aug 28, 2025	Aug NEWA
AB			14MG	A 206310	002	Aug 28, 2025	Aug NEWA
AB			21MG	A 206310	003	Aug 28, 2025	Aug NEWA
AB			28MG	A 206310	004	Aug 28, 2025	Aug NEWA
AB		RISING	7MG	A 206032	001	Sep 28, 2016	May CMFD
AB			14MG	A 206032	002	Sep 28, 2016	May CMFD
AB			21MG	A 206032	003	Sep 28, 2016	May CMFD
AB			28MG	A 206032	004	Sep 28, 2016	May CMFD
AB		VITRUVIAS	7MG	A 213985	001	Oct 11, 2022	Sep CAHN
AB			14MG	A 213985	002	Oct 11, 2022	Sep CAHN
AB			21MG	A 213985	004	Feb 06, 2024	Sep CAHN
AB			28MG	A 213985	003	Oct 11, 2022	Sep CAHN
SOLUTION; ORAL							
MEMANTINE HYDROCHLORIDE							
	@	APOZEAL PHARMS	2MG/ML	A 205446	001	Dec 07, 2015	Apr CAHN
	@	SCIEGEN PHARMS	2MG/ML	A 205446	001	Dec 07, 2015	Sep CAHN
TABLET; ORAL							
MEMANTINE HYDROCHLORIDE							
	@	POINTVIEW HLDINGS	5MG	A 090073	001	Sep 04, 2015	Apr CAHN
	@		10MG	A 090073	002	Sep 04, 2015	Apr CAHN

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB	PURACAP LABS BLU	5MG	A210587	001	Dec 11, 2020	Nov	CAHN
AB		10MG	A210587	002	Dec 11, 2020	Nov	CAHN
AB	RENATA	5MG	A209527	001	May 07, 2018	Aug	CAHN
AB		10MG	A209527	002	May 07, 2018	Aug	CAHN
AB	SOMERSET THERAPS LLC	5MG	A209527	001	May 07, 2018	Sep	CAHN
AB		10MG	A209527	002	May 07, 2018	Sep	CAHN
AB	YILING	5MG	A212947	001	Apr 03, 2020	Apr	CMFD
AB		10MG	A212947	002	Apr 03, 2020	Apr	CMFD

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

@ +	HOSPIRA	1%	N012250	001		Jul	DISC
@ +		1.5%	N012250	005		Jul	DISC
@ +		2%	N012250	002		Jul	DISC

POLOCAINE

FRESENIUS KABI USA	1%	A089407	001	Dec 01, 1986	Jul	CTEC
	2%	A089410	001	Dec 01, 1986	Jul	CTEC

POLOCAINE-MPF

FRESENIUS KABI USA	1%	A089406	001	Dec 01, 1986	Jul	CTEC
	1.5%	A089408	001	Dec 01, 1986	Jul	CTEC
	2%	A089409	001	Dec 01, 1986	Jul	CTEC

MERCAPTOPURINE

SUSPENSION; ORAL

MERCAPTOPURINE

AB	HIKMA	20MG/ML	A216418	001	Feb 26, 2025	Feb	NFTG
AB	NOVA LABS LTD	20MG/ML	N205919	001	Apr 28, 2014	Feb	CFTG

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP	ACS DOBFAR	500MG/VIAL	A091404	001	Oct 26, 2011	Apr	CHRS
AP		1GM/VIAL	A091404	002	Oct 26, 2011	Apr	CHRS
	MERREM IV						
@ +	PFIZER	500MG/VIAL	N050706	003	Jun 21, 1996	Apr	DISC
@ +		1GM/VIAL	N050706	001	Jun 21, 1996	Apr	DISC

POWDER; INTRAVENOUS

MEROPENEM

AP	BROOKS STERISCIENCE	2GM/VIAL	A219084	001	Jun 23, 2025	Jun	NFTG
AP	HQ SPCLT PHARMA	2GM/VIAL	N215212	001	Jul 26, 2023	Jun	CFTG

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

MESALAMINE

AB	ANNORA PHARMA	375MG	A219864	001	Aug 13, 2025	Aug	NEWA
AB	NOVAST LABS	375MG	A218410	001	Aug 22, 2024	Sep	CAHN

ENEMA; RECTAL

MESALAMINE

AB	NOVITIUM PHARMA	4GM/60ML	A215269	001	Apr 16, 2025	Apr	NEWA
----	-----------------	----------	---------	-----	--------------	-----	------

SUPPOSITORY; RECTAL

MESALAMINE

AB	NORVIUM BIOSCIENCE	1GM	A204354	001	Nov 24, 2015	May	CAHN
AB	QUAGEN	1GM	A204354	001	Nov 24, 2015	Sep	CAHN
AB	RISING	1GM	A219028	001	Apr 14, 2025	Apr	NEWA

TABLET, DELAYED RELEASE; ORAL

MESALAMINE

AB	AMNEAL	800MG	A215067	001	Feb 18, 2025	Feb	NEWA
----	--------	-------	---------	-----	--------------	-----	------

MESNA

TABLET; ORAL

MESNA

AB	NOVAST LABS	400MG	A218871	001	Jan 13, 2025	Aug	CAHN
AB	RICONPHARMA LLC	400MG	A218871	001	Jan 13, 2025	Jan	NFTG

MESNEX

AB	BAXTER HLTHCARE	400MG	N020855	001	Mar 21, 2002	Jan	CFTG
----	-----------------	-------	---------	-----	--------------	-----	------

METAPROTERENOL SULFATE

SYRUP;ORAL

METAPROTERENOL SULFATE

! CHARTWELL 10MG/5ML A 073632 001 Jul 22, 1992 Sep CAHN

METAXALONE

TABLET;ORAL

METAXALONE

@ NOVAST LABS 800MG A 213836 001 Oct 21, 2020 Sep CAHN

+! PRIMUS PHARMS 640MG N 022503 001 Jun 01, 2015 Oct CMFD

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL

METFORMIN HYDROCHLORIDE

AB ANNORA PHARMA 500MG/5ML A 215008 001 Mar 13, 2025 Mar NEWA

AB BIONPHARMA 500MG/5ML A 219151 001 Apr 14, 2025 Apr NEWA

AB VISTAPHARM LLC 500MG/5ML A 212677 001 Aug 19, 2022 Jan CAHN

TABLET;ORAL

METFORMIN HYDROCHLORIDE

@ AARXION ANDA HLDING 500MG A 205330 001 Oct 31, 2017 Oct CAHN

@ 850MG A 205330 002 Oct 31, 2017 Oct CAHN

@ 1GM A 205330 003 Oct 31, 2017 Oct CAHN

>D> AB ANDA REPOSITORY 500MG A 076033 001 Jan 24, 2002 Dec CAHN

AB 500MG A 076033 001 Jan 24, 2002 Sep CAHN

>D> AB 850MG A 076033 002 Jan 24, 2002 Dec CAHN

AB 850MG A 076033 002 Jan 24, 2002 Sep CAHN

>D> AB 1GM A 076033 003 Jan 24, 2002 Dec CAHN

AB 1GM A 076033 003 Jan 24, 2002 Sep CAHN

@ APOTEX 500MG A 075984 001 Apr 23, 2002 Mar DISC

@ 500MG A 090666 001 Dec 07, 2011 Mar DISC

@ 850MG A 075984 002 Apr 23, 2002 Mar DISC

@ 850MG A 090666 002 Dec 07, 2011 Mar DISC

@ 1GM A 075984 003 Apr 23, 2002 Mar DISC

@ 1GM A 090666 003 Dec 07, 2011 Mar DISC

@ GLENMARK PHARMS LTD 500MG A 078170 001 May 23, 2008 Aug DISC

@ 850MG A 078170 002 May 23, 2008 Aug DISC

@ 1GM A 078170 003 May 23, 2008 Aug DISC

>A> AB SENORES PHARMS 500MG A 076033 001 Jan 24, 2002 Dec CAHN

>A> AB 850MG A 076033 002 Jan 24, 2002 Dec CAHN

>A> AB 1GM A 076033 003 Jan 24, 2002 Dec CAHN

TABLET, EXTENDED RELEASE;ORAL

FORTAMET

@ + ANDRX LABS LLC 1GM N 021574 002 Apr 27, 2004 Jul DISC

GLUMETZA

@ + SANTARUS INC 500MG N 021748 001 Jun 03, 2005 Nov DISC

@ + 1GM N 021748 002 Jun 03, 2005 Nov DISC

METFORMIN HYDROCHLORIDE

AB3 ! AJANTA PHARMA LTD 1GM A 213962 002 Mar 09, 2021 Nov CHRS

AB1 MEDICAP LABS 500MG A 202306 001 Feb 23, 2017 Feb CAHN

AB 750MG A 202306 002 Feb 23, 2017 Feb CAHN

AB2 MPP PHARMA 500MG A 203832 001 Dec 26, 2017 May CAHN

AB2 1GM A 203832 002 Dec 26, 2017 May CAHN

@ SUN PHARM 500MG A 202917 001 Aug 01, 2016 Jan DISC

@ 1GM A 202917 002 Aug 01, 2016 Jan DISC

@ SUN PHARM INDS (IN) 500MG A 077336 001 Feb 09, 2006 Oct DISC

@ 750MG A 077336 002 Feb 09, 2006 Sep DISC

@ TWI PHARMS 500MG A 213247 001 Sep 29, 2021 Oct DISC

@ 1GM A 213247 002 Sep 29, 2021 Oct DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB TORRENT PHARMS LTD 500MG;EQ 15MG BASE A 202001 001 Feb 13, 2013 May CMFD

AB 850MG;EQ 15MG BASE A 202001 002 Feb 13, 2013 May CMFD

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE

AB DR REDDYS LABS SA 500MG;EQ 5MG BASE A 207678 001 Aug 09, 2023 Jan CTNA

AB 1GM;EQ 2.5MG BASE A 207678 002 Aug 09, 2023 Jan CTNA

AB ! 1GM;EQ 5MG BASE A 207678 003 Aug 09, 2023 Jan CTNA

TABLET, EXTENDED RELEASE;ORAL

SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE

@	SUN PHARM	500MG;EQ 5MG BASE	A206081	001	Jul 31, 2023	Jul DISC
@		1GM;EQ 2.5MG BASE	A206081	002	Jul 31, 2023	Jul DISC
@		1GM;EQ 5MG BASE	A206081	003	Jul 31, 2023	Jul DISC

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

JANUMET

AB	+	MSD SUB MERCK	500MG;EQ 50MG BASE	N022044	001	Mar 30, 2007	Nov CFTG
AB	+	!	1GM;EQ 50MG BASE	N022044	002	Mar 30, 2007	Nov CFTG

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

AB		SANDOZ	500MG;EQ 50MG BASE	A202388	001	Dec 02, 2025	Nov NFTG
AB			1GM;EQ 50MG BASE	A202388	002	Dec 02, 2025	Nov NFTG

TABLET, EXTENDED RELEASE;ORAL

JANUMET XR

AB	+	MSD SUB MERCK	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	Jun CTEC
AB	+		500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	May CFTG
AB	+		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	Jun CTEC
AB	+		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	May CFTG
AB	+	!	1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	Jun CTEC
AB	+	!	1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	May CFTG

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

AB	@	ENDO OPERATIONS	500MG;EQ 50MG BASE	A204144	001	Jun 04, 2025	Jun DISC
AB			500MG;EQ 50MG BASE	A204144	001	Jun 04, 2025	May NFTG
AB	@		1GM;EQ 50MG BASE	A204144	002	Jun 04, 2025	Jun DISC
AB			1GM;EQ 50MG BASE	A204144	002	Jun 04, 2025	May NFTG
AB	@		1GM;EQ 100MG BASE	A204144	003	Jun 04, 2025	Jun DISC
AB			1GM;EQ 100MG BASE	A204144	003	Jun 04, 2025	May NFTG

METHADONE HYDROCHLORIDE

INJECTABLE; INJECTION

METHADONE HYDROCHLORIDE

AP		HIKMA	10MG/ML	A218609	001	May 05, 2025	Apr NEWA
----	--	-------	---------	---------	-----	--------------	----------

TABLET;ORAL

METHADONE HYDROCHLORIDE

AA		HIKMA	5MG	A088109	002	Mar 08, 1983	Jul CMS1
	@	VISTAPHARM LLC	10MG	A040241	002	May 29, 1998	Aug DISC

TABLET, FOR SUSPENSION;ORAL

METHADONE HYDROCHLORIDE

AA		VISTAPHARM LLC	40MG	A075082	001	Mar 25, 1998	Jan CAHN
----	--	----------------	------	---------	-----	--------------	----------

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

AB		ANDA REPOSITORY	25MG	A040062	001	Jan 27, 1994	Sep CAHN
AB		!	50MG	A040062	002	Jan 27, 1994	Sep CAHN

METHENAMINE HIPPURATE

TABLET;ORAL

HIPREX

AB	+	ESJAY PHARMA	1GM	N017681	001		Jul CMFD
	@ +		1GM	N017681	001		May DISC

METHENAMINE HIPPURATE

AB		ZYDUS LIFESCIENCES	1GM	A219661	001	Mar 10, 2025	Feb NEWA
----	--	--------------------	-----	---------	-----	--------------	----------

UREX

AB		QUAGEN	1GM	N016151	001		Jul CAHN
----	--	--------	-----	---------	-----	--	----------

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB		AIPING PHARM INC	5MG	A040547	001	Feb 18, 2005	Mar CAHN
AB			10MG	A040547	002	Feb 18, 2005	Mar CAHN
	@		20MG	A040547	004	Feb 18, 2005	Mar CAHN
AB		SQUARE PHARMS PLC	5MG	A218830	001	Feb 05, 2025	Aug CMFD
	@		5MG	A218830	001	Feb 05, 2025	Jul DISC
AB			5MG	A218830	001	Feb 05, 2025	Jan NEWA
AB			10MG	A218830	002	Feb 05, 2025	Aug CMFD
	@		10MG	A218830	002	Feb 05, 2025	Jul DISC
AB			10MG	A218830	002	Feb 05, 2025	Jan NEWA

METHOCARBAMOL

SOLUTION;IM-IV		METHOCARBAMOL					
@	PHARMOBEDIENT	1GM/10ML (100MG/ML)	A204404	001	Dec 05, 2014	Jun	CAHN
SUSPENSION;ORAL		ATMEKSI					
+	ROSEMONT PHARMS	750MG/5ML	N219843	001	Jul 30, 2025	Jul	NEWA
TABLET;ORAL		METHOCARBAMOL					
AA	BOSTAL	500MG	A200958	001	Oct 21, 2011	May	CAHN
AA		750MG	A200958	002	Oct 21, 2011	May	CAHN
AB	!	1GM	A200958	003	Dec 06, 2021	May	CAHN
AA	PHARMOBEDIENT	500MG	A203550	001	Feb 08, 2017	Sep	CAHN
AA		750MG	A203550	002	Feb 08, 2017	Sep	CAHN
AA	POINTVIEW HLDINGS	500MG	A212623	001	Apr 30, 2021	Apr	CAHN
AA		750MG	A212623	002	Apr 30, 2021	Apr	CAHN

METHOTREXATE

SOLUTION;SUBCUTANEOUS

OTREXUP

@ +	ASSERTIO SPECCLTY	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014	Aug	CAHN
@ +		10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013	Aug	CAHN
@ +		12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	Aug	CAHN
@ +		15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013	Aug	CAHN
@ +		17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	Aug	CAHN
@ +		20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013	Aug	CAHN
@ +		22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	Aug	CAHN
@ +		25MG/0.4ML (25MG/0.4ML)	N204824	004	Oct 11, 2013	Aug	CAHN
@ +	OTTER PHARMS	10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013	Jul	DISC
@ +		12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	Jul	DISC
@ +		15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013	Jul	DISC
@ +		17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	Jul	DISC
@ +		20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013	Jul	DISC
@ +		22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	Jul	DISC
@ +		25MG/0.4ML (25MG/0.4ML)	N204824	004	Oct 11, 2013	Jul	DISC

OTREXUP PFS

@ +	ASSERTIO SPECCLTY	10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017	Aug	CAHN
@ +		15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017	Aug	CAHN
@ +		17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017	Aug	CAHN
@ +		20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017	Aug	CAHN
@ +		22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017	Aug	CAHN
@ +		25MG/ML (25MG/ML)	N204824	014	May 31, 2017	Aug	CAHN

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A040843	003	Feb 27, 2012	Nov	CTEC
----	-----------------	-------------------------------------	---------	-----	--------------	-----	------

METHYLENE BLUE

SOLUTION;INTRAVENOUS

METHYLENE BLUE

>A>	AP	CHENGDU SHUDE	50MG/10ML (5MG/ML)	A219550	001	Dec 23, 2025	Dec	NEWA
	AP	HIKMA	50MG/10ML (5MG/ML)	A216959	001	Dec 17, 2024	Jan	CAHN
	AP	MEITHEAL	50MG/10ML (5MG/ML)	A217380	001	Jan 23, 2025	Jan	CAHN
	AP	NANJING KING-FRIEND	50MG/10ML (5MG/ML)	A217380	001	Jan 23, 2025	Jan	NEWA
	AP	XIROMED	50MG/10ML (5MG/ML)	A219363	001	Jul 30, 2025	Jul	NEWA

METHYLNALTREXONE BROMIDE

SOLUTION;SUBCUTANEOUS

METHYLNALTREXONE BROMIDE

@	ACTAVIS LLC	8MG/0.4ML (8MG/0.4ML)	A208112	001	Aug 26, 2024	Mar	DISC
@		12MG/0.6ML (12MG/0.6ML)	A208112	002	Aug 26, 2024	Mar	DISC
@	MYLAN LABS LTD	12MG/0.6ML (12MG/0.6ML)	A208592	001	May 28, 2025	Jun	DISC
AP		12MG/0.6ML (12MG/0.6ML)	A208592	001	May 28, 2025	May	NFTG
RELISTOR							
+	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Mar	CTEC
+		12MG/0.6ML (12MG/0.6ML)	N021964	001	Apr 24, 2008	Jun	CTEC
AP	+	12MG/0.6ML (12MG/0.6ML)	N021964	001	Apr 24, 2008	May	CFTG
	+	12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010	Mar	CTEC

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL  
COTEMPLA XR-ODT

@ +	NEOS THERAPS INC	34.6MG	N205489	004	Aug 19, 2024	Jun	DISC
+		34.6MG	N205489	004	Aug 19, 2024	Apr	CMFD

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@	ESJAY PHARMA	5MG/5ML	A201466	001	Nov 12, 2013	Feb	CAHN
@		10MG/5ML	A201466	002	Nov 12, 2013	Feb	CAHN
AA	HIBROW HLTHCARE	5MG/5ML	A210139	001	Oct 03, 2018	Sep	CAHN
AA		10MG/5ML	A210139	002	Oct 03, 2018	Sep	CAHN

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	ABHAI LLC	5MG	A206932	001	May 11, 2017	Nov	CAHN
AB		10MG	A206932	002	May 11, 2017	Nov	CAHN
AB		20MG	A206932	003	May 11, 2017	Nov	CAHN
@	MOUNTAIN	5MG	A091159	001	Mar 12, 2014	Nov	DISC
@		10MG	A091159	002	Mar 12, 2014	Nov	DISC
@		20MG	A091159	003	Mar 12, 2014	Nov	DISC
@	MPP PHARMA	5MG	A207587	001	Mar 03, 2017	Jun	CAHN
@		10MG	A207587	002	Mar 03, 2017	Jun	CAHN
@		20MG	A207587	003	Mar 03, 2017	Jun	CAHN

TABLET, CHEWABLE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

@	STRIDES PHARMA	2.5MG	A204954	001	Jan 26, 2017	Apr	CAHN
@		5MG	A204954	002	Jan 26, 2017	Apr	CAHN
@		10MG	A204954	003	Jan 26, 2017	Apr	CAHN

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	GRANULES	18MG	A213473	001	Jul 29, 2020	Sep	CAHN
AB		27MG	A213473	002	Jul 29, 2020	Sep	CAHN
AB		36MG	A213473	003	Jul 29, 2020	Sep	CAHN
AB		54MG	A213473	004	Jul 29, 2020	Sep	CAHN

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

>D>	@	INVATECH	4MG	A087341	001		Dec	CAHN
>A>	@	RISING	4MG	A087341	001		Dec	CAHN

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE ACETATE

AB	HIKMA	80MG/ML	A219145	001	Apr 16, 2025	Apr	NEWA
----	-------	---------	---------	-----	--------------	-----	------

METHYLTESTOSTERONE

TABLET;ORAL

ANDROID 25

@	BAUSCH	25MG	A087147	001		Apr	DISC
BP		25MG	A087147	001		Mar	CAHN

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

@	FRESENIUS KABI USA	EQ 5MG BASE/ML	A091392	001	Apr 19, 2013	Jul	DISC
---	--------------------	----------------	---------	-----	--------------	-----	------

SOLUTION;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@	VISTAPHARM LLC	EQ 5MG BASE/5ML	A075051	001	Jan 26, 2001	Jan	CAHN
---	----------------	-----------------	---------	-----	--------------	-----	------

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

@	IMPAX LABS INC	EQ 5MG BASE	A071250	002	Dec 28, 1995	Jul	DISC
@		EQ 10MG BASE	A071250	001	Feb 03, 1988	Jul	DISC

METOLAZONE

TABLET; ORAL  
METOLAZONE

AB		IXORA LIFESCIENCE	2.5MG	A 218606	001	Apr 17, 2024	Aug CAHN
AB			5MG	A 218606	002	Apr 17, 2024	Aug CAHN
AB			10MG	A 218606	003	Apr 17, 2024	Aug CAHN
AB		LEADING	2.5MG	A 218606	001	Apr 17, 2024	Jun CAHN
AB			5MG	A 218606	002	Apr 17, 2024	Jun CAHN
AB			10MG	A 218606	003	Apr 17, 2024	Jun CAHN
AB		RENATA	2.5MG	A 215616	001	Oct 24, 2022	Aug CAHN
AB			5MG	A 215616	002	Oct 24, 2022	Aug CAHN
AB			10MG	A 215616	003	Oct 24, 2022	Aug CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL  
METOPROLOL SUCCINATE

AB		IPCA LABS LTD	EQ 25MG TARTRATE	A 206980	001	Jun 25, 2025	Jun NEWA	
AB			EQ 50MG TARTRATE	A 206980	002	Jun 25, 2025	Jun NEWA	
AB			EQ 100MG TARTRATE	A 206980	003	Jun 25, 2025	Jun NEWA	
AB			EQ 200MG TARTRATE	A 206980	004	Jun 25, 2025	Jun NEWA	
		TOPROL-XL						
>A>	AB	+	MELINTA THERAP	EQ 25MG TARTRATE	N 019962	004	Feb 05, 2001	Dec CAHN
>A>	AB	+	!	EQ 50MG TARTRATE	N 019962	001	Jan 10, 1992	Dec CAHN
>A>	AB	+		EQ 100MG TARTRATE	N 019962	002	Jan 10, 1992	Dec CAHN
>A>	AB	+	!	EQ 200MG TARTRATE	N 019962	003	Jan 10, 1992	Dec CAHN
>D>	AB	+	TOPROL	EQ 25MG TARTRATE	N 019962	004	Feb 05, 2001	Dec CAHN
>D>	AB	+	!	EQ 50MG TARTRATE	N 019962	001	Jan 10, 1992	Dec CAHN
>D>	AB	+		EQ 100MG TARTRATE	N 019962	002	Jan 10, 1992	Dec CAHN
>D>	AB	+	!	EQ 200MG TARTRATE	N 019962	003	Jan 10, 1992	Dec CAHN

METOPROLOL TARTRATE

SOLUTION; ORAL  
LOPRESSOR

		+	RUBICON	10MG/ML	N 219373	001	Apr 10, 2025	Apr NEWA
			LOPRESSOR					
		+	XTM CONSULTING	12.5MG	N 218698	001	Aug 28, 2025	Aug NEWA
			METOPROLOL TARTRATE					
		@	PHARMOBEDIENT	50MG	A 073666	001	Dec 21, 1993	Jun CAHN
		@		100MG	A 073666	002	Dec 21, 1993	Jun CAHN
AB			RENATA	50MG	A 074453	001	Apr 27, 1995	Aug CAHN
AB				100MG	A 074453	002	Apr 27, 1995	Aug CAHN
AB			SCIEGEN PHARMS	25MG	A 208955	001	Feb 05, 2020	Jan CAHN
AB				50MG	A 208955	002	Feb 05, 2020	Jan CAHN
AB				100MG	A 208955	003	Feb 05, 2020	Jan CAHN
		@	SUN PHARM INDS INC	25MG	A 076670	001	Jan 15, 2004	Apr DISC

METRONIDAZOLE

CREAM; TOPICAL  
METROCREAM

AB		+	GALDERMA LABS LP	0.75%	N 020531	001	Sep 20, 1995	Jun CHRS
			METRONIDAZOLE					
AB			AUROBINDO PHARMA LTD	0.75%	A 219295	001	Jul 09, 2025	Jun NEWA
AB		!	FOUGERA PHARMS	0.75%	A 076408	001	May 28, 2004	Jun CHRS
BX			ZYDUS LIFESCIENCES	0.75%	A 217128	001	Apr 21, 2023	Mar CTEC

GEL; VAGINAL

		@	+	BAUSCH	0.75%	N 020208	001	Aug 17, 1992	Aug DISC
			!	ENCUBE	0.75%	A 215610	001	Jun 16, 2023	Aug CHRS
		@			1.3%	A 216795	001	Mar 18, 2024	Jan DISC
AB			SCIEGEN PHARMS	0.75%	A 216750	001	Dec 31, 2024	Sep CAHN	
			NUVESSA						
		+	!	CHEMO RESEARCH SL	1.3%	N 205223	001	Mar 24, 2014	Jan CTEC

INJECTABLE; INJECTION

		@		BAXTER HLTHCARE CORP	500MG/100ML	A 078084	001	Mar 31, 2008	Oct DISC
--	--	---	--	----------------------	-------------	----------	-----	--------------	----------

TABLET; ORAL

				METRONIDAZOLE					
>D>	AB			LUPIN LTD	250MG	A 209096	001	Sep 12, 2017	Dec DISC
>A>		@			250MG	A 209096	001	Sep 12, 2017	Dec DISC

TABLET;ORAL

METRONIDAZOLE

>D>	AB		500MG	A209096	002	Sep 12, 2017	Dec	DISC
>A>	@		500MG	A209096	002	Sep 12, 2017	Dec	DISC
>D>	AB	STRIDES PHARMA	250MG	A070040	001	Jan 29, 1985	Dec	DISC
>A>	@		250MG	A070040	001	Jan 29, 1985	Dec	DISC
>D>	AB		500MG	A070039	001	Jan 29, 1985	Dec	DISC
>A>	@		500MG	A070039	001	Jan 29, 1985	Dec	DISC

METYRAPONE

CAPSULE;ORAL

METOPIRONE

+! ESTEVE

250MG

N012911 002 Aug 09, 1996 Jul CAHN

TABLET;ORAL

METOPIRONE

@ ESTEVE

250MG

N012911 001 Jul CAHN

METYROSINE

CAPSULE;ORAL

METYROSINE

AB CEROVENE INC 250MG  
 AB DR REDDYS LABS SA 250MG

A218620 001 Apr 09, 2025 Mar NEWA  
 A218620 001 Apr 09, 2025 Sep CAHN

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL

MEXILETINE HYDROCHLORIDE

AB		IXORA LIFESCIENCE	150MG	A215876	001	Feb 27, 2023	Aug	CAHN
AB			200MG	A215876	002	Feb 27, 2023	Aug	CAHN
AB			250MG	A215876	003	Feb 27, 2023	Aug	CAHN
AB		LEADING	150MG	A215876	001	Feb 27, 2023	Oct	CAHN
AB			200MG	A215876	002	Feb 27, 2023	Oct	CAHN
AB			250MG	A215876	003	Feb 27, 2023	Oct	CAHN
AB		QUAGEN	150MG	A215876	001	Feb 27, 2023	Nov	CAHN
AB			200MG	A215876	002	Feb 27, 2023	Nov	CAHN
AB			250MG	A215876	003	Feb 27, 2023	Nov	CAHN

MICAFUNGIN SODIUM

INJECTABLE;INTRAVENOUS

MICAFUNGIN SODIUM

AP	!	FRESENIUS KABI USA	EQ 50MG BASE/VIAL	A207344	001	May 17, 2019	Nov	CHRS
AP	!		EQ 100MG BASE/VIAL	A207344	002	May 17, 2019	Nov	CHRS
AP		QILU PHARM HAINAN	EQ 50MG BASE/VIAL	A219273	001	Apr 03, 2025	Mar	NEWA
AP			EQ 100MG BASE/VIAL	A219273	002	Apr 03, 2025	Mar	NEWA
		MYCAMINE						
	@ +	ASTELLAS	EQ 50MG BASE/VIAL	N021506	002	Mar 16, 2005	Nov	DISC
	@ +		EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006	Nov	DISC

MIDAZOLAM

SOLUTION;INTRAVENOUS

MIDAZOLAM IN 0.8% SODIUM CHLORIDE

! B BRAUN MEDICAL 50MG/50ML (1MG/ML)  
 50MG/50ML (1MG/ML)  
 ! 100MG/100ML (1MG/ML)  
 100MG/100ML (1MG/ML)  
 STERINOVA INC 50MG/50ML (1MG/ML)  
 100MG/100ML (1MG/ML)

A218454 001 May 01, 2025 Jul CHRS  
 A218454 001 May 01, 2025 May CAHN  
 A218454 002 May 01, 2025 Jul CHRS  
 A218454 002 May 01, 2025 May CAHN  
 A218454 001 May 01, 2025 Apr NFTG  
 A218454 002 May 01, 2025 Apr NFTG

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

	@	EPIC PHARMA LLC	EQ 5MG BASE/ML	A075481	001	Jun 30, 2000	Jun	CAHN
AP		HIKMA	EQ 1MG BASE/ML	A212847	001	Dec 11, 2020	Jun	CAHN
AP			EQ 5MG BASE/ML	A212847	002	Dec 11, 2020	Jun	CAHN
AP		RISING	EQ 1MG BASE/ML	A075494	001	Jun 30, 2000	Jun	CAHN
AP			EQ 5MG BASE/ML	A075494	002	Jun 30, 2000	Jun	CAHN

SOLUTION;INTRAMUSCULAR

SEIZALAM

@ + MMT EQ 50MG BASE/10ML (EQ 5MG BASE/ML)

N209566 001 Sep 14, 2018 Jul DISC

MIDODRINE HYDROCHLORIDE

TABLET;ORAL		ORVATEN					
AB	BEIJING YILING	2.5MG	A 076725	001	Nov 03, 2004	Jun	CAHN
AB	!	5MG	A 076725	002	Nov 03, 2004	Jun	CAHN
AB		10MG	A 076725	003	Nov 03, 2004	Jun	CAHN

MIFEPRISTONE

TABLET;ORAL		MIFEPRISTONE					
AB	EVITA SOLUTIONS	200MG	A 216616	001	Sep 30, 2025	Sep	NEWA

MIGLITOL

TABLET;ORAL		GLYSET					
	@ + PFIZER	25MG	N 020682	001	Dec 18, 1996	Nov	DISC
	@ +	50MG	N 020682	002	Dec 18, 1996	Nov	DISC
	@ +	100MG	N 020682	003	Dec 18, 1996	Nov	DISC
TABLET;ORAL		MIGLITOL					
	! WESTMINSTER PHARMS	25MG	A 203965	001	Feb 24, 2015	Nov	CTEC
AB	!	25MG	A 203965	001	Feb 24, 2015	Nov	CHRS
		50MG	A 203965	002	Feb 24, 2015	Nov	CTEC
		100MG	A 203965	003	Feb 24, 2015	Nov	CTEC

MIGLUSTAT

CAPSULE;ORAL		MIGLUSTAT					
	@ CHARTWELL RX	100MG	A 209325	001	Feb 03, 2022	Mar	CAHN
AB	NAVINTA LLC	100MG	A 219111	001	Mar 14, 2025	Mar	NEWA
	@ VERANOVA	100MG	A 209325	001	Feb 03, 2022	Feb	CAHN

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL		MILNACIPRAN HYDROCHLORIDE					
	@ BRECKENRIDGE	12.5MG	A 205071	001	Jan 27, 2016	Sep	CAHN
		25MG	A 205071	002	Jan 27, 2016	Sep	CAHN
		50MG	A 205071	003	Jan 27, 2016	Sep	CAHN
		100MG	A 205071	004	Jan 27, 2016	Sep	CAHN
	@ CENTAUR PHARMS PVT	12.5MG	A 205071	001	Jan 27, 2016	Sep	CAHN
		25MG	A 205071	002	Jan 27, 2016	Sep	CAHN
		50MG	A 205071	003	Jan 27, 2016	Sep	CAHN
		100MG	A 205071	004	Jan 27, 2016	Sep	CAHN
	@ HETERO LABS LTD V	12.5MG	A 205147	001	Oct 03, 2024	Apr	DISC
		25MG	A 205147	002	Oct 03, 2024	Apr	DISC
		50MG	A 205147	003	Oct 03, 2024	Apr	DISC
		100MG	A 205147	004	Oct 03, 2024	Apr	DISC
TABLET;ORAL		SAVELLA					
	+ ABBVIE	12.5MG	N 022256	001	Jan 14, 2009	Apr	CTEC
	+	25MG	N 022256	002	Jan 14, 2009	Apr	CTEC
	+!	50MG	N 022256	003	Jan 14, 2009	Apr	CTEC
	+	100MG	N 022256	004	Jan 14, 2009	Apr	CTEC

MILRINONE LACTATE

INJECTABLE;INJECTION		MILRINONE LACTATE IN DEXTROSE 5%					
AP	CAPLIN	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A 219170	001	Sep 02, 2025	Aug	NEWA
AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A 219170	002	Sep 02, 2025	Aug	NEWA

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL		MINOCYCLINE HYDROCHLORIDE						
	@ SUN PHARM INDS INC	EQ 50MG BASE	A 090867	001	May 13, 2013	Oct	DISC	
		EQ 75MG BASE	A 090867	002	May 13, 2013	Oct	DISC	
		EQ 100MG BASE	A 090867	003	May 13, 2013	Oct	DISC	
CAPSULE, EXTENDED RELEASE;ORAL		EMROSI						
	+!	JOURNEY	EQ 40MG BASE	N 219015	001	Nov 01, 2024	Mar	CPOT

INJECTABLE; INJECTION

Code	Product Name	Strength	Manufacturer	NDA	Approval Date	Expiration Date	Status
	MINOCIN						
	+! REMPEX	EQ 100MG BASE/VIAL		N050444	001		May CTEC
	MINOCYCLINE HYDROCHLORIDE						
AP	NEXUS	EQ 100MG BASE/VIAL		A214934	001	Oct 24, 2024	Mar CAHN
	TABLET, EXTENDED RELEASE; ORAL						
	MINOCYCLINE HYDROCHLORIDE						
	@ SUN PHARM	EQ 45MG BASE		A204394	001	Dec 30, 2015	Aug DISC
	@	EQ 55MG BASE		A204394	002	Oct 07, 2022	Aug DISC
	@	EQ 65MG BASE		A204394	003	Oct 07, 2022	Aug DISC
	@	EQ 80MG BASE		A204394	004	Dec 30, 2015	Aug DISC
	@	EQ 105MG BASE		A204394	005	Dec 30, 2015	Aug DISC
	@	EQ 115MG BASE		A204394	006	Oct 07, 2022	Aug DISC
	@	EQ 135MG BASE		A204394	007	Dec 30, 2015	Aug DISC

MIRABEGRON

Code	Product Name	Strength	Manufacturer	NDA	Approval Date	Expiration Date	Status
	TABLET, EXTENDED RELEASE; ORAL						
	MIRABEGRON						
	@ APOTEX	25MG		A209434	001	Jan 02, 2025	May DISC
	@	50MG		A209434	002	Jan 02, 2025	May DISC
AB	ASCENT PHARMS INC	25MG		A218172	001	Sep 24, 2025	Sep NEWA
AB		50MG		A218172	002	Sep 24, 2025	Sep NEWA
AB	MSN	25MG		A218543	001	Nov 04, 2025	Oct NEWA
AB		50MG		A218543	002	Nov 04, 2025	Oct NEWA
AB	QILU	25MG		A217989	001	Jun 30, 2025	Jun NEWA
AB		50MG		A217989	002	Jun 30, 2025	Jun NEWA
	@ SAWAI USA	50MG		A217061	001	May 06, 2025	Jun DISC
AB		50MG		A217061	001	May 06, 2025	Apr NEWA

MIRDAMETINIB

Code	Product Name	Strength	Manufacturer	NDA	Approval Date	Expiration Date	Status
	CAPSULE; ORAL						
	GOMEKLI						
	+ SPRINGWORKS	1MG		N219389	001	Feb 11, 2025	Feb NEWA
	+!	2MG		N219389	002	Feb 11, 2025	Feb NEWA
	TABLET, FOR SUSPENSION; ORAL						
	GOMEKLI						
	+! SPRINGWORKS	1MG		N219379	001	Feb 11, 2025	Feb NEWA

MIRTAZAPINE

Code	Product Name	Strength	Manufacturer	NDA	Approval Date	Expiration Date	Status
	TABLET; ORAL						
	MIRTAZAPINE						
AB	ANNORA PHARMA	7.5MG		A219721	001	Oct 02, 2025	Sep NEWA
AB		15MG		A219721	002	Oct 02, 2025	Sep NEWA
AB		30MG		A219721	003	Oct 02, 2025	Sep NEWA
AB		45MG		A219721	004	Oct 02, 2025	Sep NEWA
	TABLET, ORALLY DISINTEGRATING; ORAL						
	MIRTAZAPINE						
>D>	ACME LABS	15MG		A205798	001	Jun 01, 2017	Dec CAHN
AB		15MG		A205798	001	Jun 01, 2017	Sep CAHN
>D>	AB	30MG		A205798	002	Jun 01, 2017	Dec CAHN
AB		30MG		A205798	002	Jun 01, 2017	Sep CAHN
>D>	AB	45MG		A205798	003	Jun 01, 2017	Dec CAHN
AB		45MG		A205798	003	Jun 01, 2017	Sep CAHN
>A>	SQUARE PHARMS PLC	15MG		A205798	001	Jun 01, 2017	Dec CAHN
>A>	AB	30MG		A205798	002	Jun 01, 2017	Dec CAHN
>A>	AB	45MG		A205798	003	Jun 01, 2017	Dec CAHN

MITOMYCIN

Code	Product Name	Strength	Manufacturer	NDA	Approval Date	Expiration Date	Status
	FOR SOLUTION; TOPICAL						
	MITOSOL						
	+! GLAUKOS	0.2MG/VIAL		N022572	001	Feb 07, 2012	Aug CAHN
	INJECTABLE; INJECTION						
	MITOMYCIN						
AP	ACCORD HLTHCARE	20MG/VIAL		A064144	002	Apr 30, 1998	Apr CMFD
	@	20MG/VIAL		A064144	002	Apr 30, 1998	Jan DISC
	@ EUGIA PHARMA	5MG/VIAL		A216732	001	Oct 30, 2023	Aug DISC
	@	20MG/VIAL		A216732	002	Oct 30, 2023	Aug DISC
	@	40MG/VIAL		A216732	003	Oct 30, 2023	Aug DISC
AP	! MEITHEAL	20MG/VIAL		A214505	002	Sep 08, 2022	Jan CHRS
	POWDER; INTRAVESICAL						
	ZUSDURI						
	+! UROGEN PHARMA	40MG/VIAL		N215793	001	Jun 12, 2025	Jun NEWA

MITOTANE

TABLET;ORAL

LYSODREN

	+	!	ESTEVE	500MG	N016885	001			Jul	CAHN
--	---	---	--------	-------	---------	-----	--	--	-----	------

MODAFINIL

TABLET;ORAL

MODAFINIL

	@		WATSON LABS INC	100MG	A076715	001	Nov 01, 2012		Jun	DISC
--	---	--	-----------------	-------	---------	-----	--------------	--	-----	------

	@			200MG	A076715	002	Nov 01, 2012		Jun	DISC
--	---	--	--	-------	---------	-----	--------------	--	-----	------

PROVIGIL

AB		+	NUVO PHARMS	100MG	N020717	001	Dec 24, 1998		Jan	CAHN
----	--	---	-------------	-------	---------	-----	--------------	--	-----	------

AB		+	!	200MG	N020717	002	Dec 24, 1998		Jan	CAHN
----	--	---	---	-------	---------	-----	--------------	--	-----	------

MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

MOEXIPRIL HYDROCHLORIDE

	@		APOTEX INC	7.5MG	A078454	001	Jun 02, 2008		Mar	DISC
--	---	--	------------	-------	---------	-----	--------------	--	-----	------

	@			15MG	A078454	002	Jun 02, 2008		Mar	DISC
--	---	--	--	------	---------	-----	--------------	--	-----	------

MOMETASONE FUROATE

CREAM;TOPICAL

MOMETASONE FUROATE

AB		@	CHARTWELL MOLECULAR	0.1%	A076591	001	Apr 18, 2007		Feb	CAHN
----	--	---	---------------------	------	---------	-----	--------------	--	-----	------

	!		COSETTE	0.1%	A077447	001	May 22, 2006		Jun	CHRS
--	---	--	---------	------	---------	-----	--------------	--	-----	------

	@		GLENMARK PHARMS INC	0.1%	A078541	001	May 28, 2008		Jun	DISC
--	---	--	---------------------	------	---------	-----	--------------	--	-----	------

LOTION;TOPICAL

MOMETASONE FUROATE

	@		GLENMARK PHARMS LTD	0.1%	A090506	001	Aug 09, 2010		Jul	DISC
--	---	--	---------------------	------	---------	-----	--------------	--	-----	------

	@		SUN PHARMA CANADA	0.1%	A076788	001	Mar 15, 2006		Sep	CAHN
--	---	--	-------------------	------	---------	-----	--------------	--	-----	------

	@		TARO	0.1%	A076788	001	Mar 15, 2006		Aug	DISC
--	---	--	------	------	---------	-----	--------------	--	-----	------

OINTMENT;TOPICAL

MOMETASONE FUROATE

AB		@	GLENMARK PHARMS INC	0.1%	A078571	001	May 28, 2008		Jun	DISC
----	--	---	---------------------	------	---------	-----	--------------	--	-----	------

	!		PADAGIS US	0.1%	A076067	001	Mar 18, 2002		Jun	CHRS
--	---	--	------------	------	---------	-----	--------------	--	-----	------

POWDER;INHALATION

ASMANEX TWISTHALER

>D>		+	ORGANON LLC	0.11MG/INH	N021067	002	Feb 01, 2008		Dec	CHRS
-----	--	---	-------------	------------	---------	-----	--------------	--	-----	------

>A>		+	!	0.11MG/INH	N021067	002	Feb 01, 2008		Dec	CHRS
-----	--	---	---	------------	---------	-----	--------------	--	-----	------

SPRAY, METERED;NASAL

MOMETASONE FUROATE

AB		@	NASPRESS	0.05MG/SPRAY	A211706	001	May 15, 2025		Oct	DISC
----	--	---	----------	--------------	---------	-----	--------------	--	-----	------

				0.05MG/SPRAY	A211706	001	May 15, 2025		May	NEWA
--	--	--	--	--------------	---------	-----	--------------	--	-----	------

MONTELUKAST SODIUM

TABLET;ORAL

MONTELUKAST SODIUM

AB			PHARMOBEDIANT	EQ 10MG BASE	A202859	001	Oct 30, 2014		Sep	CAHN
----	--	--	---------------	--------------	---------	-----	--------------	--	-----	------

AB			SANDOZ INC	EQ 10MG BASE	A200889	001	Aug 03, 2012		Sep	CMFD
----	--	--	------------	--------------	---------	-----	--------------	--	-----	------

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

	@		AIPING PHARM INC	EQ 4MG BASE	A091414	001	Aug 03, 2012		Oct	CAHN
--	---	--	------------------	-------------	---------	-----	--------------	--	-----	------

	@			EQ 5MG BASE	A091414	002	Aug 03, 2012		Oct	CAHN
--	---	--	--	-------------	---------	-----	--------------	--	-----	------

	@		NEW HEIGHTSRX	EQ 4MG BASE	A091588	001	Aug 03, 2012		Aug	CAHN
--	---	--	---------------	-------------	---------	-----	--------------	--	-----	------

	@			EQ 5MG BASE	A091588	002	Aug 03, 2012		Aug	CAHN
--	---	--	--	-------------	---------	-----	--------------	--	-----	------

	@		PHARMACO	EQ 4MG BASE	A091588	001	Aug 03, 2012		Sep	CAHN
--	---	--	----------	-------------	---------	-----	--------------	--	-----	------

	@			EQ 5MG BASE	A091588	002	Aug 03, 2012		Sep	CAHN
--	---	--	--	-------------	---------	-----	--------------	--	-----	------

AB			PHARMOBEDIANT	EQ 4MG BASE	A203037	001	Oct 30, 2014		Sep	CAHN
----	--	--	---------------	-------------	---------	-----	--------------	--	-----	------

AB				EQ 5MG BASE	A203037	002	Oct 30, 2014		Sep	CAHN
----	--	--	--	-------------	---------	-----	--------------	--	-----	------

AB			UNICHEM	EQ 4MG BASE	A208621	001	Jul 02, 2018		Aug	CMFD
----	--	--	---------	-------------	---------	-----	--------------	--	-----	------

AB				EQ 5MG BASE	A208621	002	Jul 02, 2018		Aug	CMFD
----	--	--	--	-------------	---------	-----	--------------	--	-----	------

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

	@		ANDA REPOSITORY	20MG	A203158	001	Aug 04, 2021		Sep	CAHN
--	---	--	-----------------	------	---------	-----	--------------	--	-----	------

	@			30MG	A203158	002	Aug 04, 2021		Sep	CAHN
--	---	--	--	------	---------	-----	--------------	--	-----	------

	@			50MG	A203158	003	Aug 04, 2021		Sep	CAHN
--	---	--	--	------	---------	-----	--------------	--	-----	------

	@			60MG	A203158	004	Aug 04, 2021		Sep	CAHN
--	---	--	--	------	---------	-----	--------------	--	-----	------

	@			80MG	A203158	005	Aug 04, 2021		Sep	CAHN
--	---	--	--	------	---------	-----	--------------	--	-----	------

	@			100MG	A203158	006	Aug 04, 2021		Sep	CAHN
--	---	--	--	-------	---------	-----	--------------	--	-----	------

<u>SOLUTION;ORAL</u>								
<u>MORPHINE SULFATE</u>								
AA	+	HIKMA	20MG/5ML	N022195	002	Mar 17, 2008	Apr CTEC	
	+		20MG/5ML	N022195	002	Mar 17, 2008	Feb CTEC	
AA		PHARM ASSOC	10MG/5ML	A206573	002	Sep 12, 2023	Jun CMFD	
AA			100MG/5ML	A206573	001	Nov 14, 2016	Jun CMFD	
	@	RHODES PHARMS	10MG/5ML	A206308	001	Jun 22, 2017	Jan DISC	
	@		20MG/5ML	A206420	001	Jul 12, 2016	Jan DISC	
	@		100MG/5ML	A206308	002	Jun 22, 2017	Jan DISC	
	@	SANKALP LIFECARE	10MG/5ML	A201011	001	Feb 05, 2014	Apr CAHN	
	@		20MG/5ML	A201011	002	Feb 05, 2014	Apr CAHN	
	@		100MG/5ML	A201011	003	Oct 06, 2016	Apr CAHN	
AA		WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021	Apr CMFD	
	@		10MG/5ML	A211454	001	Feb 12, 2021	Feb DISC	
AA			20MG/5ML	A211454	002	Feb 12, 2021	Apr CMFD	
	@		20MG/5ML	A211454	002	Feb 12, 2021	Feb DISC	
AA			100MG/5ML	A211454	003	Feb 12, 2021	Apr CMFD	
	@		100MG/5ML	A211454	003	Feb 12, 2021	Feb DISC	
<u>TABLET;ORAL</u>								
<u>MORPHINE SULFATE</u>								
AB	+	HIKMA	15MG	N022207	001	Mar 17, 2008	Jun CAHN	
AB	+	!	30MG	N022207	002	Mar 17, 2008	Jun CAHN	
<u>TABLET, EXTENDED RELEASE;ORAL</u>								
<u>MORPHINE SULFATE</u>								
	@	NOVEL LABS INC	15MG	A203602	001	Dec 16, 2015	Feb DISC	
	@		30MG	A203602	002	Dec 16, 2015	Feb DISC	
	@		60MG	A203602	003	Dec 16, 2015	Feb DISC	
	@		100MG	A203602	004	Dec 16, 2015	Feb DISC	
	@		200MG	A203602	005	Dec 16, 2015	Feb DISC	
<u>MOTIXAFORTIDE ACETATE</u>								
<u>POWDER;SUBCUTANEOUS</u>								
<u>APHEXDA</u>								
	+	!	AYRMID PHARMA	EQ 62MG BASE/VIAL	N217159	001	Sep 08, 2023	Mar CAHN
<u>MOXIFLOXACIN HYDROCHLORIDE</u>								
<u>SOLUTION/DROPS;OPHTHALMIC</u>								
<u>MOXIFLOXACIN HYDROCHLORIDE</u>								
AT1		FDC LTD	EQ 0.5% BASE	A219475	001	Aug 04, 2025	Jul NEWA	
AT1		MANKIND PHARMA	EQ 0.5% BASE	A217988	001	Jan 27, 2025	Jan NEWA	
	@	NORVIUM BIOSCIENCE	EQ 0.5% BASE	A206447	001	Mar 30, 2020	Feb CAHN	
AT1		REGCON HOLDINGS	EQ 0.5% BASE	A202525	001	Mar 06, 2015	Sep CAHN	
<u>TABLET;ORAL</u>								
<u>MOXIFLOXACIN HYDROCHLORIDE</u>								
AB		SUNSHINE	EQ 400MG BASE	A206295	001	Sep 28, 2018	Oct CMFD	
AB		TORRENT	EQ 400MG BASE	A200160	001	Apr 03, 2014	Sep CMFD	
<u>MUPIROCIN</u>								
<u>OINTMENT;TOPICAL</u>								
<u>MUPIROCIN</u>								
AB		ENCUBE	2%	A217943	001	May 13, 2025	May NEWA	
AB		SUN PHARMA CANADA	2%	A065170	001	Sep 23, 2005	Sep CAHN	
<u>MUPIROCIN CALCIUM</u>								
<u>CREAM;TOPICAL</u>								
<u>MUPIROCIN</u>								
BX		ALEMBIC	EQ 2% BASE	A213053	001	Nov 16, 2021	Mar CTEC	
<u>MYCOPHENOLATE MOFETIL</u>								
<u>FOR SUSPENSION;ORAL</u>								
<u>MYCOPHENOLATE MOFETIL</u>								
	@	TEVA PHARMS USA	200MG/ML	A211272	001	Jan 25, 2022	Apr DISC	
AB		VISTAPHARM LLC	200MG/ML	A210370	001	Feb 12, 2019	Jan CAHN	
<u>MYCOPHENOLATE SODIUM</u>								
<u>TABLET, DELAYED RELEASE;ORAL</u>								
<u>MYCOPHENOLATE SODIUM</u>								
AB		ACCORD HLTHCARE	EQ 180MG BASE	A202555	001	Aug 23, 2017	Aug CAIN	
AB			EQ 360MG BASE	A202555	002	Aug 23, 2017	Aug CAIN	
AB		ALKEM LABS LTD	EQ 180MG BASE	A208315	001	Sep 23, 2021	Aug CAIN	
AB			EQ 360MG BASE	A208315	002	Sep 23, 2021	Aug CAIN	
AB		APOTEX INC	EQ 180MG BASE	A091558	001	Aug 21, 2012	Aug CAIN	

TABLET, DELAYED RELEASE;ORAL  
MYCOPHENOLATE SODIUM

AB		EQ 360MG BASE	A091558	002	Aug 19, 2014	Aug	CAIN
AB	AUROBINDO PHARMA LTD	EQ 180MG BASE	A218603	001	Feb 27, 2024	Aug	CAIN
AB		EQ 360MG BASE	A218603	002	Feb 27, 2024	Aug	CAIN
AB	BIOCON PHARMA	EQ 180MG BASE	A214630	001	Nov 29, 2021	Aug	CAIN
AB		EQ 180MG BASE	A217031	001	Nov 29, 2023	Aug	CAIN
AB		EQ 360MG BASE	A214630	002	Nov 29, 2021	Aug	CAIN
AB		EQ 360MG BASE	A217031	002	Nov 29, 2023	Aug	CAIN
AB	CONCORD BIOTECH LTD	EQ 180MG BASE	A211173	001	Dec 13, 2019	Aug	CAIN
AB		EQ 360MG BASE	A211173	002	Dec 13, 2019	Aug	CAIN
AB	FOSUN WANBANG	EQ 180MG BASE	A216637	001	May 29, 2024	Aug	CAIN
AB		EQ 360MG BASE	A216637	002	May 29, 2024	Aug	CAIN
AB	RK PHARMA	EQ 180MG BASE	A091248	002	Jan 08, 2014	Aug	CAIN
AB		EQ 360MG BASE	A091248	001	Jan 08, 2014	Aug	CAIN
	@ TEVA PHARMS USA	EQ 180MG BASE	A202720	001	Oct 30, 2014	Aug	CAIN
	@	EQ 360MG BASE	A202720	002	Oct 30, 2014	Aug	CAIN
AB	TWI PHARMS	EQ 180MG BASE	A214289	001	Nov 03, 2021	Aug	CAIN
AB		EQ 360MG BASE	A214289	002	Nov 03, 2021	Aug	CAIN
AB	YICHANG HUMANWELL	EQ 180MG BASE	A214376	001	Feb 10, 2021	Aug	CAIN
AB		EQ 360MG BASE	A214376	002	Feb 10, 2021	Aug	CAIN
	MYFORTIC						
AB	+ NOVARTIS	EQ 180MG BASE	N050791	001	Feb 27, 2004	Aug	CAIN
AB	+!	EQ 360MG BASE	N050791	002	Feb 27, 2004	Aug	CAIN

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE;ORAL  
MYCOPHENOLIC SODIUM

AB	FOSUN WANBANG	EQ 180MG BASE	A216637	001	May 29, 2024	Jan	CAHN
AB		EQ 360MG BASE	A216637	002	May 29, 2024	Jan	CAHN
AB	YICHANG HUMANWELL	EQ 180MG BASE	A214376	001	Feb 10, 2021	Jul	CAHN
AB		EQ 360MG BASE	A214376	002	Feb 10, 2021	Jul	CAHN

NABUMETONE

TABLET;ORAL  
NABUMETONE

	@ MPP PHARMA	500MG	A090427	001	Dec 30, 2011	Jun	CAHN
	@	750MG	A090427	002	Dec 30, 2011	Jun	CAHN

NAFCILLIN SODIUM

INJECTABLE; INJECTION  
NAFCILLIN SODIUM

	@ FRESENIUS	EQ 10GM BASE/VIAL	A206761	001	Jun 02, 2020	Apr	DISC
--	-------------	-------------------	---------	-----	--------------	-----	------

NALBUPHINE HYDROCHLORIDE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS  
NALBUPHINE

	@ ABRAXIS PHARM	10MG/ML (10MG/ML)	A070751	001	Jul 02, 1986	Mar	CPOT
	@	10MG/ML	A070751	001	Jul 02, 1986	Mar	CDFR
	@	20MG/ML (20MG/ML)	A070752	001	Sep 24, 1986	Mar	CPOT
	@	20MG/ML	A070752	001	Sep 24, 1986	Mar	CDFR
	@	200MG/10ML (20MG/ML)	A070752	002	Sep 24, 1986	Mar	NEWA
	NALBUPHINE HYDROCHLORIDE						
	@ ABBOTT	20MG/ML (20MG/ML)	A070917	001	Feb 03, 1989	Mar	CPOT
	@	20MG/ML	A070917	001	Feb 03, 1989	Mar	CDFR
	@ ABRAXIS PHARM	100MG/10ML (10MG/ML)	A070751	002	Jul 02, 1986	Mar	NEWA
	@ DR REDDYS	10MG/ML	A074471	001	Mar 19, 1998	Mar	CDFR
	@	20MG/ML	A074471	002	Mar 19, 1998	Mar	CDFR
	@	100MG/10ML (10MG/ML)	A074471	001	Mar 19, 1998	Mar	CPOT
	@	200MG/10ML (20MG/ML)	A074471	002	Mar 19, 1998	Mar	CPOT
AP	! HOSPIRA	10MG/ML (10MG/ML)	A070914	001	Feb 03, 1989	Mar	CPOT
AP	!	10MG/ML	A070914	001	Feb 03, 1989	Mar	CDFR
AP	!	10MG/ML	A070915	001	Feb 03, 1989	Mar	CDFR
AP	!	20MG/ML (20MG/ML)	A070916	001	Feb 03, 1989	Mar	CPOT
AP	!	20MG/ML	A070916	001	Feb 03, 1989	Mar	CDFR
AP	!	20MG/ML	A070918	001	Feb 03, 1989	Mar	CDFR
AP	!	100MG/10ML (10MG/ML)	A070915	001	Feb 03, 1989	Mar	CPOT
AP	!	200MG/10ML (20MG/ML)	A070918	001	Feb 03, 1989	Mar	CPOT
	@ IGI LABS INC	10MG/ML (10MG/ML)	A072070	001	Apr 10, 1989	Mar	CPOT
	@	10MG/ML	A072070	001	Apr 10, 1989	Mar	CDFR
	@	10MG/ML (10MG/ML)	A072071	001	Apr 10, 1989	Mar	CPOT
	@	10MG/ML	A072071	001	Apr 10, 1989	Mar	CDFR
	@	10MG/ML (10MG/ML)	A072072	001	Apr 10, 1989	Mar	CPOT

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS  
NALBUPHINE HYDROCHLORIDE

@		10MG/ML	A072072	001	Apr 10, 1989	Mar	CDFR
@		20MG/ML (20MG/ML)	A072073	001	Apr 10, 1989	Mar	CPOT
@		20MG/ML	A072073	001	Apr 10, 1989	Mar	CDFR
@		20MG/ML (20MG/ML)	A072074	001	Apr 10, 1989	Mar	CPOT
@		20MG/ML	A072074	001	Apr 10, 1989	Mar	CDFR
@		20MG/ML (20MG/ML)	A072075	001	Apr 10, 1989	Mar	CPOT
@		20MG/ML	A072075	001	Apr 10, 1989	Mar	CDFR
@		100MG/10ML (10MG/ML)	A072070	002	Apr 10, 1989	Mar	NEWA
@		200MG/10ML (20MG/ML)	A072073	002	Apr 10, 1989	Mar	NEWA
@	RISING	10MG/ML	A206506	001	Feb 06, 2019	Mar	CDFR
@		10MG/ML (10MG/ML)	A207595	001	Jan 11, 2019	Mar	CPOT
@		10MG/ML	A207595	001	Jan 11, 2019	Mar	CDFR
@		20MG/ML	A206506	002	Feb 06, 2019	Mar	CDFR
@		20MG/ML (20MG/ML)	A207595	002	Jan 11, 2019	Mar	CPOT
@		20MG/ML	A207595	002	Jan 11, 2019	Mar	CDFR
@		100MG/10ML (10MG/ML)	A206506	001	Feb 06, 2019	Mar	CPOT
@		200MG/10ML (20MG/ML)	A206506	002	Feb 06, 2019	Mar	CPOT
AP	SOMERSET THERAPS LLC	10MG/ML	A216049	001	Sep 19, 2024	Mar	CDFR
AP		10MG/ML (10MG/ML)	A216050	001	Sep 19, 2024	Mar	CPOT
AP		10MG/ML	A216050	001	Sep 19, 2024	Mar	CDFR
AP		20MG/ML	A216049	002	Sep 19, 2024	Mar	CDFR
AP		20MG/ML (20MG/ML)	A216050	002	Sep 19, 2024	Mar	CPOT
AP		20MG/ML	A216050	002	Sep 19, 2024	Mar	CDFR
AP		100MG/10ML (10MG/ML)	A216049	001	Sep 19, 2024	Mar	CPOT
AP		200MG/10ML (20MG/ML)	A216049	002	Sep 19, 2024	Mar	CPOT

NUBAIN

@ +	ENDO OPERATIONS	10MG/ML	N018024	001		Mar	CDFR
@ +		10MG/ML (10MG/ML)	N018024	001		Mar	CPOT
@ +		20MG/ML	N018024	002	May 27, 1982	Mar	CDFR
@ +		20MG/ML (20MG/ML)	N018024	002	May 27, 1982	Mar	CPOT
@ +		20MG/2ML (10MG/ML)	N018024	004		Mar	NEWA
@ +		100MG/10ML (10MG/ML)	N018024	003		Mar	NEWA
@ +		200MG/10ML (20MG/ML)	N018024	005	Mar 02, 1984	Mar	NEWA
@ +	PH HEALTH	10MG/ML (10MG/ML)	N018024	001		Jul	CAHN
@ +		20MG/ML (20MG/ML)	N018024	002	May 27, 1982	Jul	CAHN
@ +		20MG/2ML (10MG/ML)	N018024	004		Jul	CAHN
@ +		100MG/10ML (10MG/ML)	N018024	003		Jul	CAHN
@ +		200MG/10ML (20MG/ML)	N018024	005	Mar 02, 1984	Jul	CAHN

NALMEFENE HYDROCHLORIDE

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS  
ZURNAI (AUTOINJECTOR)

+!	PURDUE PHARMA LP	EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	Sep	CMFD
@ +		EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	Jan	DISC

NALOXEGOL OXALATE

TABLET;ORAL  
MOVANTIK

+	AVERITAS	EQ 12.5MG BASE	N204760	001	Sep 16, 2014	Sep	CAHN
+!		EQ 25MG BASE	N204760	002	Sep 16, 2014	Sep	CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HYDROCHLORIDE

AP	BAXTER HLTHCARE CORP	1MG/ML	A214785	002	Jun 03, 2025	May	NEWA
@	PH HEALTH	0.4MG/ML	A211286	001	Jan 17, 2020	Jul	CAHN
AP	STERINOVA INC	0.4MG/ML	A214211	001	Aug 21, 2025	Aug	NEWA

SPRAY;NASAL

KLOXXADO

+	HIKMA	4MG/SPRAY	N212045	002	Aug 25, 2025	Aug	NEWA
+!		8MG/SPRAY	N212045	001	Apr 29, 2021	May	CTEC
AB		8MG/SPRAY	N212045	001	Apr 29, 2021	Apr	CFTG

NALOXONE HYDROCHLORIDE

@	PADAGIS ISRAEL	8MG/SPRAY	A216719	001	Apr 24, 2025	May	DISC
AB		8MG/SPRAY	A216719	001	Apr 24, 2025	Apr	NFTG

REZENOPY

@ +	SCIENTURE	10MG/SPRAY	N215487	001	Apr 19, 2024	Aug	CAHN
@ +	SUMMIT BIOSCI	10MG/SPRAY	N215487	001	Apr 19, 2024	Jul	DISC

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

@	ALLIED	50MG	A 075434	001	Mar 08, 2000	Jul	CAHN
@	ESJAY PHARMA	50MG	A 075434	001	Mar 08, 2000	Jul	CAHN

NAPROXEN

SUSPENSION; ORAL

NAPROXEN

AB	AUROBINDO PHARMA	25MG/ML	A 216504	001	Oct 03, 2025	Sep	NEWA
----	------------------	---------	----------	-----	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

AB	AUROBINDO PHARMA USA	375MG	A 075390	001	Apr 19, 2001	Aug	CMFD
AB		500MG	A 075390	002	Apr 19, 2001	Aug	CMFD

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	EQ 2.5MG BASE	A 212661	001	Jan 28, 2025	Jan	NEWA
AB		EQ 5MG BASE	A 212661	002	Jan 28, 2025	Jan	NEWA
AB		EQ 10MG BASE	A 212661	003	Jan 28, 2025	Jan	NEWA
AB		EQ 20MG BASE	A 212661	004	Jan 28, 2025	Jan	NEWA

NELARABINE

INJECTABLE; INTRAVENOUS

NELARABINE

!	SHORLA	375MG/75ML (5MG/ML)	A 214809	002	Jul 16, 2025	Jul	NFTG
---	--------	---------------------	----------	-----	--------------	-----	------

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

AA	AARXION ANDA HLDING	500MG	A 065220	001	Jul 28, 2006	Sep	CAHN
@	AVIV PHARMA	500MG	A 065468	001	Mar 29, 2010	May	CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

>D>									
>D>	AP	+!	EXELA PHARMA	5MG/10ML (0.5MG/ML)	N 204078	001	May 31, 2013	Dec	DISC
>A>		@ +		5MG/10ML (0.5MG/ML)	N 204078	001	May 31, 2013	Dec	DISC
>D>	AP	+!		10MG/10ML (1MG/ML)	N 204078	002	May 31, 2013	Dec	DISC
>A>		@ +		10MG/10ML (1MG/ML)	N 204078	002	May 31, 2013	Dec	DISC

NEOSTIGMINE METHYLSULFATE

AP	AVET LIFESCIENCES	5MG/10ML (0.5MG/ML)	A 208230	001	Nov 25, 2022	May	CTNA
AP		10MG/10ML (1MG/ML)	A 208230	002	Nov 25, 2022	May	CTNA
>D>	AP	HIKMA	A 207042	001	Dec 28, 2015	Dec	CHRS
>A>	AP	!	A 207042	001	Dec 28, 2015	Dec	CHRS
>D>	AP		A 207042	002	Dec 28, 2015	Dec	CHRS
>A>	AP	!	A 207042	002	Dec 28, 2015	Dec	CHRS
AP	REGCON HOLDINGS	5MG/10ML (0.5MG/ML)	A 210652	001	Oct 01, 2021	Sep	CAHN
AP		10MG/10ML (1MG/ML)	A 210652	002	Oct 01, 2021	Sep	CAHN

NERANDOMILAST

TABLET; ORAL

JASCAYD

>A>		+	BOEHRINGER INGELHEIM	9MG	N 218764	001	Oct 07, 2025	Oct	NEWA
		+		9MG	N 220449	001	Dec 19, 2025	Dec	NEWA
		+!		18MG	N 218764	002	Oct 07, 2025	Oct	NEWA
>A>		+!		18MG	N 220449	002	Dec 19, 2025	Dec	NEWA

NEVIRAPINE

TABLET; ORAL

NEVIRAPINE

>D>	AB	@	PHARMOBEDIENT	200MG	A 078864	001	May 22, 2012	Sep	CAHN
>A>		@	STRIDES PHARMA	200MG	A 078195	001	May 22, 2012	Dec	DISC
		@		200MG	A 078195	001	May 22, 2012	Dec	DISC

NIACIN

TABLET, EXTENDED RELEASE;ORAL  
NIACIN

AB	MPP PHARMA	500MG	A207726	001	Jul 25, 2025	Jul	NEWA
AB		750MG	A207726	002	Jul 25, 2025	Jul	NEWA
AB		1GM	A207726	003	Jul 25, 2025	Jul	NEWA
	@ ZYDUS PHARMS	500MG	A203285	001	Apr 28, 2025	Sep	DISC
AB		500MG	A203285	001	Apr 28, 2025	Apr	NEWA
	@	750MG	A203285	002	Apr 28, 2025	Sep	DISC
AB		750MG	A203285	002	Apr 28, 2025	Apr	NEWA
	@	1GM	A203285	003	Apr 28, 2025	Sep	DISC
AB		1GM	A203285	003	Apr 28, 2025	Apr	NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL  
NICARDIPINE HYDROCHLORIDE

AB	AMNEAL	20MG	A218202	001	Apr 10, 2024	Sep	CAHN
AB		30MG	A218202	002	Apr 10, 2024	Sep	CAHN
AB	NAVINTA LLC	20MG	A218638	001	Jun 25, 2025	Jun	NEWA
AB		30MG	A218638	002	Jun 25, 2025	Jun	NEWA

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

	@ AMNEAL	25MG/10ML (2.5MG/ML)	A215406	001	Oct 31, 2024	Jan	DISC
AP	MANKIND PHARMA	25MG/10ML (2.5MG/ML)	A090671	001	Nov 17, 2009	Jun	CAHN
AP	NANJING KING FRIEND	25MG/10ML (2.5MG/ML)	A216819	001	Aug 20, 2025	Aug	NEWA
AP	QILU PHARM HAINAN	25MG/10ML (2.5MG/ML)	A219608	001	Oct 28, 2025	Oct	NEWA

INJECTABLE;INTRAVENOUS

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

AP	CAPLIN	20MG/200ML (0.1MG/ML)	A220243	001	Oct 22, 2025	Oct	NEWA
AP		40MG/200ML (0.2MG/ML)	A220243	002	Oct 22, 2025	Oct	NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL  
NIFEDIPINE

	@ SPIL	30MG	A210838	001	Apr 16, 2019	Oct	DISC
	@	60MG	A210838	002	Apr 16, 2019	Oct	DISC
	@	90MG	A210838	003	Apr 16, 2019	Oct	DISC

NILOTINIB D-TARTRATE

CAPSULE;ORAL  
NILOTINIB D-TARTRATE

	+ CIPLA	EQ 50MG BASE	N218922	001	Feb 19, 2025	Feb	NEWA
	+	EQ 150MG BASE	N218922	002	Feb 19, 2025	Feb	NEWA
	+!	EQ 200MG BASE	N218922	003	Feb 19, 2025	Feb	NEWA

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL  
NILOTINIB HYDROCHLORIDE

AB	APOTEX	EQ 50MG BASE	A203640	001	Jan 05, 2024	Apr	CMFD	
AB		EQ 150MG BASE	A203640	002	Jan 05, 2024	Apr	CMFD	
AB		EQ 200MG BASE	A203640	003	Jan 05, 2024	Apr	CMFD	
AB	DR REDDYS	EQ 50MG BASE	A218350	001	Nov 19, 2025	Nov	NEWA	
AB		EQ 150MG BASE	A218350	002	Nov 19, 2025	Nov	NEWA	
AB		EQ 200MG BASE	A218350	003	Nov 19, 2025	Nov	NEWA	
AB	HETERO LABS LTD V	EQ 150MG BASE	A209651	001	Nov 19, 2025	Nov	NEWA	
AB		EQ 200MG BASE	A209651	002	Nov 19, 2025	Nov	NEWA	
AB	MSN	EQ 50MG BASE	A218544	001	Nov 19, 2025	Nov	NEWA	
AB		EQ 150MG BASE	A218544	002	Nov 19, 2025	Nov	NEWA	
AB		EQ 200MG BASE	A218544	003	Nov 19, 2025	Nov	NEWA	
>A>	AB	TORRENT	EQ 150MG BASE	A218532	001	Dec 15, 2025	Dec	NEWA
>A>	AB		EQ 200MG BASE	A218532	002	Dec 15, 2025	Dec	NEWA
	TASIGNA							
AB	+ NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018	Apr	CTEC	
AB	+	EQ 150MG BASE	N022068	002	Jun 17, 2010	Apr	CTEC	
AB	+!	EQ 200MG BASE	N022068	001	Oct 29, 2007	Apr	CTEC	

NILOTINIB TARTRATE

TABLET;ORAL  
DANZITEN

+! AZURITY EQ 71MG BASE N219293 001 Nov 07, 2024 Nov CHRS

NIMODIPINE

SOLUTION;ORAL  
NIMODIPINE

AB ALKEM LABS LTD 6MG/ML A213409 001 Jan 22, 2025 Jan NFTG

AB NYMALIZE  
+! AZURITY 6MG/ML N203340 002 Apr 08, 2020 Jan CFTG

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL  
NISOLDIPINE

>A> AB AMTA 17MG A216606 002 Dec 12, 2025 Dec NEWA

NITAZOXANIDE

TABLET;ORAL  
NITAZOXANIDE

AB ANI PHARMS 500MG A214844 001 Feb 03, 2025 Apr CAHN

AB ANNORA PHARMA 500MG A218701 001 Apr 15, 2025 Apr NEWA

AB ! RISING 500MG A213820 001 Nov 27, 2020 Jan CTEC

AB ZENARA 500MG A214844 001 Feb 03, 2025 Jan NEWA

NITISINONE

TABLET;ORAL  
HARLIKU

+! CYCLE 2MG N209449 004 Jun 10, 2025 Jul NEWA

NITRIC OXIDE

GAS;INHALATION  
INOMAX

AA @ + MALLINCKRODT IRELAND 100PPM N020845 002 Dec 23, 1999 Jul CAHN

+! 800PPM N020845 003 Dec 23, 1999 Jul CAHN

+! 4880PPM N020845 004 Jan 17, 2023 Jul CAHN

NOXIVENT  
@ LINDE GAS EQUIP 100PPM A207141 001 Oct 02, 2018 Apr DISC

NITROFURANTOIN

SUSPENSION;ORAL  
NITROFURANTOIN

AB ANNORA PHARMA 25MG/5ML A219495 001 Jul 02, 2025 Jun NEWA

AB APPCO 25MG/5ML A208909 001 Jan 14, 2025 Jan NEWA

AB STRIDES PHARMA 25MG/5ML A201355 001 Aug 14, 2013 Apr CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL  
NITROFURANTOIN

>D> AB SUN PHARM INDUSTRIES 25MG A201722 001 Feb 16, 2016 Dec DISC

>A> @ 25MG A201722 001 Feb 16, 2016 Dec DISC

>D> AB 50MG A201722 002 Feb 16, 2016 Dec DISC

>A> @ 50MG A201722 002 Feb 16, 2016 Dec DISC

>D> AB 100MG A201722 003 Feb 16, 2016 Dec DISC

>A> @ 100MG A201722 003 Feb 16, 2016 Dec DISC

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL  
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

>D> AB @ AMNEAL PHARMS 75MG;25MG A207372 001 May 15, 2017 Jul DISC

AB MICRO LABS 75MG;25MG A217073 001 Nov 03, 2023 Dec CAHN

AB 75MG;25MG A217073 001 Nov 03, 2023 Sep CAHN

>A> AB OMSAV PHARMA 75MG;25MG A217073 001 Nov 03, 2023 Dec CAHN

NITROGLYCERIN

OINTMENT;INTRA-ANAL  
NITROGLYCERIN

>A> AB SOLARIS PHARMA CORP 0.4% A218756 001 Dec 18, 2025 Dec NEWA

AB TP ANDA HOLDINGS 0.4% A212222 001 Nov 29, 2024 Aug CAHN

OINTMENT;TRANSDERMAL  
NITROGLYCERIN

AB	ENCUBE	2%	A218235	001	Apr 15, 2025	Apr	NFTG
AB	+! FOUGERA PHARMS INC	2%	A087355	001	Jul 08, 1988	Apr	CFTG

TABLET;SUBLINGUAL  
NITROGLYCERIN

AB	RUBICON RESEARCH	0.3MG	A209779	001	May 03, 2021	Jul	CAHN
AB		0.4MG	A209779	002	May 03, 2021	Jul	CAHN
AB		0.6MG	A209779	003	May 03, 2021	Jul	CAHN

NIZATIDINE

CAPSULE;ORAL  
NIZATIDINE

@	GLENMARK PHARMS INC	150MG	A090618	001	Jul 15, 2011	Jul	DISC
@		300MG	A090618	002	Jul 15, 2011	Jul	DISC

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION  
NOREPINEPHRINE BITARTRATE

AP	ANTHEA PHARMA	EQ 1MG BASE/ML	A219924	001	Nov 25, 2025	Nov	NEWA
AP	ASPIRO	EQ 1MG BASE/ML	A219163	001	Jan 31, 2025	Jan	NEWA
AP	BIOCON PHARMA	EQ 1MG BASE/ML	A219443	001	Mar 21, 2025	Mar	NEWA
>A> AP	MSN	EQ 1MG BASE/ML	A218595	001	Dec 11, 2025	Dec	NEWA

SOLUTION;INTRAVENOUS

	NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE						
	+! INFORLIFE	EQ 32MG BASE/250ML (EQ 128MCG BASE/ML)	N215700	004	Oct 15, 2025	Oct	NEWA
	NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE						
AP	+! BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N214313	001	Jan 15, 2021	Aug	CFTG
AP	+!	EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214313	002	Jan 15, 2021	Aug	CFTG
AP	SAGENT	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	A219692	001	Aug 11, 2025	Aug	NFTG
AP		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	A219692	002	Aug 11, 2025	Aug	NFTG

NYSTATIN

CREAM;TOPICAL  
NYSTATIN

AT	AUROBINDO PHARMA	100,000 UNITS/GM	A219527	001	Mar 21, 2025	Mar	NEWA
	@ CHARTWELL RX	100,000 UNITS/GM	A065315	001	May 31, 2006	Apr	CAHN

POWDER;TOPICAL  
KLAYESTA

AT	EPIC PHARMA LLC	100,000 UNITS/GM	A210532	001	Apr 30, 2018	Oct	CTNA
	@ ADRASTEIA PHARMA	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Jun	DISC
	@ PHARMOBEDIENT	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Sep	CAHN

SUSPENSION;ORAL  
NYSTATIN

AA	MLV	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Aug	CMFD
AA	PHARMOBEDIENT	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Aug	CAHN
AA	! SENORES PHARMS	100,000 UNITS/ML	A214346	001	Mar 10, 2022	Sep	CAHN
	@ TARO	100,000 UNITS/ML	A062876	001	Feb 29, 1988	Aug	DISC
AA	XTTRIUM LABS INC	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Jan	CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL  
NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	CHARTWELL RX	100,000 UNITS/GM;0.1%	A208326	001	Oct 26, 2016	Apr	CAHN
	@ GLENMARK PHARMS LTD	100,000 UNITS/GM;0.1%	A208136	001	Oct 24, 2016	Jul	DISC

OINTMENT;TOPICAL  
NYSTATIN AND TRIAMCINOLONE ACETONIDE

	@ GLENMARK PHARMS LTD	100,000 UNITS/GM;0.1%	A208300	001	Jun 23, 2016	Jul	DISC
>D> AT	STRIDES PHARMA	100,000 UNITS/GM;0.1%	A210077	001	Jan 29, 2018	Dec	DISC
>A>	@	100,000 UNITS/GM;0.1%	A210077	001	Jan 29, 2018	Dec	DISC

OBETICHOLIC ACID

TABLET;ORAL

OICALIVA

@ +	INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016	Nov	DISC
@ +		10MG	N207999	002	May 27, 2016	Nov	DISC

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

>A>	AB	MYLAN LABS LTD	EQ 10MG BASE/VIAL	A216589	001	Dec 12, 2025	Dec	NEWA
>A>	AB		EQ 20MG BASE/VIAL	A216589	002	Dec 12, 2025	Dec	NEWA
>A>	AB		EQ 30MG BASE/VIAL	A216589	003	Dec 12, 2025	Dec	NEWA

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

@	AMNEAL	0.3%	A211524	001	Mar 01, 2024	Feb	DISC
---	--------	------	---------	-----	--------------	-----	------

SOLUTION/DROPS;OTIC

OFLOXACIN

AT	FDC LTD	0.3%	A215038	001	Jan 19, 2022	Aug	CMFD
----	---------	------	---------	-----	--------------	-----	------

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

AP	QILU	10MG/VIAL	A218116	001	May 16, 2025	May	NEWA
AP	UBI	10MG/VIAL	A211072	001	Jun 11, 2025	May	NEWA

OLICERIDINE

SOLUTION; INTRAVENOUS

OLINVYK

@ +	TREVENA	1MG/ML (1MG/ML)	N210730	001	Oct 30, 2020	Jan	DISC
@ +		2MG/2ML (1MG/ML)	N210730	002	Oct 30, 2020	Jan	DISC

OLIVE OIL; SOYBEAN OIL

EMULSION; INTRAVENOUS

CLINOLIPID 20%

+	!	BAXTER HLTHCARE CORP	16% (160GM/1000ML); 4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jun	CMFD
---	---	----------------------	--------------------------------------	---------	-----	--------------	-----	------

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB	JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Mar	CMFD
AB		20MG	A205482	002	Apr 24, 2017	Mar	CMFD
AB		40MG	A205482	003	Apr 24, 2017	Mar	CMFD

OMAVELOXOLONE

CAPSULE;ORAL

SKYCLARYS

+	!	BIOGEN US	50MG	N216718	001	Feb 28, 2023	Jan	CAHN
---	---	-----------	------	---------	-----	--------------	-----	------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

LOVAZA

AB	+	!	WAYLIS THERAP	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Feb	CAHN
----	---	---	---------------	--	---------	-----	--------------	-----	------

OMEGA-3-ACID ETHYL ESTERS

@	SUN PHARM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210834	001	Jan 09, 2020	Jul	DISC
---	-----------	--	---------	-----	--------------	-----	------

OMEPRAZOLE; SODIUM BICARBONATE

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

AB	NOVITIUM PHARMA	20MG/PACKET;1.68GM/PACKET	A219161	001	Dec 10, 2025	Nov	NEWA
AB		40MG/PACKET;1.68GM/PACKET	A219161	002	Dec 10, 2025	Nov	NEWA

OMIDENEPAG ISOPROPYL

SOLUTION;OPHTHALMIC  
OMLONTI

	+	OCUVEX THERAP	0.002%	N215092	001	Sep 22, 2022	Jun CMFD
--	---	---------------	--------	---------	-----	--------------	----------

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL  
ONDANSETRON

AB		IPCA LABS LTD	4MG	A209389	001	Oct 30, 2023	May CMFD
AB			8MG	A209389	002	Oct 30, 2023	May CMFD
	@	NORVIUM BIOSCIENCE	4MG	A078139	001	Jun 25, 2007	Feb CAHN
	@		8MG	A078139	002	Jun 25, 2007	Feb CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION  
ONDANSETRON HYDROCHLORIDE

	@	HIKMA FARMACEUTICA	EQ 2MG BASE/ML	A076781	001	Dec 26, 2006	Mar DISC
--	---	--------------------	----------------	---------	-----	--------------	----------

TABLET;ORAL  
ONDANSETRON HYDROCHLORIDE

	@	APOTEX	EQ 4MG BASE	A077306	001	Jun 25, 2007	Mar DISC
	@		EQ 8MG BASE	A077306	002	Jun 25, 2007	Mar DISC
AB		IPCA LABS LTD	EQ 4MG BASE	A203761	001	Jan 23, 2014	May CMFD
AB			EQ 8MG BASE	A203761	002	Jan 23, 2014	May CMFD

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL  
OSELTAMIVIR PHOSPHATE

AB		BEIJING JIALIN	EQ 30MG BASE	A217133	001	Oct 30, 2024	Sep CAHN
AB			EQ 75MG BASE	A217133	002	Oct 30, 2024	Sep CAHN
AB		SHANDONG	EQ 30MG BASE	A217274	001	Jul 09, 2025	Jun NEWA
AB			EQ 45MG BASE	A217274	002	Jul 09, 2025	Jun NEWA
AB			EQ 75MG BASE	A217274	003	Jul 09, 2025	Jun NEWA
AB		ZHEJIANG POLY PHARM	EQ 30MG BASE	A218009	002	Oct 02, 2025	Sep NEWA
AB			EQ 45MG BASE	A218009	003	Oct 02, 2025	Sep NEWA
AB			EQ 75MG BASE	A218009	001	Nov 24, 2023	Mar CAHN

TAMIFLU

	@ +	ROCHE	EQ 30MG BASE	N021087	003	Jul 02, 2007	Oct DISC
	@ +		EQ 45MG BASE	N021087	002	Jul 02, 2007	Nov DISC

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB		JUBILANT GENERICS	EQ 6MG BASE/ML	A213695	001	Mar 03, 2025	Feb NEWA
AB		PHARMOBEDIENT	EQ 6MG BASE/ML	A217303	001	Jul 02, 2024	Sep CAHN

OSPEMIFENE

TABLET;ORAL  
OSPEMIFENE

	@	HETERO LABS LTD V	60MG	A215574	001	Feb 13, 2024	Apr DISC
	+	DUCHESNAY	60MG	N203505	001	Feb 26, 2013	Apr CTEC

OXALIPLATIN

INJECTABLE;INTRAVENOUS  
OXALIPLATIN

	@	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017	Aug DISC
	@		100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017	Aug DISC
AP		HETERO LABS LTD VI	50MG/10ML (5MG/ML)	A217925	001	Jan 27, 2025	Jan NEWA
AP			100MG/20ML (5MG/ML)	A217925	002	Jan 27, 2025	Jan NEWA
	@	NOVAST LABS	50MG/10ML (5MG/ML)	A207562	001	Oct 16, 2018	Oct DISC

OXAPROZIN

TABLET;ORAL  
OXAPROZIN

	@	AARXION ANDA HLDING	600MG	A075842	001	Apr 12, 2001	Nov CAHN
--	---	---------------------	-------	---------	-----	--------------	----------

OXAZEPAM

CAPSULE;ORAL  
OXAZEPAM

AB		EPIC PHARMA LLC	10MG	A071756	002	Apr 19, 1988	Jul CMS1
AB			30MG	A071756	003	Apr 19, 1988	Jul CMS1
AB		LEADING	10MG	A218261	001	Mar 03, 2025	Feb NEWA
AB			15MG	A218261	002	Mar 03, 2025	Feb NEWA

	CAPSULE;ORAL							
	OXAZEPAM							
AB		30MG		A218261	003	Mar 03, 2025	Feb	NEWA
	<u>OXCARBAZEPINE</u>							
	SUSPENSION;ORAL							
	OXCARBAZEPINE							
AB	MACLEODS PHARMS LTD	300MG/5ML		A207300	001	Jul 11, 2025	Jul	NEWA
	@ PAI HOLDINGS	300MG/5ML		A211420	001	Jul 09, 2021	Jul	CAHN
	TABLET, EXTENDED RELEASE;ORAL							
	OXCARBAZEPINE							
AB	AJANTA PHARMA LTD	150MG		A217659	001	Feb 22, 2024	Apr	CMFD
AB		300MG		A217659	002	Feb 22, 2024	Apr	CMFD
AB		600MG		A217659	003	Feb 22, 2024	Apr	CMFD
	@ AUROBINDO PHARMA LTD	150MG		A219241	001	Apr 30, 2025	May	DISC
AB		150MG		A219241	001	Apr 30, 2025	Apr	NEWA
	@	300MG		A219241	002	Apr 30, 2025	May	DISC
AB		300MG		A219241	002	Apr 30, 2025	Apr	NEWA
	@	600MG		A219241	003	Apr 30, 2025	May	DISC
AB		600MG		A219241	003	Apr 30, 2025	Apr	NEWA
AB	RICONPHARMA LLC	150MG		A215796	001	Nov 22, 2024	Apr	CMFD
AB		300MG		A215796	002	Nov 22, 2024	Apr	CMFD
AB		600MG		A215796	003	Nov 22, 2024	Apr	CMFD
	<u>OXYBUTYNIN CHLORIDE</u>							
	TABLET;ORAL							
	OXYBUTYNIN CHLORIDE							
AB	AIPING PHARM INC	5MG		A074625	001	Jul 31, 1996	Jul	CAHN
	<u>OXYCODONE HYDROCHLORIDE</u>							
	SOLUTION;ORAL							
	OXYCODONE HYDROCHLORIDE							
AA	HIBROW HLTHCARE	5MG/5ML		A207511	001	Nov 23, 2016	Sep	CAHN
AA		100MG/5ML		A209897	001	Sep 06, 2017	Sep	CAHN
	@ PHARM ASSOC	100MG/5ML		A206822	001	Aug 15, 2017	Apr	DISC
	@ PHARMOBEDIANT	5MG/5ML		A206456	001	Jun 16, 2015	Aug	CAHN
	@ VISTAPHARM LLC	100MG/5ML		A202537	001	Jul 30, 2012	Jan	CAHN
	TABLET;ORAL							
	OXYCODONE HYDROCHLORIDE							
AB	ASCENT PHARMS INC	5MG		A207418	003	Nov 14, 2025	Nov	NEWA
AB		10MG		A207418	004	Nov 14, 2025	Nov	NEWA
AB		20MG		A207418	005	Nov 14, 2025	Nov	NEWA
	@ NOVEL LABS INC	5MG		A204021	001	Jun 12, 2017	Feb	DISC
	@	10MG		A204021	002	Jun 12, 2017	Feb	DISC
	@	15MG		A204021	003	Jun 12, 2017	Feb	DISC
	@	20MG		A204021	004	Jun 12, 2017	Feb	DISC
	@	30MG		A204021	005	Jun 12, 2017	Feb	DISC
	<u>PACLITAXEL</u>							
	POWDER;INTRAVENOUS							
	PACLITAXEL							
AB	CIPLA	100MG/VIAL		A209657	001	Apr 10, 2025	Mar	NEWA
AB	MYLAN	100MG/VIAL		A217877	001	Aug 19, 2025	Aug	NEWA
AB	SHUANGCHENG	100MG/VIAL		A216355	001	May 15, 2025	May	NEWA
	<u>PALBOCICLIB</u>							
	TABLET;ORAL							
	PALBOCICLIB							
	@ ZYDUS LIFESCIENCES	75MG		A215570	001	Jun 05, 2024	Apr	CAHN
	@	100MG		A215570	002	Jun 05, 2024	Apr	CAHN
	@	125MG		A215570	003	Jun 05, 2024	Apr	CAHN
	<u>PALIPERIDONE</u>							
	TABLET, EXTENDED RELEASE;ORAL							
	PALIPERIDONE							
AB	DR REDDYS	3MG		A205559	001	Feb 19, 2025	Feb	NEWA
AB		6MG		A205559	002	Feb 19, 2025	Feb	NEWA
AB		9MG		A205559	003	Feb 19, 2025	Feb	NEWA
>A>	AB	ESKAYEF	1.5MG	A218755	001	Sep 04, 2025	Dec	CAHN
	AB		1.5MG	A218755	001	Sep 04, 2025	Oct	CAHN
	AB		1.5MG	A218755	001	Sep 04, 2025	Aug	NEWA
>A>	AB		3MG	A218755	002	Sep 04, 2025	Dec	CAHN

TABLET, EXTENDED RELEASE;ORAL  
PALIPERIDONE

AB		3MG	A218755	002	Sep 04, 2025	Oct	CAHN	
AB		3MG	A218755	002	Sep 04, 2025	Aug	NEWA	
>A>	AB	6MG	A218755	003	Sep 04, 2025	Dec	CAHN	
AB		6MG	A218755	003	Sep 04, 2025	Oct	CAHN	
AB		6MG	A218755	003	Sep 04, 2025	Aug	NEWA	
>A>	AB	9MG	A218755	004	Sep 04, 2025	Dec	CAHN	
AB		9MG	A218755	004	Sep 04, 2025	Oct	CAHN	
AB		9MG	A218755	004	Sep 04, 2025	Aug	NEWA	
>D>	AB	EVEREST LIFSCIENCES	1.5MG	A218755	001	Sep 04, 2025	Dec	CAHN
AB		1.5MG	A218755	001	Sep 04, 2025	Oct	CAHN	
AB		1.5MG	A218755	001	Sep 04, 2025	Sep	CAHN	
>D>	AB		3MG	A218755	002	Sep 04, 2025	Dec	CAHN
AB		3MG	A218755	002	Sep 04, 2025	Oct	CAHN	
AB		3MG	A218755	002	Sep 04, 2025	Sep	CAHN	
>D>	AB		6MG	A218755	003	Sep 04, 2025	Dec	CAHN
AB		6MG	A218755	003	Sep 04, 2025	Oct	CAHN	
AB		6MG	A218755	003	Sep 04, 2025	Sep	CAHN	
>D>	AB		9MG	A218755	004	Sep 04, 2025	Dec	CAHN
AB		9MG	A218755	004	Sep 04, 2025	Oct	CAHN	
AB		9MG	A218755	004	Sep 04, 2025	Sep	CAHN	
@	LUPIN LTD	1.5MG	A208643	001	Jun 29, 2022	Oct	DISC	
@		3MG	A208643	002	Jun 29, 2022	Oct	DISC	
@		6MG	A208643	003	Jun 29, 2022	Oct	DISC	
@		9MG	A208643	004	Jun 29, 2022	Oct	DISC	

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR  
INVEGA SUSTENNA

+	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Oct	CTEC
+		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Oct	CTEC
+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Oct	CTEC
+	!	156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Oct	CTEC
+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Oct	CTEC

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS  
PALONOSETRON HYDROCHLORIDE

@	NOVAST LABS	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A208789	001	May 22, 2020	Sep	CAHN
---	-------------	--	---------	-----	--------------	-----	------

PALTUSOTINE HYDROCHLORIDE

TABLET;ORAL

PALSONIFY

+	CRINETICS	EQ 20MG BASE	N219070	001	Sep 25, 2025	Sep	NEWA
+	!	EQ 30MG BASE	N219070	002	Sep 25, 2025	Sep	NEWA

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL  
PANTOPRAZOLE SODIUM

AB	AUROBINDO PHARMA LTD	EQ 40MG BASE	A217923	001	Mar 31, 2025	Mar	NEWA
AB	CIPLA	EQ 40MG BASE	A217458	001	Mar 31, 2025	Mar	NEWA

INJECTABLE;INTRAVENOUS  
PANTOPRAZOLE SODIUM

AP	ALEMBIC	EQ 40MG BASE/VIAL	A219230	001	Mar 31, 2025	Mar	NEWA
AP	DEVA HOLDING AS	EQ 40MG BASE/VIAL	A215074	001	May 16, 2025	May	NEWA

POWDER;INTRAVENOUS

PANTOPRAZOLE SODIUM

AP	FRESENIUS KABI USA	EQ 40MG BASE/VIAL	A216021	001	Aug 01, 2024	May	CMFD	
@		EQ 40MG BASE/VIAL	A216021	001	Aug 01, 2024	Feb	DISC	
AP	!	HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	May	CTEC
!		EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Feb	CTEC	

TABLET, DELAYED RELEASE;ORAL  
PANTOPRAZOLE SODIUM

@	ACTAVIS TOTOWA	EQ 20MG BASE	A090797	001	Feb 07, 2011	Nov	DISC
@		EQ 40MG BASE	A090797	002	Feb 07, 2011	Nov	DISC
AB	APOTEX	EQ 20MG BASE	A091231	001	Jan 19, 2011	Nov	CAHN
AB		EQ 40MG BASE	A091231	002	Jan 19, 2011	Nov	CAHN
AB	GRAVITI PHARMS	EQ 20MG BASE	A219087	001	Jan 16, 2025	Jan	NEWA
AB		EQ 40MG BASE	A219087	002	Jan 16, 2025	Jan	NEWA
@	INGENUS PHARMS LLC	EQ 40MG BASE	A211368	001	Mar 01, 2019	Jan	DISC

PARICALCITOL

CAPSULE; ORAL		PARICALCITOL							
AB	CHARTWELL RX	1MCG		A 091412	001	Jun 24, 2014	Apr	CAHN	
AB		2MCG		A 091412	002	Jun 24, 2014	Apr	CAHN	
AB		4MCG		A 091412	003	Jun 24, 2014	Apr	CAHN	
ZEMPLAR									
@ +	ABBVIE	1MCG		N 021606	001	May 26, 2005	Nov	DISC	
SOLUTION; INTRAVENOUS		PARICALCITOL							
AP	CAPLIN	0.002MG/ML	(0.002MG/ML)	A 204910	001	Aug 17, 2016	Apr	CAHN	
AP		0.005MG/ML	(0.005MG/ML)	A 204910	002	Aug 17, 2016	Apr	CAHN	
AP		0.01MG/2ML	(0.005MG/ML)	A 204910	003	Aug 17, 2016	Apr	CAHN	
@	HIKMA PHARMS	0.002MG/ML	(0.002MG/ML)	N 205917	001	Nov 18, 2014	Jul	DISC	
@		0.005MG/ML	(0.005MG/ML)	N 205917	002	Nov 18, 2014	Jul	DISC	
@		0.01MG/2ML	(0.005MG/ML)	N 205917	003	Nov 18, 2014	Jul	DISC	

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL		PAROXETINE HYDROCHLORIDE							
AB	ALEMBIC	EQ 25MG BASE		A 217280	001	Sep 24, 2025	Sep	NEWA	
AB		EQ 37.5MG BASE		A 217280	002	Sep 24, 2025	Sep	NEWA	

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL		PAZOPANIB HYDROCHLORIDE							
	TORRENT	EQ 400MG BASE		A 219922	001	Sep 04, 2025	Aug	NFTG	

PEGULICIANINE ACETATE

POWDER; INTRAVENOUS		LUMISIGHT							
+	LUMICELL	EQ 39MG BASE/VIAL		N 214511	001	Apr 17, 2024	Aug	CPOT	

PEMETREXED DISODIUM

POWDER; INTRAVENOUS		PEMETREXED DISODIUM							
@	BAXTER HLTHCARE CORP	EQ 100MG BASE/VIAL		A 214436	001	Aug 18, 2022	May	DISC	
@		EQ 500MG BASE/VIAL		A 214436	002	Aug 18, 2022	May	DISC	
SOLUTION; INTRAVENOUS		PEMETREXED DISODIUM							
@ +	ACCORD HLTHCARE	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)		N 214408	001	Jul 19, 2022	Jun	DISC	
@ +		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)		N 214408	002	Jul 19, 2022	Jun	DISC	
@ +		EQ 850MG BASE/34ML (EQ 25MG BASE/ML)		N 214408	003	Jul 19, 2022	Jun	DISC	
@ +		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)		N 214408	004	Jul 19, 2022	Jun	DISC	

PEMETREXED DITROMETHAMINE

POWDER; INTRAVENOUS		PEMETREXED DITROMETHAMINE							
@ +	HOSPIRA	EQ 100MG BASE/VIAL		N 208746	001	Jun 10, 2022	Oct	DISC	
@ +		EQ 500MG BASE/VIAL		N 208746	002	Jun 10, 2022	Oct	DISC	

PENCICLOVIR

CREAM; TOPICAL		PENCICLOVIR							
AB	AMNEAL	1%		A 214100	001	Aug 22, 2025	Aug	NEWA	
BX	TORRENT	1%		A 216981	001	Aug 07, 2023	Mar	CTEC	

PENICILLAMINE

CAPSULE; ORAL		PENICILLAMINE							
@	APOTEX	250MG		A 213310	001	Apr 28, 2020	Sep	DISC	

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION  
 PENTAMIDINE ISETHIONATE  
 AP PHARMOBEDIANT 300MG/VIAL A206982 001 Mar 17, 2022 Sep CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL  
 PENTOXIFYLLINE  
 @ BAUSCH 400MG A075028 001 Jul 20, 1998 Sep DISC  
 AB 400MG A075028 001 Jul 20, 1998 Sep CAHN

PERAMPANEL

SUSPENSION; ORAL  
 FYCOMPA  
 AB +! CATALYST PHARMS 0.5MG/ML N208277 001 Apr 29, 2016 Jul CFTG  
 PERAMPANEL  
 AB MSN 0.5MG/ML A218152 001 Jul 11, 2025 Jul NFTG  
 TABLET; ORAL  
 FYCOMPA  
 AB + CATALYST PHARMS 2MG N202834 001 Oct 22, 2012 May CFTG  
 AB + 4MG N202834 002 Oct 22, 2012 May CFTG  
 AB + 6MG N202834 003 Oct 22, 2012 May CFTG  
 AB + 8MG N202834 004 Oct 22, 2012 May CFTG  
 AB + 10MG N202834 005 Oct 22, 2012 May CFTG  
 AB +! 12MG N202834 006 Oct 22, 2012 May CFTG  
 PERAMPANEL  
 AB MSN 2MG A218178 001 Nov 25, 2025 Nov NEWA  
 AB 4MG A218178 002 Nov 25, 2025 Nov NEWA  
 AB 6MG A218178 003 Nov 25, 2025 Nov NEWA  
 AB 8MG A218178 004 Nov 25, 2025 Nov NEWA  
 AB 10MG A218178 005 Nov 25, 2025 Nov NEWA  
 AB 12MG A218178 006 Nov 25, 2025 Nov NEWA  
 AB TARO 2MG A209538 001 Nov 25, 2025 Nov NEWA  
 AB 4MG A209538 002 Nov 25, 2025 Nov NEWA  
 AB 6MG A209538 003 Nov 25, 2025 Nov NEWA  
 AB 8MG A209538 004 Nov 25, 2025 Nov NEWA  
 AB 10MG A209538 005 Nov 25, 2025 Nov NEWA  
 AB 12MG A209538 006 Nov 25, 2025 Nov NEWA  
 AB TEVA PHARMS USA INC 2MG A209801 001 May 23, 2025 May NFTG  
 AB 4MG A209801 002 May 23, 2025 May NFTG  
 AB 6MG A209801 003 May 23, 2025 May NFTG  
 AB 8MG A209801 004 May 23, 2025 May NFTG  
 AB 10MG A209801 005 May 23, 2025 May NFTG  
 AB 12MG A209801 006 May 23, 2025 May NFTG

PERPHENAZINE

TABLET; ORAL  
 PERPHENAZINE  
 AB JUBILANT GENERICS 2MG A213694 001 Mar 18, 2025 Mar NEWA  
 AB 4MG A213694 002 Mar 18, 2025 Mar NEWA  
 AB 8MG A213694 003 Mar 18, 2025 Mar NEWA  
 AB 16MG A213694 004 Mar 18, 2025 Mar NEWA

PEXIDARTINIB HYDROCHLORIDE

CAPSULE; ORAL  
 TURALIO  
 +! DAIICHI SANKYO INC EQ 125MG BASE N211810 002 Oct 14, 2022 Nov CHRS

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL  
 PHENDIMETRAZINE TARTRATE  
 +! ACERTIS PHARMS 105MG N018074 001 May CAHN  
 TABLET; ORAL  
 BONTRIL PDM  
 AA +! BAUSCH 35MG A085272 001 Mar CAHN  
 PHENDIMETRAZINE TARTRATE  
 AA ACERTIS PHARMS 35MG A085588 001 May CAHN  
 @ MPP PHARMA 35MG A203600 001 Dec 27, 2017 May CAHN

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL  
DIBENZYLININE

@ + ADVANZ PHARMA 10MG N008708 001 Nov DISC

PHENTERMINE HYDROCHLORIDE

TABLET;ORAL  
PHENTERMINE HYDROCHLORIDE

AA PURACAP LABS BLU 37.5MG A206342 001 Nov 18, 2016 Oct CAHN

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL  
PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE

AB DR REDDYS LABS SA EQ 7.5MG BASE;46MG A208175 002 Jun 12, 2025 Jun NEWA  
 AB EQ 11.25MG BASE;69MG A208175 003 Jun 12, 2025 Jun NEWA  
 AB EQ 15MG BASE;92MG A208175 004 Jun 12, 2025 Jun NEWA  
 AB EQ 3.75MG BASE;23MG A208175 001 Jun 12, 2025 Jun NEWA

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS  
BIORPHEN

AP +! DR REDDYS LABS SA 0.5MG/5ML (0.1MG/ML) N212909 001 Oct 21, 2019 Feb CFTG  
 PHENYLEPHRINE HYDROCHLORIDE  
 AP2 +! HIKMA 50MG/5ML (10MG/ML) N203826 002 Jun 19, 2019 Oct CTEC  
 AP2 +! 100MG/10ML (10MG/ML) N203826 003 Jun 19, 2019 Oct CTEC  
 AP1 MILLA PHARMS 10MG/ML (10MG/ML) A211081 001 Jul 17, 2020 Sep CAHN  
 AP1 50MG/5ML (10MG/ML) A211081 002 Jul 17, 2020 Sep CAHN  
 AP1 100MG/10ML (10MG/ML) A211081 003 Jul 17, 2020 Sep CAHN  
 AP1 ! SANDOZ 10MG/ML (10MG/ML) A208905 001 Jan 31, 2019 Oct CMFD  
 @ 10MG/ML (10MG/ML) A208905 001 Jan 31, 2019 Aug CHRS  
 AP1 ! 50MG/5ML (10MG/ML) A208905 002 Jan 31, 2019 Oct CMFD  
 @ 50MG/5ML (10MG/ML) A208905 002 Jan 31, 2019 Aug CHRS  
 AP1 ! 100MG/10ML (10MG/ML) A208905 003 Jan 31, 2019 Oct CMFD  
 @ 100MG/10ML (10MG/ML) A208905 003 Jan 31, 2019 Aug CHRS  
 AP SOMERSET THERAPS LLC 0.5MG/5ML (0.1MG/ML) A215617 001 Feb 14, 2025 Feb NFTG  
 PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE  
 +! DR REDDYS LABS SA 20MG/250ML (0.08MG/ML) N216830 001 May 30, 2025 Jun CAHN  
 +! SINTEGICA SA 20MG/250ML (0.08MG/ML) N216830 001 May 30, 2025 May NEWA  
 VAZCULEP  
 @ + EXELA PHARMA 10MG/ML (10MG/ML) N204300 001 Jun 27, 2014 Aug DISC  
 @ + 50MG/5ML (10MG/ML) N204300 002 Jun 27, 2014 Aug DISC  
 @ + 100MG/10ML (10MG/ML) N204300 003 Jun 27, 2014 Aug DISC

PHENYTOIN

SUSPENSION;ORAL  
PHENYTOIN

@ VISTAPHARM LLC 125MG/5ML A040342 001 Jan 31, 2001 Jan CAHN  
 @ 125MG/5ML A040342 002 Aug 18, 2005 Jan CAHN

PHENYTOIN SODIUM

CAPSULE;ORAL  
EXTENDED PHENYTOIN SODIUM

>A> AUROBINDO PHARMA 100MG EXTENDED A204309 001 Jun 10, 2015 Dec CTNA  
 >A> AB MANKIND PHARMA 100MG EXTENDED A219773 001 Jan 02, 2026 Dec NEWA  
 >D> PHENYTOIN SODIUM  
 >D> AB AUROBINDO PHARMA 100MG EXTENDED A204309 001 Jun 10, 2015 Dec CTNA

PHYTONADIONE

INJECTABLE;INJECTION  
PHYTONADIONE

AB ALEMBIC 1MG/0.5ML A216444 001 Sep 08, 2025 Aug NEWA  
 AB AMNEAL 1MG/0.5ML A216601 001 Nov 04, 2025 Oct NEWA  
 AB1 CAPLIN 10MG/ML A219212 001 Apr 17, 2025 Apr NEWA

TABLET;ORAL  
PHYTONADIONE

@ HIKMA 5MG A212112 001 Dec 19, 2024 Feb DISC

PILOCARPINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC

PILOCARPINE HYDROCHLORIDE

AB	AMNEAL	1.25%	A217733	001	Apr 28, 2025	Apr	NFTG
AT	FDC LTD	1%	A217052	001	Oct 02, 2025	Sep	NEWA
AT		2%	A217052	002	Oct 02, 2025	Sep	NEWA
AT		4%	A217052	003	Oct 02, 2025	Sep	NEWA
	VUITY						
AB	+! ABBVIE	1.25%	N214028	001	Oct 28, 2021	Apr	CFTG
	SOLUTION/DROPS;OPHTHALMIC						
	ISOPTO CARPINE						
AT	+! SANDOZ	1%	N200890	001	Jun 22, 2010	Oct	CDFR
AT	+!	2%	N200890	002	Jun 22, 2010	Oct	CDFR
AT	+!	4%	N200890	003	Jun 22, 2010	Oct	CDFR
	PILOCARPINE HYDROCHLORIDE						
AT	AMNEAL	1%	A214193	001	Sep 21, 2020	Oct	CDFR
AB		1.25%	A217733	001	Apr 28, 2025	Oct	CDFR
AT		2%	A214193	002	Sep 21, 2020	Oct	CDFR
AT		4%	A214193	003	Sep 21, 2020	Oct	CDFR
AT	FDC LTD	1%	A217052	001	Oct 02, 2025	Oct	CDFR
AT		2%	A217052	002	Oct 02, 2025	Oct	CDFR
AT		4%	A217052	003	Oct 02, 2025	Oct	CDFR
AT	RISING	1%	A204398	001	Sep 27, 2017	Oct	CDFR
AT		2%	A204398	002	Sep 27, 2017	Oct	CDFR
AT		4%	A204398	003	Sep 27, 2017	Oct	CDFR
AT	SOMERSET THERAPS LLC	1%	A210384	001	Nov 25, 2019	Oct	CDFR
AT		2%	A210384	002	Nov 25, 2019	Oct	CDFR
AT		4%	A210384	003	Nov 25, 2019	Oct	CDFR
	QLOSI						
	+! ORASIS PHARMS	0.4%	N217836	001	Oct 17, 2023	Oct	CDFR
	VUITY						
AB	+! ABBVIE	1.25%	N214028	001	Oct 28, 2021	Oct	CDFR

PINDOLOL

TABLET;ORAL

PINDOLOL

AB	MPP PHARMA	5MG	A205415	001	Jan 13, 2016	May	CAHN
AB		10MG	A205415	002	Jan 13, 2016	May	CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	AIPING PHARM INC	EQ 15MG BASE	A078670	001	Feb 13, 2013	Nov	CAHN
AB		EQ 30MG BASE	A078670	002	Feb 13, 2013	Nov	CAHN
AB		EQ 45MG BASE	A078670	003	Feb 13, 2013	Nov	CAHN
	@ AVIV PHARMA	EQ 15MG BASE	A078472	001	Feb 13, 2013	May	CAHN
	@	EQ 30MG BASE	A078472	002	Feb 13, 2013	May	CAHN
	@	EQ 45MG BASE	A078472	003	Feb 13, 2013	May	CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	! APOTEX	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A206996	001	Mar 22, 2017	Nov	CAHN
AP	!	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A206996	002	Mar 22, 2017	Nov	CAHN
AP	!	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A206996	003	Mar 22, 2017	Nov	CAHN
AP	!	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207146	001	Mar 17, 2017	Nov	CAHN
AP	MILLA PHARMS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Sep	CAHN
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Sep	CAHN
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Sep	CAHN
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Sep	CAHN
AP		EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A207848	001	May 11, 2018	Sep	CAHN

POWDER;INTRAVENOUS

PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

	+! B BRAUN MEDICAL	EQ 2GM BASE/VIAL;EQ 250MG	N206056	001	Apr 03, 2025	Apr	NEWA
--	--------------------	---------------------------	---------	-----	--------------	-----	------

POWDER; INTRAVENOUS

PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

			BASE/VIAL						
	+	!	EQ 3GM BASE/VIAL;EQ 375MG	N206056	002	Apr 03, 2025	Apr	NEWA	
			BASE/VIAL						
	+	!	EQ 4GM BASE/VIAL;EQ 500MG	N206056	003	Apr 03, 2025	Apr	NEWA	
			BASE/VIAL						

PIRFENIDONE

CAPSULE; ORAL

ESBRIET

AB		+	!	LEGACY PHARMA	267MG	N022535	001	Oct 15, 2014	Nov	CAHN
----	--	---	---	---------------	-------	---------	-----	--------------	-----	------

TABLET; ORAL

ESBRIET

AB		+		LEGACY PHARMA	267MG	N208780	001	Jan 11, 2017	Nov	CAHN
		@	+		534MG	N208780	002	Jan 11, 2017	Nov	CAHN
AB		+	!		801MG	N208780	003	Jan 11, 2017	Nov	CAHN

PIRFENIDONE

AB				AUROBINDO PHARMA	267MG	A212596	001	Aug 11, 2025	Aug	NEWA
AB					801MG	A212596	002	Aug 11, 2025	Aug	NEWA

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB				SOLIS PHARMS	10MG	A074118	002	Jun 15, 1993	Apr	CAHN
AB					20MG	A074118	001	Jun 15, 1993	Apr	CAHN
>D>	AB			STRIDES PHARMA	10MG	A206136	001	Jun 20, 2017	Dec	DISC
>A>			@		10MG	A206136	001	Jun 20, 2017	Dec	DISC
>D>	AB				20MG	A206136	002	Jun 20, 2017	Dec	DISC
>A>			@		20MG	A206136	002	Jun 20, 2017	Dec	DISC

PITOLISANT HYDROCHLORIDE

TABLET; ORAL

WAKIX

	+			HARMONY	EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Feb	CAHN
	+	!			EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Feb	CAHN

PIVMECILLINAM HYDROCHLORIDE

TABLET; ORAL

PIVYA

>D>		+	!	ALEMBIC THERAP	EQ 185MG BASE	N216483	001	Apr 24, 2024	Dec	CAHN
		+	!		EQ 185MG BASE	N216483	001	Apr 24, 2024	Nov	CAHN
>A>		+	!	UTILITY THERAP	EQ 185MG BASE	N216483	001	Apr 24, 2024	Dec	CAHN

PLERIXAFOR

SOLUTION; SUBCUTANEOUS

PLERIXAFOR

AP				HETERO LABS LTD VI	24MG/1.2ML (20MG/ML)	A217560	001	Jun 16, 2025	Jun	NEWA
----	--	--	--	--------------------	----------------------	---------	-----	--------------	-----	------

PLOZASIRAN SODIUM

SOLUTION; SUBCUTANEOUS

REDEMPLO

	+	!		ARROWHEAD	EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML)	N219947	001	Nov 18, 2025	Nov	NEWA
--	---	---	--	-----------	---	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

NULYTELY

AA		+	!	AZURITY	420GM/BOT;1.48GM/BOT;5.72GM/BO T;11.2GM/BOT	N019797	001	Apr 22, 1991	Nov	CAHN
----	--	---	---	---------	---	---------	-----	--------------	-----	------

NULYTELY-FLAVORED

AA		+	!	AZURITY	420GM/BOT;1.48GM/BOT;5.72GM/BO T;11.2GM/BOT	N019797	002	Nov 18, 1994	Nov	CAHN
----	--	---	---	---------	---	---------	-----	--------------	-----	------

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

	@			SOLIS PHARMS	420GM/BOT;1.48GM/BOT;5.72GM/BO T;11.2GM/BOT	A202060	001	Mar 08, 2017	Apr	CAHN
--	---	--	--	--------------	---	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

	@			QUAGEN	120GM/PACKET;1.49GM/PACKET;3.3 6GM/PACKET;2.92GM/PACKET;	N018983	005	Oct 26, 1984	Sep	CAHN
--	---	--	--	--------	--	---------	-----	--------------	-----	------

FOR SOLUTION;ORAL								
COLYTE								
		11.36GM/PACKET						
@		227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Sep	CAHN	
@		227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Sep	CAHN	
@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Sep	CAHN	
@		360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Sep	CAHN	
COLYTE WITH FLAVOR PACKS								
@	QUAGEN	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Sep	CAHN	
COLYTE-FLAVORED								
@	QUAGEN	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Sep	CAHN	
@		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Sep	CAHN	
GOLYTELY								
@ +	AZURITY	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N019011	002	Jun 02, 1992	Nov	CAHN	
AA	+	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	N019011	001	Jul 13, 1984	Nov	CAHN	
<u>POLYMYXIN B SULFATE</u>								
INJECTABLE;INJECTION								
POLYMYXIN B SULFATE								
@	ADRASTEIA PHARMA	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Jun	DISC	
@	PHARMOBEDIENT	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Sep	CAHN	
<u>POMALIDOMIDE</u>								
CAPSULE;ORAL								
POMALIDOMIDE								
@	APOTEX	1MG	A210164	001	Jun 11, 2024	Jan	DISC	
@		2MG	A210164	002	Jun 11, 2024	Jan	DISC	
@		3MG	A210164	003	Jun 11, 2024	Jan	DISC	
@		4MG	A210164	004	Jun 11, 2024	Jan	DISC	
@	HETERO LABS LTD V	1MG	A210236	001	Sep 26, 2024	Apr	DISC	
@		2MG	A210236	002	Sep 26, 2024	Apr	DISC	
@		3MG	A210236	003	Sep 26, 2024	Apr	DISC	
@		4MG	A210236	004	Sep 26, 2024	Apr	DISC	
POMALYST								
+	BRISTOL	1MG	N204026	001	Feb 08, 2013	Apr	CTEC	
+		2MG	N204026	002	Feb 08, 2013	Apr	CTEC	
+		3MG	N204026	003	Feb 08, 2013	Apr	CTEC	
+		4MG	N204026	004	Feb 08, 2013	Apr	CTEC	
<u>POSACONAZOLE</u>								
TABLET, DELAYED RELEASE;ORAL								
POSACONAZOLE								
AB	MSN	100MG	A218434	001	Feb 24, 2025	Feb	NEWA	
AB	QILU PHARM HAINAN	100MG	A217720	001	Apr 23, 2025	Apr	NEWA	
<u>POTASSIUM CHLORIDE</u>								
CAPSULE, EXTENDED RELEASE;ORAL								
KLOR-CON								
@	UPSHER SMITH LABS	8MEQ	A203106	001	Jul 10, 2015	Oct	DISC	
@		10MEQ	A203106	002	Jul 10, 2015	Oct	DISC	
POTASSIUM CHLORIDE								
>D>	AB	LUPIN LTD	8MEQ	A203002	001	Dec 18, 2015	Dec	DISC
>A>	@		8MEQ	A203002	001	Dec 18, 2015	Dec	DISC
>D>	AB		10MEQ	A203002	002	Dec 18, 2015	Dec	DISC
>A>	@		10MEQ	A203002	002	Dec 18, 2015	Dec	DISC
>D>	AB	STRIDES PHARMA	8MEQ	A205549	001	Dec 08, 2015	Dec	DISC
>A>	@		8MEQ	A205549	001	Dec 08, 2015	Dec	DISC
>D>	AB		10MEQ	A205549	002	Dec 08, 2015	Dec	DISC
>A>	@		10MEQ	A205549	002	Dec 08, 2015	Dec	DISC
FOR SOLUTION;ORAL								
POTASSIUM CHLORIDE								
AA	AJENAT PHARMS	20MEQ	A212183	001	May 06, 2019	Jan	CAHN	

FOR SOLUTION;ORAL

POTASSIUM CHLORIDE

AA	ANDA REPOSITORY	20MEQ	A219009	001	Jul 11, 2025	Sep	CAHN
AA	+ GENUS	20MEQ	N208019	001	Aug 19, 2015	Nov	CHRS
AA	+!	20MEQ	N208019	001	Aug 19, 2015	Jan	CHRS
	+!	40MEQ	N208019	003	Aug 25, 2023	Nov	CMFD
	@ +	40MEQ	N208019	003	Aug 25, 2023	Jan	DISC
AA	GUARDIAN DRUG	20MEQ	A219009	001	Jul 11, 2025	Jul	NEWA

INJECTABLE;INJECTION

POTASSIUM CHLORIDE

AP	NEXUS	2MEQ/ML	A217704	001	Aug 14, 2023	Mar	CAHN
----	-------	---------	---------	-----	--------------	-----	------

SOLUTION;ORAL

POKONZA

	+ GENUS LIFESCIENCES	10MEQ/15ML	N206814	003	Nov 25, 2025	Nov	NEWA
--	----------------------	------------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

AA	AJENAT PHARMS	20MEQ/15ML	A216156	001	Mar 07, 2023	Jan	CAHN
AA		40MEQ/15ML	A216156	002	Mar 07, 2023	Jan	CAHN
AA	ASCENT PHARMS INC	20MEQ/15ML	A211992	001	Apr 09, 2025	Mar	NEWA
AA		40MEQ/15ML	A211992	002	Apr 09, 2025	Mar	NEWA
AA	AUROBINDO PHARMA	20MEQ/15ML	A216536	001	Nov 20, 2025	Nov	NEWA
AA		40MEQ/15ML	A216536	002	Nov 20, 2025	Nov	NEWA
AA	MACLEODS PHARMS LTD	20MEQ/15ML	A218733	001	Sep 10, 2025	Aug	NEWA
AA		40MEQ/15ML	A218733	002	Sep 10, 2025	Aug	NEWA
>A>	AA QUAGEN	20MEQ/15ML	A215716	001	Dec 22, 2025	Dec	NEWA
>A>	AA	40MEQ/15ML	A215716	002	Dec 22, 2025	Dec	NEWA
AA	TARO	20MEQ/15ML	A218960	001	Jul 22, 2025	Jul	NEWA

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

	@ AMNEAL	10MEQ	A212861	001	May 08, 2020	Oct	DISC
	@	20MEQ	A212861	003	May 08, 2020	Oct	DISC
AB1	GUANGZHOU NOVAKEN	10MEQ	A214395	001	Jan 28, 2021	Apr	CAHN
AB1		20MEQ	A214395	002	Jan 28, 2021	Apr	CAHN
AB2	NORVIUM BIOSCIENCE	8MEQ	A204662	001	Aug 21, 2014	May	CAHN
AB2		10MEQ	A204662	002	Aug 21, 2014	May	CAHN

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	OTSUKA ICU MEDCL	149MG/100ML;450MG/100ML	A078446	001	Sep 10, 2008	May	CAHN
----	------------------	-------------------------	---------	-----	--------------	-----	------

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION;INTRAVENOUS

POTASSIUM PHOSPHATES

AP	CIPLA	1.18GM/5ML (236MG/ML); 1.12GM/5ML (224MG/ML)	A217892	001	Jan 24, 2025	Jan	NEWA
AP		3.54GM/15ML (236MG/ML); 3.36GM/15ML (224MG/ML)	A217892	002	Jan 24, 2025	Jan	NEWA
AP		11.8GM/50ML (236MG/ML); 11.2GM/50ML (224MG/ML)	A217892	003	Jan 24, 2025	Jan	NEWA
AP	HOSPIRA	3.54GM/15ML (236MG/ML); 3.36GM/15ML	A217459	001	Sep 11, 2025	Sep	NEWA
	POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE						
	+! FRESENIUS KABI USA	1.18GM/100ML (11.8MG/ML); 1.12GM/100ML (11.2MG/ML)	N212832	004	May 09, 2025	May	NEWA
	+!	1.18GM/250ML (4.72MG/ML); 1.12GM/250ML (4.48MG/ML)	N212832	005	May 09, 2025	May	NEWA

PRALATREXATE

SOLUTION;INTRAVENOUS

FOLOTYN

AP	+ ACROTECH BIOPHARMA	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009	Feb	CFTG
AP	+!	40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009	Feb	CFTG
	PRALATREXATE						
AP	DR REDDYS	20MG/ML (20MG/ML)	A206183	001	Mar 10, 2025	Feb	NFTG
AP		40MG/2ML (20MG/ML)	A206183	002	Mar 10, 2025	Feb	NFTG

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

	@ AVIV PHARMA	0.125MG	A091450	001	Oct 08, 2010	May	CAHN
	@	0.25MG	A091450	002	Oct 08, 2010	May	CAHN
	@	0.5MG	A091450	003	Oct 08, 2010	May	CAHN
	@	1MG	A091450	004	Oct 08, 2010	May	CAHN

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

	@		1.5MG	A091450	005	Oct 08, 2010	May CAHN
AB		PHARMOBEDIENT	0.125MG	A090151	001	Apr 30, 2012	Aug CAHN
AB			0.25MG	A090151	002	Apr 30, 2012	Aug CAHN
AB			0.5MG	A090151	003	Apr 30, 2012	Aug CAHN
AB			0.75MG	A090151	006	Apr 30, 2012	Aug CAHN
AB			1MG	A090151	004	Apr 30, 2012	Aug CAHN
AB			1.5MG	A090151	005	Apr 30, 2012	Aug CAHN

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS

SYMLIN

	@ +	ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007	Oct DISC
	@ +		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Oct DISC

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

PRASUGREL

>D>	AB	AMNEAL PHARMS	EQ 5MG BASE	A205913	001	Jun 19, 2018	Dec DISC
>A>		@	EQ 5MG BASE	A205913	001	Jun 19, 2018	Dec DISC
>D>	AB		EQ 10MG BASE	A205913	002	Jun 19, 2018	Dec DISC
>A>		@	EQ 10MG BASE	A205913	002	Jun 19, 2018	Dec DISC

PREDNISOLONE

SOLUTION;ORAL

PREDNISOLONE

AA	!	CHARTWELL RX	15MG/5ML	A040323	001	May 13, 1999	Jun CDFR
	@	HIKMA	15MG/5ML	A040401	001	Feb 27, 2003	Jun CDFR
	@	IVAX SUB TEVA PHARMS	15MG/5ML	A040287	001	May 28, 1999	Jun CDFR
AA		LANNETT CO INC	15MG/5ML	A040775	001	Sep 21, 2007	Jun CDFR
	@	NESHER PHARMS	15MG/5ML	A040364	001	Apr 10, 2002	Jun CDFR
	@	PHARM ASSOC	15MG/5ML	A040399	001	Mar 05, 2003	Jun CDFR
AA			15MG/5ML	A040571	001	Aug 25, 2005	Jun CDFR
	@	PHARMOBEDIENT CNSLTG	15MG/5ML	A040313	001	Sep 10, 2003	Jun CDFR
	@	TEVA PHARMS	15MG/5ML	A040322	001	Jan 19, 2000	Jun CDFR
AA		TP ANDA HOLDINGS	15MG/5ML	A219509	001	Jun 23, 2025	Aug CAHN
AA		TULEX PHARMS INC	15MG/5ML	A219509	001	Jun 23, 2025	Jun NEWA
	@	WE PHARMS	15MG/5ML	A040192	001	May 28, 1998	Jun CDFR
		PRELONE					
AA		TEVA	15MG/5ML	A089081	001	Feb 04, 1986	Jun CDFR

PREDNISOLONE ACETATE

SUSPENSION;ORAL

FLO-PRED

	@	SUN PHARMA CANADA	EQ 5MG BASE/5ML	N022067	001	Jan 17, 2008	Aug CAHN
	@		EQ 15MG BASE/5ML	N022067	002	Jan 17, 2008	Aug CAHN

SUSPENSION/DROPS;OPHTHALMIC

PREDNISOLONE ACETATE

AB		AMNEAL	1%	A218256	001	Jun 11, 2025	May NEWA
----	--	--------	----	---------	-----	--------------	----------

PREDNISONE

TABLET;ORAL

PREDNISONE

	@	AIPING PHARM INC	5MG	A080336	002		Jan CAHN
AB	+	HIKMA	1MG	A080352	002	Apr 22, 1982	Apr CMS1
AB	+		2.5MG	A080352	003	Apr 22, 1982	Apr CMS1
AB	+		10MG	A080352	004		Apr CMS1
AB	+		20MG	A080352	005		Apr CMS1
AB	+		50MG	A080352	006		Apr CMS1
AB		MYLAN	5MG	A083677	002		Aug CMS1
AB			10MG	A083677	003	Dec 04, 1985	Aug CMS1
AB		POINTVIEW HLDINGS	5MG	A212629	001	Dec 05, 2023	Apr CAHN
AB			10MG	A212629	002	Dec 05, 2023	Apr CAHN
AB			20MG	A212629	003	Dec 05, 2023	Apr CAHN

TABLET, DELAYED RELEASE;ORAL

PREDNISONE

	!	DR REDDYS	1MG	A219477	001	Oct 01, 2025	Sep NEWA
			2MG	A219477	002	Oct 01, 2025	Sep NEWA

PREGABALIN

CAPSULE; ORAL

PREGABALIN

	@	ACTAVIS ELIZABETH	25MG	A 091025	001	Jul 09, 2020	Apr	DISC
	@		50MG	A 091025	002	Jul 09, 2020	Apr	DISC
	@		75MG	A 091025	003	Jul 09, 2020	Apr	DISC
	@		100MG	A 091025	004	Jul 09, 2020	Apr	DISC
	@		150MG	A 091025	005	Jul 09, 2020	Apr	DISC
	@		200MG	A 091025	006	Jul 09, 2020	Apr	DISC
	@		225MG	A 091025	007	Jul 09, 2020	Apr	DISC
	@		300MG	A 091025	008	Jul 09, 2020	Apr	DISC
	@	APOTEX	25MG	A 211685	001	Jul 07, 2021	Apr	DISC
	@		50MG	A 211685	002	Jul 07, 2021	Apr	DISC
	@		75MG	A 211685	003	Jul 07, 2021	Apr	DISC
	@		100MG	A 211685	004	Jul 07, 2021	Apr	DISC
	@		150MG	A 211685	005	Jul 07, 2021	Apr	DISC
	@		200MG	A 211685	006	Jul 07, 2021	Apr	DISC
	@		225MG	A 211685	007	Jul 07, 2021	Apr	DISC
	@		300MG	A 211685	008	Jul 07, 2021	Apr	DISC
>A>	AB	ESKAYEF	25MG	A 212988	001	Mar 08, 2022	Dec	CAHN
	AB		25MG	A 212988	001	Mar 08, 2022	Oct	CAHN
>A>	AB		50MG	A 212988	002	Mar 08, 2022	Dec	CAHN
	AB		50MG	A 212988	002	Mar 08, 2022	Oct	CAHN
>A>	AB		75MG	A 212988	003	Mar 08, 2022	Dec	CAHN
	AB		75MG	A 212988	003	Mar 08, 2022	Oct	CAHN
>A>	AB		100MG	A 212988	004	Mar 08, 2022	Dec	CAHN
	AB		100MG	A 212988	004	Mar 08, 2022	Oct	CAHN
>A>	AB		150MG	A 212988	005	Mar 08, 2022	Dec	CAHN
	AB		150MG	A 212988	005	Mar 08, 2022	Oct	CAHN
>A>	AB		200MG	A 212988	006	Mar 08, 2022	Dec	CAHN
	AB		200MG	A 212988	006	Mar 08, 2022	Oct	CAHN
>A>	AB		225MG	A 212988	007	Mar 08, 2022	Dec	CAHN
	AB		225MG	A 212988	007	Mar 08, 2022	Oct	CAHN
>A>	AB		300MG	A 212988	008	Mar 08, 2022	Dec	CAHN
	AB		300MG	A 212988	008	Mar 08, 2022	Oct	CAHN
		HLTHCARE	25MG	A 091222	001	Feb 21, 2025	Feb	NEWA
			50MG	A 091222	002	Feb 21, 2025	Feb	NEWA
			75MG	A 091222	003	Feb 21, 2025	Feb	NEWA
			100MG	A 091222	004	Feb 21, 2025	Feb	NEWA
			150MG	A 091222	005	Feb 21, 2025	Feb	NEWA
			200MG	A 091222	006	Feb 21, 2025	Feb	NEWA
			225MG	A 091222	007	Feb 21, 2025	Feb	NEWA
			300MG	A 091222	008	Feb 21, 2025	Feb	NEWA
		JUBILANT GENERICS	25MG	A 209530	001	May 20, 2025	May	NEWA
			50MG	A 209530	002	May 20, 2025	May	NEWA
			75MG	A 209530	003	May 20, 2025	May	NEWA
			100MG	A 209530	004	May 20, 2025	May	NEWA
			150MG	A 209530	005	May 20, 2025	May	NEWA
			200MG	A 209530	006	May 20, 2025	May	NEWA
			225MG	A 209530	007	May 20, 2025	May	NEWA
			300MG	A 209530	008	May 20, 2025	May	NEWA
	@	MACLEODS PHARMS LTD	25MG	A 205924	001	Nov 12, 2024	Jun	DISC
	@		50MG	A 205924	002	Nov 12, 2024	Jun	DISC
	@		75MG	A 205924	003	Nov 12, 2024	Jun	DISC
	@		100MG	A 205924	004	Nov 12, 2024	Jun	DISC
	@		150MG	A 205924	005	Nov 12, 2024	Jun	DISC
	@		200MG	A 205924	006	Nov 12, 2024	Jun	DISC
	@		225MG	A 205924	007	Nov 12, 2024	Jun	DISC
	@		300MG	A 205924	008	Nov 12, 2024	Jun	DISC
	AB	PHARMOBEDIENT	25MG	A 091222	001	Feb 21, 2025	Sep	CAHN
	AB		50MG	A 091222	002	Feb 21, 2025	Sep	CAHN
	AB		75MG	A 091222	003	Feb 21, 2025	Sep	CAHN
	AB		100MG	A 091222	004	Feb 21, 2025	Sep	CAHN
	AB		150MG	A 091222	005	Feb 21, 2025	Sep	CAHN
	AB		200MG	A 091222	006	Feb 21, 2025	Sep	CAHN
	AB		225MG	A 091222	007	Feb 21, 2025	Sep	CAHN
	AB		300MG	A 091222	008	Feb 21, 2025	Sep	CAHN
	AB	REGCON HOLDINGS	25MG	A 208113	001	May 17, 2024	Sep	CAHN
	AB		50MG	A 208113	002	May 17, 2024	Sep	CAHN
	AB		75MG	A 208113	004	May 17, 2024	Sep	CAHN
	AB		100MG	A 208113	005	May 17, 2024	Sep	CAHN
	AB		150MG	A 208113	003	May 17, 2024	Sep	CAHN
	AB		200MG	A 208113	006	May 17, 2024	Sep	CAHN

CAPSULE;ORAL  
PREGABALIN

AB		225MG	A208113	007	May 17, 2024	Sep	CAHN	
AB		300MG	A208113	008	May 17, 2024	Sep	CAHN	
AB	RENATA	50MG	A210585	001	Dec 26, 2019	Aug	CAHN	
AB		75MG	A210585	002	Dec 26, 2019	Aug	CAHN	
AB		100MG	A210585	003	Dec 26, 2019	Aug	CAHN	
AB		150MG	A210585	004	Dec 26, 2019	Aug	CAHN	
AB		200MG	A210585	005	Dec 26, 2019	Aug	CAHN	
AB		300MG	A210585	006	Dec 26, 2019	Aug	CAHN	
AB	SOMERSET THERAPS LLC	50MG	A210585	001	Dec 26, 2019	Sep	CAHN	
AB		75MG	A210585	002	Dec 26, 2019	Sep	CAHN	
AB		100MG	A210585	003	Dec 26, 2019	Sep	CAHN	
AB		150MG	A210585	004	Dec 26, 2019	Sep	CAHN	
AB		200MG	A210585	005	Dec 26, 2019	Sep	CAHN	
AB		300MG	A210585	006	Dec 26, 2019	Sep	CAHN	
AB	TORRENT	25MG	A206942	001	Feb 21, 2025	Feb	NEWA	
AB		50MG	A206942	002	Feb 21, 2025	Feb	NEWA	
AB		75MG	A206942	003	Feb 21, 2025	Feb	NEWA	
AB		100MG	A206942	004	Feb 21, 2025	Feb	NEWA	
AB		150MG	A206942	005	Feb 21, 2025	Feb	NEWA	
AB		200MG	A206942	006	Feb 21, 2025	Feb	NEWA	
AB		225MG	A206942	007	Feb 21, 2025	Feb	NEWA	
AB		300MG	A206942	008	Feb 21, 2025	Feb	NEWA	
>D>	AB	WESTMINSTER PHARMS	25MG	A212988	001	Mar 08, 2022	Dec	CAHN
	AB		25MG	A212988	001	Mar 08, 2022	Nov	CAHN
	AB		25MG	A212988	001	Mar 08, 2022	Aug	CAHN
>D>	AB		50MG	A212988	002	Mar 08, 2022	Dec	CAHN
	AB		50MG	A212988	002	Mar 08, 2022	Nov	CAHN
	AB		50MG	A212988	002	Mar 08, 2022	Aug	CAHN
>D>	AB		75MG	A212988	003	Mar 08, 2022	Dec	CAHN
	AB		75MG	A212988	003	Mar 08, 2022	Nov	CAHN
	AB		75MG	A212988	003	Mar 08, 2022	Aug	CAHN
>D>	AB		100MG	A212988	004	Mar 08, 2022	Dec	CAHN
	AB		100MG	A212988	004	Mar 08, 2022	Nov	CAHN
	AB		100MG	A212988	004	Mar 08, 2022	Aug	CAHN
>D>	AB		150MG	A212988	005	Mar 08, 2022	Dec	CAHN
	AB		150MG	A212988	005	Mar 08, 2022	Nov	CAHN
	AB		150MG	A212988	005	Mar 08, 2022	Aug	CAHN
>D>	AB		200MG	A212988	006	Mar 08, 2022	Dec	CAHN
	AB		200MG	A212988	006	Mar 08, 2022	Nov	CAHN
	AB		200MG	A212988	006	Mar 08, 2022	Aug	CAHN
>D>	AB		225MG	A212988	007	Mar 08, 2022	Dec	CAHN
	AB		225MG	A212988	007	Mar 08, 2022	Nov	CAHN
	AB		225MG	A212988	007	Mar 08, 2022	Aug	CAHN
>D>	AB		300MG	A212988	008	Mar 08, 2022	Dec	CAHN
	AB		300MG	A212988	008	Mar 08, 2022	Nov	CAHN
	AB		300MG	A212988	008	Mar 08, 2022	Aug	CAHN

TABLET, EXTENDED RELEASE;ORAL  
PREGABALIN

AB	AIPING PHARM INC	330MG	A217857	001	Jan 28, 2025	Sep	CAHN
	@ ALVOGEN	82.5MG	A211593	001	Apr 13, 2021	Feb	DISC
	@	165MG	A211593	002	Apr 13, 2021	Feb	DISC
	@	330MG	A211593	003	Apr 13, 2021	Feb	DISC
	@ APOTEX	165MG	A213313	001	Apr 13, 2021	Jan	DISC
	@	330MG	A213313	002	Apr 13, 2021	Jan	DISC
AB	HQ PHARMA	330MG	A217857	001	Jan 28, 2025	Jan	NEWA

PRIMIDONE

TABLET;ORAL  
PRIMIDONE

@	CHARTWELL RX	50MG	A040862	001	Oct 03, 2008	Apr	CAHN
@		250MG	A040862	002	Oct 03, 2008	Apr	CAHN

PROBENECID; SULOPENEM ETZADROXIL

TABLET;ORAL  
ORLYNVAH

+!	ITERUM THERAP	500MG;500MG	N213972	001	Oct 25, 2024	Oct	CMFD
@ +		500MG;500MG	N213972	001	Oct 25, 2024	Apr	DISC

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION  
PROCAINAMIDE HYDROCHLORIDE

AP	CAPLIN	100MG/ML	A218674	001	Feb 04, 2025	Jan	NEWA
AP		500MG/ML	A218674	002	Feb 04, 2025	Jan	NEWA

PROCHLORPERAZINE

SUPPOSITORY; RECTAL  
COMPAZINE

@ +	GLAXOSMITHKLINE	2.5MG	N011127	003		Mar	CRLD
@ +		5MG	N011127	001		Mar	CMS1
@ +		5MG	N011127	001		Mar	CRLD
@ +		25MG	N011127	002		Mar	CMS1
@ +		25MG	N011127	002		Mar	CRLD

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION  
PROCHLORPERAZINE EDISYLATE

@	NEXUS	EQ 5MG BASE/ML	A204860	001	Feb 15, 2019	Apr	DISC
---	-------	----------------	---------	-----	--------------	-----	------

PROCHLORPERAZINE MALEATE

TABLET; ORAL  
PROCHLORPERAZINE MALEATE

AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A218734	001	Sep 08, 2025	Aug	NEWA
AB		EQ 10MG BASE	A218734	002	Sep 08, 2025	Aug	NEWA
AB	CEROVENE INC	EQ 5MG BASE	A217847	001	May 19, 2025	May	NEWA
AB		EQ 10MG BASE	A217847	002	May 19, 2025	May	NEWA
AB	DR REDDYS LABS SA	EQ 5MG BASE	A217847	001	May 19, 2025	Sep	CAHN
AB		EQ 10MG BASE	A217847	002	May 19, 2025	Sep	CAHN

PROGESTERONE

CAPSULE; ORAL  
PROMETRIUM

AB	+ ACERTIS PHARMS	100MG	N019781	001	May 14, 1998	May	CAHN
AB	+!	200MG	N019781	002	Oct 15, 1999	May	CAHN
	@	300MG	N019781	003	Oct 15, 1999	May	CAHN

INSERT; VAGINAL  
ENDOMETRIN

AB	+! FERRING	100MG	N022057	001	Jun 21, 2007	Sep	CFTG
AB	XIROMED	100MG	A218391	001	Sep 19, 2025	Sep	NFTG

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL  
PROMETHAZINE HYDROCHLORIDE

@	TARO	12.5MG	A040603	001	Oct 26, 2006	Aug	DISC
@		25MG	A040603	002	Oct 26, 2006	Aug	DISC

SYRUP; ORAL  
PROMETHAZINE HYDROCHLORIDE

AA	COSETTE	6.25MG/5ML	A091675	001	Jun 28, 2012	Jun	CAHN
AA	PHARM ASSOC	6.25MG/5ML	A040643	001	Apr 26, 2006	Aug	CMFD
AA	STRIDES PHARMA	6.25MG/5ML	A040891	001	Mar 13, 2009	Apr	CAHN
	@ TARO	6.25MG/5ML	A040718	001	Apr 04, 2007	Aug	DISC
AA	+! XTTRIUM LABS INC	6.25MG/5ML	A087953	001	Nov 15, 1982	Feb	CAHN

TABLET; ORAL  
PROMETHAZINE HYDROCHLORIDE

>D>	@ INVATECH	12.5MG	A084233	001		Dec	CAHN
>D>	@	25MG	A085146	001		Dec	CAHN
>D>	@	50MG	A085146	002		Dec	CAHN
>A>	@ RISING	12.5MG	A084233	001		Dec	CAHN
>A>	@	25MG	A085146	001		Dec	CAHN
>A>	@	50MG	A085146	002		Dec	CAHN
>D>	AB STRIDES PHARMA	12.5MG	A209177	001	Jun 30, 2017	Dec	DISC
>A>	@	12.5MG	A209177	001	Jun 30, 2017	Dec	DISC
>D>	AB	25MG	A209177	002	Jun 30, 2017	Dec	DISC
>A>	@	25MG	A209177	002	Jun 30, 2017	Dec	DISC
>D>	AB	50MG	A209177	003	Jun 30, 2017	Dec	DISC
>A>	@	50MG	A209177	003	Jun 30, 2017	Dec	DISC

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
PROPARACAINE HYDROCHLORIDE

AT	MANKIND PHARMA	0.5%	A 219136	001	May 21, 2025	May	NEWA
AT	MICRO LABS	0.5%	A 219294	001	Oct 20, 2025	Oct	NEWA

PROPOFOL

INJECTABLE; INJECTION  
PROPOFOL

AB	NANJING KING FRIEND	10MG/ML	A 217945	001	Dec 02, 2025	Nov	NEWA
----	---------------------	---------	----------	-----	--------------	-----	------

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
PROPRANOLOL HYDROCHLORIDE

AB	ANDA REPOSITORY	60MG	A 078065	001	Jan 26, 2007	Sep	CAHN
AB		80MG	A 078065	002	Jan 26, 2007	Sep	CAHN
AB		120MG	A 078065	003	Jan 26, 2007	Sep	CAHN
AB		160MG	A 078065	004	Jan 26, 2007	Sep	CAHN

SOLUTION;ORAL

HEMANGEOL

+	!	PIERRE	4.28MG/ML	N 205410	001	Mar 14, 2014	Oct	CAHN
---	---	--------	-----------	----------	-----	--------------	-----	------

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

@		NORTHSTAR HLTHCARE	10MG	A 078213	001	Jan 10, 2008	Oct	DISC
@			20MG	A 078213	002	Jan 10, 2008	Oct	DISC
@			40MG	A 078213	003	Jan 10, 2008	Oct	DISC
@			60MG	A 078213	004	Jan 10, 2008	Oct	DISC
@			80MG	A 078213	005	Jan 10, 2008	Oct	DISC

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

>D>	AB	+	!	ENDO OPERATIONS	50MG	N 006188	001	Dec	CAHN
>A>	AB	+	!	PH HEALTH	50MG	N 006188	001	Dec	CAHN

PROTAMINE SULFATE

POWDER; INTRAVENOUS

PROTAMINE SULFATE

@		PHARMACIA AND UPJOHN	50MG/VIAL	N 007413	001			Aug	CDFR
@			250MG/VIAL	N 007413	002	Aug 02, 1984		Aug	CDFR

SOLUTION; INTRAVENOUS

PROTAMINE SULFATE

!		FRESENIUS KABI USA	10MG/ML	A 089454	001	Apr 07, 1987		Aug	CDFR
!			50MG/5ML (10MG/ML)	A 089454	001	Apr 07, 1987		Aug	CPOT
!			250MG/25ML (10MG/ML)	A 089454	002	Apr 07, 1987		Aug	NEWA
@		HIKMA	10MG/ML	A 089474	001	Nov 05, 1986		Aug	CDFR
@			10MG/ML	A 089475	001	Nov 05, 1986		Aug	CDFR
@			50MG/5ML (10MG/ML)	A 089474	001	Nov 05, 1986		Aug	CPOT
@			50MG/5ML (10MG/ML)	A 089475	002	Jun 07, 1988		Aug	NEWA
@			250MG/25ML (10MG/ML)	A 089475	001	Nov 05, 1986		Aug	CPOT
@	+	LILLY	10MG/ML	N 006460	002			Aug	CDFR
@	+		50MG/5ML (10MG/ML)	N 006460	002			Aug	CPOT
@	+		250MG/25ML (10MG/ML)	N 006460	003			Aug	DISC
+			250MG/25ML (10MG/ML)	N 006460	003			Aug	NEWA

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

PROTRIPTYLINE HYDROCHLORIDE

AB	!	EPIC PHARMA LLC	10MG	A 202220	002	Nov 19, 2012	Apr	CHRS
	@	HIKMA	5MG	A 078913	001	Sep 16, 2008	Apr	DISC
	@		10MG	A 078913	002	Sep 16, 2008	Apr	DISC

PRUCALOPRIDE SUCCINATE

TABLET;ORAL

PRUCALOPRIDE SUCCINATE

AB		AGGREGA	EQ 1MG BASE	A 219193	001	Jun 24, 2025	Jun	NEWA
AB			EQ 2MG BASE	A 219193	002	Jun 24, 2025	Jun	NEWA
AB		ALKEM LABS LTD	EQ 1MG BASE	A 218295	001	Jun 24, 2025	Jun	NEWA
AB			EQ 2MG BASE	A 218295	002	Jun 24, 2025	Jun	NEWA
AB		AMNEAL	EQ 1MG BASE	A 218812	001	Jun 24, 2025	Sep	CAHN
AB			EQ 2MG BASE	A 218812	002	Jun 24, 2025	Sep	CAHN

## TABLET;ORAL

## PRUCALOPRIDE SUCCINATE

AB	ANNORA PHARMA	EQ 1MG BASE	A219160	001	Jun 24, 2025	Jun	NEWA
AB		EQ 2MG BASE	A219160	002	Jun 24, 2025	Jun	NEWA
AB	APOTEX	EQ 1MG BASE	A218977	001	Jun 24, 2025	Jun	NEWA
AB		EQ 2MG BASE	A218977	002	Jun 24, 2025	Jun	NEWA
AB	APPCO	EQ 1MG BASE	A218963	001	Jun 24, 2025	Jun	NEWA
AB		EQ 2MG BASE	A218963	002	Jun 24, 2025	Jun	NEWA
AB	H2-PHARMA	EQ 1MG BASE	A219216	001	Jun 24, 2025	Jun	NEWA
AB		EQ 2MG BASE	A219216	002	Jun 24, 2025	Jun	NEWA
AB	HIKMA	EQ 1MG BASE	A217662	001	Jun 24, 2025	Jun	NEWA
AB		EQ 2MG BASE	A217662	002	Jun 24, 2025	Jun	NEWA
AB	LUPIN LTD	EQ 1MG BASE	A218847	001	Jun 24, 2025	Jun	NEWA
AB		EQ 2MG BASE	A218847	002	Jun 24, 2025	Jun	NEWA
AB	MSN	EQ 1MG BASE	A218177	001	Jun 24, 2025	Jun	NEWA
AB		EQ 2MG BASE	A218177	002	Jun 24, 2025	Jun	NEWA
AB	SKG PHARMA	EQ 1MG BASE	A218812	001	Jun 24, 2025	Jun	NEWA
AB		EQ 2MG BASE	A218812	002	Jun 24, 2025	Jun	NEWA
AB	SOMERSET THERAP	EQ 1MG BASE	A219078	001	Jun 24, 2025	Jun	NEWA
AB		EQ 2MG BASE	A219078	002	Jun 24, 2025	Jun	NEWA
AB	SPECGX LLC	EQ 1MG BASE	A219193	001	Jun 24, 2025	Aug	CAHN
AB		EQ 2MG BASE	A219193	002	Jun 24, 2025	Aug	CAHN
@	TORRENT	EQ 1MG BASE	A218778	001	Jun 24, 2025	Jul	DISC
AB		EQ 1MG BASE	A218778	001	Jun 24, 2025	Jun	NEWA
@		EQ 2MG BASE	A218778	002	Jun 24, 2025	Jul	DISC
AB		EQ 2MG BASE	A218778	002	Jun 24, 2025	Jun	NEWA
AB	ZENARA	EQ 1MG BASE	A218795	001	Jun 24, 2025	Jun	NEWA
AB		EQ 2MG BASE	A218795	002	Jun 24, 2025	Jun	NEWA
AB	ZYDUS LIFESCIENCES	EQ 1MG BASE	A218056	001	Aug 07, 2025	Sep	CAHN
AB		EQ 2MG BASE	A218056	002	Aug 07, 2025	Sep	CAHN
AB	ZYDUS PHARMS	EQ 1MG BASE	A218056	001	Aug 07, 2025	Aug	NEWA
AB		EQ 2MG BASE	A218056	002	Aug 07, 2025	Aug	NEWA

PYRIMETHAMINE

## TABLET;ORAL

## PYRIMETHAMINE

@	ALVOGEN	25MG	A211271	001	Jul 27, 2021	May	DISC
---	---------	------	---------	-----	--------------	-----	------

QUETIAPINE FUMARATE

## TABLET;ORAL

## QUETIAPINE FUMARATE

AB	GRAVITI PHARMS	EQ 25MG BASE	A077380	001	Mar 27, 2012	Feb	CAHN
AB		EQ 50MG BASE	A077380	002	Mar 27, 2012	Feb	CAHN
AB		EQ 100MG BASE	A077380	003	Mar 27, 2012	Feb	CAHN
AB		EQ 150MG BASE	A077380	004	Mar 27, 2012	Feb	CAHN
AB		EQ 200MG BASE	A077380	005	Mar 27, 2012	Feb	CAHN
AB		EQ 300MG BASE	A077380	006	Mar 27, 2012	Feb	CAHN
AB		EQ 400MG BASE	A077380	007	Mar 27, 2012	Feb	CAHN
@	SUN PHARM	EQ 200MG BASE	A201190	004	Mar 27, 2012	Sep	DISC
	SEROQUEL						
AB	+! CHEPLAPHARM	EQ 25MG BASE	N020639	001	Sep 26, 1997	Mar	CAHN
AB	+	EQ 50MG BASE	N020639	007	Oct 04, 2005	Mar	CAHN
AB	+	EQ 100MG BASE	N020639	002	Sep 26, 1997	Mar	CAHN
@	+	EQ 150MG BASE	N020639	004	Dec 20, 1998	Mar	CAHN
AB	+	EQ 200MG BASE	N020639	003	Sep 26, 1997	Mar	CAHN
AB	+!	EQ 300MG BASE	N020639	005	Jul 26, 2000	Mar	CAHN
AB	+	EQ 400MG BASE	N020639	006	Oct 04, 2005	Mar	CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	QUETIAPINE FUMARATE						
AB	MEDICAP LABS	EQ 50MG BASE	A202939	001	May 09, 2017	Feb	CAHN
AB		EQ 150MG BASE	A202939	002	May 09, 2017	Feb	CAHN
AB		EQ 200MG BASE	A202939	003	May 09, 2017	Feb	CAHN
AB		EQ 300MG BASE	A202939	004	May 09, 2017	Feb	CAHN
AB		EQ 400MG BASE	A202939	005	May 09, 2017	Feb	CAHN
	SEROQUEL XR						
AB	+ CHEPLAPHARM	EQ 50MG BASE	N022047	001	May 17, 2007	Mar	CAHN
AB	+	EQ 150MG BASE	N022047	005	Aug 11, 2008	Mar	CAHN
AB	+!	EQ 200MG BASE	N022047	002	May 17, 2007	Mar	CAHN
AB	+	EQ 300MG BASE	N022047	003	May 17, 2007	Mar	CAHN
AB	+	EQ 400MG BASE	N022047	004	May 17, 2007	Mar	CAHN

RALTEGRAVIR POTASSIUM

TABLET;ORAL

		ISENTRESS							
		+	MSD SUB MERCK	EQ 400MG BASE	N022145	001	Oct 12, 2007	Jan	CTEC
			ISENTRESS HD						
AB		+	MSD SUB MERCK	EQ 600MG BASE	N022145	002	May 26, 2017	Apr	CFTG
			RALTEGRAVIR POTASSIUM						
		@	HETERO LABS LTD III	EQ 400MG BASE	A203540	001	Dec 19, 2024	Jan	DISC
AB			LUPIN LTD	EQ 600MG BASE	A217990	001	May 06, 2025	Apr	NFTG

RAMELTEON

TABLET;ORAL

			RAMELTEON						
AB			APPCO	8MG	A213815	001	Oct 26, 2020	Mar	CAHN
BX			AUROBINDO PHARMA LTD	8MG	A215972	001	Jul 10, 2023	Mar	CTEC
		@	GRANULES	8MG	A213186	001	Aug 21, 2020	Nov	DISC
>D>	BX		I3 PHARMS	8MG	A212650	001	Apr 10, 2020	Dec	CTEC
>A>	AB			8MG	A212650	001	Apr 10, 2020	Dec	CTEC
	BX			8MG	A212650	001	Apr 10, 2020	Mar	CTEC
	BX		XIROMED	8MG	A216209	001	Nov 25, 2022	Mar	CTEC

RAMIPRIL

CAPSULE;ORAL

			ALTACE						
		@ +	KING PHARMS LLC	1.25MG	N019901	001	Jan 28, 1991	Jul	DISC
		@ +		2.5MG	N019901	002	Jan 28, 1991	Jul	DISC
		@ +		5MG	N019901	003	Jan 28, 1991	Jul	DISC
		@ +		10MG	N019901	004	Jan 28, 1991	Jul	DISC
			RAMIPRIL						
AB		!	LUPIN	10MG	A077626	004	Jun 09, 2008	Jul	CHRS
			SOLUTION;ORAL						
			VOSTALLY						
		+	ROSEMONT PHARMS	1MG/ML	N219757	001	Jul 23, 2025	Jul	NEWA

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

			RANITIDINE HYDROCHLORIDE						
		@	APOTEX	EQ 150MG BASE	A074680	001	Sep 12, 1997	Mar	DISC
		@		EQ 300MG BASE	A074680	002	Sep 12, 1997	Mar	DISC
		@	GLENMARK PHARMS INC	EQ 150MG BASE	A078542	001	Nov 19, 2008	Aug	DISC
		@		EQ 300MG BASE	A078542	002	Nov 19, 2008	Aug	DISC
		@	MPP PHARMA	EQ 150MG BASE	A203694	001	Nov 30, 2017	Jun	CAHN
		@		EQ 300MG BASE	A203694	002	Nov 30, 2017	Jun	CAHN

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

			RANOLAZINE						
AB			ARTHUR GRP	500MG	A212781	001	Mar 23, 2020	Jan	CAHN
AB				1GM	A212781	002	Mar 23, 2020	Jan	CAHN
AB		!	CADILA	1GM	A210188	002	Aug 19, 2019	Mar	CHRS
AB			JUBILANT GENERICS	500MG	A211361	001	Apr 15, 2025	Apr	NEWA
AB				1GM	A211361	002	Apr 15, 2025	Apr	NEWA
		@	SUN PHARM	500MG	A211707	001	May 28, 2019	Mar	DISC
		@		1GM	A211707	002	May 28, 2019	Mar	DISC
		@	TORRENT	500MG	A210407	001	Feb 04, 2025	Jun	DISC
AB				500MG	A210407	001	Feb 04, 2025	Jan	NEWA
		@		1GM	A210407	002	Feb 04, 2025	Jun	DISC
AB				1GM	A210407	002	Feb 04, 2025	Jan	NEWA

RASAGILINE MESYLATE

TABLET;ORAL

			RASAGILINE MESYLATE						
>D>		@	CARNEGIE	EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Dec	CMFD
>A>	AB			EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Dec	CMFD
		@		EQ 0.5MG BASE	A201942	001	Nov 18, 2021	Apr	CAHN
>D>		@		EQ 1MG BASE	A201942	002	Nov 18, 2021	Dec	CMFD
>A>	AB			EQ 1MG BASE	A201942	002	Nov 18, 2021	Dec	CMFD
		@		EQ 1MG BASE	A201942	002	Nov 18, 2021	Apr	CAHN
AB			RISING	EQ 0.5MG BASE	A218163	001	Apr 09, 2024	Sep	CAHN
AB				EQ 1MG BASE	A218163	002	Apr 09, 2024	Sep	CAHN
AB			TORRENT	EQ 0.5MG BASE	A210150	001	May 05, 2025	Apr	NEWA

	TABLET;ORAL							
	RASAGILINE MESYLATE							
AB		EQ 1MG BASE		A210150	002	May 05, 2025	Apr	NEWA
	<u>REGORAFENIB</u>							
	TABLET;ORAL							
	REGORAFENIB							
	@	ACTAVIS LABS FL	40MG	A209728	001	Jan 13, 2025	Jul	DISC
AB			40MG	A209728	001	Jan 13, 2025	Jan	NFTG
	STIVARGA							
	+	BAYER HLTHCARE	40MG	N203085	001	Sep 27, 2012	Jul	CTEC
AB	+		40MG	N203085	001	Sep 27, 2012	Jan	CFTG
	<u>RELUGOLIX</u>							
	TABLET;ORAL							
	ORGOVYX							
	+	SUMITOMO PHARMA AM	120MG	N214621	001	Dec 18, 2020	Aug	CAHN
	<u>REMDESIVIR</u>							
	SOLUTION;INTRAVENOUS							
	VEKLURY							
	@ +	GILEAD SCIENCES INC	100MG/20ML (5MG/ML)	N214787	002	Oct 22, 2020	Jun	DISC
	<u>REMIBRUTINIB</u>							
	TABLET;ORAL							
	RHAPSIDO							
	+	NOVARTIS	25MG	N218436	001	Sep 30, 2025	Sep	NEWA
	<u>REPAGLINIDE</u>							
	TABLET;ORAL							
	REPAGLINIDE							
	@	QUAGEN	0.5MG	A090252	001	Aug 23, 2013	Sep	CAHN
	@		1MG	A090252	002	Jan 22, 2014	Sep	CAHN
	@		2MG	A090252	003	Jan 22, 2014	Sep	CAHN
	@	SUN PHARM INDS INC	1MG	A077571	002	Jul 11, 2013	Feb	DISC
	@		2MG	A077571	003	Jul 11, 2013	Feb	DISC
	<u>REPOTRECTINIB</u>							
	CAPSULE;ORAL							
	AUGTYRO							
	+	BRISTOL	160MG	N218213	002	Jun 11, 2024	Jul	CHRS
	<u>RIBAVIRIN</u>							
	FOR SOLUTION;INHALATION							
	RIBAVIRIN							
	!	NAVINTA LLC	6GM/VIAL	A207366	001	Oct 06, 2016	Aug	CHRS
			6GM/VIAL	A207366	001	Oct 06, 2016	Aug	CTEC
	VIRAZOLE							
	@ +	BAUSCH	6GM/VIAL	N018859	001	Dec 31, 1985	Aug	DISC
	<u>RIBOFLAVIN 5'-PHOSPHATE</u>							
	SOLUTION/DROPS;OPHTHALMIC							
	EPIOXA HD/EPIOXA KIT							
>D>	+	GLAUKOS	0.239%;0.177%	N219910	001	Oct 17, 2025	Dec	CAIN
	+		0.239%;0.177%	N219910	001	Oct 17, 2025	Oct	NEWA
	PHOTREXA							
>D>	+	GLAUKOS	0.146%	N203324	001	Apr 15, 2016	Dec	CAIN
>A>	<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM</u>							
>A>	SOLUTION/DROPS;OPHTHALMIC							
>A>	EPIOXA HD/EPIOXA KIT							
>A>	+	GLAUKOS	0.239%;0.177%	N219910	001	Oct 17, 2025	Dec	CAIN
>A>	+		EQ 0.239% BASE/ML;EQ 0.177% BASE/ML	N219910	001	Oct 17, 2025	Dec	CPOT
>A>	PHOTREXA							
>A>	+	GLAUKOS	0.146%	N203324	001	Apr 15, 2016	Dec	CAIN
>A>	PHOTREXA VISCOUS IN DEXTRAN		20%/PHOTREXA					
>A>	+	GLAUKOS	0.146%	N203324	001	Apr 15, 2016	Dec	CTNA
>A>	+		EQ 0.146% BASE/ML;EQ 0.146% BASE/ML	N203324	001	Apr 15, 2016	Dec	CPOT

RIFABUTIN

	CAPSULE;ORAL							
	RIFABUTIN							
>D>	AB	LUPIN LTD	150MG	A090033	001	Feb 24, 2014	Dec	DISC
>A>		@	150MG	A090033	001	Feb 24, 2014	Dec	DISC

RIFAMPIN

	CAPSULE;ORAL							
	RIFADIN							
	@ +	SANOFI AVENTIS US	150MG	N050420	002		Apr	CMS1

RILPIVIRINE HYDROCHLORIDE

	TABLET, FOR SUSPENSION;ORAL							
	EDURANT PED							
	+	JANSSEN PRODS	EQ 2.5MG BASE	N219016	001	Mar 15, 2024	May	CMFD

RILUZOLE

	TABLET;ORAL							
	RILUZOLE							
AB		NORVIUM BIOSCIENCE	50MG	A203042	001	Jul 01, 2013	Feb	CAHN
	@	PHARMOBEDIENT	50MG	A203042	001	Jul 01, 2013	Aug	DISC

RILZABRUTINIB

	TABLET;ORAL							
	WAYRILZ							
	+	GENZYME CORP	400MG	N219685	001	Aug 29, 2025	Aug	NEWA

RISDIPLAM

	TABLET;ORAL							
	EVRYSDI							
	+	GENENTECH INC	5MG	N219285	001	Feb 11, 2025	Feb	NEWA

RISEDRONATE SODIUM

	TABLET;ORAL							
	RISEDRONATE SODIUM							
AB		AUROBINDO PHARMA	150MG	A206768	001	Oct 21, 2016	Oct	CTEC
	TABLET, DELAYED RELEASE;ORAL							
	RISEDRONATE SODIUM							
	@	SUN PHARM	35MG	A203925	001	Jul 09, 2019	Apr	DISC

RISPERIDONE

	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR							
	RYKINDO							
	@ +	SHANDONG LUYE	12.5MG	N212849	001	Jan 13, 2023	Jul	DISC
	INJECTABLE;INTRAMUSCULAR							
	RISPERIDONE							
AB		AMNEAL	12.5MG/VIAL	A218586	001	Sep 02, 2025	Aug	NEWA
AB			25MG/VIAL	A218586	002	Sep 02, 2025	Aug	NEWA
AB			37.5MG/VIAL	A218586	003	Sep 02, 2025	Aug	NEWA
AB			50MG/VIAL	A218586	004	Sep 02, 2025	Aug	NEWA
AB		NANOMI	25MG/VIAL	A211220	001	Sep 02, 2025	Aug	NEWA
AB			37.5MG/VIAL	A211220	002	Sep 02, 2025	Aug	NEWA
AB			50MG/VIAL	A211220	003	Sep 02, 2025	Aug	NEWA
	SOLUTION;ORAL							
	RISPERIDONE							
AA		ANI PHARMS	1MG/ML	A076440	001	Jan 30, 2009	Oct	CMFD
AA		APOZEAL PHARMS	1MG/ML	A078909	001	Jul 29, 2009	Jul	CMFD
	@		1MG/ML	A078909	001	Jul 29, 2009	Apr	CAHN
	@	LANNETT CO INC	1MG/ML	A079158	001	Dec 03, 2010	Feb	DISC
	@	TARO	1MG/ML	A090347	001	Feb 07, 2011	Jul	DISC
	TABLET;ORAL							
	RISPERIDONE							
	@	APOTEX INC	0.25MG	A077953	001	Sep 15, 2008	Mar	DISC
	@		0.5MG	A077953	002	Sep 15, 2008	Mar	DISC
	@		1MG	A077953	003	Sep 15, 2008	Mar	DISC
	@		2MG	A077953	004	Sep 15, 2008	Mar	DISC
	@		3MG	A077953	005	Sep 15, 2008	Mar	DISC
	@		4MG	A077953	006	Sep 15, 2008	Mar	DISC
AB		JUBILANT CADISTA	0.25MG	A078828	001	Mar 23, 2009	Nov	CMFD
AB			0.5MG	A078828	002	Mar 23, 2009	Nov	CMFD
AB			1MG	A078828	003	Mar 23, 2009	Nov	CMFD

TABLET;ORAL  
RISPERIDONE

AB		2MG	A 078828	004	Mar 23, 2009	Nov	CMFD
AB		3MG	A 078828	005	Mar 23, 2009	Nov	CMFD
AB		4MG	A 078828	006	Mar 23, 2009	Nov	CMFD
AB	RENATA	0.25MG	A 078707	001	Dec 29, 2008	Aug	CAHN
AB		0.5MG	A 078707	002	Dec 29, 2008	Aug	CAHN
AB		1MG	A 078707	003	Dec 29, 2008	Aug	CAHN
AB		2MG	A 078707	004	Dec 29, 2008	Aug	CAHN
AB		3MG	A 078707	005	Dec 29, 2008	Aug	CAHN
AB		4MG	A 078707	006	Dec 29, 2008	Aug	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL  
RISPERIDONE

>D>	AB	ANDA REPOSITORY	0.5MG	A 077328	001	Feb 24, 2009	Dec	CAHN
>D>	AB		1MG	A 077328	002	Oct 05, 2009	Dec	CAHN
>D>	AB		2MG	A 077328	003	Feb 24, 2009	Dec	CAHN
>D>	AB		3MG	A 077328	004	Nov 30, 2009	Dec	CAHN
>D>	AB		4MG	A 077328	005	Nov 30, 2009	Dec	CAHN
>A>	AB	SENORES PHARMS	0.5MG	A 077328	001	Feb 24, 2009	Dec	CAHN
>A>	AB		1MG	A 077328	002	Oct 05, 2009	Dec	CAHN
>A>	AB		2MG	A 077328	003	Feb 24, 2009	Dec	CAHN
>A>	AB		3MG	A 077328	004	Nov 30, 2009	Dec	CAHN
>A>	AB		4MG	A 077328	005	Nov 30, 2009	Dec	CAHN
	@	SUN PHARM INDS LTD	0.5MG	A 078464	001	Apr 08, 2013	Jul	DISC
	@		1MG	A 078464	002	Apr 08, 2013	Jul	DISC
	@		2MG	A 078464	003	Apr 08, 2013	Jul	DISC
	@		3MG	A 078464	004	Apr 08, 2013	Jul	DISC
	@		4MG	A 078464	005	Apr 08, 2013	Jul	DISC

RITONAVIR

CAPSULE;ORAL  
RITONAVIR

		QUAGEN	100MG	A 205024	001	Feb 16, 2024	Sep	CAHN
--	--	--------	-------	----------	-----	--------------	-----	------

RIVAROXABAN

FOR SUSPENSION;ORAL  
RIVAROXABAN

AB		ALKEM LABS LTD	1MG/ML	A 218502	001	Jun 26, 2025	Jun	NFTG
AB		LUPIN LTD	1MG/ML	A 218195	001	Sep 25, 2025	Sep	NEWA
AB	XARELTO							
AB	+!	JANSSEN PHARMS	1MG/ML	N 215859	001	Dec 20, 2021	Jun	CFTG

TABLET;ORAL

RIVAROXABAN

AB		AIPING PHARM INC	10MG	A 216995	001	May 14, 2025	Sep	CAHN
AB			15MG	A 216995	002	May 14, 2025	Sep	CAHN
AB			20MG	A 216995	003	May 14, 2025	Sep	CAHN
AB	ALEMBIC		2.5MG	A 210301	001	May 14, 2025	May	NEWA
AB			10MG	A 210301	002	May 14, 2025	May	NFTG
AB			15MG	A 210301	003	May 14, 2025	May	NFTG
AB			20MG	A 210301	004	May 14, 2025	May	NFTG
AB	APOTEX		2.5MG	A 217810	001	May 02, 2025	Apr	NEWA
AB			10MG	A 208579	001	Nov 14, 2025	Nov	NEWA
AB			15MG	A 208579	002	Nov 14, 2025	Nov	NEWA
AB			20MG	A 208579	003	Nov 14, 2025	Nov	NEWA
AB	ASCENT PHARMS INC		2.5MG	A 219332	001	May 14, 2025	May	NEWA
AB			10MG	A 219332	002	May 14, 2025	May	NFTG
AB			15MG	A 219332	003	May 14, 2025	May	NFTG
AB			20MG	A 219332	004	May 14, 2025	May	NFTG
AB	AUROBINDO PHARMA LTD		2.5MG	A 208544	001	Apr 10, 2025	Apr	NEWA
AB			10MG	A 208544	002	May 15, 2025	May	NEWA
AB			15MG	A 208544	003	May 15, 2025	May	NEWA
AB			20MG	A 208544	004	May 15, 2025	May	NEWA
AB	BIOCON PHARMA		2.5MG	A 218107	001	May 14, 2025	May	NEWA
AB			10MG	A 218107	002	May 14, 2025	May	NFTG
AB			15MG	A 218107	003	May 14, 2025	May	NFTG
AB			20MG	A 218107	004	May 14, 2025	May	NFTG
AB	BRECKENRIDGE		10MG	A 208220	001	May 15, 2025	May	NEWA
AB			15MG	A 208220	002	May 15, 2025	May	NEWA
AB			20MG	A 208220	003	May 15, 2025	May	NEWA
AB	CHANGZHOU PHARM		10MG	A 216995	001	May 14, 2025	May	NFTG
AB			15MG	A 216995	002	May 14, 2025	May	NFTG
AB			20MG	A 216995	003	May 14, 2025	May	NFTG
AB	DR REDDYS		2.5MG	A 208534	001	May 14, 2025	May	NEWA

TABLET;ORAL  
RIVAROXABAN

AB			10MG	A208534	002	May 14, 2025	May	NFTG
AB			15MG	A208534	003	May 14, 2025	May	NFTG
AB			20MG	A208534	004	May 14, 2025	May	NFTG
AB	INDOCO		2.5MG	A218445	001	Aug 11, 2025	Aug	NEWA
AB			10MG	A218445	002	Aug 11, 2025	Aug	NEWA
AB			15MG	A218445	003	Aug 11, 2025	Aug	NEWA
AB			20MG	A218445	004	Aug 11, 2025	Aug	NEWA
AB	@	INVAGEN PHARMS	10MG	A208543	001	May 14, 2025	Aug	DISC
AB			10MG	A208543	001	May 14, 2025	May	NFTG
AB	@		15MG	A208543	002	May 14, 2025	Aug	DISC
AB			15MG	A208543	002	May 14, 2025	May	NFTG
AB	@		20MG	A208543	003	May 14, 2025	Aug	DISC
AB			20MG	A208543	003	May 14, 2025	May	NFTG
AB		LUPIN LTD	2.5MG	A208555	001	Mar 03, 2025	Feb	NFTG
AB			10MG	A208555	002	May 14, 2025	May	NFTG
AB			15MG	A208555	003	May 14, 2025	May	NFTG
AB			20MG	A208555	004	May 14, 2025	May	NFTG
AB		MACLEODS PHARMS LTD	2.5MG	A213114	001	May 14, 2025	May	NEWA
AB			10MG	A213114	002	May 14, 2025	May	NFTG
AB			15MG	A213114	003	May 14, 2025	May	NFTG
AB			20MG	A213114	004	May 14, 2025	May	NFTG
AB		MSN	2.5MG	A208546	001	Oct 24, 2025	Oct	NEWA
AB	@		10MG	A208546	002	Oct 24, 2025	Oct	DISC
AB			10MG	A208546	002	Oct 24, 2025	Oct	NEWA
AB	@		15MG	A208546	003	Oct 24, 2025	Oct	DISC
AB			15MG	A208546	003	Oct 24, 2025	Oct	NEWA
AB	@		20MG	A208546	004	Oct 24, 2025	Oct	DISC
AB			20MG	A208546	004	Oct 24, 2025	Oct	NEWA
AB		SCIEGEN PHARMS	2.5MG	A218117	001	Jul 31, 2025	Jul	NEWA
AB			10MG	A218117	002	Jul 31, 2025	Jul	NEWA
AB			15MG	A218117	003	Jul 31, 2025	Jul	NEWA
AB			20MG	A218117	004	Jul 31, 2025	Jul	NEWA
AB		SUNSHINE	10MG	A213348	001	May 14, 2025	May	NFTG
AB			15MG	A213348	002	May 14, 2025	May	NFTG
AB			20MG	A213348	003	May 14, 2025	May	NFTG
AB		TARO	2.5MG	A208557	001	Mar 03, 2025	Feb	NFTG
AB			10MG	A208557	002	Oct 07, 2025	Sep	NEWA
AB			15MG	A208557	003	Oct 07, 2025	Sep	NEWA
AB			20MG	A208557	004	Oct 07, 2025	Sep	NEWA
<u>XARELTO</u>								
AB	+	JANSSEN PHARMS	2.5MG	N022406	004	Oct 11, 2018	Feb	CFTG
AB	+		10MG	N022406	001	Jul 01, 2011	May	CFTG
AB	+		15MG	N022406	002	Nov 04, 2011	May	CFTG
AB	+		20MG	N022406	003	Nov 04, 2011	May	CFTG

RIVASTIGMINE

## FILM, EXTENDED RELEASE;TRANSDERMAL

## RIVASTIGMINE

	@	ALVOGEN	4.6MG/24HR	A204403	001	Sep 03, 2015	Mar	DISC
	@		9.5MG/24HR	A204403	002	Sep 03, 2015	Mar	DISC
	@		13.3MG/24HR	A204403	003	Aug 31, 2015	Mar	DISC
AB		YICHANG HUMANWELL	4.6MG/24HR	A215445	001	Sep 23, 2025	Sep	NEWA
AB			9.5MG/24HR	A215445	002	Sep 23, 2025	Sep	NEWA
AB			13.3MG/24HR	A215445	003	Sep 23, 2025	Sep	NEWA

RIZATRIPTAN BENZOATE

## TABLET;ORAL

## RIZATRIPTAN BENZOATE

AB		NORVIUM BIOSCIENCE	EQ 5MG BASE	A201993	001	Dec 31, 2012	Feb	CAHN
AB			EQ 10MG BASE	A201993	002	Dec 31, 2012	Feb	CAHN
<u>TABLET, ORALLY DISINTEGRATING;ORAL</u>								
	@	NATCO PHARMA LTD	EQ 5MG BASE	A203478	001	Jul 01, 2013	Jun	DISC
	@		EQ 10MG BASE	A203478	002	Jul 01, 2013	Jun	DISC

ROCURONIUM BROMIDE

## INJECTABLE;INJECTION

## ROCURONIUM BROMIDE

>A>	AP	KNACK	50MG/5ML (10MG/ML)	A213476	001	Jan 06, 2026	Dec	NEWA
>A>	AP		100MG/10ML (10MG/ML)	A213476	002	Jan 06, 2026	Dec	NEWA
AP		MANKIND PHARMA	50MG/5ML (10MG/ML)	A219674	001	May 29, 2025	May	NEWA

INJECTABLE; INJECTION  
ROCURONIUM BROMIDE

AP			100MG/10ML (10MG/ML)	A219674	002	May 29, 2025	May NEWA	
	@	RISING	50MG/5ML (10MG/ML)	A204918	001	Jul 12, 2024	Sep CAHN	
	@		100MG/10ML (10MG/ML)	A204918	002	Jul 12, 2024	Sep CAHN	
SOLUTION; INTRAVENOUS								
ROCURONIUM BROMIDE								
>A>		+!	B BRAUN MEDICAL	50MG/5ML (10MG/ML)	N219108	001	Oct 24, 2025	Dec CAHN
		+!	FRESENIUS KABI USA	50MG/5ML (10MG/ML)	N217472	001	Jun 09, 2025	Jun NEWA
		+!		100MG/10ML (10MG/ML)	N217472	002	Jun 09, 2025	Jun NEWA
>D>		+!	STERINOVA INC	50MG/5ML (10MG/ML)	N219108	001	Oct 24, 2025	Dec CAHN
		+!		50MG/5ML (10MG/ML)	N219108	001	Oct 24, 2025	Oct NEWA

ROFLUMILAST

CREAM; TOPICAL  
ZORYVE

		+!	ARCUTIS	0.05%	N215985	003	Oct 04, 2025	Oct NEWA
--	--	----	---------	-------	---------	-----	--------------	----------

TABLET; ORAL

ROFLUMILAST

>D>	@	ANDA REPOSITORY	250MCG	A208236	002	Oct 19, 2023	Dec CAHN
>D>	@		500MCG	A208236	001	Oct 03, 2018	Dec CAHN
AB		AUROBINDO PHARMA LTD	250MCG	A213298	002	Jan 31, 2025	Jan NEWA
>A>	@	SENORES PHARMS	250MCG	A208236	002	Oct 19, 2023	Dec CAHN
	@		250MCG	A208236	002	Oct 19, 2023	Feb CAHN
>A>	@		500MCG	A208236	001	Oct 03, 2018	Dec CAHN
	@		500MCG	A208236	001	Oct 03, 2018	Feb CAHN
	@	TORRENT	250MCG	A208272	002	Oct 18, 2024	Sep DISC

ROPINIROLE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ROPINIROLE HYDROCHLORIDE

	@	AUROBINDO PHARMA USA	EQ 2MG BASE	A200462	001	Oct 15, 2012	Aug CAHN
	@		EQ 3MG BASE	A200462	002	Oct 15, 2012	Aug CAHN
	@		EQ 4MG BASE	A200462	003	Oct 15, 2012	Aug CAHN
	@		EQ 6MG BASE	A200462	004	Oct 15, 2012	Aug CAHN
	@		EQ 8MG BASE	A200462	005	Oct 15, 2012	Aug CAHN
	@		EQ 12MG BASE	A200462	006	Oct 15, 2012	Aug CAHN
AB		ELITE LABS INC	EQ 2MG BASE	A217862	001	Nov 10, 2025	Oct NEWA
AB			EQ 4MG BASE	A217862	002	Nov 10, 2025	Oct NEWA
AB			EQ 6MG BASE	A217862	003	Nov 10, 2025	Oct NEWA
AB			EQ 8MG BASE	A217862	004	Nov 10, 2025	Oct NEWA
AB			EQ 12MG BASE	A217862	005	Nov 10, 2025	Oct NEWA

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

AP		ANTHEA PHARMA	20MG/10ML (2MG/ML)	A219883	004	Oct 08, 2025	Nov CAHN
AP			40MG/20ML (2MG/ML)	A219883	001	Mar 21, 2025	Nov CAHN
AP			40MG/20ML (2MG/ML)	A219883	001	Mar 21, 2025	Mar NEWA
AP			100MG/20ML (5MG/ML)	A219883	005	Oct 08, 2025	Nov CAHN
AP			150MG/30ML (5MG/ML)	A219883	002	Mar 21, 2025	Nov CAHN
AP			150MG/30ML (5MG/ML)	A219883	002	Mar 21, 2025	Mar NEWA
AP			200MG/20ML (10MG/ML)	A219883	003	Mar 21, 2025	Nov CAHN
AP			200MG/20ML (10MG/ML)	A219883	003	Mar 21, 2025	Mar NEWA
AP		NEOCUBES PHARMA	20MG/10ML (2MG/ML)	A219883	004	Oct 08, 2025	Sep NEWA
AP			40MG/20ML (2MG/ML)	A219883	001	Mar 21, 2025	Sep CAHN
AP			100MG/20ML (5MG/ML)	A219883	005	Oct 08, 2025	Sep NEWA
AP			150MG/30ML (5MG/ML)	A219883	002	Mar 21, 2025	Sep CAHN
AP			200MG/20ML (10MG/ML)	A219883	003	Mar 21, 2025	Sep CAHN

ROSUVASTATIN CALCIUM

TABLET; ORAL

CRESTOR

AB		+	ASTRAZENECA	EQ 5MG BASE	N021366	002	Aug 12, 2003	Jan CAHN
AB		+		EQ 10MG BASE	N021366	003	Aug 12, 2003	Jan CAHN
AB		+		EQ 20MG BASE	N021366	004	Aug 12, 2003	Jan CAHN
AB		+		EQ 40MG BASE	N021366	005	Aug 12, 2003	Jan CAHN

ROSUVASTATIN CALCIUM

>D>	AB		LUPIN	EQ 5MG BASE	A205587	001	Jul 31, 2017	Dec DISC
>A>		@		EQ 5MG BASE	A205587	001	Jul 31, 2017	Dec DISC
>D>	AB			EQ 10MG BASE	A205587	002	Jul 31, 2017	Dec DISC
>A>		@		EQ 10MG BASE	A205587	002	Jul 31, 2017	Dec DISC
>D>	AB			EQ 20MG BASE	A205587	003	Jul 31, 2017	Dec DISC

## TABLET;ORAL

## ROSUVASTATIN CALCIUM

>A>	@		EQ 20MG BASE	A205587	003	Jul 31, 2017	Dec	DISC
>D>	AB		EQ 40MG BASE	A205587	004	Jul 31, 2017	Dec	DISC
>A>	@		EQ 40MG BASE	A205587	004	Jul 31, 2017	Dec	DISC
	@	MACLEODS PHARMS LTD	EQ 5MG BASE	A207296	001	Nov 06, 2024	Jun	DISC
	@		EQ 10MG BASE	A207296	002	Nov 06, 2024	Jun	DISC
	@		EQ 20MG BASE	A207296	003	Nov 06, 2024	Jun	DISC
	@		EQ 40MG BASE	A207296	004	Nov 06, 2024	Jun	DISC
	@	MANKIND PHARMA	EQ 5MG BASE	A206603	001	May 16, 2025	Sep	DISC
AB			EQ 5MG BASE	A206603	001	May 16, 2025	May	NEWA
	@		EQ 10MG BASE	A206603	002	May 16, 2025	Sep	DISC
AB			EQ 10MG BASE	A206603	002	May 16, 2025	May	NEWA
	@		EQ 20MG BASE	A206603	003	May 16, 2025	Sep	DISC
AB			EQ 20MG BASE	A206603	003	May 16, 2025	May	NEWA
	@		EQ 40MG BASE	A206603	004	May 16, 2025	Sep	DISC
AB			EQ 40MG BASE	A206603	004	May 16, 2025	May	NEWA
AB		RENATA	EQ 5MG BASE	A207062	001	Oct 31, 2016	Aug	CAHN
AB			EQ 10MG BASE	A207062	002	Oct 31, 2016	Aug	CAHN
AB			EQ 20MG BASE	A207062	003	Oct 31, 2016	Aug	CAHN
AB			EQ 40MG BASE	A207062	004	Oct 31, 2016	Aug	CAHN
AB		ZHEJIANG JINGXIN	EQ 5MG BASE	A206513	001	Mar 01, 2019	May	CMFD
AB			EQ 10MG BASE	A206513	002	Mar 01, 2019	May	CMFD
AB			EQ 20MG BASE	A206513	003	Mar 01, 2019	May	CMFD
AB			EQ 40MG BASE	A206513	004	Mar 01, 2019	May	CMFD

RUFINAMIDE

## SUSPENSION;ORAL

## RUFINAMIDE

AB		HIKMA	40MG/ML	A207363	001	Apr 23, 2019	Jun	CAHN
AB		MSN	40MG/ML	A214817	001	Apr 15, 2025	Apr	NEWA

SACUBITRIL; VALSARTAN

## TABLET;ORAL

## SACUBITRIL AND VALSARTAN

AB		DR REDDYS	24MG;26MG	A213627	001	Jan 13, 2025	Jan	NEWA
AB			49MG;51MG	A213627	002	Jan 13, 2025	Jan	NEWA
AB			97MG;103MG	A213627	003	Jan 13, 2025	Jan	NEWA
AB		HETERO LABS LTD III	24MG;26MG	A213668	001	Jul 17, 2025	Jul	NEWA
AB			49MG;51MG	A213668	002	Jul 17, 2025	Jul	NEWA
AB			97MG;103MG	A213668	003	Jul 17, 2025	Jul	NEWA
AB		LUPIN	24MG;26MG	A213808	001	Jan 08, 2025	Jan	NEWA
AB			49MG;51MG	A213808	002	Jan 08, 2025	Jan	NEWA
AB			97MG;103MG	A213808	003	Jan 08, 2025	Jan	NEWA
AB		MSN	24MG;26MG	A213748	001	Jul 16, 2025	Jul	NEWA
AB			49MG;51MG	A213748	002	Jul 16, 2025	Jul	NEWA
AB			97MG;103MG	A213748	003	Jul 16, 2025	Jul	NEWA
AB		NOVUGEN PHARMA SDN	24MG;26MG	A213611	001	Jul 16, 2025	Jul	NEWA
AB			49MG;51MG	A213611	002	Jul 16, 2025	Jul	NEWA
AB			97MG;103MG	A213611	003	Jul 16, 2025	Jul	NEWA

SAFINAMIDE MESYLATE

## TABLET;ORAL

## SAFINAMIDE MESYLATE

AB		ZENARA	EQ 50MG BASE	A215913	001	Jun 13, 2025	Jun	NEWA
AB			EQ 100MG BASE	A215913	002	Jun 13, 2025	Jun	NEWA

SAPROPTERIN DIHYDROCHLORIDE

## POWDER;ORAL

## SAPROPTERIN DIHYDROCHLORIDE

>D>	AB	HOPEWELL PHARMA	100MG/PACKET	A216432	001	Sep 03, 2025	Dec	CAHN
	AB		100MG/PACKET	A216432	001	Sep 03, 2025	Aug	NEWA
>D>	AB		500MG/PACKET	A216432	002	Sep 03, 2025	Dec	CAHN
	AB		500MG/PACKET	A216432	002	Sep 03, 2025	Aug	NEWA
>A>	AB	TP ANDA HOLDINGS	100MG/PACKET	A216432	001	Sep 03, 2025	Dec	CAHN
>A>	AB		500MG/PACKET	A216432	002	Sep 03, 2025	Dec	CAHN
		ZELVYSIA						
AB		AUCTA	100MG/PACKET	A218645	001	Apr 29, 2025	Jun	CAHN
AB			500MG/PACKET	A218645	002	Apr 29, 2025	Jun	CAHN
AB		SHANGHAI AUCYUN	100MG/PACKET	A218645	001	Apr 29, 2025	Apr	NEWA
AB			500MG/PACKET	A218645	002	Apr 29, 2025	Apr	NEWA

TABLET;ORAL  
SAPROPTERIN DIHYDROCHLORIDE

AB	AUROBINDO PHARMA	100MG	A216797	001	Jun 09, 2025	May NEWA
AB	ZENARA	100MG	A218797	001	Jun 11, 2025	May NEWA

SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL  
SAXAGLIPTIN

@	SUN PHARM	EQ 2.5MG BASE	A206078	001	Jul 31, 2023	Jul DISC
@		EQ 5MG BASE	A206078	002	Jul 31, 2023	Jul DISC

SCOPOLAMINE

SYSTEM;TRANSDERMAL  
SCOPOLAMINE

AB	AMNEALS PHARMS	1MG/72HR	A218384	001	Jun 09, 2025	May NEWA
AB	! RICONPHARMA LLC	1MG/72HR	A212342	001	Nov 24, 2020	Apr CHRS
AB	+ BAXTER HLTHCARE CORP	1MG/72HR	N017874	001		Apr CHRS

SEBETRALSTAT

TABLET;ORAL  
EKTERLY

+!	KALVISTA	300MG	N219301	001	Jul 03, 2025	Jul NEWA
----	----------	-------	---------	-----	--------------	----------

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL  
ELDEPRYL

@ +	QUAGEN	5MG	N020647	001	May 15, 1996	Sep CAHN
-----	--------	-----	---------	-----	--------------	----------

TABLET;ORAL  
SELEGILINE HYDROCHLORIDE

>A>	AB	I3 PHARMS	5MG	A074672	001	Apr 01, 1997	Dec CAHN
>D>	AB	MLV	5MG	A074672	001	Apr 01, 1997	Dec CAHN
	AB		5MG	A074672	001	Apr 01, 1997	Sep CAHN
	@ +	QUAGEN	5MG	N019334	001	Jun 05, 1989	Sep CAHN

SELENIOS ACID

SOLUTION;INTRAVENOUS  
SELENIOS ACID

AP	+!	AM REGENT	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	N209379	003	Aug 30, 2021	May CFTG
>D>	+!		EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021	Dec CFTG
>A>	AP	+!	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021	Dec CFTG
		+!	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021	Feb CTEC
AP	+!		EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021	Jan CFTG
AP	+!		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	N209379	001	Apr 30, 2019	Feb CFTG
AP		ASPIRO	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	A219633	001	Jun 11, 2025	May NFTG
AP			EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219633	002	Jun 11, 2025	May NEWA
AP		CIPLA	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	A218661	001	Jul 21, 2025	Jul NEWA
AP			EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218661	002	Jul 21, 2025	Jul NEWA
AP		FRESENIUS KABI USA	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	A218779	001	Feb 10, 2025	Jan NFTG
	@		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218779	001	Feb 10, 2025	Jul DISC
AP			EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218779	001	Feb 10, 2025	Feb CMS1
AP		GLAND	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219629	001	Jul 08, 2025	Jun NEWA
>A>	AP	RK PHARMA	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	A218536	001	Dec 31, 2025	Dec NFTG
>A>	AP		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218536	002	Dec 31, 2025	Dec NEWA
AP		SUN PHARM	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219547	001	Feb 20, 2025	Feb NEWA

SELINEXOR

TABLET; ORAL

XPOVIO

+	KARYOPHARM THERAPS	10MG	N212306	005	Mar 10, 2025	Mar	NEWA
+		80MG	N212306	006	Oct 20, 2025	Oct	NEWA

SELPERCATINIB

CAPSULE; ORAL

RETEVMO

+	ELI LILLY AND CO	40MG	N213246	001	May 08, 2020	Jan	CAHN
+	!	80MG	N213246	002	May 08, 2020	Jan	CAHN

TABLET; ORAL

RETEVMO

+	ELI LILLY AND CO	40MG	N218160	001	Apr 10, 2024	Jan	CAHN
+		80MG	N218160	002	Apr 10, 2024	Jan	CAHN
+		120MG	N218160	003	Apr 10, 2024	Jan	CAHN
+	!	160MG	N218160	004	Apr 10, 2024	Jan	CAHN

SELUMETINIB SULFATE

GRANULE; ORAL

KOSELUGO

+	ASTRAZENECA	EQ 5MG BASE	N219943	001	Sep 10, 2025	Sep	NEWA
+	!	EQ 7.5MG BASE	N219943	002	Sep 10, 2025	Sep	NEWA

SEMAGLUTIDE

SOLUTION; SUBCUTANEOUS

OZEMPIC

@ +	NOVO	2MG/1.5ML (1.34MG/ML)	N209637	001	Dec 05, 2017	Sep	DISC
-----	------	-----------------------	---------	-----	--------------	-----	------

TABLET; ORAL

RYBELSUS

+	!	NOVO	1.5MG	N213051	004	Dec 09, 2024	Oct	CHRS
+	!		4MG	N213051	005	Dec 09, 2024	Oct	CHRS

>A> WEGOVY

>A>	+	NOVO	1.5MG	N218316	001	Dec 22, 2025	Dec	NEWA
>A>	+		4MG	N218316	002	Dec 22, 2025	Dec	NEWA
>A>	+		9MG	N218316	003	Dec 22, 2025	Dec	NEWA
>A>	+	!	25MG	N218316	004	Dec 22, 2025	Dec	NEWA

SEPIAPTERIN

POWDER; ORAL

SEPHIENCE

+	PTC THERAP	250MG/PACKET	N219666	001	Jul 28, 2025	Jul	NEWA
+	!	1GM/PACKET	N219666	002	Jul 28, 2025	Jul	NEWA

SERTRALINE HYDROCHLORIDE

CAPSULE; ORAL

SERTRALINE HYDROCHLORIDE

AB	+	ALMATICA	EQ 150MG BASE	N215133	001	Oct 04, 2021	Jul	CFTG
AB	+		EQ 200MG BASE	N215133	002	Oct 04, 2021	Jul	CFTG
AB		ZENARA	EQ 150MG BASE	A218853	001	Jul 16, 2025	Jul	NFTG
AB			EQ 200MG BASE	A218853	002	Jul 16, 2025	Jul	NFTG

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB		HERITAGE	EQ 25MG BASE	A076465	001	Aug 11, 2006	Nov	CAHN
AB			EQ 50MG BASE	A076465	002	Aug 11, 2006	Nov	CAHN
AB			EQ 100MG BASE	A076465	003	Aug 11, 2006	Nov	CAHN
AB		PHARMACO	EQ 25MG BASE	A076882	001	Feb 06, 2007	Sep	CAHN
AB			EQ 50MG BASE	A076882	002	Feb 06, 2007	Sep	CAHN
AB			EQ 100MG BASE	A076882	003	Feb 06, 2007	Sep	CAHN
	@	QUAGEN	EQ 25MG BASE	A078626	001	Jan 31, 2008	Sep	CAHN
	@		EQ 50MG BASE	A078626	002	Jan 31, 2008	Sep	CAHN
	@		EQ 100MG BASE	A078626	003	Jan 31, 2008	Sep	CAHN

SEVABERTINIB

TABLET; ORAL

HYRNUO

+	!	BAYER HEALTHCARE	10MG	N219972	001	Nov 19, 2025	Nov	NEWA
---	---	------------------	------	---------	-----	--------------	-----	------

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL		SEVELAMER CARBONATE					
	@	INVAGEN PHARMS	800MG/PACKET	A206234	001	Jul 12, 2024	Jan DISC
	@		2.4GM/PACKET	A206234	002	Jul 12, 2024	Jan DISC
	@	TORRENT	800MG/PACKET	A215909	001	Feb 27, 2025	Jun DISC
AB			800MG/PACKET	A215909	001	Feb 27, 2025	Feb NEWA
	@		2.4GM/PACKET	A215909	002	Feb 27, 2025	Jun DISC
AB			2.4GM/PACKET	A215909	002	Feb 27, 2025	Feb NEWA
TABLET;ORAL		SEVELAMER CARBONATE					
	@	EPIC PHARMA LLC	800MG	A212970	001	Apr 09, 2020	Jun CAHN
AB		NAVINTA LLC	800MG	A219931	001	Oct 27, 2025	Oct NEWA

SEVELAMER HYDROCHLORIDE

TABLET;ORAL		SEVELAMER HYDROCHLORIDE					
BX		AUROBINDO PHARMA LTD	400MG	A212599	001	Jul 11, 2023	Mar CTEC
BX			800MG	A212599	002	Jul 11, 2023	Mar CTEC
AB		NAVINTA LLC	800MG	A218966	001	Feb 03, 2025	Jan NEWA

SILDENAFIL CITRATE

FILM;ORAL		VYBRIQUE					
>A>							
>A>	+	IBSA	EQ 25MG BASE	N210858	001	Dec 16, 2025	Dec NEWA
>A>	+		EQ 50MG BASE	N210858	002	Dec 16, 2025	Dec NEWA
>A>	+		EQ 75MG BASE	N210858	003	Dec 16, 2025	Dec NEWA
>A>	+	!	EQ 100MG BASE	N210858	004	Dec 16, 2025	Dec NEWA
FOR SUSPENSION;ORAL		SILDENAFIL CITRATE					
AB		APPCO	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Feb CAHN
AB		CHARTWELL RX	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Feb CAHN
	@	LUPIN LTD	EQ 10MG BASE/ML	A211638	001	Mar 23, 2022	Nov DISC
	@	TARO	EQ 10MG BASE/ML	A215522	001	Nov 16, 2021	Aug DISC
TABLET;ORAL		SILDENAFIL CITRATE					
AB		JUBILANT GENERICS	EQ 20MG BASE	A202954	001	Mar 06, 2025	Feb NEWA
	@	MYLAN	EQ 25MG BASE	A201171	001	Mar 25, 2019	Aug DISC
	@		EQ 50MG BASE	A201171	002	Mar 25, 2019	Sep DISC
	@		EQ 100MG BASE	A201171	003	Mar 25, 2019	Oct DISC
AB		UMEDICA	EQ 25MG BASE	A209302	003	Jun 15, 2021	Sep CTEC
AB			EQ 50MG BASE	A209302	001	Aug 25, 2020	Sep CTEC
AB			EQ 100MG BASE	A209302	002	Aug 25, 2020	Sep CTEC

SILODOSIN

CAPSULE;ORAL		RAPAFLO					
	@ +	ABBVIE	4MG	N022206	001	Oct 08, 2008	Jul DISC
	@ +		8MG	N022206	002	Oct 08, 2008	Jul DISC
SILODOSIN							
AB	!	LUPIN LTD	4MG	A206541	001	Dec 03, 2018	Jul CHRS
	@	TORRENT	4MG	A210396	001	Feb 10, 2025	Jun DISC
AB			4MG	A210396	001	Feb 10, 2025	Jan NEWA
	@		8MG	A210396	002	Feb 10, 2025	Jun DISC
AB			8MG	A210396	002	Feb 10, 2025	Jan NEWA

SIMVASTATIN

TABLET;ORAL		SIMVASTATIN					
AB		GRAVITI PHARMS	5MG	A077752	005	Jan 23, 2008	Feb CAHN
AB			10MG	A077752	001	Dec 20, 2006	Feb CAHN
AB			20MG	A077752	002	Dec 20, 2006	Feb CAHN
AB			40MG	A077752	003	Dec 20, 2006	Feb CAHN
AB			80MG	A077752	004	Dec 20, 2006	Feb CAHN
AB		INVAGEN PHARMS	5MG	A206557	005	Oct 27, 2025	Oct NEWA

SIPONIMOD

TABLET; ORAL

MAYZENT

	+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	May CTEC
AB	+		EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Apr CFTG
	+		EQ 1MG BASE	N209884	003	Aug 24, 2021	May CTEC
AB	+		EQ 1MG BASE	N209884	003	Aug 24, 2021	Apr CFTG
	+		EQ 2MG BASE	N209884	002	Mar 26, 2019	May CTEC
AB	+		EQ 2MG BASE	N209884	002	Mar 26, 2019	Apr CFTG

SIPONIMOD

	@	RICONPHARMA LLC	EQ 0.25MG BASE	A218444	001	Apr 22, 2025	May DISC
AB			EQ 0.25MG BASE	A218444	001	Apr 22, 2025	Apr NFTG
	@		EQ 1MG BASE	A218444	002	Apr 22, 2025	May DISC
AB			EQ 1MG BASE	A218444	002	Apr 22, 2025	Apr NFTG
	@		EQ 2MG BASE	A218444	003	Apr 22, 2025	May DISC
AB			EQ 2MG BASE	A218444	003	Apr 22, 2025	Apr NFTG

SIROLIMUS

POWDER; INTRAVENOUS

FYARRO

	+	AADI SUB	100MG/VIAL	N213312	001	Nov 22, 2021	Mar CAHN
--	---	----------	------------	---------	-----	--------------	----------

SOLUTION; ORAL

SIROLIMUS

AA		RISING	1MG/ML	A215116	001	Jul 15, 2025	Jul NEWA
----	--	--------	--------	---------	-----	--------------	----------

SITAGLIPTIN HYDROCHLORIDE

SOLUTION; ORAL

BRYNOVIN

	+	AZURITY	EQ 25MG BASE/ML	N219122	001	Jan 16, 2025	Jan NEWA
--	---	---------	-----------------	---------	-----	--------------	----------

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

>D>	+	MERCK SHARP DOHME	EQ 25MG BASE	N021995	001	Oct 16, 2006	Dec CFTG
>A>	AB		EQ 25MG BASE	N021995	001	Oct 16, 2006	Dec CFTG
>D>	+		EQ 50MG BASE	N021995	002	Oct 16, 2006	Dec CFTG
>A>	AB		EQ 50MG BASE	N021995	002	Oct 16, 2006	Dec CFTG
>D>	+		EQ 100MG BASE	N021995	003	Oct 16, 2006	Dec CFTG
>A>	AB		EQ 100MG BASE	N021995	003	Oct 16, 2006	Dec CFTG
>A>		SITAGLIPTIN PHOSPHATE					
>A>	AB	WATSON LABS INC	EQ 25MG BASE	A202327	001	Dec 30, 2025	Dec NFTG
>A>	AB		EQ 50MG BASE	A202327	002	Dec 30, 2025	Dec NFTG
>A>	AB		EQ 100MG BASE	A202327	003	Dec 30, 2025	Dec NFTG

SODIUM ACETATE

SOLUTION; INTRAVENOUS

SODIUM ACETATE

AP		AMNEAL	100MEQ/50ML (2MEQ/ML)	A218469	001	Aug 08, 2025	Aug NEWA
AP			200MEQ/100ML (2MEQ/ML)	A218469	002	Aug 08, 2025	Aug NEWA
AP		SOMERSET THERAPS LLC	100MEQ/50ML (2MEQ/ML)	A219826	001	Sep 18, 2025	Sep NEWA
AP			200MEQ/100ML (2MEQ/ML)	A219826	002	Sep 18, 2025	Sep NEWA

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE

AP		ANTHEA PHARMA	1MEQ/ML	A219701	001	Jun 26, 2025	Jun NEWA
AP		FRESENIUS KABI USA	0.5MEQ/ML	A206688	001	Aug 25, 2025	Aug NEWA
AP			1MEQ/ML	A206688	002	Aug 25, 2025	Aug NEWA
AP		HOSPIRA	1MEQ/ML	A202495	001	Mar 06, 2017	Nov CTEC
AP			1MEQ/ML	A202495	001	Mar 06, 2017	Nov CTEC
AP		NEOCUBES PHARMA	1MEQ/ML	A219701	001	Jun 26, 2025	Sep CAHN

SOLUTION; INTRAVENOUS

SODIUM BICARBONATE

>A>	AP	ANTHEA PHARMA	50MEQ/50ML (1MEQ/ML)	A219701	001	Jun 26, 2025	Dec CAHN	
	AP	!	EXELA PHARMA	0.5MEQ/ML	A211091	001	Jun 20, 2019	Nov CDFR
	AP	!		0.9MEQ/ML	A211091	002	Jun 20, 2019	Nov CDFR
	AP	!		1MEQ/ML	A211091	003	Jun 20, 2019	Nov CDFR
	AP	!		5MEQ/10ML (0.5MEQ/ML)	A211091	001	Jun 20, 2019	Nov CPOT
	AP	!		10MEQ/10ML (1MEQ/ML)	A211091	003	Jun 20, 2019	Nov CPOT
	AP	!		44.6MEQ/50ML (0.9MEQ/ML)	A211091	002	Jun 20, 2019	Nov CPOT
	AP	!		50MEQ/50ML (1MEQ/ML)	A211091	004	Jun 20, 2019	Nov NEWA

SOLUTION;INTRAVENOUS  
SODIUM BICARBONATE

AP		FRESENIUS KABI USA	0.5MEQ/ML	A206688	001	Aug 25, 2025	Nov	CDFR
AP			1MEQ/ML	A206688	002	Aug 25, 2025	Nov	CDFR
AP			2.5MEQ/5ML (0.5MEQ/ML)	A206688	001	Aug 25, 2025	Nov	CPOT
AP			50MEQ/50ML (1MEQ/ML)	A206688	002	Aug 25, 2025	Nov	CPOT
AP		HOSPIRA	0.5MEQ/ML	A202679	001	Mar 07, 2017	Nov	CDFR
AP	!		0.5MEQ/ML	A202981	001	Mar 04, 2016	Nov	CDFR
	@		0.9MEQ/ML	A077394	001	Nov 09, 2005	Nov	CDFR
AP			0.9MEQ/ML	A202494	001	Mar 06, 2017	Nov	CDFR
	@		1MEQ/ML	A077394	002	Nov 09, 2005	Nov	CDFR
AP			1MEQ/ML	A202432	001	Sep 26, 2017	Nov	CDFR
AP			1MEQ/ML	A202495	001	Mar 06, 2017	Nov	CDFR
AP	!		2.5MEQ/5ML (0.5MEQ/ML)	A202981	001	Mar 04, 2016	Nov	CPOT
AP			5MEQ/10ML (0.5MEQ/ML)	A202679	001	Mar 07, 2017	Nov	CPOT
AP			10MEQ/10ML (1MEQ/ML)	A202495	001	Mar 06, 2017	Nov	CPOT
	@		44.6MEQ/50ML (0.9MEQ/ML)	A077394	001	Nov 09, 2005	Nov	CPOT
AP			44.6MEQ/50ML (0.9MEQ/ML)	A202494	001	Mar 06, 2017	Nov	CPOT
	@		50MEQ/50ML (1MEQ/ML)	A077394	002	Nov 09, 2005	Nov	CPOT
AP			50MEQ/50ML (1MEQ/ML)	A202432	001	Sep 26, 2017	Nov	CPOT
AP			50MEQ/50ML (1MEQ/ML)	A202494	002	Mar 06, 2017	Nov	CPOT
AP			1MEQ/ML	A202494	002	Mar 06, 2017	Nov	CDFR
AP		INTL MEDICATION SYS	1MEQ/ML	A203449	001	Sep 19, 2017	Nov	CDFR
AP			50MEQ/50ML (1MEQ/ML)	A203449	001	Sep 19, 2017	Nov	CPOT
AP		LONG GROVE PHARMS	1MEQ/ML	A216042	001	Feb 27, 2024	Nov	CDFR
AP			50MEQ/50ML (1MEQ/ML)	A216042	001	Feb 27, 2024	Nov	CPOT
AP		NEOCUBES PHARMA	1MEQ/ML	A219701	001	Jun 26, 2025	Nov	CDFR
>D>	AP		50MEQ/50ML (1MEQ/ML)	A219701	001	Jun 26, 2025	Dec	CAHN
AP			50MEQ/50ML (1MEQ/ML)	A219701	001	Jun 26, 2025	Nov	CPOT
AP		OMNIVIUM PHARMS	1MEQ/ML	A216364	001	Jun 15, 2023	Nov	CDFR
AP			50MEQ/50ML (1MEQ/ML)	A216364	001	Jun 15, 2023	Nov	CPOT
AP		STERISCIENCE	1MEQ/ML	A217594	001	Jun 28, 2023	Nov	CDFR
AP			50MEQ/50ML (1MEQ/ML)	A217594	001	Jun 28, 2023	Nov	CPOT

SODIUM BICARBONATE IN PLASTIC CONTAINER

@ +	ABBOTT	0.9MEQ/ML	N019443	001	Jun 03, 1986	Nov	CDFR
@ +		1MEQ/ML	N019443	002	Jun 03, 1986	Nov	CDFR
@ +		44.6MEQ/50ML (0.9MEQ/ML)	N019443	001	Jun 03, 1986	Nov	CPOT
@ +		50MEQ/50ML (1MEQ/ML)	N019443	002	Jun 03, 1986	Nov	CPOT

SODIUM CHLORIDE

INJECTABLE;INJECTION  
SODIUM CHLORIDE 0.9%

@ +	MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012	Aug	DISC
@ +		18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Aug	DISC
@ +		22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Aug	DISC
@ +		27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Aug	DISC
@ +		45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Aug	DISC

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		GVS TM	900MG/100ML	A076316	001	Oct 27, 2004	Sep	CAHN
AP	+	OTSUKA ICU MEDCL	900MG/100ML	N016366	001		May	CAHN

SOLUTION;INJECTION  
SODIUM CHLORIDE 0.9%

AP		NEXUS	90MG/10ML (9MG/ML)	A217535	001	Aug 23, 2023	Mar	CAHN
AP			180MG/20ML (9MG/ML)	A217535	002	Aug 23, 2023	Mar	CAHN

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE;INJECTION  
FERRLECIT

AB	+	SANOFI AVENTIS US	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)	N020955	001	Feb 18, 1999	Aug	CAIN
AB		HIKMA	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)	A078215	001	Mar 31, 2011	Aug	CAIN

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS  
SODIUM FLUORIDE F-18

@	ESSENTIAL ISOTOPES	10-200mCi/ML	A204541	001	Oct 29, 2014	Oct	DISC
@	HOT SHOTS NM LLC	10-200mCi/ML	A204530	001	Jul 29, 2015	Oct	DISC

SODIUM IODIDE I-131

	SOLUTION;ORAL						
	SODIUM IODIDE I 131						
AA	@	CARDINAL HLTH 414	250-1000mCi	A213615	001	Jun 12, 2025	Nov DISC
			250-1000mCi	A213615	001	Jun 12, 2025	Jun NEWA
	@	SUN PHARM INDS INC	50mCi/ML	N017315	001		Nov CAHN

SODIUM NITROPRUSSIDE

	INJECTABLE;INJECTION						
	SODIUM NITROPRUSSIDE						
	@	XIROMED	25MG/ML	A211277	001	Oct 29, 2020	Jan DISC

SODIUM OXYBATE

	SOLUTION;ORAL						
	SODIUM OXYBATE						
AA		AMNEAL	0.5GM/ML	A203631	001	Sep 10, 2025	Aug NEWA
AA		ASCENT PHARMS INC	0.5GM/ML	A210523	001	Nov 05, 2025	Oct NEWA
		XYREM					
AA	+!	JAZZ PHARMS	0.5GM/ML	N021196	001	Jul 17, 2002	Aug CTEC

SODIUM PHENYLEBUTYRATE

	FOR SUSPENSION;ORAL						
	OLPRUVA						
	+	ACER	0.5GM/PACKET	N214860	007	Oct 10, 2025	Oct NEWA
	+		1GM/PACKET	N214860	008	Oct 10, 2025	Oct NEWA

SODIUM POLYSTYRENE SULFONATE

	POWDER;ORAL, RECTAL						
	SODIUM POLYSTYRENE SULFONATE						
AA		AJENAT PHARMS	454GM/BOT	A205727	001	Feb 23, 2016	Jan CAHN
	SUSPENSION;ORAL, RECTAL						
	SODIUM POLYSTYRENE SULFONATE						
AA		LYNE	15GM/60ML	A214912	001	Jun 10, 2025	May NEWA

SOLIFENACIN SUCCINATE

	SUSPENSION;ORAL						
	VESICARE LS						
	@ +	ASTELLAS	1MG/ML	N209529	001	May 26, 2020	Jul DISC
	TABLET;ORAL						
	SOLIFENACIN SUCCINATE						
AB		BOSTAL	5MG	A210281	001	May 20, 2019	Aug CAHN
AB			10MG	A210281	002	May 20, 2019	Aug CAHN
>A>	!	SCIEGEN PHARMS	10MG	A211657	002	May 20, 2019	Dec CHRS
>D>		SCIEGEN PHARMS INC	10MG	A211657	002	May 20, 2019	Dec CHRS
	@	TORRENT	5MG	A209424	001	Mar 04, 2025	Jun DISC
AB			5MG	A209424	001	Mar 04, 2025	Feb NEWA
	@		10MG	A209424	002	Mar 04, 2025	Jun DISC
AB			10MG	A209424	002	Mar 04, 2025	Feb NEWA
>D>	VESICARE						
>D>	AB	+ ASTELLAS	5MG	N021518	001	Nov 19, 2004	Dec DISC
>A>	@ +		5MG	N021518	001	Nov 19, 2004	Dec DISC
>D>	AB	+!	10MG	N021518	002	Nov 19, 2004	Dec DISC
>A>	@ +		10MG	N021518	002	Nov 19, 2004	Dec DISC

SORAFENIB TOSYLATE

	TABLET;ORAL						
	SORAFENIB TOSYLATE						
AB	@	APOTEX	EQ 200MG BASE	A212228	001	Jan 27, 2025	Mar DISC
			EQ 200MG BASE	A212228	001	Jan 27, 2025	Jan NEWA

SPIRONOLACTONE

	SUSPENSION;ORAL						
	SPIRONOLACTONE						
AB		HETERO LABS LTD III	25MG/5ML	A218085	001	Feb 21, 2025	Feb NEWA
	TABLET;ORAL						
	SPIRONOLACTONE						
AB		ANNORA PHARMA	25MG	A217761	001	Jul 25, 2025	Jul NEWA
AB			50MG	A217761	002	Jul 25, 2025	Jul NEWA
AB			100MG	A217761	003	Jul 25, 2025	Jul NEWA
AB		GRAVITI PHARMS	25MG	A219494	001	Jan 23, 2025	Jan NEWA
AB			50MG	A219494	002	Jan 23, 2025	Jan NEWA

TABLET;ORAL  
SPIRONOLACTONE

AB 100MG A219494 003 Jan 23, 2025 Jan NEWA

STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

+! HOSPIRA 100% (5.2ML) N018801 006 May 02, 2023 Sep CMFD

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

@ TARO 100% A077393 001 Aug 11, 2006 Aug DISC

STREPTOZOCIN

INJECTABLE;INJECTION

ZANOSAR

@ + TEVA PHARMS USA 1GM/VIAL N050577 001 May 07, 1982 Feb DISC

SUCCINYLMCHOLINE CHLORIDE

INJECTABLE;INJECTION

SUCCINYLMCHOLINE CHLORIDE

AP FRESENIUS KABI USA 20MG/ML A217885 001 Feb 21, 2025 Feb NEWA

AP REGCON HOLDINGS 20MG/ML A214308 001 May 22, 2020 Sep CAHN

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

SUCCINYLMCHOLINE CHLORIDE

AP FRESENIUS KABI USA 100MG/5ML (20MG/ML) A217884 001 Feb 11, 2025 Jan NEWA

SUCRALFATE

SUSPENSION;ORAL

SUCRALFATE

>A> AB GLENMARK PHARMS LTD 1GM/10ML A212141 001 Jan 05, 2026 Dec NEWA

AB PADAGIS US 1GM/10ML A211780 001 Apr 14, 2025 Apr NEWA

TABLET;ORAL

SUCRALFATE

AB CHARTWELL RX 1GM A074415 001 Jun 08, 1998 Apr CAHN

SUGAMMADEX SODIUM

SOLUTION;INTRAVENOUS

SUGAMMADEX SODIUM

AP B BRAUN MEDICAL EQ 200MG BASE/2ML (EQ 100MG BASE/ML) A214279 001 Aug 05, 2025 Sep CAHN

AP FISIOPHARMA EQ 200MG BASE/2ML (EQ 100MG BASE/ML) A214279 001 Aug 05, 2025 Jul NEWA

SULFACETAMIDE SODIUM

LOTION;TOPICAL

SULFACETAMIDE SODIUM

@ TARO 10% A078668 001 May 20, 2009 Jul DISC

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM

@ PHARMOBEDIANT 10% A040215 001 May 25, 1999 Sep CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL

SEPTRA

>D> AB MONARCH PHARMS 400MG;80MG N017376 001 Dec DISC

>A> @ 400MG;80MG N017376 001 Dec DISC

SEPTRA DS

>D> AB MONARCH PHARMS 800MG;160MG N017376 002 Dec DISC

>A> @ 800MG;160MG N017376 002 Dec DISC

SULFAMETHOXAZOLE AND TRIMETHOPRIM

@ AIPING PHARM INC 400MG;80MG A070890 002 Nov 13, 1986 Aug CMS1

SULFANILAMIDE

CREAM;VAGINAL

AVC

@ + PHARMOBEDIANT 15% N006530 003 Jan 27, 1987 Sep CAHN

SUPPOSITORY;VAGINAL

AVC

@ PHARMOBEDIANT 1.05GM N006530 004 Jan 27, 1987 Sep CAHN

<u>SULFASALAZINE</u>							
TABLET;ORAL							
SULFASALAZINE							
AB	RISING	500MG	A219046	001	Nov 04, 2025	Oct	NEWA
<u>SULINDAC</u>							
TABLET;ORAL							
SULINDAC							
AB	EPIC PHARMA	150MG	A072711	002	Mar 25, 1991	Mar	CMS1
<u>SUMATRIPTAN</u>							
SPRAY;NASAL							
SUMATRIPTAN							
AB	REGCON HOLDINGS	20MG/SPRAY	A208967	001	Feb 17, 2021	Sep	CAHN
<u>SUMATRIPTAN SUCCINATE</u>							
INJECTABLE;SUBCUTANEOUS							
IMITREX STATDOSE							
AB	+! GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N020080	002	Feb 01, 2006	Oct	CTEC
SUMATRIPTAN SUCCINATE							
AB	ALEMBIC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A213518	001	Nov 06, 2025	Oct	NEWA
AB		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A213518	002	Nov 06, 2025	Oct	NEWA
AB	SUN PHARM	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358	001	Jun 21, 2011	Jun	CMFD
TABLET;ORAL							
SUMATRIPTAN SUCCINATE							
AB	IPCA LABS LTD	EQ 25MG BASE	A206019	001	Jul 15, 2025	Jul	NEWA
AB		EQ 50MG BASE	A206019	002	Jul 15, 2025	Jul	NEWA
AB		EQ 100MG BASE	A206019	003	Jul 15, 2025	Jul	NEWA
	@ SUN PHARM INDS	EQ 25MG BASE	A078295	001	Aug 10, 2009	Jul	DISC
	@	EQ 50MG BASE	A078295	002	Aug 10, 2009	Jul	DISC
	@	EQ 100MG BASE	A078295	003	Aug 10, 2009	Jul	DISC
AB	ZHEJIANG	EQ 25MG BASE	A200263	001	Jun 19, 2012	Sep	CAHN
AB		EQ 50MG BASE	A200263	002	Jun 19, 2012	Sep	CAHN
AB		EQ 100MG BASE	A200263	003	Jun 19, 2012	Sep	CAHN
<u>SUNITINIB MALATE</u>							
CAPSULE;ORAL							
SUNITINIB MALATE							
AB	FOSUN WANBANG	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Jan	CAHN
AB		EQ 25MG BASE	A218012	002	Aug 21, 2023	Jan	CAHN
AB		EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Jan	CAHN
AB		EQ 50MG BASE	A218012	004	Aug 21, 2023	Jan	CAHN
AB	MSN	EQ 12.5MG BASE	A214824	001	Feb 14, 2025	Feb	NEWA
AB		EQ 25MG BASE	A214824	002	Feb 14, 2025	Feb	NEWA
AB		EQ 37.5MG BASE	A214824	003	Feb 14, 2025	Feb	NEWA
AB		EQ 50MG BASE	A214824	004	Feb 14, 2025	Feb	NEWA
<u>SUNVOZERTINIB</u>							
TABLET;ORAL							
ZEGFROVY							
	+ DIZAL JIANGSU	150MG	N219839	001	Jul 02, 2025	Jul	NEWA
	+!	200MG	N219839	002	Jul 02, 2025	Jul	NEWA
<u>SUZETRIGINE</u>							
TABLET;ORAL							
JOURNAVX							
	+! VERTEX PHARMS INC	50MG	N219209	001	Jan 30, 2025	Jan	NEWA
<u>TACROLIMUS</u>							
CAPSULE;ORAL							
TACROLIMUS							
AB	AJENAT PHARMS	EQ 0.5MG BASE	A206651	001	Nov 30, 2017	Jan	CAHN
AB		EQ 1MG BASE	A206651	002	Nov 30, 2017	Jan	CAHN
AB		EQ 5MG BASE	A206651	003	Nov 30, 2017	Jan	CAHN
	@ HANGZHOU ZHONGMEI	EQ 0.5MG BASE	A210929	001	Apr 17, 2023	Jul	DISC
	@	EQ 1MG BASE	A210929	002	Apr 17, 2023	Jul	DISC
	@	EQ 5MG BASE	A210929	003	Apr 17, 2023	Jul	DISC

INJECTABLE; INJECTION  
PROGRAF

AP	+!	ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994	Jan CTEC
		TACROLIMUS					
AP		NEXUS	EQ 5MG BASE/ML	A217108	001	Feb 12, 2025	Jan NEWA
		OINTMENT; TOPICAL					
		TACROLIMUS					
BX		ENCUBE	0.1%	A212387	001	Oct 10, 2023	Mar CTEC

TADALAFIL

TABLET; ORAL  
TADALAFIL

>A>	AB1	FOURRTS LABS	2.5MG	A217606	001	Aug 13, 2024	Dec CAHN
>A>	AB1		5MG	A217606	002	Aug 13, 2024	Dec CAHN
>A>	AB1		10MG	A217606	003	Aug 13, 2024	Dec CAHN
>A>	AB1		20MG	A217606	004	Aug 13, 2024	Dec CAHN
>D>	AB1	HIBROW HLTHCARE	2.5MG	A217606	001	Aug 13, 2024	Dec CAHN
	AB1		2.5MG	A217606	001	Aug 13, 2024	Sep CAHN
>D>	AB1		5MG	A217606	002	Aug 13, 2024	Dec CAHN
	AB1		5MG	A217606	002	Aug 13, 2024	Sep CAHN
>D>	AB1		10MG	A217606	003	Aug 13, 2024	Dec CAHN
	AB1		10MG	A217606	003	Aug 13, 2024	Sep CAHN
>D>	AB1		20MG	A217606	004	Aug 13, 2024	Dec CAHN
	AB1		20MG	A217606	004	Aug 13, 2024	Sep CAHN
	AB1	UMEDICA	2.5MG	A211298	001	Oct 23, 2020	Sep CTEC
	AB1		5MG	A211298	002	Oct 23, 2020	Sep CTEC
	AB1		10MG	A211298	003	Oct 23, 2020	Sep CTEC
	AB1		20MG	A211298	004	Oct 23, 2020	Sep CTEC

TALAZOPARIB TOSYLATE

CAPSULE; ORAL  
TALZENNA

@ +	PFIZER	EQ 0.1MG BASE	N211651	005	Jun 20, 2023	Feb DISC
@ +		EQ 0.25MG BASE	N211651	001	Oct 16, 2018	Feb DISC
@ +		EQ 0.35MG BASE	N211651	006	Jun 20, 2023	Feb DISC
@ +		EQ 0.5MG BASE	N211651	003	Sep 20, 2021	Feb DISC
@ +		EQ 0.75MG BASE	N211651	004	Sep 20, 2021	Feb DISC
@ +		EQ 1MG BASE	N211651	002	Oct 16, 2018	Feb DISC

TALETRECTINIB ADIPATE

CAPSULE; ORAL  
IBTROZI

+!	NUVATION	EQ 200MG BASE	N219713	001	Jun 11, 2025	Jun NEWA
----	----------	---------------	---------	-----	--------------	----------

TAMOXIFEN CITRATE

TABLET; ORAL  
TAMOXIFEN CITRATE

@	APOTEX	EQ 10MG BASE	A090878	001	Sep 23, 2011	Mar DISC
@		EQ 20MG BASE	A090878	002	Sep 23, 2011	Mar DISC

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL  
FLOMAX

@ +	SANOFI	0.4MG	N020579	001	Apr 15, 1997	Feb DISC
	TAMSULOSIN HYDROCHLORIDE					
AB	ASCENT PHARMS INC	0.4MG	A214730	001	May 04, 2022	Feb CMFD
AB	GRAVITI PHARMS	0.4MG	A219767	001	May 01, 2025	Apr NEWA
AB	! ZYDUS PHARMS USA INC	0.4MG	A078225	001	Apr 27, 2010	Feb CHRS

TAPINAROF

CREAM; TOPICAL  
VTAMA

+!	ORGANON LLC	1%	N215272	001	May 23, 2022	May CAHN
----	-------------	----	---------	-----	--------------	----------

TAVABOROLE

SOLUTION; TOPICAL  
TAVABOROLE

@	AMNEAL	5%	A212256	001	Nov 25, 2020	Jul DISC
@	TARO	5%	A212215	001	May 07, 2021	Jul DISC

TAZAROTENE

## CREAM; TOPICAL

## AVAGE

AB	+	ALMIRALL	0.1%	N021184	003	Sep 30, 2002	Oct	CAHN
----	---	----------	------	---------	-----	--------------	-----	------

## TAZAROTENE

AB		COSETTE	0.05%	A208662	002	Mar 10, 2025	Feb	NEWA
----	--	---------	-------	---------	-----	--------------	-----	------

AB		LONG GROVE PHARMS	0.05%	A214560	001	Nov 24, 2025	Nov	NEWA
----	--	-------------------	-------	---------	-----	--------------	-----	------

AB		SUN PHARMA CANADA	0.1%	A208258	001	Apr 03, 2017	Sep	CAHN
----	--	-------------------	------	---------	-----	--------------	-----	------

## TAZORAC

AB	+	ALMIRALL	0.05%	N021184	001	Sep 29, 2000	Oct	CAHN
----	---	----------	-------	---------	-----	--------------	-----	------

AB	+		0.1%	N021184	002	Sep 29, 2000	Oct	CAHN
----	---	--	------	---------	-----	--------------	-----	------

## GEL; TOPICAL

## TAZORAC

AB	+	ABBVIE	0.05%	N020600	001	Jun 13, 1997	Aug	CAHN
----	---	--------	-------	---------	-----	--------------	-----	------

AB	+		0.1%	N020600	002	Jun 13, 1997	Aug	CAHN
----	---	--	------	---------	-----	--------------	-----	------

AB	+	ALMIRALL	0.05%	N020600	001	Jun 13, 1997	Oct	CAHN
----	---	----------	-------	---------	-----	--------------	-----	------

AB	+		0.1%	N020600	002	Jun 13, 1997	Oct	CAHN
----	---	--	------	---------	-----	--------------	-----	------

## LOTION; TOPICAL

## ARAZLO

	+	BAUSCH	0.045%	N211882	001	Dec 18, 2019	Aug	CTEC
--	---	--------	--------	---------	-----	--------------	-----	------

AB	+		0.045%	N211882	001	Dec 18, 2019	Jul	CFTG
----	---	--	--------	---------	-----	--------------	-----	------

## TAZAROTENE

	@	PADAGIS ISRAEL	0.045%	A215393	001	Jul 29, 2025	Aug	DISC
--	---	----------------	--------	---------	-----	--------------	-----	------

AB			0.045%	A215393	001	Jul 29, 2025	Jul	NFTG
----	--	--	--------	---------	-----	--------------	-----	------

TECHNETIUM TC-99M MEDRONATE KIT

## INJECTABLE; INJECTION

## OSTEOLITE

	@	SUN PHARM INDS INC	N/A	N017972	001		Feb	CAHN
--	---	--------------------	-----	---------	-----	--	-----	------

TECHNETIUM TC-99M OXIDRONATE KIT

## INJECTABLE; INJECTION

## TECHNESCAN HDP

	+	CURIUM	N/A	N018321	001		Nov	CTNA
--	---	--------	-----	---------	-----	--	-----	------

TECHNETIUM TC-99M PENTETATE KIT

## INJECTABLE; INJECTION

## DRAXIMAGE DTPA

AP	+	JUBILANT	N/A	N018511	001	Dec 29, 1989	Mar	CFTG
----	---	----------	-----	---------	-----	--------------	-----	------

## TECHNETIUM TC-99M PENTETATE KIT

AP		CURIUM	N/A	A215146	001	Mar 26, 2025	Mar	NFTG
----	--	--------	-----	---------	-----	--------------	-----	------

TECHNETIUM TC-99M SESTAMIBI KIT

## INJECTABLE; INJECTION

## TECHNETIUM TC 99M SESTAMIBI

	@	SUN PHARM INDS INC	10-30mCi	A079157	001	Jul 10, 2009	May	DISC
--	---	--------------------	----------	---------	-----	--------------	-----	------

TECHNETIUM TC-99M SODIUM PERTECHNETATE

## SOLUTION; INJECTION, ORAL

## SODIUM PERTECHNETATE TC 99M

	@	SUN PHARM INDS INC	12mCi/ML	N017321	001		May	CAHN
--	---	--------------------	----------	---------	-----	--	-----	------

	@		24mCi/ML	N017321	002		May	CAHN
--	---	--	----------	---------	-----	--	-----	------

	@		48mCi/ML	N017321	003		May	CAHN
--	---	--	----------	---------	-----	--	-----	------

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

## SOLUTION; INTRAVENOUS

## ULTRA-TECHNEKOW V4

	+	CURIUM	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	Jun	CTNA
--	---	--------	-------------------	---------	-----	--------------	-----	------

	@		0.25-3 CI/GENERATOR	N017243	002		Jun	CTNA
--	---	--	---------------------	---------	-----	--	-----	------

## SOLUTION; INTRAVENOUS, ORAL

## DRYTEC

	@ +	GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013	Jun	CTNA
--	-----	---------------	----------------------	---------	-----	--------------	-----	------

	@		830-16600mCi/GENERATOR	N017693	001		Jun	CTNA
--	---	--	------------------------	---------	-----	--	-----	------

TELMISARTAN

## TABLET; ORAL

## MICARDIS

	@ +	BOEHRINGER INGELHEIM	20MG	N020850	003	Apr 04, 2000	Oct	DISC
--	-----	----------------------	------	---------	-----	--------------	-----	------

	@ +		80MG	N020850	002	Nov 10, 1998	Jul	DISC
--	-----	--	------	---------	-----	--------------	-----	------

AB	+		80MG	N020850	002	Nov 10, 1998	Feb	CHRS
----	---	--	------	---------	-----	--------------	-----	------

TABLET;ORAL

TELMISARTAN

	@	HETERO LABS LTD V	20MG	A205901	001	Apr 22, 2016	Oct	DISC
	@		40MG	A205901	002	Apr 22, 2016	Oct	DISC
	@		80MG	A205901	003	Apr 22, 2016	Oct	DISC
AB	!	INVENTIA	80MG	A205150	003	Oct 30, 2015	Feb	CHRS
AB		JUBILANT GENERICS	20MG	A204164	001	Aug 22, 2016	Nov	CMFD
AB			40MG	A204164	002	Aug 22, 2016	Nov	CMFD
AB			80MG	A204164	003	Aug 22, 2016	Nov	CMFD
AB		MACLEODS PHARMS LTD	20MG	A203986	001	Jan 15, 2025	Jan	NEWA
AB			40MG	A203986	002	Jan 15, 2025	Jan	NEWA
AB			80MG	A203986	003	Jan 15, 2025	Jan	NEWA
AB		TORRENT	20MG	A203171	001	Jul 07, 2014	Sep	CMFD
AB			40MG	A203171	002	Jul 07, 2014	Sep	CMFD
AB			80MG	A203171	003	Jul 07, 2014	Sep	CMFD

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

	@	SUN PHARM INDUSTRIES	7.5MG	A078581	001	Sep 08, 2009	Mar	DISC
--	---	----------------------	-------	---------	-----	--------------	-----	------

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

	@	EIRGEN	5MG	A203898	001	Feb 10, 2016	Aug	CAHN
	@		20MG	A203898	002	Feb 10, 2016	Aug	CAHN
AB			100MG	A203898	003	Feb 10, 2016	Aug	CAHN
AB			140MG	A203898	004	Feb 10, 2016	Aug	CAHN
AB			180MG	A203898	005	Feb 10, 2016	Aug	CAHN
AB			250MG	A203898	006	Feb 10, 2016	Aug	CAHN
	@	NEXTSOURCE	5MG	A203898	001	Feb 10, 2016	Mar	CAHN
	@		20MG	A203898	002	Feb 10, 2016	Mar	CAHN
	@		100MG	A203898	003	Feb 10, 2016	Mar	CAHN
AB			100MG	A203898	003	Feb 10, 2016	Mar	CMFD
	@		140MG	A203898	004	Feb 10, 2016	Mar	CAHN
AB			140MG	A203898	004	Feb 10, 2016	Mar	CMFD
	@		180MG	A203898	005	Feb 10, 2016	Mar	CAHN
AB			180MG	A203898	005	Feb 10, 2016	Mar	CMFD
	@		250MG	A203898	006	Feb 10, 2016	Mar	CAHN
AB			250MG	A203898	006	Feb 10, 2016	Mar	CMFD
	@	TRI-SOURCE PHARMA	5MG	A203898	001	Feb 10, 2016	Apr	CAHN
	@		20MG	A203898	002	Feb 10, 2016	Apr	CAHN
AB			100MG	A203898	003	Feb 10, 2016	Apr	CAHN
AB			140MG	A203898	004	Feb 10, 2016	Apr	CAHN
AB			180MG	A203898	005	Feb 10, 2016	Apr	CAHN
AB			250MG	A203898	006	Feb 10, 2016	Apr	CAHN

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

>A>	AB	MICRO LABS	300MG	A206157	001	Dec 18, 2025	Dec	NEWA
-----	----	------------	-------	---------	-----	--------------	-----	------

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB		AJANTA PHARMA LTD	EQ 1MG BASE	A219482	001	May 12, 2025	May	NEWA
AB			EQ 2MG BASE	A219482	002	May 12, 2025	May	NEWA
AB			EQ 5MG BASE	A219482	003	May 12, 2025	May	NEWA
AB			EQ 10MG BASE	A219482	004	May 12, 2025	May	NEWA
	@	HIKMA	EQ 1MG BASE	A075498	001	Apr 12, 2001	Jun	CAHN
	@		EQ 2MG BASE	A075498	002	Apr 12, 2001	Jun	CAHN
	@		EQ 5MG BASE	A075498	003	Apr 12, 2001	Jun	CAHN
	@		EQ 10MG BASE	A075498	004	Apr 12, 2001	Jun	CAHN

SOLUTION;ORAL

TEZRULY

	@ +	NOVITIUM PHARMA	EQ 1MG BASE/ML	N218139	001	Jul 29, 2024	Oct	DISC
--	-----	-----------------	----------------	---------	-----	--------------	-----	------

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

>D>	AB	ANDA REPOSITORY	EQ 250MG BASE	A 076390	001	Jul 02, 2007	Dec CAHN
	@	BRECKENRIDGE PHARM	EQ 250MG BASE	A 077714	001	Jun 04, 2010	Mar DISC
>A>	AB	SENORES PHARMS	EQ 250MG BASE	A 076390	001	Jul 02, 2007	Dec CAHN

TERIFLUNOMIDE

TABLET;ORAL

TERIFLUNOMIDE

	@	APOTEX	7MG	A 209601	001	Nov 02, 2018	Feb DISC
	@		14MG	A 209601	002	Nov 02, 2018	Feb DISC
	@	CONCORD BIOTECH LTD	7MG	A 218663	001	Apr 07, 2025	Nov DISC
AB			7MG	A 218663	001	Apr 07, 2025	Mar NEWA
	@		14MG	A 218663	002	Apr 07, 2025	Nov DISC
AB			14MG	A 218663	002	Apr 07, 2025	Mar NEWA
	@	SOMERSET THERAPS LLC	7MG	A 209702	001	Feb 28, 2020	Sep CAHN
	@		14MG	A 209702	002	Feb 28, 2020	Sep CAHN
	@	WELDING	7MG	A 209702	001	Feb 28, 2020	Jun CAHN
	@		14MG	A 209702	002	Feb 28, 2020	Jun CAHN

TERIPARATIDE

SOLUTION;SUBCUTANEOUS

BONSITY

		ALVOGEN	0.56MG/2.24ML (0.25MG/ML)	N 211939	001	Oct 04, 2019	Feb CPOT
		FORTEO					
AP	+	LILLY	0.56MG/2.24ML (0.25MG/ML)	N 021318	002	Jun 25, 2008	Feb CPOT
		TERIPARATIDE					
AP	+	ALMAJECT	0.56MG/2.24ML (0.25MG/ML)	N 218771	001	Jun 04, 2024	Feb CPOT
AP	+		0.6MG/2.4ML (0.25MG/ML)	N 218771	001	Jun 04, 2024	Feb CTEC
>A>	AP	AMPHASTAR PHARMS INC	0.56MG/2.24ML (0.25MG/ML)	A 213641	001	Dec 12, 2025	Dec NEWA
AP		APOTEX	0.56MG/2.24ML (0.25MG/ML)	A 211097	001	Nov 16, 2023	Feb CPOT
AP		TEVA PHARMS USA	0.56MG/2.24ML (0.25MG/ML)	A 208569	001	Nov 16, 2023	Feb CPOT

TESTOSTERONE

GEL, METERED;TRANSDERMAL

TESTOSTERONE

	@	TWI PHARMS	1.62% (20.25MG/1.25GM ACTUATION)	A 209390	001	Sep 23, 2019	Aug DISC
--	---	------------	----------------------------------	----------	-----	--------------	----------

SOLUTION, METERED;TRANSDERMAL

TESTOSTERONE

	@	ENCUBE	30MG/1.5ML ACTUATION	A 212301	001	Jan 11, 2021	Jan DISC
	@	TWI PHARMS	30MG/1.5ML ACTUATION	A 209836	001	Sep 03, 2021	Jun DISC

TESTOSTERONE UNDECANOATE

CAPSULE;ORAL

KYZATREX

	@ +	MARIUS	100MG	N 213953	001	Jul 27, 2022	Sep DISC
	+		100MG	N 213953	001	Jul 27, 2022	Aug CAHN
	+		150MG	N 213953	002	Jul 27, 2022	Aug CAHN
	+		200MG	N 213953	003	Jul 27, 2022	Aug CAHN

THEOPHYLLINE

SOLUTION, ELIXIR;ORAL

ELIXOPHYLLIN

AA	+	SOLIS PHARMS	80MG/15ML	A 085186	001		Apr CAHN
----	---	--------------	-----------	----------	-----	--	----------

TABLET, EXTENDED RELEASE;ORAL

THEOPHYLLINE

	@	AJANTA PHARMA LTD	300MG	A 218401	002	Mar 26, 2025	Jul DISC
AB			300MG	A 218401	002	Mar 26, 2025	Mar NEWA
	@		450MG	A 218401	001	Jan 13, 2025	Jul DISC
AB			450MG	A 218401	001	Jan 13, 2025	Jan NEWA
AB		MPP PHARMA	400MG	A 040560	003	Apr 21, 2006	Jun CAHN
AB	!		600MG	A 040560	002	Apr 21, 2006	Jun CAHN
	@	RHODES PHARMS	300MG	A 214113	001	May 11, 2023	Jan DISC

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION  
THIAMINE HYDROCHLORIDE

AP	GLAND	100MG/ML	A217800	001	Feb 24, 2025	Feb	NEWA
----	-------	----------	---------	-----	--------------	-----	------

THIOTEPA

INJECTABLE; INJECTION  
THIOTEPA

AP	REGCON HOLDINGS	15MG/VIAL	A211831	001	Dec 08, 2021	Oct	CAHN
	POWDER; INTRACAVITARY, INTRAVENOUS, INTRAVESICAL						
	THIOTEPA						

AP	REGCON HOLDINGS	15MG/VIAL	A217559	001	Aug 20, 2024	Sep	CAHN
	POWDER; INTRAVENOUS						
	TEPADINA AND SODIUM CHLORIDE						

	+! ADIENNE SA	200MG	N208264	003	Apr 10, 2025	May	NEWA
	SOLUTION; INTRAVENOUS						
	TEPYLUTE						

	+! SHORLA	100MG/10ML (10MG/ML)	N216984	002	Feb 26, 2025	Mar	NEWA
--	-----------	----------------------	---------	-----	--------------	-----	------

TIAGABINE HYDROCHLORIDE

TABLET; ORAL  
TIAGABINE HYDROCHLORIDE

@	SUN PHARM INDS	2MG	A077555	001	Nov 04, 2011	Jun	DISC
@		4MG	A077555	002	Nov 04, 2011	Jun	DISC

TICAGRELOR

TABLET; ORAL  
BRILINTA

AB	+ ASTRAZENECA	60MG	N022433	002	Sep 03, 2015	Mar	CTEC
	TICAGRELOR						

AB	ALEMBIC	60MG	A208576	002	Oct 28, 2025	Oct	NEWA
AB		90MG	A208576	001	May 01, 2025	Apr	NEWA
AB	ALKEM LABS LTD	60MG	A210219	001	Oct 28, 2025	Oct	NEWA
AB	AMNEAL	60MG	A208531	002	Oct 28, 2025	Oct	NEWA
AB	APOTEX	60MG	A208584	002	Oct 28, 2025	Oct	NEWA
AB		90MG	A208584	001	May 01, 2025	Apr	NEWA
AB	CHANGZHOU PHARM	60MG	A216187	001	Oct 28, 2025	Oct	NEWA
AB		90MG	A216187	002	Oct 28, 2025	Oct	NEWA
AB	DR REDDYS	60MG	A208541	002	Oct 28, 2025	Oct	NEWA
AB	INVAGEN PHARMS	60MG	A208537	002	Oct 28, 2025	Oct	NEWA
AB		90MG	A208537	001	May 05, 2025	Apr	NEWA
AB	MACLEODS PHARMS LTD	60MG	A212258	001	Oct 28, 2025	Oct	NEWA
AB		90MG	A212258	002	Oct 28, 2025	Oct	NEWA
AB	MSN	60MG	A208596	002	Oct 28, 2025	Oct	NEWA
AB		90MG	A208596	001	Apr 07, 2020	Mar	CMFD
	@	90MG	A208596	001	Apr 07, 2020	Feb	CAHN
AB	MYLAN	60MG	A208597	001	Jul 09, 2021	Jul	CMFD
AB		90MG	A208597	002	Jul 09, 2021	Jul	CMFD
AB	SCIEGEN PHARMS	60MG	A218962	001	Oct 28, 2025	Oct	NEWA
AB		90MG	A218962	002	Oct 28, 2025	Oct	NEWA
AB	SUNSHINE	60MG	A208508	002	Oct 28, 2025	Oct	NEWA
AB		90MG	A208508	001	Apr 06, 2020	Mar	CMFD
AB	TARO	60MG	A211498	001	Oct 28, 2025	Oct	NEWA
AB		90MG	A211498	002	Oct 28, 2025	Oct	NEWA
AB	WATSON LABS INC	60MG	A208390	001	Sep 04, 2018	Mar	CMFD
AB		90MG	A208390	002	Sep 04, 2018	Mar	CMFD

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL  
TICLOPIDINE HYDROCHLORIDE

@	APOTEX	250MG	A075089	001	Jul 01, 1999	Mar	DISC
---	--------	-------	---------	-----	--------------	-----	------

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC  
BETIMOL

@ +	THEA PHARMA	0.25%	N020439	001	Mar 31, 1995	Jun	DISC
-----	-------------	-------	---------	-----	--------------	-----	------

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC  
TIMOLOL MALEATE

@	APOTEX	EQ 0.5% BASE	A204936	001	Apr 17, 2015	May	DISC
@	PHARMOBEDIENT	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Sep	CAHN

TIOPRONIN

TABLET, DELAYED RELEASE;ORAL  
TIOPRONIN

AB	AMNEAL	100MG	A216278	002	Aug 29, 2025	Aug	NEWA
	VENXXIVA						
AB	TORRENT	100MG	A216990	001	Jan 30, 2024	Aug	CTNA
AB		300MG	A216990	002	Jan 30, 2024	Aug	CTNA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL  
TIZANIDINE HYDROCHLORIDE

AB	ANDA REPOSITORY	EQ 4MG BASE	A213365	001	May 13, 2024	Sep	CAHN
AB		EQ 6MG BASE	A213365	002	May 13, 2024	Sep	CAHN
AB	RUBICON RESEARCH	EQ 2MG BASE	A213798	001	May 27, 2020	Aug	CAHN
AB		EQ 4MG BASE	A213798	002	May 27, 2020	Aug	CAHN
AB		EQ 6MG BASE	A213798	003	May 27, 2020	Aug	CAHN
AB	!	EQ 8MG BASE	A213798	004	Aug 28, 2025	Aug	NFTG

TABLET;ORAL  
TIZANIDINE HYDROCHLORIDE

AB	RISING	EQ 2MG BASE	A076354	001	Mar 28, 2003	Aug	CMFD
AB		EQ 4MG BASE	A076354	002	Mar 28, 2003	Aug	CMFD

TOBRAMYCIN

POWDER;INHALATION  
TOBI PODHALER

+	VIATRIS	28MG	N201688	001	Mar 22, 2013	Feb	CAHN
---	---------	------	---------	-----	--------------	-----	------

SOLUTION;INHALATION  
TOBI

AN	+	VIATRIS	300MG/5ML	N050753	001	Dec 22, 1997	Feb	CAHN
----	---	---------	-----------	---------	-----	--------------	-----	------

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION  
TOBRAMYCIN SULFATE

@	EUGIA PHARMA	EQ 1.2GM BASE/VIAL	A217519	001	Jun 21, 2023	Aug	DISC
---	--------------	--------------------	---------	-----	--------------	-----	------

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE;ORAL  
TOFACITINIB CITRATE

AB	AJANTA PHARMA LTD	EQ 11MG BASE	A219542	001	Aug 19, 2025	Aug	NEWA	
@	AUROBINDO PHARMA LTD	EQ 11MG BASE	A218462	001	Jun 03, 2024	Aug	CTNA	
AB	BIOCON PHARMA	EQ 11MG BASE	A219442	001	Nov 17, 2025	Nov	NEWA	
@	DEXCEL	EQ 11MG BASE	A218668	001	Dec 16, 2024	Apr	DISC	
AB	SINOTHERAPEUTICS INC	EQ 11MG BASE	A216001	001	Sep 30, 2025	Sep	NEWA	
@	ZYDUS PHARMS	EQ 11MG BASE	A214264	001	Aug 19, 2021	Aug	CTNA	
@		EQ 22MG BASE	A214264	002	Aug 19, 2021	Aug	CTNA	
	XELJANZ XR							
AB	+	PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016	Aug	CTEC
	+		EQ 11MG BASE	N208246	001	Feb 23, 2016	Apr	CTEC

TOLMETIN SODIUM

CAPSULE;ORAL  
TOLMETIN SODIUM

>D>	@	ANDA REPOSITORY	EQ 400MG BASE	A073290	001	Nov 27, 1991	Dec	CAHN
	@		EQ 400MG BASE	A073290	001	Nov 27, 1991	Sep	CAHN
>A>	@	SENORES PHARMS	EQ 400MG BASE	A073290	001	Nov 27, 1991	Dec	CAHN

TOLTERODINE TARTRATE

TABLET;ORAL  
TOLTERODINE TARTRATE

AB	PTS CONSULTING	1MG	A204721	001	Jan 24, 2020	Mar	CAHN
AB		2MG	A204721	002	Jan 24, 2020	Mar	CAHN
AB	RISING	1MG	A210775	001	Dec 30, 2019	Jul	CAHN
AB		2MG	A210775	002	Dec 30, 2019	Jul	CAHN

TOLVAPTAN

TABLET;ORAL

JYNARQUE

AB2	+	OTSUKA	15MG	N204441	001	Apr 23, 2018	Apr	CFTG
AB2	+		30MG	N204441	002	Apr 23, 2018	Apr	CFTG
AB	+	!	45MG	N204441	003	Apr 23, 2018	Apr	CFTG
AB2	+		60MG	N204441	004	Apr 23, 2018	Apr	CFTG
AB	+		90MG	N204441	005	Apr 23, 2018	Apr	CFTG

SAMSCA

AB1	+	OTSUKA	15MG	N022275	001	May 19, 2009	Apr	CTEC
AB1	+	!	30MG	N022275	002	May 19, 2009	Apr	CTEC

TOLVAPTAN

AB1		ALKEM LABS LTD	15MG	A211891	003	Sep 06, 2022	Apr	CTEC
AB1			30MG	A211891	001	May 19, 2020	Apr	CTEC
AB1		APOTEX	15MG	A207605	002	Sep 06, 2022	Apr	CTEC
AB2			15MG	A218381	001	Nov 10, 2025	Oct	NEWA
AB1			30MG	A207605	001	May 19, 2020	Apr	CTEC
AB2			30MG	A218381	002	Nov 10, 2025	Oct	NEWA
AB			45MG	A218381	003	Nov 10, 2025	Oct	NEWA
AB2			60MG	A218381	004	Nov 10, 2025	Oct	NEWA
AB			90MG	A218381	005	Nov 10, 2025	Oct	NEWA
AB1		ENDO OPERATIONS	15MG	A206119	001	Feb 15, 2022	Apr	CTEC
AB1			30MG	A206119	002	Feb 15, 2022	Apr	CTEC
AB1		HETERO LABS LTD V	15MG	A205646	002	Sep 06, 2022	Apr	CTEC
AB1			30MG	A205646	001	Jul 16, 2021	Apr	CTEC
AB2		LUPIN LTD	15MG	A216063	001	Apr 23, 2025	Apr	NFTG
AB2			30MG	A216063	002	Apr 23, 2025	Apr	NFTG
AB			45MG	A216063	003	Apr 23, 2025	Apr	NFTG
AB2			60MG	A216063	004	Apr 23, 2025	Apr	NFTG
AB			90MG	A216063	005	Apr 23, 2025	Apr	NFTG
AB1		MSN	15MG	A216949	001	Jun 21, 2023	Apr	CTEC
AB1			30MG	A216949	002	Jun 21, 2023	Apr	CTEC

TOPIRAMATE

CAPSULE;ORAL

TOPIRAMATE

AB		RUBICON	15MG	A216683	001	May 27, 2025	May	NEWA
AB			25MG	A216683	002	May 27, 2025	May	NEWA
AB			50MG	A216683	003	May 27, 2025	May	NEWA
>D>	AB	TEVA	15MG	A076575	001	Apr 17, 2009	Dec	DISC
>A>	@		15MG	A076575	001	Apr 17, 2009	Dec	DISC
>D>	AB		25MG	A076575	002	Apr 17, 2009	Dec	DISC
>A>	@		25MG	A076575	002	Apr 17, 2009	Dec	DISC
AB		ZYDUS PHARMS USA INC	50MG	A078877	003	Oct 23, 2024	May	CTEC

CAPSULE, EXTENDED RELEASE;ORAL

TOPIRAMATE

>D>	@	AJANTA PHARMA LTD	25MG	A215663	001	Aug 15, 2023	Dec	CMFD
>A>	AB1		25MG	A215663	001	Aug 15, 2023	Dec	CMFD
	AB2		25MG	A219564	001	Sep 02, 2025	Aug	NEWA
>D>	@		50MG	A215663	002	Aug 15, 2023	Dec	CMFD
>A>	AB1		50MG	A215663	002	Aug 15, 2023	Dec	CMFD
	AB2		50MG	A219564	002	Sep 02, 2025	Aug	NEWA
>D>	@		100MG	A215663	003	Aug 15, 2023	Dec	CMFD
>A>	AB1		100MG	A215663	003	Aug 15, 2023	Dec	CMFD
	AB2		100MG	A219564	003	Sep 02, 2025	Aug	NEWA
	AB2		150MG	A219564	004	Sep 02, 2025	Aug	NEWA
>D>	@		200MG	A215663	004	Aug 15, 2023	Dec	CMFD
>A>	AB1		200MG	A215663	004	Aug 15, 2023	Dec	CMFD
	AB2		200MG	A219564	005	Sep 02, 2025	Aug	NEWA

TABLET;ORAL

TOPIRAMATE

AB		PHARMACO	25MG	A077733	001	Mar 27, 2009	Sep	CAHN
AB			50MG	A077733	002	Mar 27, 2009	Sep	CAHN
AB			100MG	A077733	003	Mar 27, 2009	Sep	CAHN
AB			200MG	A077733	004	Mar 27, 2009	Sep	CAHN
	@	SENORES PHARMS	25MG	A090353	001	Sep 01, 2010	May	CAHN
	@		50MG	A090353	002	Sep 01, 2010	May	CAHN
	@		100MG	A090353	003	Sep 01, 2010	May	CAHN
	@		200MG	A090353	004	Sep 01, 2010	May	CAHN
	@	SUN PHARM	200MG	A090278	004	Mar 27, 2009	May	DISC

TORSEMIDE

TABLET; ORAL  
TORSEMIDE

AB		COREPHARMA	5MG	A 076894	001	May 31, 2005	Apr	CAHN
AB			10MG	A 076894	002	May 31, 2005	Apr	CAHN
AB			20MG	A 076894	003	May 31, 2005	Apr	CAHN
AB			100MG	A 076894	004	May 31, 2005	Apr	CAHN
	@	HIKMA	5MG	A 076943	001	Mar 01, 2005	Sep	DISC
	@		10MG	A 076943	002	Mar 01, 2005	Sep	DISC

>A> TRADIPITANT

>A> CAPSULE; ORAL  
>A> NEREUS

>A>		+! VANDA PHARMS INC	85MG	N220152	001	Dec 30, 2025	Dec	NEWA
-----	--	---------------------	------	---------	-----	--------------	-----	------

TRAMADOL HYDROCHLORIDE

TABLET; ORAL  
TRAMADOL HYDROCHLORIDE

AB		APDM PHARMS	50MG	A 090404	001	Jan 31, 2011	Feb	CAHN
	@	APOTEX	50MG	A 075981	001	Jul 10, 2002	Mar	DISC
AB		GRAVITI PHARMS	50MG	A 075968	001	Jun 25, 2002	Sep	CMFD
	@	MERRO PHARM USA	50MG	A 206706	001	Jul 02, 2019	Feb	DISC
	@	PURACAP LABS BLU	50MG	A 206706	001	Jul 02, 2019	Oct	CAHN
AB		SENORES PHARMS	50MG	A 090404	001	Jan 31, 2011	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL  
TRAMADOL HYDROCHLORIDE

AB1	!	LUPIN LTD	100MG	A 200503	001	Aug 29, 2011	Jan	CTEC
AB1			200MG	A 200503	002	Aug 29, 2011	Jan	CTEC
AB1			300MG	A 200503	003	Aug 29, 2011	Jan	CTEC
AB1		MACLEODS PHARMS LTD	100MG	A 209404	001	Jan 31, 2025	Jan	NEWA
AB1			200MG	A 209404	002	Jan 31, 2025	Jan	NEWA
AB1			300MG	A 209404	003	Jan 31, 2025	Jan	NEWA

TRAMETINIB DIMETHYL SULFOXIDE

TABLET; ORAL  
TRAMETINIB DIMETHYL SULFOXIDE

	@	HIKMA	EQ 0.5MG	A 219002	001	Aug 06, 2024	Feb	CAHN
	@		EQ 2MG	A 219002	002	Aug 06, 2024	Feb	CAHN

TRANEXAMIC ACID

INJECTABLE; INJECTION  
TRANEXAMIC ACID

	@	FRESENIUS KABI USA	100MG/ML	A 091596	001	Mar 02, 2012	Jan	DISC
AP		MILLA PHARMS	100MG/ML	A 212676	001	Jul 17, 2019	Sep	CAHN

SOLUTION; INTRAVENOUS  
TRANEXAMIC ACID

AP		HERITAGE	1GM/100ML (10MG/ML)	A 218896	001	Jun 02, 2025	Aug	CAHN
AP		RTU PHARMA SA	1GM/100ML (10MG/ML)	A 218896	001	Jun 02, 2025	May	NEWA

TABLET; ORAL  
TRANEXAMIC ACID

AB		APPCO	650MG	A 218729	001	Jun 11, 2025	May	NEWA
AB		BIONPHARMA	650MG	A 219123	001	Aug 19, 2025	Aug	NEWA

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC  
TRAVATAN Z

AT2		+! SANDOZ	0.004%	N021994	001	Sep 21, 2006	Feb	CTEC
	@	ALEMBIC	0.004%	A 210458	001	Dec 20, 2019	Feb	DISC
>A> AT2		APOTEX	0.004%	A 214687	001	Dec 17, 2025	Dec	NEWA
AT2	!	CHARTWELL RX	0.004%	A 203431	001	Jul 10, 2015	Feb	CTEC
AT2		GLAND	0.004%	A 091340	001	Mar 01, 2013	Feb	CTEC
AT2		MICRO LABS	0.004%	A 218159	001	Jul 12, 2024	Feb	CTEC
AT2		MYLAN	0.004%	A 203767	001	Mar 19, 2021	Feb	CTEC
AT2		SOMERSET THERAPS LLC	0.004%	A 205050	001	Jul 07, 2017	Feb	CTEC
AT2			0.004%	A 217228	001	Sep 23, 2024	Feb	CTEC

TREOSULFAN

POWDER; INTRAVENOUS  
GRAFAPEX

+	!	MEDEXUS	1GM/VIAL	N214759	001	Jan 21, 2025	Jan	CAHN
+	!		5GM/VIAL	N214759	002	Jan 21, 2025	Jan	CAHN
+	!	MGFKSMB	1GM/VIAL	N214759	001	Jan 21, 2025	Jan	NEWA
+	!		5GM/VIAL	N214759	002	Jan 21, 2025	Jan	NEWA

TREPROSTINIL

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS  
REMODULIN

@	+	UNITED THERAP	0.1MG/ML	N021272	006	Sep 28, 2023	Jun	DISC
@	+		0.2MG/ML	N021272	007	Sep 28, 2023	Jun	DISC
@	+		20MG/ML	N021272	005	Jul 30, 2021	Jun	DISC

TREPROSTINIL

@		PH HEALTH	1MG/ML	A209382	001	Sep 24, 2019	Oct	DISC
@			2.5MG/ML	A209382	002	Sep 24, 2019	Oct	DISC
@			5MG/ML	A209382	003	Sep 24, 2019	Oct	DISC
@			10MG/ML	A209382	004	Sep 24, 2019	Oct	DISC

POWDER; INHALATION

TYVASO DPI

+	!	UNITED THERAP	0.032MG/INH	N214324	002	May 23, 2022	Jan	CHRS
+	!		0.048MG/INH	N214324	003	May 23, 2022	Jan	CHRS
+	!		0.08MG/INH	N214324	005	Oct 24, 2024	Jan	CHRS

TREPROSTINIL SODIUM

POWDER; INHALATION

YUTREPIA

+	!	LIQUIDIA TECH	EQ 0.0265MG BASE/INH	N213005	001	May 23, 2025	May	NEWA
+	!		EQ 0.053MG BASE/INH	N213005	002	May 23, 2025	May	NEWA
+	!		EQ 0.0795MG BASE/INH	N213005	003	May 23, 2025	May	NEWA
+	!		EQ 0.106MG BASE/INH	N213005	004	May 23, 2025	May	NEWA

TRETINOIN

CAPSULE; ORAL

TRETINOIN

	@	BARR LABS INC	10MG	A077684	001	Jun 22, 2007	Feb	DISC
AB	!	ENDO OPERATIONS	10MG	A201687	001	Oct 24, 2012	Feb	CHRS

CREAM; TOPICAL

TRETINOIN

AB		ALEMBIC	0.025%	A218399	001	Aug 14, 2025	Aug	NEWA
AB		ENCUBE	0.025%	A217831	001	Jul 10, 2025	Jul	NEWA

GEL; TOPICAL

AVITA

@		RISING	0.025%	N020400	001	Jan 29, 1998	Aug	CAHN
---	--	--------	--------	---------	-----	--------------	-----	------

RETIN-A

AB	+	!	BAUSCH	0.01%	N017955	001		Jan	CAHN
----	---	---	--------	-------	---------	-----	--	-----	------

TRETINOIN

AB		AUROBINDO PHARMA LTD	0.01%	A218246	001	Jan 13, 2025	Jan	NEWA
AB			0.025%	A218245	001	Feb 27, 2025	Feb	NEWA
AB		ENCUBE	0.01%	A217588	001	Mar 03, 2025	Feb	NEWA
AB			0.025%	A217587	001	Mar 03, 2025	Feb	NEWA
	@	RISING	0.04%	A202567	001	Jul 17, 2013	Aug	CAHN
	@		0.1%	A202026	001	Jul 17, 2013	Aug	CAHN

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

	@	GLENMARK PHARMS LTD	0.1%	A207117	001	Aug 05, 2016	Jul	DISC
>D>	AT	STRIDES PHARMA	0.025%	A210346	001	Feb 11, 2019	Dec	DISC
>A>		@	0.025%	A210346	001	Feb 11, 2019	Dec	DISC
>D>	AT		0.1%	A210346	002	Feb 11, 2019	Dec	DISC
>A>		@	0.1%	A210346	002	Feb 11, 2019	Dec	DISC
>D>	AT		0.5%	A210346	003	Feb 11, 2019	Dec	DISC
>A>		@	0.5%	A210346	003	Feb 11, 2019	Dec	DISC

GEL; TOPICAL

ARISTOGEL

@	+	ASTELLAS	0.1%	A083380	001		Feb	CRLD
---	---	----------	------	---------	-----	--	-----	------

INJECTABLE; INJECTION

KENALOG-10						
AB	+ APOTHECON	10MG/ML	N012041	001		Feb CTEC
TRIAMCINOLONE ACETONIDE						
AB	ALEMBIC	40MG/ML	A218601	001	Oct 17, 2025	Oct NEWA
AB	DR REDDYS	10MG/ML	A218773	001	Mar 12, 2025	Feb NEWA
AB		40MG/ML	A218421	001	Apr 11, 2025	Apr NEWA

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE						
	@ BEACH PRODS	0.025%	A204608	001	Jul 07, 2016	May CAHN
AT	! XTTRIUM LABS INC	0.025%	A088450	001	Apr 01, 1985	Feb CAHN
AT	!	0.1%	A088451	001	Apr 03, 1985	Feb CAHN

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE						
	@ GLENMARK PHARMS LTD	0.5%	A206379	001	Jul 22, 2016	Jul DISC
	@ GLENMARK SPECLT	0.1%	A208320	001	Aug 22, 2017	Jul DISC
AT	SENORES PHARMS	0.05%	A213619	001	Nov 10, 2020	Sep CAHN
AT	SUN PHARMA CANADA	0.1%	A040037	001	Sep 30, 1994	Aug CAHN

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN						
	@ + ETHYPHARM	5MG/ML	N016466	001		May CAHN
	@ +	20MG/ML	N016466	002		May CAHN

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE						
AA	CHARTWELL RX	2MG/5ML	A040251	001	Sep 27, 1999	Aug CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TIGAN						
AP	+! PH HEALTH	100MG/ML	N017530	001		Oct CTEC
	+!	100MG/ML	N017530	001		Aug CAHN
TRIMETHOBENZAMIDE HYDROCHLORIDE						
AP	BPI LABS	100MG/ML	A219606	001	Oct 16, 2025	Oct NEWA

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL						
	@ + TEVA WOMENS	EQ 25MG BASE	N016792	001		Jun CAHN
	@ +	EQ 50MG BASE	N016792	002		Jun CAHN
	@ +	EQ 100MG BASE	N016792	003	Sep 15, 1982	Jun CAHN

TROFINETIDE

>A>	FOR SOLUTION; ORAL					
>A>	DAYBUE STIX					
>A>	+!	ACADIA PHARMS INC	5000MG/PACKET	N219884	001	Dec 11, 2025
>A>	+!		6000MG/PACKET	N219884	002	Dec 11, 2025
>A>	+!		8000MG/PACKET	N219884	003	Dec 11, 2025

TROSPIUM CHLORIDE

TABLET; ORAL

TROSPIUM CHLORIDE						
AB	CHARTWELL RX	20MG	A215781	001	Feb 16, 2022	Sep CAHN
AB	ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Feb CAHN

TROSPIUM CHLORIDE; XANOMELINE TARTRATE

CAPSULE; ORAL

COBENFY						
	+!	BRISTOL-MYERS	20MG;EQ 50MG BASE	N216158	001	Sep 26, 2024
	+		30MG;EQ 125MG BASE	N216158	003	Sep 26, 2024

URSODIOL

CAPSULE; ORAL

URSODIOL						
>D>	AB	AMNEAL PHARMS CO	300MG	A211301	001	Oct 16, 2018
>A>	@		300MG	A211301	001	Oct 16, 2018
	@	QUAGEN	300MG	A090530	001	Feb 17, 2010

TABLET;ORAL

	URSO 250							
	@ + ABBVIE	250MG	N020675	001	Dec 10, 1997	Jun	DISC	
AB	+	250MG	N020675	001	Dec 10, 1997	Jun	CAHN	
	URSO FORTE							
	@ + ABBVIE	500MG	N020675	002	Jul 21, 2004	Jun	DISC	
AB	+!	500MG	N020675	002	Jul 21, 2004	Jun	CAHN	
	URSODIOL							
AB	! ZYDUS LIFESCIENCES	500MG	A211145	002	Oct 30, 2018	Jun	CHRS	

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

	@ AIPING PHARM INC	EQ 500MG BASE	A077478	001	May 24, 2010	Nov	CAHN	
	@	EQ 1GM BASE	A077478	002	May 24, 2010	Nov	CAHN	
	@ APOTEX	EQ 500MG BASE	A090500	001	Apr 04, 2014	Mar	DISC	

VALBENAZINE TOSYLATE

CAPSULE;ORAL

INGREZZA

	+ NEUROCRINE	EQ 60MG BASE	N209241	003	Apr 23, 2021	Feb	CTEC	
	VALBENAZINE TOSYLATE							
	@ ZYDUS LIFESCIENCES	EQ 40MG BASE	A216137	001	Aug 07, 2024	Feb	DISC	
	@	EQ 60MG BASE	A216137	002	Aug 07, 2024	Feb	DISC	
	@	EQ 80MG BASE	A216137	003	Aug 07, 2024	Feb	DISC	

VALGANCICLOVIR HYDROCHLORIDE

TABLET;ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB	SPH ZHONGXI PHARM	EQ 450MG BASE	A218027	001	Apr 16, 2025	Apr	NEWA	
----	-------------------	---------------	---------	-----	--------------	-----	------	--

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

>A>	@ CHARTWELL RX	250MG	A070631	001	Jun 11, 1987	Dec	CAHN	
>D>	@ UPSHER SMITH LABS	250MG	A070631	001	Jun 11, 1987	Dec	CAHN	

SYRUP;ORAL

VALPROIC ACID

	@ PAI HOLDINGS	250MG/5ML	A077105	001	Jul 29, 2005	Apr	CAHN	
--	----------------	-----------	---------	-----	--------------	-----	------	--

VALSARTAN

SOLUTION;ORAL

PREXXARTAN

	@ + CARMEL BIOSCIENCES	4MG/ML	N209139	001	Dec 19, 2017	May	CPOT	
	VALSARTAN							
AB	! NOVITIUM PHARMA	4MG/ML	A214102	001	Nov 02, 2021	May	CTEC	
	!	4MG/ML	A214102	001	Nov 02, 2021	May	CPOT	
AB	RUBICON	4MG/ML	A216460	001	Jun 05, 2025	May	NEWA	

TABLET;ORAL

VALSARTAN

>D>	AB	ACME LABS	40MG	A205347	001	Apr 09, 2018	Dec	CAHN
	AB		40MG	A205347	001	Apr 09, 2018	Sep	CAHN
>D>	AB		80MG	A205347	002	Apr 09, 2018	Dec	CAHN
	AB		80MG	A205347	002	Apr 09, 2018	Sep	CAHN
>D>	AB		160MG	A205347	003	Apr 09, 2018	Dec	CAHN
	AB		160MG	A205347	003	Apr 09, 2018	Sep	CAHN
>D>	AB		320MG	A205347	004	Apr 09, 2018	Dec	CAHN
	AB		320MG	A205347	004	Apr 09, 2018	Sep	CAHN
	@	RENATA	40MG	A218169	001	Aug 05, 2024	Aug	CAHN
	@		40MG	A218169	001	Aug 05, 2024	Feb	DISC
AB			40MG	A218169	001	Aug 05, 2024	Jan	CAHN
	@		80MG	A218169	002	Aug 05, 2024	Aug	CAHN
	@		80MG	A218169	002	Aug 05, 2024	Feb	DISC
AB			80MG	A218169	002	Aug 05, 2024	Jan	CAHN
	@		160MG	A218169	003	Aug 05, 2024	Aug	CAHN
	@		160MG	A218169	003	Aug 05, 2024	Feb	DISC
AB			160MG	A218169	003	Aug 05, 2024	Jan	CAHN
	@		320MG	A218169	004	Aug 05, 2024	Aug	CAHN
	@		320MG	A218169	004	Aug 05, 2024	Feb	DISC
AB			320MG	A218169	004	Aug 05, 2024	Jan	CAHN
	@	SOMERSET THERAPS LLC	40MG	A218169	001	Aug 05, 2024	Sep	CAHN
	@		80MG	A218169	002	Aug 05, 2024	Sep	CAHN

TABLET;ORAL  
VALSARTAN

	@		160MG	A218169	003	Aug 05, 2024	Sep	CAHN
	@		320MG	A218169	004	Aug 05, 2024	Sep	CAHN
>A>	AB	SQUARE PHARMS PLC	40MG	A205347	001	Apr 09, 2018	Dec	CAHN
>A>	AB		80MG	A205347	002	Apr 09, 2018	Dec	CAHN
>A>	AB		160MG	A205347	003	Apr 09, 2018	Dec	CAHN
>A>	AB		320MG	A205347	004	Apr 09, 2018	Dec	CAHN

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

>D>	@	ABON PHARMS LLC	EQ 125MG BASE	A065478	001	Apr 09, 2012	Dec	CAHN
	@		EQ 125MG BASE	A065478	001	Apr 09, 2012	Jul	CAHN
>D>	@		EQ 250MG BASE	A065478	002	Apr 09, 2012	Dec	CAHN
	@		EQ 250MG BASE	A065478	002	Apr 09, 2012	Jul	CAHN
>A>	@	PAI HOLDINGS	EQ 125MG BASE	A065478	001	Apr 09, 2012	Dec	CAHN
>A>	@		EQ 250MG BASE	A065478	002	Apr 09, 2012	Dec	CAHN

FOR SOLUTION;ORAL

VANCOVICIN HYDROCHLORIDE

>D>	AA	!	ANI PHARMS	EQ 250MG BASE/5ML	A061667	002	Jul 13, 1983	Dec	CTEC
>A>		!		EQ 250MG BASE/5ML	A061667	002	Jul 13, 1983	Dec	CTEC
			VANCOMYCIN HYDROCHLORIDE						
>D>	AA		AMNEAL	EQ 250MG BASE/5ML	A215338	001	Jun 23, 2023	Dec	DISC
>A>		@		EQ 250MG BASE/5ML	A215338	001	Jun 23, 2023	Dec	DISC

INJECTABLE;INJECTION

VANCOVICIN HYDROCHLORIDE

	@	STERISCIENCE	EQ 500MG BASE/VIAL	A060180	001		Apr	CAHN
	@		EQ 500MG BASE/VIAL	A062476	001	Mar 15, 1984	Apr	CAHN
	@		EQ 500MG BASE/VIAL	A062716	001	Mar 13, 1987	Apr	CAHN
	@		EQ 500MG BASE/VIAL	A062812	001	Nov 17, 1987	Apr	CAHN
	@		EQ 1GM BASE/VIAL	A060180	002	Mar 21, 1986	Apr	CAHN
	@		EQ 1GM BASE/VIAL	A062476	002	Mar 21, 1986	Apr	CAHN
	@		EQ 1GM BASE/VIAL	A062716	002	Mar 13, 1987	Apr	CAHN
	@		EQ 1GM BASE/VIAL	A062812	002	Nov 17, 1987	Apr	CAHN
	@		EQ 10GM BASE/VIAL	A062812	003	Nov 17, 1987	Apr	CAHN
		VANCOMYCIN HYDROCHLORIDE						
	@	HOSPIRA INC	EQ 10GM BASE/VIAL	A065455	001	Apr 29, 2009	Jul	DISC
AP		MEDIMETRIKS PHARMS	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Jan	CMFD
AP			EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Jan	CMFD
	@	PLANO PHARMS	EQ 500MG BASE/VIAL	A090250	001	Apr 27, 2010	Mar	CAHN
	@		EQ 1GM BASE/VIAL	A090250	002	Apr 27, 2010	Mar	CAHN
	@		EQ 5GM BASE/VIAL	A201048	001	Aug 10, 2012	Mar	CAHN
	@		EQ 10GM BASE/VIAL	A201048	002	Aug 10, 2012	Mar	CAHN

POWDER;INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

AP		GLAND	EQ 750MG BASE/VIAL	A218140	001	Mar 21, 2025	Mar	NEWA	
AP			EQ 1.25GM BASE/VIAL	A218140	002	Mar 21, 2025	Mar	NEWA	
AP			EQ 1.5GM BASE/VIAL	A218140	003	Mar 21, 2025	Mar	NEWA	
AP		+!	MYLAN LABS LTD	EQ 750MG BASE/VIAL	N209481	002	Jul 10, 2018	Mar	CFTG
AP			STERISCIENCE	EQ 750MG BASE/VIAL	A215324	001	Oct 02, 2025	Sep	NEWA
AP			EQ 1.25GM BASE/VIAL	A215324	002	Oct 02, 2025	Sep	NEWA	
AP			EQ 1.5GM BASE/VIAL	A215324	003	Oct 02, 2025	Sep	NEWA	

POWDER;INTRAVENOUS, ORAL

VANCOMYCIN HYDROCHLORIDE

	+!	ZHEJIANG NOVUS PHARM	EQ 1.5MG BASE/VIAL	N210274	007	Aug 01, 2025	Aug	NEWA
	+!		EQ 750MG BASE/VIAL	N210274	005	Aug 01, 2025	Aug	NEWA
	+!		EQ 1.25GM BASE/VIAL	N210274	006	Aug 01, 2025	Aug	NEWA

SOLUTION;INTRAVENOUS

TYZAVAN

	+!	HIKMA	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N211962	001	Feb 15, 2019	Jul	CTNA
	+!		EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N211962	005	May 13, 2020	Jul	CTNA
	+!		EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N211962	002	Feb 15, 2019	Jul	CTNA
	+!		EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N211962	006	May 13, 2020	Jul	CTNA
	+!		EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N211962	003	Feb 15, 2019	Jul	CTNA
	+!		EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML)	N211962	007	May 13, 2020	Jul	CTNA
	+!		EQ 2GM BASE/400ML (EQ 5MG BASE/ML)	N211962	004	Feb 15, 2019	Jul	CTNA

VARENICLINE TARTRATE

TABLET;ORAL

CHANTIX

AB	+	PF PRISM CV	EQ 0.5MG BASE	N021928	001	May 10, 2006	Sep	CMFD
AB	+		EQ 1MG BASE	N021928	002	May 10, 2006	Sep	CMFD
VARENICLINE TARTRATE								
AB		AUROBINDO PHARMA	EQ 0.5MG BASE	A214595	001	May 02, 2025	Apr	NEWA
AB			EQ 1MG BASE	A214595	002	May 02, 2025	Apr	NEWA
AB		HANDA PHARMS LLC	EQ 0.5MG BASE	A213268	001	May 21, 2025	May	NEWA
AB			EQ 1MG BASE	A213268	002	May 21, 2025	May	NEWA
AB		KANCHAN HLTHCARE	EQ 0.5MG BASE	A217151	001	Jul 25, 2023	Sep	CAHN
AB			EQ 1MG BASE	A217151	002	Jul 25, 2023	Sep	CAHN
AB		MICRO LABS	EQ 0.5MG BASE	A218302	001	Oct 29, 2025	Oct	NEWA
AB			EQ 1MG BASE	A218302	002	Oct 29, 2025	Oct	NEWA
AB		NORVIUM BIOSCIENCE	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	May	CAHN
AB			EQ 1MG BASE	A202019	002	Feb 28, 2024	May	CAHN
AB		PHARMOBEDIENT	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	Jul	CAHN
AB			EQ 1MG BASE	A202019	002	Feb 28, 2024	Jul	CAHN
	@	PIRAMAL	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Feb	DISC
	@		EQ 1MG BASE	A217115	002	Jul 23, 2024	Feb	DISC
	@	RHODES PHARMS	EQ 0.5MG BASE	A213268	001	May 21, 2025	Oct	DISC
AB			EQ 0.5MG BASE	A213268	001	May 21, 2025	Jul	CAHN
	@		EQ 1MG BASE	A213268	002	May 21, 2025	Oct	DISC
AB			EQ 1MG BASE	A213268	002	May 21, 2025	Jul	CAHN
AB		SHILPA	EQ 0.5MG BASE	A216615	001	Apr 08, 2025	Mar	NEWA
AB			EQ 1MG BASE	A216615	002	Apr 08, 2025	Mar	NEWA
AB		VIWIT PHARM	EQ 0.5MG BASE	A212879	001	May 06, 2025	Apr	NEWA
AB			EQ 1MG BASE	A212879	002	May 06, 2025	Apr	NEWA

VASOPRESSIN

SOLUTION;INTRAVENOUS

VASOPRESSIN IN DEXTROSE 5%

AP		GLAND	40UNITS/100ML (0.4UNITS/ML)	A216963	002	Aug 22, 2025	Aug	NFTG
		VASOPRESSIN IN SODIUM CHLORIDE 0.9%						
	@ +	LONG GROVE PHARMS	50UNITS/50ML (1UNIT/ML)	N217766	003	Jul 11, 2024	May	DISC
		VASOSTRICT						
AP	+!	PH HEALTH	40UNITS/100ML (0.4UNITS/ML)	N204485	003	Apr 15, 2020	Aug	CFTG

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EFFEXOR XR

>D>	@	UPJOHN	EQ 100MG BASE	N020699	003	Oct 20, 1997	Dec	CRLD
>A>	@ +		EQ 100MG BASE	N020699	003	Oct 20, 1997	Dec	CRLD

VENLAFAXINE HYDROCHLORIDE

AB		MEDICAP LABS	EQ 37.5MG BASE	A201272	001	Nov 23, 2018	Feb	CAHN
AB			EQ 75MG BASE	A201272	002	Nov 23, 2018	Feb	CAHN
AB			EQ 150MG BASE	A201272	003	Nov 23, 2018	Feb	CAHN
AB		SCIEGEN PHARMS	EQ 37.5MG BASE	A078865	001	Apr 14, 2011	Jul	CAHN
AB			EQ 75MG BASE	A078865	002	Apr 14, 2011	Jul	CAHN
AB			EQ 150MG BASE	A078865	003	Apr 14, 2011	Jul	CAHN

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

	@	PHARMOBEDIENT	EQ 25MG BASE	A077166	001	Jun 13, 2008	Sep	CAHN
	@		EQ 37.5MG BASE	A077166	002	Jun 13, 2008	Sep	CAHN
	@		EQ 50MG BASE	A077166	003	Jun 13, 2008	Sep	CAHN
	@		EQ 75MG BASE	A077166	004	Jun 13, 2008	Sep	CAHN
	@		EQ 100MG BASE	A077166	005	Jun 13, 2008	Sep	CAHN

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		ABON PHARMS LLC	EQ 150MG BASE	A217841	001	Feb 07, 2025	Jan	NEWA
AB			EQ 225MG BASE	A217841	002	Feb 07, 2025	Jan	NEWA
AB		ADAPTIS	EQ 75MG BASE	A213927	001	Jan 21, 2021	Sep	CAHN
AB		MPP PHARMA	EQ 150MG BASE	A205468	002	Mar 24, 2017	May	CAHN
AB			EQ 225MG BASE	A205468	003	Mar 24, 2017	May	CAHN
	@	TORRENT	EQ 37.5MG BASE	A218180	001	Jan 28, 2025	Jun	DISC
AB			EQ 37.5MG BASE	A218180	001	Jan 28, 2025	Jan	NEWA
	@		EQ 75MG BASE	A218180	002	Jan 28, 2025	Jun	DISC
AB			EQ 75MG BASE	A218180	002	Jan 28, 2025	Jan	NEWA
	@		EQ 150MG BASE	A218180	003	Jan 28, 2025	Jun	DISC
AB			EQ 150MG BASE	A218180	003	Jan 28, 2025	Jan	NEWA
	@		EQ 225MG BASE	A218180	004	Jan 28, 2025	Jun	DISC
AB			EQ 225MG BASE	A218180	004	Jan 28, 2025	Jan	NEWA

VERAPAMIL HYDROCHLORIDE

		INJECTABLE; INJECTION					
		VERAPAMIL HYDROCHLORIDE					
AP	ASPIRO	2.5MG/ML	A218218	001	Nov 13, 2025	Nov	NEWA
		TABLET, EXTENDED RELEASE; ORAL					
		VERAPAMIL HYDROCHLORIDE					
AB	ZYDUS LIFESCIENCES	120MG	A219252	001	Nov 24, 2025	Nov	NEWA
AB		180MG	A219252	002	Nov 24, 2025	Nov	NEWA
AB		240MG	A219252	003	Nov 24, 2025	Nov	NEWA

VIBEGRON

		TABLET; ORAL					
		GEMTESA					
	+!	SUMITOMO PHARMA AM	75MG	N213006	001	Dec 23, 2020	Aug CAHN

VIGABATRIN

		FOR SOLUTION; ORAL					
		VIGABATRIN					
	@	DEXCEL	500MG/PACKET	A214992	001	May 13, 2021	Sep DISC
		TABLET; ORAL					
		VIGABATRIN					
	@	AMNEAL PHARMS	500MG	A210042	001	Jun 22, 2022	Feb DISC
>D>	@	CARNEGIE	500MG	A215519	001	Apr 28, 2023	Dec CMFD
>A>	AB		500MG	A215519	001	Apr 28, 2023	Dec CMFD
	@		500MG	A215519	001	Apr 28, 2023	May CAHN
	@	RYAN LABS	500MG	A215519	001	Apr 28, 2023	Jan DISC

VIMSELTINIB

		CAPSULE; ORAL					
		ROMVIMZA					
	+	DECIPHERA PHARMS	14MG	N219304	001	Feb 14, 2025	Feb NEWA
	+		20MG	N219304	002	Feb 14, 2025	Feb NEWA
	+!		30MG	N219304	003	Feb 14, 2025	Feb NEWA

VORICONAZOLE

		FOR SUSPENSION; ORAL					
		VORICONAZOLE					
AB		HETERO LABS LTD V	200MG/5ML	A211598	001	Aug 08, 2025	Aug NEWA
AB		ZHEJIANG POLY PHARM	200MG/5ML	A216805	001	Jan 02, 2024	Mar CAHN
		POWDER; INTRAVENOUS					
		VFEND					
AP	+!	PF PRISM CV	200MG/VIAL	N021267	001	May 24, 2002	Sep CDFR
		VORICONAZOLE					
>D>	AP	ALMAJECT	200MG/VIAL	A206398	001	Mar 23, 2016	Dec DISC
>A>	@		200MG/VIAL	A206398	001	Mar 23, 2016	Dec DISC
AP			200MG/VIAL	A206398	001	Mar 23, 2016	Sep CDFR
AP		ASPIRO	200MG/VIAL	A218533	001	Apr 03, 2024	Sep CDFR
	@	EUGIA PHARMA	200MG/VIAL	A212162	001	Feb 02, 2023	Sep CDFR
AP		GLAND	200MG/VIAL	A211099	001	Mar 31, 2020	Sep CDFR
AP		HIKMA	200MG/VIAL	N208562	001	Mar 09, 2017	Sep CDFR
AP		MEITHEAL	200MG/VIAL	A214516	001	May 09, 2022	Sep CDFR
	@	PHARMOBEDIANT	200MG/VIAL	A210849	001	Oct 11, 2022	Sep CDFR
AP		SANDOZ INC	200MG/VIAL	A090862	001	May 30, 2012	Sep CDFR
AP		SLATE RUN PHARMA	200MG/VIAL	A211661	001	Nov 30, 2018	Sep CDFR
AP		UBI	200MG/VIAL	A211264	001	Mar 09, 2023	Sep CDFR
AP		ZYDUS PHARMS	200MG/VIAL	A208983	001	Jul 16, 2018	Sep CDFR
		SOLUTION; INTRAVENOUS					
		VORICONAZOLE					
	!	HAINAN POLY PHARM	200MG/20ML (10MG/ML)	A220043	001	Nov 14, 2025	Nov NFTG

WARFARIN SODIUM

		TABLET; ORAL					
		WARFARIN SODIUM					
	@	AIPING PHARM INC	1MG	A200104	001	Jun 27, 2013	Jul CAHN
	@		2MG	A200104	002	Jun 27, 2013	Jul CAHN
	@		2.5MG	A200104	003	Jun 27, 2013	Jul CAHN
	@		3MG	A200104	004	Jun 27, 2013	Jul CAHN
	@		4MG	A200104	005	Jun 27, 2013	Jul CAHN
	@		5MG	A200104	006	Jun 27, 2013	Jul CAHN
	@		6MG	A200104	007	Jun 27, 2013	Jul CAHN
	@		7.5MG	A200104	008	Jun 27, 2013	Jul CAHN

TABLET;ORAL  
WARFARIN SODIUM  
@

10MG

A200104 009 Jun 27, 2013 Jul CAHN

ZALEPLON

CAPSULE;ORAL  
SONATA

@ + PFIZER  
@ +

5MG  
10MG

N020859 001 Aug 13, 1999 Aug DISC  
N020859 002 Aug 13, 1999 Aug DISC

ZALEPLON

AB ! UNICHEM

10MG

A078989 002 Jun 06, 2008 Aug CHRS

ZANUBRUTINIB

CAPSULE;ORAL  
BRUKINSA

@ + BEONE MEDICINES USA  
+!

80MG  
80MG

N213217 001 Nov 14, 2019 Aug DISC  
N213217 001 Nov 14, 2019 Apr CAHN

TABLET;ORAL  
BRUKINSA

+! BEONE MEDICINES USA

160MG

N218785 001 Jun 10, 2025 Jun NEWA

ZIFTOMENIB

CAPSULE;ORAL  
KOMZIFTI

+! KURA

200MG

N220305 001 Nov 13, 2025 Nov NEWA

ZILEUTON

TABLET;ORAL  
ZYFLO

@ + CHIESI  
@ +

300MG  
600MG

N020471 001 Dec 09, 1996 Oct CRLD  
N020471 003 Dec 09, 1996 Oct DISC

ZINC ACETATE

CAPSULE;ORAL  
GALZIN

+ ETON  
+!

EQ 25MG ZINC  
EQ 50MG ZINC

N020458 001 Jan 28, 1997 Jan CAHN  
N020458 002 Jan 28, 1997 Jan CAHN

ZINC CHLORIDE

INJECTABLE;INJECTION  
ZINC CHLORIDE

AP RK PHARMA  
AP STIRA

EQ 1MG ZINC/ML  
EQ 1MG ZINC/ML

A217625 001 Apr 14, 2025 May CAHN  
A217625 001 Apr 14, 2025 Apr NEWA

ZINC SULFATE

SOLUTION;INTRAVENOUS  
ZINC SULFATE

AP ASPIRO

EQ 10MG BASE/10ML (EQ 1MG  
BASE/ML)

A219585 001 May 01, 2025 Apr NEWA

AP

EQ 25MG BASE/5ML (EQ 5MG  
BASE/ML)

A219585 002 May 01, 2025 Apr NEWA

AP

EQ 30MG BASE/10ML (EQ 3MG  
BASE/ML)

A219585 003 May 01, 2025 Apr NEWA

AP RK PHARMA

EQ 10MG BASE/10ML (EQ 1MG  
BASE/ML)

A217624 001 Jun 10, 2025 Sep CAHN

AP

EQ 25MG BASE/5ML (EQ 5MG  
BASE/ML)

A217624 002 Jun 10, 2025 Sep CAHN

AP

EQ 30MG BASE/10ML (EQ 3MG  
BASE/ML)

A217624 003 Jun 10, 2025 Sep CAHN

AP STIRA

EQ 10MG BASE/10ML (EQ 1MG  
BASE/ML)

A217624 001 Jun 10, 2025 May NEWA

AP

EQ 25MG BASE/5ML (EQ 5MG  
BASE/ML)

A217624 002 Jun 10, 2025 May NEWA

AP

EQ 30MG BASE/10ML (EQ 3MG  
BASE/ML)

A217624 003 Jun 10, 2025 May NEWA

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL  
ZIPRASIDONE HYDROCHLORIDE

>D> AB LUPIN PHARMS

EQ 20MG BASE

A077560 001 Mar 02, 2012 Dec DISC

>A> @

EQ 20MG BASE

A077560 001 Mar 02, 2012 Dec DISC

>D> AB

EQ 40MG BASE

A077560 002 Mar 02, 2012 Dec DISC

>A> @

EQ 40MG BASE

A077560 002 Mar 02, 2012 Dec DISC

>D> AB

EQ 60MG BASE

A077560 003 Mar 02, 2012 Dec DISC

CAPSULE;ORAL  
ZIPRASIDONE HYDROCHLORIDE

>A>	@	EQ 60MG BASE	A077560	003	Mar 02, 2012	Dec	DISC
>D>	AB	EQ 80MG BASE	A077560	004	Mar 02, 2012	Dec	DISC
>A>	@	EQ 80MG BASE	A077560	004	Mar 02, 2012	Dec	DISC

ZIPRASIDONE MESYLATE

POWDER;INTRAMUSCULAR  
ZIPRASIDONE MESYLATE

AP	STERISCIENCE	EQ 20MG BASE/VIAL	A217595	001	Sep 03, 2025	Aug	NEWA
----	--------------	-------------------	---------	-----	--------------	-----	------

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS  
ZOLEDRONIC ACID

@	APOTEX	EQ 5MG BASE/100ML	A204367	001	Dec 24, 2015	Mar	DISC
@	NOVAST LABS	EQ 4MG BASE/5ML	A208968	001	Feb 19, 2020	Sep	CAHN

SOLUTION;INTRAVENOUS  
ZOLEDRONIC ACID

@	HOSPIRA	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015	Aug	DISC
---	---------	---------------------------------------	---------	-----	--------------	-----	------

>A> ZOLIFLODACIN

FOR SUSPENSION;ORAL  
NUZOLVENCE

>A>	+	ENTASIS THERAP	3GM/PACKET	N219491	001	Dec 12, 2025	Dec	NEWA
-----	---	----------------	------------	---------	-----	--------------	-----	------

ZOLMITRIPTAN

SPRAY;NASAL  
ZOLMITRIPTAN

AB	PADAGIS ISRAEL	5MG/SPRAY	A212469	002	Sep 30, 2021	Apr	CHRS
----	----------------	-----------	---------	-----	--------------	-----	------

ZOMIG  
+

AB	AMNEAL	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Apr	CHRS
----	--------	-------------	---------	-----	--------------	-----	------

TABLET;ORAL  
ZOLMITRIPTAN

AB	CHARTWELL RX	2.5MG	A206973	001	Jun 30, 2017	Oct	CAHN
AB		5MG	A206973	002	Jun 30, 2017	Oct	CAHN

ZOLPIDEM TARTRATE

TABLET;ORAL  
AMBIEN

AB	+	COSETTE	5MG	N019908	001	Dec 16, 1992	Jan	CAHN
AB	+		10MG	N019908	002	Dec 16, 1992	Jan	CAHN

ZOLPIDEM TARTRATE  
@ APOTEX INC  
@

		5MG	A077884	001	Apr 23, 2007	Mar	DISC
		10MG	A077884	002	Apr 23, 2007	Mar	DISC

TABLET;SUBLINGUAL  
EDLUAR

AB	+	VIATRIS	5MG	N021997	001	Mar 13, 2009	Feb	CAHN
AB	+		10MG	N021997	002	Mar 13, 2009	Feb	CAHN

TABLET, EXTENDED RELEASE;ORAL  
AMBIEN CR

AB	+	COSETTE	6.25MG	N021774	002	Sep 02, 2005	Jan	CAHN
AB	+		12.5MG	N021774	001	Sep 02, 2005	Jan	CAHN

ZOLPIDEM TARTRATE  
@ APOTEX  
@

		6.25MG	A200266	001	Sep 10, 2013	Mar	DISC
		12.5MG	A200266	002	Sep 10, 2013	Mar	DISC

ZONGERTINIB

TABLET;ORAL  
HERNEXEOS

	+	BOEHRINGER INGELHEIM	60MG	N219042	001	Aug 08, 2025	Aug	NEWA
--	---	----------------------	------	---------	-----	--------------	-----	------

ZONISAMIDE

CAPSULE;ORAL  
ZONISAMIDE

@	APOTEX	25MG	A077642	001	Dec 22, 2005	Mar	DISC
@		50MG	A077642	002	Dec 22, 2005	Mar	DISC
@		100MG	A077642	003	Dec 22, 2005	Mar	DISC
@	CHARTWELL RX	25MG	A077650	001	Apr 20, 2006	Aug	CAHN
@		50MG	A077650	002	Apr 20, 2006	Aug	CAHN
@		100MG	A077650	003	Apr 20, 2006	Aug	CAHN
@	MACLEODS PHARMS LTD	25MG	A219507	001	May 12, 2025	Jul	DISC

CAPSULE;ORAL		ZONISAMIDE							
AB			25MG	A 219507	001	May 12, 2025	May	NEWA	
	@		50MG	A 219507	002	May 12, 2025	Jul	DISC	
AB			50MG	A 219507	002	May 12, 2025	May	NEWA	
	@		100MG	A 219507	003	May 12, 2025	Jul	DISC	
AB			100MG	A 219507	003	May 12, 2025	May	NEWA	
	@	SUN PHARM INDS (IN)	25MG	A 077634	001	Mar 17, 2006	Jul	DISC	
	@		50MG	A 077634	002	Mar 17, 2006	Jul	DISC	
	@		100MG	A 077634	003	Mar 17, 2006	Jul	DISC	

ACETAMINOPHEN

TABLET, EXTENDED RELEASE;ORAL  
ACETAMINOPHEN

@	HERITAGE	650MG	A207035	001	May 31, 2018	Nov	DISC
		650MG	A207035	001	May 31, 2018	Nov	CAHN

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL  
ACETAMINOPHEN AND IBUPROFEN

>A>		LNK INTL INC	250MG;125MG	A220126	001	Dec 11, 2025	Dec	NEWA
	@	STRIDES PHARMA	250MG;125MG	A217241	001	Jan 17, 2025	Jul	DISC
			250MG;125MG	A217241	001	Jan 17, 2025	Jan	NEWA
>A>		TARO	250MG;125MG	A219053	001	Jan 02, 2026	Dec	NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL  
AZELASTINE HYDROCHLORIDE ALLERGY

	AUROBINDO PHARMA	0.2055MG/SPRAY	A216561	001	Jan 27, 2025	Jan	NEWA
--	------------------	----------------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL  
CETIRIZINE HYDROCHLORIDE ALLERGY

@	AIPING PHARM INC	5MG	A202277	002	Mar 11, 2014	Jul	CAHN
@		10MG	A202277	004	Mar 11, 2014	Jul	CAHN
@	TARO	5MG	A078072	001	Jul 22, 2009	Aug	DISC
@		5MG	A078072	003	Jul 22, 2009	Aug	DISC

CETIRIZINE HYDROCHLORIDE HIVES

@	AIPING PHARM INC	5MG	A202277	001	Mar 11, 2014	Jul	CAHN
@		10MG	A202277	003	Mar 11, 2014	Jul	CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	TARO	10MG	A078072	002	Jul 22, 2009	Aug	DISC
@		10MG	A078072	004	Jul 22, 2009	Aug	DISC

ZYRTEC ALLERGY

+	KENVUE BRANDS	5MG	N019835	003	Nov 16, 2007	Apr	CMFD
---	---------------	-----	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@	UNICHEM	5MG;120MG	A210507	001	Sep 10, 2024	Jun	DISC
---	---------	-----------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE

CLOTH;TOPICAL  
READYPREP CHG

+	MEDLINE INDUSTRIES	2%	N207964	001	Nov 20, 2018	Aug	CHRS
+		2%	N207964	001	Nov 20, 2018	Aug	CRLD

CIMETIDINE

TABLET;ORAL  
CIMETIDINE

@	APOTEX	100MG	A074948	001	Jun 19, 1998	Mar	DISC
@		200MG	A074948	002	Jul 26, 2002	Mar	DISC

CLOTRIMAZOLE

CREAM;VAGINAL  
TRIVAGIZOLE 3

	SUN PHARMA CANADA	2%	N021143	001	Apr 12, 2000	Aug	CAHN
--	-------------------	----	---------	-----	--------------	-----	------

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; NAPROXEN SODIUM

TABLET, EXTENDED RELEASE;ORAL  
MUCINEX 12HR COLD & FEVER MULTI-SYMPOM

>A>	+	RB HLTH	30MG;600MG;110MG	N217338	001	Dec 22, 2025	Dec	NEWA
-----	---	---------	------------------	---------	-----	--------------	-----	------

DOCOSANOL

CREAM;TOPICAL  
DOCOSANOL

	DR REDDYS	10%	A214613	001	Oct 03, 2025	Sep	NEWA
		10%	A215505	001	Oct 23, 2025	Oct	NEWA
	SUN PHARMA CANADA	10%	A214454	001	Oct 26, 2023	Sep	CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL  
ESOMEPRAZOLE MAGNESIUM

@	AMNEAL PHARMS NY	EQ 20MG BASE	A209716	001	Jun 05, 2019	Aug	DISC
	GUARDIAN DRUG	EQ 20MG BASE	A216149	001	Mar 15, 2023	May	CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL  
FEXOFENADINE HYDROCHLORIDE

	CONTRACT PHARMACAL	60MG	A219032	001	Feb 28, 2025	Feb	NEWA
		180MG	A219032	002	Feb 28, 2025	Feb	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@	AUROBINDO PHARMA LTD	180MG;240MG	A215232	001	Apr 17, 2025	Oct	DISC
		180MG;240MG	A215232	001	Apr 17, 2025	Apr	NEWA
	L PERRIGO CO	60MG;120MG	A216792	001	Oct 07, 2025	Sep	NEWA

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL  
FLUTICASONE PROPIONATE

	RUBICON	0.05MG/SPRAY	A219060	001	Aug 15, 2025	Aug	NEWA
--	---------	--------------	---------	-----	--------------	-----	------

IBUPROFEN

SUSPENSION;ORAL  
IBUPROFEN

	STRIDES PHARMA	100MG/5ML	A211666	001	Feb 22, 2021	Aug	CMFD
--	----------------	-----------	---------	-----	--------------	-----	------

SUSPENSION/DROPS;ORAL  
IBUPROFEN

	AUROBINDO PHARMA LTD	40MG/ML	A213506	001	Apr 08, 2024	May	CMFD
--	----------------------	---------	---------	-----	--------------	-----	------

TABLET;ORAL  
IBUPROFEN

>D>	STRIDES PHARMA	200MG	A206989	001	Jun 29, 2018	Dec	DISC
>A>	@	200MG	A206989	001	Jun 29, 2018	Dec	DISC
>D>		200MG	A207052	001	May 30, 2017	Dec	DISC
>A>	@	200MG	A207052	001	May 30, 2017	Dec	DISC
>D>	STRIDES PHARMA INTL	200MG	A070481	001	Sep 24, 1986	Dec	DISC
>A>	@	200MG	A070481	001	Sep 24, 1986	Dec	DISC

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET;ORAL  
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

	AUROBINDO PHARMA LTD	200MG;30MG	A213565	001	Mar 10, 2023	Sep	CMFD
	STRIDES PHARMA	200MG;30MG	A077628	001	Aug 14, 2006	Apr	CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL  
LEVOCETIRIZINE DIHYDROCHLORIDE

@	APOTEX	5MG	A211443	001	Apr 21, 2021	Jan	DISC
	SANKALP LIFECARE	5MG	A211551	001	Nov 20, 2018	Jul	CAHN

LEVONORGESTREL

TABLET;ORAL  
LEVONORGESTREL

	ANNORA PHARMA	1.5MG	A219102	001	Sep 30, 2025	Sep	NEWA
--	---------------	-------	---------	-----	--------------	-----	------

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL  
LOPERAMIDE HYDROCHLORIDE

>A>	AUROBINDO PHARMA	2MG	A220372	001	Dec 29, 2025	Dec	NEWA
-----	------------------	-----	---------	-----	--------------	-----	------

SOLUTION;ORAL  
IMODIUM A-D

@ +	KENVUE BRANDS	1MG/5ML	N019487	001	Mar 01, 1988	Apr	DISC
+	!	1MG/7.5ML	N019487	002	Jul 08, 2004	Sep	CDFR

LOPERAMIDE HYDROCHLORIDE

	BIONPHARMA	1MG/7.5ML	A220100	001	Sep 19, 2025	Sep	NEWA
@	PAI HOLDINGS	1MG/5ML	A074352	001	Nov 17, 1995	Feb	CAHN
	PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011	Sep	CDFR
@	WOCKHARDT BIO AG	1MG/5ML	A074730	001	Aug 28, 1997	Apr	DISC

	TABLET;ORAL								
	LOPERAMIDE HYDROCHLORIDE								
	MARKSANS PHARMA	2MG	A220153	001	Nov 17, 2025	Nov	NEWA		
	<u>LORATADINE</u>								
	CAPSULE;ORAL								
	LORATADINE								
	AUROBINDO PHARMA	10MG	A211900	001	Mar 24, 2023	Jun	CMFD		
	@ CATALENT PHARMA	10MG	A215127	001	Feb 28, 2025	Jun	DISC		
		10MG	A215127	001	Feb 28, 2025	Feb	NEWA		
	SUSPENSION;ORAL								
	LORATADINE								
	@ + SUN PHARMA CANADA	1MG/ML	N021734	001	Oct 04, 2005	Aug	CAHN		
	@ + TARO	1MG/ML	N021734	001	Oct 04, 2005	Aug	DISC		
	TABLET;ORAL								
	LORATADINE								
>D>	ADAPTIS	10MG	A219223	001	Nov 21, 2024	Dec	CAHN		
		10MG	A219223	001	Nov 21, 2024	Sep	CAHN		
>A>	MARKSANS PHARMA	10MG	A219223	001	Nov 21, 2024	Dec	CAHN		
	TABLET, CHEWABLE;ORAL								
	LORATADINE								
	SUN PHARM	10MG	A210088	002	Apr 25, 2025	Apr	NEWA		
	<u>MINOXIDIL</u>								
	SOLUTION;TOPICAL								
	MINOXIDIL EXTRA STRENGTH (FOR MEN)								
	TARO	5%	A217998	001	Jun 30, 2025	Jun	NEWA		
	<u>MOMETASONE FUROATE</u>								
	SPRAY, METERED;NASAL								
	MOMETASONE FUROATE								
	@ AUROBINDO PHARMA	0.05MG/SPRAY	A217498	001	Nov 22, 2024	May	DISC		
	<u>NAPROXEN SODIUM</u>								
	TABLET;ORAL								
	NAPROXEN SODIUM								
>D>	ADAPTIS	220MG	A074635	001	Jan 13, 1997	Dec	CAHN		
		220MG	A074635	001	Jan 13, 1997	Sep	CAHN		
>A>	CONTRACT PHARMACAL	220MG	A074635	001	Jan 13, 1997	Dec	CAHN		
	@ NOVELGENIX THERAPS	220MG	A207612	001	Nov 16, 2018	Apr	DISC		
	<u>NICOTINE POLACRILEX</u>								
	TROCHE/LOZENGE;ORAL								
	NICOTINE POLACRILEX								
	DR REDDYS LABS SA	EQ 2MG BASE	A215276	001	Jul 17, 2025	Jul	NEWA		
		EQ 4MG BASE	A215276	002	Jul 17, 2025	Jul	NEWA		
	<u>OLOPATADINE HYDROCHLORIDE</u>								
	SOLUTION/DROPS;OPHTHALMIC								
	OLOPATADINE HYDROCHLORIDE								
	BAUSCH AND LOMB INC	EQ 0.1% BASE	A206046	001	Jul 26, 2017	May	CMFD		
		EQ 0.2% BASE	A206087	001	Dec 05, 2017	Feb	CMFD		
	FDC LTD	EQ 0.2% BASE	A217051	001	Jul 14, 2025	Jul	NEWA		
>A>	GLAND	EQ 0.7% BASE	A213514	001	Jan 06, 2026	Dec	NEWA		
	GLENMARK PHARMS INC	EQ 0.2% BASE	A219557	001	Feb 28, 2025	Feb	NEWA		
	RISING	EQ 0.1% BASE	A204392	001	Mar 21, 2018	May	CMFD		
		EQ 0.2% BASE	A204620	001	Jun 16, 2020	Apr	CMFD		
	<u>OMEPRAZOLE</u>								
	TABLET, DELAYED RELEASE;ORAL								
	OMEPRAZOLE								
	@ APOTEX	20MG	A210070	001	Feb 11, 2019	Jan	DISC		
	<u>OMEPRAZOLE MAGNESIUM</u>								
	CAPSULE, DELAYED RELEASE;ORAL								
	OMEPRAZOLE MAGNESIUM								
>A>	DEXCEL	EQ 20MG BASE	A216096	001	May 24, 2022	Dec	CAHN		
>D>	L PERRIGO CO	EQ 20MG BASE	A216096	001	May 24, 2022	Dec	CAHN		
	TABLET, DELAYED RELEASE;ORAL								
	OMEPRAZOLE MAGNESIUM								
	MARKSANS PHARMA	EQ 20MG BASE	A218829	001	Aug 07, 2025	Aug	NEWA		

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

MIRALAX

	+	BAYER HEALTHCARE LLC	17GM/PACKET	N022015	002	Oct 06, 2006	Aug	NEWA
		POLYETHYLENE GLYCOL 3350						
		ANI PHARMS	17GM/PACKET	A202850	002	Nov 30, 2021	Aug	NEWA
		ANNORA PHARMA	17GM/PACKET	A214990	002	Apr 14, 2021	Aug	NEWA
		AUROBINDO PHARMA LTD	17GM/PACKET	A209017	002	Apr 23, 2024	Aug	NEWA
		NOVEL LABS INC	17GM/PACKET	A091077	002	Jun 27, 2011	Aug	NEWA
		SHREE HARI INTL	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Aug	CAHN
>D>		STRIDES PHARMA INTL	17GM/SCOOPFUL	A079214	001	Jan 31, 2013	Dec	DISC
>A>	@		17GM/SCOOPFUL	A079214	001	Jan 31, 2013	Dec	DISC

POTASSIUM IODIDE

TABLET;ORAL

THYROSAFE

		BTG INTL	130MG	A076350	002	Apr 02, 2025	Mar	NFTG
--	--	----------	-------	---------	-----	--------------	-----	------

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

>A>	!	AUROBINDO PHARMA LTD	240MG	A218854	001	Dec 29, 2025	Dec	NFTG
		SUDAFED 24 HOUR						
	@ +	KENVUE BRANDS	240MG	N020021	002	Dec 15, 1992	Oct	DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND  
RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER 2025**

NO DECEMBER 2025 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO DECEMBER 2025 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 001	11673877	Mar 27, 2038	DS DP U-2830			
	12383543	Jul 28, 2037	U-2830			
<u>ABIRATERONE ACETATE; NIRAPARIB TOSYLATE - AKEEGA</u>						
N 216793 002	11673877	Mar 27, 2038	DS DP U-2830			
	12383543	Jul 28, 2037	U-2830			
<u>ABROCITINIB - CIBINQO</u>						
N 213871 001 >A>	9035074	Jan 14, 2036	DS DP			
<u>ABROCITINIB - CIBINQO</u>						
N 213871 002 >A>	9035074	Jan 14, 2036	DS DP			
<u>ABROCITINIB - CIBINQO</u>						
N 213871 003 >A>	9035074	Jan 14, 2036	DS DP			
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	10167291	Jul 01, 2036	DP U-2145		I-960	Jan 16, 2028
	10167291	Jul 01, 2036	DP U-2519			
	10167291	Jul 01, 2036	DP U-2666			
	10167291	Jul 01, 2036	DP U-2667			
	10167291	Jul 01, 2036	DP U-2668			
	10167291	Jul 01, 2036	DP U-2669			
	10167291	Jul 01, 2036	DP U-2670			
	10167291	Jul 01, 2036	DP U-2671			
	10167291	Jul 01, 2036	DP U-2682			
	10167291	Jul 01, 2036	DP U-2683			
	10167291	Jul 01, 2036	DP U-2684			
	10167291	Jul 01, 2036	DP U-2685			
	10167291	Jul 01, 2036	DP U-2686			
	10167291	Jul 01, 2036	DP U-2687			
	10167291	Jul 01, 2036	DP U-4109			
	10272083	Jan 21, 2035	U-2519			
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	10272083	Jan 21, 2035	U-4109			
	9758524	Jul 11, 2032	U-2145			
	9758524	Jul 11, 2032	U-4108			
	9796721	Jul 01, 2036	DS DP U-2145			
	9796721	Jul 01, 2036	DS DP U-2666			
	9796721	Jul 01, 2036	DS DP U-2667			
	9796721	Jul 01, 2036	DS DP U-2668			
	9796721	Jul 01, 2036	DS DP U-2669			
	9796721	Jul 01, 2036	DS DP U-2670			
	9796721	Jul 01, 2036	DS DP U-2671			
	9796721	Jul 01, 2036	DS DP U-4108			
<u>ACALABRUTINIB MALEATE - CALQUENCE</u>						
N 216387 001	10272083	Jan 21, 2035	U-2519		I-960	Jan 16, 2028
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	10272083	Jan 21, 2035	U-4109			
	11059829	Jul 01, 2036	DS DP U-2145			
	11059829	Jul 01, 2036	DS DP U-2666			
	11059829	Jul 01, 2036	DS DP U-2667			
	11059829	Jul 01, 2036	DS DP U-2668			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACALABRUTINIB MALEATE - CALQUENCE</u>						
N 216387 001	11059829	Jul 01, 2036	DS DP U-2669			
	11059829	Jul 01, 2036	DS DP U-2670			
	11059829	Jul 01, 2036	DS DP U-2671			
	11059829	Jul 01, 2036	DS DP U-4108			
	9758524	Jul 11, 2032	U-2145			
	9758524	Jul 11, 2032	U-4108			
<u>ACECLIDINE HYDROCHLORIDE - VIZZ</u>						
N 218585 001	10052313	Mar 24, 2034	DP U-3741		NCE	Jul 31, 2030
	11179328	Mar 24, 2034	U-3741			
	12128036	Oct 08, 2039	U-3741			
	12414942	Mar 15, 2044	U-3741			
	9844537	Mar 24, 2034	DP U-3741			
<u>ACETAMINOPHEN - ACETAMINOPHEN</u>						
A 214331 002					PC	Jan 07, 2026
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	10383834	Nov 13, 2028	U-2262			
	10383834	Nov 13, 2028	U-2621			
	10383834*PED	May 13, 2029				
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 002	8748413	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 003	8748413	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; IBUPROFEN SODIUM - COMBOGESIC IV</u>						
N 215320 001	12220392	Oct 26, 2031	U-4306			
	12220392	Oct 26, 2031	U-4307			
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001					D-196	Nov 26, 2027
<u>ACOLTREMOM - TRYPTYR</u>						
N 217370 001	10028920	Sep 08, 2031	U-1900		NCE	May 28, 2030
	11850221	Dec 16, 2042	DP U-1900			
	12336971	Dec 16, 2042	U-1900			
	9095609	Sep 08, 2031	DP U-1900			
	9433679	Sep 08, 2031	U-1900			
<u>ACORAMIDIS HYDROCHLORIDE - ATTRUBY</u>						
N 216540 001	9913826	May 05, 2031	U-4046		ODE-506	Nov 22, 2031
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001	12281113	Sep 10, 2041	DS DP			
	12336995	Feb 05, 2041	U-3953			
	12383503	Aug 21, 2043	DP			
<u>AFAMELANOTIDE - SCENESSE</u>						
N 210797 001	8334265	Jan 20, 2033	U-2638			
<u>AFICAMTEN - MYOORZO</u>						
N 219083 001					>A> NCE	Dec 19, 2030
<u>AFICAMTEN - MYOORZO</u>						
N 219083 002					>A> NCE	Dec 19, 2030
<u>AFICAMTEN - MYOORZO</u>						
N 219083 003					>A> NCE	Dec 19, 2030

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AFICAMTEN - MYOORZO</u>						
N 219083	004				>A> NCE	Dec 19, 2030
<u>ALBUMIN HUMAN - OPTISON</u>						
N 020899	001				NPP	May 09, 2028
<u>ALBUTEROL SULFATE; BUDESONIDE - AIRSUPRA</u>						
N 214070	001				>A> M-317	Sep 15, 2028
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747	001	7396341	Oct 10, 2026	DP	Y	
		7837235	Mar 13, 2028	DP	Y	
		8733341	Oct 16, 2030	DP	Y	
		9027967	Mar 31, 2027	DP	Y	
<u>ALPELISIB - VIJOICE</u>						
N 215039	001	>A> 11433059	Feb 17, 2037	U-4359		
		12427141	Feb 17, 2037	U-4288		
<u>ALPELISIB - VIJOICE</u>						
N 215039	002	>A> 11433059	Feb 17, 2037	U-4359		
		12427141	Feb 17, 2037	U-4288		
<u>ALPELISIB - VIJOICE</u>						
N 215039	003	>A> 11433059	Feb 17, 2037	U-4359		
		12427141	Feb 17, 2037	U-4288		
<u>ALPELISIB - VIJOICE</u>						
N 218466	001	>A> 11433059	Feb 17, 2037	U-4359		
		12427141	Feb 17, 2037	U-4288		
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944	001	12233033	Aug 23, 2038	U-2106		
		12233033	Aug 23, 2038	U-2224		
		12233033	Aug 23, 2038	U-3180		
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944	002	12233033	Aug 23, 2038	U-2106		
		12233033	Aug 23, 2038	U-2224		
		12233033	Aug 23, 2038	U-3180		
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356	001	12168021	May 15, 2035	U-2414		
		12168022	May 15, 2035	U-2414		
		12377114	May 15, 2035	U-2414		
<u>AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - PERIKABIVEN IN PLASTIC CONTAINER</u>						
N 200656	001	12390398	May 03, 2036	DP		
<u>AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - PERIKABIVEN IN PLASTIC CONTAINER</u>						
N 200656	002	12390398	May 03, 2036	DP		
<u>AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - PERIKABIVEN IN PLASTIC CONTAINER</u>						
N 200656	003	12390398	May 03, 2036	DP		
<u>AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - KABIVEN IN PLASTIC CONTAINER</u>						
N 200656	004	12390398	May 03, 2036	DP		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - KABIVEN IN PLASTIC CONTAINER</u>						
N 200656 005	12390398	May 03, 2036	DP			
<u>AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - KABIVEN IN PLASTIC CONTAINER</u>						
N 200656 006	12390398	May 03, 2036	DP			
<u>AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL - KABIVEN IN PLASTIC CONTAINER</u>						
N 200656 007	12390398	May 03, 2036	DP			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	11179574	Oct 13, 2036	U-804			
	11446512	Jan 17, 2037	U-804			
	11697028	Oct 13, 2036	U-804			
	12290700	Oct 13, 2036	U-804			
	12296011	Jan 12, 2038	U-3163			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001	12280146	Dec 08, 2043	DP			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 001	12005042	Feb 09, 2038	U-1744			
	12005042	Feb 09, 2038	U-2754			
	12005042	Feb 09, 2038	U-3467			
	12194022	Mar 10, 2031	U-1744			
	12194022	Mar 10, 2031	U-3467			
	12329740	Feb 09, 2038	U-2754			
	12329740	Feb 09, 2038	U-3467			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 002	12005042	Feb 09, 2038	U-1744			
	12005042	Feb 09, 2038	U-2754			
	12005042	Feb 09, 2038	U-3467			
	12194022	Mar 10, 2031	U-1744			
	12194022	Mar 10, 2031	U-3467			
	12329740	Feb 09, 2038	U-2754			
	12329740	Feb 09, 2038	U-3467			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	12336984	Oct 06, 2037	U-3447			
	12336984	Oct 06, 2037	U-3448			
	12383498	Oct 06, 2037	DP			
<u>AMLODIPINE BESYLATE - NORLIQVA</u>						
N 214439 001	12005141	Feb 24, 2041	DP U-3309			
	12005141	Feb 24, 2041	DP U-3310			
	12005141	Feb 24, 2041	DP U-3311			
	12226528	Feb 24, 2041	DP U-3309			
	12226528	Feb 24, 2041	DP U-3310			
	12226528	Feb 24, 2041	DP U-3311			
	12440441	Feb 24, 2041	DP U-3309			
	12440441	Feb 24, 2041	DP U-3310			
	12440441	Feb 24, 2041	DP U-3311			
<u>AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK</u>						
N 219423 001	10322117	Jan 23, 2038	DP		NP	Jun 05, 2028
	12465599	Jan 23, 2038	DP			
<u>AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK</u>						
N 219423 002	10799487	Jan 23, 2038	DP U-3448		NP	Jun 05, 2028
	12465599	Jan 23, 2038	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN - WIDAPLIK</u>						
N 219423	003				NP	Jun 05, 2028
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 5</u>						
N 210526	001	12458592	Feb 11, 2040	U-3538		
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 10</u>						
N 210526	002	12458592	Feb 11, 2040	U-3538		
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 15</u>						
N 210526	003	12458592	Feb 11, 2040	U-3538		
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANAVEL XR 20</u>						
N 210526	004	12458592	Feb 11, 2040	U-3538		
<u>APALUTAMIDE - ERLEADA</u>						
N 210951	001	12303493	Dec 03, 2035	DP		
		12303497	Jan 30, 2040	U-4201		
		12303497	Jan 30, 2040	U-4202		
<u>APALUTAMIDE - ERLEADA</u>						
N 210951	002	12303493	Dec 03, 2035	DP		
		12303497	Jan 30, 2040	U-4201		
		12303497	Jan 30, 2040	U-4202		
<u>APIXABAN - ELIQUIS</u>						
N 202155	001	6967208	Nov 21, 2026	DS DP U-1167	NPP	Apr 17, 2028
		6967208	Nov 21, 2026	DS DP U-1200	PED	Oct 17, 2028
		6967208	Nov 21, 2026	DS DP U-1301		
		6967208	Nov 21, 2026	DS DP U-1302		
		6967208	Nov 21, 2026	DS DP U-1323		
		6967208	Nov 21, 2026	DS DP U-1501		
		6967208	Nov 21, 2026	DS DP U-1502		
		6967208	Nov 21, 2026	DS DP U-1729		
		6967208	Nov 21, 2026	DS DP U-1730		
		6967208	Nov 21, 2026	DS DP U-4178		
		6967208*PED	May 21, 2027			
		9326945	Feb 24, 2031	DP		
		9326945*PED	Aug 24, 2031			
<u>APIXABAN - ELIQUIS</u>						
N 202155	002	6967208	Nov 21, 2026	DS DP U-1200	NPP	Apr 17, 2028
		6967208	Nov 21, 2026	DS DP U-1301	PED	Oct 17, 2028
		6967208	Nov 21, 2026	DS DP U-1302		
		6967208	Nov 21, 2026	DS DP U-1323		
		6967208	Nov 21, 2026	DS DP U-4178		
		6967208*PED	May 21, 2027			
		9326945	Feb 24, 2031	DP		
		9326945*PED	Aug 24, 2031			
<u>APIXABAN - ELIQUIS</u>						
N 202155	003	6967208	Nov 21, 2026	DS DP U-4179	NS	Apr 17, 2028
		6967208*PED	May 21, 2027		PED	Oct 17, 2028
		9326945	Feb 24, 2031	DP		
		9326945*PED	Aug 24, 2031			
<u>APIXABAN - ELIQUIS SPRINKLE</u>						
N 220073	001	11896586	Nov 22, 2040	DP U-4180	NP	Apr 17, 2028
		11896586*PED	May 22, 2041		PED	Oct 17, 2028
		6967208	Nov 21, 2026	DS DP U-4180		
		6967208*PED	May 21, 2027			
<u>APOMORPHINE HYDROCHLORIDE - ONAPGO</u>						
N 214056	001				NP	Feb 03, 2028

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA XR</u>						
N 210745 001	10092541	May 29, 2034	U-2659		M-299	Jul 20, 2026
	11752129	May 27, 2042	DP U-4264		ODE*	Jul 19, 2026
	11752129	May 27, 2042	DP U-4265		PED	Jan 19, 2027
	11752129	May 27, 2042	DP U-4266		PED	Jan 20, 2027
	11969409	May 27, 2042	DP			
	12427136	May 27, 2042	U-1858			
	12427136	May 27, 2042	U-4290			
	12427136	May 27, 2042	U-4291			
	7427638	Feb 16, 2028	DS DP			
<u>APREPITANT - CINVANTI</u>						
N 209296 001	12290520	Sep 18, 2035	DP			
<u>APREPITANT - APONVIE</u>						
N 216457 001	12290520	Sep 18, 2035	DP			
<u>APROCITENTAN - TRYVIO</u>						
N 217686 001	12297189	Feb 26, 2038	DP			
<u>ARIPIPRAZOLE - MEZOFY</u>						
N 211448 001	9694008	Aug 07, 2033	DP			
<u>ARIPIPRAZOLE - MEZOFY</u>						
N 211448 002	9694008	Aug 07, 2033	DP			
<u>ARIPIPRAZOLE - MEZOFY</u>						
N 211448 003	9694008	Aug 07, 2033	DP			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	11969469	Oct 24, 2033	DP			
	12251381	Apr 06, 2039	U-543			
	12311027	Sep 19, 2033	DP U-543			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	11969469	Oct 24, 2033	DP			
	12251381	Apr 06, 2039	U-543			
	12311027	Sep 19, 2033	DP U-543			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	11969469	Oct 24, 2033	DP			
	12251381	Apr 06, 2039	U-543			
	12311027	Sep 19, 2033	DP U-543			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	11969469	Oct 24, 2033	DP			
	12251381	Apr 06, 2039	U-543			
	12311027	Sep 19, 2033	DP U-543			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830 001	12251381	Apr 06, 2039	U-543			
<u>ARTICAINE HYDROCHLORIDE - CYKLX</u>						
N 218643 001					NP	Aug 15, 2028
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 001	12252478	May 14, 2040	DP		>A> M-318	Oct 02, 2028
	12252479	May 17, 2040	U-1374			
	8829195	Oct 29, 2035	DS U-1374			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 002	12252478	May 14, 2040	DP		>A> M-318	Oct 02, 2028
	12252479	May 17, 2040	U-1374			
	8829195	Oct 29, 2035	DS U-1374			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 002	12252478	May 14, 2040	DP		>A> M-318	Oct 02, 2028
	12252479	May 17, 2040	U-1374			
	8829195	Oct 29, 2035	DS U-1374			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 003	12252478	May 14, 2040	DP		>A> M-318	Oct 02, 2028
	12252479	May 17, 2040	U-1374			
	8829195	Oct 29, 2035	DS U-1374			
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 001	12090148	Jul 29, 2041	U-3534			
	12350259	Feb 27, 2043	U-4234			
	12383545	Jun 06, 2039	U-3534			
	12465598	Sep 27, 2042	U-4355			
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 002	12090148	Jul 29, 2041	U-3534			
	12383545	Jun 06, 2039	U-3534			
<u>ATOGEPAANT - QULIPTA</u>						
N 215206 003	12383545	Jun 06, 2039	U-3534			
<u>ATORVASTATIN CALCIUM - ATORVALIO</u>						
N 213260 001	12370136	Jun 07, 2037	DP			
<u>ATRASENTAN HYDROCHLORIDE - VANRAFIA</u>						
N 219208 001	10016393	Jul 07, 2034	DP		NCE	Apr 02, 2030
	11491137	Dec 16, 2040	U-3980			
	11874283	Feb 18, 2032	U-3980			
	11998526	Dec 16, 2040	U-3980			
	12121509	Dec 16, 2040	U-3980			
	12370174	Dec 16, 2040	U-3980			
	8623819	Aug 22, 2028	U-3980			
	9364458	Jul 07, 2034	DP U-3980			
<u>AVACINCAPTAD PEGOL SODIUM - IZERVAY</u>						
N 217225 001	7579456	Feb 14, 2026	DS			
	9617546	Feb 14, 2026	DS U-3673			
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	>A> 11603356	Nov 27, 2039	DS DP U-3558			
<u>AVAPRITINIB - AYWAKIT</u>						
N 212608 004	12252494	Apr 10, 2040	U-3506			
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001					I-974	Jul 24, 2028
<u>AVATROMBOPAG MALEATE - DOPTELET SPRINKLE</u>						
N 219696 001	7638536	Jul 28, 2027	DS DP		NP	Jul 24, 2028
<u>AVIBACTAM SODIUM; AZTREONAM - EMBLAVEO</u>						
N 217906 001	7112592	Jan 07, 2026	DS DP U-4147		NP	Feb 07, 2028
	7612087	Nov 12, 2026	DP		GAIN	Feb 07, 2033
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
	9284314	Jun 15, 2032	DS			
	9695122	Jun 15, 2032	DS DP			
<u>AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE - AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)</u>						
N 219616 001	11400090	Oct 29, 2038	U-4196		NCE	May 08, 2030
	11517573	Sep 11, 2040	U-4196			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE - AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)</u>						
N 219616 001	11517573	Sep 11, 2040	U-4205			
	11873296	Dec 29, 2042	DP U-4196			
	7897792	Feb 09, 2027	DS DP			
	7928109	Aug 21, 2029	DS DP			
	8247411	Apr 17, 2028	DS DP			
<u>BACLOFEN - BACLOFEN</u>						
A 214445 001					PC	Jul 14, 2025
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001					M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002					M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003					M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001					M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 002	10392406	Apr 27, 2036	DS			
	10633397	Apr 27, 2036	U-2816			
	10633397	Apr 27, 2036	U-3000			
	10759814	Aug 09, 2037	DS DP			
	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
	11925648	Apr 21, 2041	DP			
	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 003	10392406	Apr 27, 2036	DS			
	10633397	Apr 27, 2036	U-2816			
	10633397	Apr 27, 2036	U-3000			
	10759814	Aug 09, 2037	DS DP			
	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
	11925648	Apr 21, 2041	DP			
	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	10022509	May 18, 2031	DP	Y		
	10022510	May 18, 2031	DP	Y		
	10086156	May 18, 2031	DP	Y		
	9463289	May 18, 2031	DP	Y		
	9808587	May 18, 2031	DP	Y		
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	10022509	May 18, 2031	DP	Y		
	10022510	May 18, 2031	DP	Y		
	10086156	May 18, 2031	DP	Y		
	9463289	May 18, 2031	DP	Y		
	9808587	May 18, 2031	DP	Y		
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	10022509	May 18, 2031	DP	Y		
	10022510	May 18, 2031	DP	Y		
	10086156	May 18, 2031	DP	Y		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	10561808	Jan 01, 2032	DP	Y		
	10695512	May 18, 2031	DP	Y		
	11395889	May 18, 2031	DP	Y		
	12296089	Jan 26, 2038	DP			
	8132712	Sep 07, 2028	DP	Y		
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	10022509	May 18, 2031	DP	Y		
	10022510	May 18, 2031	DP	Y		
	10086156	May 18, 2031	DP	Y		
	10561808	Jan 01, 2032	DP	Y		
	10695512	May 18, 2031	DP	Y		
	11395889	May 18, 2031	DP	Y		
	11865247	Jan 26, 2038	DP	Y		
	11896759	Jan 26, 2038	DP	Y		
	12296089	Jan 26, 2038	DP			
	8132712	Sep 07, 2028	DP	Y		
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 002					ODE*	Aug 09, 2026
<u>BELUMOSUDIL MESYLATE - REZUROCK</u>						
N 214783 001	10183931	Oct 07, 2033	U-3246			
	10183931	Oct 07, 2033	U-4260			
	10696660	Oct 07, 2033	U-3246			
	10696660	Oct 07, 2033	U-4260			
	8357693	Jun 20, 2034	DS DP U-4259			
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001	12358870	Jun 30, 2042	DP		I-968	May 14, 2028
	9908845	Sep 05, 2034	DS DP U-3201			
	9908845	Sep 05, 2034	DS DP U-4176			
	9908845	Sep 05, 2034	DS DP U-4195			
	RE49948	Sep 05, 2034	DS DP U-3201			
	RE49948	Sep 05, 2034	DS DP U-4176			
	RE49948	Sep 05, 2034	DS DP U-4195			
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	12398087	Jun 19, 2040	DS DP			
	12404227	Jun 19, 2040	DS U-4258			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	12398087	Jun 19, 2040	DS DP			
	12404227	Jun 19, 2040	DS U-4258			
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	12138248	Jan 28, 2031	DP			
	12350257	Jan 28, 2031	DP U-1542			
	12350257	Jan 28, 2031	DP U-1971			
	12350257	Jan 28, 2031	DP U-1972			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	12138248	Jan 28, 2031	DP			
	12350257	Jan 28, 2031	DP U-1542			
	12350257	Jan 28, 2031	DP U-1971			
	12350257	Jan 28, 2031	DP U-1972			
<u>BENDAMUSTINE HYDROCHLORIDE - VIVIMUSTA</u>						
N 212209 001	11707450	Jul 29, 2042	DP			
	12208086	Jul 29, 2042	DP			
	12419867	Jul 29, 2042	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 001	12208167	Feb 26, 2044	DP U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 002	12208167	Feb 26, 2044	DP U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 003	12208167	Feb 26, 2044	DP U-713			
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	12257348	May 23, 2041	DP U-3947			
	12295935	Dec 27, 2040	U-3356			
	12350382	Feb 03, 2028	DP			
<u>BENZOYL PEROXIDE; TRETINOIN - TWYNEO</u>						
N 214902 001	12257348	May 23, 2041	DP U-3987			
	12295935	Dec 27, 2040	U-3987			
	12357602	Jul 12, 2038	DP U-3987			
	>A> 12491163	May 23, 2041	DP U-3987			
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	10125102	Apr 07, 2035	DS U-3010		ODE-333	Dec 03, 2027
	10125102*PED	Oct 07, 2035			PED	Jun 03, 2028
	10329260	Mar 09, 2035	DS			
	10329260*PED	Sep 09, 2035				
	10662160	Nov 01, 2039	DS U-3010			
	10662160*PED	May 01, 2040				
	10689346	Mar 09, 2035			U-3010	
	10689346*PED	Sep 09, 2035				
	11117867	Nov 01, 2039	DP U-3010			
	11117867*PED	May 01, 2040				
	11230530	Mar 09, 2035			U-3300	
	11230530*PED	Sep 09, 2035				
	11618733	Nov 01, 2039			U-3300	
	11618733*PED	May 01, 2040				
	11708333	Mar 09, 2035			U-3300	
	11708333*PED	Sep 09, 2035				
	12116346	Mar 09, 2035	DS			
	12116346*PED	Sep 09, 2035				
	12344585	Nov 01, 2039			U-3010	
	12344585*PED	May 01, 2040				
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	10125102	Apr 07, 2035	DS U-3010		ODE-333	Dec 03, 2027
	10125102*PED	Oct 07, 2035			PED	Jun 03, 2028
	10329260	Mar 09, 2035	DS			
	10329260*PED	Sep 09, 2035				
	10662160	Nov 01, 2039	DS U-3010			
	10662160*PED	May 01, 2040				
	10689346	Mar 09, 2035			U-3010	
	10689346*PED	Sep 09, 2035				
	11117867	Nov 01, 2039	DP U-3010			
	11117867*PED	May 01, 2040				
	11230530	Mar 09, 2035			U-3300	
	11230530*PED	Sep 09, 2035				
	11618733	Nov 01, 2039			U-3300	
	11618733*PED	May 01, 2040				
	11708333	Mar 09, 2035			U-3300	
	11708333*PED	Sep 09, 2035				
	12116346	Mar 09, 2035	DS			
	12116346*PED	Sep 09, 2035				
	12344585	Nov 01, 2039			U-3010	
	12344585*PED	May 01, 2040				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 001					>A> NP >A> PED	Dec 11, 2028 Jun 11, 2029
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 002					>A> NP >A> PED	Dec 11, 2028 Jun 11, 2029
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 003					>A> NP >A> PED	Dec 11, 2028 Jun 11, 2029
<u>BEROTRALSTAT DIHYDROCHLORIDE - ORLADEYO</u>						
N 219776 004					>A> NP >A> PED	Dec 11, 2028 Jun 11, 2029
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - WYNZORA</u>						
N 213422 001	12440499	Mar 18, 2039	DP U-1408			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>BIMATOPROST - ZOLYMBUS</u>						
N 217307 001	10314780	Jun 08, 2036	DP U-1295		NDF	Sep 09, 2028
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	7777050	Mar 13, 2026	DS DP			
<u>BIRCH TRITERPENES - FILSUVEZ</u>						
N 215064 001	12268695	Jan 04, 2039	U-3811			
	8828444	Jun 21, 2026	DP			
<u>BIVALIRUDIN - ANGIOMAX RTU</u>						
N 211215 001	12472224	May 20, 2039	DP U-3817			
<u>BOSENTAN - BOSENTAN</u>						
A 213154 001					PC	Feb 14, 2026
<u>BRENSOCATIB - BRINSUPRI</u>						
N 217673 001	10287258	Jan 21, 2035	DS U-4257		NCE	Aug 12, 2030
	10669245	Jan 21, 2035	DS U-4257			
	11655221	Jan 21, 2035	DP U-4257			
	11655222	Jan 21, 2035	DS U-4257			
	11655223	Jan 21, 2035	DS U-4257			
	11655224	Jan 21, 2035	DP U-4257			
	11673871	Jan 21, 2035	DP U-4257			
	11773069	Jan 21, 2035	DP U-4257			
	11814359	Jan 21, 2035	DS U-4257			
	12054465	Jan 21, 2035	DS U-4257			
	12059424	Feb 21, 2040	DP			
	12201638	Mar 01, 2039	DP			
	9522894	Mar 12, 2035	DS			
	9815805	Jan 21, 2035	U-4257			
<u>BRENSOCATIB - BRINSUPRI</u>						
N 217673 002	10287258	Jan 21, 2035	DS U-4257		NCE	Aug 12, 2030
	10669245	Jan 21, 2035	DS U-4257			
	11655221	Jan 21, 2035	DP U-4257			
	11655222	Jan 21, 2035	DS U-4257			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRENSOCATIB - BRINSUPRI</u>						
N 217673 002	11655223	Jan 21, 2035	DS U-4257			
	11655224	Jan 21, 2035	DP U-4257			
	11673871	Jan 21, 2035	DP U-4257			
	11773069	Jan 21, 2035	DP U-4257			
	11814359	Jan 21, 2035	DS U-4257			
	12054465	Jan 21, 2035	DS U-4257			
	12059424	Feb 21, 2040	DP			
	12201638	Mar 01, 2039	DP			
	9522894	Mar 12, 2035	DS			
	9815805	Jan 21, 2035	U-4257			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 001					M-315	May 09, 2028
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 002					M-315	May 09, 2028
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 003					M-315	May 09, 2028
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 004					M-315	May 09, 2028
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 005					M-315	May 09, 2028
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 006					M-315	May 09, 2028
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001	12171882	Jan 23, 2043	U-4085			
	12171882	Jan 23, 2043	U-4086			
	12171883	Jan 23, 2043	DP			
	12311057	Jan 23, 2043	DP U-4085			
	12311057	Jan 23, 2043	DP U-4086			
	12311057	Jan 23, 2043	DP U-4204			
<u>BUMETANIDE - ENBUMYST</u>						
N 219500 001	11123319	Dec 04, 2040	DP			
	11260038	Dec 04, 2040	U-4279			
	12329731	Dec 04, 2040	DP U-4279			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	12226610	Feb 02, 2043	U-4148			
	12226610	Feb 02, 2043	U-4149			
	12226610	Feb 02, 2043	U-4150			
	12251468	Jul 02, 2044	DP U-4152			
	12296047	Jan 22, 2041	DP U-4184			
	12318483	Jul 02, 2044	U-4152			
	12370142	Jul 02, 2044	DP U-4152			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	12226610	Feb 02, 2043	U-4148			
	12226610	Feb 02, 2043	U-4149			
	12226610	Feb 02, 2043	U-4150			
	12251468	Jul 02, 2044	DP U-4152			
	12296047	Jan 22, 2041	DP U-4184			
	12318483	Jul 02, 2044	U-4152			
	12370142	Jul 02, 2044	DP U-4152			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001					M-314	Feb 21, 2028

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002					M-314	Feb 21, 2028
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 001	12161640	Jul 26, 2032	DP U-4100			
	12318379	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 002	12161640	Jul 26, 2032	DP U-4100			
	12318379	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 003	12161640	Jul 26, 2032	DP U-4100			
	12318379	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 004	12161640	Jul 26, 2032	DP U-4100			
	12318379	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 005	12161640	Jul 26, 2032	DP U-4100			
	12318379	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 006	12161640	Jul 26, 2032	DP U-4100			
	12318379	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 007	12161640	Jul 26, 2032	DP U-4100			
	12318379	Jul 26, 2032	DP U-4100			
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11065248	Nov 05, 2034	U-3419			
	11123344	Nov 05, 2034	U-3419			
	11571417	Nov 05, 2034	U-3419			
	11576909	Nov 05, 2034	U-3419			
	11590124	Nov 05, 2034	U-3419			
	12310961	Jan 20, 2043	U-3419			
	12357697	Jan 20, 2043	U-3419			
	12390428	Dec 01, 2041	U-3419			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	12453712	Oct 27, 2030	U-4334			
<u>CABOTEGRAVIR - APRETUDE</u>						
N 215499 001	8410103	Feb 04, 2031	DS DP			
<u>CABOTEGRAVIR SODIUM - VOCABRIA</u>						
N 212887 001	8410103	Feb 04, 2031	DS DP U-3348			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	11389448	Apr 13, 2032	DP			
	12178815	Jul 18, 2038	U-3348			
	8410103	Feb 04, 2031	DS DP U-3348			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	11389448	Apr 13, 2032	DP			
	12178815	Jul 18, 2038	U-3348			
	8410103	Feb 04, 2031	DS DP U-3348			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	11098015	Jan 15, 2030	U-3225			
	11098015	Jan 15, 2030	U-4131			
	11098015	Jan 15, 2030	U-4156			
	12128039	Feb 10, 2032	DP U-1220			
	12128039	Feb 10, 2032	DP U-1480			
	12128039	Feb 10, 2032	DP U-2488			
	12128039	Feb 10, 2032	DP U-3225			
	12128039	Feb 10, 2032	DP U-4131			
	12128039	Feb 10, 2032	DP U-4156			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11098015	Jan 15, 2030	U-4131			
	11098015	Jan 15, 2030	U-4156			
	12128039	Feb 10, 2032	DP U-1220			
	12128039	Feb 10, 2032	DP U-1480			
	12128039	Feb 10, 2032	DP U-2488			
	12128039	Feb 10, 2032	DP U-3225			
	12128039	Feb 10, 2032	DP U-4131			
	12128039	Feb 10, 2032	DP U-4156			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11098015	Jan 15, 2030	U-4131			
	11098015	Jan 15, 2030	U-4156			
	12128039	Feb 10, 2032	DP U-1220			
	12128039	Feb 10, 2032	DP U-1480			
	12128039	Feb 10, 2032	DP U-2488			
	12128039	Feb 10, 2032	DP U-3225			
	12128039	Feb 10, 2032	DP U-4131			
	12128039	Feb 10, 2032	DP U-4156			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 208418 004	10130646	Jul 25, 2037	DP			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 208418 005	10130646	Jul 25, 2037	DP			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					NPP	Dec 18, 2027
					PED	Jun 18, 2028
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					NPP	Dec 18, 2027
					PED	Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					NPP	Dec 18, 2027
					PED	Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					NPP	Dec 18, 2027
					PED	Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					NPP	Dec 18, 2027
					PED	Jun 18, 2028

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANTHARIDIN - YCANTH</u>						
N 212905 001	12233042	Aug 22, 2038	DP U-3663			
	12290651	Feb 19, 2041	DP			
<u>CAPIVASERTIB - TRUOAP</u>						
N 218197 001	12252495	Oct 10, 2028	U-3762			
<u>CAPIVASERTIB - TRUOAP</u>						
N 218197 002	12252495	Oct 10, 2028	U-3762			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 001	10596178	Jul 22, 2035	DP			
	12208101	Jul 22, 2035	DP			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 002	10596178	Jul 22, 2035	DP			
	12208101	Jul 22, 2035	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 001	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	12295931	Dec 21, 2041	U-1649			
	12295931	Dec 21, 2041	U-219			
	12295931	Dec 21, 2041	U-4004			
	12295931	Dec 21, 2041	U-4005			
	12303481	Dec 21, 2041	U-1649			
	12303481	Dec 21, 2041	U-219			
	12303481	Dec 21, 2041	U-4004			
	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			
	12303605	Oct 07, 2034	DP			
	12370163	Dec 21, 2041	U-1649			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 001	12370163	Dec 21, 2041	U-219			
	12370163	Dec 21, 2041	U-4004			
	12370163	Dec 21, 2041	U-4005			
	12403099	Oct 07, 2034	DP			
	12447139	Dec 21, 2041	U-1649			
	12447139	Dec 21, 2041	U-219			
	12447139	Dec 21, 2041	U-4004			
	12447139	Dec 21, 2041	U-4005			
	12453710	Dec 21, 2041	U-1649			
	12453710	Dec 21, 2041	U-219			
	12453710	Dec 21, 2041	U-4004			
	12453710	Dec 21, 2041	U-4005			
	12458616	Dec 21, 2041	U-1649			
	12458616	Dec 21, 2041	U-219			
	12458616	Dec 21, 2041	U-4004			
	12458616	Dec 21, 2041	U-4005			
>A>	12491164	Oct 07, 2034	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 002	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	12295931	Dec 21, 2041	U-1649			
	12295931	Dec 21, 2041	U-219			
	12295931	Dec 21, 2041	U-4004			
	12295931	Dec 21, 2041	U-4005			
	12303481	Dec 21, 2041	U-1649			
	12303481	Dec 21, 2041	U-219			
	12303481	Dec 21, 2041	U-4004			
	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			
	12303605	Oct 07, 2034	DP			
	12370163	Dec 21, 2041	U-1649			
	12370163	Dec 21, 2041	U-219			
	12370163	Dec 21, 2041	U-4004			
	12370163	Dec 21, 2041	U-4005			
	12403099	Oct 07, 2034	DP			
	12447139	Dec 21, 2041	U-1649			
	12447139	Dec 21, 2041	U-219			
	12447139	Dec 21, 2041	U-4004			
	12447139	Dec 21, 2041	U-4005			
	12453710	Dec 21, 2041	U-1649			
	12453710	Dec 21, 2041	U-219			
	12453710	Dec 21, 2041	U-4004			
	12453710	Dec 21, 2041	U-4005			
	12458616	Dec 21, 2041	U-1649			
	12458616	Dec 21, 2041	U-219			
	12458616	Dec 21, 2041	U-4004			
	12458616	Dec 21, 2041	U-4005			
>A>	12491164	Oct 07, 2034	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 003	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 003	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	12295931	Dec 21, 2041	U-1649			
	12295931	Dec 21, 2041	U-219			
	12295931	Dec 21, 2041	U-4004			
	12295931	Dec 21, 2041	U-4005			
	12303481	Dec 21, 2041	U-1649			
	12303481	Dec 21, 2041	U-219			
	12303481	Dec 21, 2041	U-4004			
	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			
	12303605	Oct 07, 2034	DP			
	12370163	Dec 21, 2041	U-1649			
	12370163	Dec 21, 2041	U-219			
	12370163	Dec 21, 2041	U-4004			
	12370163	Dec 21, 2041	U-4005			
	12403099	Oct 07, 2034	DP			
	12447139	Dec 21, 2041	U-1649			
	12447139	Dec 21, 2041	U-219			
	12447139	Dec 21, 2041	U-4004			
	12447139	Dec 21, 2041	U-4005			
	12453710	Dec 21, 2041	U-1649			
	12453710	Dec 21, 2041	U-219			
	12453710	Dec 21, 2041	U-4004			
	12453710	Dec 21, 2041	U-4005			
	12458616	Dec 21, 2041	U-1649			
	12458616	Dec 21, 2041	U-219			
	12458616	Dec 21, 2041	U-4004			
	12458616	Dec 21, 2041	U-4005			
>A>	12491164	Oct 07, 2034	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 004	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
	12263148	Dec 21, 2041	U-1649			
	12263148	Dec 21, 2041	U-219			
	12263148	Dec 21, 2041	U-4004			
	12263148	Dec 21, 2041	U-4005			
	12263149	Dec 21, 2041	U-1649			
	12263149	Dec 21, 2041	U-219			
	12263149	Dec 21, 2041	U-4004			
	12263149	Dec 21, 2041	U-4005			
	12274793	Oct 07, 2034	DP			
	12295931	Dec 21, 2041	U-1649			
	12295931	Dec 21, 2041	U-219			
	12295931	Dec 21, 2041	U-4004			
	12295931	Dec 21, 2041	U-4005			
	12303481	Dec 21, 2041	U-1649			
	12303481	Dec 21, 2041	U-219			
	12303481	Dec 21, 2041	U-4004			
	12303481	Dec 21, 2041	U-4005			
	12303482	Dec 21, 2041	U-1649			
	12303482	Dec 21, 2041	U-219			
	12303482	Dec 21, 2041	U-4004			
	12303482	Dec 21, 2041	U-4005			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 004	12303605	Oct 07, 2034	DP			
	12370163	Dec 21, 2041	U-1649			
	12370163	Dec 21, 2041	U-219			
	12370163	Dec 21, 2041	U-4004			
	12370163	Dec 21, 2041	U-4005			
	12403099	Oct 07, 2034	DP			
	12447139	Dec 21, 2041	U-1649			
	12447139	Dec 21, 2041	U-219			
	12447139	Dec 21, 2041	U-4004			
	12447139	Dec 21, 2041	U-4005			
	12453710	Dec 21, 2041	U-1649			
	12453710	Dec 21, 2041	U-219			
	12453710	Dec 21, 2041	U-4004			
	12453710	Dec 21, 2041	U-4005			
	12458616	Dec 21, 2041	U-1649			
	12458616	Dec 21, 2041	U-219			
	12458616	Dec 21, 2041	U-4004			
	12458616	Dec 21, 2041	U-4005			
>A>	12491164	Oct 07, 2034	DP			
<u>CARBOPLATIN - KYXATA</u>						
N 219921 001	12427104	Apr 01, 2045	DP			
<u>CARBOPLATIN - KYXATA</u>						
N 219921 002	12427104	Apr 01, 2045	DP			
<u>CARBOPLATIN - KYXATA</u>						
N 219921 003	12427104	Apr 01, 2045	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	7417042	Jul 20, 2026	DS DP		M-14	May 22, 2028
	7417042*PED	Jan 20, 2027			PED	Nov 22, 2028
	7737112	Dec 07, 2027	DP			
	7737112*PED	Jun 07, 2028				
	9493582	Feb 27, 2033	DP			
	9493582*PED	Aug 27, 2033				
	RE47954	Oct 21, 2029	U-3449			
	RE47954*PED	Apr 21, 2030				
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	7417042	Jul 20, 2026	DS DP		M-14	May 22, 2028
	7417042*PED	Jan 20, 2027			PED	Nov 22, 2028
	7737112	Dec 07, 2027	DP			
	7737112*PED	Jun 07, 2028				
	9493582	Feb 27, 2033	DP			
	9493582*PED	Aug 27, 2033				
	RE47954	Oct 21, 2029	U-3449			
	RE47954*PED	Apr 21, 2030				
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 003	7417042	Jul 20, 2026	DS DP		M-14	May 22, 2028
	7417042*PED	Jan 20, 2027			PED	Nov 22, 2028
	7737112	Dec 07, 2027	DP			
	7737112*PED	Jun 07, 2028				
	9493582	Feb 27, 2033	DP			
	9493582*PED	Aug 27, 2033				
	RE47954	Oct 21, 2029	U-3449			
	RE47954*PED	Apr 21, 2030				
<u>CASIMERSEN - AMONDYS 45</u>						
N 213026 001	RE48960	Feb 16, 2029	DS DP	U-3087		
	RE48960	Feb 16, 2029	DS DP	U-3088		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CEDAZURIDINE; DECITABINE - INQOVI</u>						
N 212576 001	12195496	Oct 07, 2040	DP			
	12239653	Feb 24, 2041	U-2865			
	12239653	Feb 24, 2041	U-2866			
<u>CERTINIB - ZYKADIA</u>						
N 211225 001	12357630	Dec 13, 2037	U-3096			
<u>CHENODIOL - CTEXLI</u>						
N 219488 001					NP	Feb 21, 2028
<u>CHLOROPROCAINE HYDROCHLORIDE - IHEEZO</u>						
N 216227 001	11969403	May 14, 2039	DP			
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819 001				>A> NPP		Dec 09, 2028
<u>CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE - CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE</u>						
A 218273 001				>A> CGT		Jun 02, 2026
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	12458634	Jan 27, 2038	DP			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	12337002	Jul 24, 2028	DP U-3280			
	>A> 8143240	Jan 12, 2027	U-2942			
	8865690	Dec 27, 2025	U-2942			
<u>CLINDAMYCIN PHOSPHATE - XACIATO</u>						
N 215650 001	12303563	Sep 22, 2036	DP			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 001	12290597	Sep 05, 2039	DP U-724			
	12403090	Sep 05, 2039	DP U-724			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833 002	12290597	Sep 05, 2039	DP U-724			
	12403090	Sep 05, 2039	DP U-724			
<u>CLONIDINE HYDROCHLORIDE - JAVADIN</u>						
N 220256 001	12233049	Jul 15, 2042	DP			
	12440474	Jul 15, 2042	DP			
<u>CLOTTRIMAZOLE - CLOTIC</u>						
N 217628 001	12246006	May 26, 2042	DP U-4276		NP GAIN	Sep 26, 2028 Sep 26, 2033
<u>COBICISTAT - TYBOST</u>						
N 203094 002	10039718	Oct 06, 2032	DP			
	10039718*PED	Apr 06, 2033				
	8148374	Sep 03, 2029	DS DP U-1279			
	8148374*PED	Mar 03, 2030				
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	8148374	Sep 03, 2029	DS DP U-1279			
	8148374	Sep 03, 2029	DS DP U-2939			
	8148374	Sep 03, 2029	DS DP U-4162			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 002	10039718	Oct 06, 2032	DP			
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-4162			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 002	10039718	Oct 06, 2032	DP			
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-4162			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	12274751	Nov 22, 2036	U-2814			
<u>COLCHICINE - LODOCO</u>						
N 215727 001	12233035	Nov 01, 2033	U-4132			
	12280025	Nov 01, 2033	U-4168			
	12364675	Nov 01, 2033	U-3639			
<u>COPPER - MIUDELLA</u>						
N 218201 001	10022264	Mar 22, 2034	DP		NP	Feb 24, 2028
	10159596	Aug 14, 2032	DP			
	10166141	Jun 13, 2034	DP			
	10188546	Aug 14, 2032	DP			
	10398588	Feb 24, 2034	DP U-4155			
	10918516	Jan 23, 2037	DP			
	11207209	Aug 16, 2034	DP			
	11850181	Aug 14, 2032	DP			
	12138199	Oct 18, 2033	DP			
	9089418	Apr 09, 2033	DP			
	9265652	Apr 28, 2034	U-4155			
	9427351	Aug 14, 2032	DP			
	9610191	Feb 24, 2034	U-4155			
<u>COPPER CU-64 DOTATATE - DETECTNET</u>						
N 213227 001	10383961	Jul 02, 2033	U-2951			
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 003	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 004	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
<u>CORTICOTROPIN - ACTHAR GEL</u>						
N 008372 008	11752199	Jul 18, 2041	U-3686			
	11752199	Jul 18, 2041	U-3687			
	11752199	Jul 18, 2041	U-3688			
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	12233105	Oct 27, 2043	U-3904			
	12233105	Oct 27, 2043	U-3905			
	12233105	Oct 27, 2043	U-3906			
	12233105	Oct 27, 2043	U-3907			
	12233105	Oct 27, 2043	U-3908			
	12233105	Oct 27, 2043	U-3909			
	12233105	Oct 27, 2043	U-3910			
	12233105	Oct 27, 2043	U-3911			
	12233105	Oct 27, 2043	U-3912			
	12233105	Oct 27, 2043	U-3913			
	12233105	Oct 27, 2043	U-3914			
	12233105	Oct 27, 2043	U-3915			
	12233105	Oct 27, 2043	U-3916			
	12233105	Oct 27, 2043	U-3917			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	12233105	Oct 27, 2043	U-3918			
	12233105	Oct 27, 2043	U-3919			
	12233105	Oct 27, 2043	U-3920			
	12233105	Oct 27, 2043	U-3921			
	12233105	Oct 27, 2043	U-3922			
	12233105	Oct 27, 2043	U-3923			
	12233105	Oct 27, 2043	U-3924			
	12233105	Oct 27, 2043	U-3925			
	12233105	Oct 27, 2043	U-3926			
	12324787	Oct 27, 2043	DP			
	12440542	Oct 27, 2043	DP U-3904			
	12440542	Oct 27, 2043	DP U-3905			
	12440542	Oct 27, 2043	DP U-3906			
	12440542	Oct 27, 2043	DP U-3907			
	12440542	Oct 27, 2043	DP U-3908			
	12440542	Oct 27, 2043	DP U-3909			
	12440542	Oct 27, 2043	DP U-3910			
	12440542	Oct 27, 2043	DP U-3911			
	12440542	Oct 27, 2043	DP U-3912			
	12440542	Oct 27, 2043	DP U-3913			
	12440542	Oct 27, 2043	DP U-3914			
	12440542	Oct 27, 2043	DP U-3915			
	12440542	Oct 27, 2043	DP U-3916			
	12440542	Oct 27, 2043	DP U-3917			
	12440542	Oct 27, 2043	DP U-3918			
	12440542	Oct 27, 2043	DP U-3919			
	12440542	Oct 27, 2043	DP U-3920			
	12440542	Oct 27, 2043	DP U-3921			
	12440542	Oct 27, 2043	DP U-3922			
	12440542	Oct 27, 2043	DP U-3923			
	12440542	Oct 27, 2043	DP U-3924			
	12440542	Oct 27, 2043	DP U-3925			
	12440542	Oct 27, 2043	DP U-3926			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 001	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 002	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 003	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CRINECERFONT - CRENESSITY</u>						
N 218820 001	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CYCLOBENZAPRINE HYDROCHLORIDE - TONMYA</u>						
N 219428 001	10117936	Mar 14, 2034	DP		NP	Aug 15, 2028
	10864175	Mar 14, 2034	DP			
	9636408	Mar 14, 2034	DP			
	9956188	Mar 14, 2034	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 001	12329767	Feb 15, 2036	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 002	12329767	Feb 15, 2036	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 003	12329767	Feb 15, 2036	DP			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8292129	Feb 25, 2031	DP	Y		
	8561859	Apr 16, 2032	DP	Y		
	9669974	May 11, 2034	DP	Y		
	9676525	Feb 07, 2034	DP	Y		
<u>CYCLOSPORINE - VEVYE</u>						
N 217469 001	>A> 12496326	Sep 29, 2036			U-3627	
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 001	>A> 7772243	Sep 27, 2032	DS DP			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 002	>A> 7772243	Sep 27, 2032	DS DP			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 003	>A> 7772243	Sep 27, 2032	DS DP			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	>A> 12213988	Apr 01, 2041			U-4140	
	>A> 12213988*PED	Oct 01, 2041				
	>A> 12409186	Apr 01, 2041			U-4140	
	>A> 12409186*PED	Oct 01, 2041				
	>A> 12472194	Jul 18, 2039			U-4346	
	>A> 12472194*PED	Jan 18, 2040				
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIO</u>						
N 214985 001					M-200	Sep 30, 2027
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIO</u>						
N 214985 002					M-200	Sep 30, 2027
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	10835515	Jan 28, 2036	DP U-2605		I-971	Jun 03, 2028
	10835515	Jan 28, 2036	DP U-4208			
	10835515	Jan 28, 2036	DP U-4209			
	10835515	Jan 28, 2036	DP U-4210			
	12329742	May 14, 2042	DP			
	8975254	Mar 25, 2033	DS DP U-4208			
	8975254	Mar 25, 2033	DS DP U-4209			
	8975254	Mar 25, 2033	DS DP U-4210			
	9657003	Oct 27, 2030	DS DP U-4208			
	9657003	Oct 27, 2030	DS DP U-4209			
	9657003	Oct 27, 2030	DS DP U-4210			
<u>DASATINIB - PHYRAGO</u>						
N 216099 001	12433891	Jan 22, 2041			U-3767	
	12433891	Jan 22, 2041			U-3768	
	12433891	Jan 22, 2041			U-3769	
	12433891	Jan 22, 2041			U-3770	
	12433891	Jan 22, 2041			U-3771	
	12433891	Jan 22, 2041			U-3772	
	12465606	Jan 22, 2041	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - PHYRAGO</u>						
N 216099 002	12433891	Jan 22, 2041	U-3767			
	12433891	Jan 22, 2041	U-3768			
	12433891	Jan 22, 2041	U-3769			
	12433891	Jan 22, 2041	U-3770			
	12433891	Jan 22, 2041	U-3771			
	12433891	Jan 22, 2041	U-3772			
	12465606	Jan 22, 2041	DP			
<u>DASATINIB - PHYRAGO</u>						
N 216099 003	12433891	Jan 22, 2041	U-3767			
	12433891	Jan 22, 2041	U-3768			
	12433891	Jan 22, 2041	U-3769			
	12433891	Jan 22, 2041	U-3770			
	12433891	Jan 22, 2041	U-3771			
	12433891	Jan 22, 2041	U-3772			
	12465606	Jan 22, 2041	DP			
<u>DASATINIB - PHYRAGO</u>						
N 216099 004	12433891	Jan 22, 2041	U-3767			
	12433891	Jan 22, 2041	U-3768			
	12433891	Jan 22, 2041	U-3769			
	12433891	Jan 22, 2041	U-3770			
	12433891	Jan 22, 2041	U-3771			
	12433891	Jan 22, 2041	U-3772			
	12465606	Jan 22, 2041	DP			
<u>DASATINIB - PHYRAGO</u>						
N 216099 005	12433891	Jan 22, 2041	U-3767			
	12433891	Jan 22, 2041	U-3768			
	12433891	Jan 22, 2041	U-3769			
	12433891	Jan 22, 2041	U-3770			
	12433891	Jan 22, 2041	U-3771			
	12433891	Jan 22, 2041	U-3772			
	12465606	Jan 22, 2041	DP			
<u>DASATINIB - PHYRAGO</u>						
N 216099 006	12433891	Jan 22, 2041	U-3767			
	12433891	Jan 22, 2041	U-3768			
	12433891	Jan 22, 2041	U-3769			
	12433891	Jan 22, 2041	U-3770			
	12433891	Jan 22, 2041	U-3771			
	12433891	Jan 22, 2041	U-3772			
	12465606	Jan 22, 2041	DP			
<u>DELGOCITINIB - ANZUPGO</u>						
N 219155 001	8609647	Sep 19, 2031	DS DP U-4237		NCE	Jul 23, 2030
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	12161653	Feb 17, 2032	U-1940			
<u>DEURUXOLITINIB PHOSPHATE - LEOSELVI</u>						
N 217900 001	12247034	May 10, 2044	DS DP			
	12285432	Aug 11, 2042	U-3976			
	12364699	Oct 10, 2044	U-3976			
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 001	10022352	Apr 09, 2027	DP U-4081		NCE	Dec 20, 2029
	10047053	May 17, 2032	DS			
	10081621	Mar 25, 2031	DP U-4087			
	10239867	Apr 09, 2027	DS DP U-4090			
	10646481	Aug 13, 2029	DP			
	11066417	Feb 14, 2039	DS DP			
	11564916	Aug 13, 2029	U-4095			
	11578062	Mar 25, 2031	DP U-4096			
	11639347	Apr 09, 2027	DS DP U-4090			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 001	11866450	Feb 14, 2039	U-4082			
	11873300	Aug 13, 2040	DS DP U-4083			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-4090			
	8354427	Jul 06, 2026	U-4091			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-4082			
	8598181	May 01, 2027	U-4090			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-4084			
	8754224	Dec 28, 2026	DS DP			
	8865902	May 17, 2032	DS DP			
	9181192	May 17, 2032	DS DP U-4094			
	9512079	May 17, 2032	DS DP U-4098			
	9670163	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4080			
	9974781	Apr 09, 2027	DP U-4082			
>A>	RE50453	Jul 10, 2031	DS DP			
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 002	10022352	Apr 09, 2027	DP U-4081		NCE	Dec 20, 2029
	10047053	May 17, 2032	DS			
	10058546	Jul 15, 2033	U-4218			
	10081621	Mar 25, 2031	DP U-4087			
	10206877	Apr 14, 2035	DP U-4092			
	10239867	Apr 09, 2027	DS DP U-4090			
	10646481	Aug 13, 2029	DP			
	11066417	Feb 14, 2039	DS DP			
	11564916	Aug 13, 2029	U-4095			
	11578062	Mar 25, 2031	DP U-4096			
	11639347	Apr 09, 2027	DS DP U-4090			
	11866450	Feb 14, 2039	U-4082			
	11873300	Aug 13, 2040	DS DP U-4083			
	11951212	Apr 14, 2035	DP U-4089			
	12186306	Jan 10, 2043	U-4088			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-4090			
	8354427	Jul 06, 2026	U-4091			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-4082			
	8598181	May 01, 2027	U-4090			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-4084			
	8754224	Dec 28, 2026	DS DP			
	8865902	May 17, 2032	DS DP			
	9012496	Jul 15, 2033	U-4097			
	9181192	May 17, 2032	DS DP U-4094			
	9512079	May 17, 2032	DS DP U-4098			
	9670163	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4080			
	9974781	Apr 09, 2027	DP U-4082			
>A>	RE50453	Jul 10, 2031	DS DP			
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742 001					NPP	Apr 07, 2028
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	12364683	Jan 12, 2043	U-4029		>A> M-82	Nov 19, 2028
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	12364683	Jan 12, 2043	U-4029		>A> M-82	Nov 19, 2028

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	12268664	Mar 27, 2029	DP		NPP	Apr 15, 2028
	12324852	Oct 16, 2032	U-4173			
	12337061	Jun 13, 2032	U-4173			
	8927497	Jul 21, 2025	DP U-4173			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 002	12268664	Mar 27, 2029	DP		NPP	Apr 15, 2028
	12324852	Oct 16, 2032	U-4173			
	12337061	Jun 13, 2032	U-4173			
	8927497	Jul 21, 2025	DP U-4173			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 003	12268664	Mar 27, 2029	DP		NPP	Apr 15, 2028
	12324852	Oct 16, 2032	U-4173			
	12337061	Jun 13, 2032	U-4173			
	8927497	Jul 21, 2025	DP U-4173			
<u>DIAZOXIDE CHOLINE - VYKAT XR</u>						
N 216665 001	12178823	Nov 12, 2035	U-4167		NP	Mar 26, 2028
	12343348	Nov 12, 2035	U-4211			
	12419895	Nov 12, 2035	U-4275			
	7572789	Dec 20, 2026	DS DP			
	7799777	Mar 05, 2029	DS			
	9757384	Nov 12, 2035	U-4167			
<u>DIAZOXIDE CHOLINE - VYKAT XR</u>						
N 216665 002	12178823	Nov 12, 2035	U-4167		NP	Mar 26, 2028
	12343348	Nov 12, 2035	U-4211			
	12419895	Nov 12, 2035	U-4275			
	7572789	Dec 20, 2026	DS DP			
	7799777	Mar 05, 2029	DS			
	9757384	Nov 12, 2035	U-4167			
<u>DIAZOXIDE CHOLINE - VYKAT XR</u>						
N 216665 003	12178823	Nov 12, 2035	U-4167		NP	Mar 26, 2028
	12343348	Nov 12, 2035	U-4211			
	12419895	Nov 12, 2035	U-4275			
	7572789	Dec 20, 2026	DS DP			
	7799777	Mar 05, 2029	DS			
	9757384	Nov 12, 2035	U-4167			
<u>DIHYDROERGOTAMINE MESYLATE - BREKIYA (AUTOINJECTOR)</u>						
N 215400 001	10532049	Feb 26, 2039	DP			
	11304942	Feb 26, 2039	DP			
	11819501	Feb 26, 2039	U-4188			
	11819501	Feb 26, 2039	U-848			
<u>DIHYDROERGOTAMINE MESYLATE - ATZUMI</u>						
N 217901 001	10758532	Dec 11, 2039	DP		NP	Apr 30, 2028
	10792253	Aug 04, 2037	DP			
	11744967	Oct 12, 2041	DP			
	11872314	Aug 04, 2037	DP			
	12102754	Oct 12, 2041	DP			
	12263162	Dec 11, 2039	DP			
<u>DIROXIMEL FUMARATE - VUMERITY</u>						
N 211855 001	8669281	Oct 29, 2033	DS DP			
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 001	12161767	Dec 30, 2036	DS DP U-3334			
	12168075	Dec 30, 2036	U-3334			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 002	12161767	Dec 30, 2036	DS DP U-3334			
	12168075	Dec 30, 2036	U-3334			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE</u>						
A 208328 001					PC	Jul 15, 2025
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE</u>						
A 208328 002					PC	Jul 15, 2025
<u>DONIDALORSEN SODIUM - DAWNZERA (AUTOINJECTOR)</u>						
N 219407 001	10294477	May 01, 2035	DS DP U-3010			
	9127276	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
	9315811	Oct 21, 2032			U-3010	
	9670492	Aug 28, 2034	DS			
<u>DORDAVIPRONE HYDROCHLORIDE - MODEYSO</u>						
N 219876 001	10172862	Jan 30, 2037			NCE	Aug 06, 2030
	10369154	Jan 30, 2037			U-4254	
	11976068	Mar 01, 2036	DP			
	12102639	Jan 30, 2037			U-4254	
	9265765	Jul 26, 2034	DP			
	9629842	Apr 30, 2032			U-4254	
	RE46290	Apr 30, 2032			U-4254	
<u>DOXECITINE; DOXRIBTIMINE - KYGEVVI</u>						
N 219792 001	>A> 10471087	Aug 07, 2036			NCE	Nov 03, 2030
	>A> 11649259	Aug 19, 2040	DP U-4358			
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 020862 001					M-14	Jun 11, 2028
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 020862 002					M-14	Jun 11, 2028
<u>DOXERCALCIFEROL - HECTOROL</u>						
N 020862 003					M-14	Jun 11, 2028
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	12280151	Jun 28, 2031	DP			
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	12233074	Feb 09, 2043	DP U-3152			
	12427114	Jun 17, 2036	DP U-3152			
	12458649	Oct 01, 2043			U-3152	
	7732430	Jan 15, 2028	DP U-3152			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	12171742	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	12171742	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	12171742	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	12171742	Apr 13, 2037	DP			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 001	12213983	Apr 26, 2035	U-2412			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DUVELISIB - COPIKTRA</u>						
N 211155 002	12213983	Apr 26, 2035	U-2412			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	12194025	Nov 12, 2041	U-4111			
	12285409	Nov 01, 2039	DP			
	12310946	Nov 12, 2041	U-4111			
	>A> 12478611	Nov 12, 2041	U-4111			
<u>ELACESTRANT HYDROCHLORIDE - ORSERDU</u>						
N 217639 001	10420734	Oct 03, 2036	U-3524			
	11819480	Feb 28, 2037	U-3523			
<u>ELACESTRANT HYDROCHLORIDE - ORSERDU</u>						
N 217639 002	10420734	Oct 03, 2036	U-3524			
	11819480	Feb 28, 2037	U-3523			
<u>ELAFIBRANOR - IOIRVO</u>						
N 218860 001	12233038	Mar 30, 2037	U-1854			
	12295927	Mar 30, 2037	U-1854			
	12295928	Mar 30, 2037	U-1854			
	12310935	Mar 30, 2037	U-1854			
<u>ELAMIPRETIDE HYDROCHLORIDE - FORZINITY</u>						
N 215244 001	11083771	Feb 28, 2034	U-4277		NCE	Sep 19, 2030
	11083772	Feb 28, 2034	U-4277			
	11771734	Feb 28, 2034	U-4277			
	12268724	Feb 28, 2034	U-4277			
	7576061	Jan 20, 2026	DS DP			
	9687519	Feb 28, 2034	U-4277			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10081621	Mar 25, 2031	DP U-3032		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-3157		ODE-512	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4075			
	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10239867	Apr 09, 2027	DS DP U-4056			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4067			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	12350262	Jul 17, 2038	U-4221			
	12458635	Aug 13, 2029	DP U-4330			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	8629162	Jun 24, 2025	U-3030			
	8629162	Jun 24, 2025	U-3146			
	8629162	Jun 24, 2025	U-4079			
	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
>A>	RE50453	Jul 10, 2031	DS DP			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	10081621	Mar 25, 2031	DP U-3157		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-4075		ODE*	Oct 21, 2026
	10239867	Apr 09, 2027	DS DP U-3158		ODE*	Dec 21, 2027
	10239867	Apr 09, 2027	DS DP U-4056		ODE-512	Dec 20, 2031
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4069			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	12350262	Jul 17, 2038	U-4222			
	12458635	Aug 13, 2029	DP U-4330			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8629162	Jun 24, 2025	U-3146			
	8629162	Jun 24, 2025	U-4079			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
>A>	RE50453	Jul 10, 2031	DS DP			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 001	10081621	Mar 25, 2031	DP U-3600		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-4065		ODE-512	Dec 20, 2031
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 001	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	12214083	Feb 27, 2033	DP U-4141			
	12458635	Aug 13, 2029	DP U-4333			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8629162	Jun 24, 2025	U-3592			
	8629162	Jun 24, 2025	U-4072			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
>A>	RE50453	Jul 10, 2031	DS DP			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	10081621	Mar 25, 2031	DP U-3600		ODE-512	Dec 20, 2031
	10081621	Mar 25, 2031	DP U-4065			
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	12214083	Feb 27, 2033	DP U-4141			
	12350262	Jul 17, 2038	U-4220			
	12458635	Aug 13, 2029	DP U-4333			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8629162	Jun 24, 2025	U-3592			
	8629162	Jun 24, 2025	U-4072			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
>A>	RE50453	Jul 10, 2031	DS DP			
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	12465586	Jun 05, 2032	U-3042			
	12465586	Jun 05, 2032	U-3043			
<u>ELINZANETANT - LYNKUET</u>						
N 219469 001	10195205	May 18, 2036	U-3622		NCE	Oct 24, 2030
	10774091	Mar 13, 2039	DP			
	11787820	Mar 13, 2039	U-3622			
	12264164	Mar 13, 2039	U-3622			
	7683056	Sep 15, 2026	DS DP			
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 206788 001					PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 206788 002					PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 206788 003					PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 206788 004					PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 216620 001					PC	Nov 09, 2025
<u>ELTROMBOPAG OLAMINE - ELTROMBOPAG OLAMINE</u>						
A 216620 002					PC	Nov 09, 2025
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	11813275	Apr 03, 2034	U-3759			
	11813275	Apr 03, 2034	U-3760			
	11813275*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4171			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4171			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12178819	May 04, 2027	DP			
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12178819	May 04, 2027	DP			
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	11666590	Apr 03, 2034	U-4154			
	11813275	Apr 03, 2034	U-3759			
	11813275*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	11666590	Apr 03, 2034	U-4154			
	11813275	Apr 03, 2034	U-3759			
	11813275*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	11666590	Apr 03, 2034	U-4154			
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	11666590	Apr 03, 2034	U-4154			
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	12263153	Apr 03, 2034	U-4154			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	11666590	Apr 03, 2034	U-4154			
	11813275	Apr 03, 2034	U-3759			
	11813275*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	11666590	Apr 03, 2034	U-4154			
	11813275	Apr 03, 2034	U-3759			
	11813275*PED	Oct 03, 2034				
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	11666590	Apr 03, 2034	U-4154			
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			
	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	11666590	Apr 03, 2034	U-4154			
	11833166	Apr 03, 2034	U-3776			
	11833166	Apr 03, 2034	U-3777			
	11833166*PED	Oct 03, 2034				
	12115179	Feb 11, 2030	U-4023			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	12115179*PED	Aug 11, 2030				
	12263153	Apr 03, 2034	U-4154			
	12427162	Apr 03, 2034	U-4287			
	12433906	Apr 03, 2034	U-4293			
	12433906	Apr 03, 2034	U-4294			
	12433906	Apr 03, 2034	U-4295			
	12433906	Apr 03, 2034	U-4296			
	12433906	Apr 03, 2034	U-4304			
	12433906*PED	Oct 03, 2034				
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 208452 001					PC	Nov 23, 2025
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	7390791	Jan 07, 2025	DS DP		M-316	Jun 20, 2028
	7390791*PED	Jul 07, 2025				
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002	7390791	Jan 07, 2025	DS DP		M-316	Jun 20, 2028
	7390791*PED	Jul 07, 2025				
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001					I-957	Dec 20, 2027
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	10005761	Aug 27, 2030	U-2335		I-957	Dec 20, 2027
	10005761	Aug 27, 2030	U-2802			
	10005761	Aug 27, 2030	U-2803			
	10005761	Aug 27, 2030	U-3738			
	10005761	Aug 27, 2030	U-4051			
	10258622	Nov 21, 2032	U-2802			
	10258622	Nov 21, 2032	U-4051			
	8541575	Feb 26, 2030	DS DP U-2335			
	8541575	Feb 26, 2030	DS DP U-2802			
	8541575	Feb 26, 2030	DS DP U-2803			
	8541575	Feb 26, 2030	DS DP U-3738			
	8541575	Feb 26, 2030	DS DP U-4051			
	9314464	Jul 04, 2031	U-2336			
	9314464	Jul 04, 2031	U-2802			
	9314464	Jul 04, 2031	U-2803			
	9314464	Jul 04, 2031	U-3738			
	9314464	Jul 04, 2031	U-4051			
	9474754	Aug 05, 2033	U-2802			
	9474754	Aug 05, 2033	U-4051			
	9850230	Aug 27, 2030	U-2334			
	9850230	Aug 27, 2030	U-2802			
	9850230	Aug 27, 2030	U-2803			
	9850230	Aug 27, 2030	U-3738			
	9850230	Aug 27, 2030	U-4051			
<u>ENSARTINIB HYDROCHLORIDE - ENSACOVE</u>						
N 218171 001	10899744	Jun 01, 2037	DS U-4099		NCE	Dec 18, 2029
	8551995	Feb 09, 2029	DS			
	9126947	Nov 29, 2031	DS			
	9296724	Jun 18, 2029	DS U-4099			
<u>ENSARTINIB HYDROCHLORIDE - ENSACOVE</u>						
N 218171 002	10899744	Jun 01, 2037	DS U-4099		NCE	Dec 18, 2029
	8551995	Feb 09, 2029	DS			
	9126947	Nov 29, 2031	DS			
	9296724	Jun 18, 2029	DS U-4099			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENSARTINIB HYDROCHLORIDE - ENSACOVE</u>						
N 218171 002	10899744	Jun 01, 2037	DS	U-4099	NCE	Dec 18, 2029
	8551995	Feb 09, 2029	DS			
	9126947	Nov 29, 2031	DS			
	9296724	Jun 18, 2029	DS	U-4099		
<u>ENSIFENTRINE - OHTUVAYRE</u>						
N 217389 001	12251384	Jun 25, 2044		DP		
	12409180	Feb 20, 2043		DP		
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	8299057	Mar 10, 2032	DS DP			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	8299057	Mar 10, 2032	DS DP			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 218550 001					ODE*	Aug 15, 2026
					ODE*	Aug 15, 2026
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	12161628	Feb 23, 2037		U-4101		
	12161628	Feb 23, 2037		U-4102		
	12161628	Feb 23, 2037		U-4103		
	12161628	Feb 23, 2037		U-4104		
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 001	12161628	Feb 23, 2037		U-4101		
	12161628	Feb 23, 2037		U-4102		
	12161628	Feb 23, 2037		U-4103		
	12161628	Feb 23, 2037		U-4104		
	>A> 12502357	Sep 11, 2033		U-4363		
	>A> 12502357	Sep 11, 2033		U-4364		
	>A> 12502357	Sep 11, 2033		U-4365		
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 002	12161628	Feb 23, 2037		U-4101		
	12161628	Feb 23, 2037		U-4102		
	12161628	Feb 23, 2037		U-4103		
	12161628	Feb 23, 2037		U-4104		
	12447128	Sep 11, 2033		U-4312		
	12447128	Sep 11, 2033		U-4313		
	12447128	Sep 11, 2033		U-4314		
	>A> 12502357	Sep 11, 2033		U-4363		
	>A> 12502357	Sep 11, 2033		U-4364		
	>A> 12502357	Sep 11, 2033		U-4365		
<u>EPHEDRINE SULFATE - EPHEDRINE SULFATE</u>						
A 218271 001					PC	Feb 21, 2026
<u>EPHEDRINE SULFATE - EPHEDRINE SULFATE</u>						
A 218271 002					PC	Feb 21, 2026
<u>EPINEPHRINE - EPINEPHRINE</u>						
A 213708 001					PC	Jun 03, 2025
<u>EPINEPHRINE - EPINEPHRINE</u>						
A 219239 001					CGT	Sep 03, 2025
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	12280024	Mar 13, 2035		DP		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	12280024	Mar 13, 2035	DP			
<u>EPINEPHRINE - NEFFY</u>						
N 214697 001	12324838	Feb 06, 2039	DP			
<u>EPINEPHRINE - NEFFY</u>						
N 214697 002	10576156	Feb 06, 2038	DP			
	10682414	Feb 06, 2039		U-3979		
	11173209	Feb 06, 2038		U-3979		
	11191838	Feb 06, 2039	DP	U-3979		
	11717571	Feb 06, 2039		U-3979		
	11744895	Feb 06, 2039		U-3979		
	11918655	Feb 06, 2039		U-3979		
	12324838	Feb 06, 2039	DP			
<u>EPLONTERSEN SODIUM - WAINUA (AUTOINJECTOR)</u>						
N 217388 001	8101743	Apr 01, 2026	DS DP			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	10869844	Sep 10, 2035	U-3034		I-959	Jan 17, 2028
	10869844	Sep 10, 2035	U-3035			
	10869844	Sep 10, 2035	U-3036			
	10869844	Sep 10, 2035	U-4113			
	10869844	Sep 10, 2035	U-4114			
	11173134	Sep 10, 2035	U-3257			
	11173134	Sep 10, 2035	U-3536			
	11173134	Sep 10, 2035	U-4115			
	11311500	Sep 10, 2035	U-3034			
	11311500	Sep 10, 2035	U-3035			
	11311500	Sep 10, 2035	U-3036			
	11311500	Sep 10, 2035	U-4116			
	11311500	Sep 10, 2035	U-4117			
	11446260	Mar 14, 2034	U-3444			
	11446260	Mar 14, 2034	U-3445			
	11446260	Mar 14, 2034	U-3446			
	11446260	Mar 14, 2034	U-4118			
	11446260	Mar 14, 2034	U-4119			
	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			
	11883526	Feb 18, 2040	U-4120			
	8785500	Mar 05, 2033	U-2502			
	8785500	Mar 05, 2033	U-4112			
	9592207	Mar 20, 2027	U-2502			
	9592207	Mar 20, 2027	U-4112			
<u>ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE</u>						
A 211199 001					PC	Nov 02, 2025
<u>ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE</u>						
A 211199 002					PC	Nov 02, 2025
<u>ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE</u>						
A 211199 003					PC	Nov 02, 2025
<u>ESLICARBAZEPINE ACETATE - ESLICARBAZEPINE ACETATE</u>						
A 211199 004					PC	Nov 02, 2025
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	12325714	Sep 27, 2033	DS DP			
	7300935	Jan 28, 2029	DS			
<u>ESTROGENS, CONJUGATED - CONJUGATED ESTROGENS</u>						
A 214023 001					CGT	Apr 15, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTROGENS, CONJUGATED - CONJUGATED ESTROGENS</u>						
A 214023	002				CGT	Apr 15, 2026
<u>ESTROGENS, CONJUGATED - CONJUGATED ESTROGENS</u>						
A 214025	001				CGT	Apr 15, 2026
<u>ESTROGENS, CONJUGATED - CONJUGATED ESTROGENS</u>						
A 214025	002				CGT	Apr 15, 2026
<u>ESTROGENS, CONJUGATED - CONJUGATED ESTROGENS</u>						
A 214025	003				CGT	Apr 15, 2026
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - FEMLYV</u>						
N 218718	001	12178824	Jun 24, 2041	DP		
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627	001	12303518	Jun 21, 2039	DP		
<u>ETRASIMOD ARGININE - VELSIPIITY</u>						
N 216956	001	12377071	Jan 06, 2036	U-4255		
<u>ETRIPIAMIL - CARDAMYST</u>						
N 218571	001				>A> NCE	Dec 12, 2030
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565	001	7612109	Feb 05, 2026	DS DP		
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565	002	7612109	Feb 05, 2026	DS DP		
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565	003	7612109	Feb 05, 2026	DS DP		
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565	004	7612109	Feb 05, 2026	DS DP		
<u>FERRIC MALTOL - ACCRUFER</u>						
N 212320	001				>A> NPP	Dec 19, 2028
<u>FERUMOXYTOL - FERABRIGHT</u>						
N 219868	001				NP	Oct 16, 2028
<u>FERUMOXYTOL - FERABRIGHT</u>						
N 219868	002				NP	Oct 16, 2028
<u>FEZOLINETANT - VEOZAH</u>						
N 216578	001	10836768	Mar 28, 2034	U-3622		
<u>FINERENONE - KERENDIA</u>						
N 215341	001				I-970	Jul 11, 2028
<u>FINERENONE - KERENDIA</u>						
N 215341	002				I-970	Jul 11, 2028
<u>FINERENONE - KERENDIA</u>						
N 215341	003	8436180 RE49826	Apr 12, 2029 Jul 29, 2035	DS DP DS	NCE NS	Jul 09, 2026 Jul 11, 2028
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589	001	9566260	Jul 30, 2026	DP U-2366		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 002	9566260	Jul 30, 2026	DP U-2366			
<u>FITUSIRAN SODIUM - OFITLIA</u>						
N 219019 001	11091759	Dec 07, 2036	U-4165		NCE	Mar 28, 2030
	9127274	Mar 22, 2033	DS DP U-4165		ODE-510	Mar 28, 2032
	9376680	Mar 15, 2033	DS DP U-4165		ODE-511	Mar 28, 2032
<u>FITUSIRAN SODIUM - OFITLIA</u>						
N 219019 002	11091759	Dec 07, 2036	U-4165		NCE	Mar 28, 2030
	9127274	Mar 22, 2033	DS DP U-4165		ODE-510	Mar 28, 2032
	9376680	Mar 15, 2033	DS DP U-4165		ODE-511	Mar 28, 2032
<u>FLORBETABEN F-18 - NEURACEO</u>						
N 204677 001	9308284	Jul 14, 2032	DP			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 001	8506929	Apr 30, 2027	DS DP U-4217			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 002	8506929	Apr 30, 2027	DS DP U-4217			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 003	8506929	Apr 30, 2027	DS DP U-4217			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008 004	7687052	Apr 30, 2027	DS DP U-4217			
	8506929	Apr 30, 2027	DS DP U-4217			
<u>FLOTUFOLASTAT F-18 GALLIUM - POSLUMA</u>						
N 216023 001	12357711	Nov 22, 2038	DS			
	12377176	Nov 22, 2038	DS			
	12390540	Aug 23, 2038	DS			
	12427207	Nov 27, 2041	DP			
<u>FLUOCINOLONE ACETONIDE - ILUVIEN</u>						
N 201923 001	9849027	Nov 07, 2028	DP U-4157			
	9849027	Nov 07, 2028	DP U-708			
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 001	12396986	Nov 29, 2030	DP			
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 002	12396986	Nov 29, 2030	DP			
<u>FOSCARBIDOPA; FOSLEVODOPA - VYALEV</u>						
N 216962 001	12251365	Jun 10, 2040	U-4030		NP	Oct 16, 2027
<u>FOSDENOPTERIN HYDROBROMIDE - NULIBRY</u>						
N 214018 001	7504095	Apr 09, 2029	DP U-3092			
<u>FOSFOMYCIN DISODIUM - CONTEPO</u>						
N 212271 001	10086006	Oct 12, 2034	U-4332			
	11541064	Jan 30, 2039	U-4331			
	9345717	Oct 27, 2034	U-4332			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	12208109	Jun 02, 2037	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	12208109	Jun 02, 2037	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 001	>A> 7829574	Mar 23, 2032	DS DP			
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564 002	>A> 7829574	Mar 23, 2032	DS DP			
<u>FUROSEMIDE - FUROSCIX</u>						
N 209988 001	12370168	Apr 03, 2034	DP U-3462			
<u>FUTIBATINIB - LYTGOBI</u>						
N 214801 001	9108973	Feb 13, 2033	DS DP U-3456			
<u>FUTIBATINIB - LYTGOBI</u>						
N 214801 002	10434103	Mar 31, 2036	DS DP		NCE	Sep 30, 2027
	11833151	Nov 05, 2039	DP		ODE*	Sep 30, 2029
	9108973	Feb 13, 2033	DS DP U-3456			
<u>GALLIUM GA-68 GOZETOTIDE - GOZELLIX</u>						
N 219592 001	11027031	Jul 28, 2035	U-3317			
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001	12115169	Sep 30, 2042	U-3374		>A> D-197	Oct 16, 2028
	12268696	Sep 30, 2042	U-3374			
<u>GEMCITABINE HYDROCHLORIDE - INLEXZO</u>						
N 219683 001	10729823	Aug 19, 2034	DP		NP	Sep 09, 2028
	12403086	Jun 28, 2030	DP			
	12447241	Aug 19, 2034	DP			
	8679094	Apr 15, 2032	DP			
<u>GEPIRONE HYDROCHLORIDE - EXXUA</u>						
N 021164 001	7538116	Sep 02, 2030	U-3699			
<u>GEPIRONE HYDROCHLORIDE - EXXUA</u>						
N 021164 002	7538116	Sep 02, 2030	U-3699			
<u>GEPIRONE HYDROCHLORIDE - EXXUA</u>						
N 021164 003	7538116	Sep 02, 2030	U-3699			
<u>GEPIRONE HYDROCHLORIDE - EXXUA</u>						
N 021164 004	7538116	Sep 02, 2030	U-3699			
<u>GEPOTIDACIN MESYLATE - BLUJEP A</u>						
N 218230 001	>A> 10702521	Aug 20, 2035	U-4361		>A> I-978	Dec 11, 2028
	>A> 11229646	Aug 20, 2035	U-4361		NCE	Mar 25, 2030
	8389524	Feb 12, 2029	DS DP U-4166		GAIN	Mar 25, 2035
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	10028937	Jun 10, 2030	U-2141		I-967	Jun 10, 2028
	10028937	Jun 10, 2030	U-3237			
	10028937	Jun 10, 2030	U-4206			
	10028937*PED	Dec 10, 2030				
	10039754	Jun 10, 2030	U-2141			
	10039754	Jun 10, 2030	U-3237			
	10039754	Jun 10, 2030	U-4206			
	10039754*PED	Dec 10, 2030				
	10286029	Mar 14, 2034	U-3237			
	10286029	Mar 14, 2034	U-4206			
	10286029*PED	Sep 14, 2034				
	11484534	Mar 14, 2034	U-3237			
	11484534	Mar 14, 2034	U-4206			
	11484534*PED	Sep 14, 2034				
	8648037	Jan 19, 2032	DS DP U-2141			
	8648037	Jan 19, 2032	DS DP U-3237			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	8648037	Jan 19, 2032	DS DP U-4206			
	8648037*PED	Jul 19, 2032				
	9586978	Nov 06, 2030	U-2141			
	9586978	Nov 06, 2030	U-3237			
	9586978	Nov 06, 2030	U-4206			
	9586978*PED	May 06, 2031				
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 215110 001	10028937	Jun 10, 2030	U-3238		I-967	Jun 10, 2028
	10028937	Jun 10, 2030	U-4206			
	10028937*PED	Dec 10, 2030				
	10039754	Jun 10, 2030	U-3238			
	10039754	Jun 10, 2030	U-4206			
	10039754*PED	Dec 10, 2030				
	10286029	Mar 14, 2034	U-3238			
	10286029	Mar 14, 2034	U-4206			
	10286029*PED	Sep 14, 2034				
	8648037	Jan 19, 2032	DS DP U-3238			
	8648037	Jan 19, 2032	DS DP U-4206			
	8648037*PED	Jul 19, 2032				
	9586978	Nov 06, 2030	U-3238			
	9586978	Nov 06, 2030	U-4206			
	9586978*PED	May 06, 2031				
<u>GLUCAGON - GLUCAGON</u>						
A 218813 001					CGT	Apr 18, 2026
<u>GLUCAGON - BAOSIMI</u>						
N 210134 001	12370241	Feb 16, 2036	DP U-2604			
<u>GLYCEROL PHENYLBUTYRATE - GLYCEROL PHENYLBUTYRATE</u>						
A 205742 001					PC	Apr 15, 2026
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO</u>						
N 216903 001	12383491	Oct 25, 2038	DP			
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 001	7696182	May 16, 2026	DS DP U-3774			
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520 002	7696182	May 16, 2026	DS DP U-3774			
<u>HYDROCHLOROTHIAZIDE - INZIROO</u>						
N 219141 001	11878022	Jan 23, 2044	DP U-4138			
	11878022	Jan 23, 2044	DP U-4139			
<u>HYDROCORTISONE - KHINDIVI</u>						
N 218980 001	11904046	Feb 23, 2043	DP U-4216			
	12133914	Feb 23, 2043	U-4215			
<u>HYDROXYUREA - XROMI</u>						
N 216593 001	12409156	Dec 23, 2041	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	12201690	Jun 14, 2039	DP			
	12364698	Apr 06, 2036	DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	12171738	Feb 09, 2030	U-4105			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	12171738	Feb 09, 2030	U-4105			
<u>ILOPROST - AURLUMYN</u>						
N 217933 001	12409183	Jul 18, 2044	U-4263			
	12409184	Aug 06, 2041	DP			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 001	12171778	Jun 16, 2039	U-3956			
	12442000	Mar 15, 2033	U-3956			
	9388415	Sep 09, 2026	U-3956			
	9388416	Sep 09, 2026	U-3956			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 002	12171778	Jun 16, 2039	U-3956			
	12442000	Mar 15, 2033	U-3956			
	9388415	Sep 09, 2026	U-3956			
	9388416	Sep 09, 2026	U-3956			
<u>IMLUNESTRANT TOSYLATE - INLURIYO</u>						
N 218881 001	10654866	Jul 11, 2039	DS DP U-4278		NCE	Sep 25, 2030
	11117902	Jul 11, 2039	DS DP U-4278			
<u>INAVOLISIB - ITOVEBI</u>						
N 219249 001	12410189	Jun 14, 2038	U-4024			
<u>INAVOLISIB - ITOVEBI</u>						
N 219249 002	12410189	Jun 14, 2038	U-4024			
<u>INCLISIRAN SODIUM - LEOVIO</u>						
N 214012 001	10125369	Aug 18, 2034	DS DP U-4249			
	10131907	Aug 24, 2028	DS DP U-4249			
	10851377	Aug 25, 2036	U-4249			
	12460206	Aug 18, 2034	DS DP			
	8106022	Dec 12, 2029	DS DP U-4249			
	8222222	Dec 29, 2027	U-4249			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INCLISIRAN SODIUM - LEOVIO</u>						
N 214012 001	8809292	May 10, 2027	DS DP U-4249			
	8828956	Dec 04, 2028	DS DP U-4249			
	9370582	Dec 04, 2028	DS DP U-4249			
<u>IOMEPROL - IOMERVU</u>						
N 216016 001					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 002					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 003					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 004					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 005					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 006					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 007					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 008					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 009					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 010					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 011					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 012					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 013					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017 001					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017 002					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017 003					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017 004					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017 005					NCE	Nov 27, 2029

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IOMEPROL - IOMERVU</u>						
N 216017	006				NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017	007				NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017	008				NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017	009				NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017	010				NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017	011				NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017	012				NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017	013				NCE	Nov 27, 2029
<u>IOPAMIDOL - ISOVUE-300</u>						
N 018735	002				I-975	Oct 10, 2028
<u>IOPAMIDOL - ISOVUE-370</u>						
N 018735	003				I-975	Oct 10, 2028
<u>IOPAMIDOL - ISOVUE-200</u>						
N 018735	006				I-975	Oct 10, 2028
<u>IOPAMIDOL - ISOVUE-250</u>						
N 018735	007				I-975	Oct 10, 2028
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527	001	8474447	Jan 17, 2030	DP	Y	
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u>						
N 218276	001	10093663	Jul 14, 2034	U-3980	I-963	Mar 20, 2028
		10093663	Jul 14, 2034	U-4161		
		12285422	Aug 30, 2038	U-4181		
		12384758	May 17, 2041	U-3980		
		12384758	May 17, 2041	U-4161		
		12453726	Jul 15, 2041	U-4300		
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793	001	12364691	Jun 12, 2033	U-1848		
<u>IRON SUCROSE - IRON SUCROSE</u>						
A 208977	001				CGT	Feb 08, 2026
<u>IRON SUCROSE - IRON SUCROSE</u>						
A 212559	002				CGT	Feb 07, 2026
<u>IRON SUCROSE - IRON SUCROSE</u>						
A 212559	003				CGT	Feb 07, 2026
<u>IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE</u>						
A 214051	001				PC	Jan 11, 2025

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE</u>						
A 214051	002				PC	Jan 11, 2025
<u>IVACAFTOR - KALYDECO</u>						
N 203188	001	10646481	Aug 13, 2029	DP	ODE-338	Dec 21, 2027
		10646481*PED	Feb 13, 2030		PED	Jun 21, 2028
		11564916	Aug 13, 2029	U-3530		
		11564916*PED	Feb 13, 2030			
		12458635	Aug 13, 2029	DP U-4339		
		12458635*PED	Feb 13, 2030			
		8354427	Jul 06, 2026	U-1311		
		8354427	Jul 06, 2026	U-1905		
		8354427*PED	Jan 06, 2027			
		8410274	Dec 28, 2026	DP		
		8410274*PED	Jun 28, 2027			
		8754224	Dec 28, 2026	DS DP		
		8754224*PED	Jun 28, 2027			
		9670163	Dec 28, 2026	DP U-1311		
		9670163*PED	Jun 28, 2027			
<u>IVACAFTOR - KALYDECO</u>						
N 207925	001	10272046	Feb 27, 2033	DP U-2531	M-14	May 22, 2028
		10272046*PED	Aug 27, 2033		ODE-236	Apr 29, 2026
		10646481	Aug 13, 2029	DP	ODE-338	Dec 21, 2027
		10646481*PED	Feb 13, 2030		PED	Oct 29, 2026
		11147770	Feb 27, 2033	DP U-3339	PED	Jun 21, 2028
		11147770*PED	Aug 27, 2033		PED	Nov 22, 2028
		11564916	Aug 13, 2029	U-3528		
		11564916*PED	Feb 13, 2030			
		11752106	Feb 27, 2033	DP U-3697		
		11752106*PED	Aug 27, 2033			
		12214083	Feb 27, 2033	DP U-4126		
		12214083*PED	Aug 27, 2033			
		12458635	Aug 13, 2029	DP U-4337		
		12458635*PED	Feb 13, 2030			
		7495103	May 20, 2027	DS DP		
		7495103*PED	Nov 20, 2027			
		8324242	Aug 05, 2027	U-1311		
		8324242	Aug 05, 2027	U-1906		
		8324242	Aug 05, 2027	U-2527		
		8324242*PED	Feb 05, 2028			
		8354427	Jul 06, 2026	U-1311		
		8354427	Jul 06, 2026	U-1905		
		8354427	Jul 06, 2026	U-2528		
		8354427*PED	Jan 06, 2027			
		8410274	Dec 28, 2026	DP		
		8410274*PED	Jun 28, 2027			
		8754224	Dec 28, 2026	DS DP		
		8754224*PED	Jun 28, 2027			
		8883206	Feb 27, 2033	DP		
		8883206*PED	Aug 27, 2033			
		9670163	Dec 28, 2026	DP U-1311		
		9670163	Dec 28, 2026	DP U-2530		
		9670163*PED	Jun 28, 2027			
<u>IVACAFTOR - KALYDECO</u>						
N 207925	002	10272046	Feb 27, 2033	DP U-2531	M-14	May 22, 2028
		10272046*PED	Aug 27, 2033		ODE-236	Apr 29, 2026
		10646481	Aug 13, 2029	DP	ODE-338	Dec 21, 2027
		10646481*PED	Feb 13, 2030		PED	Oct 29, 2026
		11147770	Feb 27, 2033	DP U-3339	PED	Jun 21, 2028
		11147770*PED	Aug 27, 2033		PED	Nov 22, 2028
		11564916	Aug 13, 2029	U-3528		
		11564916*PED	Feb 13, 2030			
		11752106	Feb 27, 2033	DP U-3697		
		11752106*PED	Aug 27, 2033			
		12214083	Feb 27, 2033	DP U-4126		
		12214083*PED	Aug 27, 2033			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	12458635	Aug 13, 2029	DP U-4337			
	12458635*PED	Feb 13, 2030				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027			U-1311	
	8324242	Aug 05, 2027			U-1906	
	8324242	Aug 05, 2027			U-2527	
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026			U-1311	
	8354427	Jul 06, 2026			U-1905	
	8354427	Jul 06, 2026			U-2528	
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003	10272046	Feb 27, 2033	DP U-2967		M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			ODE-236	Apr 29, 2026
	10646481	Aug 13, 2029	DP		ODE-338	Dec 21, 2027
	10646481*PED	Feb 13, 2030			PED	Oct 29, 2026
	11147770	Feb 27, 2033	DP U-3339		PED	Jun 21, 2028
	11147770*PED	Aug 27, 2033			PED	Nov 22, 2028
	11564916	Aug 13, 2029			U-3528	
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				
	12214083	Feb 27, 2033	DP U-4128			
	12214083*PED	Aug 27, 2033				
	12458635	Aug 13, 2029	DP U-4337			
	12458635*PED	Feb 13, 2030				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027			U-1311	
	8324242	Aug 05, 2027			U-1906	
	8324242	Aug 05, 2027			U-2963	
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026			U-1311	
	8354427	Jul 06, 2026			U-1905	
	8354427	Jul 06, 2026			U-2964	
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2966			
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR - KALYDECO</u>						
N 207925 004	10272046	Feb 27, 2033	DP U-3605		M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			NPP	May 03, 2026
	10646481	Aug 13, 2029	DP		ODE-435	May 03, 2030
	10646481*PED	Feb 13, 2030			PED	Nov 03, 2026
	11147770	Feb 27, 2033	DP U-3604		PED	Nov 22, 2028
	11147770*PED	Aug 27, 2033			PED	Nov 03, 2030
	11564916	Aug 13, 2029			U-3603	
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 004	12214083	Feb 27, 2033	DP U-4127			
	12214083*PED	Aug 27, 2033				
	12458635	Aug 13, 2029	DP U-4337			
	12458635*PED	Feb 13, 2030				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-3609			
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-3608			
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-3606			
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR - KALYDECO</u>						
N 207925 005	10272046	Feb 27, 2033	DP U-3605		M-14	May 22, 2028
	10272046*PED	Aug 27, 2033			NPP	May 03, 2026
	10646481	Aug 13, 2029	DP		ODE-435	May 03, 2030
	10646481*PED	Feb 13, 2030			PED	Nov 03, 2026
	11147770	Feb 27, 2033	DP U-3604		PED	Nov 22, 2028
	11147770*PED	Aug 27, 2033			PED	Nov 03, 2030
	11564916	Aug 13, 2029	U-3603			
	11564916*PED	Feb 13, 2030				
	11752106	Feb 27, 2033	DP U-3697			
	11752106*PED	Aug 27, 2033				
	12214083	Feb 27, 2033	DP U-4127			
	12214083*PED	Aug 27, 2033				
	12458635	Aug 13, 2029	DP U-4337			
	12458635*PED	Feb 13, 2030				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-3609			
	8324242*PED	Feb 05, 2028				
	8354427	Jul 06, 2026	U-3608			
	8354427*PED	Jan 06, 2027				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8883206	Feb 27, 2033	DP			
	8883206*PED	Aug 27, 2033				
	9670163	Dec 28, 2026	DP U-3606			
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	12458635	Aug 13, 2029	DP U-4336			
	>A> RE50453	Jul 10, 2031	DS DP			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	12458635	Aug 13, 2029	DP U-4336			
	>A> RE50453	Jul 10, 2031	DS DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	10076513	Dec 04, 2028	DP U-2411			
	10076513*PED	Jun 04, 2029				
	10597384	Dec 04, 2028	DS DP U-2777			
	10597384*PED	Jun 04, 2029				
	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11052075	Dec 04, 2028	DP U-3181			
	11052075*PED	Jun 04, 2029				
	11564916	Aug 13, 2029	U-3529			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3984			
	12065432*PED	Jun 04, 2029				
	12458635	Aug 13, 2029	DP U-4338			
	12458635*PED	Feb 13, 2030				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-1973			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1911			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-1718			
	8716338	Sep 20, 2030	DP U-1910			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-1717			
	8741933	Nov 08, 2026	U-1909			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-1717			
	8846718	Jul 02, 2029	U-1908			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-1908			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-1912			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DS DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-1911			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2276			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	10597384	Dec 04, 2028	DS DP U-2777			
	10597384*PED	Jun 04, 2029				
	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11052075	Dec 04, 2028	DP U-3181			
	11052075*PED	Jun 04, 2029				
	11564916	Aug 13, 2029	U-3529			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3984			
	12065432*PED	Jun 04, 2029				
	12458635	Aug 13, 2029	DP U-4338			
	12458635*PED	Feb 13, 2030				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-1973			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-1911			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-1910			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-1909			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-1908			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-1908			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-1912			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-1911			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2276			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	10597384	Dec 04, 2028	DS DP U-2778		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	12458635	Aug 13, 2029	DP U-4335			
	12458635*PED	Feb 13, 2030				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-2374			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-2374			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-2396			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-2374			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-2375			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-2375			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-2397			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-2376			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2376			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	10597384	Dec 04, 2028	DS DP U-2778		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	12458635	Aug 13, 2029	DP U-4335			
	12458635*PED	Feb 13, 2030				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-2374			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-2374			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-2396			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-2374			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-2375			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-2375			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-2397			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-2376			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2376			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	10597384	Dec 04, 2028	DS DP U-3430		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	12458635	Aug 13, 2029	DP U-4335			
	12458635*PED	Feb 13, 2030				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-3424			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-3424			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-3426			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-3424			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-3427			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-3427			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-3428			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-3429			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-3429			
	9931334*PED	Jun 28, 2027				
<u>IVERMECTIN - IVERMECTIN</u>						
A 215922 002					CGT	Oct 01, 2025
<u>LACTULOSE - LACTULOSE</u>						
A 217914 001					CGT	Sep 13, 2025
<u>LACTULOSE - LACTULOSE</u>						
A 217914 002					CGT	Sep 13, 2025
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 001	8637512	Jan 07, 2029	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 002	8637512	Jan 07, 2029	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 003	8637512	Jan 07, 2029	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 004	8637512	Jan 07, 2029	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 005	8637512	Jan 07, 2029	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 006	8637512	Jan 07, 2029	DP			
<u>LAMOTRIGINE - SUBVENITE</u>						
N 218879 001	11596634	May 29, 2040	U-4271			
	11596634	May 29, 2040	U-4272			
	11596634	May 29, 2040	U-4273			
	11612566	May 29, 2040	U-4271			
	11612566	May 29, 2040	U-4272			
	11612566	May 29, 2040	U-4273			
<u>LANDIOLOL HYDROCHLORIDE - RAPIBLYK</u>						
N 217202 001	10722516	Apr 25, 2034	U-4235			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	11337967	May 16, 2037	U-4123			
	11974998	May 16, 2037	U-4124			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	11337967	May 16, 2037	U-4123			
	11974998	May 16, 2037	U-4124			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	11337967	May 16, 2037	U-4123			
	11974998	May 16, 2037	U-4124			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	12257246	Jul 07, 2030	U-2718			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	12257246	Jul 07, 2030	U-2718			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 003	12257246	Jul 07, 2030	U-2718			
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 001	12138351	Apr 13, 2041	DP			
	12318390	Apr 18, 2038	DP			
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 002	12138351	Apr 13, 2041	DP			
	12318390	Apr 18, 2038	DP			
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211672 001	8071643	Mar 25, 2033	DS DP			
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211673 001	12121582	Jun 14, 2036	DP			
	8071643	Mar 25, 2033	DS DP			
<u>LENACAPAVIR SODIUM - YEZTUGO</u>						
N 220018 001	10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
	11267799	Aug 16, 2038	DS		NP	Jun 18, 2028
	11807625	Nov 25, 2040	U-4190			
	9951043	Feb 28, 2034	DS DP U-4190			
<u>LENACAPAVIR SODIUM - YEZTUGO</u>						
N 220020 001	10071985	Aug 17, 2037	DS DP		NCE	Dec 22, 2027
	11267799	Aug 16, 2038	DS		NP	Jun 18, 2028
	9951043	Feb 28, 2034	DS DP U-4190			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	12083112	Mar 03, 2036	U-3996			
	12083112	Mar 03, 2036	U-3997			
	12083112*PED	Sep 03, 2036				
	12226409	May 15, 2038	U-4146			
	12226409*PED	Nov 15, 2038				
>A>	12508313	Oct 04, 2030	DP			
>A>	12508313*PED	Apr 04, 2031				
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	12083112	Mar 03, 2036	U-3996			
	12083112	Mar 03, 2036	U-3997			
	12083112*PED	Sep 03, 2036				
	12226409	May 15, 2038	U-4146			
	12226409*PED	Nov 15, 2038				
>A>	12508313	Oct 04, 2030	DP			
>A>	12508313*PED	Apr 04, 2031				
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	12419894	Apr 14, 2036	DP			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021343 001	12397120	Dec 22, 2041	U-4001			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021379 001	12397120	Dec 22, 2041	U-4001			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021488 001	12397120	Dec 22, 2041	U-4001			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021731 001	12397120	Dec 22, 2041	U-4001			
<u>LEUPROLIDE ACETATE - FENSOLVI KIT</u>						
N 213150 001	12397120	Dec 22, 2041	U-3611			
<u>LEUPROLIDE MESYLATE - CAMCEVI ETM</u>						
N 219745 001					NS	Aug 25, 2028
<u>LEVACETYLLLEUCINE - AONEURSA</u>						
N 219132 001	11400067	Apr 19, 2037	U-4170			
	12433862	Apr 19, 2037	U-4284			
	12433863	Apr 19, 2037	U-4285			
<u>LEVODOPA - INBRIJA</u>						
N 209184 001 >A>	12458615	Oct 21, 2033	U-2484			
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001	12377096	Mar 02, 2040	U-4236		NCE*	Dec 30, 2026
	9918984	May 03, 2028	U-3283			
<u>LIDOCAINE - BONDLIDO</u>						
N 215029 001					NP	Sep 24, 2028
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	7304036	Aug 30, 2026	DS DP U-1278			
	7304036	Aug 30, 2026	DS DP U-1516			
	7304036	Aug 30, 2026	DS DP U-4345			
	7304036*PED	Feb 28, 2027				
	8748573	Oct 30, 2031	U-1515			
	8748573	Oct 30, 2031	U-1516			
	8748573	Oct 30, 2031	U-4345			
	8748573*PED	Apr 30, 2032				
	8802628	Oct 30, 2031	DP			
	8802628*PED	Apr 30, 2032				
	8933030	Feb 17, 2031	DP U-4345			
	8933030*PED	Aug 17, 2031				
	9708371	Aug 16, 2033	DP U-1515			
	9708371	Aug 16, 2033	DP U-1516			
	9708371	Aug 16, 2033	DP U-4345			
	9708371*PED	Feb 16, 2034				
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	7304036	Aug 30, 2026	DS DP U-1278			
	7304036	Aug 30, 2026	DS DP U-1516			
	7304036*PED	Feb 28, 2027				
	8748573	Oct 30, 2031	U-1515			
	8748573	Oct 30, 2031	U-1516			
	8748573*PED	Apr 30, 2032				
	8802628	Oct 30, 2031	DP			
	8802628*PED	Apr 30, 2032				
	8933030	Feb 17, 2031	DP			
	8933030*PED	Aug 17, 2031				
	9708371	Aug 16, 2033	DP U-1515			
	9708371*PED	Feb 16, 2034				
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	10675325	Aug 11, 2031	DP			
	10675325*PED	Feb 11, 2032				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	10702576	Aug 11, 2031	U-1516			
	10702576	Aug 11, 2031	U-3644			
	10702576*PED	Feb 11, 2032				
	7304036	Aug 30, 2026	DS DP U-1516			
	7304036	Aug 30, 2026	DS DP U-3644			
	7304036*PED	Feb 28, 2027				
	8933030	Feb 17, 2031	DP U-1516			
	8933030	Feb 17, 2031	DP U-3644			
	8933030*PED	Aug 17, 2031				
	9708371	Aug 16, 2033	DP U-1516			
	9708371	Aug 16, 2033	DP U-3644			
	9708371*PED	Feb 16, 2034				
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	12178819	May 04, 2027	DP			
	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	12364700	Jun 08, 2037	U-4224			
	12364700*PED	Dec 08, 2037				
<u>LIRAGLUTIDE - LIRAGLUTIDE</u>						
A 214568 001					PC	Feb 24, 2026
<u>LISDEXAMFETAMINE DIMESYLATE - ARYNTE</u>						
N 219847 001	11576878	Aug 30, 2040	DP			
	12433859	Apr 16, 2040	DP U-842			
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	12186360	Nov 06, 2035	DP			
	12433931	Nov 06, 2035	U-1723			
	12433931	Nov 06, 2035	U-1864			
	12433931	Nov 06, 2035	U-3			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 001	7838531	Jul 26, 2029	U-3070			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 002	7838531	Jul 26, 2029	U-3070			
<u>LOSARTAN POTASSIUM - ARBLI</u>						
N 218772 001	11890273	Oct 07, 2041	DP			
	12156869	Oct 07, 2041	DP U-4158			
	12156869	Oct 07, 2041	DP U-4159			
	12156869	Oct 07, 2041	DP U-4160			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOTILANER - XDEMY</u>						
N 217603 001	12171750	Dec 14, 2038	U-3674			
	12213964	Dec 14, 2038	DP			
	12364685	Dec 14, 2038	DP			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	11690842	Aug 30, 2039	DP U-3362		I-904	Nov 05, 2028
	11690842	Aug 30, 2039	DP U-3363			
	11690842	Aug 30, 2039	DP U-4341			
	11753419	Dec 10, 2040	DP	Y		
	11806348	Aug 30, 2039	DP U-3362			
	11806348	Aug 30, 2039	DP U-3363			
	11806348	Aug 30, 2039	DP U-4341			
	11980617	Oct 27, 2039	U-3940			
	11980617	Oct 27, 2039	U-4342			
	12070459	Aug 30, 2039	DP U-3362			
	12070459	Aug 30, 2039	DP U-3363			
	12070459	Aug 30, 2039	DP U-4341			
	12122792	Dec 10, 2040	DP U-4019			
	12122792	Dec 10, 2040	DP U-4020			
	12122792	Dec 10, 2040	DP U-4340			
	12409176	Mar 15, 2039	U-4261			
	12410195	Dec 10, 2040	DP			
	9199995	Mar 12, 2029	U-2713			
	9199995	Mar 12, 2029	U-4343			
	RE48839	Aug 19, 2033	U-3271			
	RE48839	Aug 19, 2033	U-4344			
	RE48839	Aug 19, 2033	U-814			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002	11052084	Aug 30, 2039	DP U-3362		I-904	Nov 05, 2028
	11052084	Aug 30, 2039	DP U-3363			
	11052084	Aug 30, 2039	DP U-4341			
	11690842	Aug 30, 2039	DP U-3362			
	11690842	Aug 30, 2039	DP U-3363			
	11690842	Aug 30, 2039	DP U-4341			
	11753419	Dec 10, 2040	DP	Y		
	11806348	Aug 30, 2039	DP U-3362			
	11806348	Aug 30, 2039	DP U-3363			
	11806348	Aug 30, 2039	DP U-4341			
	11980617	Oct 27, 2039	U-3940			
	11980617	Oct 27, 2039	U-4342			
	12122792	Dec 10, 2040	DP U-4019			
	12122792	Dec 10, 2040	DP U-4020			
	12122792	Dec 10, 2040	DP U-4340			
	12409176	Mar 15, 2039	U-4261			
	12410195	Dec 10, 2040	DP			
	9199995	Mar 12, 2029	U-2713			
	9199995	Mar 12, 2029	U-4343			
	RE48825	Mar 12, 2029	DS			
	RE48839	Aug 19, 2033	U-3271			
	RE48839	Aug 19, 2033	U-4344			
	RE48839	Aug 19, 2033	U-814			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003	11052084	Aug 30, 2039	DP U-3362		I-904	Nov 05, 2028
	11052084	Aug 30, 2039	DP U-3363			
	11052084	Aug 30, 2039	DP U-4341			
	11690842	Aug 30, 2039	DP U-3362			
	11690842	Aug 30, 2039	DP U-3363			
	11690842	Aug 30, 2039	DP U-4341			
	11753419	Dec 10, 2040	DP	Y		
	11806348	Aug 30, 2039	DP U-3362			
	11806348	Aug 30, 2039	DP U-3363			
	11806348	Aug 30, 2039	DP U-4341			
	11980617	Oct 27, 2039	U-3940			
	11980617	Oct 27, 2039	U-4342			
	12122792	Dec 10, 2040	DP U-4019			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003	12122792	Dec 10, 2040	DP U-4020			
	12122792	Dec 10, 2040	DP U-4340			
	12409176	Mar 15, 2039	U-4261			
	12410195	Dec 10, 2040	DP			
	9199995	Mar 12, 2029	U-2713			
	9199995	Mar 12, 2029	U-4343			
	RE48825	Mar 12, 2029	DS			
	RE48839	Aug 19, 2033	U-3271			
	RE48839	Aug 19, 2033	U-4344			
	RE48839	Aug 19, 2033	U-814			
<u>LURBINECTEDIN - ZEPZELCA</u>						
N 213702 001	12324806	May 29, 2040	U-4212		>A> I-977	Oct 02, 2028
	12433890	May 29, 2040	U-4305			
	12440490	May 29, 2040	U-4252			
	7763615	Dec 13, 2029	DS DP U-2836			
	7763615	Dec 13, 2029	DS DP U-4299			
<u>LUTETIUM LU 177 DOTATATE - LUTATHERA</u>						
N 208700 001	>A> 12168063	Jul 25, 2038	DP U-4036			
	>A> 12168063*PED	Jan 25, 2039				
	>A> 12415003	Jul 25, 2038	U-4036			
	>A> 12415003*PED	Jan 25, 2039				
	>A> 12491272	Jul 25, 2038	U-4036			
	>A> 12491272*PED	Jan 25, 2039				
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAKETAN - PLUVICTO</u>						
N 215833 001	10406240	Aug 15, 2028	DS DP U-4169		I-965	Mar 28, 2028
	11318121	Aug 15, 2028	DS DP U-4169			
	11951190	Nov 12, 2035	U-4169			
	12208102	Sep 18, 2041	U-4169			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	10946015	Sep 11, 2026	DP U-1445		M-187	Feb 28, 2028
	10946015*PED	Mar 11, 2027			PED	Aug 28, 2028
	7094781	Dec 05, 2025	DS DP			
	7094781*PED	Jun 05, 2026				
	8268847	Apr 18, 2029	U-1446			
	8268847*PED	Oct 18, 2029				
	8367685	Oct 04, 2028	DP U-1445			
	8367685*PED	Apr 04, 2029				
	9265762	May 29, 2027	DP U-1820			
	9265762*PED	Nov 29, 2027				
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 001	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	10946015*PED	Mar 11, 2027			ODE-475	Mar 22, 2031
	7094781	Dec 05, 2025	DS DP		PED	Sep 22, 2027
	7094781*PED	Jun 05, 2026			PED	Sep 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
	8268847*PED	Oct 18, 2029				
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 002	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	10946015*PED	Mar 11, 2027			ODE-475	Mar 22, 2031
	7094781	Dec 05, 2025	DS DP		PED	Sep 22, 2027
	7094781*PED	Jun 05, 2026			PED	Sep 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
	8268847*PED	Oct 18, 2029				
<u>MAGNESIUM SULFATE - MAGNESIUM SULFATE</u>						
A 219777 001					CGT	Feb 01, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MAGNESIUM SULFATE - MAGNESIUM SULFATE</u>						
A 219777 004					CGT	Feb 01, 2026
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE</u>						
N 215344 001	12239659	Jun 14, 2044	U-4143			
	12290529	Aug 02, 2044	DP			
	12433914	Jun 14, 2044	U-4143			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 002	12350267	Oct 26, 2032	U-3973			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 219485 001	10512657	Oct 26, 2032	U-4186		I-938	Mar 13, 2027
	11229647	Feb 12, 2040	U-4187		NCE	Sep 29, 2026
	11229661	Oct 26, 2032	U-4186			
	11260053	May 26, 2031	U-4187			
	11376251	Oct 26, 2032	U-4187			
	11497745	Feb 12, 2040	U-4187			
	12296050	Oct 05, 2043	DP U-4186			
	12296050	Oct 05, 2043	DP U-4187			
	12350267	Oct 26, 2032	U-3973			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 219485 002	10512657	Oct 26, 2032	U-4186		I-938	Mar 13, 2027
	11229647	Feb 12, 2040	U-4187		NCE	Sep 29, 2026
	11229661	Oct 26, 2032	U-4186			
	11260053	May 26, 2031	U-4187			
	11376251	Oct 26, 2032	U-4187			
	11497745	Feb 12, 2040	U-4187			
	12296050	Oct 05, 2043	DP U-4186			
	12296050	Oct 05, 2043	DP U-4187			
	12350267	Oct 26, 2032	U-3973			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 219485 003	10512657	Oct 26, 2032	U-4186		I-938	Mar 13, 2027
	11229647	Feb 12, 2040	U-4187		NCE	Sep 29, 2026
	11229661	Oct 26, 2032	U-4186			
	11260053	May 26, 2031	U-4187			
	11376251	Oct 26, 2032	U-4187			
	11497745	Feb 12, 2040	U-4187			
	12296050	Oct 05, 2043	DP U-4186			
	12296050	Oct 05, 2043	DP U-4187			
	12350267	Oct 26, 2032	U-3973			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 219485 004	10512657	Oct 26, 2032	U-4186		I-938	Mar 13, 2027
	11229647	Feb 12, 2040	U-4187		NCE	Sep 29, 2026
	11229661	Oct 26, 2032	U-4186			
	11260053	May 26, 2031	U-4187			
	11376251	Oct 26, 2032	U-4187			
	11497745	Feb 12, 2040	U-4187			
	12296050	Oct 05, 2043	DP U-4186			
	12296050	Oct 05, 2043	DP U-4187			
	12350267	Oct 26, 2032	U-3973			
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001	12213989	Nov 18, 2042	U-4137			
	12295940	Oct 11, 2043	DS DP			
	12433907	Nov 18, 2042	U-4289			
	12447169	Oct 27, 2031	U-4329			
	12447170	Nov 18, 2042	U-4328			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 001	RE50050	Apr 28, 2036	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 002	RE50050	Apr 28, 2036	DS DP			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 003	RE50050	Apr 28, 2036	DS DP			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 004	RE50050	Apr 28, 2036	DS DP			
<u>MELOXICAM - QAMZOVA</u>						
N 217593 001	12059423	Jul 19, 2040	DS DP			
<u>MELOXICAM - XIFYRM</u>						
N 218395 001	12263176	Jul 31, 2041	DP			
<u>MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO</u>						
N 215431 001	10029010	Apr 11, 2036	U-4133		NP	Jan 30, 2028
	10058614	Apr 11, 2036	DP			
	10137131	Apr 11, 2036	DP U-1719			
	10195278	Apr 11, 2036	U-1719			
	10265324	Apr 11, 2036	U-1719			
	10363312	Apr 11, 2036	U-1719			
	10369224	Apr 11, 2036	U-4134			
	10426839	Apr 11, 2036	U-4135			
	10463736	Apr 11, 2036	DP			
	10471014	Apr 11, 2036	U-1719			
	10471069	Apr 11, 2036	U-1719			
	10512692	Apr 11, 2036	U-1719			
	10512693	Apr 11, 2036	U-1719			
	10517950	Apr 11, 2036	U-1719			
	10532101	Apr 11, 2036	U-1719			
	10537642	Apr 11, 2036	U-1719			
	10561664	Apr 11, 2036	U-1719			
	10583144	Apr 11, 2036	U-1719			
	10653777	Apr 11, 2036	U-1719			
	10688102	Apr 11, 2036	U-1719			
	10688185	Apr 11, 2036	U-1719			
	10695429	Apr 11, 2036	U-1719			
	10695430	Apr 11, 2036	U-1719			
	10702535	Apr 11, 2036	U-4136			
	10702602	Apr 11, 2036	U-1719			
	10722583	Apr 11, 2036	U-1719			
	10729696	Apr 11, 2036	U-1719			
	10729697	Apr 11, 2036	U-1719			
	10729773	Apr 11, 2036	U-1719			
	10758617	Apr 11, 2036	U-1719			
	10758618	Apr 11, 2036	U-1719			
	10780165	Apr 11, 2036	U-1719			
	10780166	Apr 11, 2036	U-1719			
	10799588	Apr 11, 2036	U-1719			
	10821181	Apr 11, 2036	U-1719			
	10821182	Apr 11, 2036	U-1719			
	10894053	Apr 11, 2036	U-1719			
	10905693	Apr 11, 2036	U-1719			
	10918722	Apr 11, 2036	U-1719			
	10933136	Apr 11, 2036	U-1719			
	10933137	Apr 11, 2036	U-1719			
	10940153	Apr 11, 2036	U-1719			
	10987358	Apr 11, 2036	U-1719			
	11013805	Apr 11, 2036	U-1719			
	11013806	Apr 11, 2036	U-1719			
	11020483	Apr 11, 2036	U-1719			
	11045549	Apr 11, 2036	U-1719			
	11135295	Apr 11, 2036	U-1719			
	11207328	Apr 11, 2036	U-1719			
	11219626	Apr 11, 2036	U-1719			
	11285213	Apr 11, 2036	U-1719			
	11331323	Apr 11, 2036	U-1719			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO</u>						
N 215431 001	11369684	Apr 11, 2036	U-1719			
	11426414	Apr 11, 2036	U-1719			
	11471464	Apr 11, 2036	U-1719			
	11471465	Apr 11, 2036	U-1719			
	11504429	Apr 11, 2036	U-1719			
	11510927	Apr 11, 2036	U-1719			
	11571428	Apr 11, 2036	U-1719			
	11602563	Apr 11, 2036	U-1719			
	11607456	Apr 11, 2036	U-1719			
	11617755	Apr 11, 2036	U-1719			
	11617756	Apr 11, 2036	U-1719			
	11617791	Apr 11, 2036	U-1719			
	11628173	Apr 11, 2036	U-1719			
	11712441	Apr 11, 2036	U-1719			
	11738085	Apr 11, 2036	U-1719			
	11759522	Apr 11, 2036	U-1719			
	11801250	Apr 11, 2036	U-1719			
	11806354	Apr 11, 2036	U-1719			
	11826370	Apr 11, 2036	U-1719			
	11865117	Apr 11, 2036	U-1719			
	12128052	May 28, 2040	U-1719			
	12370196	Dec 29, 2041	U-1719			
	>A> 12472256	May 18, 2038	U-4356			
	>A> 12472257	May 18, 2038	U-4134			
	>A> 12472258	May 18, 2038	DP			
	>A> 12485176	Apr 11, 2036	U-4133			
	9821075	Apr 11, 2036	DP U-1719			
<u>MERCAPTOPYRINE - MERCAPTOPYRINE</u>						
A 216418 001					CGT	Aug 25, 2025
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	12478606	Jan 08, 2038	U-3421			
<u>MESNA - MESNA</u>						
A 218871 001					CGT	Jul 13, 2025
<u>METHOCARBAMOL - ATMEKSI</u>						
N 219843 001	12390439	Oct 09, 2044	DP U-4253			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	12357642	Mar 19, 2030	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	12357642	Mar 19, 2030	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	12357642	Mar 19, 2030	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	12357642	Mar 19, 2030	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	12357642	Mar 19, 2030	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	12357642	Mar 19, 2030	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	12357642	Mar 19, 2030	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	12357642	Mar 19, 2030	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	12396947	Jan 02, 2033	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	12303592	Aug 03, 2027	DP U-4197			
	12303592	Aug 03, 2027	DP U-4198			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	12303592	Aug 03, 2027	DP U-4197			
	12303592	Aug 03, 2027	DP U-4198			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	12303592	Aug 03, 2027	DP U-4197			
	12303592	Aug 03, 2027	DP U-4198			
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	12194008	Dec 22, 2029	U-2843			
	12194009	Dec 22, 2029	U-2843			
	12377064	Nov 17, 2038	U-2843			
<u>METRONIDAZOLE - LIKMEZ</u>						
N 216755 001	12257236	Jan 16, 2039	DP U-3169			
	12257236	Jan 16, 2039	DP U-4163			
	12257236	Jan 16, 2039	DP U-4164			
<u>MICAFUNGIN SODIUM - MICAFUNGIN IN SODIUM CHLORIDE 0.9%</u>						
N 216142 001	12403173	Dec 15, 2037	DP			
<u>MICAFUNGIN SODIUM - MICAFUNGIN IN SODIUM CHLORIDE 0.9%</u>						
N 216142 002	12403173	Dec 15, 2037	DP			
<u>MICAFUNGIN SODIUM - MICAFUNGIN IN SODIUM CHLORIDE 0.9%</u>						
N 216142 003	12403173	Dec 15, 2037	DP			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	12280042	May 30, 2038	DS U-2371			
<u>MIGLUSTAT - OPFOLDA</u>						
N 215211 001	12246062	Sep 16, 2038	U-3726			
	12414985	Dec 29, 2036	U-3726			
	12419937	Mar 07, 2033	U-3726			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	12059409	Sep 28, 2029	DP			
	12059409*PED	Mar 28, 2030				
	12097189	Sep 28, 2029	U-2996			
	12097189	Sep 28, 2029	U-3670			
	12097189*PED	Mar 28, 2030				
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	12059409	Sep 28, 2029	DP			
	12059409*PED	Mar 28, 2030				
	12097189	Sep 28, 2029	U-2996			
	12097189	Sep 28, 2029	U-3670			
	12097189*PED	Mar 28, 2030				
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219379 001	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041	U-4130			
	11571402	Feb 17, 2041	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219379 001	11806321	Feb 17, 2041	U-4130			
	11806322	Apr 09, 2043	U-4130			
	11819487	Feb 17, 2041	U-4130			
	11839595	Mar 16, 2043	U-4130			
	11883375	Mar 16, 2043	U-4130			
	12011424	Feb 17, 2041	U-4130			
	12029711	Mar 15, 2044	DP U-4130			
	12037306	Feb 17, 2041	U-4130			
	12090128	Feb 17, 2041	DP U-4130			
	12220390	Mar 16, 2043	U-4130			
	12257215	Mar 16, 2043	U-4130			
	12263146	Feb 17, 2041	U-4130			
	12295925	Feb 17, 2041	U-4130			
	12324791	Mar 16, 2043	U-4130			
	12357597	Feb 17, 2041	U-4130			
	12390430	Oct 10, 2044	U-4130			
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219389 001	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041	U-4130			
	11806321	Feb 17, 2041	U-4130			
	11806322	Apr 09, 2043	U-4130			
	11819487	Feb 17, 2041	U-4130			
	11839595	Mar 16, 2043	U-4130			
	11883375	Mar 16, 2043	U-4130			
	12011424	Feb 17, 2041	U-4130			
	12029711	Mar 15, 2044	DP U-4130			
	12037306	Feb 17, 2041	U-4130			
	12220390	Mar 16, 2043	U-4130			
	12257215	Mar 16, 2043	U-4130			
	12263146	Feb 17, 2041	U-4130			
	12275688	Feb 17, 2041	DP U-4130			
	12295925	Feb 17, 2041	U-4130			
	12324791	Mar 16, 2043	U-4130			
	12383517	Mar 15, 2044	DP U-4130			
	12390430	Oct 10, 2044	U-4130			
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219389 002	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041	U-4130			
	11806321	Feb 17, 2041	U-4130			
	11806322	Apr 09, 2043	U-4130			
	11819487	Feb 17, 2041	U-4130			
	11839595	Mar 16, 2043	U-4130			
	11883375	Mar 16, 2043	U-4130			
	12029711	Mar 15, 2044	DP U-4130			
	12037306	Feb 17, 2041	U-4130			
	12220390	Mar 16, 2043	U-4130			
	12257215	Mar 16, 2043	U-4130			
	12263146	Feb 17, 2041	U-4130			
	12275688	Feb 17, 2041	DP U-4130			
	12295925	Feb 17, 2041	U-4130			
	12324791	Mar 16, 2043	U-4130			
	12383517	Mar 15, 2044	DP U-4130			
	12390430	Oct 10, 2044	U-4130			
<u>MITOMYCIN - JELMYTO</u>						
N 211728 001	12268745	Jan 20, 2031	U-4172			
<u>MITOMYCIN - ZUSDURI</u>						
N 215793 001	10039832	Jan 20, 2031	U-4256		NP	Jun 12, 2028
	12440568	Jan 20, 2031	U-4256			
	9040074	Jan 20, 2031	DP U-4256			
	9950069	Jan 20, 2031	DP U-4256			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS</u>						
N 211746 001	12303635	Apr 08, 2039	DS DP			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	10918615	Feb 27, 2035	DP U-1384			
	10918616	Feb 27, 2035	U-1384			
	10918617	Feb 27, 2035	DP			
	10945985	Feb 27, 2035	DP			
	11590095	Feb 27, 2035	U-1384			
<u>MOTIXAFORTIDE ACETATE - APHEXDA</u>						
N 217159 001	12257285	Dec 29, 2041	DP			
	12268725	Dec 29, 2041	DP			
<u>MOXIDECTIN - MOXIDECTIN</u>						
N 210867 001					NPP	Feb 07, 2028
<u>MYCOPHENOLATE MOFETIL - MYHIBBIN</u>						
N 216482 001	12194143	Aug 16, 2039	DP U-1752			
	12226526	Aug 16, 2039	DP U-1752			
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	12350377	May 13, 2033	DP			
	RE46365	Feb 24, 2031	DS DP			
<u>NALMEFENE HYDROCHLORIDE - OPVEE</u>						
N 217470 001	12290596	Aug 04, 2042	U-4182			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001	12414915	Aug 26, 2034	DP			
<u>NALOXONE HYDROCHLORIDE - RIVIVE</u>						
N 217722 001	12458591	May 11, 2032	U-3671			
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 001					NPP	Mar 27, 2028
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 002					NPP	Mar 27, 2028
<u>NEDOSIRAN SODIUM - RIVFLOZA</u>						
N 215842 003					NPP	Mar 27, 2028
<u>NERANDOMILAST - JASCAYD</u>						
N 218764 001	11406638	Oct 22, 2038	U-4297		NCE	Oct 07, 2030
	11813266	Oct 22, 2038	U-4292			
	8609670	Aug 23, 2032	DS			
	8754073	Nov 26, 2029	DS DP U-4298			
	9802954	Feb 19, 2034	U-4298			
<u>NERANDOMILAST - JASCAYD</u>						
N 218764 002	11406638	Oct 22, 2038	U-4297		NCE	Oct 07, 2030
	11813266	Oct 22, 2038	U-4292			
	8609670	Aug 23, 2032	DS			
	8754073	Nov 26, 2029	DS DP U-4298			
	9802954	Feb 19, 2034	U-4298			
<u>NILOTINIB HYDROCHLORIDE - NILOTINIB HYDROCHLORIDE</u>						
A 203640 001					PC	Nov 19, 2025
<u>NILOTINIB HYDROCHLORIDE - NILOTINIB HYDROCHLORIDE</u>						
A 203640 002					PC	Nov 19, 2025

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NILOTINIB HYDROCHLORIDE - NILOTINIB HYDROCHLORIDE</u>						
A 203640	003				PC	Nov 19, 2025
<u>NILOTINIB TARTRATE - DANZITEN</u>						
N 219293	001	12403140	Feb 18, 2040	DP		
<u>NILOTINIB TARTRATE - DANZITEN</u>						
N 219293	002	12403140	Feb 18, 2040	DP		
<u>NIMODIPINE - NYMALIZE</u>						
N 203340	002	12186308	Apr 16, 2038	DP U-2804		
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876	001	11730725	Jan 25, 2039	DP		
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876	002	11730725	Jan 25, 2039	DP		
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876	003	11730725	Jan 25, 2039	DP		
<u>NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)</u>						
N 217188	001				D-195	Jan 31, 2028
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677	001	12234210	Jul 08, 2042	DP		
		12247012	Jul 08, 2042	DP		
		12297177	Aug 09, 2039	DP		
		7795447	Aug 18, 2030	DS		
		7951958	Mar 11, 2025	DS		
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677	002	12234210	Jul 08, 2042	DP		
		12247012	Jul 08, 2042	DP		
		12297177	Aug 09, 2039	DP		
		7795447	Aug 18, 2030	DS		
		7951958	Mar 11, 2025	DS		
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677	003	12234210	Jul 08, 2042	DP		
		12247012	Jul 08, 2042	DP		
		12297177	Aug 09, 2039	DP		
		7795447	Aug 18, 2030	DS		
		7951958	Mar 11, 2025	DS		
<u>NITRIC OXIDE - INOMAX</u>						
N 020845	003	11931377	Jun 30, 2029	DS DP U-3903		
		11931377*PED	Dec 30, 2029			
		9279794	Feb 19, 2035	DP U-1823		
		9279794*PED	Aug 19, 2035			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845	004	11931377	Jun 30, 2029	DS DP U-3903		
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313	001	12290494	Mar 08, 2041	DP		
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE</u>						
N 214313	002	12290494	Mar 08, 2041	DP		
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628	001	12245996	Jan 30, 2038	DP		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 002	12245996	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 003	12245996	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 001	RE49422	Feb 26, 2035	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 002	RE49422	Feb 26, 2035	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 003	10251848	Feb 26, 2035	DP			
	RE49422	Feb 26, 2035	DP			
	RE49443	Feb 26, 2035	DP			
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	12246054	Feb 03, 2036		U-2857		
	12251418	Feb 03, 2036		U-2857		
<u>OCTREOTIDE ACETATE - BYNFEZIA PEN</u>						
N 213224 001	12350475	Dec 29, 2041		U-4007		
	12350475	Dec 29, 2041		U-4008		
	12350475	Dec 29, 2041		U-4009		
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	10011633	Nov 08, 2031		U-3186		
	10011633	Nov 08, 2031		U-3648		
	10093697	Nov 08, 2031		U-3186		
	10093697	Nov 08, 2031		U-3648		
	10487111	Nov 08, 2031		U-3186		
	10487111	Nov 08, 2031		U-3648		
	11365182	Jun 20, 2039		U-3186		
	11365182	Jun 20, 2039		U-3648		
	11732006	Nov 08, 2031		U-3186		
	11732006	Nov 08, 2031		U-3648		
	12187812	Nov 08, 2031		U-3186		
	12187812	Nov 08, 2031		U-3648		
	12447156	Nov 12, 2041		U-3186		
	9694018	Nov 08, 2031		U-3186		
	9694018	Nov 08, 2031		U-3648		
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	10011633	Nov 08, 2031		U-3186		
	10011633	Nov 08, 2031		U-3648		
	10093697	Nov 08, 2031		U-3186		
	10093697	Nov 08, 2031		U-3648		
	10487111	Nov 08, 2031		U-3186		
	10487111	Nov 08, 2031		U-3648		
	11365182	Jun 20, 2039		U-3186		
	11365182	Jun 20, 2039		U-3648		
	11732006	Nov 08, 2031		U-3186		
	11732006	Nov 08, 2031		U-3648		
	12187812	Nov 08, 2031		U-3186		
	12187812	Nov 08, 2031		U-3648		
	12447156	Nov 12, 2041		U-3186		
	9694018	Nov 08, 2031		U-3186		
	9694018	Nov 08, 2031		U-3648		
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	10011633	Nov 08, 2031		U-3186		
	10011633	Nov 08, 2031		U-3648		
	10093697	Nov 08, 2031		U-3186		
	10093697	Nov 08, 2031		U-3648		
	10487111	Nov 08, 2031		U-3648		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	10487111	Nov 08, 2031	U-3648			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3648			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3648			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	12447156	Nov 12, 2041	U-3186			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	10011633	Nov 08, 2031	U-3186			
	10011633	Nov 08, 2031	U-3648			
	10093697	Nov 08, 2031	U-3186			
	10093697	Nov 08, 2031	U-3648			
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3648			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3648			
	11732006	Nov 08, 2031	U-3186			
	11732006	Nov 08, 2031	U-3648			
	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
	12447156	Nov 12, 2041	U-3186			
	9694018	Nov 08, 2031	U-3186			
	9694018	Nov 08, 2031	U-3648			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	12194035	Aug 23, 2031	U-3141			
	12390474	Nov 12, 2041	DP			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	12194035	Aug 23, 2031	U-3141			
	12390474	Nov 12, 2041	DP			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	12194035	Aug 23, 2031	U-3141			
	12390474	Nov 12, 2041	DP			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	12194035	Aug 23, 2031	U-3141			
	12390474	Nov 12, 2041	DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	12178816	Oct 07, 2029	DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	12178816	Oct 07, 2029	DP			
<u>OLEZARSEN SODIUM - TRYNGOLZA (AUTOINJECTOR)</u>						
N 218614 001	9127276	May 01, 2034	DS		ODE-515	Dec 19, 2031
	9157082	Apr 27, 2032	U-4050			
	9163239	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
	9593333	Feb 14, 2034	U-4050			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	7396341	Oct 10, 2026	DP	Y		
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP	Y		
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP	Y		
	9027967	Mar 31, 2027	DP	Y		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814 001	12275715	Sep 18, 2035	DS DP U-3684			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	9265740	Oct 24, 2030	DP U-1569			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	9265740	Mar 05, 2029	DP			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001					M-270	Dec 20, 2027
<u>OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEF</u>						
N 213593 001	12329752	Jul 16, 2039	DP			
	12440566	Jul 16, 2039	DP			
<u>OMIDENEPAG ISOPROPYL - OMLONTI</u>						
N 215092 001	12290511	Dec 27, 2038	U-3454			
	12295946	Jan 08, 2035	DP U-3454			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 001	10709691	Oct 12, 2035	U-2770			
	10709691	Oct 12, 2035	U-4177			
	8609862	Jan 13, 2031	U-2770			
	8609862	Jan 13, 2031	U-4177			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 002	10709691	Oct 12, 2035	U-2770			
	10709691	Oct 12, 2035	U-4177			
	8609862	Jan 13, 2031	U-2770			
	8609862	Jan 13, 2031	U-4177			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	12465608	Nov 26, 2042	U-3823			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	12465608	Nov 26, 2042	U-3823			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	12246094	Aug 24, 2027	DP			
	12280152	Aug 24, 2027	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADÉ</u>						
N 208552 001	12350255	Jun 11, 2035	U-3494			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	8481573	Mar 24, 2033	DS DP U-2774			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	8481573	Mar 24, 2033	DS DP U-2774			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	8481573	Mar 24, 2033	DS DP U-2774			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	10723730	Feb 08, 2034	DS DP		M-14	Sep 16, 2028
	10723730*PED	Aug 08, 2034			PED	Mar 16, 2029
	RE47739	Mar 05, 2027	DS DP			
	RE47739*PED	Sep 05, 2027				
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	10723730	Feb 08, 2034	DS DP		M-14	Sep 16, 2028
	10723730*PED	Aug 08, 2034			PED	Mar 16, 2029
	RE47739	Mar 05, 2027	DS DP			
	RE47739*PED	Sep 05, 2027				
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	10723730	Feb 08, 2034	DS DP		M-14	Sep 16, 2028
	10723730*PED	Aug 08, 2034			PED	Mar 16, 2029
	RE47739	Mar 05, 2027	DS DP			
	RE47739*PED	Sep 05, 2027				
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	10723730	Feb 08, 2034	DS DP		M-14	Sep 16, 2028
	10723730*PED	Aug 08, 2034			PED	Mar 16, 2029
	11065250	Aug 19, 2036	DP			
	11065250*PED	Feb 19, 2037				
	RE47739	Mar 05, 2027	DS DP			
	RE47739*PED	Sep 05, 2027				
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	10723730	Feb 08, 2034	DS DP		M-14	Sep 16, 2028
	10723730*PED	Aug 08, 2034			PED	Mar 16, 2029
	11065250	Aug 19, 2036	DP			
	11065250*PED	Feb 19, 2037				
	RE47739	Mar 05, 2027	DS DP			
	RE47739*PED	Sep 05, 2027				
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	10723730	Feb 08, 2034	DS DP		M-14	Sep 16, 2028
	10723730*PED	Aug 08, 2034			PED	Mar 16, 2029
	11065250	Aug 19, 2036	DP			
	11065250*PED	Feb 19, 2037				
	RE47739	Mar 05, 2027	DS DP			
	RE47739*PED	Sep 05, 2027				
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 005	12208100	May 07, 2041	U-3359			
	12208100	May 07, 2041	U-4110			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 006	12208100	May 07, 2041	U-3359			
	12208100	May 07, 2041	U-4110			
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 001	12295989	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
	12403182	Nov 12, 2042	DP U-3982			
	12453778	Sep 28, 2037	U-3982			
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 002	12295989	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
	12403182	Nov 12, 2042	DP U-3982			
	12453778	Sep 28, 2037	U-3982			
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 003	12295989	Sep 28, 2037	U-3982		NCE	Aug 09, 2029
	12403182	Nov 12, 2042	DP U-3982			
	12453778	Sep 28, 2037	U-3982			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 001	12201614	Jun 08, 2037	U-4031			
	12458626	Jun 08, 2037	U-3676			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 002	12201614	Jun 08, 2037	U-4031			
	12458626	Jun 08, 2037	U-3676			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 003	12201614	Jun 08, 2037	U-4031			
	12458626	Jun 08, 2037	U-3676			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 004	12201614	Jun 08, 2037	U-4031			
	12458626	Jun 08, 2037	U-3676			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 005	12201614	Jun 08, 2037	U-4031			
	12458626	Jun 08, 2037	U-3676			
<u>PALTUSOTINE HYDROCHLORIDE - PALSONIFY</u>						
N 219070 001	10351547	Jul 12, 2037	DS DP U-4283		NCE	Sep 25, 2030
	10464918	Jan 16, 2039	DS			
	10597377	Jul 12, 2037	DS DP U-4283			
	10875839	Jul 12, 2037	U-4283			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALTUSOTINE HYDROCHLORIDE - PALSONIFY</u>						
N 219070 001	11266641	Sep 07, 2041	DP U-4283			
	11414397	Jul 12, 2037	DS DP U-4283			
	11957674	Sep 07, 2041	U-4283			
	12208092	Mar 25, 2044	U-4282			
	9896432	Jul 12, 2037	DS DP U-4283			
<u>PALTUSOTINE HYDROCHLORIDE - PALSONIFY</u>						
N 219070 002	10351547	Jul 12, 2037	DS DP U-4283		NCE	Sep 25, 2030
	10464918	Jan 16, 2039	DS			
	10597377	Jul 12, 2037	DS DP U-4283			
	10875839	Jul 12, 2037	U-4283			
	11266641	Sep 07, 2041	DP U-4283			
	11414397	Jul 12, 2037	DS DP U-4283			
	11957674	Sep 07, 2041	U-4283			
	12208092	Mar 25, 2044	U-4282			
	9896432	Jul 12, 2037	DS DP U-4283			
<u>PATISIRAN SODIUM - ONPATRO</u>						
N 210922 001	8168775	Aug 10, 2032	DS DP U-2378			
<u>PAZOPANIB HYDROCHLORIDE - PAZOPANIB HYDROCHLORIDE</u>						
A 219922 001					CGT	May 06, 2026
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	10875893	Nov 15, 2033	DS U-3124		I-972	Jul 28, 2028
	10875893	Nov 15, 2033	DS U-4242			
	11040107	Apr 09, 2038	DP U-3172			
	11040107	Apr 09, 2038	DP U-3173			
	11040107	Apr 09, 2038	DP U-3174			
	11040107	Apr 09, 2038	DP U-4241			
	11292815	Nov 15, 2033	DS DP U-3124			
	11292815	Nov 15, 2033	DS DP U-3354			
	11292815	Nov 15, 2033	DS DP U-4242			
	11292815	Nov 15, 2033	DS DP U-4243			
	11661441	Jan 13, 2033	DS U-3124			
	11661441	Jan 13, 2033	DS U-4242			
	11844841	Dec 09, 2038	DP U-3172			
	11844841	Dec 09, 2038	DP U-3173			
	11844841	Dec 09, 2038	DP U-3174			
	11844841	Dec 09, 2038	DP U-4241			
	12290566	Dec 14, 2038	DP U-4174			
	12290566	Dec 14, 2038	DP U-4175			
	12290566	Dec 14, 2038	DP U-4238			
	12290566	Dec 14, 2038	DP U-4239			
	12290566	Dec 14, 2038	DP U-4240			
	9169307	Nov 18, 2027	DS U-3123			
	9169307	Nov 18, 2027	DS U-4244			
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	12458695	Dec 14, 2038	DP			
<u>PEGULICIANINE ACETATE - LUMISIGHT</u>						
N 214511 001	11592396	Sep 01, 2030	DS			
<u>PEMETREXED - PEMFEXY</u>						
N 209472 001	12115164	Feb 19, 2036	U-4246			
	12115164	Feb 19, 2036	U-4247			
	12115164	Feb 19, 2036	U-4248			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001	>A> 10131667	Apr 17, 2034	U-2809			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002	>A> 10131667	Apr 17, 2034	U-2809			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003	>A> 10131667	Apr 17, 2034	U-2809			
<u>PERAMPANEL - PERAMPANEL</u>						
A 209801 001					PC	Nov 25, 2025
<u>PERAMPANEL - PERAMPANEL</u>						
A 209801 002					PC	Nov 25, 2025
<u>PERAMPANEL - PERAMPANEL</u>						
A 209801 003					PC	Nov 25, 2025
<u>PERAMPANEL - PERAMPANEL</u>						
A 209801 004					PC	Nov 25, 2025
<u>PERAMPANEL - PERAMPANEL</u>						
A 209801 005					PC	Nov 25, 2025
<u>PERAMPANEL - PERAMPANEL</u>						
A 209801 006					PC	Nov 25, 2025
<u>PERFLUOROHEXYLOCTANE - MIEBO</u>						
N 216675 001	>A> 10576154	Oct 01, 2035	U-1900			
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	12201615	Dec 25, 2039	U-3804			
	12201616	Oct 25, 2039	U-3804			
	12350366	Jan 31, 2034	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - IMPHENTIV</u>						
N 203826 004	12257342	Sep 26, 2036	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - IMPHENTIV</u>						
N 203826 005	12257342	Sep 26, 2036	DP			
<u>PHYTONADIONE - PHYTONADIONE</u>						
A 214966 001					CGT	Sep 06, 2025
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001	>A> 10464905	Dec 16, 2036	U-3518			
	>A> 10464905	Dec 16, 2036	U-4362			
	>A> 10695323	Dec 16, 2036	DS DP U-3518			
	>A> 10695323	Dec 16, 2036	DS DP U-4362			
	>A> 10918622	Dec 16, 2036	U-3518			
	>A> 10918622	Dec 16, 2036	U-4362			
	>A> 12220401	Dec 16, 2036	DS DP U-3518			
	>A> 12220401	Dec 16, 2036	DS DP U-4362			
	12268666	Jul 29, 2039	DP			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002	>A> 10464905	Dec 16, 2036	U-3518			
	>A> 10464905	Dec 16, 2036	U-4362			
	>A> 10695323	Dec 16, 2036	DS DP U-3518			
	>A> 10695323	Dec 16, 2036	DS DP U-4362			
	>A> 10918622	Dec 16, 2036	U-3518			
	>A> 10918622	Dec 16, 2036	U-4362			
	>A> 12220401	Dec 16, 2036	DS DP U-3518			
	>A> 12220401	Dec 16, 2036	DS DP U-4362			
	12268666	Jul 29, 2039	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PLAZOMICIN SULFATE - ZEMDRI</u>						
N 210303 001 >A>	8383596	Jun 25, 2032	DS U-2328			
<u>PLOZASIRAN SODIUM - REDEMPLO</u>						
N 219947 001 >A>	10294474	Mar 07, 2037	DS DP U-4360			
>A>	10597657	Sep 10, 2038	DS DP U-4360			
>A>	11174481	Mar 07, 2037	DS DP			
>A>	11214801	Sep 10, 2038	DS DP U-4360			
>A>	12365899	Sep 10, 2038	DS DP U-4360			
<u>PONESIMOD - PONVORY</u>						
N 213498 001	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 002	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 003	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 004	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 005	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 006	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 007	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 008	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 009	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 010	12336980	Dec 10, 2035	U-3103			
	RE43728	Nov 16, 2029	DS DP			
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE</u>						
N 212832 004	11813291	Oct 12, 2041	DP U-4185			
	11925661	Oct 12, 2041	DP U-4185			
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE</u>						
N 212832 005	11813291	Oct 12, 2041	DP U-4185			
	11925661	Oct 12, 2041	DP U-4185			
<u>PROGESTERONE - PROGESTERONE</u>						
A 218391 001				CGT		Mar 22, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PRUCALOPRIDE SUCCINATE - MOTTEGRITY</u>						
N 210166 001					M-14	Jul 10, 2028
<u>PRUCALOPRIDE SUCCINATE - MOTTEGRITY</u>						
N 210166 002					M-14	Jul 10, 2028
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
N 217604 001	12233166	Jun 18, 2038	DP			
<u>RAMIPRIL - VOSTALLY</u>						
N 219757 001	12343338	Aug 16, 2039	DP U-4233			
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	12325714	Sep 27, 2033	DS DP			
	12336990	Sep 29, 2037		U-3020		
	7300935	Jan 28, 2029	DS			
<u>REMIBRUTINIB - RHAPSIDO</u>						
N 218436 001	10457647	Nov 13, 2034		U-4280	NCE	Sep 30, 2030
	12419889	Jan 20, 2043		U-4281		
	9512084	Nov 13, 2034	DS DP			
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 001	12187739	Jul 05, 2036	DP		ODE-483	Jun 13, 2031
	12310968	Jul 20, 2036		U-3755		
	RE50634	Jan 23, 2035	DS DP			
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 002	12187739	Jul 05, 2036	DP		ODE-483	Jun 13, 2031
	12310968	Jul 20, 2036		U-3755		
	RE50634	Jan 23, 2035	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 001	12377104	Feb 04, 2045		U-3861		
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 002	12377104	Feb 04, 2045		U-3861		
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 003	12377104	Feb 04, 2045		U-3861		
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	12285417	Aug 29, 2039		U-2440		
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 001	11479557	Jun 08, 2037	DP U-4045		ODE-504	Nov 15, 2031
	11479557	Jun 08, 2037	DP U-4327		ODE-505	Nov 15, 2031
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 002	11479557	Jun 08, 2037	DP U-4045		ODE-504	Nov 15, 2031
	11479557	Jun 08, 2037	DP U-4327		ODE-505	Nov 15, 2031
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 003	11479557	Jun 08, 2037	DP U-4045		ODE-504	Nov 15, 2031
	11479557	Jun 08, 2037	DP U-4327		ODE-505	Nov 15, 2031
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	12419894	Apr 14, 2036	DP			
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - EPIOXA HD/EPIOXA KIT</u>						
N 219910 001					NP	Oct 17, 2028

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	10703763	Feb 27, 2026	U-2848			
	8741904	Feb 27, 2026	DS DP U-2848			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 002	10703763	Feb 27, 2026	U-1708			
	10703763	Feb 27, 2026	U-2847			
	8309569	Jul 18, 2029	U-1707	Y		
	8309569	Jul 18, 2029	U-1708	Y		
	8741904	Feb 27, 2026	DS DP U-1707			
	8741904	Feb 27, 2026	DS DP U-1708			
	8741904	Feb 27, 2026	DS DP U-2847			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001					NPP PED	Mar 15, 2027 Sep 15, 2027
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT PED</u>						
N 219016 001					NP PED	Mar 15, 2027 Sep 15, 2027
<u>RILZABRUTINIB - WAYRILZ</u>						
N 219685 001	11708370	Feb 20, 2041	DS		NCE	Aug 29, 2030
	12178818	Oct 13, 2040	U-4267			
	8940744	Sep 06, 2033	DS DP U-4270			
	9266895	Sep 06, 2033	DS DP U-4268			
	9580427	Mar 01, 2033	DS DP			
	9994576	Sep 06, 2033	DS DP U-4268			
	9994576	Sep 06, 2033	DS DP U-4269			
<u>RIMEGEPANT SULFATE - NURTEC ODT</u>						
N 212728 001	8314117	Feb 27, 2034	DS DP U-2718			
	8314117	Feb 27, 2034	DS DP U-3142			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	12213967	Dec 30, 2040	DP			
	12213968	Dec 30, 2040	DP			
	12226406	Dec 30, 2040	DP			
	12295944	Aug 12, 2040	U-4183			
	12318373	Aug 12, 2040	U-4191			
	12318374	Dec 30, 2040	DP			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001	12350273	Oct 01, 2038	U-1943			
<u>RISDIPLAM - EVRYSDI</u>						
N 219285 001	11534444	Oct 04, 2038	U-1943		M-270	Oct 03, 2026
	11827646	Jan 25, 2036	U-1943		NCE	Aug 07, 2025
	12122789	Apr 15, 2041	DS DP			
	12350273	Oct 01, 2038	U-1943			
	9586955	Feb 08, 2033	DS DP			
	9969754	May 11, 2035	DS DP U-1943			
<u>RISPERIDONE - RISPERIDONE</u>						
A 211220 001					>A> CGT	May 12, 2026
<u>RISPERIDONE - RISPERIDONE</u>						
A 211220 002					CGT	May 09, 2026
<u>RISPERIDONE - RISPERIDONE</u>						
A 211220 003					CGT	May 09, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - UZEDY</u>						
N 213586 001	12128132	Sep 11, 2040	DP U-543			
	12128132	Sep 11, 2040	DP U-601			
	12329851	Mar 17, 2042	U-4214			
	12383493	Sep 11, 2040	DP U-543			
	12383493	Sep 11, 2040	DP U-601			
	8221778	Nov 12, 2027	DP U-543			
	8221778	Nov 12, 2027	DP U-601			
<u>RISPERIDONE - UZEDY</u>						
N 213586 002	12128132	Sep 11, 2040	DP U-543			
	12128132	Sep 11, 2040	DP U-601			
	12329851	Mar 17, 2042	U-4214			
	12383493	Sep 11, 2040	DP U-543			
	12383493	Sep 11, 2040	DP U-601			
	8221778	Nov 12, 2027	DP U-543			
	8221778	Nov 12, 2027	DP U-601			
<u>RISPERIDONE - UZEDY</u>						
N 213586 003	12128132	Sep 11, 2040	DP U-543			
	12128132	Sep 11, 2040	DP U-601			
	12329851	Mar 17, 2042	U-4214			
	12383493	Sep 11, 2040	DP U-543			
	12383493	Sep 11, 2040	DP U-601			
	8221778	Nov 12, 2027	DP U-543			
	8221778	Nov 12, 2027	DP U-601			
<u>RISPERIDONE - UZEDY</u>						
N 213586 004	12329851	Mar 17, 2042	U-4214			
	12383493	Sep 11, 2040	DP U-543			
<u>RISPERIDONE - UZEDY</u>						
N 213586 005	12329851	Mar 17, 2042	U-4214			
	12383493	Sep 11, 2040	DP U-543			
<u>RISPERIDONE - UZEDY</u>						
N 213586 006	12329851	Mar 17, 2042	U-4214			
	12383493	Sep 11, 2040	DP U-543			
<u>RISPERIDONE - UZEDY</u>						
N 213586 007	12329851	Mar 17, 2042	U-4214			
	12383493	Sep 11, 2040	DP U-543			
<u>ROCURONIUM BROMIDE - ROCURONIUM BROMIDE</u>						
N 219108 001	11998605	Jul 22, 2039	DP			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 001	12220409	Jun 07, 2037	DP			
	12257242	Jun 07, 2037	DP			
	12310956	Jun 07, 2037	U-3748			
	12336983	Jun 07, 2037	DP			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 002	12220409	Jun 07, 2037	DP			
	12257242	Jun 07, 2037	DP			
	12310956	Jun 07, 2037	U-3970			
	12336983	Jun 07, 2037	DP			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 003	10940142	Jun 07, 2037	DP		NS	Oct 04, 2028
	11129818	Aug 25, 2037	U-4301			
	11793796	Jun 07, 2037	DP			
	11819496	Jun 07, 2037	U-4301			
	11992480	Jun 07, 2037	U-4301			
	12005051	Jun 07, 2037	U-4301			
	12005052	Jun 07, 2037	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 003	12011437	Jun 07, 2037	DP			
	12016848	Jun 07, 2037	DP			
	12042487	Jun 07, 2037	DP			
	12220409	Jun 07, 2037	DP			
	12257242	Jun 07, 2037	DP			
	12310956	Jun 07, 2037	U-4301			
	12336983	Jun 07, 2037	DP			
	9884050	Jun 07, 2037	DP			
	9907788	Jun 07, 2037	U-4301			
<u>ROFLUMILAST - ZORYVE</u>						
N 217242 001	11129818	Aug 25, 2037	U-3773		I-969	May 22, 2028
	11129818	Aug 25, 2037	U-4203			
	11819496	Jun 07, 2037	U-3773			
	11819496	Jun 07, 2037	U-4203			
	11992480	Jun 07, 2037	U-3773			
	11992480	Jun 07, 2037	U-4203			
	12005051	Jun 07, 2037	U-3773			
	12005051	Jun 07, 2037	U-4203			
	12220409	Jun 07, 2037	DP			
	12257242	Jun 07, 2037	DP			
	12310956	Jun 07, 2037	U-3773			
	12310956	Jun 07, 2037	U-4203			
	12329751	Dec 03, 2041	U-3773			
	12336983	Jun 07, 2037	DP			
	12390453	Jun 07, 2037	DP			
	12453721	Aug 19, 2042	DP			
	9907788	Jun 07, 2037	U-3773			
	9907788	Jun 07, 2037	U-4203			
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	12226419	May 20, 2031	DP		NPP	Sep 18, 2028
	12233067	Jul 28, 2040	U-4151			
<u>SARECYCLINE HYDROCHLORIDE - SEYSARA</u>						
N 209521 001	8318706	Jan 03, 2032	DS DP U-2405			
<u>SARECYCLINE HYDROCHLORIDE - SEYSARA</u>						
N 209521 002	8318706	Jan 03, 2032	DS DP U-2405			
<u>SARECYCLINE HYDROCHLORIDE - SEYSARA</u>						
N 209521 003	8318706	Jan 03, 2032	DS DP U-2405			
<u>SEBETRALSTAT - EKTERLY</u>						
N 219301 001	10364238	Nov 26, 2035	DS DP		NCE	Jul 03, 2030
	10611758	Nov 26, 2035	U-4223			
	11001578	Nov 26, 2035	DS DP			
	11084809	Nov 26, 2035	DS DP U-4223			
	11198691	Nov 26, 2035	U-4223			
	11230537	Dec 25, 2037	DS DP			
	11234939	Jan 26, 2039	DP U-4223			
	11739068	Jun 23, 2037	U-4223			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	12280037	Dec 11, 2041	U-3302			
<u>SELADELPAR LYSINE - LIVDELZI</u>						
N 217899 001	7301050	Aug 02, 2026	DS DP			
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	12291508	Jul 26, 2032	U-2584			
	12291508	Jul 26, 2032	U-2855			
	12291508	Jul 26, 2032	U-3018			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE	
<u>SELINEXOR - XPOVIO</u>							
N 212306 002	12291508	Jul 26, 2032	U-2584				
	12291508	Jul 26, 2032	U-2855				
	12291508	Jul 26, 2032	U-3018				
<u>SELINEXOR - XPOVIO</u>							
N 212306 003	12291508	Jul 26, 2032	U-2584				
	12291508	Jul 26, 2032	U-2855				
	12291508	Jul 26, 2032	U-3018				
<u>SELINEXOR - XPOVIO</u>							
N 212306 004	12291508	Jul 26, 2032	U-2584				
	12291508	Jul 26, 2032	U-2855				
	12291508	Jul 26, 2032	U-3018				
<u>SELINEXOR - XPOVIO</u>							
N 212306 005	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026	
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027	
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027	
	10544108	Jul 26, 2032	U-2584				
	10544108	Jul 26, 2032	U-3018				
	11034660	Jul 26, 2032	U-2584				
	11034660	Jul 26, 2032	U-3018				
	11746102	Aug 14, 2035	U-2584				
	11746102	Aug 14, 2035	U-2855				
	11746102	Aug 14, 2035	U-3018				
	11753401	Aug 14, 2035	DP U-2584				
	11753401	Aug 14, 2035	DP U-2855				
	11753401	Aug 14, 2035	DP U-3018				
	11787771	Jul 26, 2032	U-2584				
	11787771	Jul 26, 2032	U-2855				
	11787771	Jul 26, 2032	U-3018				
	11807629	Aug 14, 2035	DS				
	12291508	Jul 26, 2032	U-2584				
	12291508	Jul 26, 2032	U-2855				
	12291508	Jul 26, 2032	U-3018				
	8999996	Jul 03, 2033	DS DP				
	9079865	Jul 26, 2032	U-2584				
	9079865	Jul 26, 2032	U-2855				
	9079865	Jul 26, 2032	U-3018				
	9714226	Jul 26, 2032	DS DP				
	<u>SELINEXOR - XPOVIO</u>						
	N 212306 006	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
10519139		Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027	
10544108		Jul 26, 2032	U-2584				
10544108		Jul 26, 2032	U-3018				
11034660		Jul 26, 2032	U-2584				
11034660		Jul 26, 2032	U-3018				
11746102		Aug 14, 2035	U-2584				
11746102		Aug 14, 2035	U-3018				
11753401		Aug 14, 2035	DP U-2584				
11753401		Aug 14, 2035	DP U-3018				
11787771		Jul 26, 2032	U-2584				
11787771		Jul 26, 2032	U-3018				
11807629		Aug 14, 2035	DS				
12291508		Jul 26, 2032	U-2584				
12291508		Jul 26, 2032	U-3018				
8999996		Jul 03, 2033	DS DP				
9079865		Jul 26, 2032	U-2584				
9079865		Jul 26, 2032	U-3018				
9714226		Jul 26, 2032	DS DP				
<u>SELPERCATINIB - RETEVMO</u>							
N 213246 001		10112942	Oct 10, 2037	DS DP		M-311	Sep 27, 2027
		10112942*PED	Apr 10, 2038			M-312	Sep 27, 2027
		10137124	Oct 10, 2037	U-3450		NPP	May 29, 2027
		10137124	Oct 10, 2037	U-3949		ODE-301	May 08, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001	10137124	Oct 10, 2037	U-3950		ODE-302	May 08, 2027
	10137124	Oct 10, 2037	U-3951		ODE-303	May 08, 2027
	10137124*PED	Apr 10, 2038			ODE-409	Sep 21, 2029
	10172851	Oct 10, 2037	U-3450		ODE-412	Sep 21, 2029
	10172851	Oct 10, 2037	U-3949		ODE-484	May 29, 2031
	10172851	Oct 10, 2037	U-3950		ODE-485	May 29, 2031
	10172851	Oct 10, 2037	U-3951		ODE-487	May 29, 2031
	10172851*PED	Apr 10, 2038			PED	Nov 08, 2027
	10584124	Oct 10, 2038	DS U-3450		PED	Nov 08, 2027
	10584124	Oct 10, 2038	DS U-3949		PED	Nov 08, 2027
	10584124	Oct 10, 2038	DS U-3950		PED	Nov 29, 2027
	10584124	Oct 10, 2038	DS U-3951		PED	Mar 27, 2028
	10584124*PED	Apr 10, 2039			PED	Mar 27, 2028
	10786489	Oct 10, 2038	DP U-3450		PED	Mar 21, 2030
	10786489	Oct 10, 2038	DP U-3949		PED	Mar 21, 2030
	10786489	Oct 10, 2038	DP U-3950		PED	Nov 29, 2031
	10786489	Oct 10, 2038	DP U-3951		PED	Nov 29, 2031
	10786489*PED	Apr 10, 2039			PED	Nov 29, 2031
	>A> 12138250	Oct 10, 2038	U-3450			
	>A> 12138250	Oct 10, 2038	U-3949			
	>A> 12138250	Oct 10, 2038	U-3950			
	>A> 12138250	Oct 10, 2038	U-3951			
	>A> 12138250*PED	Apr 10, 2039				
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 002	10112942	Oct 10, 2037	DS DP		M-311	Sep 27, 2027
	10112942*PED	Apr 10, 2038			M-312	Sep 27, 2027
	10137124	Oct 10, 2037	U-3450		NPP	May 29, 2027
	10137124	Oct 10, 2037	U-3949		ODE-301	May 08, 2027
	10137124	Oct 10, 2037	U-3950		ODE-302	May 08, 2027
	10137124	Oct 10, 2037	U-3951		ODE-303	May 08, 2027
	10137124*PED	Apr 10, 2038			ODE-409	Sep 21, 2029
	10172851	Oct 10, 2037	U-3450		ODE-412	Sep 21, 2029
	10172851	Oct 10, 2037	U-3949		ODE-484	May 29, 2031
	10172851	Oct 10, 2037	U-3950		ODE-485	May 29, 2031
	10172851	Oct 10, 2037	U-3951		ODE-487	May 29, 2031
	10172851*PED	Apr 10, 2038			PED	Nov 08, 2027
	10584124	Oct 10, 2038	DS U-3450		PED	Nov 08, 2027
	10584124	Oct 10, 2038	DS U-3949		PED	Nov 08, 2027
	10584124	Oct 10, 2038	DS U-3950		PED	Nov 29, 2027
	10584124	Oct 10, 2038	DS U-3951		PED	Mar 27, 2028
	10584124*PED	Apr 10, 2039			PED	Mar 27, 2028
	10786489	Oct 10, 2038	DP U-3450		PED	Mar 21, 2030
	10786489	Oct 10, 2038	DP U-3949		PED	Mar 21, 2030
	10786489	Oct 10, 2038	DP U-3950		PED	Nov 29, 2031
	10786489	Oct 10, 2038	DP U-3951		PED	Nov 29, 2031
	10786489*PED	Apr 10, 2039			PED	Nov 29, 2031
	>A> 12138250	Oct 10, 2038	U-3450			
	>A> 12138250	Oct 10, 2038	U-3949			
	>A> 12138250	Oct 10, 2038	U-3950			
	>A> 12138250	Oct 10, 2038	U-3951			
	>A> 12138250*PED	Apr 10, 2039				
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 001	10112942	Oct 10, 2037	DS DP		M-311	Sep 27, 2027
	10112942*PED	Apr 10, 2038			M-312	Sep 27, 2027
	10137124	Oct 10, 2037	U-3450		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3949		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3950		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3951		ODE*	Sep 21, 2029
	10137124*PED	Apr 10, 2038			ODE*	Sep 21, 2029
	10172851	Oct 10, 2037	U-3450		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3949		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3950		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3951		PED	Nov 08, 2027
	10172851*PED	Apr 10, 2038			PED	Nov 08, 2027
	>A> 12138250	Oct 10, 2038	U-3450		PED	Nov 08, 2027
	>A> 12138250	Oct 10, 2038	U-3949		PED	Mar 27, 2028

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 001	>A> 12138250	Oct 10, 2038	U-3950		PED	Mar 27, 2028
	>A> 12138250	Oct 10, 2038	U-3951		PED	Mar 21, 2030
	>A> 12138250*PED	Apr 10, 2039			PED	Mar 21, 2030
					PED	Nov 29, 2031
					PED	Nov 29, 2031
					PED	Nov 29, 2031
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 002	10112942	Oct 10, 2037	DS DP		M-311	Sep 27, 2027
	10112942*PED	Apr 10, 2038			M-312	Sep 27, 2027
	10137124	Oct 10, 2037	U-3450		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3949		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3950		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3951		ODE*	Sep 21, 2029
	10137124*PED	Apr 10, 2038			ODE*	Sep 21, 2029
	10172851	Oct 10, 2037	U-3450		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3949		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3950		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3951		PED	Nov 08, 2027
	10172851*PED	Apr 10, 2038			PED	Nov 08, 2027
	>A> 12138250	Oct 10, 2038	U-3450		PED	Nov 08, 2027
	>A> 12138250	Oct 10, 2038	U-3949		PED	Mar 27, 2028
	>A> 12138250	Oct 10, 2038	U-3950		PED	Mar 27, 2028
	>A> 12138250	Oct 10, 2038	U-3951		PED	Mar 21, 2030
	>A> 12138250*PED	Apr 10, 2039			PED	Mar 21, 2030
					PED	Nov 29, 2031
					PED	Nov 29, 2031
					PED	Nov 29, 2031
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 003	10112942	Oct 10, 2037	DS DP		M-311	Sep 27, 2027
	10112942*PED	Apr 10, 2038			M-312	Sep 27, 2027
	10137124	Oct 10, 2037	U-3450		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3949		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3950		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3951		ODE*	Sep 21, 2029
	10137124*PED	Apr 10, 2038			ODE*	Sep 21, 2029
	10172851	Oct 10, 2037	U-3450		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3949		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3950		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3951		PED	Nov 08, 2027
	10172851*PED	Apr 10, 2038			PED	Nov 08, 2027
	>A> 12138250	Oct 10, 2038	U-3450		PED	Nov 08, 2027
	>A> 12138250	Oct 10, 2038	U-3949		PED	Mar 27, 2028
	>A> 12138250	Oct 10, 2038	U-3950		PED	Mar 27, 2028
	>A> 12138250	Oct 10, 2038	U-3951		PED	Mar 21, 2030
	>A> 12138250*PED	Apr 10, 2039			PED	Mar 21, 2030
					PED	Nov 29, 2031
					PED	Nov 29, 2031
					PED	Nov 29, 2031
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 004	10112942	Oct 10, 2037	DS DP		M-311	Sep 27, 2027
	10112942*PED	Apr 10, 2038			M-312	Sep 27, 2027
	10137124	Oct 10, 2037	U-3450		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3949		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3950		ODE*	May 08, 2027
	10137124	Oct 10, 2037	U-3951		ODE*	Sep 21, 2029
	10137124*PED	Apr 10, 2038			ODE*	Sep 21, 2029
	10172851	Oct 10, 2037	U-3450		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3949		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3950		ODE*	May 29, 2031
	10172851	Oct 10, 2037	U-3951		PED	Nov 08, 2027
	10172851*PED	Apr 10, 2038			PED	Nov 08, 2027
	>A> 12138250	Oct 10, 2038	U-3450		PED	Nov 08, 2027
	>A> 12138250	Oct 10, 2038	U-3949		PED	Mar 27, 2028
	>A> 12138250	Oct 10, 2038	U-3950		PED	Mar 27, 2028

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 004	>A> 12138250	Oct 10, 2038	U-3951		PED	Mar 21, 2030
	>A> 12138250*PED	Apr 10, 2039			PED	Mar 21, 2030
					PED	Nov 29, 2031
					PED	Nov 29, 2031
					PED	Nov 29, 2031
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	12220403	Mar 26, 2029	DP		NPP	Sep 10, 2028
	12318367	Mar 26, 2029	DP		>A> NPP	Nov 19, 2028
	>A> 12364684	Mar 26, 2029	U-4357			
	>A> 7425637	Mar 13, 2028	DS			
	8178693	Mar 13, 2026	DS DP			
	>A> 9562017	Dec 12, 2026	DS U-4357			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	12220403	Mar 26, 2029	DP		NPP	Sep 10, 2028
	12318367	Mar 26, 2029	DP		>A> NPP	Nov 19, 2028
	>A> 12364684	Mar 26, 2029	U-4357			
	>A> 7425637	Mar 13, 2028	DS			
	8178693	Mar 13, 2026	DS DP			
	>A> 9562017	Dec 12, 2026	DS U-4357			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 219943 001	>A> 7425637	Mar 13, 2028	DS		NP	Sep 10, 2028
	8178693	Mar 13, 2026	DS DP		>A> NPP	Nov 19, 2028
	9156795	Dec 12, 2026	DS DP		ODE*	Apr 10, 2027
	>A> 9562017	Dec 12, 2026	DS U-4357			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 219943 002	>A> 7425637	Mar 13, 2028	DS		NP	Sep 10, 2028
	8178693	Mar 13, 2026	DS DP		>A> NPP	Nov 19, 2028
	9156795	Dec 12, 2026	DS DP		ODE*	Apr 10, 2027
	>A> 9562017	Dec 12, 2026	DS U-4357			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	8684969	Oct 20, 2025	DP	Y		
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 27, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	8684969	Oct 20, 2025	DP	Y		
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 29, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 003	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	12295988	Oct 10, 2038	U-2628			
	8684969	Oct 20, 2025	DP	Y		
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 29, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 004	10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	10357616	Jan 20, 2026	DP	Y		
	10376652	Jan 20, 2026	DP	Y		
	11097063	Jul 17, 2026	DP	Y		
	8684969	Oct 20, 2025	DP	Y		
	8920383	Jul 17, 2026	DP	Y		
	9108002	Jan 20, 2026	DP	Y		
	9132239	Feb 01, 2032	DP	Y		
	9457154	Sep 29, 2027	DP	Y		
	9616180	Jan 20, 2026	DP	Y		
	9687611	Feb 27, 2027	DP	Y		
	9775953	Jul 17, 2026	DP	Y		
	9861757	Jan 20, 2026	DP	Y		
	RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	10278923	May 02, 2034	U-2628		I-976	Oct 17, 2028
	12239739	May 02, 2034	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	10278923	May 02, 2034	U-2628		I-976	Oct 17, 2028
	12239739	May 02, 2034	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	10278923	May 02, 2034	U-2628		I-976	Oct 17, 2028
	12239739	May 02, 2034	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 004	10278923	May 02, 2034	DS DP U-2628		I-976	Oct 17, 2028
	11382957	Dec 16, 2031	DS DP			
	12239739	May 02, 2034	DS DP U-2628			
	12396953	Feb 01, 2039	DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 005	10278923	May 02, 2034	DS DP U-2628		I-976	Oct 17, 2028
	11382957	Dec 16, 2031	DS DP			
	12239739	May 02, 2034	DS DP U-2628			
	12396953	Feb 01, 2039	DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 006	10278923	May 02, 2034	DS DP U-2628		I-976	Oct 17, 2028
	11382957	Dec 16, 2031	DS DP			
	12239739	May 02, 2034	DS DP U-2628			
	12396953	Feb 01, 2039	DP U-2628			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DS DP U-2628			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001	11478533	May 13, 2040	U-3861		I-973	Aug 15, 2028
	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002	11478533	May 13, 2040	U-3861		I-973	Aug 15, 2028
	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003	11478533	May 13, 2040	U-3861		I-973	Aug 15, 2028
	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004	11478533	May 13, 2040	U-3861		I-973	Aug 15, 2028
	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	11478533	May 13, 2040	U-3861		I-973	Aug 15, 2028
	12214017	Aug 24, 2038	DP U-3162			
<u>SEPIAPTERIN - SEPHIENCE</u>						
N 219666 001	11072614	Apr 16, 2038	DS U-4251		NCE	Jul 28, 2030
	11752154	Sep 04, 2038	DP U-4251			
	12213982	Sep 04, 2038	U-4251			
	12257252	Mar 06, 2042	U-4250			
<u>SEPIAPTERIN - SEPHIENCE</u>						
N 219666 002	11072614	Apr 16, 2038	DS U-4251		NCE	Jul 28, 2030
	11752154	Sep 04, 2038	DP U-4251			
	12213982	Sep 04, 2038	U-4251			
	12257252	Mar 06, 2042	U-4250			
<u>SERTRALINE HYDROCHLORIDE - SERTRALINE HYDROCHLORIDE</u>						
A 218853 001					CGT	Jan 18, 2026
<u>SERTRALINE HYDROCHLORIDE - SERTRALINE HYDROCHLORIDE</u>						
A 218853 002					CGT	Jan 18, 2026
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001	8039435	Aug 21, 2032	DS DP		NPP ODE-508 ODE-509	Dec 20, 2027 Dec 20, 2031 Dec 20, 2031
<u>SEVABERTINIB - HYRNUO</u>						
N 219972 001	10428063	Jan 25, 2036	DS DP		NCE	Nov 19, 2030
<u>SILDENAFIL CITRATE - LIOREV</u>						
N 214952 001	12186321	Dec 24, 2038	DP U-3582			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 001	11944602	Apr 23, 2036	U-3889			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	11944602	Apr 23, 2036	U-3889			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 003	11944602	Apr 23, 2036	U-3889			
<u>SITAGLIPTIN HYDROCHLORIDE - BRYNOVIN</u>						
N 219122 001	11944621	Oct 23, 2040	DP			
	12295953	Oct 23, 2040	DP			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	12304813	Feb 10, 2030	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001	12226377	Jul 21, 2037	DP			
	12303478	Jul 21, 2037	U-4189			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	12226377	Jul 21, 2037	DP			
	12303478	Jul 21, 2037	U-4189			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	12226377	Jul 21, 2037	DP			
	12303478	Jul 21, 2037	U-4189			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	12226377	Jul 21, 2037	DP			
	12303478	Jul 21, 2037	U-4189			
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 007	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM PHENYL BUTYRATE - OLPRUVA</u>						
N 214860 008	11154521	Oct 17, 2036	DP			
	11202767	Oct 17, 2036	U-3502			
	11433041	Oct 17, 2036	DP			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	12304813	Feb 10, 2030	DP			
<u>SOFOSEBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 002					>A> ODE*	Mar 19, 2027
					>A> PED	Sep 19, 2027
<u>SOFPIRONIUM BROMIDE - SOFDRA</u>						
N 217347 001	12156865	May 22, 2034	DP U-2398			
	12357609	May 22, 2034	DP U-2398			
	12398102	May 22, 2034	DP U-2398			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	12194016	Mar 19, 2040	U-4106			
	12209059	Jun 07, 2026	U-2548			
	12263145	Dec 30, 2042	U-3693			
	12318362	Mar 19, 2040	U-3765			
	12384743	Nov 01, 2038	DS DP U-2548			
	12390419	Sep 05, 2037	DP U-2548			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	12194016	Mar 19, 2040	U-4106			
	12209059	Jun 07, 2026	U-2548			
	12384743	Nov 01, 2038	DS DP U-2548			
	12390419	Sep 05, 2037	DP U-2548			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	12194016	Mar 19, 2040				
	12209059	Jun 07, 2026				
	12384743	Nov 01, 2038	DS DP			
	12390419	Sep 05, 2037	DP			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	12390431	Aug 14, 2038				
	12403109	Aug 14, 2028				
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	12290495	Apr 01, 2034				
	12290495	Apr 01, 2034				
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001	11236091	May 20, 2040	DS DP		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040				
	11426404	Sep 15, 2040				
	11827635	May 20, 2040	DS DP			
	11827635	May 20, 2040	DS DP			
	12280056	Nov 18, 2039				
	12398133	May 20, 2040	DS DP			
	12398133	May 20, 2040	DS DP			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 002	11236091	May 20, 2040	DS DP		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040				
	11426404	Sep 15, 2040				
	11827635	May 20, 2040	DS DP			
	11827635	May 20, 2040	DS DP			
	12280056	Nov 18, 2039				
	12398133	May 20, 2040	DS DP			
	12398133	May 20, 2040	DS DP			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 003	11236091	May 20, 2040	DS DP		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP		ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040				
	11426404	Sep 15, 2040				
	11827635	May 20, 2040	DS DP			
	11827635	May 20, 2040	DS DP			
	12280056	Nov 18, 2039				
	12398133	May 20, 2040	DS DP			
	12398133	May 20, 2040	DS DP			
<u>SUCCINYLCHOLINE CHLORIDE - SUCCINYLCHOLINE CHLORIDE</u>						
N 215143 001	12295932	Nov 02, 2041	DP			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001					NPP PED	Dec 12, 2027 Jun 12, 2028
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002					NPP PED	Dec 12, 2027 Jun 12, 2028
<u>SUNVOZERTINIB - ZEGFROVY</u>						
N 219839 001	11007198	Jan 28, 2039	DS DP		NCE	Jul 02, 2030
	11504375	Jan 28, 2039	DS DP			
	11896597	Jan 28, 2039	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUNVOZERTINIB - ZEGFROVY</u>						
N 219839 002	11007198	Jan 28, 2039	DS DP		NCE	Jul 02, 2030
	11504375	Jan 28, 2039	DS DP U-3220			
	11896597	Jan 28, 2039	DS DP U-3220			
<u>SUZETRIGINE - JOURNAVX</u>						
N 219209 001	11834441	Dec 04, 2040	DS DP U-4125		NCE	Jan 30, 2030
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	12403095	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	12403095	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	12403095	May 30, 2028	DP			
<u>TADALAFIL - TADLIO</u>						
N 214522 001	12186322	Dec 24, 2038	DP U-3397			
<u>TAFAMIDIS - VYNDAMAX</u>						
N 212161 001	7214695	Dec 19, 2026	DS DP			
	7214696	Dec 19, 2026	U-2524			
<u>TAFAMIDIS MEGLUMINE - VYNDAQEL</u>						
N 211996 001	7214695	Dec 19, 2026	DS DP			
	7214696	Dec 19, 2026	U-2524			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 001 >A>	8012976	Jul 27, 2029	DS DP			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 002 >A>	8012976	Jul 27, 2029	DS DP			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 003 >A>	8012976	Jul 27, 2029	DS DP			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 004 >A>	8012976	Jul 27, 2029	DS DP			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 005 >A>	8012976	Jul 27, 2029	DS DP			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 006 >A>	8012976	Jul 27, 2029	DS DP			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 001 >A>	8012976	Jul 27, 2029	DS DP			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 002 >A>	8012976	Jul 27, 2029	DS DP			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 003 >A>	8012976	Jul 27, 2029	DS DP			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 004 >A>	8012976	Jul 27, 2029	DS DP			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 005 >A>	8012976	Jul 27, 2029	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 006 >A>	8012976	Jul 27, 2029	DS DP			
<u>TALETRECTINIB ADIPATE - IBTROZI</u>						
N 219713 001	9187489	Jun 03, 2033	DS DP U-4207		NCE	Jun 11, 2030
	9751887	Jun 03, 2033	DS DP U-4207			
<u>TAPINAROF - VTAMA</u>						
N 215272 001	10426743	May 19, 2036	U-2625		I-956	Dec 12, 2027
	10426743	May 19, 2036	U-4048			
	11497718	Nov 13, 2039	U-4048			
	11612573	May 19, 2036	U-2625			
	11612573	May 19, 2036	U-4048			
	11938099	Nov 13, 2039	U-4048			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	12201604	Jan 25, 2033	U-3003			
	12201604	Jan 25, 2033	U-3865			
<u>TASIMELTEON - HETLIOZ LQ</u>						
N 214517 001	12201604	Jan 25, 2033	U-3003			
	12447141	Dec 11, 2040	U-3003			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	11052093	Sep 12, 2031	DS DP U-2736			
	11052093	Sep 12, 2031	DS DP U-2852			
	11052093	Sep 12, 2031	DS DP U-2853			
	12161645	Sep 12, 2031	U-2853			
	12162865	Jun 12, 2034	U-2736			
	12168014	May 03, 2038	U-2736			
	12168014	May 03, 2038	U-2852			
	12168014	May 03, 2038	U-2853			
	12168015	Sep 12, 2031	DS DP			
	12168016	Sep 12, 2031	U-2736			
	12168016	Sep 12, 2031	U-2853			
<u>TECOVIRIMAT - TPOXX</u>						
N 208627 001	12433868	Mar 23, 2031	DP			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001					NPP	Apr 04, 2028
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001					NPP	Apr 04, 2028
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>TERAZOSIN HYDROCHLORIDE - TEZRULY</u>						
N 218139 001	11224572	Feb 01, 2041	DP U-3990			
	11224572	Feb 01, 2041	DP U-3991			
	12427108	Feb 01, 2041	DP U-3990			
	12427108	Feb 01, 2041	DP U-3991			
<u>TESTOSTERONE - NATESTO</u>						
N 205488 001 >A>	11744838	Mar 17, 2034	U-4366			
>A>	11744838	Mar 17, 2034	U-4367			
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	12310978	Feb 21, 2039	U-4194			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 001	12357643	Mar 15, 2033	DP U-2506			
	12403146	Mar 29, 2041	DP U-2506			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 002	12357643	Mar 15, 2033	DP U-2506			
	12403146	Mar 29, 2041	DP U-2506			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 003	12357643	Mar 15, 2033	DP U-2506			
	12403146	Mar 29, 2041	DP U-2506			
<u>TETRACAINE HYDROCHLORIDE - TETRACAINE HYDROCHLORIDE</u>						
A 217227 001					CGT	Jun 25, 2025
<u>THIOTEPA - TEPADINA AND SODIUM CHLORIDE</u>						
N 208264 003	9931458	May 31, 2037	DP			
<u>THIOTEPA - TEPYLUTE</u>						
N 216984 002	11975013	Aug 16, 2041	DP			
<u>TICAGRELOR - TICAGRELOR</u>						
A 208390 001					PC	Oct 28, 2025
<u>TICAGRELOR - TICAGRELOR</u>						
A 208531 001					PC	Oct 28, 2025
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	7396341	Oct 10, 2026	DP	Y		
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP	Y		
	7837235*PED	Sep 13, 2028				
	8733341	Oct 16, 2030	DP	Y		
	8733341*PED	Apr 16, 2031				
	9027967	Mar 31, 2027	DP	Y		
	9027967*PED	Sep 30, 2027				
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001	7300931	Dec 28, 2030	DS DP			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 001	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 002	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 002	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 003	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 004	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 005	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 005	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
<u>TIRZEPATIDE - MOUNJARO (AUTOINJECTOR)</u>						
N 215866 006	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	12295987	Dec 30, 2041	U-4192			
	12295987	Dec 30, 2041	U-4193			
	12343382	Jul 22, 2039	U-4229			
	12343382	Jul 22, 2039	U-4230			
	12343382	Jul 22, 2039	U-4231			
	12343382	Jul 22, 2039	U-4232			
	12453755	Jun 14, 2039	U-4315			
	12453755	Jun 14, 2039	U-4316			
	12453755	Jun 14, 2039	U-4317			
	12453755	Jun 14, 2039	U-4318			
	12453755	Jun 14, 2039	U-4319			
	12453755	Jun 14, 2039	U-4320			
	12453755	Jun 14, 2039	U-4321			
	12453755	Jun 14, 2039	U-4322			
	12453755	Jun 14, 2039	U-4323			
	12453755	Jun 14, 2039	U-4324			
	12453755	Jun 14, 2039	U-4325			
	12453755	Jun 14, 2039	U-4326			
	12453756	Jun 14, 2039	DP			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
	12453756	Jun 14, 2039	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			
	12453758	Jul 22, 2039	U-4311			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012	12343382	Jul 22, 2039	U-4227		I-958	Dec 20, 2027
	12343382	Jul 22, 2039	U-4228			
	12453756	Jun 14, 2039	DP			
	12453758	Jul 22, 2039	U-4308			
	12453758	Jul 22, 2039	U-4309			
	12453758	Jul 22, 2039	U-4310			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012	12453758	Jul 22, 2039	U-4311			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	7166722	Nov 16, 2028	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	7166722	Nov 16, 2028	DS DP			
<u>TIZANIDINE HYDROCHLORIDE - ONTRALFY</u>						
N 216190 001	12263158	May 07, 2042	DP U-2779			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	RE41783	Dec 08, 2025	DS		M-14	Feb 21, 2028
	RE41783*PED	Jun 08, 2026			PED	Aug 21, 2028
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 002	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	11253523	Mar 14, 2034	U-3326			
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
	11253523*PED	Sep 14, 2034				
	9937181	Mar 14, 2034	DP			
	9937181*PED	Sep 14, 2034				
	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 002	10639309	Mar 14, 2034	DP			
	10639309*PED	Sep 14, 2034				
	11253523	Mar 14, 2034	U-3326			
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
	11253523*PED	Sep 14, 2034				
	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 213082 001	RE41783	Dec 08, 2025	DS		M-14	Feb 21, 2028
	RE41783*PED	Jun 08, 2026			PED	Aug 21, 2028
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063 001					PC	Nov 08, 2025
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063 002					PC	Nov 08, 2025
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063 003					PC	Nov 08, 2025
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063 004					PC	Nov 08, 2025
<u>TOLVAPTAN - TOLVAPTAN</u>						
A 216063 005					PC	Nov 08, 2025

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TOPIRAMATE</u>						
A 216683	003				CGT	Feb 01, 2026
<u>TOPIRAMATE - TOPIRAMATE</u>						
A 217795	001				PC	Jan 05, 2026
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679	001	12290503	Aug 21, 2040	DP U-3413		
		12290503	Aug 21, 2040	DP U-3414		
		12290503	Aug 21, 2040	DP U-3415		
<u>TRADIPITANT - NEREUS</u>						
N 220152	001				>A> NCE	Dec 30, 2030
<u>TRAVOPROST - IDOSE TR</u>						
N 218010	001	12201555	Feb 14, 2031	DS DP		
		12201557	Jun 18, 2030	DS DP U-4129		
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759	001	7199162	Mar 21, 2026	U-4142	NCE ODE-513 ODE-514	Jan 21, 2030 Jan 21, 2032 Jan 21, 2032
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759	002	7199162	Mar 21, 2026	U-4142	NCE ODE-513 ODE-514	Jan 21, 2030 Jan 21, 2032 Jan 21, 2032
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324	001	11357782	May 14, 2027	U-1849		
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324	002	11357782	May 14, 2027	U-1849		
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324	003	11357782	May 14, 2027	U-1849		
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324	004	11357782	May 14, 2027	U-1849		
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324	005	11357782	May 14, 2027	U-1849		
<u>TREPROSTINIL SODIUM - YUTREPIA</u>						
N 213005	001	10898494	May 05, 2037	U-4200	NP	May 23, 2028
		11660304	May 05, 2037	U-4200		
		11712442	May 05, 2037	U-4200		
		11744835	May 05, 2037	DP		
		11744836	May 05, 2037	DP		
		12390475	May 05, 2037	DP		
<u>TREPROSTINIL SODIUM - YUTREPIA</u>						
N 213005	002	10898494	May 05, 2037	U-4200	NP	May 23, 2028
		11660304	May 05, 2037	U-4200		
		11712442	May 05, 2037	U-4200		
		11744835	May 05, 2037	DP		
		11744836	May 05, 2037	DP		
		12390475	May 05, 2037	DP		
<u>TREPROSTINIL SODIUM - YUTREPIA</u>						
N 213005	003	10898494	May 05, 2037	U-4200	NP	May 23, 2028
		11660304	May 05, 2037	U-4200		
		11712442	May 05, 2037	U-4200		
		11744835	May 05, 2037	DP		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL SODIUM - YUTREPIA</u>						
N 213005 003	11744836	May 05, 2037	DP			
	12390475	May 05, 2037	DP			
<u>TREPROSTINIL SODIUM - YUTREPIA</u>						
N 213005 004	10898494	May 05, 2037	U-4200		NP	May 23, 2028
	11660304	May 05, 2037	U-4200			
	11712442	May 05, 2037	U-4200			
	11744835	May 05, 2037	DP			
	11744836	May 05, 2037	DP			
	12390475	May 05, 2037	DP			
<u>TRIAMCINOLONE ACETONIDE - XIPERE</u>						
N 211950 001	12419833	Apr 16, 2040	DP U-3234			
<u>TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR</u>						
N 215760 001	12358861	May 03, 2039	DS DP U-4262			
	12358862	May 03, 2039	DS DP U-4262			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	12168666	Nov 13, 2040	DS DP			
	8598186	Dec 30, 2034	DS DP			
<u>TROFINETIDE - DAYBUE STIX</u>						
N 219884 001					>A> NCE	Mar 10, 2028
					>A> ODE*	Mar 10, 2030
<u>TROFINETIDE - DAYBUE STIX</u>						
N 219884 002					>A> NCE	Mar 10, 2028
					>A> ODE*	Mar 10, 2030
<u>TROFINETIDE - DAYBUE STIX</u>						
N 219884 003					>A> NCE	Mar 10, 2028
					>A> ODE*	Mar 10, 2030
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	>A> 7452895	Nov 16, 2026	DS DP U-2788			
	>A> 7452895	Nov 16, 2026	DS DP U-4153			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	>A> 7452895	Nov 16, 2026	DS DP U-2788			
	>A> 7452895	Nov 16, 2026	DS DP U-4153			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	12168004	Jan 30, 2035	DP			
	12194030	Dec 22, 2041	U-4121			
	12194030	Dec 22, 2041	U-4122			
	12220408	Jan 30, 2035	DP			
	12310953	Jan 30, 2035	DP			
	12329750	Dec 22, 2041	U-4213			
	12458632	Jan 30, 2035	DP			
	12458633	Jan 30, 2035	DP			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	12168004	Jan 30, 2035	DP			
	12220408	Jan 30, 2035	DP			
	12310953	Jan 30, 2035	DP			
	12458632	Jan 30, 2035	DP			
	12458633	Jan 30, 2035	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	12396986	Nov 29, 2030	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	11564922	Mar 09, 2038	U-3624		I-966	Apr 28, 2028
	11564922	Mar 09, 2038	U-4303			
	11607411	Mar 09, 2038	U-3341			
	11607411	Mar 09, 2038	U-4302			
	12365689	Oct 17, 2036	U-3945			
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	11564922	Mar 09, 2038	U-3624			
	11564922	Mar 09, 2038	U-4303			
	11607411	Mar 09, 2038	U-3341			
	11607411	Mar 09, 2038	U-4302			
<u>UPADACITINIB - RINVOO</u>						
N 211675 003	11564922	Mar 09, 2038	U-3624			
	11564922	Mar 09, 2038	U-4303			
	11607411	Mar 09, 2038	U-3341			
	11607411	Mar 09, 2038	U-4302			
<u>UPADACITINIB - RINVOO LQ</u>						
N 218347 001	12365689	Oct 17, 2036	U-3945			
<u>VAMOROLONE - AGAMREE</u>						
N 215239 001	12201639	Mar 17, 2040	DS DP U-3747			
<u>VANCOMYCIN HYDROCHLORIDE - TYZAVAN</u>						
N 211962 001	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - TYZAVAN</u>						
N 211962 002	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - TYZAVAN</u>						
N 211962 003	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - TYZAVAN</u>						
N 211962 004	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - TYZAVAN</u>						
N 211962 005	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - TYZAVAN</u>						
N 211962 006	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - TYZAVAN</u>						
N 211962 007	12161690	Nov 06, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 003	12186362	Jan 30, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 004	12186362	Jan 30, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 005	12186362	Jan 30, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 006	12186362	Jan 30, 2035	DP			
<u>VASOPRESSIN - VASOPRESSIN IN SODIUM CHLORIDE 0.9%</u>						
N 217569 001	12447190	Sep 27, 2044	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VASOPRESSIN - VASOPRESSIN IN SODIUM CHLORIDE 0.9%</u>						
N 217569 002	12447190	Sep 27, 2044	DP			
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	12180219	Mar 12, 2034	DS DP		I-955	Dec 18, 2027
	>A> 12357636	Jul 06, 2042		U-4219		
	8247415	Dec 23, 2034	DS DP	U-3045		
	8247415	Dec 23, 2034	DS DP	U-4219		
<u>VIGABATRIN - VIGAFYDE</u>						
N 217684 001	12290499	Oct 17, 2042	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 001	9662338	Apr 02, 2035	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002	9662338	Apr 02, 2035	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	9662338	Apr 02, 2035	DP			
<u>VILTOLARSEN - VILTEPSO</u>						
N 212154 001	9079934	Apr 03, 2034	DS DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 001	11103507	Feb 03, 2040		U-4145	NCE	Feb 14, 2030
	11679110	Feb 03, 2040		U-4145		
	12285430	Dec 23, 2039		U-4145		
	12447149	Dec 06, 2044	DP			
	12485120	Dec 23, 2039		U-4145		
	9181223	Mar 14, 2034	DS DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 002	11103507	Feb 03, 2040		U-4145	NCE	Feb 14, 2030
	11679110	Feb 03, 2040		U-4145		
	12285430	Dec 23, 2039		U-4145		
	12447149	Dec 06, 2044	DP			
	12485120	Dec 23, 2039		U-4145		
	9181223	Mar 14, 2034	DS DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 003	11103507	Feb 03, 2040		U-4145	NCE	Feb 14, 2030
	11679110	Feb 03, 2040		U-4145		
	12285430	Dec 23, 2039		U-4145		
	12447149	Dec 06, 2044	DP			
	12485120	Dec 23, 2039		U-4145		
	9181223	Mar 14, 2034	DS DP			
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	7332472	Jan 17, 2026	DS DP	U-3056		
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 001					NCE GAIN	May 03, 2027 May 03, 2032
<u>VONOPRAZAN FUMARATE - VOQUEZNA</u>						
N 215151 002					NCE GAIN	May 03, 2027 May 03, 2032
<u>VORASIDENIB - VORANIGO</u>						
N 218784 001	12433895	Jul 11, 2034		U-4286		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORASIDENIB - VORANIGO</u>						
N 218784 002	12433895	Jul 11, 2034	U-4286			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001	12233106	Jul 11, 2042	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	12233106	Jul 11, 2042	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003	12233106	Jul 11, 2042	U-3927			
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001					ODE*	Nov 25, 2026
<u>VUTRISIRAN SODIUM - AMVUTTRA</u>						
N 215515 001					I-964	Mar 20, 2028
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 218785 001	10570139	Apr 22, 2034	U-1745		I-817	Jan 19, 2026
	10570139	Apr 22, 2034	U-2145		I-936	Mar 07, 2027
	10570139	Apr 22, 2034	U-2537		ODE*	Nov 14, 2026
	10570139	Apr 22, 2034	U-2666		ODE*	Aug 31, 2028
	10570139	Apr 22, 2034	U-3063		ODE*	Sep 14, 2028
	10570139	Apr 22, 2034	U-3486		ODE*	Jan 19, 2030
	10570139	Apr 22, 2034	U-3860		ODE*	Mar 07, 2031
	10927117	Aug 15, 2037	DS DP			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11142528	Apr 22, 2034	DP U-3860			
	11591340	Aug 15, 2037	U-1745			
	11591340	Aug 15, 2037	U-2145			
	11591340	Aug 15, 2037	U-2537			
	11591340	Aug 15, 2037	U-2666			
	11591340	Aug 15, 2037	U-3063			
	11591340	Aug 15, 2037	U-3486			
	11591340	Aug 15, 2037	U-3727			
	11591340	Aug 15, 2037	U-3728			
	11591340	Aug 15, 2037	U-3729			
	11701357	Jun 24, 2039	U-3860			
	11786531	Jan 19, 2043	U-3715			
	11786531	Jan 19, 2043	U-3716			
	11786531	Jan 19, 2043	U-3717			
	11786531	Jan 19, 2043	U-3718			
	11786531	Jan 19, 2043	U-3719			
	11786531	Jan 19, 2043	U-3720			
	11786531	Jan 19, 2043	U-3875			
	11851437	Aug 15, 2037	DS DP			
	11884674	Aug 15, 2037	U-1745			
	11884674	Aug 15, 2037	U-2145			
	11884674	Aug 15, 2037	U-2537			
	11884674	Aug 15, 2037	U-2666			
	11884674	Aug 15, 2037	U-3063			
	11884674	Aug 15, 2037	U-3486			
	11884674	Aug 15, 2037	U-3860			
	11896596	Jan 19, 2043	U-3715			
	11896596	Jan 19, 2043	U-3716			
	11896596	Jan 19, 2043	U-3717			
	11896596	Jan 19, 2043	U-3718			
	11896596	Jan 19, 2043	U-3719			
	11896596	Jan 19, 2043	U-3720			
	11896596	Jan 19, 2043	U-3875			
	11911386	Jan 19, 2043	U-3715			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 218785 001	11911386	Jan 19, 2043	U-3716			
	11911386	Jan 19, 2043	U-3717			
	11911386	Jan 19, 2043	U-3718			
	11911386	Jan 19, 2043	U-3719			
	11911386	Jan 19, 2043	U-3720			
	11911386	Jan 19, 2043	U-3875			
	11970500	Aug 15, 2037	U-1745			
	11970500	Aug 15, 2037	U-2145			
	11970500	Aug 15, 2037	U-2537			
	11970500	Aug 15, 2037	U-2666			
	11970500	Aug 15, 2037	U-3063			
	11970500	Aug 15, 2037	U-3486			
	11970500	Aug 15, 2037	U-3860			
	12233069	Jun 10, 2040	DP			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
	9447106	Apr 22, 2034	DS DP U-3860			
<u>ZIFTOMENIB - KOMZIFTI</u>						
N 220305 001	10077271	Mar 16, 2036	DS DP		NCE	Nov 13, 2030
	10174041	Mar 16, 2036	U-4350			
	10174041	Mar 16, 2036	U-4354			
	10781218	Mar 15, 2037	DS DP			
	10869868	Jan 26, 2037	U-4352			
	10869868	Jan 26, 2037	U-4353			
	11673898	Mar 15, 2037	U-4350			
	11673898	Mar 15, 2037	U-4351			
	11944627	Sep 06, 2038	U-4347			
	11944627	Sep 06, 2038	U-4349			
	12410184	Jul 16, 2044	DS DP U-4347			
	12410184	Jul 16, 2044	DS DP U-4348			
<u>ZOLIFLODACIN - NUZOLVENCE</u>						
N 219491 001					>A> NCE	Dec 12, 2030
					>A> GAIN	Dec 12, 2035
<u>ZONGERTINIB - HERNEXEOS</u>						
N 219042 001	11608343	Jul 21, 2041	DS DP U-4245		NCE	Aug 08, 2030
	12171739	Nov 15, 2026	DS DP			
<u>ZONISAMIDE - ZONISADE</u>						
N 214273 001	>A> 12491179	Aug 18, 2038	DP			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 001	11884696	Aug 23, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 002	11884696	Aug 23, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 003	11884696	Aug 23, 2037	U-2552			

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 45<sup>TH</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)